"","Name","MOA","Target","Disease Area","Indication","SMILES","Phase","SLC","SLC.count","SCN","SCN.count","PTGS","PTGS.count","MAO","MAO.count","HTR","HTR.count","HRH","HRH.count","GABR","GABR.count","DRD","DRD.count","CHR","CHR.count","ADR","ADR.count","Parkinson's Disease","depression","pain relief","schizophrenia"
"1","(+)-borneol","gaba receptor agonist","GABRA1, TRPA1, TRPM8, TRPV3","neurology/psychiatry","postherpetic neuralgia","O[C@@H]1[C@](C2(C)C)(C)CC[C@]2([H])C1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1
"2","(R)-(-)-apomorphine","dopamine receptor agonist","ADRA2A, ADRA2B, ADRA2C, CALY, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR5A","neurology/psychiatry","Parkinson's Disease","CN1CCc2cccc-3c2[C@H]1Cc1ccc(O)c(O)c-31, CN1CCc2cccc-3c2[C@H]1Cc1ccc(O)c(O)c-31, CN1CCc2cccc-3c2[C@H]1Cc1ccc(O)c(O)c-31, CN1CCc2cccc-3c2[C@H]1Cc1ccc(O)c(O)c-31","Launched",0,0,0,0,0,0,0,0,1,7,0,0,0,0,1,5,0,0,1,3,1,1,1,1
"3","(R)-(-)-rolipram","phosphodiesterase inhibitor","PDE4A, PDE4B, PDE4C, PDE4D, PDE5A",NA,NA,"COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4","(R)-baclofen","benzodiazepine receptor agonist","GABBR1, GABBR2",NA,NA,"NC[C@H](CC(O)=O)c1ccc(Cl)cc1, NC[C@H](CC(O)=O)c1ccc(Cl)cc1, NC[C@H](CC(O)=O)c1ccc(Cl)cc1, NC[C@H](CC(O)=O)c1ccc(Cl)cc1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"5","(r)-ketorolac","cyclooxygenase inhibitor","CDC42, RAC1",NA,NA,"OC(=O)[C@@H]1CCn2c1ccc2C(=O)c1ccccc1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"6","(S)-(+)-rolipram","phosphodiesterase inhibitor","PDE4B, PDE4D",NA,NA,"COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"7","[sar9,met(o2)11]-substance-p","tachykinin antagonist","TACR1",NA,NA,"CC(C)C[C@H](NC(=O)CN(C)C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCS(C)(=O)=O)C(N)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"8","A-1070722","glycogen synthase kinase inhibitor","GSK3A, GSK3B",NA,NA,"COc1ccc2c(NC(=O)Nc3cccc(n3)C(F)(F)F)ccnc2c1, COc1ccc2c(NC(=O)Nc3cccc(n3)C(F)(F)F)ccnc2c1, COc1ccc2c(NC(=O)Nc3cccc(n3)C(F)(F)F)ccnc2c1, COc1ccc2c(NC(=O)Nc3cccc(n3)C(F)(F)F)ccnc2c1, COc1ccc2c(NC(=O)Nc3cccc(n3)C(F)(F)F)ccnc2c1, COc1ccc2c(NC(=O)Nc3cccc(n3)C(F)(F)F)ccnc2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"9","A-1120","retinoid receptor ligand","RBP4",NA,NA,"OC(=O)c1ccccc1NC(=O)N1CCC(CC1)c1ccccc1C(F)(F)F, OC(=O)c1ccccc1NC(=O)N1CCC(CC1)c1ccccc1C(F)(F)F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"10","A-317491","purinergic receptor antagonist","P2RX3",NA,NA,"OC(=O)c1cc(C(O)=O)c(cc1C(O)=O)C(=O)N(Cc1cccc(Oc2ccccc2)c1)[C@H]1CCCc2ccccc12, OC(=O)c1cc(C(O)=O)c(cc1C(O)=O)C(=O)N(Cc1cccc(Oc2ccccc2)c1)[C@H]1CCCc2ccccc12, OC(=O)c1cc(C(O)=O)c(cc1C(O)=O)C(=O)N(Cc1cccc(Oc2ccccc2)c1)[C@H]1CCCc2ccccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"11","A-366","histone lysine methyltransferase inhibitor","EHMT1, EHMT2",NA,NA,"COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|, COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|, COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|, COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|, COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|, COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"12","A-412997","dopamine receptor agonist","DRD4",NA,NA,"Cc1cccc(NC(=O)CN2CCC(CC2)c2ccccn2)c1, Cc1cccc(NC(=O)CN2CCC(CC2)c2ccccn2)c1, Cc1cccc(NC(=O)CN2CCC(CC2)c2ccccn2)c1, Cc1cccc(NC(=O)CN2CCC(CC2)c2ccccn2)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0
"13","A-438079","purinergic receptor antagonist","P2RX7",NA,NA,"Clc1cccc(-c2nnnn2Cc2cccnc2)c1Cl, Clc1cccc(-c2nnnn2Cc2cccnc2)c1Cl, Clc1cccc(-c2nnnn2Cc2cccnc2)c1Cl","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"14","A-582941","nicotinic receptor agonist","CHRNA7",NA,NA,"CN1C[C@H]2CN(C[C@H]2C1)c1ccc(nn1)-c1ccccc1, CN1C[C@H]2CN(C[C@H]2C1)c1ccc(nn1)-c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
"15","A-61603","adrenergic receptor agonist","ADRA1A, ADRA1B, ADRA1D",NA,NA,"CS(=O)(=O)Nc1c(O)ccc2[C@H](CCCc12)C1=NCCN1 |&1:11,r,t:18|, CS(=O)(=O)Nc1c(O)ccc2[C@H](CCCc12)C1=NCCN1 |&1:11,r,t:18|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0
"16","A-674563","AKT inhibitor","AKT1, PKIA, PRKACA",NA,NA,"Cc1[nH]nc2ccc(cc12)-c1cncc(OC[C@@H](N)Cc2ccccc2)c1, Cc1[nH]nc2ccc(cc12)-c1cncc(OC[C@@H](N)Cc2ccccc2)c1, Cc1[nH]nc2ccc(cc12)-c1cncc(OC[C@@H](N)Cc2ccccc2)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"17","A-784168","transient receptor potential channel antagonist","TRPV1",NA,NA,"FC(F)(F)c1cccnc1N1CCC(=CC1)C(=O)Nc1ccc(cc1)S(=O)(=O)C(F)(F)F |c:14|, FC(F)(F)c1cccnc1N1CCC(=CC1)C(=O)Nc1ccc(cc1)S(=O)(=O)C(F)(F)F |c:14|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"18","A-803467","sodium channel blocker","SCN10A",NA,NA,"COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1, COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1","Preclinical",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"19","A-804598","purinergic receptor antagonist","P2RX7",NA,NA,"C[C@H](N\C(NC#N)=N/c1cccc2ncccc12)c1ccccc1, C[C@H](\N=C(\NC#N)Nc1cccc2ncccc12)c1ccccc1, C[C@H](\N=C(\NC#N)Nc1cccc2ncccc12)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"20","A-839977","purinergic receptor antagonist","P2RX7",NA,NA,"Clc1cccc(c1Cl)-n1nnnc1NCc1ccccc1Oc1ccccn1, Clc1cccc(c1Cl)-n1nnnc1NCc1ccccc1Oc1ccccn1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"21","A-867744","acetylcholine receptor allosteric modulator","CHRNA3, CHRNA4, CHRNA7",NA,NA,"CCC(=O)c1cc(-c2ccc(Cl)cc2)n(c1C)-c1ccc(cc1)S(N)(=O)=O, CCC(=O)c1cc(-c2ccc(Cl)cc2)n(c1C)-c1ccc(cc1)S(N)(=O)=O, CCC(=O)c1cc(-c2ccc(Cl)cc2)n(c1C)-c1ccc(cc1)S(N)(=O)=O, CCC(=O)c1cc(-c2ccc(Cl)cc2)n(c1C)-c1ccc(cc1)S(N)(=O)=O, CCC(=O)c1cc(-c2ccc(Cl)cc2)n(c1C)-c1ccc(cc1)S(N)(=O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0
"22","A-887826","sodium channel blocker","SCN10A",NA,NA,"CCCCOc1ccc(cc1Cl)-c1cncc(c1)C(=O)NCc1cccnc1N1CCOCC1, CCCCOc1ccc(cc1Cl)-c1cncc(c1)C(=O)NCc1cccnc1N1CCOCC1","Preclinical",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"23","A-922500","diacylglycerol O acyltransferase inhibitor","DGAT1",NA,NA,"OC(=O)[C@@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1, OC(=O)[C@@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1, OC(=O)[C@@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"24","A-939572","stearoyl-CoA desaturase inhibitor","SCD",NA,NA,"CNC(=O)c1cccc(NC(=O)N2CCC(CC2)Oc2ccccc2Cl)c1, CNC(=O)c1cccc(NC(=O)N2CCC(CC2)Oc2ccccc2Cl)c1, CNC(=O)c1cccc(NC(=O)N2CCC(CC2)Oc2ccccc2Cl)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"25","A-967079","transient receptor potential channel antagonist","TRPA1",NA,NA,"CC\C(=N/O)\C(\C)=C\c1ccc(F)cc1, CC\C(=N/O)\C(\C)=C\c1ccc(F)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"26","A-987306","histamine receptor antagonist","ADORA1, AVPR1A, CCR1, CHRM1, CHRM2, CHRM3, CHRM4, DRD3, HTR1A, HTR1B, HTR2A, HTR2B, HTR3A, TACR2",NA,NA,"Nc1nc(N2CCNCC2)c2CCC3=C([C@@H]4CCCC[C@@H]4O3)c2n1 |t:14|, Nc1nc(N2CCNCC2)c2CCC3=C([C@@H]4CCCC[C@@H]4O3)c2n1 |t:14|","Preclinical",0,0,0,0,0,0,0,0,1,5,0,0,0,0,1,1,1,4,0,0,0,0,0,0
"27","AA-29504","GABA receptor positive allosteric modulator","GABRA1, GABRA4, GABRB3",NA,NA,"CCOC(=O)Nc1ccc(NCc2c(C)cc(C)cc2C)cc1N, CCOC(=O)Nc1ccc(NCc2c(C)cc(C)cc2C)cc1N, CCOC(=O)Nc1ccc(NCc2c(C)cc(C)cc2C)cc1N","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0
"28","ab-680","cd antagonist","NT5E","oncology","pancreatic cancer","C[C@H](Nc1cc(Cl)nc2c1cnn2[C@@H]3O[C@H](COP(=O)(O)CP(=O)(O)O)[C@@H](O)[C@H]3O)c4ccccc4F","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"29","abamectin","benzodiazepine receptor agonist","GABBR1, GABBR2","infectious disease","gastrointestinal parasites","[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@H](O[C@@]4([H])C[C@H](OC)[C@@H](O[C@@]5([H])C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@@]5(O[C@H](C(C)C)[C@@H](C)C=C5)O4)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O |c:4,54,t:6,37,64|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"30","abametapir","metalloproteinase inhibitor","MMP9",NA,NA,"Cc1ccc(nc1)-c1ccc(C)cn1, Cc1ccc(nc1)-c1ccc(C)cn1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"31","abarelix","gonadotropin releasing factor hormone receptor antagonist","GNRHR",NA,NA,"CC(C)C[C@H](NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"32","ABC-294640","sphingosine kinase inhibitor","SPHK2",NA,NA,"Clc1ccc(cc1)[C@]12C[C@H]3C[C@H](C[C@](C3)(C1)C(=O)NCc1ccncc1)C2 |&1:7,9,11,13|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"33","abemaciclib","CDK inhibitor","CDK4, CDK6","oncology","breast cancer","CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1, CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1, CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1, CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1, CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1, CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1, CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1, CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1, CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"34","abiraterone","androgen biosynthesis inhibitor","CYP11B1, CYP17A1","oncology","prostate cancer","C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c1cccnc1 |c:21,t:7|, C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c1cccnc1 |c:21,t:7|, C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c1cccnc1 |c:21,t:7|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"35","abiraterone-acetate","androgen biosynthesis inhibitor","CYP17A1","oncology","prostate cancer","CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1 |c:16,29|, CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1 |c:16,29|, CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1 |c:16,29|, CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1 |c:16,29|, CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1 |c:16,29|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"36","ABT-239","histamine receptor antagonist","HRH1, HRH2, HRH3",NA,NA,"C[C@@H]1CCCN1CCc1cc2cc(ccc2o1)-c1ccc(cc1)C#N","Phase 1",0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0
"37","abt-418 (hydrochloride)","nicotinic receptor agonist","CHRNA4, CHRNA7, HTR3A","neurology/psychiatry","alzheimer's disease","CN1CCC[C@H]1c1cc(C)no1.Cl |a:5|","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,2,0,0,1,1,1,1
"38","ABT-491","platelet activating factor receptor antagonist","PTAFR",NA,NA,"CN(C)C(=O)n1cc(C(=O)c2ccc(Cn3c(C)nc4cnccc34)c(F)c2)c2c(cccc12)C#C, CN(C)C(=O)n1cc(C(=O)c2ccc(Cn3c(C)nc4cnccc34)c(F)c2)c2c(cccc12)C#C, CN(C)C(=O)n1cc(C(=O)c2ccc(Cn3c(C)nc4cnccc34)c(F)c2)c2c(cccc12)C#C","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"39","ABT-639","calcium channel blocker","CACNA1G, CACNA1H, CACNA1I",NA,NA,"Fc1ccccc1NS(=O)(=O)c1cc(C(=O)N2CCN3CCC[C@@H]3C2)c(Cl)cc1F, Fc1ccccc1NS(=O)(=O)c1cc(C(=O)N2CCN3CCC[C@@H]3C2)c(Cl)cc1F, Fc1ccccc1NS(=O)(=O)c1cc(C(=O)N2CCN3CCC[C@@H]3C2)c(Cl)cc1F","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"40","ABT-702","adenosine kinase inhibitor","ADK",NA,NA,"Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1, Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"41","ABT-724","dopamine receptor agonist","DRD4",NA,NA,"C(N1CCN(CC1)c1ccccn1)c1nc2ccccc2[nH]1, C(N1CCN(CC1)c1ccccn1)c1nc2ccccc2[nH]1, C(N1CCN(CC1)c1ccccn1)c1nc2ccccc2[nH]1, C(N1CCN(CC1)c1ccccn1)c1nc2ccccc2[nH]1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0
"42","ABT-737","BCL inhibitor","BCL2, BCL2L1, BCL2L2",NA,NA,"CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"43","ABT-751","tubulin polymerization inhibitor","TUBB",NA,NA,"COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"44","ab928","adenosine receptor antagonist","ADORA2A, ADORA2B","oncology","non-small cell lung cancer (nsclc)","Cc1c(cccc1c2cc(nc(N)n2)c3cn(Cc4cccc(n4)C(C)(C)O)nn3)C#N","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"45","AC-186","estrogen receptor agonist","ESR2",NA,NA,"Oc1ccc(cc1)C1(CCC(F)(F)CC1)c1ccccc1F, Oc1ccc(cc1)C1(CCC(F)(F)CC1)c1ccccc1F, Oc1ccc(cc1)C1(CCC(F)(F)CC1)c1ccccc1F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"46","AC-261066","retinoid receptor agonist","RARB",NA,NA,"CCCCOCCOc1nc(sc1C)-c1ccc(C(O)=O)c(F)c1, CCCCOCCOc1nc(sc1C)-c1ccc(C(O)=O)c(F)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"47","AC-264613","PAR agonist","F2RL1",NA,NA,"C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1, C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1, C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1, C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"48","AC-55541","PARP inhibitor","PARP2",NA,NA,"C\C(=N/NC(=O)[C@@H](NC(=O)c1ccccc1)c1n[nH]c(=O)c2ccccc12)c1cccc(Br)c1 |&1:6,r|, C\C(=N/NC(=O)[C@@H](NC(=O)c1ccccc1)c1n[nH]c(=O)c2ccccc12)c1cccc(Br)c1 |&1:6,r|, C\C(=N/NC(=O)[C@@H](NC(=O)c1ccccc1)c1n[nH]c(=O)c2ccccc12)c1cccc(Br)c1 |&1:6,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"49","AC-55649","retinoid receptor agonist","RARA, RARB",NA,NA,"CCCCCCCCc1ccc(cc1)-c1ccc(cc1)C(O)=O, CCCCCCCCc1ccc(cc1)-c1ccc(cc1)C(O)=O, CCCCCCCCc1ccc(cc1)-c1ccc(cc1)C(O)=O, CCCCCCCCc1ccc(cc1)-c1ccc(cc1)C(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"50","AC-710","PDGFR tyrosine kinase receptor inhibitor","CSF1R, FLT3, KIT, PDGFRA, PDGFRB",NA,NA,"CCN1C(C)(C)CC(CC1(C)C)Oc1ccc(nc1)C(=O)Nc1ccc(NC(=O)Nc2cc(on2)C(C)(C)C)cc1, CCN1C(C)(C)CC(CC1(C)C)Oc1ccc(nc1)C(=O)Nc1ccc(NC(=O)Nc2cc(on2)C(C)(C)C)cc1, CCN1C(C)(C)CC(CC1(C)C)Oc1ccc(nc1)C(=O)Nc1ccc(NC(=O)Nc2cc(on2)C(C)(C)C)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"51","AC-7954-(+/-)","urotensin receptor agonist","UTS2R",NA,NA,"CN(C)CC[C@]1(Cc2ccccc2C(=O)O1)c1ccc(Cl)cc1 |&1:5|, CN(C)CC[C@]1(Cc2ccccc2C(=O)O1)c1ccc(Cl)cc1 |&1:5|, CN(C)CC[C@]1(Cc2ccccc2C(=O)O1)c1ccc(Cl)cc1 |&1:5|, CN(C)CC[C@]1(Cc2ccccc2C(=O)O1)c1ccc(Cl)cc1 |&1:5|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"52","acalabrutinib","Bruton's tyrosine kinase (BTK) inhibitor","BTK","hematologic malignancy","mantle cell lymphoma (MCL)","CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(cc2)C(=O)Nc2ccccn2)c2c(N)nccn12, CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(cc2)C(=O)Nc2ccccn2)c2c(N)nccn12, CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(cc2)C(=O)Nc2ccccn2)c2c(N)nccn12, CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(cc2)C(=O)Nc2ccccn2)c2c(N)nccn12, CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(cc2)C(=O)Nc2ccccn2)c2c(N)nccn12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"53","acalisib","PI3K inhibitor","PIK3CB, PIK3CD",NA,NA,"C[C@H](Nc1ncnc2nc[nH]c12)c1nc2ccc(F)cc2c(=O)n1-c1ccccc1, C[C@H](Nc1ncnc2nc[nH]c12)c1nc2ccc(F)cc2c(=O)n1-c1ccccc1, C[C@H](Nc1ncnc2nc[nH]c12)c1nc2ccc(F)cc2c(=O)n1-c1ccccc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"54","acamprosate","glutamate receptor antagonist","GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, GRM5","neurology/psychiatry","abstinence from alcohol","CC(=O)NCCCS(O)(=O)=O, CC(=O)NCCCS(O)(=O)=O, CC(=O)NCCCS(O)(=O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,1,16,0,0,0,0,0,0,1,1,1,1
"55","acarbose","glucosidase inhibitor","AMY2A, MGAM","endocrinology","diabetes mellitus","C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O |t:37|, C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O |t:37|, C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O |t:37|, C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O |t:37|, C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O |t:37|, C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O |t:37|, C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O |t:37|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"56","ACDPP","glutamate receptor antagonist","GRM5",NA,NA,"CN(C)c1nc(N)c(nc1Cl)C(=O)Nc1cccnc1, CN(C)c1nc(N)c(nc1Cl)C(=O)Nc1cccnc1, CN(C)c1nc(N)c(nc1Cl)C(=O)Nc1cccnc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"57","acebutolol","adrenergic receptor antagonist","ADRB1","cardiology","hypertension, ventricular arrhythmias","CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(c1)C(C)=O, CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(c1)C(C)=O, CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(c1)C(C)=O, CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(c1)C(C)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"58","acebutolol hydrochloride","adrenergic receptor antagonist","CES2","Cardiology","angina pectoris","CCCC(=O)Nc1ccc(OC[C@@H](O)CNC(C)C)c(c1)C(C)=O |&1:12,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"59","acecainide","polarization inhibitor","SCN5A",NA,NA,"CCN(CC)CCNC(=O)c1ccc(NC(C)=O)cc1, CCN(CC)CCNC(=O)c1ccc(NC(C)=O)cc1, CCN(CC)CCNC(=O)c1ccc(NC(C)=O)cc1, CCN(CC)CCNC(=O)c1ccc(NC(C)=O)cc1","Phase 3",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"60","aceclidine","acetylcholine receptor agonist","CHRM1, CHRM2, CHRM3, CHRM4, CHRM5","ophthalmology","glaucoma","CC(=O)O[C@H]1CN2CCC1CC2 |&1:4,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,5,0,0,1,1,1,1
"61","aceclofenac","prostanoid receptor antagonist","PTGS2","rheumatology","rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, periarthritis, lumbago, ischiadynia","OC(=O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl, OC(=O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl, OC(=O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl, OC(=O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl","Launched",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"62","acefylline","adenosine receptor agonist","ADORA1","pulmonary","asthma","Cn1c2ncn(CC(O)=O)c2c(=O)n(C)c1=O, Cn1c2ncn(CC(O)=O)c2c(=O)n(C)c1=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"63","acemetacin","cyclooxygenase inhibitor","PTGS1, PTGS2","rheumatology","osteoarthritis","COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(O)=O)c2c1","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"64","acenocoumarol","vitamin K antagonist","VKORC1","hematology","deep vein thrombosis (DVT)","CC(=O)C[C@@H](c1ccc(cc1)[N+]([O-])=O)c1c(O)c2ccccc2oc1=O |&1:4,r|, CC(=O)C[C@@H](c1ccc(cc1)[N+]([O-])=O)c1c(O)c2ccccc2oc1=O |&1:4,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"65","acepromazine","dopamine receptor antagonist","ADRA1A, ADRA1B, DRD1, DRD2, HTR1A, HTR2A","neurology/psychiatry","sedative","CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(C)=O, CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(C)=O, CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(C)=O","Launched",0,0,0,0,0,0,0,0,1,2,0,0,0,0,1,2,0,0,1,2,1,1,1,1
"66","acetazolamide","carbonic anhydrase inhibitor","AQP1, CA1, CA12, CA14, CA2, CA3, CA4, CA7","ophthalmology","glaucoma","CC(=O)Nc1nnc(s1)S(N)(=O)=O, CC(=O)Nc1nnc(s1)S(N)(=O)=O, CC(=O)Nc1nnc(s1)S(N)(=O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"67","acetohexamide","ATP channel blocker","ABCC8, KCNJ1, KCNJ10, KCNJ11","endocrinology","diabetes mellitus","CC(=O)c1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, CC(=O)c1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, CC(=O)c1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"68","acetohydroxamic-acid","urease inhibitor","MMP12","infectious disease","urinary tract infections","CC(=O)NO, CC(=O)NO","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"69","acetophenazine","dopamine receptor antagonist","DRD1, DRD2","neurology/psychiatry","psychosis","CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(CCO)CC3)c2c1, CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(CCO)CC3)c2c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,1,1,1,1
"70","acetyl-farnesyl-cysteine","methyltransferase inhibitor","PPARG","dermatology","acne vulgaris (AV)","CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC[C@H](NC(C)=O)C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC[C@H](NC(C)=O)C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC[C@H](NC(C)=O)C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC[C@H](NC(C)=O)C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC[C@H](NC(C)=O)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"71","acetyl-11-keto-beta-boswellic-acid","lipoxygenase inhibitor","HSD11B1, HSD11B2",NA,NA,"C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |a:1,4,8,15,19,24,29,34,35,&1:14,&2:26,c:10|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"72","acetylcholine","acetylcholine receptor agonist","ACHE, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA2","neurology/psychiatry, gastroenterology, pulmonary","drowsiness, fatigue, headache, indigestion, chest congestion","CC(=O)OCC[N+](C)(C)C, CC(=O)OCC[N+](C)(C)C, CC(=O)OCC[N+](C)(C)C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,6,0,0,1,1,1,1
"73","acetylcysteine","mucolytic agent","ACY1, CHUK, GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3A, GSS, IKBKB, RELA, SLC7A11","gastroenterology","acetaminophen overdose, hepatic injury","CC(=O)N[C@@H](CS)C(O)=O, CC(=O)N[C@@H](CS)C(O)=O, CC(=O)N[C@@H](CS)C(O)=O, CC(=O)N[C@@H](CS)C(O)=O","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"74","acexamic-acid","5 alpha reductase inhibitor","GAST","dermatology","wound healing","CC(=O)NCCCCCC(O)=O, CC(=O)NCCCCCC(O)=O, CC(=O)NCCCCCC(O)=O, CC(=O)NCCCCCC(O)=O, CC(=O)NCCCCCC(O)=O, CC(=O)NCCCCCC(O)=O, CC(=O)NCCCCCC(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"75","acifran","cholesterol inhibitor","HCAR2, HCAR3",NA,NA,"C[C@]1(OC(=CC1=O)C(O)=O)c1ccccc1 |&1:1,r,c:3|, C[C@]1(OC(=CC1=O)C(O)=O)c1ccccc1 |&1:1,r,c:3|, C[C@]1(OC(=CC1=O)C(O)=O)c1ccccc1 |&1:1,r,c:3|, C[C@]1(OC(=CC1=O)C(O)=O)c1ccccc1 |&1:1,r,c:3|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"76","acipimox","cholesterol inhibitor","HCAR2","endocrinology","hyperlipidemia","Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"77","acitretin","retinoid receptor agonist","RARA, RARB, RARG, RBP1, RXRA, RXRB, RXRG, STAT3","dermatology","psoriasis","COc1cc(C)c(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)c(C)c1C, COc1cc(C)c(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)c(C)c1C, COc1cc(C)c(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)c(C)c1C, COc1cc(C)c(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)c(C)c1C, COc1cc(C)c(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)c(C)c1C, COc1cc(C)c(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)c(C)c1C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"78","acivicin","gamma glutamyltransferase inhibitor","CTPS1",NA,NA,"N[C@H]([C@@H]1CC(Cl)=NO1)C(O)=O |c:5|, N[C@H]([C@@H]1CC(Cl)=NO1)C(O)=O |c:5|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"79","aclarubicin","topoisomerase inhibitor","TOP1, TOP2A","hematologic malignancy","acute myeloid leukemia (AML)","CC[C@@]1(O)C[C@H](O[C@H]2C[C@@H]([C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4CCC(=O)[C@H](C)O4)[C@H](C)O3)[C@H](C)O2)N(C)C)c2c(O)c3C(=O)c4c(O)cccc4C(=O)c3cc2[C@H]1C(=O)OC, CC[C@@]1(O)C[C@@H](O[C@H]2C[C@@H]([C@@H](O[C@H]3C[C@@H](O)[C@@H](O[C@H]4CCC(=O)[C@@H](C)O4)[C@@H](C)O3)[C@@H](C)O2)N(C)C)c2c(O)c3C(=O)c4c(O)cccc4C(=O)c3cc2[C@@H]1C(=O)OC |&1:2,&2:5,&3:7,&4:9,&5:10,&6:12,&7:14,&8:16,&9:18,&10:23,&11:26,&12:29,&13:53,r|, CC[C@@]1(O)C[C@H](O[C@H]2C[C@@H]([C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4CCC(=O)[C@H](C)O4)[C@H](C)O3)[C@H](C)O2)N(C)C)c2c(O)c3C(=O)c4c(O)cccc4C(=O)c3cc2[C@H]1C(=O)OC","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"80","aclidinium","acetylcholine receptor antagonist","CHRM1, CHRM2, CHRM3, CHRM4, CHRM5","pulmonary","bronchitis, emphysema, chronic obstructive pulmonary disease (COPD)","OC(C(=O)O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)(c1cccs1)c1cccs1, OC(C(=O)O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)(c1cccs1)c1cccs1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,5,0,0,1,1,1,1
"81","acotiamide","acetylcholinesterase inhibitor","ACHE, CHRM1, CHRM2","gastroenterology","dyspepsia","COc1cc(O)c(cc1OC)C(=O)Nc2nc(cs2)C(=O)NCCN(C(C)C)C(C)C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,1,1,1,1
"82","acriflavine","hypoxia inducible factor inhibitor","HIF1A","infectious disease","fungal infection","Nc1ccc2cc3ccc(N)cc3nc2c1.C[n+]1c2cc(N)ccc2cc2ccc(N)cc12, Nc1ccc2cc3ccc(N)cc3nc2c1.C[n+]1c2cc(N)ccc2cc2ccc(N)cc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"83","acriflavinium","hypoxia inducible factor inhibitor","HIF1A","infectious disease","fungal infection","C[n+]1c2cc(N)ccc2cc2ccc(N)cc12, C[n+]1c2cc(N)ccc2cc2ccc(N)cc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"84","acrivastine","histamine receptor antagonist","HRH1","allergy","allergic rhinitis","Cc1ccc(cc1)C(=C/CN1CCCC1)\c1cccc(\C=C\C(O)=O)n1, Cc1ccc(cc1)C(=C/CN1CCCC1)\c1cccc(\C=C\C(O)=O)n1, Cc1ccc(cc1)C(=C/CN1CCCC1)\c1cccc(\C=C\C(O)=O)n1, Cc1ccc(cc1)C(=C/CN1CCCC1)\c1cccc(\C=C\C(O)=O)n1, Cc1ccc(cc1)C(=C/CN1CCCC1)\c1cccc(\C=C\C(O)=O)n1","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"85","ACT-132577","endothelin receptor antagonist","EDNRA, EDNRB","pulmonary","pulmonary arterial hypertension (PAH)","NS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, NS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, NS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"86","ACT-462206","orexin receptor antagonist","HCRTR1, HCRTR2",NA,NA,"COc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1C(=O)Nc1cc(C)cc(C)c1, COc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1C(=O)Nc1cc(C)cc(C)c1, COc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1C(=O)Nc1cc(C)cc(C)c1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"87","act-709478","calcium channel blocker","CACNA1G","neurology/psychiatry","epilepsy","FC(F)(F)C1(CC1)c1ccc(CC(=O)Nc2ccn(Cc3ccc(cn3)C#N)n2)cc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"88","ACTB-1003","FGFR inhibitor, VEGFR inhibitor","KDR, TEK",NA,NA,"COCc1c(CN2CCOCC2)n2ncnc(N)c2c1-c1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)c(F)c1, COCc1c(CN2CCOCC2)n2ncnc(N)c2c1-c1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)c(F)c1, COCc1c(CN2CCOCC2)n2ncnc(N)c2c1-c1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)c(F)c1, COCc1c(CN2CCOCC2)n2ncnc(N)c2c1-c1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)c(F)c1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"89","ACY-1215","HDAC inhibitor","HDAC1, HDAC2, HDAC3, HDAC6, HDAC8",NA,NA,"ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1, ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1, ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1, ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1, ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1, ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"90","acyclovir","DNA polymerase inhibitor","PNP","infectious disease","genitial herpes, shingles, chicken pox","Nc1nc(=O)c2ncn(COCCO)c2[nH]1, Nc1nc(=O)c2ncn(COCCO)c2[nH]1, Nc1nc(=O)c2ncn(COCCO)c2[nH]1, Nc1nc(=O)c2ncn(COCCO)c2[nH]1, Nc1nc(=O)c2ncn(COCCO)c2[nH]1, Nc1nc(=O)c2ncn(COCCO)c2[nH]1, Nc1nc(=O)c2ncn(COCCO)c2[nH]1, Nc1nc(=O)c2ncn(COCCO)c2[nH]1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"91","AD-5467","aldose reductase inhibitor","AKR1B1",NA,NA,"CC(C)[C@H]1Oc2c(cccc2N(CC(O)=O)C1=S)C(C)C |&1:3,r|, CC(C)[C@H]1Oc2c(cccc2N(CC(O)=O)C1=S)C(C)C |&1:3,r|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"92","adapalene","retinoid receptor agonist","RARA, RARB, RARG, RXRA, RXRB, RXRG","dermatology","acne vulgaris (AV)","COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"93","adaprev","TGF beta receptor inhibitor","AKR1B1, GPI, HK1, M6PR, PYGM",NA,NA,"O[C@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O |a:3,10,12,14,&1:1|, O[C@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O |a:3,10,12,14,&1:1|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"94","adaptavir","CC chemokine receptor antagonist","CCR5",NA,NA,"C[C@@H](O)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](C)N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(N)=O, C[C@@H](O)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](C)N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(N)=O, C[C@@H](O)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](C)N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(N)=O, C[C@@H](O)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](C)N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(N)=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"95","adarotene","retinoid receptor agonist","RARB, RARG",NA,NA,"OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"96","adatanserin","serotonin receptor agonist, serotonin receptor antagonist","HTR1A, HTR2A",NA,NA,"O=C(NCCN1CCN(CC1)c1ncccn1)C12CC3CC(CC(C3)C1)C2, O=C(NCCN1CCN(CC1)c1ncccn1)C12CC3CC(CC(C3)C1)C2, O=C(NCCN1CCN(CC1)c1ncccn1)C12CC3CC(CC(C3)C1)C2, O=C(NCCN1CCN(CC1)c1ncccn1)C12CC3CC(CC(C3)C1)C2","Phase 2",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"97","adenine","protein synthesis stimulant","ACACB, ACP1, APRT, MTAP, PECR, SRPK2",NA,NA,"Nc1ncnc2nc[nH]c12, Nc1ncnc2nc[nH]c12, Nc1ncnc2nc[nH]c12, Nc1ncnc2nc[nH]c12, Nc1ncnc2nc[nH]c12, Nc1ncnc2nc[nH]c12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"98","adenosine","adenosine receptor agonist","ADORA1, ADORA2A, ADORA2B, ADORA3, PI4K2A, PI4K2B, TRPM4","cardiology","Wolff-Parkinson-White Syndrome (WPW)","Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"99","adenosine-phosphate","adenosine receptor agonist","ACSL1, ACSS1, ACSS2, ADCY1, ADK, CREB1, FBP1, HINT1, PDE4B, PDE4D, PIM1, PRKAA1, PRKAB1, PRKAB2, PYGL, TRPM4",NA,NA,"Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"100","adenosine-triphosphate","adenosine receptor agonist","ABCA1, ABCB1, ABCB11, ABCC2, ABCC8, ABCC9, ABCG1, ABL1, ABL2, ACSL1, ACSS1, ACSS2, ACVR1, ACVR1B, ACVRL1, ADCY1, ADRBK1, ADRBK2, AFG3L2, AKT1, ALK, AMHR2, APAF1, ARAF, ASNA1, ASNS, ASS1, CDK15, GPR17, ITPR1, NAE1, NT5C2, P2RY1, P2RY11, P2RY13, P2RY2, P2RY4, PRKAA1, RYR1, RYR2, RYR3, SLC25A4, TNK2, TRPM4, TRPM7",NA,NA,"Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O","Phase 2",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0
"101","adiphenine","acetylcholine receptor antagonist","CHRNA1","neurology/psychiatry","spasms","CCN(CC)CCOC(=O)C(c1ccccc1)c1ccccc1, CCN(CC)CCOC(=O)C(c1ccccc1)c1ccccc1, CCN(CC)CCOC(=O)C(c1ccccc1)c1ccccc1, CCN(CC)CCOC(=O)C(c1ccccc1)c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,1
"102","adipic-acid","solute carrier family member inhibitor","SLC22A6",NA,NA,"OC(=O)CCCCC(O)=O","Preclinical",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"103","adiporon","adiponectin receptor agonist","ADIPOR1, ADIPOR2",NA,NA,"O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1, O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1, O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1, O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1, O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"104","ADL5859","opioid receptor agonist","OPRD1",NA,NA,"CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"105","adoprazine","dopamine receptor antagonist, serotonin receptor agonist","DRD2, HTR1A",NA,NA,"Fc1ccc(cc1)-c1cncc(CN2CCN(CC2)c2cccc3OCCOc23)c1, Fc1ccc(cc1)-c1cncc(CN2CCN(CC2)c2cccc3OCCOc23)c1, Fc1ccc(cc1)-c1cncc(CN2CCN(CC2)c2cccc3OCCOc23)c1","Phase 2",0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0
"106","adrenalone","adrenergic receptor agonist","ADRA1A","hematology","hemorrhage","CNCC(=O)c1ccc(O)c(O)c1, CNCC(=O)c1ccc(O)c(O)c1, CNCC(=O)c1ccc(O)c(O)c1, CNCC(=O)c1ccc(O)c(O)c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"107","adrenosterone","11-beta hydroxysteroid dehydrogenase inhibitor","HSD11B1, HSD11B2",NA,NA,"C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O |t:9|, C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O |t:9|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"108","adriforant (hydrochloride)","histamine receptor antagonist","HRH4","dermatology","dermatitis","NC1=NC(N2C[C@H](NC)CC2)=CC(NCC3CC3)=N1.[H]Cl.[H]Cl.[H]Cl","Phase 2",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"109","ADX-10059","glutamate receptor negative allosteric modulator","GRM5",NA,NA,"Cc1cc(C)c(N)c(n1)C#Cc1cccc(F)c1, Cc1cc(C)c(N)c(n1)C#Cc1cccc(F)c1, Cc1cc(C)c(N)c(n1)C#Cc1cccc(F)c1, Cc1cc(C)c(N)c(n1)C#Cc1cccc(F)c1, Cc1cc(C)c(N)c(n1)C#Cc1cccc(F)c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"110","ADX-47273","glutamate receptor modulator","GRM5",NA,NA,"Fc1ccc(cc1)C(=O)N1CCC[C@@H](C1)c1nc(no1)-c1ccc(F)cc1, Fc1ccc(cc1)C(=O)N1CCC[C@@H](C1)c1nc(no1)-c1ccc(F)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"111","AEE788","EGFR inhibitor, VEGFR inhibitor","EGFR, ERBB2, ERBB4, FGFR2, FGFR3, KDR",NA,NA,"CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"112","afalanine","dopamine receptor agonist","DRD2",NA,NA,"CC(=O)N[C@@H](Cc1ccccc1)C(O)=O, CC(=O)N[C@@H](Cc1ccccc1)C(O)=O, CC(=O)N[C@@H](Cc1ccccc1)C(O)=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0
"113","afamelanotide","melatonin receptor agonist, melanocyte-stimulating hormone mimetic","MC1R, MC3R, MC4R, MC5R","dermatology","erythropoietic protoporphyria (epp)","CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(N)=O, CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(N)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"114","afatinib","EGFR inhibitor","EGFR, ERBB2, ERBB4","oncology","non-small cell lung cancer (NSCLC)","CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"115","afimoxifene","estrogen receptor antagonist","ESR1, ESR2, ESRRG, PLD1, PRKCD, PRKCE, PRKCQ, PRKCZ",NA,NA,"CC\C(=C(/c1ccc(O)cc1)c1ccc(OCCN(C)C)cc1)c1ccccc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"116","afoxolaner","gaba receptor antagonist","GABRA1","infectious disease","flea control","FC(F)(F)CNC(=O)CNC(=O)c1ccc(C2=NOC(C2)(c3cc(Cl)cc(c3)C(F)(F)F)C(F)(F)F)c4ccccc14","Launched",0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1
"117","AF38469","sortilin inhibitor","SORT1",NA,NA,"Cc1cccc(NC(=O)c2ccc(cc2C(O)=O)C(F)(F)F)n1, Cc1cccc(NC(=O)c2ccc(cc2C(O)=O)C(F)(F)F)n1, Cc1cccc(NC(=O)c2ccc(cc2C(O)=O)C(F)(F)F)n1, Cc1cccc(NC(=O)c2ccc(cc2C(O)=O)C(F)(F)F)n1, Cc1cccc(NC(=O)c2ccc(cc2C(O)=O)C(F)(F)F)n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"118","AG-1024","insulin growth factor receptor inhibitor","IGF1R",NA,NA,"CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O, CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"119","AG-14361","PARP inhibitor","PARP1",NA,NA,"CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"120","AG-490","EGFR inhibitor, JAK inhibitor","EGFR, JAK2, JAK3",NA,NA,"Oc1ccc(\C=C(/C#N)C(=O)NCc2ccccc2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)NCc2ccccc2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)NCc2ccccc2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)NCc2ccccc2)cc1O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"121","AG-555","tyrosine kinase inhibitor","CDK2",NA,NA,"Oc1ccc(\C=C(/C#N)C(=O)NCCCc2ccccc2)cc1O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"122","AGI-5198","isocitrate dehydrogenase inhibitor","IDH1",NA,NA,"Cc1nccn1CC(=O)N([C@@H](C(=O)NC1CCCCC1)c1ccccc1C)c1cccc(F)c1 |&1:10,r|, Cc1nccn1CC(=O)N([C@@H](C(=O)NC1CCCCC1)c1ccccc1C)c1cccc(F)c1 |&1:10,r|, Cc1nccn1CC(=O)N([C@@H](C(=O)NC1CCCCC1)c1ccccc1C)c1cccc(F)c1 |&1:10,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"123","AGI-6780","isocitrate dehydrogenase inhibitor","IDH2",NA,NA,"FC(F)(F)c1cccc(NC(=O)Nc2cc(ccc2-c2ccsc2)S(=O)(=O)NC2CC2)c1, FC(F)(F)c1cccc(NC(=O)Nc2cc(ccc2-c2ccsc2)S(=O)(=O)NC2CC2)c1, FC(F)(F)c1cccc(NC(=O)Nc2cc(ccc2-c2ccsc2)S(=O)(=O)NC2CC2)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"124","AGM-1470","cell cycle inhibitor","METAP2",NA,NA,"CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)NC(=O)CCl |a:2,3,6,10,13,&1:9|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"125","agmatine","nitric oxide synthase inhibitor","ADRA2C, ASIC3, CACNA1B, CHRNA1, GRIN1, KCNJ1, NISCH",NA,NA,"NCCCCNC(N)=N, NCCCCNC(N)=N, NCCCCNC(N)=N","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0
"126","AGN-192403","imidazoline receptor ligand","NISCH",NA,NA,"CC(C)[C@@H]1[C@H]2CC[C@@H](C2)[C@H]1N |a:3,9,&1:4,&2:7|, CC(C)[C@@H]1[C@H]2CC[C@@H](C2)[C@H]1N |a:3,9,&1:4,&2:7|, CC(C)[C@@H]1[C@H]2CC[C@@H](C2)[C@H]1N |a:3,9,&1:4,&2:7|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"127","AGN-194310","retinoid receptor antagonist","RXRA, RXRB, RXRG",NA,NA,"CCc1ccc(cc1)C1=CC(C)(C)Sc2ccc(cc12)C#Cc1ccc(cc1)C(O)=O |t:9|, CCc1ccc(cc1)C1=CC(C)(C)Sc2ccc(cc12)C#Cc1ccc(cc1)C(O)=O |t:9|, CCc1ccc(cc1)C1=CC(C)(C)Sc2ccc(cc12)C#Cc1ccc(cc1)C(O)=O |t:9|, CCc1ccc(cc1)C1=CC(C)(C)Sc2ccc(cc12)C#Cc1ccc(cc1)C(O)=O |t:9|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"128","AGN-195183","retinoid receptor agonist","RARA",NA,NA,"CC1(C)CCC(C)(C)c2c(Cl)c(O)c(cc12)C(=O)Nc1cc(F)c(C(O)=O)c(F)c1, CC1(C)CCC(C)(C)c2c(Cl)c(O)c(cc12)C(=O)Nc1cc(F)c(C(O)=O)c(F)c1","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"129","agomelatine","melatonin receptor agonist, serotonin receptor antagonist","HTR2A, HTR2B, HTR2C, MTNR1A, MTNR1B","neurology/psychiatry","depression","COc1ccc2cccc(CCNC(C)=O)c2c1, COc1ccc2cccc(CCNC(C)=O)c2c1, COc1ccc2cccc(CCNC(C)=O)c2c1","Launched",0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"130","AH-7614","free fatty acid receptor antagonist","FFAR4",NA,NA,"Cc1ccc(cc1)S(=O)(=O)NC1c2ccccc2Oc2ccccc12, Cc1ccc(cc1)S(=O)(=O)NC1c2ccccc2Oc2ccccc12, Cc1ccc(cc1)S(=O)(=O)NC1c2ccccc2Oc2ccccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"131","AH11110","adrenergic receptor ligand","ADRA1B",NA,NA,"O[C@@H](COc1ccccc1-c1ccccc1)CC(=N)N1CCCCC1 |&1:1|, O[C@@H](COc1ccccc1-c1ccccc1)CC(=N)N1CCCCC1 |&1:1|, O[C@@H](COc1ccccc1-c1ccccc1)CC(=N)N1CCCCC1 |&1:1|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
"132","AH6809","prostanoid receptor antagonist","PTGDR, PTGER1, PTGER2, PTGER3",NA,NA,"CC(C)Oc1ccc2c(c1)oc1ccc(cc1c2=O)C(O)=O, CC(C)Oc1ccc2c(c1)oc1ccc(cc1c2=O)C(O)=O, CC(C)Oc1ccc2c(c1)oc1ccc(cc1c2=O)C(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"133","AI-10-49","core binding factor inhibitor","CBFB",NA,NA,"FC(F)(F)Oc1ccc2nc([nH]c2c1)-c1ccc(OCCOCCOc2ccc(nc2)-c2nc3ccc(OC(F)(F)F)cc3[nH]2)cn1, FC(F)(F)Oc1ccc2nc([nH]c2c1)-c1ccc(OCCOCCOc2ccc(nc2)-c2nc3ccc(OC(F)(F)F)cc3[nH]2)cn1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"134","AIM-100","tyrosine kinase inhibitor","TNK2",NA,NA,"C(Nc1ncnc2oc(c(-c3ccccc3)c12)-c1ccccc1)[C@@H]1CCCO1, C(Nc1ncnc2oc(c(-c3ccccc3)c12)-c1ccccc1)[C@@H]1CCCO1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"135","ajmaline","sodium channel blocker","KCNH2, KCNQ1","cardiology, Tachycardias, cardiology, Tachycardias","wolff-parkinson-white syndrome (wpw), atrial fibrillation (af), Wolff-Parkinson-White Syndrome (WPW), atrial fibrillation (af)","[H][C@]12C[C@]34[C@H](O)[C@@]1([H])[C@]1([H])C[C@]([H])(N2[C@H](O)[C@@]1([H])CC)[C@]3([H])N(C)c1ccccc41, [H][C@]12C[C@]34[C@H](O)[C@@]1([H])[C@]1([H])C[C@]([H])(N2[C@H](O)[C@@]1([H])CC)[C@]3([H])N(C)c1ccccc41, CC[C@H]1C2CC3[C@@H]4N(C)c5ccccc5[C@]44C[C@@H](C2C4O)N3[C@@H]1O, CC[C@H]1C2CC3[C@@H]4N(C)c5ccccc5[C@]44C[C@@H](C2C4O)N3[C@@H]1O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"136","AJ76-(+)","dopamine receptor antagonist","DRD2, DRD3, DRD4",NA,NA,"CCCN[C@@H]1CCc2c(OC)cccc2[C@@H]1C, CCCN[C@@H]1CCc2c(OC)cccc2[C@@H]1C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0
"137","AK-7","SIRT inhibitor","SIRT2",NA,NA,"Brc1cccc(NC(=O)c2cccc(c2)S(=O)(=O)N2CCCCCC2)c1, Brc1cccc(NC(=O)c2cccc(c2)S(=O)(=O)N2CCCCCC2)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"138","AKBA","lipoxygenase inhibitor","ALOX5",NA,NA,"C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |c:10|, C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |c:10|, C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |c:10|, C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |c:10|, C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |c:10|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"139","AL-8697","p38 MAPK inhibitor","MAPK14",NA,NA,"Cc1c(F)cc(cc1-c1c(F)cn2c(nnc2c1F)C(C)(C)C)C(=O)NC1CC1, Cc1c(F)cc(cc1-c1c(F)cn2c(nnc2c1F)C(C)(C)C)C(=O)NC1CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"140","alacepril","angiotensin converting enzyme inhibitor","ACE","cardiology","hypertension","C[C@H](CSC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O, C[C@H](CSC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O, C[C@H](CSC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O, C[C@H](CSC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"141","alantolactone","apoptosis stimulant, STAT inhibitor","STAT3",NA,NA,"C[C@H]1CCC[C@]2(C)C[C@H]3OC(=O)C(=C)[C@H]3C=C12 |t:16|, C[C@H]1CCC[C@]2(C)C[C@H]3OC(=O)C(=C)[C@H]3C=C12 |t:16|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"142","alaproclate","serotonin receptor antagonist","SLC6A4",NA,NA,"C[C@@H](N)C(=O)OC(C)(C)Cc1ccc(Cl)cc1 |&1:1|, C[C@@H](N)C(=O)OC(C)(C)Cc1ccc(Cl)cc1 |&1:1|","Phase 2",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"143","alarelin","gonadotropin releasing factor hormone receptor antagonist","GNRH1",NA,NA,"CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1, CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"144","albendazole","tubulin polymerization inhibitor","TUBA1A, TUBB, TUBB4B","infectious disease","cystic hydatid disease, parenchymal neurocysticercosis","CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"145","albuterol","adrenergic receptor agonist","ADRB2","pulmonary","asthma","CC(C)(C)NC[C@@H](O)c1ccc(O)c(CO)c1 |&1:6|, CC(C)(C)NC[C@@H](O)c1ccc(O)c(CO)c1 |&1:6|, CC(C)(C)NC[C@@H](O)c1ccc(O)c(CO)c1 |&1:6|, CC(C)(C)NCC(O)c1ccc(O)c(CO)c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"146","alcaftadine","histamine receptor antagonist","HRH1","allergy","allergic conjunctivitis","CN1CCC(CC1)=C1c2ncc(C=O)n2CCc2ccccc12, CN1CCC(CC1)=C1c2ncc(C=O)n2CCc2ccccc12","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"147","alclofenac","cyclooxygenase inhibitor","PTGS1","rheumatology","rheumatoid arthritis","OC(=O)Cc1ccc(OCC=C)c(Cl)c1, OC(=O)Cc1ccc(OCC=C)c(Cl)c1","Launched",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"148","alclometasone dipropionate","glucocorticoid receptor agonist","NR3C1","Dermatology","corticosteroid-responsive dermatoses","[H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])[C@H](Cl)CC2=CC(=O)C=C[C@]12C |c:37,t:33|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"149","alclometasone-dipropionate","glucocorticoid receptor agonist","CYP3A4, NR3C1, SERPINA6","dermatology","corticosteroid-responsive dermatoses","CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@H]2[C@H]3[C@H](Cl)CC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |a:14,17,19,28,30,31,34,&1:8,&2:18,c:26,t:22|, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@H]2[C@H]3[C@H](Cl)CC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |a:14,17,19,28,30,31,34,&1:8,&2:18,c:26,t:22|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"150","alcuronium","muscle relaxant","CHRM1, CHRM2, CHRM3, CHRM4, CHRNA7","neurology/psychiatry","muscle relaxant","OC\C=C1/C[N@+]2(CC=C)CC[C@@]34[C@@H]2C[C@@H]1\C1=C\N2[C@@H]5\C(=C/N([C@@H]31)c1ccccc41)[C@H]1C[C@H]3[C@@]5(CC[N@@+]3(CC=C)C\C1=C/CO)c1ccccc21 |a:5,11,12,14,29,31,32,35,&1:18,&2:22,c:21,t:17,TLB:2:3:13:11.15.22,20:19:30:35.39.40,10:11:3.4.5:13,41:40:30:18.19.32,28:11:3.4.5:13,THB:34:35:30:18.19.32,16:15:3.4.5:13,33:32:30:35.39.40,36:35:30:18.19.32,6:5:13:11.15.22,9:5:13:11.15.22,44:32:30:35.39.40|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,5,0,0,1,1,1,1
"151","alda-1","aldehyde dehydrogenase activator","ALDH2",NA,NA,"Clc1cccc(Cl)c1C(=O)NCc1ccc2OCOc2c1, Clc1cccc(Cl)c1C(=O)NCc1ccc2OCOc2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"152","aldose reductase-in-1","aldose reductase inhibitor","AKR1B1","cardiology","cardiomyopathy","OC(=O)CC1=NN(Cc2nc3cc(ccc3s2)C(F)(F)F)C(=O)c4nccnc14","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"153","aldoxorubicin","topoisomerase inhibitor","TOP2A",NA,NA,"COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(\CO)=N\NC(=O)CCCCCN1C(=O)C=CC1=O |c:55|, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(\CO)=N\NC(=O)CCCCCN1C(=O)C=CC1=O |c:55|, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(\CO)=N\NC(=O)CCCCCN1C(=O)C=CC1=O |c:55|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"154","alectinib","ALK tyrosine kinase receptor inhibitor","ALK, MET","oncology","non-small cell lung cancer (NSCLC)","CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"155","aleglitazar","ppar receptor agonist","PPARA, PPARG","endocrinology","diabetes mellitus","CC1=C(CCOC2=CC=C(C[C@@H](C(O)=O)OC)C3=C2C=CS3)N=C(C4=CC=CC=C4)O1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"156","alendronate","bone resorption inhibitor","ATP6V1A, FDPS, PTPN4, PTPRE, PTPRS","orthopedics","osteoporosis","NCCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCCC(O)(P(O)(O)=O)P(O)(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"157","alexidine","phosphatidylglycerophosphatase inhibitor","PTPMT1",NA,NA,"CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29,&2:4,&3:11,&4:24,w:11.10,24.24|, CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29,&2:4,&3:11,&4:24,w:11.10,24.24|, CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29,&2:4,&3:11,&4:24,w:11.10,24.24|, CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29,&2:4,&3:11,&4:24,w:11.10,24.24|, CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29,&2:4,&3:11,&4:24,w:11.10,24.24|, CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29,&2:4,&3:11,&4:24,w:11.10,24.24|, CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29,&2:4,&3:11,&4:24,w:11.10,24.24|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"158","alfacalcidol","vitamin D receptor agonist","CYP27B1, VDR","endocrinology","vitamin D deficiency","CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"159","alflutinib","protein tyrosine kinase inhibitor","EGFR","oncology","non-small cell lung cancer (nsclc)","CN(C)CCN(C)c1nc(OCC(F)(F)F)c(Nc2nccc(n2)c3cn(C)c4ccccc34)cc1NC(=O)C=C","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"160","alfuzosin","adrenergic receptor antagonist","ADRA1A, ADRA1B, ADRA1D, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A","urology","benign prostatic hyperplasia (BPH)","COc1cc2nc(nc(N)c2cc1OC)N(C)CCCNC(=O)[C@H]1CCCO1 |&1:23|, COc1cc2nc(nc(N)c2cc1OC)N(C)CCCNC(=O)[C@H]1CCCO1 |&1:23|, COc1cc2nc(nc(N)c2cc1OC)N(C)CCCNC(=O)[C@H]1CCCO1 |&1:23|","Launched",0,0,1,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,1,1,1,1
"161","alicapistat","calpain inhibitor","CAPN1, CAPN2","neurology/psychiatry","alzheimer's disease","O=C(N[C@H](Cc1ccccc1)C(=O)C(=O)NC1CC1)[C@H]1CCC(=O)N1Cc1ccccc1 |&1:3|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"162","alimemazine","histamine receptor agonist, histamine receptor antagonist","HRH1","neurology/psychiatry, allergy, pulmonary","sedative, urticaria, itching, cough suppressant","C[C@@H](CN(C)C)CN1c2ccccc2Sc2ccccc12 |&3:1|, C[C@@H](CN(C)C)CN1c2ccccc2Sc2ccccc12 |&3:1|, C[C@@H](CN(C)C)CN1c2ccccc2Sc2ccccc12 |&3:1|","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"163","alisertib","Aurora kinase inhibitor","AURKA",NA,NA,"COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"164","aliskiren-hemifumarate","renin inhibitor","REN","cardiology","hypertension","COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC, COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC, COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC, COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC, COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC, COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"165","alk2-in-1","alk inihibitor","ALK","oncology","glioma","CCOC1(CCN(CC1)C(C)C)c1ccc(nc1)-c1cc2c(ccnn2c1)N1CCN(CC1)C(=O)O[C@@H]1CCOC1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"166","allicin","cytokine production inhibitor","TRPA1, TRPV1",NA,NA,"C=CCS[S@@](=O)CC=C |&1:4,r|, C=CCS[S@@](=O)CC=C |&1:4,r|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"167","allopurinol","xanthine oxidase inhibitor","XDH","rheumatology, urology","gout, kidney stones","O=c1nc[nH]c2n[nH]cc12, O=c1nc[nH]c2n[nH]cc12, O=c1nc[nH]c2n[nH]cc12, O=c1nc[nH]c2n[nH]cc12, O=c1nc[nH]c2n[nH]cc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"168","allylestrenol","steroidal progestin","ESR1, PGR, SLC6A9","obstetrics/gynecology","premature labor","C[C@]12CC[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)CC=C |t:8|","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"169","allylisothiocyanate","TRPV agonist","TRPA1",NA,NA,"C=CCN=C=S, C=CCN=C=S","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"170","alminoprofen","cyclooxygenase inhibitor","PTGS1, PTGS2","cardiology","edema","CC(C(=O)O)c1ccc(NCC(=C)C)cc1","Preclinical",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"171","almitrine","neurotransmitter agonist","ATP1A1","pulmonary","chronic obstructive pulmonary disease (COPD)","Fc1ccc(cc1)C(N1CCN(CC1)c1nc(NCC=C)nc(NCC=C)n1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(CC1)c1nc(NCC=C)nc(NCC=C)n1)c1ccc(F)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"172","almonertinib","egfr inhibitor","EGFR","oncology","non-small cell lung cancer (nsclc)","COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2nccc(n2)c3cn(C4CC4)c5ccccc35","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"173","almorexant","orexin receptor antagonist","HCRTR1, HCRTR2",NA,NA,"CNC(=O)[C@H](N1CCc2cc(OC)c(OC)cc2[C@@H]1CCc1ccc(cc1)C(F)(F)F)c1ccccc1, CNC(=O)[C@H](N1CCc2cc(OC)c(OC)cc2[C@@H]1CCc1ccc(cc1)C(F)(F)F)c1ccccc1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"174","almotriptan","serotonin receptor agonist","HTR1B, HTR1D","neurology/psychiatry","migraine headache","CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12, CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12, CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12","Launched",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"175","aloe-emodin","anticancer agent","CASP8",NA,NA,"OCc1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"176","alofanib","fgfr inhibitor","FGFR2","oncology","ovarian cancer","Cc1cc(c(NS(=O)(=O)c2cccc(c2)C(O)=O)cc1-c1cccnc1)[N+]([O-])=O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"177","alogliptin","dipeptidyl peptidase inhibitor","DPP4","endocrinology","diabetes mellitus","Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"178","alosetron","serotonin receptor antagonist","HTR3A",NA,NA,"Cc1nc[nH]c1CN1CCc2c(C1=O)c1ccccc1n2C, Cc1nc[nH]c1CN1CCc2c(C1=O)c1ccccc1n2C, Cc1nc[nH]c1CN1CCc2c(C1=O)c1ccccc1n2C","Withdrawn",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"179","aloxistatin","protease inhibitor","CTSG",NA,NA,"CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"180","alpelisib","PI3K inhibitor","PIK3CA, PIK3CB, PIK3CD, PIK3CG","oncology","breast cancer","Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F, Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F, Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F, Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F, Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F, Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F, Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"181","alpha-asarone","cytochrome P450 inhibitor, HMGCR inhibitor","HMGCR",NA,NA,"COc1cc(OC)c(\C=C\C)cc1OC","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"182","alpha-linolenic-acid","omega 3 fatty acid stimulant","ELOVL4, FADS1, FADS2, FFAR1, FFAR4, PTGS2, SLC8A1, TRPV1",NA,NA,"CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O, CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O, CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O, CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O, CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O","Phase 3",1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"183","alpha-methylhistamine-dihydrobromide-(R)-(-)","histamine receptor agonist","HRH3",NA,NA,"C[C@@H](N)Cc1cnc[nH]1, C[C@@H](N)Cc1cnc[nH]1","Preclinical",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
"184","alpha-methylhistamine-dihydrobromide-(S)-(+)","histamine receptor agonist","HRH3",NA,NA,"C[C@H](N)Cc1cnc[nH]1, C[C@H](N)Cc1cnc[nH]1","Preclinical",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
"185","alpha-methylserotonin","serotonin receptor agonist","HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR4",NA,NA,"C[C@@H](N)Cc1c[nH]c2ccc(O)cc12 |&1:1|","Preclinical",0,0,0,0,0,0,0,0,1,7,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"186","alpidem","benzodiazepine receptor agonist","GABRA1",NA,NA,"CCCN(CCC)C(=O)Cc1c(nc2ccc(Cl)cn12)-c1ccc(Cl)cc1, CCCN(CCC)C(=O)Cc1c(nc2ccc(Cl)cn12)-c1ccc(Cl)cc1, CCCN(CCC)C(=O)Cc1c(nc2ccc(Cl)cn12)-c1ccc(Cl)cc1","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0
"187","alprenolol","adrenergic receptor antagonist","ADRB1, ADRB2","cardiology","angina pectoris","CC(C)NCC(O)COc1ccccc1CC=C, CC(C)NC[C@@H](O)COc1ccccc1CC=C |&1:5,r|, CC(C)NC[C@@H](O)COc1ccccc1CC=C |&1:5,r|, CC(C)NC[C@@H](O)COc1ccccc1CC=C |&1:5,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,1,1,1,1
"188","alprostadil","prostanoid receptor agonist","CATSPER1, CATSPER2, CATSPER3, CATSPER4, PTGDR, PTGER1, PTGER2, PTGER4, PTGIR","cardiology","congenital heart defects","CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"189","alrestatin","aldose reductase inhibitor","AKR1B1",NA,NA,"OC(=O)CN1C(=O)c2cccc3cccc(C1=O)c23, OC(=O)CN1C(=O)c2cccc3cccc(C1=O)c23, OC(=O)CN1C(=O)c2cccc3cccc(C1=O)c23","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"190","altanserin","serotonin receptor antagonist","HTR2A",NA,NA,"Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1","Phase 2",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"191","altinicline","nicotinic receptor agonist","CHRNA4, CHRNB2",NA,NA,"CN1CCC[C@H]1c1cncc(c1)C#C, CN1CCC[C@H]1c1cncc(c1)C#C","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0
"192","altiratinib","MET inhibitor, VEGFR inhibitor","KDR, MET, TEK",NA,NA,"Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1, Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1, Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1, Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1, Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1, Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1, Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1, Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"193","altrenogest","progestogen hormone","PGR","endocrinology","estrus","C[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@]2(O)CC=C, C[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC=C |c:2,4,10|, C[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC=C |c:2,4,10|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"194","alverine","muscle relaxant","HTR1A","gastroenterology","irritable bowel syndrome, diverticular disease","CCN(CCCc1ccccc1)CCCc1ccccc1, CCN(CCCc1ccccc1)CCCc1ccccc1, CCN(CCCc1ccccc1)CCCc1ccccc1","Launched",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"195","alvespimycin","HSP inhibitor","HSP90AA1",NA,NA,"CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"196","alvimopan","opioid receptor antagonist","OPRD1, OPRK1, OPRM1","gastroenterology","postoperative ileus","C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(O)=O)CC[C@@]1(C)c1cccc(O)c1, C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(O)=O)CC[C@@]1(C)c1cccc(O)c1, C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(O)=O)CC[C@@]1(C)c1cccc(O)c1, C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(O)=O)CC[C@@]1(C)c1cccc(O)c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"197","alvocidib","CDK inhibitor","CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM",NA,NA,"CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"198","ALX-5407","glycine transporter inhibitor","SLC6A9",NA,NA,"CN(CC[C@@H](Oc1ccc(cc1)-c1ccccc1)c1ccc(F)cc1)CC(O)=O, CN(CC[C@@H](Oc1ccc(cc1)-c1ccccc1)c1ccc(F)cc1)CC(O)=O, CN(CC[C@@H](Oc1ccc(cc1)-c1ccccc1)c1ccc(F)cc1)CC(O)=O","Phase 1",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"199","AM-1241","cannabinoid receptor agonist","CNR1, CNR2",NA,NA,"CN1CCCC[C@@H]1Cn1cc(C(=O)c2cc(ccc2I)[N+]([O-])=O)c2ccccc12 |&1:6,r|, CN1CCCC[C@@H]1Cn1cc(C(=O)c2cc(ccc2I)[N+]([O-])=O)c2ccccc12 |&1:6,r|, CN1CCCC[C@@H]1Cn1cc(C(=O)c2cc(ccc2I)[N+]([O-])=O)c2ccccc12 |&1:6,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"200","AM-24","lipoxygenase inhibitor","ALOX5",NA,NA,"Oc1c(I)cc(I)cc1I, Oc1c(I)cc(I)cc1I, Oc1c(I)cc(I)cc1I","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"201","AM-251","cannabinoid receptor antagonist","CNR1, GPR18, GPR55",NA,NA,"Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"202","AM-281","cannabinoid receptor antagonist","CNR1, CNR2, GPR55",NA,NA,"Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCOCC1, Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCOCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"203","AM-404","cyclooxygenase inhibitor, FAAH inhibitor, TRPV antagonist","CNR1, CNR2, FAAH, TRPV1",NA,NA,"CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"204","AM-580","retinoid receptor agonist","RARA",NA,NA,"CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"205","AM-630","cannabinoid receptor antagonist","CNR1, CNR2",NA,NA,"COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12, COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12, COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12, COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12, COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12, COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"206","AM-92016","potassium channel blocker","GRIN1",NA,NA,"CN(CCc1ccc(Cl)c(Cl)c1)C[C@@H](O)COc1ccc(NS(C)(=O)=O)cc1 |&1:13|, CN(CCc1ccc(Cl)c(Cl)c1)C[C@@H](O)COc1ccc(NS(C)(=O)=O)cc1 |&1:13|, CN(CCc1ccc(Cl)c(Cl)c1)C[C@@H](O)COc1ccc(NS(C)(=O)=O)cc1 |&1:13|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"207","amantadine","glutamate receptor antagonist","DRD2, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A","infectious disease, neurology/psychiatry","influenza A virus infection, Parkinson's Disease","NC12CC3CC(CC(C3)C1)C2, NC12CC3CC(CC(C3)C1)C2, NC12CC3CC(CC(C3)C1)C2, NC12CC3CC(CC(C3)C1)C2","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1
"208","ambenonium","cholinesterase inhibitor","ACHE","neurology/psychiatry","myasthenia gravis","CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl, CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl, CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl, CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"209","ambrisentan","endothelin receptor antagonist","EDNRA, EDNRB","pulmonary","pulmonary arterial hypertension (PAH)","COC([C@H](Oc1nc(C)cc(C)n1)C(O)=O)(c1ccccc1)c1ccccc1, COC([C@H](Oc1nc(C)cc(C)n1)C(O)=O)(c1ccccc1)c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"210","ambroxol","sodium channel blocker","CYP3A4","pulmonary","bronchitis","Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 |r|, Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 |r|, Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 |r|, Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 |r|, Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 |r|, Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 |r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"211","amcinonide","glucocorticoid receptor agonist","NR3C1","Dermatology, dermatology","dermatitis, corticosteroid-responsive dermatoses","CC(=O)OCC(=O)[C@@]12OC3(CCCC3)O[C@@H]1C[C@H]1[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |a:7,15,27,29,31,34,&1:17,&2:18,c:27,t:23|, CC(=O)OCC(=O)[C@@]12OC3(CCCC3)O[C@@H]1C[C@H]1[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |a:7,15,27,29,31,34,&1:17,&2:18,c:27,t:23|, CC(=O)OCC(=O)[C@@]12OC3(CCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |c:27,t:23|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"212","AMD-3465","CC chemokine receptor antagonist","CXCR4",NA,NA,"C(NCc1ccccn1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(NCc1ccccn1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(NCc1ccccn1)c1ccc(CN2CCCNCCNCCCNCC2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"213","AMD11070","CC chemokine receptor antagonist","CCR5, CXCR4",NA,NA,"NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc12, NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc12, NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc12","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"214","amezinium","adrenergic receptor agonist","ADRB2","cardiology","hypotension","COc1cc(N)cn[n+]1-c1ccccc1, COc1cc(N)cn[n+]1-c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"215","amfenac","cyclooxygenase inhibitor","PTGS1, PTGS2","neurology/psychiatry","pain relief","Nc1c(CC(O)=O)cccc1C(=O)c1ccccc1, Nc1c(CC(O)=O)cccc1C(=O)c1ccccc1","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"216","amflutizole","xanthine oxidase inhibitor","XDH",NA,NA,"Nc1c(snc1-c1cccc(c1)C(F)(F)F)C(O)=O, Nc1c(snc1-c1cccc(c1)C(F)(F)F)C(O)=O, Nc1c(snc1-c1cccc(c1)C(F)(F)F)C(O)=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"217","amg 333","transient receptor potential channel antagonist","TRPM8","neurology/psychiatry","migraine headache","OC(=O)c1ccc(nc1)C(=O)N[C@@H](c1ccc(OC(F)(F)F)c(F)c1)c1ncccc1F |a:12|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"218","AMG-PERK-44","PERK inhibitor","EIF2AK4",NA,NA,"Cc1ccc2cc(ccc2n1)-c1c(C)ccc(C(=O)c2c(-c3ccccc3)n(C)n(-c3ccccc3)c2=O)c1N, Cc1ccc2cc(ccc2n1)-c1c(C)ccc(C(=O)c2c(-c3ccccc3)n(C)n(-c3ccccc3)c2=O)c1N, Cc1ccc2cc(ccc2n1)-c1c(C)ccc(C(=O)c2c(-c3ccccc3)n(C)n(-c3ccccc3)c2=O)c1N","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"219","AMG-208","tyrosine kinase inhibitor","MET",NA,NA,"COc1ccc2c(OCc3nnc4ccc(nn34)-c3ccccc3)ccnc2c1, COc1ccc2c(OCc3nnc4ccc(nn34)-c3ccccc3)ccnc2c1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"220","AMG-232","MDM inhibitor","MDM2",NA,NA,"CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"221","AMG-319","PI3K inhibitor","PIK3CD",NA,NA,"C[C@H](Nc1ncnc2nc[nH]c12)c1cc2ccc(F)cc2nc1-c1ccccn1, C[C@H](Nc1ncnc2nc[nH]c12)c1cc2ccc(F)cc2nc1-c1ccccn1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"222","AMG-337","MET inhibitor","MET",NA,NA,"COCCOc1cnc2ccn([C@H](C)c3nnc4c(F)cc(cn34)-c3cnn(C)c3)c(=O)c2c1, COCCOc1cnc2ccn([C@H](C)c3nnc4c(F)cc(cn34)-c3cnn(C)c3)c(=O)c2c1, COCCOc1cnc2ccn([C@H](C)c3nnc4c(F)cc(cn34)-c3cnn(C)c3)c(=O)c2c1, COCCOc1cnc2ccn([C@H](C)c3nnc4c(F)cc(cn34)-c3cnn(C)c3)c(=O)c2c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"223","AMG-487-(+/-)","CC chemokine receptor antagonist","CXCR3",NA,NA,"CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1 |&1:20,r|, CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1 |&1:20,r|, CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1 |&1:20,r|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"224","AMG-517","TRPV antagonist","TRPV1",NA,NA,"CC(=O)Nc1nc2c(Oc3cc(ncn3)-c3ccc(cc3)C(F)(F)F)cccc2s1, CC(=O)Nc1nc2c(Oc3cc(ncn3)-c3ccc(cc3)C(F)(F)F)cccc2s1, CC(=O)Nc1nc2c(Oc3cc(ncn3)-c3ccc(cc3)C(F)(F)F)cccc2s1, CC(=O)Nc1nc2c(Oc3cc(ncn3)-c3ccc(cc3)C(F)(F)F)cccc2s1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"225","AMG-548","MAP kinase inhibitor","MAPK11, MAPK12, MAPK13, MAPK14",NA,NA,"Cn1c(NC[C@@H](N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O, Cn1c(NC[C@@H](N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O, Cn1c(NC[C@@H](N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O, Cn1c(NC[C@@H](N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"226","AMG-837","free fatty acid receptor agonist","FFAR1",NA,NA,"CC#C[C@@H](CC(O)=O)c1ccc(OCc2cccc(c2)-c2ccc(cc2)C(F)(F)F)cc1, CC#C[C@@H](CC(O)=O)c1ccc(OCc2cccc(c2)-c2ccc(cc2)C(F)(F)F)cc1, CC#C[C@@H](CC(O)=O)c1ccc(OCc2cccc(c2)-c2ccc(cc2)C(F)(F)F)cc1, CC#C[C@@H](CC(O)=O)c1ccc(OCc2cccc(c2)-c2ccc(cc2)C(F)(F)F)cc1, CC#C[C@@H](CC(O)=O)c1ccc(OCc2cccc(c2)-c2ccc(cc2)C(F)(F)F)cc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"227","AMG-925","CDK inhibitor, FLT3 inhibitor","CDK4, CDK6, FLT3",NA,NA,"C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCc4n3)C(=O)CO)nc12 |r|, C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCc4n3)C(=O)CO)nc12 |r|, C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCc4n3)C(=O)CO)nc12 |r|, C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCc4n3)C(=O)CO)nc12 |r|, C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCc4n3)C(=O)CO)nc12 |r|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"228","AMG-9810","TRPV antagonist","TRPV1",NA,NA,"CC(C)(C)c1ccc(\C=C\C(=O)Nc2ccc3OCCOc3c2)cc1, CC(C)(C)c1ccc(\C=C\C(=O)Nc2ccc3OCCOc3c2)cc1, CC(C)(C)c1ccc(\C=C\C(=O)Nc2ccc3OCCOc3c2)cc1, CC(C)(C)c1ccc(\C=C\C(=O)Nc2ccc3OCCOc3c2)cc1, CC(C)(C)c1ccc(\C=C\C(=O)Nc2ccc3OCCOc3c2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"229","AMG319","PI3K inhibitor","PIK3CD",NA,NA,"C[C@@H](Nc1ncnc2nc[nH]c12)c1cc2ccc(F)cc2nc1-c1ccccn1 |&1:1,r|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"230","AMG458","MET inhibitor","MET",NA,NA,"COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1, COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1, COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"231","AMG900","Aurora kinase inhibitor","AURKA, AURKB, AURKC",NA,NA,"Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12, Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12, Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12, Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12, Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"232","AMI-1","protein arginine N-methyltransferase inhibitor","PRMT1",NA,NA,"Oc1cc(cc2cc(NC(=O)Nc3ccc4c(O)cc(cc4c3)S(O)(=O)=O)ccc12)S(O)(=O)=O, Oc1cc(cc2cc(NC(=O)Nc3ccc4c(O)cc(cc4c3)S(O)(=O)=O)ccc12)S(O)(=O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"233","amibegron","adrenergic receptor agonist","ADRB3",NA,NA,"CCOC(=O)COc1ccc2CC[C@@H](Cc2c1)NC[C@H](O)c1cccc(Cl)c1, CCOC(=O)COc1ccc2CC[C@@H](Cc2c1)NC[C@H](O)c1cccc(Cl)c1, CCOC(=O)COc1ccc2CC[C@@H](Cc2c1)NC[C@H](O)c1cccc(Cl)c1, CCOC(=O)COc1ccc2CC[C@@H](Cc2c1)NC[C@H](O)c1cccc(Cl)c1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
"234","amiflamine","monoamine oxidase inhibitor","MAOA, SLC6A2",NA,NA,"C[C@@H](N)Cc1ccc(cc1C)N(C)C |&1:1,r|, C[C@@H](N)Cc1ccc(cc1C)N(C)C |&1:1,r|","Phase 1",1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"235","amifostine","reducing agent","ALPPL2, ENPP1","nephrology","renal toxicity","NCCCNCCSP(O)(O)=O, NCCCNCCSP(O)(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"236","amiloride","sodium channel blocker","AOC1, ASIC1, ASIC2, ASIC3, PKD2, PKD2L1, PLAU, SCNN1A, SCNN1B, SCNN1D, SCNN1G, SLC9A1, TRPC7, TRPV2","cardiology","hypertension, congestive heart failure","NC(=N)NC(=O)c1nc(Cl)c(N)nc1N, NC(=N)NC(=O)c1nc(Cl)c(N)nc1N, NC(=N)NC(=O)c1nc(Cl)c(N)nc1N, NC(=N)NC(=O)c1nc(Cl)c(N)nc1N, NC(=N)NC(=O)c1nc(Cl)c(N)nc1N, NC(=N)NC(=O)c1nc(Cl)c(N)nc1N, NC(=N)NC(=O)c1nc(Cl)c(N)nc1N","Launched",1,1,1,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"237","amineptine","dopamine receptor agonist","SLC6A2, SLC6A4",NA,NA,"OC(=O)CCCCCCNC1c2ccccc2CCc2ccccc12, OC(=O)CCCCCCNC1c2ccccc2CCc2ccccc12, OC(=O)CCCCCCNC1c2ccccc2CCc2ccccc12","Withdrawn",1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"238","aminocaproic-acid","plasminogen activator inhibitor","LPA, PLAT, PLG","hematology","fibrinolytic bleeding","NCCCCCC(O)=O, NCCCCCC(O)=O, NCCCCCC(O)=O, NCCCCCC(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"239","aminoglutethimide","glucocorticoid receptor antagonist","CYP11A1, CYP19A1","endocrinology, oncology","Cushing's syndrome, breast cancer","CC[C@]1(CCC(=O)NC1=O)c1ccc(N)cc1 |&1:2,r|, CC[C@]1(CCC(=O)NC1=O)c1ccc(N)cc1 |&1:2,r|, CC[C@]1(CCC(=O)NC1=O)c1ccc(N)cc1 |&1:2,r|, CC[C@]1(CCC(=O)NC1=O)c1ccc(N)cc1 |&1:2,r|, CC[C@]1(CCC(=O)NC1=O)c1ccc(N)cc1 |&1:2,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"240","aminoguanidine","nitric oxide synthase inhibitor","AKR1B1, NOS2, TIMP3",NA,NA,"NN=C(N)N, NN=C(N)N, NN=C(N)N","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"241","aminomethyltransferase","nitric oxide synthase inhibitor","NOS2",NA,NA,"C[C@H]1CCN=C(N)S1 |&1:1,t:4|, C[C@H]1CCN=C(N)S1 |&1:1,t:4|, C[C@H]1CCN=C(N)S1 |&1:1,t:4|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"242","aminopentamide","acetylcholine receptor antagonist","CHRM1","gastroenterology","acute abdominal visceral spasm, hypertrophic gastritis (GHG), nausea","CC(CC(C(N)=O)(c1ccccc1)c1ccccc1)N(C)C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,1
"243","aminophylline","adenosine receptor antagonist","ADORA1, ADORA2A, ADORA2B, ADORA3, HDAC2, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A","pulmonary","asthma, bronchitis, emphysema","Cn1c2nc[nH]c2c(=O)n(C)c1=O, Cn1c2nc[nH]c2c(=O)n(C)c1=O, Cn1c2nc[nH]c2c(=O)n(C)c1=O, Cn1c2nc[nH]c2c(=O)n(C)c1=O, Cn1c2nc[nH]c2c(=O)n(C)c1=O, Cn1c2nc[nH]c2c(=O)n(C)c1=O, Cn1c2nc[nH]c2c(=O)n(C)c1=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"244","aminopterin","dihydrofolate reductase inhibitor","DHFR, SLC46A1",NA,NA,"Nc1nc(N)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1, Nc1nc(N)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1, Nc1nc(N)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1","Phase 3",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"245","aminopurvalanol-a","CDK inhibitor, tyrosine kinase inhibitor","CDK1, CDK2, CDK5",NA,NA,"CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"246","aminosalicylate","cyclooxygenase inhibitor","ALOX5, CHUK, PLA2G2E, PTGS1, PTGS2","gastroenterology","inflammatory bowel disease, ulcerative colitis","Nc1ccc(C(O)=O)c(O)c1, Nc1ccc(C(O)=O)c(O)c1, Nc1ccc(C(O)=O)c(O)c1, Nc1ccc(C(O)=O)c(O)c1","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"247","aminothiadiazole","inosine monophosphate dehydrogenase inhibitor","ADORA3, IMPDH1",NA,NA,"Nc1nncs1, Nc1nncs1, Nc1nncs1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"248","aminothiazole","cyclin D inhibitor","NOS2",NA,NA,"Nc1nccs1, Nc1nccs1, Nc1nccs1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"249","amiodarone","potassium channel blocker","ADRB1, CACNA1H, CACNA2D2, KCNA7, KCNH2","cardiology","ventricular arrhythmias","CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1, CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1, CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1, CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1, CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1, CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1, CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1, CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"250","amisulpride","dopamine receptor antagonist","DRD2","neurology/psychiatry","psychosis, bipolar disorder, schizophrenia","CCN1CCC[C@@H]1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC |&1:6,r|, CCN1CCC[C@@H]1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC |&1:6,r|, CCN1CCC[C@@H]1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC |&1:6,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1
"251","amitifadine","serotonin transporter (SERT) inhibitor","SLC6A2, SLC6A3, SLC6A4",NA,NA,"Clc1ccc(cc1Cl)[C@@]12C[C@@H]1CNC2 |&1:8,&2:10|, Clc1ccc(cc1Cl)[C@@]12C[C@@H]1CNC2 |&1:8,&2:10|","Phase 3",1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"252","amitraz","adrenergic receptor agonist","ADRA1A, ADRA2A","infectious disease","generalized demodicosis","CN(\C=N\c1ccc(C)cc1C)\C=N\c1ccc(C)cc1C, CN(\C=N\c1ccc(C)cc1C)\C=N\c1ccc(C)cc1C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,1,1,1,1
"253","amitriptyline","norepinephrine inhibitor, norepinephrine reuptake inhibitor, serotonin receptor antagonist, serotonin‚Äìnorepinephrine reuptake inhibitor (SNRI)","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRB1, ADRB2, ADRB3, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, HRH2, HRH4, HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6, HTR7, KCNA1, KCND2, KCND3, KCNQ2, KCNQ3, NTRK1, NTRK2, OPRD1, OPRK1, OPRM1, SIGMAR1, SLC6A2, SLC6A4","neurology/psychiatry","depression","CN(C)CCC=C1c2ccccc2CCc2ccccc12, CN(C)CCC=C1c2ccccc2CCc2ccccc12, CN(C)CCC=C1c2ccccc2CCc2ccccc12","Launched",1,2,0,0,0,0,0,0,1,7,1,3,0,0,0,0,1,5,1,7,1,1,1,1
"254","amlexanox","histamine receptor modulator","FGF1, IL3, PDE4A, PDE4B, PDE4C, PDE4D, S100A12, S100A13","dental, pulmonary, ophthalmology, allergy","aphthous ulcers, asthma, conjunctivitis, allergic rhinitis","CC(C)c1ccc2oc3nc(N)c(cc3c(=O)c2c1)C(O)=O, CC(C)c1ccc2oc3nc(N)c(cc3c(=O)c2c1)C(O)=O, CC(C)c1ccc2oc3nc(N)c(cc3c(=O)c2c1)C(O)=O, CC(C)c1ccc2oc3nc(N)c(cc3c(=O)c2c1)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"255","amlodipine","calcium channel blocker","CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNA2D1","cardiology","hypertension, chronic stable angina, vasospastic angina, coronary artery disease (CAD)","CCOC(=O)C1=C(COCCN)NC(C)=C([C@H]1c1ccccc1Cl)C(=O)OC |&1:16,r,c:5,14|, CCOC(=O)C1=C(COCCN)NC(C)=C([C@H]1c1ccccc1Cl)C(=O)OC |&1:16,r,c:5,14|, CCOC(=O)C1=C(COCCN)NC(C)=C([C@H]1c1ccccc1Cl)C(=O)OC |&1:16,r,c:5,14|, CCOC(=O)C1=C(COCCN)NC(C)=C([C@H]1c1ccccc1Cl)C(=O)OC |&1:16,r,c:5,14|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"256","ammonium-glycyrrhizinate","thrombin inhibitor","HSD11B1, HSD11B2, SLCO1B1, SLCO1B3","dermatology","cosmetic","CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C(O)=O)C(O)=O |t:18|","Launched",1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"257","ammonium-perfluorocaprylate","Pim kinase inhibitor","PIM1",NA,NA,"OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F, OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"258","AMN-082","glutamate receptor modulator","GRM7",NA,NA,"C(CNC(c1ccccc1)c1ccccc1)NC(c1ccccc1)c1ccccc1, C(CNC(c1ccccc1)c1ccccc1)NC(c1ccccc1)c1ccccc1, C(CNC(c1ccccc1)c1ccccc1)NC(c1ccccc1)c1ccccc1, C(CNC(c1ccccc1)c1ccccc1)NC(c1ccccc1)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"259","amodiaquine","histamine receptor agonist","HNMT","infectious disease","malaria","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O, CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O, CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O, CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O, CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O, CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O, CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"260","amonafide","topoisomerase inhibitor","TOP2A, TOP2B",NA,NA,"CN(C)CCN1C(=O)c2cccc3cc(N)cc(C1=O)c23, CN(C)CCN1C(=O)c2cccc3cc(N)cc(C1=O)c23, CN(C)CCN1C(=O)c2cccc3cc(N)cc(C1=O)c23","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"261","amoxapine","norepinephrine reputake inhibitor","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, HRH1, HRH4, HTR1A, HTR1B, HTR2A, HTR2B, HTR2C, HTR3A, HTR6, HTR7, SLC6A2, SLC6A3, SLC6A4","neurology/psychiatry","depression","Clc1ccc2Oc3ccccc3N=C(N3CCNCC3)c2c1 |t:13|, Clc1ccc2Oc3ccccc3N=C(N3CCNCC3)c2c1 |t:13|, Clc1ccc2Oc3ccccc3N=C(N3CCNCC3)c2c1 |t:13|, Clc1ccc2Oc3ccccc3N=C(N3CCNCC3)c2c1 |t:13|","Launched",1,3,0,0,0,0,0,0,1,8,1,2,1,16,1,5,1,5,1,6,1,1,1,1
"262","amoxicillin","penicillin binding protein inhibitor","CYP2C19, SLC15A1, SLC15A2, SLC22A6","infectious disease, gastroenterology","skin infections, duodenal ulcer disease, gonorrhea, ear infections, throat infections, genitourinary tract infections, respiratory tract infections","CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O","Launched",1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"263","AMPA-(RS)","glutamate receptor agonist","GRIN1",NA,NA,"Cc1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:8|, Cc1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:8|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"264","AMPA-(S)","glutamate receptor agonist","GRIA2, GRIN1",NA,NA,"Cc1o[nH]c(=O)c1C[C@H](N)C(O)=O, Cc1o[nH]c(=O)c1C[C@H](N)C(O)=O, Cc1o[nH]c(=O)c1C[C@H](N)C(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"265","ampalex","glutamate receptor agonist","GRIA1, GRIA2, GRIA3, GRIA4",NA,NA,"O=C(N1CCCCC1)c1ccc2nccnc2c1, O=C(N1CCCCC1)c1ccc2nccnc2c1, O=C(N1CCCCC1)c1ccc2nccnc2c1, O=C(N1CCCCC1)c1ccc2nccnc2c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"266","amperozide","dopamine receptor antagonist","FAAH, HTR2A","neurology/psychiatry","psychosis","CCNC(=O)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1, CCNC(=O)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1, CCNC(=O)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1","Launched",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"267","ampiroxicam","cyclooxygenase inhibitor","PTGS1, PTGS2","neurology/psychiatry","pain relief","CCOC(=O)O[C@@H](C)OC1=C(N(C)S(=O)(=O)c2ccccc12)C(=O)Nc1ccccn1 |&1:6,r,t:9|, CCOC(=O)O[C@@H](C)OC1=C(N(C)S(=O)(=O)c2ccccc12)C(=O)Nc1ccccn1 |&1:6,r,t:9|, CCOC(=O)O[C@@H](C)OC1=C(N(C)S(=O)(=O)c2ccccc12)C(=O)Nc1ccccn1 |&1:6,r,t:9|, CCOC(=O)O[C@@H](C)OC1=C(N(C)S(=O)(=O)c2ccccc12)C(=O)Nc1ccccn1 |&1:6,r,t:9|, CCOC(=O)O[C@@H](C)OC1=C(N(C)S(=O)(=O)c2ccccc12)C(=O)Nc1ccccn1 |&1:6,r,t:9|","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"268","amrinone","phosphodiesterase inhibitor","PDE3A, PDE3B, PDE4B, TNF","cardiology","congestive heart failure","Nc1cc(c[nH]c1=O)-c1ccncc1, Nc1cc(c[nH]c1=O)-c1ccncc1, Nc1cc(c[nH]c1=O)-c1ccncc1, Nc1cc(c[nH]c1=O)-c1ccncc1, Nc1cc(c[nH]c1=O)-c1ccncc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"269","amrubicin","topoisomerase inhibitor","TOP2A, TOP2B","oncology","small cell lung cancer","CC(=O)[C@@]1(N)C[C@H](O[C@H]2C[C@H](O)[C@H](O)CO2)c2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c2C1, CC(=O)[C@@]1(N)C[C@H](O[C@H]2C[C@H](O)[C@H](O)CO2)c2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c2C1, CC(=O)[C@@]1(N)C[C@H](O[C@H]2C[C@H](O)[C@H](O)CO2)c2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c2C1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"270","amsacrine","topoisomerase inhibitor","KCNH2, TOP2A","hematologic malignancy","acute lymphoblastic leukemia (ALL)","COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12, COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12, COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12, COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12, COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"271","amthamine","histamine receptor agonist","HRH2",NA,NA,"Cc1nc(N)sc1CCN, Cc1nc(N)sc1CCN","Preclinical",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
"272","amtolmetin-guacil","cyclooxygenase inhibitor","PTGS1, PTGS2","rheumatology","rheumatoid arthritis, osteoarthritis","COc1ccccc1OC(=O)CNC(=O)Cc1ccc(C(=O)c2ccc(C)cc2)n1C, COc1ccccc1OC(=O)CNC(=O)Cc1ccc(C(=O)c2ccc(C)cc2)n1C, COc1ccccc1OC(=O)CNC(=O)Cc1ccc(C(=O)c2ccc(C)cc2)n1C","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"273","amuvatinib","FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAD51 inhibitor, RET tyrosine kinase inhibitor","KIT, MET",NA,NA,"S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12, S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12, S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12, S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12, S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12, S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12, S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12, S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12, S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"274","amxt-1501 tetrahydrochloride","ornithine decarboxylase inhibitor","ODC1, TPO","oncology","neuroblastoma","CCCCCCCCCCCCCCCC(=O)NCCCC[C@@H](N)C(=O)NCCCNCCCCNCCCN.Cl.Cl.Cl.Cl","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"275","amygdalin","caspase activator","CASP3",NA,NA,"OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"276","amylmetacresol is a component of strepsis mixture","sodium channel blocker","SCN2A","otolaryngology","sore throat","CCCCCC1=C(C=C(C=C1)C)O","Launched",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"277","amyloid p-in-1","beta amyloid inhibitor","APP","neurology/psychiatry","alzheimer's disease","O=C(CCCCC(=O)N1CCC[C@@H]1C(=O)OCOC(=O)OC2CCOCC2)N3CCC[C@@H]3C(=O)OCOC(=O)OC4CCOCC4","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"278","AM679","cannabinoid receptor agonist, lipoxygenase inhibitor","ALOX5AP, CNR1, CNR2",NA,NA,"COc1cnc(nc1)-c1ccc(Cn2c(CC(C)(C)C(O)=O)c(SC(C)(C)C)c3cc(OC[C@@H]4Cc5ccccc5N4C(C)=O)ccc23)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"279","ANA-12","tropomyosin receptor kinase inhibitor","NTRK2",NA,NA,"O=C(Nc1ccccc1C(=O)N[C@H]1CCCCNC1=O)c1cc2ccccc2s1 |&1:12,r|, O=C(Nc1ccccc1C(=O)N[C@H]1CCCCNC1=O)c1cc2ccccc2s1 |&1:12,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"280","anacetrapib","cholesteryl ester transfer protein inhibitor","CETP",NA,NA,"COc1cc(F)c(cc1-c1ccc(cc1CN1[C@@H](C)[C@H](OC1=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(F)(F)F)C(C)C","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"281","anagliptin","dipeptidyl peptidase inhibitor","DPP4","endocrinology","diabetes mellitus","Cc1cc2ncc(cn2n1)C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N, Cc1cc2ncc(cn2n1)C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N, Cc1cc2ncc(cn2n1)C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"282","anagrelide","phosphodiesterase inhibitor","PDE3A","hematology, hematologic malignancy","thrombocythemia, myeloproliferative neoplasms","Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"283","anamorelin","growth hormone secretagogue receptor agonist","GHSR",NA,NA,"CN(C)N(C)C(=O)[C@@]1(Cc2ccccc2)CCCN(C1)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)C(C)(C)N, CN(C)N(C)C(=O)[C@@]1(Cc2ccccc2)CCCN(C1)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)C(C)(C)N","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"284","anandamide","cannabinoid receptor agonist","CACNA1G, CACNA1H, CACNA1I, CNR1, CNR2, GLRA1, GPR18, GPR55, KCNA2, KCNK3, KCNK9, TRPM8, TRPV1",NA,NA,"CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"285","anastrozole","aromatase inhibitor","CYP19A1","oncology","breast cancer","CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N, CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N, CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N, CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"286","andarine","androgen receptor modulator","AR",NA,NA,"CC(=O)Nc1ccc(OC[C@](C)(O)C(=O)Nc2ccc(c(c2)C(F)(F)F)[N+]([O-])=O)cc1, CC(=O)Nc1ccc(OC[C@](C)(O)C(=O)Nc2ccc(c(c2)C(F)(F)F)[N+]([O-])=O)cc1, CC(=O)Nc1ccc(OC[C@](C)(O)C(=O)Nc2ccc(c(c2)C(F)(F)F)[N+]([O-])=O)cc1, CC(=O)Nc1ccc(OC[C@](C)(O)C(=O)Nc2ccc(c(c2)C(F)(F)F)[N+]([O-])=O)cc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"287","andrographolide","tumor necrosis factor production inhibitor","IL1B, IL6, NFKB1, NFKB2, TNF",NA,NA,"C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H](C\C=C3/[C@H](O)COC3=O)C(=C)CC[C@H]12","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"288","anguidine","protein synthesis inhibitor, apoptosis stimulant","SLC5A1","Endocrinology","diabetes mellitus","CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@]11CO1 |c:9|, CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1 |c:9|, CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1 |c:9|, CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1 |c:9|, CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1 |c:9|","Preclinical",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"289","aniracetam","glutamate receptor agonist","DRD2, GRIA1, GRIA2, GRIA3, GRIA4, HTR2A",NA,NA,"COc1ccc(cc1)C(=O)N1CCCC1=O, COc1ccc(cc1)C(=O)N1CCCC1=O, COc1ccc(cc1)C(=O)N1CCCC1=O, COc1ccc(cc1)C(=O)N1CCCC1=O, COc1ccc(cc1)C(=O)N1CCCC1=O","Launched",0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0
"290","anisindione","vitamin K antagonist","GGCX","hematology","deep vein thrombosis (DVT)","COc1ccc(cc1)C1C(=O)c2ccccc2C1=O, COc1ccc(cc1)C1C(=O)c2ccccc2C1=O, COc1ccc(cc1)C1C(=O)c2ccccc2C1=O, COc1ccc(cc1)C1C(=O)c2ccccc2C1=O, COc1ccc(cc1)C1C(=O)c2ccccc2C1=O, COc1ccc(cc1)C1C(=O)c2ccccc2C1=O, COc1ccc(cc1)C1C(=O)c2ccccc2C1=O, COc1ccc(cc1)C1C(=O)c2ccccc2C1=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"291","anisodamine","lipid peroxidase inhibitor","ADRA1A",NA,NA,"CN1[C@H]2C[C@H](O)[C@H]1C[C@H](C2)OC(=O)[C@H](CO)c1ccccc1 |a:4,6,8,13,&1:2,THB:5:4:1:7.8.9|, CN1[C@H]2C[C@H](O)[C@H]1C[C@H](C2)OC(=O)[C@H](CO)c1ccccc1 |a:4,6,8,13,&1:2,THB:5:4:1:7.8.9|, CN1[C@H]2C[C@H](O)[C@H]1C[C@H](C2)OC(=O)[C@H](CO)c1ccccc1 |a:4,6,8,13,&1:2,THB:5:4:1:7.8.9|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
"292","anisomycin","DNA synthesis inhibitor","NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1",NA,NA,"COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1, COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1, COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1, COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1, COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"293","anlotinib","PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","KDR, PDGFRB",NA,NA,"COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1, COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1, COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1, COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1, COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"294","anpirtoline","serotonin receptor agonist","HTR1B",NA,NA,"Clc1cccc(SC2CCNCC2)n1, Clc1cccc(SC2CCNCC2)n1, Clc1cccc(SC2CCNCC2)n1, Clc1cccc(SC2CCNCC2)n1, Clc1cccc(SC2CCNCC2)n1","Phase 1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"295","ANR-94","adenosine receptor antagonist","ADORA2A",NA,NA,"CCOc1nc2c(N)ncnc2n1CC, CCOc1nc2c(N)ncnc2n1CC","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"296","ansofaxine hydrochloride","dopamine-norepinephrine reuptake inhibitor","ADRA1A, DRD2, HTR2A","neurology/psychiatry","depression","CN(C)C[C@H](c1ccc(OC(=O)c2ccc(C)cc2)cc1)C1(O)CCCCC1.Cl |&1:4,r|","Phase 3",0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,1,1
"297","antagonist-g","neuropeptide receptor antagonist","MAPK8",NA,NA,"CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCNC(N)=N)C(N)=O, CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCNC(N)=N)C(N)=O, CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCNC(N)=N)C(N)=O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"298","antalarmin","corticotropin releasing factor receptor antagonist","CRHR1",NA,NA,"CCCCN(CC)c1nc(C)nc2n(c(C)c(C)c12)-c1c(C)cc(C)cc1C, CCCCN(CC)c1nc(C)nc2n(c(C)c(C)c12)-c1c(C)cc(C)cc1C, CCCCN(CC)c1nc(C)nc2n(c(C)c(C)c12)-c1c(C)cc(C)cc1C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"299","antazoline","antihistamine","HRH1","ophthalmology, otolaryngology","conjunctivitis, nasal congestion","C(N(Cc1ccccc1)c1ccccc1)C1=NCCN1 |t:17|, C(N(Cc1ccccc1)c1ccccc1)C1=NCCN1 |t:17|, C(N(Cc1ccccc1)c1ccccc1)C1=NCCN1 |t:17|, C(N(Cc1ccccc1)c1ccccc1)C1=NCCN1 |t:17|","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"300","anthraquinone","CDC inhibitor","CDC25B",NA,NA,"O=C1c2ccccc2C(=O)c2ccccc12, O=C1c2ccccc2C(=O)c2ccccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"301","antimycin-A","ATP synthase inhibitor","CYCS",NA,NA,"CCCCCC[C@@H]1[C@@H](OC(=O)CC(C)C)[C@H](C)OC(=O)[C@@H](NC(=O)c2cccc(NC=O)c2O)[C@@H](C)OC1=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"302","antineoplaston a10","p53 activator","DPM1, LGALS1","oncology","brainstem glioma","O=C(Cc1ccccc1)N[C@H]2CCC(=O)NC2=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"303","AP-18","transient receptor potential channel antagonist","TRPA1",NA,NA,"C\C(=C/c1ccc(Cl)cc1)\C(\C)=N\O, C\C(=C/c1ccc(Cl)cc1)\C(\C)=N\O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"304","apabetalone","apolipoprotein expression enhancer","BRD3",NA,NA,"COc1cc(OC)c2c(c1)[nH]c(nc2=O)-c1cc(C)c(OCCO)c(C)c1, COc1cc(OC)c2c(c1)[nH]c(nc2=O)-c1cc(C)c(OCCO)c(C)c1, COc1cc(OC)c2c(c1)[nH]c(nc2=O)-c1cc(C)c(OCCO)c(C)c1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"305","apafant","platelet activating factor receptor antagonist","PTAFR",NA,NA,"Cc1nnc2CN=C(c3cc(CCC(=O)N4CCOCC4)sc3-n12)c1ccccc1Cl |c:6|, Cc1nnc2CN=C(c3cc(CCC(=O)N4CCOCC4)sc3-n12)c1ccccc1Cl |c:6|, Cc1nnc2CN=C(c3cc(CCC(=O)N4CCOCC4)sc3-n12)c1ccccc1Cl |c:6|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"306","apatinib","RET tyrosine kinase inhibitor","CSK, KDR, KIT, RET",NA,NA,"O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1, O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1, O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"307","APC-100","androgen receptor antagonist, anti-inflammatory agent","AR",NA,NA,"Cc1c(C)c2OC(C)(C)CCc2c(C)c1O, Cc1c(C)c2OC(C)(C)CCc2c(C)c1O","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"308","APcK-110","KIT inhibitor","KIT, STAT3",NA,NA,"COc1cc(OC)cc(c1)-c1ccc2c([nH]nc2n1)-c1ccc(F)cc1, COc1cc(OC)cc(c1)-c1ccc2c([nH]nc2n1)-c1ccc(F)cc1, COc1cc(OC)cc(c1)-c1ccc2c([nH]nc2n1)-c1ccc(F)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"309","APD597","glucose dependent insulinotropic receptor agonist","GPR119",NA,NA,"COc1c(Nc2ccc(nc2C)S(C)(=O)=O)ncnc1OC1CCN(CC1)C(=O)OC(C)C, COc1c(Nc2ccc(nc2C)S(C)(=O)=O)ncnc1OC1CCN(CC1)C(=O)OC(C)C","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"310","APD668","glucose dependent insulinotropic receptor agonist","GPR119",NA,NA,"CC(C)OC(=O)N1CCC(CC1)Oc1ncnc2n(ncc12)-c1ccc(cc1F)S(C)(=O)=O, CC(C)OC(=O)N1CCC(CC1)Oc1ncnc2n(ncc12)-c1ccc(cc1F)S(C)(=O)=O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"311","API-001","sigma receptor antagonist","SIGMAR1",NA,NA,"Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1, Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1, Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"312","API-1","AKT inhibitor","AKT1, AKT2, AKT3",NA,NA,"NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c2c1=O, NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c2c1=O, NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c2c1=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"313","apigenin","casein kinase inhibitor, cell proliferation inhibitor","AKR1B1, AR, CDK6, CFTR, CYP19A1, CYP1B1, HSD17B1",NA,NA,"Oc1ccc(cc1)-c1cc(=O)c2c(O)cc(O)cc2o1, Oc1ccc(cc1)-c1cc(=O)c2c(O)cc(O)cc2o1, Oc1ccc(cc1)-c1cc(=O)c2c(O)cc(O)cc2o1, Oc1ccc(cc1)-c1cc(=O)c2c(O)cc(O)cc2o1, Oc1ccc(cc1)-c1cc(=O)c2c(O)cc(O)cc2o1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"314","apixaban","coagulation factor inhibitor","F10","neurology/psychiatry, hematology, cardiology","stroke, systemic embolism, pulmonary embolism (PE), atrial fibrillation (AF), deep vein thrombosis (DVT)","COc1ccc(cc1)-n1nc(C(N)=O)c2CCN(C(=O)c12)c1ccc(cc1)N1CCCCC1=O, COc1ccc(cc1)-n1nc(C(N)=O)c2CCN(C(=O)c12)c1ccc(cc1)N1CCCCC1=O, COc1ccc(cc1)-n1nc(C(N)=O)c2CCN(C(=O)c12)c1ccc(cc1)N1CCCCC1=O, COc1ccc(cc1)-n1nc(C(N)=O)c2CCN(C(=O)c12)c1ccc(cc1)N1CCCCC1=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"315","apocynin","NADPH oxidase inhibitor","NOX4",NA,NA,"COc1cc(ccc1O)C(C)=O, COc1cc(ccc1O)C(C)=O, COc1cc(ccc1O)C(C)=O, COc1cc(ccc1O)C(C)=O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"316","apoptosis-activator-II","carboxylesterase inhibitor","BCHE, CES1",NA,NA,"Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl, Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl, Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl, Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"317","APR-246","p53 activator","TP53",NA,NA,"COC[C@@]1(CO)N2CCC(CC2)C1=O |&1:3,r,TLB:2:3:7.8:10.11|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"318","apraclonidine","adrenergic receptor agonist","ADRA1A, ADRA2A, ADRA2B, ADRA2C","ophthalmology","glaucoma, intraocular pressure","Nc1cc(Cl)c(NC2=NCCN2)c(Cl)c1 |t:7|, Nc1cc(Cl)c(NC2=NCCN2)c(Cl)c1 |t:7|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,4,1,1,1,1
"319","apratastat","matrix metalloprotease inhibitor, tumor necrosis factor production inhibitor","ADAM17, MMP1, MMP13, MMP9",NA,NA,"CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(OCC#CCO)cc1, CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(OCC#CCO)cc1, CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(OCC#CCO)cc1, CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(OCC#CCO)cc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"320","apremilast","phosphodiesterase inhibitor","PDE4A, PDE4B, PDE4C, PDE4D","dermatology, rheumatology","psoriasis, psoriatic arthritis","CCOc1cc(ccc1OC)[C@@H](CS(C)(=O)=O)N1C(=O)c2cccc(NC(C)=O)c2C1=O, CCOc1cc(ccc1OC)[C@@H](CS(C)(=O)=O)N1C(=O)c2cccc(NC(C)=O)c2C1=O, CCOc1cc(ccc1OC)[C@@H](CS(C)(=O)=O)N1C(=O)c2cccc(NC(C)=O)c2C1=O, CCOc1cc(ccc1OC)[C@@H](CS(C)(=O)=O)N1C(=O)c2cccc(NC(C)=O)c2C1=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"321","aprepitant","tachykinin antagonist","TACR1","gastroenterology","nausea, vomiting","C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"322","aprindine","voltage-gated sodium channel blocker","CALM1, SCN5A","cardiology","cardiac arrythmia","CCN(CC)CCCN(C1Cc2ccccc2C1)c1ccccc1, CCN(CC)CCCN(C1Cc2ccccc2C1)c1ccccc1","Launched",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"323","aptiganel","glutamate receptor antagonist","GRIN1",NA,NA,"CCc1cccc(c1)N(C)C(=N)Nc1cccc2ccccc12, CCc1cccc(c1)N(C)C(=N)Nc1cccc2ccccc12, CCc1cccc(c1)N(C)C(=N)Nc1cccc2ccccc12","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"324","APTO-253","kr√ºppel-like factor expression enhancer","KLF4",NA,NA,"Cc1[nH]c2ccc(F)cc2c1-c1nc2c([nH]1)c1cccnc1c1ncccc21, Cc1[nH]c2ccc(F)cc2c1-c1nc2c([nH]1)c1cccnc1c1ncccc21, Cc1[nH]c2ccc(F)cc2c1-c1nc2c([nH]1)c1cccnc1c1ncccc21, Cc1[nH]c2ccc(F)cc2c1-c1nc2c([nH]1)c1cccnc1c1ncccc21, Cc1[nH]c2ccc(F)cc2c1-c1nc2c([nH]1)c1cccnc1c1ncccc21","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"325","APY-29","serine/threonine kinase inhibitor","ERN1",NA,NA,"C1CC1c1cc(Nc2ccnc(Nc3ccc4nc[nH]c4c3)n2)[nH]n1, C1CC1c1cc(Nc2ccnc(Nc3ccc4nc[nH]c4c3)n2)[nH]n1, C1CC1c1cc(Nc2ccnc(Nc3ccc4nc[nH]c4c3)n2)[nH]n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"326","APY0201","phosphoinositide dependent kinase inhibitor","IL12A, IL12B, PIKFYVE",NA,NA,"Cc1cccc(\C=N\Nc2cc(N3CCOCC3)n3nc(cc3n2)-c2ccncc2)c1, Cc1cccc(\C=N\Nc2cc(N3CCOCC3)n3nc(cc3n2)-c2ccncc2)c1, Cc1cccc(\C=N\Nc2cc(N3CCOCC3)n3nc(cc3n2)-c2ccncc2)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"327","AP26113","ALK tyrosine kinase receptor inhibitor","ALK, EGFR",NA,NA,"COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"328","AQ-RA741","acetylcholine receptor antagonist","CHRM2",NA,NA,"CCN(CC)CCCCC1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1, CCN(CC)CCCCC1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1, CCN(CC)CCCCC1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
"329","AR-A014418","glycogen synthase kinase inhibitor","GSK3B",NA,NA,"COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1, COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1, COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1, COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1, COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"330","AR-C155858","monocarboxylate transporter inhibitor","SLC16A1, SLC16A7",NA,NA,"CC(C)Cn1c2sc(Cc3c(C)n[nH]c3C)c(C(=O)N3C[C@H](O)CO3)c2c(=O)n(C)c1=O, CC(C)Cn1c2sc(Cc3c(C)n[nH]c3C)c(C(=O)N3C[C@H](O)CO3)c2c(=O)n(C)c1=O","Preclinical",1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"331","AR-12","phosphoinositide dependent kinase inhibitor","PDPK1",NA,NA,"NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"332","ar-13324 m1 metabolite","protein kinase c inhibitor","PRKCA, ROCK1","ophthalmology","macular degeneration","NC[C@@H](C(=O)Nc1ccc2cnccc2c1)c1ccc(CO)cc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"333","AR-42","HDAC inhibitor","HDAC1",NA,NA,"CC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1, CC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1, CC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"334","ar-9281","epoxide hydolase inhibitor","EPHX2","cardiology","hypertension","CC(=O)N1CCC(CC1)NC(=O)NC23CC4CC(CC(C4)C2)C3","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"335","arachidonic-acid","cytochrome P450 inhibitor","CLCN2, KCNJ4, KCNK10, KCNK18, KCNK2, PRKCZ, PTGS1, TRPC6, TRPM2",NA,NA,"CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O","Phase 1",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"336","aranidipine","l-type calcium channel blocker","CACNA1C","cardiology","hypertension","COC(=O)C1=C(C)NC(=C(C1c2ccccc2[N+](=O)[O-])C(=O)OCC(=O)C)C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"337","arbidol","cytochrome P450 inhibitor","CYP3A4","infectious disease","influenza A virus infection","CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12, CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12, CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12, CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"338","arbutamine","adrenergic receptor agonist","ADRB1, ADRB2, ADRB3","cardiology","coronary artery disease (cad)","Oc1ccc(cc1O)[C@@H](O)CNCCCCc2ccc(O)cc2","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,1,1,1,1
"339","arbutin","melanin inhibitor","TYR",NA,NA,"OC[C@H]1O[C@@H](Oc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O","Phase 2/Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"340","ARC-239","adrenergic receptor antagonist","ADRA2A, ADRA2B, ADRA2C",NA,NA,"COc1ccccc1N1CCN(CCN2C(=O)c3ccccc3C(C)(C)C2=O)CC1, COc1ccccc1N1CCN(CCN2C(=O)c3ccccc3C(C)(C)C2=O)CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0
"341","arctigenin","MEK inhibitor","CHUK, MAP2K1",NA,NA,"COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc2ccc(O)c(OC)c2)cc1OC, COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc2ccc(O)c(OC)c2)cc1OC, COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc2ccc(O)c(OC)c2)cc1OC","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"342","arcyriaflavin-a","CDK inhibitor","CCND1, CDK4",NA,NA,"O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"343","ardeparin","thrombin inhibitor","SERPIND1",NA,NA,"CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](OC)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"344","arecaidine-but-2-ynyl-ester","acetylcholine receptor agonist","CHRM2",NA,NA,"CC#CCOC(=O)C1=CCCN(C)C1 |t:7|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
"345","arecaidine-propargyl-ester","acetylcholine receptor agonist","CHRM1, CHRM2, CHRM3, CHRM4",NA,NA,"CN1CCC=C(C1)C(=O)OCC#C |c:4|, CN1CCC=C(C1)C(=O)OCC#C |c:4|, CN1CCC=C(C1)C(=O)OCC#C |c:4|, CN1CCC=C(C1)C(=O)OCC#C |c:4|, CN1CCC=C(C1)C(=O)OCC#C |c:4|, CN1CCC=C(C1)C(=O)OCC#C |c:4|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0
"346","arecoline","acetylcholine receptor agonist","CHRM1, CHRM2, CHRM3, CHRM4",NA,NA,"COC(=O)C1=CCCN(C)C1 |t:4|, COC(=O)C1=CCCN(C)C1 |t:4|, COC(=O)C1=CCCN(C)C1 |t:4|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0
"347","argatroban","thrombin inhibitor","F2","hematology","heparin-induced thrombocytopenia (HIT)","C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1cccc2C[C@@H](C)CNc12 |a:1,5,12,&1:30|, C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1cccc2C[C@@H](C)CNc12 |a:1,5,12,&1:30|, C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1cccc2C[C@@H](C)CNc12 |a:1,5,12,&1:30|, C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1cccc2C[C@@H](C)CNc12 |a:1,5,12,&1:30|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"348","arglabin","farnesyltransferase inhibitor","FNTA, NFKB1",NA,NA,"CC1=CC[C@]23O[C@@]2(C)CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]13 |t:1|, CC1=CC[C@]23O[C@@]2(C)CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]13 |t:1|, CC1=CC[C@]23O[C@@]2(C)CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]13 |t:1|, CC1=CC[C@]23O[C@@]2(C)CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]13 |t:1|, CC1=CC[C@]23O[C@@]2(C)CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]13 |t:1|, CC1=CC[C@]23O[C@@]2(C)CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]13 |t:1|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"349","arimoclomol","superoxide dismutase inhibitor","HSPA1A, SOD1","neurology/psychiatry","amyotrophic lateral sclerosis (als)","O[C@@H](CO\N=C(/Cl)\c1ccc[n+]([O-])c1)CN2CCCCC2","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"350","aripiprazole","serotonin receptor agonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7","neurology/psychiatry","depression, schizophrenia, bipolar disorder","Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl","Launched",0,0,0,0,0,0,0,0,1,9,1,1,0,0,1,5,1,5,1,5,1,1,1,1
"351","arofylline","phosphodiesterase inhibitor","PDE4A",NA,NA,"CCCn1c(=O)n(-c2ccc(Cl)cc2)c2nc[nH]c2c1=O, CCCn1c(=O)n(-c2ccc(Cl)cc2)c2nc[nH]c2c1=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"352","arotinolol","adrenergic receptor antagonist","ADRB3","cardiology, neurology/psychiatry","hypertension, tremors","CC(C)(C)NC[C@@H](O)CSc1nc(cs1)-c1ccc(s1)C(N)=O |&1:6,r|, CC(C)(C)NC[C@@H](O)CSc1nc(cs1)-c1ccc(s1)C(N)=O |&1:6,r|, CC(C)(C)NC[C@@H](O)CSc1nc(cs1)-c1ccc(s1)C(N)=O |&1:6,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"353","ARQ-092","AKT inhibitor","AKT2",NA,NA,"Nc1ncccc1-c1nc2ccc(nc2n1-c1ccc(cc1)C1(N)CCC1)-c1ccccc1, Nc1ncccc1-c1nc2ccc(nc2n1-c1ccc(cc1)C1(N)CCC1)-c1ccccc1, Nc1ncccc1-c1nc2ccc(nc2n1-c1ccc(cc1)C1(N)CCC1)-c1ccccc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"354","ARQ-621","kinesin-like spindle protein inhibitor","KIF11",NA,NA,"NCCCN([C@H](CC#C)c1nc2cc(Cl)ccc2c(=O)n1Nc1ccccc1)C(=O)c1cccc(Cl)c1F, NCCCN([C@H](CC#C)c1nc2cc(Cl)ccc2c(=O)n1Nc1ccccc1)C(=O)c1cccc(Cl)c1F, NCCCN([C@H](CC#C)c1nc2cc(Cl)ccc2c(=O)n1Nc1ccccc1)C(=O)c1cccc(Cl)c1F","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"355","ARRY-334543","EGFR inhibitor","ERBB2",NA,NA,"C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 |c:34|, C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 |c:34|, C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 |c:34|","Phase 2/Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"356","arsenic-trioxide","apoptosis stimulant","AKT1, CCND1, IKBKB, JUN, MAPK1, MAPK3, TXNRD1","gastroenterology","diarrhea","O=[As]O[As]=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"357","artemether","antimalarial agent","ATP1A1","infectious disease","malaria","CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3, CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3, CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3, CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3, CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3, CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"358","artemisinin","DNA synthesis inhibitor","CYP2B6","infectious disease","malaria","C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"359","arundic-acid","astrocyte modulating agent","PTGS2, S100B",NA,NA,"CCCCCC[C@@H](CCC)C(O)=O, CCCCCC[C@@H](CCC)C(O)=O","Phase 2/Phase 3",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"360","ARV-825","bromodomain inhibitor","BRD4",NA,NA,"Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(OCCOCCOCCOCCNc3cccc4C(=O)N([C@H]5CCC(=O)NC5=O)C(=O)c34)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |a:9,&1:39,c:8|, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(OCCOCCOCCOCCNc3cccc4C(=O)N([C@H]5CCC(=O)NC5=O)C(=O)c34)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |a:9,&1:39,c:8|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"361","AS-1269574","glucose dependent insulinotropic receptor agonist","GPR119",NA,NA,"Cc1cc(NCCO)nc(n1)-c1ccc(Br)cc1, Cc1cc(NCCO)nc(n1)-c1ccc(Br)cc1, Cc1cc(NCCO)nc(n1)-c1ccc(Br)cc1, Cc1cc(NCCO)nc(n1)-c1ccc(Br)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"362","AS-1892802","rho associated kinase inhibitor","ROCK1",NA,NA,"OC[C@@H](NC(=O)Nc1ccc(cc1)-c1ccncc1)c1ccccc1, OC[C@@H](NC(=O)Nc1ccc(cc1)-c1ccncc1)c1ccccc1, OC[C@@H](NC(=O)Nc1ccc(cc1)-c1ccncc1)c1ccccc1, OC[C@@H](NC(=O)Nc1ccc(cc1)-c1ccncc1)c1ccccc1, OC[C@@H](NC(=O)Nc1ccc(cc1)-c1ccncc1)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"363","AS-1949490","SHIP2 phosphatase inhibitor","INPP5D",NA,NA,"C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1, C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1, C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1, C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1, C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"364","AS-2034178","free fatty acid receptor agonist","FFAR1",NA,NA,"OC(=O)CCc1ccc(NCc2cccc3N(CCOc4ccccc4)CCCc23)cc1F, OC(=O)CCc1ccc(NCc2cccc3N(CCOc4ccccc4)CCCc23)cc1F, OC(=O)CCc1ccc(NCc2cccc3N(CCOc4ccccc4)CCCc23)cc1F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"365","AS-2444697","interleukin inhibitor","IRAK4",NA,NA,"Cc1cc(ccn1)-c1nc(co1)C(=O)Nc1cn(nc1C(N)=O)C1CCOCC1, Cc1cc(ccn1)-c1nc(co1)C(=O)Nc1cn(nc1C(N)=O)C1CCOCC1, Cc1cc(ccn1)-c1nc(co1)C(=O)Nc1cn(nc1C(N)=O)C1CCOCC1, Cc1cc(ccn1)-c1nc(co1)C(=O)Nc1cn(nc1C(N)=O)C1CCOCC1, Cc1cc(ccn1)-c1nc(co1)C(=O)Nc1cn(nc1C(N)=O)C1CCOCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"366","AS-252424","PI3K inhibitor","PIK3CG",NA,NA,"Oc1cc(F)ccc1-c1ccc(\C=C2/SC(=O)NC2=O)o1, Oc1cc(F)ccc1-c1ccc(\C=C2/SC(=O)NC2=O)o1, Oc1cc(F)ccc1-c1ccc(\C=C2/SC(=O)NC2=O)o1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"367","AS-604850","PI3K inhibitor","PIK3CA, PIK3CG",NA,NA,"FC1(F)Oc2ccc(\C=C3/SC(=O)NC3=O)cc2O1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"368","AS-703026","MEK inhibitor","MAP2K1, MAP2K2",NA,NA,"OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F, OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F, OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F, OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F, OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F, OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F, OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"369","AS-77","potassium channel blocker","KCNA3, KCNA5, KCNN4",NA,NA,"O=c1ccc2c(OCCCCOc3ccccc3)c3ccoc3cc2o1, O=c1ccc2c(OCCCCOc3ccccc3)c3ccoc3cc2o1, O=c1ccc2c(OCCCCOc3ccccc3)c3ccoc3cc2o1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"370","asaraldehyde","cyclooxygenase inhibitor","PTGS2",NA,NA,"COc1cc(OC)c(C=O)cc1OC, COc1cc(OC)c(C=O)cc1OC","Preclinical",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"371","ASC-J9","androgen receptor enhancer","AR",NA,NA,"COc1ccc(\C=C\C(O)=CC(=O)\C=C\c2ccc(OC)c(OC)c2)cc1OC, COc1ccc(\C=C\C(O)=CC(=O)\C=C\c2ccc(OC)c(OC)c2)cc1OC, COc1ccc(\C=C\C(O)=CC(=O)\C=C\c2ccc(OC)c(OC)c2)cc1OC, COc1ccc(\C=C\C(O)=CC(=O)\C=C\c2ccc(OC)c(OC)c2)cc1OC, COc1ccc(\C=C\C(O)=CC(=O)\C=C\c2ccc(OC)c(OC)c2)cc1OC","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"372","ascomycin","calcineurin inhibitor","FKBP1A",NA,NA,"CC[C@@H]1\C=C(C)\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\C)=C\[C@@H]1CC[C@@H](O)[C@@H](C1)OC |c:3|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"373","ascorbic-acid","antioxidant","SLC23A1, SLC23A2","endocrinology","scurvy","OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:2,4,&1:10|, OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:2,4,&1:10|, OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:2,4,&1:10|, OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:2,4,&1:10|, OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:2,4,&1:10|, OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:2,4,&1:10|","Launched",1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"374","asenapine","dopamine receptor antagonist, serotonin receptor antagonist","DRD2, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A","neurology/psychiatry","schizophrenia, bipolar disorder","[H][C@]12CN(C)C[C@]1([H])c1cc(Cl)ccc1Oc1ccccc21 |&1:1,6|, [H][C@]12CN(C)C[C@]1([H])c1cc(Cl)ccc1Oc1ccccc21 |&1:1,6|","Launched",0,0,0,0,0,0,0,0,1,5,1,1,0,0,1,1,0,0,0,0,1,1,1,1
"375","asiatic-acid","apoptosis stimulant","PYGM",NA,NA,"C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"376","asimadoline","opioid receptor agonist","OPRK1",NA,NA,"CN([C@H](CN1CC[C@H](O)C1)c1ccccc1)C(=O)C(c1ccccc1)c1ccccc1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"377","ASP-2535","glycine transporter inhibitor","SLC6A9",NA,NA,"CC(C)c1nnc(-c2ccc(nc2)-c2ccccc2)n1-c1cccc2nonc12, CC(C)c1nnc(-c2ccc(nc2)-c2ccccc2)n1-c1cccc2nonc12, CC(C)c1nnc(-c2ccc(nc2)-c2ccccc2)n1-c1cccc2nonc12","Phase 1",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"378","aspirin","cyclooxygenase inhibitor","AKR1C1, ASIC3, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3, PTGS1, PTGS2, RPS6KA3, TP53","neurology/psychiatry, endocrinology, dental","headache, fever, toothache, muscle pain","CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"379","ASP3026","ALK tyrosine kinase receptor inhibitor","ALK",NA,NA,"COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"380","asp5878","fgfr inhibitor","FGFR3",NA,NA,"OCCN1N=CC(NC2=NC=C(OCC3=C(F)C(OC)=CC(OC)=C3F)C=N2)=C1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"381","AST-1306","EGFR inhibitor","EGFR, ERBB2",NA,NA,"Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1, Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1, Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1, Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"382","astemizole","histamine receptor antagonist","HRH1, KCNH1, KCNH2",NA,NA,"COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1","Withdrawn",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
"383","asymmetrical-dimethylarginine","nitric oxide synthase inhibitor","NOS2, NOS3",NA,NA,"CN(C)C(=N)NCCC[C@H](N)C(O)=O, CN(C)C(=N)NCCC[C@H](N)C(O)=O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"384","AT-1015","serotonin receptor antagonist","HTR2A",NA,NA,"O=CN1CCC(CC1)C(=O)NCCN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:29|, O=CN1CCC(CC1)C(=O)NCCN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:29|","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"385","AT-7519","CDK inhibitor","CDK1, CDK2, CDK4, CDK5, CDK6, CDK9",NA,NA,"Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1, Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1, Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1, Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1, Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1, Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1, Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"386","AT-9283","Aurora kinase inhibitor, JAK inhibitor","AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A",NA,NA,"O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1, O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1, O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1, O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1, O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1, O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1, O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1, O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1, O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"387","ataluren","CFTR channel agonist, dystrophin stimulant","DMD","genetics, pulmonary","duchenne muscular dystrophy (DMD), cystic fibrosis","OC(=O)c1cccc(c1)-c1noc(n1)-c1ccccc1F, OC(=O)c1cccc(c1)-c1noc(n1)-c1ccccc1F","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"388","atamparib","parp inhibitor","TIPARP","oncology","carcinoid tumors","C[C@@H](COCCC(=O)N1CCN(CC1)c2ncc(cn2)C(F)(F)F)NC3=C(C(=O)NN=C3)C(F)(F)F","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"389","ATB-346","cyclooxygenase inhibitor","PTGER2",NA,NA,"COc1ccc2cc(ccc2c1)[C@@H](C)C(=O)Oc1ccc(cc1)C(N)=S |&1:12,r|, COc1ccc2cc(ccc2c1)[C@@H](C)C(=O)Oc1ccc(cc1)C(N)=S |&1:12,r|, COc1ccc2cc(ccc2c1)[C@@H](C)C(=O)Oc1ccc(cc1)C(N)=S |&1:12,r|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"390","atenolol-(+/-)","adrenergic receptor antagonist","ADRB1, ADRB2, LTF, PLA2G2E","cardiology","hypertension, angina pectoris","CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1 |&1:5,r|, CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1 |&1:5,r|, CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1 |&1:5,r|, CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1 |&1:5,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,1,1,1,1
"391","atiprimod","JAK inhibitor, STAT inhibitor","JAK2, STAT3",NA,NA,"CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1, CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1, CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1, CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1, CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1, CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1, CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1, CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"392","atizoram","phosphodiesterase inhibitor","PDE4A, PDE4B, PDE4C, PDE4D",NA,NA,"COc1ccc(cc1O[C@H]1C[C@@H]2CC[C@H]1C2)C1CNC(=O)NC1, COc1ccc(cc1O[C@H]1C[C@@H]2CC[C@H]1C2)C1CNC(=O)NC1, COc1ccc(cc1O[C@H]1C[C@@H]2CC[C@H]1C2)C1CNC(=O)NC1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"393","atm-3507","tropomyosin receptor kinase inhibitor","TPM3","oncology","ovarian cancer","CN1CCN(CCCn2c(C)c(C)c3cc(Oc4cccc(c4)C(=O)N5CCN(CCc6ccc(F)cc6)CC5)ccc23)CC1",NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"394","ATN-161","integrin antagonist","ITGA5, ITGAV, ITGB1, ITGB3",NA,NA,"CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O, CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O, CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O, CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O, CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O, CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"395","atomoxetine","norepinephrine transporter inhibitor","GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, SLC6A2, SLC6A3, SLC6A4","neurology/psychiatry","attention-deficit/hyperactivity disorder (ADHD)","CNCC[C@@H](Oc1ccccc1C)c1ccccc1, CNCC[C@@H](Oc1ccccc1C)c1ccccc1, CNCC[C@@H](Oc1ccccc1C)c1ccccc1, CNCC[C@@H](Oc1ccccc1C)c1ccccc1","Launched",1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"396","atorvastatin","HMGCR inhibitor","AHR, DPP4, HMGCR","neurology/psychiatry, cardiology","stroke, heart attack","CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"397","atosiban","oxytocin receptor antagonist","AVPR1A, AVPR1B, AVPR2, OXT, OXTR","Birth, neurology/psychiatry, cardiology, endocrinology","premature labor, stroke, angina pectoris, myocardial infarction, hyperlipidemia","CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@@H](C)CC)[C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)cc1, CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@@H](C)CC)[C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)cc1 |a:8,17,21,33,37,41,50,54,&1:29|, CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@@H](C)CC)[C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)cc1 |a:8,17,21,33,37,41,50,54,&1:29|, CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@@H](C)CC)[C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)cc1 |a:8,17,21,33,37,41,50,54,&1:29|, CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@@H](C)CC)[C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)cc1 |a:8,17,21,33,37,41,50,54,&1:29|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"398","ATPA","glutamate receptor agonist","GRIK1",NA,NA,"CC(C)(C)c1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:11,r|, CC(C)(C)c1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:11,r|, CC(C)(C)c1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:11,r|, CC(C)(C)c1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:11,r|, CC(C)(C)c1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:11,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"399","atr inhibitor 2","atr kinase inhibitor","ATR","oncology","ovarian cancer","Nc1nn2cc(F)cnc2c1C(=O)Nc1cncc(F)c1N1CCC(CC1)C(=O)N1CCN(CC1)C1COC1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"400","atrasentan","endothelin receptor antagonist","EDNRA",NA,NA,"CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1c1ccc(OC)cc1)C(O)=O)c1ccc2OCOc2c1, CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1c1ccc(OC)cc1)C(O)=O)c1ccc2OCOc2c1, CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1c1ccc(OC)cc1)C(O)=O)c1ccc2OCOc2c1, CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1c1ccc(OC)cc1)C(O)=O)c1ccc2OCOc2c1, CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1c1ccc(OC)cc1)C(O)=O)c1ccc2OCOc2c1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"401","atropine","acetylcholine receptor antagonist","CHRM1, CHRM2, CHRM3","ophthalmology","cycloplegia, mydriasis, amblyopia","CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,1,1,1,1
"402","atropine-oxide","acetylcholine receptor antagonist","CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",NA,NA,"C[N@@+]1([O-])[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1 |&1:3,6,8,&2:1,&3:13|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,5,0,0,0,0,0,0
"403","AT13148","protein kinase inhibitor","AKT1, AKT2, AKT3, ROCK1, ROCK2, SGK3",NA,NA,"NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1, NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1, NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1, NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1, NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1, NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"404","AT13387","HSP inhibitor","HSP90AA1",NA,NA,"CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"405","AT7867","AKT inhibitor","AKT2, GSK3B, PKIA, PRKACA",NA,NA,"Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"406","auranofin","NFkB pathway inhibitor","IKBKB, PRDX5, TRPA1","rheumatology","rheumatoid arthritis","CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O, CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O, CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O, CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O, CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"407","aurora-a-inhibitor-i","Aurora kinase inhibitor","AURKA",NA,NA,"CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1, CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1, CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1, CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1, CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"408","aurothioglucose","PKC inhibitor","PRKCI","rheumatology","rheumatoid arthritis","OC[C@H]1OC(S[Au])[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"409","autotaxin-modulator-1","autotaxin inhibitor","ENPP2",NA,NA,"C[C@@H](N1[C@H]2CC[C@@H]1C[C@@H](C2)C(O)=O)c1ccc2ccc(O[C@H]3CC[C@H](CC3)C(F)(F)F)c(c2c1)C(F)(F)F |a:1,21,24,&1:3,&2:6,&3:8,wU:8.11,21.22,24.29,wD:1.0,3.2,6.6,(6.23,2.09,;5.61,1.02,;4.07,1.02,;3.25,-.38,;2.26,.16,;2.26,1.96,;3.29,2.4,;1.65,2.4,;.83,1.02,;1.62,-.38,;-.71,1.02,;-1.33,2.09,;-1.33,-.04,;6.38,-.31,;5.62,-1.65,;6.4,-2.98,;7.94,-2.98,;8.71,-4.31,;10.25,-4.31,;11.01,-2.97,;12.56,-2.97,;13.33,-4.31,;14.87,-4.31,;15.64,-5.64,;14.86,-6.98,;13.32,-6.97,;12.56,-5.64,;15.63,-8.31,;16.86,-8.31,;15.02,-9.38,;16.25,-9.38,;10.24,-1.64,;8.71,-1.65,;7.94,-.32,;11.01,-.31,;12.24,-.3,;10.39,.76,;11.62,.76,)|, C[C@@H](N1[C@H]2CC[C@@H]1C[C@@H](C2)C(O)=O)c1ccc2ccc(O[C@H]3CC[C@H](CC3)C(F)(F)F)c(c2c1)C(F)(F)F |a:1,21,24,&1:3,&2:6,&3:8,wU:8.11,21.22,24.29,wD:1.0,3.2,6.6,(6.23,2.09,;5.61,1.02,;4.07,1.02,;3.25,-.38,;2.26,.16,;2.26,1.96,;3.29,2.4,;1.65,2.4,;.83,1.02,;1.62,-.38,;-.71,1.02,;-1.33,2.09,;-1.33,-.04,;6.38,-.31,;5.62,-1.65,;6.4,-2.98,;7.94,-2.98,;8.71,-4.31,;10.25,-4.31,;11.01,-2.97,;12.56,-2.97,;13.33,-4.31,;14.87,-4.31,;15.64,-5.64,;14.86,-6.98,;13.32,-6.97,;12.56,-5.64,;15.63,-8.31,;16.86,-8.31,;15.02,-9.38,;16.25,-9.38,;10.24,-1.64,;8.71,-1.65,;7.94,-.32,;11.01,-.31,;12.24,-.3,;10.39,.76,;11.62,.76,)|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"410","AV-412","protein tyrosine kinase inhibitor","EGFR, ERBB2",NA,NA,"CN1CCN(CC1)C(C)(C)C#Cc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=C, CN1CCN(CC1)C(C)(C)C#Cc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=C, CN1CCN(CC1)C(C)(C)C#Cc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=C","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"411","AV-608","tachykinin antagonist","TACR1",NA,NA,"FC(F)(F)c1cc(cc(c1)C(F)(F)F)C(=O)N1CC[C@@H](C[C@H]1Cc1ccc(Cl)cc1)NC(=O)c1ccnc2ccccc12, FC(F)(F)c1cc(cc(c1)C(F)(F)F)C(=O)N1CC[C@@H](C[C@H]1Cc1ccc(Cl)cc1)NC(=O)c1ccnc2ccccc12","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"412","avagacestat","gamma secretase inhibitor","PSEN1",NA,NA,"NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(cc1F)-c1ncon1)S(=O)(=O)c1ccc(Cl)cc1, NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(cc1F)-c1ncon1)S(=O)(=O)c1ccc(Cl)cc1, NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(cc1F)-c1ncon1)S(=O)(=O)c1ccc(Cl)cc1, NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(cc1F)-c1ncon1)S(=O)(=O)c1ccc(Cl)cc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"413","avanafil","phosphodiesterase inhibitor","PDE5A","urology","erectile dysfunction","COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl, COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl, COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl, COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl, COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"414","avasimibe","ACAT inhibitor","CES1",NA,NA,"CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"415","avatrombopag","thrombopoietin receptor agonist","MPL","hematology","thrombocytopenia","OC(=O)C1CCN(CC1)c1ncc(cc1Cl)C(=O)Nc1nc(-c2cc(Cl)cs2)c(s1)N1CCN(CC1)C1CCCCC1, OC(=O)C1CCN(CC1)c1ncc(cc1Cl)C(=O)Nc1nc(-c2cc(Cl)cs2)c(s1)N1CCN(CC1)C1CCCCC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"416","AVE-0991","angiotensin receptor agonist","MRGPRX1",NA,NA,"CCNC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(Cn2c(C=O)c(OC)nc2-c2ccccc2)cc1, CCNC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(Cn2c(C=O)c(OC)nc2-c2ccccc2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"417","AVL-292","Bruton's tyrosine kinase (BTK) inhibitor","BTK, YES1",NA,NA,"COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1, COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1, COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1, COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1, COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1, COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1, COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"418","AVN-944","inosine monophosphate dehydrogenase inhibitor","IMPDH1, IMPDH2",NA,NA,"CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1, CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1, CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1, CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1, CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1, CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"419","axitinib","PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, FLT1, FLT4, KDR, PLK4","oncology","renal cell carcinoma (RCC)","CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"420","AZ-10417808","caspase inhibitor","CASP3",NA,NA,"[O-][N+](=O)c1cc(C(=O)NCC=C)c2[nH]c(Nc3ccc(Cl)c(Cl)c3)nc(=O)c2c1, [O-][N+](=O)c1cc(C(=O)NCC=C)c2[nH]c(Nc3ccc(Cl)c(Cl)c3)nc(=O)c2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"421","AZ-10606120","purinergic receptor antagonist","P2RX7",NA,NA,"OCCNCCNc1ccc2c(NC(=O)CC34CC5CC(CC(C5)C3)C4)cccc2n1, OCCNCCNc1ccc2c(NC(=O)CC34CC5CC(CC(C5)C3)C4)cccc2n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"422","AZ-12080282","hedgehog pathway inhibitor","DHH",NA,NA,"Cc1ccc(cc1NC(=O)c1ccc(OCc2ccccn2)cc1)-c1ncc[nH]1, Cc1ccc(cc1NC(=O)c1ccc(OCc2ccccn2)cc1)-c1ncc[nH]1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"423","AZ-628","RAF inhibitor","BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"424","azacitidine","DNA methyltransferase inhibitor","DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)","Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"425","azacyclonol","histamine receptor antagonist","HRH1",NA,NA,"OC(C1CCNCC1)(c1ccccc1)c1ccccc1, OC(C1CCNCC1)(c1ccccc1)c1ccccc1, OC(C1CCNCC1)(c1ccccc1)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
"426","azaguanine-8","purine antagonist","PNP",NA,NA,"Nc1nc2nn[nH]c2c(=O)[nH]1, Nc1nc2nn[nH]c2c(=O)[nH]1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"427","azaperone","dopamine receptor antagonist","DRD2, DRD3","neurology/psychiatry","sedative","Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1, Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1, Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1, Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,1,1,1,1
"428","azapropazone","cyclooxygenase inhibitor","PTGS2",NA,NA,"CCC[C@H]1C(=O)N2N(C1=O)c1cc(C)ccc1N=C2N(C)C |r,c:19|, CCC[C@H]1C(=O)N2N(C1=O)c1cc(C)ccc1N=C2N(C)C |r,c:19|","Withdrawn",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"429","azasetron","serotonin receptor antagonist","HTR3A, HTR3B","infectious disease","genitial herpes","CN1C(=O)COc2c1cc(Cl)cc2C(=O)N[C@H]1CN2CCC1CC2 |&1:16|, CN1C(=O)COc2c1cc(Cl)cc2C(=O)N[C@H]1CN2CCC1CC2 |&1:16|","Launched",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"430","azatadine","histamine receptor antagonist","HRH1","allergy","allergic rhinitis","CN1CCC(CC1)=C1c2ccccc2CCc2cccnc12, CN1CCC(CC1)=C1c2ccccc2CCc2cccnc12, CN1CCC(CC1)=C1c2ccccc2CCc2cccnc12","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"431","azathioprine","dehydrogenase inhibitor","HPRT1, IMPDH1, PPAT","transplant, rheumatology","renal homotransplantation, rheumatoid arthritis","Cn1cnc(c1Sc1ncnc2nc[nH]c12)[N+]([O-])=O, Cn1cnc(c1Sc1ncnc2nc[nH]c12)[N+]([O-])=O, Cn1cnc(c1Sc1ncnc2nc[nH]c12)[N+]([O-])=O, Cn1cnc(c1Sc1ncnc2nc[nH]c12)[N+]([O-])=O, Cn1cnc(c1Sc1ncnc2nc[nH]c12)[N+]([O-])=O, Cn1cnc(c1Sc1ncnc2nc[nH]c12)[N+]([O-])=O, Cn1cnc(c1Sc1ncnc2nc[nH]c12)[N+]([O-])=O, Cn1cnc(c1Sc1ncnc2nc[nH]c12)[N+]([O-])=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"432","azd-0364","erk1 and erk2 phosphorylation inhibitor","MAPK1","oncology","non-small cell lung cancer (nsclc)","COC[C@H]1Cn2cc(nc2C(=O)N1Cc1ccc(F)c(F)c1)-c1nc(Nc2ccnn2C)ncc1C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"433","azd-4017","11-beta hydroxysteroid dehydrogenase inhibitor","GGT1, HSD11B1","endocrinology","obesity","CCCSc1nc(ccc1C(=O)NC1CCCCC1)N1CCC[C@@H](CC(O)=O)C1 |a:23|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"434","azd-7648","dna protein kinase inhibitor","PRKDC","oncology","melanoma","Cc1cc2ncnn2cc1Nc1ncc2n(C)c(=O)n(C3CCOCC3)c2n1","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"435","AZD1080","glycogen synthase kinase inhibitor","GSK3A, GSK3B",NA,NA,"O=C1Nc2ccc(cc2C1c1ccc(CN2CCOCC2)cn1)C#N, O=C1Nc2ccc(cc2C1c1ccc(CN2CCOCC2)cn1)C#N, O=C1Nc2ccc(cc2C1c1ccc(CN2CCOCC2)cn1)C#N, O=C1Nc2ccc(cc2C1c1ccc(CN2CCOCC2)cn1)C#N, O=C1Nc2ccc(cc2C1c1ccc(CN2CCOCC2)cn1)C#N, O=C1Nc2ccc(cc2C1c1ccc(CN2CCOCC2)cn1)C#N","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"436","AZD1208","Pim kinase inhibitor","PIM1, PIM2, PIM3",NA,NA,"N[C@@H]1CCCN(C1)c1c(\C=C2/SC(=O)NC2=O)cccc1-c1ccccc1, N[C@@H]1CCCN(C1)c1c(\C=C2/SC(=O)NC2=O)cccc1-c1ccccc1, N[C@@H]1CCCN(C1)c1c(\C=C2/SC(=O)NC2=O)cccc1-c1ccccc1, N[C@@H]1CCCN(C1)c1c(\C=C2/SC(=O)NC2=O)cccc1-c1ccccc1, N[C@@H]1CCCN(C1)c1c(\C=C2/SC(=O)NC2=O)cccc1-c1ccccc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"437","AZD1283","purinergic receptor antagonist","P2RY12",NA,NA,"CCOC(=O)c1cc(C#N)c(nc1C)N1CCC(CC1)C(=O)NS(=O)(=O)Cc1ccccc1, CCOC(=O)c1cc(C#N)c(nc1C)N1CCC(CC1)C(=O)NS(=O)(=O)Cc1ccccc1, CCOC(=O)c1cc(C#N)c(nc1C)N1CCC(CC1)C(=O)NS(=O)(=O)Cc1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"438","AZD1446","acetylcholine receptor agonist","CHRNA4, CHRNB2",NA,NA,"Clc1ccc(o1)C(=O)N1C[C@H]2CNC[C@@H]2C1 |&1:10,&2:14,r|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0
"439","AZD1480","JAK inhibitor","JAK1, JAK2, JAK3",NA,NA,"C[C@H](Nc1ncc(Cl)c(Nc2cc(C)n[nH]2)n1)c1ncc(F)cn1, C[C@H](Nc1ncc(Cl)c(Nc2cc(C)n[nH]2)n1)c1ncc(F)cn1, C[C@H](Nc1ncc(Cl)c(Nc2cc(C)n[nH]2)n1)c1ncc(F)cn1, C[C@H](Nc1ncc(Cl)c(Nc2cc(C)n[nH]2)n1)c1ncc(F)cn1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"440","azd1940","cannabinoid receptor agonist","CNR1, CNR2","neurology/psychiatry","acute pain","CCS(=O)(=O)Nc1ccc2n(CC3CCC(F)(F)CC3)c(nc2c1)C(C)(C)C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"441","AZD1981","CRTH receptor antagonist","PTGDR2",NA,NA,"CC(=O)Nc1cccc2n(CC(O)=O)c(C)c(Sc3ccc(Cl)cc3)c12, CC(=O)Nc1cccc2n(CC(O)=O)c(C)c(Sc3ccc(Cl)cc3)c12, CC(=O)Nc1cccc2n(CC(O)=O)c(C)c(Sc3ccc(Cl)cc3)c12","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"442","AZD2014","mTOR inhibitor","MTOR",NA,NA,"CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"443","azd2098","ccr antagonist","CCR4","pulmonary","asthma","O=S(C1=CC=CC(Cl)=C1Cl)(NC2=NC=CN=C2OC)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"444","AZD2858","glycogen synthase kinase inhibitor","GSK3B",NA,NA,"CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1, CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1, CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1, CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1, CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"445","AZD3264","IKK inhibitor","IKBKB",NA,NA,"Cc1noc(C)c1-c1ccc(-c2cc(C(N)=O)c(NC(N)=O)s2)c(O[C@H]2CCNC2)c1, Cc1noc(C)c1-c1ccc(-c2cc(C(N)=O)c(NC(N)=O)s2)c(O[C@H]2CCNC2)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"446","AZD3463","ALK tyrosine kinase receptor inhibitor, insulin growth factor receptor inhibitor","ALK, IGF1R",NA,NA,"COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"447","AZD3514","androgen receptor modulator","AR",NA,NA,"CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|, CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|, CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|, CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|, CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|, CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|, CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|, CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"448","AZD3759","EGFR inhibitor","EGFR",NA,NA,"COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC(=O)N1CCN(C)C[C@H]1C, COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC(=O)N1CCN(C)C[C@H]1C","Phase 2/Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"449","AZD3839","beta-secretase inhibitor","BACE1",NA,NA,"NC1=N[C@@](c2cccc(F)c12)(c1cccc(c1)-c1cncnc1)c1ccnc(c1)C(F)F |t:1|, NC1=N[C@@](c2cccc(F)c12)(c1cccc(c1)-c1cncnc1)c1ccnc(c1)C(F)F |t:1|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"450","AZD3965","monocarboxylate transporter inhibitor","SLC16A1",NA,NA,"CC(C)n1c2sc(Cc3c(C)[nH]nc3C(F)(F)F)c(C(=O)N3C[C@](C)(O)CO3)c2c(=O)n(C)c1=O, CC(C)n1c2sc(Cc3c(C)[nH]nc3C(F)(F)F)c(C(=O)N3C[C@](C)(O)CO3)c2c(=O)n(C)c1=O","Phase 1",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"451","AZD3988","diacylglycerol kinase inhibitor","DGAT1",NA,NA,"OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(NC(=O)c2nnc(Nc3ccc(F)c(F)c3)o2)cc1 |r|, OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(NC(=O)c2nnc(Nc3ccc(F)c(F)c3)o2)cc1 |r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"452","AZD4282","glutamate receptor antagonist","AGXT, AGXT2, ALAS1, ALAS2, BAAT, GARS, GATM, GCAT, GCSH, GLDC, GLRA1, GLRA2, GLRA3, GLRB, GLYAT, GLYATL1, GLYATL2, GNMT, GPR18, GPRC6A, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3B, GSS, PIPOX, SHMT1, SHMT2, SLC32A1, SLC36A1, SLC6A5, SLC6A9",NA,NA,"NCC(O)=O, NCC(O)=O","Phase 1",1,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"453","AZD4547","FGFR inhibitor","FGFR1, FGFR2, FGFR3, FGFR4, IGF1R, KDR",NA,NA,"COc1cc(CCc2cc(NC(=O)c3ccc(cc3)N3C[C@H](C)N[C@H](C)C3)[nH]n2)cc(OC)c1, COc1cc(CCc2cc(NC(=O)c3ccc(cc3)N3C[C@H](C)N[C@H](C)C3)[nH]n2)cc(OC)c1, COc1cc(CCc2cc(NC(=O)c3ccc(cc3)N3C[C@H](C)N[C@H](C)C3)[nH]n2)cc(OC)c1","Phase 2/Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"454","AZD5069","CC chemokine receptor antagonist","CXCR2",NA,NA,"C[C@@H](Oc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1)[C@@H](O)CO","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"455","AZD5363","AKT inhibitor","AKT1, AKT2, AKT3",NA,NA,"NC1(CCN(CC1)c1ncnc2[nH]ccc12)C(=O)N[C@@H](CCO)c1ccc(Cl)cc1, NC1(CCN(CC1)c1ncnc2[nH]ccc12)C(=O)N[C@@H](CCO)c1ccc(Cl)cc1, NC1(CCN(CC1)c1ncnc2[nH]ccc12)C(=O)N[C@@H](CCO)c1ccc(Cl)cc1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"456","azd5423","glucocorticoid receptor modulator","BGLAP, NR3C1","pulmonary","chronic obstructive pulmonary disease (copd)","COc1cccc(c1)[C@@H](Oc1ccc2n(ncc2c1)-c1ccc(F)cc1)[C@H](C)NC(=O)C(F)(F)F |a:8,26|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"457","AZD5438","CDK inhibitor","KCNH2",NA,NA,"CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"458","AZD5582","XIAP inhibitor","BIRC2, BIRC3, XIAP",NA,NA,"CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]1[C@@H](Cc2ccccc12)OCC#CC#CCO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](C)NC)C1CCCCC1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]1[C@@H](Cc2ccccc12)OCC#CC#CCO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](C)NC)C1CCCCC1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]1[C@@H](Cc2ccccc12)OCC#CC#CCO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](C)NC)C1CCCCC1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]1[C@@H](Cc2ccccc12)OCC#CC#CCO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](C)NC)C1CCCCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"459","AZD6482","PI3K inhibitor","PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,"C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"460","AZD6738","ATR kinase inhibitor","ATR",NA,NA,"C[C@@H]1COCCN1c1cc(nc(n1)-c1ccnc2[nH]ccc12)C1(CC1)[S@@](C)(=N)=O |a:1,&1:25|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"461","AZD6765","glutamate receptor antagonist","GRIN1",NA,NA,"N[C@@H](Cc1ccccn1)c1ccccc1 |&1:1,r|, N[C@@H](Cc1ccccn1)c1ccccc1 |&1:1,r|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"462","AZD7545","pyruvate dehydrogenase kinase inhibitor","PDK1",NA,NA,"CN(C)C(=O)c1ccc(cc1)S(=O)(=O)c1ccc(NC(=O)[C@@](C)(O)C(F)(F)F)c(Cl)c1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"463","AZD7687","diacylglycerol O acyltransferase inhibitor","DGAT1",NA,NA,"Cc1nc(C)c(nc1C(N)=O)-c1ccc(cc1)[C@H]1CC[C@H](CC(O)=O)CC1 |r|, Cc1nc(C)c(nc1C(N)=O)-c1ccc(cc1)[C@H]1CC[C@H](CC(O)=O)CC1 |r|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"464","AZD7762","CHK inhibitor","CHEK1, CHEK2",NA,NA,"NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"465","AZD8055","mTOR inhibitor","MTOR",NA,NA,"COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"466","AZD8186","PI3K inhibitor","PIK3CB, PIK3CD",NA,NA,"C[C@@H](Nc1cc(F)cc(F)c1)c1cc(cc2c1oc(cc2=O)N1CCOCC1)C(=O)N(C)C, C[C@@H](Nc1cc(F)cc(F)c1)c1cc(cc2c1oc(cc2=O)N1CCOCC1)C(=O)N(C)C, C[C@@H](Nc1cc(F)cc(F)c1)c1cc(cc2c1oc(cc2=O)N1CCOCC1)C(=O)N(C)C, C[C@@H](Nc1cc(F)cc(F)c1)c1cc(cc2c1oc(cc2=O)N1CCOCC1)C(=O)N(C)C","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"467","azd8329","11-beta hydroxysteroid dehydrogenase inhibitor","HSD11B1","endocrinology","obesity","CC(C)(C)c1c(cnn1-c1ccc(cc1)C(O)=O)C(=O)NC1C2CC3CC(C2)CC1C3","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"468","AZD8330","MEK inhibitor","MAP3K1",NA,NA,"Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O, Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O, Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O, Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O, Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O, Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"469","AZD8835","PI3K inhibitor","PIK3CA, PIK3CD",NA,NA,"CCn1nc(nc1-c1cnc(N)c(n1)-c1nnc(o1)C(C)(C)C)C1CCN(CC1)C(=O)CCO, CCn1nc(nc1-c1cnc(N)c(n1)-c1nnc(o1)C(C)(C)C)C1CCN(CC1)C(=O)CCO, CCn1nc(nc1-c1cnc(N)c(n1)-c1nnc(o1)C(C)(C)C)C1CCN(CC1)C(=O)CCO, CCn1nc(nc1-c1cnc(N)c(n1)-c1nnc(o1)C(C)(C)C)C1CCN(CC1)C(=O)CCO","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"470","AZD8931","EGFR inhibitor","EGFR, ERBB2, ERBB3",NA,NA,"CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC, CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC, CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC, CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC, CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC, CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"471","AZD9272","glutamate receptor antagonist","GRM5",NA,NA,"Fc1ccc(nc1)-c1noc(n1)-c1cc(F)cc(c1)C#N, Fc1ccc(nc1)-c1noc(n1)-c1cc(F)cc(c1)C#N, Fc1ccc(nc1)-c1noc(n1)-c1cc(F)cc(c1)C#N","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"472","AZD9496","estrogen receptor agonist","ESR1",NA,NA,"C[C@@H]1Cc2c([nH]c3ccccc23)[C@H](N1CC(C)(C)F)c1c(F)cc(\C=C\C(O)=O)cc1F, C[C@@H]1Cc2c([nH]c3ccccc23)[C@H](N1CC(C)(C)F)c1c(F)cc(\C=C\C(O)=O)cc1F, C[C@@H]1Cc2c([nH]c3ccccc23)[C@H](N1CC(C)(C)F)c1c(F)cc(\C=C\C(O)=O)cc1F, C[C@@H]1Cc2c([nH]c3ccccc23)[C@H](N1CC(C)(C)F)c1c(F)cc(\C=C\C(O)=O)cc1F","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"473","AZD9668","elastase inhibitor","ELANE",NA,NA,"Cc1c(cc(C(=O)NCc2ccc(cn2)S(C)(=O)=O)c(=O)n1-c1cccc(c1)C(F)(F)F)-c1ccnn1C, Cc1c(cc(C(=O)NCc2ccc(cn2)S(C)(=O)=O)c(=O)n1-c1cccc(c1)C(F)(F)F)-c1ccnn1C, Cc1c(cc(C(=O)NCc2ccc(cn2)S(C)(=O)=O)c(=O)n1-c1cccc(c1)C(F)(F)F)-c1ccnn1C","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"474","azelaic-acid","tyrosinase inhibitor","AKR1D1, SRD5A2, TYR","dermatology","rosacea","OC(=O)CCCCCCCC(O)=O, OC(=O)CCCCCCCC(O)=O, OC(=O)CCCCCCCC(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"475","azelastine","histamine receptor antagonist","HRH1","ophthalmology","conjunctivitis","CN1CCC[C@@H](CC1)n1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O |&1:5|, CN1CCC[C@@H](CC1)n1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O |&1:5|, CN1CCC[C@@H](CC1)n1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O |&1:5|, CN1CCC[C@@H](CC1)n1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O |&1:5|","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"476","azeliragon","RAGE receptor antagonist","AGER",NA,NA,"CCCCc1nc(cn1-c1ccc(Oc2ccc(Cl)cc2)cc1)-c1ccc(OCCCN(CC)CC)cc1, CCCCc1nc(cn1-c1ccc(Oc2ccc(Cl)cc2)cc1)-c1ccc(OCCCN(CC)CC)cc1, CCCCc1nc(cn1-c1ccc(Oc2ccc(Cl)cc2)cc1)-c1ccc(OCCCN(CC)CC)cc1, CCCCc1nc(cn1-c1ccc(Oc2ccc(Cl)cc2)cc1)-c1ccc(OCCCN(CC)CC)cc1, CCCCc1nc(cn1-c1ccc(Oc2ccc(Cl)cc2)cc1)-c1ccc(OCCCN(CC)CC)cc1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"477","azelnidipine","calcium channel blocker","CACNA1C","cardiology","hypertension","CC(C)OC(=O)C1=C(C)NC(N)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1 |r,c:6,11|, CC(C)OC(=O)C1=C(C)NC(N)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1 |r,c:6,11|, CC(C)OC(=O)C1=C(C)NC(N)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1 |r,c:6,11|, CC(C)OC(=O)C1=C(C)NC(N)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1 |r,c:6,11|, CC(C)OC(=O)C1=C(C)NC(N)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1 |r,c:6,11|, CC(C)OC(=O)C1=C(C)NC(N)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1 |r,c:6,11|, CC(C)OC(=O)C1=C(C)NC(N)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1 |r,c:6,11|, CC(C)OC(=O)C1=C(C)NC(N)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1 |r,c:6,11|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"478","azilsartan","angiotensin receptor antagonist","AGTR1, AGTR2","cardiology","hypertension","CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"479","azilsartan-medoxomil","angiotensin receptor antagonist","AGTR1, AGTR2","cardiology","hypertension","CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"480","azimilide","potassium channel blocker","KCNA5",NA,NA,"CN1CCN(CCCCN2C(=O)CN(\N=C\c3ccc(o3)-c3ccc(Cl)cc3)C2=O)CC1, CN1CCN(CCCCN2C(=O)CN(\N=C\c3ccc(o3)-c3ccc(Cl)cc3)C2=O)CC1, CN1CCN(CCCCN2C(=O)CN(\N=C\c3ccc(o3)-c3ccc(Cl)cc3)C2=O)CC1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"481","azithromycin","bacterial 50S ribosomal subunit inhibitor","MLNR","infectious disease","pelvic inflammatory disease, pneumonia","CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"482","AZM-475271","SRC inhibitor","SRC",NA,NA,"COc1ccc(Cl)c(Nc2ncnc3cc(OCC4CCN(C)CC4)c(OC)cc23)c1, COc1ccc(Cl)c(Nc2ncnc3cc(OCC4CCN(C)CC4)c(OC)cc23)c1, COc1ccc(Cl)c(Nc2ncnc3cc(OCC4CCN(C)CC4)c(OC)cc23)c1, COc1ccc(Cl)c(Nc2ncnc3cc(OCC4CCN(C)CC4)c(OC)cc23)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"483","azosemide","electrolyte reabsorption inhibitor","SLC12A1, SLC12A2","cardiology","edema","NS(=O)(=O)c1cc(-c2nn[nH]n2)c(NCc2cccs2)cc1Cl, NS(=O)(=O)c1cc(-c2nn[nH]n2)c(NCc2cccs2)cc1Cl, NS(=O)(=O)c1cc(-c2nn[nH]n2)c(NCc2cccs2)cc1Cl, NS(=O)(=O)c1cc(-c2nn[nH]n2)c(NCc2cccs2)cc1Cl","Launched",1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"484","AZ191","DYRK inhibitor","DYRK1B",NA,NA,"COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1, COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1, COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1, COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1, COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1, COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"485","AZ20","ATR kinase inhibitor","ATR, MTOR",NA,NA,"C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O, C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"486","AZ505","histone lysine methyltransferase inhibitor","SMYD2",NA,NA,"Oc1ccc(CCNCCN(C2CCCCC2)C(=O)CCNCCc2ccc(Cl)c(Cl)c2)c2OCC(=O)Nc12, Oc1ccc(CCNCCN(C2CCCCC2)C(=O)CCNCCc2ccc(Cl)c(Cl)c2)c2OCC(=O)Nc12, Oc1ccc(CCNCCN(C2CCCCC2)C(=O)CCNCCc2ccc(Cl)c(Cl)c2)c2OCC(=O)Nc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"487","AZ5104","EGFR inhibitor","EGFR",NA,NA,"COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1c[nH]c2ccccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"488","AZ960","JAK inhibitor","JAK2",NA,NA,"C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"489","A12B4C3","polynucleotide kinase/phosphatase inhibitor","PNKP",NA,NA,"CCCCCCCCCC[C@@H](O)[C@H]1C=C[C@H]2[C@@H](N1Nc1ccc(cc1)[N+]([O-])=O)C(=O)N(C2=O)c1ccccc1 |&1:10,&2:12,r,c:13|, CCCCCCCCCC[C@@H](O)[C@H]1C=C[C@H]2[C@@H](N1Nc1ccc(cc1)[N+]([O-])=O)C(=O)N(C2=O)c1ccccc1 |&1:10,&2:12,r,c:13|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"490","A205804","ICAM1 expression inhibitor","ICAM1, SELE",NA,NA,"Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1, Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1, Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1, Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1, Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1, Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1, Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"491","A61603","adrenergic receptor agonist","ADRA1A",NA,NA,"CS(=O)(=O)Nc1c(O)ccc2[C@@H](CCCc12)C1=NCCN1 |r,t:18|, CS(=O)(=O)Nc1c(O)ccc2[C@@H](CCCc12)C1=NCCN1 |r,t:18|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
"492","A66","PI3K inhibitor","PIK3CA",NA,NA,"Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(n1)C(C)(C)C, Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(n1)C(C)(C)C, Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(n1)C(C)(C)C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"493","A740003","purinergic receptor antagonist","P2RX7",NA,NA,"COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|, COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|, COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|, COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|, COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|, COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|, COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"494","A77636","dopamine receptor agonist","CALY",NA,NA,"NC[C@@H]1O[C@@H](Cc2c(O)c(O)ccc12)[C@@]12CC3CC(CC(C3)C1)C2, NC[C@@H]1O[C@@H](Cc2c(O)c(O)ccc12)[C@@]12CC3CC(CC(C3)C1)C2, NC[C@@H]1O[C@@H](Cc2c(O)c(O)ccc12)[C@@]12CC3CC(CC(C3)C1)C2","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"495","A922500","diacylglycerol O acyltransferase inhibitor","DGAT1",NA,NA,"OC(=O)[C@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"496","bacitracin","bacterial cell wall synthesis inhibitor","IDE","infectious disease","first-aid antibiotic","CCC(C)C(N)C1=NC(CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H]1CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC1=O)[C@@H](C)CC, CC[C@H](C)[C@H](N)C1=N[C@@H](CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H]1CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC1=O)[C@@H](C)CC |t:6|, CCC(C)C(N)C1=NC(CS1)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)CC)C(=O)NCCCCC1NC(=O)C(CC(N)=O)NC(=O)C(CC(O)=O)NC(=O)C(Cc2c[nH]cn2)NC(=O)C(Cc2ccccc2)NC(=O)C(NC(=O)C(CCCN)NC1=O)C(C)CC","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"497","baclofen","benzodiazepine receptor agonist","GABBR1, GABBR2, KCTD12, KCTD16, KCTD8","neurology/psychiatry","multiple sclerosis, spasms","NC[C@@H](CC(O)=O)c1ccc(Cl)cc1 |&1:2|, NC[C@@H](CC(O)=O)c1ccc(Cl)cc1 |&1:2|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"498","BADGE","PPAR receptor antagonist","PPARG",NA,NA,"CC(C)(c1ccc(OC[C@H]2CO2)cc1)c1ccc(OC[C@H]2CO2)cc1 |&1:9,&2:20,r|, CC(C)(c1ccc(OC[C@H]2CO2)cc1)c1ccc(OC[C@H]2CO2)cc1 |&1:9,&2:20,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"499","bafetinib","Bcr-Abl kinase inhibitor, LYN tyrosine kinase inhibitor","ABL1, BCR, LYN",NA,NA,"CN(C)[C@H]1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cncnc3)c2)C1, CN(C)[C@H]1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cncnc3)c2)C1, CN(C)[C@H]1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cncnc3)c2)C1, CN(C)[C@H]1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cncnc3)c2)C1, CN(C)[C@H]1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cncnc3)c2)C1, CN(C)[C@H]1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cncnc3)c2)C1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"500","BAG-956","phosphoinositide dependent kinase inhibitor","PIK3CG",NA,NA,"Cc1nc2cnc3ccc(cc3c2n1-c1ccc(cc1)C(C)(C)C#N)C#Cc1cccnc1, Cc1nc2cnc3ccc(cc3c2n1-c1ccc(cc1)C(C)(C)C#N)C#Cc1cccnc1, Cc1nc2cnc3ccc(cc3c2n1-c1ccc(cc1)C(C)(C)C#N)C#Cc1cccnc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"501","baicalein","lipoxygenase inhibitor","ALOX5, GLO1, PREP, SELL, SELP, TNF, XDH",NA,NA,"Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1, Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1, Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1, Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1, Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1, Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1, Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"502","baicalin","beta glucuronidase inhibitor","PREP","neurology/psychiatry","anxiety","O[C@H]1[C@H](Oc2cc3oc(cc(O)c3c(=O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O, O[C@H]1[C@H](Oc2cc3oc(cc(O)c3c(=O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O, O[C@H]1[C@H](Oc2cc3oc(cc(O)c3c(=O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O, O[C@H]1[C@H](Oc2cc3oc(cc(O)c3c(=O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O, O[C@H]1[C@H](Oc2cc3oc(cc(O)c3c(=O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"503","bakuchiol","DNA polymerase inhibitor","HIF1A",NA,NA,"CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1, CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1, CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1, CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1, CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"504","balaglitazone","insulin sensitizer, PPAR receptor partial agonist","PPARG",NA,NA,"Cn1c(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)nc2ccccc2c1=O |r|, Cn1c(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)nc2ccccc2c1=O |r|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"505","balicatib","cathepsin inhibitor","CTSK",NA,NA,"CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N, CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N, CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N, CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N, CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"506","balovaptan","vasopressin receptor antagonist","AVPR1A, AVPR2, HTR2B, OXTR",NA,NA,"CN1CC2=NN=C([C@H]3CC[C@H](OC4=NC=CC=C4)CC3)[N@]2[C@]5=CC=C(Cl)C=C5C1","Phase 3",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"507","balsalazide","cyclooxygenase inhibitor","ALOX5, PPARG, PTGS1, PTGS2","gastroenterology","ulcerative colitis","OC(=O)CCNC(=O)c1ccc(cc1)\N=N\c1ccc(O)c(c1)C(O)=O","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"508","bambuterol","adrenergic receptor agonist","ADRB2, BCHE","pulmonary","asthma","CN(C)C(=O)Oc1cc(OC(=O)N(C)C)cc(c1)C(O)CNC(C)(C)C, CN(C)C(=O)Oc1cc(OC(=O)N(C)C)cc(c1)[C@@H](O)CNC(C)(C)C |&1:18,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"509","BAM7","BAX activator","BAX",NA,NA,"CCOc1ccccc1N\N=C1/C(C)=NN(C1=O)c1nc(cs1)-c1ccccc1 |c:14|, CCOc1ccccc1N\N=C1/C(C)=NN(C1=O)c1nc(cs1)-c1ccccc1 |c:14|, CCOc1ccccc1N\N=C1/C(C)=NN(C1=O)c1nc(cs1)-c1ccccc1 |c:14|, CCOc1ccccc1N\N=C1/C(C)=NN(C1=O)c1nc(cs1)-c1ccccc1 |c:14|, CCOc1ccccc1N\N=C1/C(C)=NN(C1=O)c1nc(cs1)-c1ccccc1 |c:14|, CCOc1ccccc1N\N=C1/C(C)=NN(C1=O)c1nc(cs1)-c1ccccc1 |c:14|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"510","BAN-ORL-24","nociceptin/orphanin FQ receptor antagonist","OPRL1",NA,NA,"O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1, O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1, O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1, O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"511","banoxantrone","topoisomerase inhibitor","TOP2A",NA,NA,"C[N+](C)([O-])CCNc1ccc(NCC[N+](C)(C)[O-])c2C(=O)c3c(O)ccc(O)c3C(=O)c12","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"512","barasertib","Aurora kinase inhibitor","AURKA, AURKB",NA,NA,"CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1)CCOP(O)(O)=O, CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1)CCOP(O)(O)=O, CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1)CCOP(O)(O)=O, CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1)CCOP(O)(O)=O","Phase 2/Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"513","barasertib-HQPA","Aurora kinase inhibitor","AURKB",NA,NA,"CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1","Phase 2/Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"514","bardoxolone","nuclear factor erythroid derived, like (NRF2) activator","NOS2, PPARG",NA,NA,"CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O |t:17,21|, CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O |t:17,21|, CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O |t:17,21|, CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O |t:17,21|, CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O |t:17,21|, CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O |t:17,21|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"515","bardoxolone-methyl","nuclear factor erythroid derived, like (NRF2) activator","PPARG, STAT3",NA,NA,"COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:16,20|, COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:16,20|, COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:16,20|, COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:16,20|, COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:16,20|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"516","baricitinib","JAK inhibitor","JAK1, JAK2","rheumatology","rheumatoid arthritis","CCS(=O)(=O)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12, CCS(=O)(=O)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12, CCS(=O)(=O)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12, CCS(=O)(=O)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12, CCS(=O)(=O)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"517","basimglurant","glutamate receptor antagonist","GRM5",NA,NA,"Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(F)cc1, Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(F)cc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"518","batabulin","tubulin polymerisation inhibitor","TUBB","oncology","breast cancer","O=S(C1=C(F)C(F)=C(F)C(F)=C1F)(NC2=CC=C(OC)C(F)=C2)=O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"519","batimastat","matrix metalloprotease inhibitor","ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8",NA,NA,"CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"520","bavisant","histamine receptor antagonist","HRH3",NA,NA,"O=C(N1CCN(CC1)C1CC1)c1ccc(CN2CCOCC2)cc1, O=C(N1CCN(CC1)C1CC1)c1ccc(CN2CCOCC2)cc1, O=C(N1CCN(CC1)C1CC1)c1ccc(CN2CCOCC2)cc1","Phase 2",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
"521","BAX-channel-blocker","cytochrome C release inhibitor","BAX",NA,NA,"O[C@@H](CN1CCNCC1)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:1|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"522","bay 2416964","antitumor agent","AHR","oncology","non-small cell lung cancer (nsclc)","C[C@@H](CO)NC(=O)c1cc(nn(-c2cnn(C)c2)c1=O)-c1ccc(Cl)cc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"523","BAY-K-8644-(s)-(-)","L-type calcium channel activator","CACNA1C",NA,NA,"COC(=O)C1=C(C)NC(C)=C([C@H]1c1ccccc1C(F)(F)F)[N+]([O-])=O |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@H]1c1ccccc1C(F)(F)F)[N+]([O-])=O |c:4,9|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"524","BAY-11-7082","NFkB pathway inhibitor","RELA",NA,NA,"Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"525","BAY-11-7085","NFkB pathway inhibitor","NFKBIA",NA,NA,"CC(C)(C)c1ccc(cc1)S(=O)(=O)\C=C\C#N, CC(C)(C)c1ccc(cc1)S(=O)(=O)\C=C\C#N","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"526","BAY-41-2272","guanylyl cyclase activator","GUCY1A3, GUCY1B3",NA,NA,"Nc1nc(ncc1C1CC1)-c1nn(Cc2ccccc2F)c2ncccc12, Nc1nc(ncc1C1CC1)-c1nn(Cc2ccccc2F)c2ncccc12, Nc1nc(ncc1C1CC1)-c1nn(Cc2ccccc2F)c2ncccc12, Nc1nc(ncc1C1CC1)-c1nn(Cc2ccccc2F)c2ncccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"527","BAY-60-6583","adenosine receptor agonist","ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,"NC(=O)CSc1nc(N)c(C#N)c(-c2ccc(OCC3CC3)cc2)c1C#N, NC(=O)CSc1nc(N)c(C#N)c(-c2ccc(OCC3CC3)cc2)c1C#N","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"528","BAY-60-7550","phosphodiesterase inhibitor","PDE2A",NA,NA,"COc1ccc(Cc2nc(=O)c3c(C)nc([C@@H](CCCc4ccccc4)[C@@H](C)O)n3[nH]2)cc1OC","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"529","BAY-61-3606","SYK inhibitor","SYK",NA,NA,"COc1ccc(cc1OC)-c1cc2nccn2c(Nc2ncccc2C(N)=O)n1, COc1ccc(cc1OC)-c1cc2nccn2c(Nc2ncccc2C(N)=O)n1, COc1ccc(cc1OC)-c1cc2nccn2c(Nc2ncccc2C(N)=O)n1, COc1ccc(cc1OC)-c1cc2nccn2c(Nc2ncccc2C(N)=O)n1, COc1ccc(cc1OC)-c1cc2nccn2c(Nc2ncccc2C(N)=O)n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"530","bay-85-8501","elastase inhibitor","ELANE",NA,NA,"CN1[C@@H](C(C#N)=C(C)N(C1=O)c1cccc(c1)C(F)(F)F)c1ccc(cc1S(C)(=O)=O)C#N |a:2,t:5|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"531","BAY-87-2243","hypoxia inducible factor inhibitor","HIF1A",NA,NA,"Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1, Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1, Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1, Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1, Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1, Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1, Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"532","bazedoxifene","selective estrogen receptor modulator (SERM)","ESR1, ESR2","orthopedics, endocrinology","osteoporosis, menopause","Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"533","BAZ2-ICR","bromodomain inhibitor","ZNF215",NA,NA,"Cn1cc(CCn2cnc(-c3cnn(C)c3)c2-c2ccc(cc2)C#N)cn1, Cn1cc(CCn2cnc(-c3cnn(C)c3)c2-c2ccc(cc2)C#N)cn1, Cn1cc(CCn2cnc(-c3cnn(C)c3)c2-c2ccc(cc2)C#N)cn1, Cn1cc(CCn2cnc(-c3cnn(C)c3)c2-c2ccc(cc2)C#N)cn1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"534","BC-11","urokinase inhibitor","PLAU",NA,NA,"NC(=N)SCc1ccc(cc1)B(O)O, NC(=N)SCc1ccc(cc1)B(O)O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"535","BCTC","TRPV antagonist","TRPV1",NA,NA,"CC(C)(C)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2Cl)cc1, CC(C)(C)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2Cl)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"536","BCX-1470","complement inhibitor, serine protease inhibitor","CFD",NA,NA,"NC(=N)c1cc2ccc(OC(=O)c3cccs3)cc2s1, NC(=N)c1cc2ccc(OC(=O)c3cccs3)cc2s1, NC(=N)c1cc2ccc(OC(=O)c3cccs3)cc2s1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"537","BD-1047","adrenergic receptor antagonist","SIGMAR1",NA,NA,"CN(C)CCN(C)CCc1ccc(Cl)c(Cl)c1, CN(C)CCN(C)CCc1ccc(Cl)c(Cl)c1, CN(C)CCN(C)CCc1ccc(Cl)c(Cl)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"538","BD-1063","sigma receptor antagonist","SIGMAR1",NA,NA,"CN1CCN(CCc2ccc(Cl)c(Cl)c2)CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"539","BE-2254","adrenergic receptor antagonist","ADRA1A",NA,NA,"Oc1ccc(CCNC[C@H]2CCc3ccccc3C2=O)cc1 |r|, Oc1ccc(CCNC[C@H]2CCc3ccccc3C2=O)cc1 |r|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
"540","beclomethasone","glucocorticoid receptor agonist","NR3C1, SERPINA6","allergy","allergic rhinitis","C[C@H]1C[C@H]2[C@H]3CCC4=CC(=O)C=C[C@@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]2(C)[C@@]1(O)C(=O)CO |&1:1,&2:3,&3:4,&4:13,&5:15,&6:17,&7:20,&8:22,r,c:11,t:7|, C[C@H]1C[C@H]2[C@H]3CCC4=CC(=O)C=C[C@@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]2(C)[C@@]1(O)C(=O)CO |&1:1,&2:3,&3:4,&4:13,&5:15,&6:17,&7:20,&8:22,r,c:11,t:7|, C[C@H]1C[C@H]2[C@H]3CCC4=CC(=O)C=C[C@@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]2(C)[C@@]1(O)C(=O)CO |&1:1,&2:3,&3:4,&4:13,&5:15,&6:17,&7:20,&8:22,r,c:11,t:7|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"541","beclomethasone-dipropionate","glucocorticoid receptor agonist","GPR97, NR3C1","allergy","allergic rhinitis","CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C |c:25,t:21|, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C |c:25,t:21|, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C |c:25,t:21|, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C |c:25,t:21|, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C |c:25,t:21|, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C |c:25,t:21|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"542","begacestat","gamma secretase inhibitor","PSEN1",NA,NA,"OC[C@@H](NS(=O)(=O)c1ccc(Cl)s1)C(C(F)(F)F)C(F)(F)F, OC[C@@H](NS(=O)(=O)c1ccc(Cl)s1)C(C(F)(F)F)C(F)(F)F, OC[C@@H](NS(=O)(=O)c1ccc(Cl)s1)C(C(F)(F)F)C(F)(F)F, OC[C@@H](NS(=O)(=O)c1ccc(Cl)s1)C(C(F)(F)F)C(F)(F)F","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"543","belinostat","HDAC inhibitor","HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9","hematologic malignancy","peripheral T-cell lymphoma (PTCL)","ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1, ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1, ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1, ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1, ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1, ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1, ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1, ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"544","belvarafenib","raf inhibitor","ARAF, BRAF, NRAS","oncology","melanoma","Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"545","belzutifan","hif modulator","EPAS1","oncology","renal cell carcinoma (rcc)","CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c3[C@@H](F)[C@@H](F)[C@@H](O)c13","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"546","bemegride","chemoreceptor agonist","GABRA1","critical care","poison antidote","CCC1(C)CC(=O)NC(=O)C1, CCC1(C)CC(=O)NC(=O)C1, CCC1(C)CC(=O)NC(=O)C1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1
"547","bemesetron","serotonin receptor antagonist","HTR3A, HTR3B",NA,NA,"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1cc(Cl)cc(Cl)c1 |r,THB:0:1:3.4:6.7.8|","Phase 3",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"548","bempedoic-acid","AMPK inhibitor","ACLY",NA,NA,"CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O, CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"549","benazepril","angiotensin converting enzyme inhibitor","ACE","cardiology","hypertension","CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"550","bendazac","cyclooxygenase inhibitor","PTGS1, PTGS2","neurology/psychiatry, rheumatology","muscle pain, joint pain","OC(=O)COc1nn(Cc2ccccc2)c2ccccc12","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"551","bendroflumethiazide","sodium/potassium/chloride transporter inhibitor","SLC12A1, SLC12A3","cardiology","hypertension","NS(=O)(=O)c1cc2c(N[C@@H](Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F |&1:9,r|","Launched",1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"552","benfluorex","gluconeogenesis inhibitor","HMGCR",NA,NA,"C[C@@H](Cc1cccc(c1)C(F)(F)F)NCCOC(=O)c1ccccc1 |r|","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"553","benfotiamine","antioxidant","AGER","rheumatology","lumbago","C\C(N(Cc1cnc(C)nc1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)c1ccccc1, C\C(N(Cc1cnc(C)nc1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)c1ccccc1, C\C(N(Cc1cnc(C)nc1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)c1ccccc1, C\C(N(Cc1cnc(C)nc1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"554","benidipine","calcium channel blocker","CACNA1C, CACNA1G","cardiology","hypertension","COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"555","benperidol","dopamine receptor antagonist","DRD2","neurology/psychiatry","schizophrenia","Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O, Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1
"556","benproperine","antitussive","SCN5A","pulmonary","cough suppressant","C[C@@H](COc1ccccc1Cc1ccccc1)N1CCCCC1 |&1:1,r|, C[C@@H](COc1ccccc1Cc1ccccc1)N1CCCCC1 |&1:1,r|","Launched",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"557","benserazide","DOPA decarboxylase inhibitor","DDC","neurology/psychiatry","Parkinson's Disease","NC(CO)C(=O)NNCc1ccc(O)c(O)c1O, NC(CO)C(=O)NNCc1ccc(O)c(O)c1O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"558","benzamil","sodium channel blocker","ASIC1, PKD2L1, SCNN1A, SCNN1B, SCNN1D, SCNN1G, SLC8A1",NA,NA,"NC(NCc1ccccc1)=NC(=O)c1nc(Cl)c(N)nc1N, NC(NCc1ccccc1)=NC(=O)c1nc(Cl)c(N)nc1N, NC(NCc1ccccc1)=NC(=O)c1nc(Cl)c(N)nc1N","Phase 2",1,1,1,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"559","benzbromarone","chloride channel blocker","ABCC1","rheumatology","gout","CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1, CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1, CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"560","benzethonium","sodium channel blocker","SCN10A","infectious disease","first-aid antiseptic","CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1","Launched",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"561","benzocaine","sodium channel blocker","SCN10A","infectious disease","first-aid antiseptic","CCOC(=O)c1ccc(N)cc1, CCOC(=O)c1ccc(N)cc1, CCOC(=O)c1ccc(N)cc1, CCOC(=O)c1ccc(N)cc1","Launched",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"562","benzoic-acid","food preservative","DAO, HRSP12, PRDX5, RAB9A","infectious disease","tinea pedis","OC(=O)c1ccccc1, OC(=O)c1ccccc1, OC(=O)c1ccccc1, OC(=O)c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"563","benzonatate","local anesthetic","SCN5A","pulmonary","cough suppressant","CCCCNc1ccc(cc1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC, CCCCNc1ccc(cc1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC","Launched",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"564","benzoquinonium-dibromide","cholinergic receptor antagonist","CHRNA1",NA,NA,"CC[N+](CC)(CCCNC1=CC(=O)C(NCCC[N+](CC)(CC)Cc2ccccc2)=CC1=O)Cc1ccccc1 |c:30,t:9|, CC[N+](CC)(CCCNC1=CC(=O)C(NCCC[N+](CC)(CC)Cc2ccccc2)=CC1=O)Cc1ccccc1 |c:30,t:9|, CC[N+](CC)(CCCNC1=CC(=O)C(NCCC[N+](CC)(CC)Cc2ccccc2)=CC1=O)Cc1ccccc1 |c:30,t:9|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
"565","benzotript","CCK receptor antagonist","CCKAR, CCKBR",NA,NA,"OC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1 |&1:3,r|, OC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"566","benzquinamide","dopamine receptor agonist","DRD2, PTGS2","gastroenterology","nausea","CCN(CC)C(=O)C1CN2CCc3cc(OC)c(OC)cc3C2CC1OC(=O)C","Withdrawn",0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1
"567","benzthiazide","carbonic anhydrase inhibitor","CA2","cardiology","hypertension, edema","NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)=CSCc2ccccc2)cc1Cl, NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)=CSCc2ccccc2)cc1Cl, NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)=CSCc2ccccc2)cc1Cl, NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)=CSCc2ccccc2)cc1Cl, NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)=CSCc2ccccc2)cc1Cl, NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)=CSCc2ccccc2)cc1Cl, NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)=CSCc2ccccc2)cc1Cl","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"568","benztropine-mesylate","acetylcholine receptor antagonist","CHRM1, HRH1, SLC6A3","neurology/psychiatry","extrapyramidal symptoms (EPS), Parkinson's Disease","CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccccc1)c1ccccc1","Launched",1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1
"569","benzyl-benzoate","lipase inhibitor","LIPE","allergy","sweet itch","O=C(OCc1ccccc1)c1ccccc1, O=C(OCc1ccccc1)c1ccccc1, O=C(OCc1ccccc1)c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"570","bepotastine","histamine receptor antagonist","HRH1","ophthalmology","conjunctivitis","OC(=O)CCCN1CCC(CC1)O[C@@H](c1ccc(Cl)cc1)c1ccccn1, OC(=O)CCCN1CCC(CC1)O[C@@H](c1ccc(Cl)cc1)c1ccccn1, OC(=O)CCCN1CCC(CC1)O[C@@H](c1ccc(Cl)cc1)c1ccccn1","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"571","bepridil","calcium channel blocker","KCNQ4","cardiology","angina pectoris","CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1, CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1, CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1, CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1, CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"572","berberine","LDL receptor activator","LDLR",NA,NA,"COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC, COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC, COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC, COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC, COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"573","bergenin","interleukin inhibitor","IL1B, TNF",NA,NA,"COc1c(O)cc2C(=O)O[C@@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]3c2c1O, COc1c(O)cc2C(=O)O[C@@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]3c2c1O, COc1c(O)cc2C(=O)O[C@@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]3c2c1O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"574","besifovir","antiviral","GPT","infectious disease","hepatitis b","Nc1ncc2ncn(CC3(CC3)OCP(O)(O)=O)c2n1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"575","beta-amyloid-synthesis-inhibitor","beta amyloid synthesis inhibitor","APP",NA,NA,"Oc1cccc(Nc2ccc(Nc3cccc(O)c3)nn2)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"576","beta-CCB","benzodiazepine receptor ligand","GABRA1, GABRG2",NA,NA,"CCCCOC(=O)c1cc2c(cn1)[nH]c1ccccc21, CCCCOC(=O)c1cc2c(cn1)[nH]c1ccccc21","Launched",0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0
"577","beta-elemene","apoptosis stimulant","MMP2, MMP9",NA,NA,"CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@@H](C1)C(C)=C, CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@@H](C1)C(C)=C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"578","beta-funaltrexamine","opioid receptor antagonist","OPRD1, OPRK1, OPRM1",NA,NA,"COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45, COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45, COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45, COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45, COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"579","beta-hydroxy-beta-methylbutyrate","protein synthesis stimulant","MTOR",NA,NA,"CC(C)(O)CC(O)=O.CC(C)(O)CC(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"580","beta-lapachone","topoisomerase inhibitor","TOP1",NA,NA,"CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"581","betahistine","histamine receptor agonist, histamine receptor antagonist","HRH1, HRH3","neurology/psychiatry","Meniere's disease","CNCCc1ccccn1, CNCCc1ccccn1, CNCCc1ccccn1","Launched",0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,1,1,1,1
"582","betamethasone","glucocorticoid receptor agonist","NR3C1","dermatology","corticosteroid-responsive dermatoses","C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]2(C)[C@]1(O)C(=O)CO, C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|, C[C@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO",NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"583","betamethasone-acetate","glucocorticoid receptor agonist","NR3C1","dermatology","corticosteroid-responsive dermatoses","C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O |c:11,t:7|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"584","betamethasone-dipropionate","anti-inflammatory agent","NR3C1","dermatology","corticosteroid-responsive dermatoses","CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:25,t:21|, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:25,t:21|, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:25,t:21|, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:25,t:21|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"585","betamethasone-valerate","glucocorticoid receptor agonist","NR3C1","dermatology","corticosteroid-responsive dermatoses","CCCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO |c:19,t:15|, CCCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO |c:19,t:15|, CCCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO |c:19,t:15|, CCCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO |c:19,t:15|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"586","betaxolol","adrenergic receptor antagonist","ADRB1, ADRB2","ophthalmology","intraocular pressure, glaucoma, ocular hypertension","CC(C)NC[C@@H](O)COc1ccc(CCOCC2CC2)cc1 |&1:5,r|, CC(C)NC[C@@H](O)COc1ccc(CCOCC2CC2)cc1 |&1:5,r|, CC(C)NC[C@@H](O)COc1ccc(CCOCC2CC2)cc1 |&1:5,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,1,1,1,1
"587","betazole","histamine receptor agonist","HRH2","gastroenterology","gastric hypersecretion diagnostic","NCCc1ccn[nH]1","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"588","bethanechol","acetylcholine receptor agonist","CHRM1, CHRM2, CHRM3, CHRM4","urology","urinary retention","C[C@@H](C[N+](C)(C)C)OC(N)=O |r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,1,1,1,1
"589","BETP","GLP receptor positive allosteric modulator","GLP1R",NA,NA,"CC[S@](=O)c1nc(cc(n1)C(F)(F)F)-c1cccc(OCc2ccccc2)c1 |&1:2,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"590","betrixaban","coagulation factor inhibitor","KCNH2","hematology","deep vein thrombosis (DVT)","COc1ccc(NC(=O)c2ccc(cc2)C(=N)N(C)C)c(c1)C(=O)Nc1ccc(Cl)cn1, COc1ccc(NC(=O)c2ccc(cc2)C(=N)N(C)C)c(c1)C(=O)Nc1ccc(Cl)cn1, COc1ccc(NC(=O)c2ccc(cc2)C(=N)N(C)C)c(c1)C(=O)Nc1ccc(Cl)cn1, COc1ccc(NC(=O)c2ccc(cc2)C(=N)N(C)C)c(c1)C(=O)Nc1ccc(Cl)cn1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"591","betulinic-acid","apoptosis stimulant, NFkB pathway inhibitor","GPBAR1",NA,NA,"CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"592","bexarotene","retinoid receptor agonist","RXRA, RXRB, RXRG","hematologic malignancy","cutaneous T-cell lymphoma (CTCL)","Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C, Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C, Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C, Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"593","bezafibrate","PPAR receptor agonist","PPARA, PPARD, PPARG","cardiology","cholesterol","CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O, CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O, CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O, CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"594","BGT226","PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CG",NA,NA,"COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1, COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1, COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1, COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1, COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1, COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"595","BHQ","ATPase inhibitor","ATP2A1",NA,NA,"CC(C)(C)c1cc(O)c(cc1O)C(C)(C)C, CC(C)(C)c1cc(O)c(cc1O)C(C)(C)C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"596","BI-D1870","ribosomal protein inhibitor","RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA6",NA,NA,"CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|, CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|, CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|, CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|, CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|, CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|, CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|, CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|, CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"597","BI-2536","PLK inhibitor","BRD4, PLK1, PLK2, PLK3",NA,NA,"CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"598","BI-78D3","JNK inhibitor","MAPK8",NA,NA,"[O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"599","BI-847325","Aurora kinase inhibitor, MEK inhibitor","AURKA, AURKB, AURKC, MAP2K1, MAP2K2",NA,NA,"CCNC(=O)C#Cc1ccc2\C(=C(/Nc3ccc(CN(C)C)cc3)c3ccccc3)C(=O)Nc2c1, CCNC(=O)C#Cc1ccc2\C(=C(/Nc3ccc(CN(C)C)cc3)c3ccccc3)C(=O)Nc2c1, CCNC(=O)C#Cc1ccc2\C(=C(/Nc3ccc(CN(C)C)cc3)c3ccccc3)C(=O)Nc2c1, CCNC(=O)C#Cc1ccc2\C(=C(/Nc3ccc(CN(C)C)cc3)c3ccccc3)C(=O)Nc2c1, CCNC(=O)C#Cc1ccc2\C(=C(/Nc3ccc(CN(C)C)cc3)c3ccccc3)C(=O)Nc2c1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"600","BIBN4096","calcitonin antagonist","CALCA, CALCRL, RAMP1",NA,NA,"NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1, NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1, NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1, NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1, NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"601","BIBR-1532","telomerase inhibitor","TERT",NA,NA,"C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1, C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1, C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1, C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1, C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1, C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"602","BIBU-1361","EGFR inhibitor","EGFR",NA,NA,"CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"603","BIBX-1382","EGFR inhibitor","EGFR, ERBB2",NA,NA,"CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"604","bicalutamide","androgen receptor antagonist","AR","oncology","prostate cancer","CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F |&1:1|, CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F |&1:1|, CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F |&1:1|, CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F |&1:1|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"605","bicuculline-(+)","GABA receptor antagonist","GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, KCNN1",NA,NA,"CN1CCc2cc3OCOc3cc2[C@H]1[C@@H]1OC(=O)c2c1ccc1OCOc21","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,1,6,0,0,0,0,0,0,0,0,0,0
"606","bicyclol","NFkB pathway inhibitor","HSPA1A, HSPB1","infectious disease","hepatitis B, hepatitis C","COC(=O)c1cc(OC)c2OCOc2c1-c1c2OCOc2c(OC)cc1CO, COC(=O)c1cc(OC)c2OCOc2c1-c1c2OCOc2c(OC)cc1CO","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"607","bifemelane","acetylcholine release enhancer","MAOA, MAOB","ophthalmology, neurology/psychiatry","glaucoma, senile dementia","CNCCCCOc1ccccc1Cc1ccccc1, CNCCCCOc1ccccc1Cc1ccccc1, CNCCCCOc1ccccc1Cc1ccccc1","Launched",0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"608","BIIB021","HSP inhibitor","HSP90AA1",NA,NA,"COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"609","biib068","bruton's tyrosine kinase (btk) inhibitor","BTK",NA,NA,"CC(C)OC1CN(C1)C(=O)NCc1ccc(cc1C)-c1ccnc(Nc2cnn(C)c2)n1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"610","bilastine","histamine receptor antagonist","HRH1","ophthalmology","conjunctivitis","CCOCCn1c(nc2ccccc12)C1CCN(CCc2ccc(cc2)C(C)(C)C(O)=O)CC1, CCOCCn1c(nc2ccccc12)C1CCN(CCc2ccc(cc2)C(C)(C)C(O)=O)CC1","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"611","bilobalide","GABA receptor modulator","GLRA1, GLRA2, GLRB, HTR3A, HTR3B",NA,NA,"CC(C)(C)[C@]1(O)C[C@@H]2OC(=O)C[C@@]22C(=O)O[C@@H]3OC(=O)[C@H](O)[C@]123","Preclinical",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"612","bimatoprost","prostanoid receptor agonist","AKR1C3, PTGER1, PTGER3, PTGFR","ophthalmology","intraocular pressure, glaucoma, ocular hypertension, intraocular pressure, glaucoma, ocular hypertension","CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCc1ccccc1, CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(O)CCc1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"613","bimosiamose","p selectin inhibitor","ICAM1, SELE, SELP","pulmonary","chronic obstructive pulmonary disease (copd)","OC[C@H]1O[C@H](Oc2ccc(CCCCCCc3ccc(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)c(c3)-c3cccc(CC(O)=O)c3)cc2-c2cccc(CC(O)=O)c2)[C@@H](O)[C@@H](O)[C@@H]1O |a:2,4,21,23,26,28,30,56,58,60|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"614","BIMU-8","serotonin receptor agonist","HTR4",NA,NA,"CC(C)n1c2ccccc2n(C(=O)N[C@@H]2C[C@@H]3CC[C@H](C2)N3C)c1=O |&1:14,16,19|","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"615","BINA","glutamate receptor positive allosteric modulator","GRM2",NA,NA,"Cc1c2C(=O)[C@H](Cc2cc(OCc2cccc(c2)-c2ccc(cc2)C(O)=O)c1C)C1CCCC1 |&1:5,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"616","bindarit","NFkB pathway inhibitor","CCL2, CCL7, CCL8",NA,NA,"CC(C)(OCc1nn(Cc2ccccc2)c2ccccc12)C(O)=O, CC(C)(OCc1nn(Cc2ccccc2)c2ccccc12)C(O)=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"617","binimetinib","MEK inhibitor","MAP2K1, MAP2K2","oncology","melanoma","Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"618","BIO-1211","integrin antagonist","ITGA4, ITGB1",NA,NA,"CC(C)C[C@H](NC(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(O)=O, CC(C)C[C@H](NC(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(O)=O, CC(C)C[C@H](NC(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(O)=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"619","BIO-5192","integrin inhibitor","ITGA4, ITGB1",NA,NA,"CC(C)C[C@H](N(C)C(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)NCC[C@H](NC(=O)[C@@H]1CCCN1S(=O)(=O)c1cc(Cl)cc(Cl)c1)C(O)=O, CC(C)C[C@H](N(C)C(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)NCC[C@H](NC(=O)[C@@H]1CCCN1S(=O)(=O)c1cc(Cl)cc(Cl)c1)C(O)=O, CC(C)C[C@H](N(C)C(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)NCC[C@H](NC(=O)[C@@H]1CCCN1S(=O)(=O)c1cc(Cl)cc(Cl)c1)C(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"620","biotin","vitamin B","ACACA, ACACB, HLCS, MCCC1, MCCC2, PC, PCCA, PCCB, SLC5A6",NA,NA,"OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12, OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12, OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"621","bipenamol","dipeptidyl peptidase inhibitor","CTSC",NA,NA,"NCc1ccccc1Sc1ccccc1CO, NCc1ccccc1Sc1ccccc1CO","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"622","biperiden","acetylcholine receptor antagonist","CHRM1, CHRM2, CHRM3, CHRM4, CHRM5","neurology/psychiatry","Parkinson's Disease","O[C@@](CCN1CCCCC1)([C@@H]1C[C@@H]2C[C@H]1C=C2)c1ccccc1 |&1:12,14,&2:10,&3:1,c:17|, O[C@@](CCN1CCCCC1)([C@@H]1C[C@@H]2C[C@H]1C=C2)c1ccccc1 |&1:12,14,&2:10,&3:1,c:17|, O[C@@](CCN1CCCCC1)([C@@H]1C[C@@H]2C[C@H]1C=C2)c1ccccc1 |&1:12,14,&2:10,&3:1,c:17|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,5,0,0,1,1,1,1
"623","birinapant","XIAP inhibitor","BIRC2, XIAP",NA,NA,"CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"624","BIRT-377","lymphocyte function-associated antigen negative modulator","ICAM1",NA,NA,"CN1C(=O)N(C(=O)[C@@]1(C)Cc1ccc(Br)cc1)c1cc(Cl)cc(Cl)c1, CN1C(=O)N(C(=O)[C@@]1(C)Cc1ccc(Br)cc1)c1cc(Cl)cc(Cl)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"625","bis(maltolato)oxovanadium(IV)","tyrosine phosphatase inhibitor","PTPN1",NA,NA,"Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O, Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O, Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O, Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"626","bisindolylmaleimide-IX","PKC inhibitor","AKT1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SIRT1",NA,NA,"Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12 |t:4|, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12 |t:4|, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12 |t:4|, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12 |t:4|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"627","bismuth-subgallate","nitric oxide synthase inhibitor","NOS1","gastroenterology","internal deoderant","O[Bi]1Oc2cc(cc(O)c2O1)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"628","bisoprolol","adrenergic receptor antagonist","ADRB1","cardiology","hypertension","CC(C)NC[C@@H](O)COc1ccc(COCCOC(C)C)cc1 |&1:5|, CC(C)NC[C@@H](O)COc1ccc(COCCOC(C)C)cc1 |&1:5|, CC(C)NC[C@@H](O)COc1ccc(COCCOC(C)C)cc1 |&1:5|, CC(C)NC[C@@H](O)COc1ccc(COCCOC(C)C)cc1 |&1:5|, CC(C)NC[C@@H](O)COc1ccc(COCCOC(C)C)cc1 |&1:5|, CC(C)NC[C@@H](O)COc1ccc(COCCOC(C)C)cc1 |&1:5|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"629","bisphenol-A","synthetic estrogen","AR, ESR1, ESR2, ESRRG, PPARG",NA,NA,"CC(C)(c1ccc(O)cc1)c1ccc(O)cc1, CC(C)(c1ccc(O)cc1)c1ccc(O)cc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"630","bithionol","autotaxin inhibitor","ESR1, ESR2, MCL1",NA,NA,"Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O, Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O, Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O, Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O, Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O, Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O, Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O, Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O, Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"631","bitopertin","glycine transporter inhibitor","SLC6A5, SLC6A9",NA,NA,"C[C@H](Oc1ccc(cc1C(=O)N1CCN(CC1)c1ncc(cc1F)C(F)(F)F)S(C)(=O)=O)C(F)(F)F, C[C@H](Oc1ccc(cc1C(=O)N1CCN(CC1)c1ncc(cc1F)C(F)(F)F)S(C)(=O)=O)C(F)(F)F","Phase 3",1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"632","bivalirudin","thrombin inhibitor","F2","cardiology","angina pectoris","CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"633","BIX-01294","histone lysine methyltransferase inhibitor","EHMT1, EHMT2",NA,NA,"COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"634","BIX-02188","MEK inhibitor","MAP2K5",NA,NA,"CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(N)=O)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(N)=O)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(N)=O)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(N)=O)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(N)=O)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(N)=O)c2ccccc2)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"635","BIX-02189","MEK inhibitor","MAP2K5, MAPK7",NA,NA,"CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(=O)N(C)C)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(=O)N(C)C)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(=O)N(C)C)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(=O)N(C)C)c2ccccc2)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"636","blebbistatin-(+/-)","ATPase inhibitor","MYH14, MYH2",NA,NA,"Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccccc1 |&1:10,r,t:5|, Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccccc1 |&1:10,r,t:5|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"637","blonanserin","dopamine receptor antagonist, serotonin receptor antagonist","DRD2, HTR2A","neurology/psychiatry","schizophrenia","CCN1CCN(CC1)c1cc(-c2ccc(F)cc2)c2CCCCCCc2n1, CCN1CCN(CC1)c1cc(-c2ccc(F)cc2)c2CCCCCCc2n1, CCN1CCN(CC1)c1cc(-c2ccc(F)cc2)c2CCCCCCc2n1, CCN1CCN(CC1)c1cc(-c2ccc(F)cc2)c2CCCCCCc2n1","Launched",0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,1,1,1
"638","BLU9931","FGFR inhibitor","FGFR4",NA,NA,"COc1cc(OC)c(Cl)c(c1Cl)-c1ccc2nc(Nc3c(C)cccc3NC(=O)C=C)ncc2c1, COc1cc(OC)c(Cl)c(c1Cl)-c1ccc2nc(Nc3c(C)cccc3NC(=O)C=C)ncc2c1, COc1cc(OC)c(Cl)c(c1Cl)-c1ccc2nc(Nc3c(C)cccc3NC(=O)C=C)ncc2c1, COc1cc(OC)c(Cl)c(c1Cl)-c1ccc2nc(Nc3c(C)cccc3NC(=O)C=C)ncc2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"639","BML-190","cannabinoid receptor inverse agonist","CNR2",NA,NA,"COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"640","BMS-CCR2-22","CC chemokine receptor antagonist","CCR2",NA,NA,"CSc1ccc(cc1)C(=O)N[C@@H]1CCCC[C@@H]1NC(=O)CNC(=O)c1cc(ccc1NC(=O)NC(C)C)C(F)(F)F, CSc1ccc(cc1)C(=O)N[C@@H]1CCCC[C@@H]1NC(=O)CNC(=O)c1cc(ccc1NC(=O)NC(C)C)C(F)(F)F, CSc1ccc(cc1)C(=O)N[C@@H]1CCCC[C@@H]1NC(=O)CNC(=O)c1cc(ccc1NC(=O)NC(C)C)C(F)(F)F, CSc1ccc(cc1)C(=O)N[C@@H]1CCCC[C@@H]1NC(=O)CNC(=O)c1cc(ccc1NC(=O)NC(C)C)C(F)(F)F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"641","BMS-182874","endothelin receptor antagonist","EDNRA",NA,NA,"CN(C)c1cccc2c(cccc12)S(=O)(=O)Nc1onc(C)c1C, CN(C)c1cccc2c(cccc12)S(=O)(=O)Nc1onc(C)c1C, CN(C)c1cccc2c(cccc12)S(=O)(=O)Nc1onc(C)c1C","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"642","BMS-191011","potassium channel activator","KCNMA1",NA,NA,"Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F, Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F, Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F, Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F, Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"643","BMS-265246","CDK inhibitor","CDK1, CDK2",NA,NA,"CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"644","BMS-309403","fatty acid binding protein inhibitor","FABP4",NA,NA,"CCc1c(c(nn1-c1ccccc1-c1cccc(OCC(O)=O)c1)-c1ccccc1)-c1ccccc1, CCc1c(c(nn1-c1ccccc1-c1cccc(OCC(O)=O)c1)-c1ccccc1)-c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"645","BMS-345541","IKK inhibitor","CHUK, IKBKB",NA,NA,"Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"646","BMS-387032","CDK inhibitor, cell cycle inhibitor, MCL1 inhibitor","CDK2, CDK7, CDK9",NA,NA,"CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1, CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1, CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1, CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1, CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"647","BMS-470539","melanocortin receptor agonist","MC1R",NA,NA,"CCCC(=O)C1(CCN(CC1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)[C@@H](N)Cc1cncn1C)c1ccccc1, CCCC(=O)C1(CCN(CC1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)[C@@H](N)Cc1cncn1C)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"648","BMS-536924","IGF-1 inhibitor","AKT1, CCNE1, CDK2, CYP3A4, ERBB2, IGF1R, KDR, LCK, MAPK1, MET, PDGFRA, PDGFRB",NA,NA,"Cc1cc(cc2[nH]c(nc12)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O)N1CCOCC1, Cc1cc(cc2[nH]c(nc12)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O)N1CCOCC1, Cc1cc(cc2[nH]c(nc12)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O)N1CCOCC1, Cc1cc(cc2[nH]c(nc12)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O)N1CCOCC1, Cc1cc(cc2[nH]c(nc12)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O)N1CCOCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"649","BMS-566419","inosine monophosphate dehydrogenase inhibitor","IMPDH1, IMPDH2",NA,NA,"CCN1CCN(CC1)c1ccc(cn1)C(C)(C)NC(=O)c1cc2[nH]c3ccccc3c(=O)c2cc1F, CCN1CCN(CC1)c1ccc(cn1)C(C)(C)NC(=O)c1cc2[nH]c3ccccc3c(=O)c2cc1F, CCN1CCN(CC1)c1ccc(cn1)C(C)(C)NC(=O)c1cc2[nH]c3ccccc3c(=O)c2cc1F, CCN1CCN(CC1)c1ccc(cn1)C(C)(C)NC(=O)c1cc2[nH]c3ccccc3c(=O)c2cc1F, CCN1CCN(CC1)c1ccc(cn1)C(C)(C)NC(=O)c1cc2[nH]c3ccccc3c(=O)c2cc1F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"650","BMS-587101","integrin antagonist","ITGAL, ITGB2",NA,NA,"CN1C(=O)N(C(=O)[C@]11CN(Cc2cc(cs2)C(O)=O)C[C@H]1c1ccc(cc1)C#N)c1cc(Cl)cc(Cl)c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"651","BMS-599626","EGFR inhibitor, protein tyrosine kinase inhibitor","EGFR, ERBB2, ERBB4",NA,NA,"Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12, Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12, Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12, Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"652","BMS-649","retinoid receptor agonist","RXRA",NA,NA,"CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"653","BMS-688521","ICAM1 antagonist, leukocyte function-associated antigen receptor antagonist","ICAM1",NA,NA,"CN1C(=O)N(C(=O)[C@]11CN(C[C@H]1c1ccc(cc1)C#N)c1ccc(cn1)C(O)=O)c1cc(Cl)cc(Cl)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"654","BMS-690514","EGFR inhibitor, VEGFR inhibitor","EGFR, ERBB2, FLT3, KDR",NA,NA,"COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"655","BMS-754807","IGF-1 inhibitor","AKT1, IGF1R",NA,NA,"C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"656","BMS-777607","AXL kinase inhibitor, c-Met inhibitor, FLT3 inhibitor, hepatocyte growth factor receptor inhibitor, macrophage migration inhibiting factor inhibitor, tyrosine kinase inhibitor","AXL, MERTK, MET, MST1R, TYRO3",NA,NA,"CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1, CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"657","BMS-817378","c-Met inhibitor, VEGFR inhibitor","KDR, MET",NA,NA,"Nc1nccc(Oc2ccc(NC(=O)c3cn(COP(O)(O)=O)cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl, Nc1nccc(Oc2ccc(NC(=O)c3cn(COP(O)(O)=O)cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"658","BMS-833923","smoothened receptor antagonist","SMO",NA,NA,"CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1, CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1, CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1, CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1, CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1, CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1, CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"659","BMS-863233","CDC inhibitor","CDC7, PIM1",NA,NA,"Clc1ccc2oc3c(nc([nH]c3=O)[C@@H]3CCCN3)c2c1, Clc1ccc2oc3c(nc([nH]c3=O)[C@@H]3CCCN3)c2c1, Clc1ccc2oc3c(nc([nH]c3=O)[C@@H]3CCCN3)c2c1, Clc1ccc2oc3c(nc([nH]c3=O)[C@@H]3CCCN3)c2c1, Clc1ccc2oc3c(nc([nH]c3=O)[C@@H]3CCCN3)c2c1, Clc1ccc2oc3c(nc([nH]c3=O)[C@@H]3CCCN3)c2c1","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"660","BMS-986020","lysophosphatidic acid receptor antagonist","LPAR1",NA,NA,"C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(cc1)C1(CC1)C(O)=O)c1ccccc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"661","BMY-14802","sigma receptor antagonist","HTR1A",NA,NA,"O[C@@H](CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1 |&1:1|, O[C@@H](CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1 |&1:1|, O[C@@H](CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1 |&1:1|, O[C@@H](CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1 |&1:1|, O[C@@H](CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1 |&1:1|, O[C@@H](CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1 |&1:1|","Phase 2",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"662","BMY-45778","IP1 prostacyclin receptor agonist","PTGIR",NA,NA,"OC(=O)COc1cccc(c1)-c1ocnc1-c1nc(c(o1)-c1ccccc1)-c1ccccc1, OC(=O)COc1cccc(c1)-c1ocnc1-c1nc(c(o1)-c1ccccc1)-c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"663","BMY-7378","adrenergic receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA1D, HTR1A",NA,NA,"COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1, COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1, COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1, COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,3,0,0,0,0
"664","boceprevir","HCV inhibitor","CMA1, CTSA, CTSF, CTSK, CTSL, CTSS","infectious disease","hepatitis C","CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)N[C@@H](CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C |a:8,13,14,15,&1:19|, CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)N[C@@H](CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C |a:8,13,14,15,&1:19|, CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)N[C@@H](CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C |a:8,13,14,15,&1:19|, CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)N[C@@H](CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C |a:8,13,14,15,&1:19|, CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)N[C@@H](CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C |a:8,13,14,15,&1:19|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"665","bortezomib","NFkB pathway inhibitor, proteasome inhibitor","PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA","hematologic malignancy","multiple myeloma, mantle cell lymphoma (MCL)","CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"666","bosentan","endothelin receptor antagonist","EDNRA, EDNRB","pulmonary","pulmonary arterial hypertension (PAH)","COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(cc2)C(C)(C)C)nc(nc1OCCO)-c1ncccn1, COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(cc2)C(C)(C)C)nc(nc1OCCO)-c1ncccn1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"667","bosutinib","Abl kinase inhibitor, Bcr-Abl kinase inhibitor, SRC inhibitor","ABL1, BCR, CAMK1D, CAMK2G, CDK2, FRK, FYN, HCK, LYN, MAP2K1, MAP2K2, MAP3K2, MAP4K5, SRC, STK10, STK24, STK4, TNK2, TXK","hematologic malignancy","chronic myeloid leukemia (CML)","COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl, COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl, COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl, COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl, COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl, COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl, COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"668","BP-554","serotonin receptor agonist","HTR1A",NA,NA,"C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1, C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1, C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1, C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1, C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"669","BP-897","dopamine receptor agonist","ADRA1A, ADRA1D, ADRA2A, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2B",NA,NA,"COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1, COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1","Phase 2",0,0,0,0,0,0,0,0,1,2,0,0,0,0,1,4,0,0,1,3,0,0,0,0
"670","BQ-123","endothelin receptor antagonist","EDNRA",NA,NA,"[H][C@@]12CCCN1C(=O)[C@@]([H])(CC(O)=O)NC(=O)[C@@H](Cc1c[nH]c3ccccc13)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC2=O)C(C)C","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"671","BQ-788","endothelin receptor antagonist","EDNRB",NA,NA,"CCCC[C@@H](NC(=O)[C@@H](Cc1cn(C(=O)OC)c2ccccc12)NC(=O)[C@H](CC(C)(C)C)NC(=O)N1[C@@H](C)CCC[C@H]1C)C(O)=O, CCCC[C@@H](NC(=O)[C@@H](Cc1cn(C(=O)OC)c2ccccc12)NC(=O)[C@H](CC(C)(C)C)NC(=O)N1[C@@H](C)CCC[C@H]1C)C(O)=O, CCCC[C@@H](NC(=O)[C@@H](Cc1cn(C(=O)OC)c2ccccc12)NC(=O)[C@H](CC(C)(C)C)NC(=O)N1[C@@H](C)CCC[C@H]1C)C(O)=O, CCCC[C@@H](NC(=O)[C@@H](Cc1cn(C(=O)OC)c2ccccc12)NC(=O)[C@H](CC(C)(C)C)NC(=O)N1[C@@H](C)CCC[C@H]1C)C(O)=O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"672","BQU57","Ras GTPase inhibitor","RALA, RALB",NA,NA,"Cc1nn(C)c2OC(=N)C(C#N)[C@@H](c12)c1ccc(cc1)C(F)(F)F |&1:12,r|, Cc1nn(C)c2OC(=N)C(C#N)[C@@H](c12)c1ccc(cc1)C(F)(F)F |&1:12,r|, Cc1nn(C)c2OC(=N)C(C#N)[C@@H](c12)c1ccc(cc1)C(F)(F)F |&1:12,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"673","BRD4770","histone lysine methyltransferase inhibitor","EHMT2",NA,NA,"COC(=O)c1ccc2n(CCCc3ccccc3)c(NC(=O)c3ccccc3)nc2c1, COC(=O)c1ccc2n(CCCc3ccccc3)c(NC(=O)c3ccccc3)nc2c1, COC(=O)c1ccc2n(CCCc3ccccc3)c(NC(=O)c3ccccc3)nc2c1, COC(=O)c1ccc2n(CCCc3ccccc3)c(NC(=O)c3ccccc3)nc2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"674","BRD7389","ribosomal protein inhibitor","RPS6KA1, RPS6KA2, RPS6KA3",NA,NA,"O=C1c2ccccc2-c2c(NCCc3ccccc3)c(=O)[nH]c3cccc1c23, O=C1c2ccccc2-c2c(NCCc3ccccc3)c(=O)[nH]c3cccc1c23, O=C1c2ccccc2-c2c(NCCc3ccccc3)c(=O)[nH]c3cccc1c23, O=C1c2ccccc2-c2c(NCCc3ccccc3)c(=O)[nH]c3cccc1c23","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"675","BRD9876","kinesin inhibitor","KIF11",NA,NA,"CC(C)(C)c1ccc2cc(C#N)c(cc2c1)C#N, CC(C)(C)c1ccc2cc(C#N)c(cc2c1)C#N","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"676","brefeldin-A","protein synthesis inhibitor","ARF1, CYTH2",NA,NA,"C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5,16|, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5,16|, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5,16|, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5,16|, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5,16|, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5,16|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"677","bremelanotide","melanocortin receptor agonist","MC1R, MC2R, MC3R, MC4R, MC5R","neurology/psychiatry","hypoactive sexual desire disorder","CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC1=O)C(O)=O, CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC1=O)C(O)=O, CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC1=O)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"678","brequinar","dihydroorotate dehydrogenase inhibitor","DHODH",NA,NA,"Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F, Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F, Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"679","bretazenil","GABA benzodiazepine site receptor partial agonist","GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6",NA,NA,"CC(C)(C)OC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1c(Br)cccc-21, CC(C)(C)OC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1c(Br)cccc-21, CC(C)(C)OC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1c(Br)cccc-21","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,1,6,0,0,0,0,0,0,0,0,0,0
"680","bretylium","norepinephrine inhibitor","ATP1A1","cardiology","ventricular arrhythmias, ventricular fibrillation (VF), ventricular tachycardia (VT)","CC[N+](C)(C)Cc1ccccc1Br, CC[N+](C)(C)Cc1ccccc1Br, CC[N+](C)(C)Cc1ccccc1Br, CC[N+](C)(C)Cc1ccccc1Br","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"681","brexpiprazole","dopamine receptor partial agonist","DRD2","neurology/psychiatry","depression, schizophrenia","O=c1ccc2ccc(OCCCCN3CCN(CC3)c3cccc4sccc34)cc2[nH]1, O=c1ccc2ccc(OCCCCN3CCN(CC3)c3cccc4sccc34)cc2[nH]1, O=c1ccc2ccc(OCCCCN3CCN(CC3)c3cccc4sccc34)cc2[nH]1, O=c1ccc2ccc(OCCCCN3CCN(CC3)c3cccc4sccc34)cc2[nH]1, O=c1ccc2ccc(OCCCCN3CCN(CC3)c3cccc4sccc34)cc2[nH]1, O=c1ccc2ccc(OCCCCN3CCN(CC3)c3cccc4sccc34)cc2[nH]1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1
"682","briciclib","cyclin D inhibitor","CCND1",NA,NA,"COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(OP(O)(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(OP(O)(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(OP(O)(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(OP(O)(O)=O)c2)c(OC)c1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"683","brigatinib","ALK tyrosine kinase receptor inhibitor, EGFR inhibitor","ALK, EGFR","oncology","non-small cell lung cancer (NSCLC)","COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"684","brimonidine","adrenergic receptor agonist","ADRA2A, ADRA2B, ADRA2C","ophthalmology","intraocular pressure, glaucoma, ocular hypertension","Brc1c(NC2=NCCN2)ccc2nccnc12 |t:4|, Brc1c(NC2=NCCN2)ccc2nccnc12 |t:4|, Brc1c(NC2=NCCN2)ccc2nccnc12 |t:4|, Brc1c(NC2=NCCN2)ccc2nccnc12 |t:4|, Brc1c(NC2=NCCN2)ccc2nccnc12 |t:4|, Brc1c(NC2=NCCN2)ccc2nccnc12 |t:4|, Brc1c(NC2=NCCN2)ccc2nccnc12 |t:4|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,1,1,1,1
"685","brinzolamide","carbonic anhydrase inhibitor","CA1, CA12, CA14, CA2, CA4, CA5A, CA7","ophthalmology","intraocular pressure, glaucoma, ocular hypertension","CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O, CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O, CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O, CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"686","brivanib","FGFR inhibitor, VEGFR inhibitor","CYP3A4, FGFR1, FLT1, KCNH2, KDR",NA,NA,"C[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C, C[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C, C[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C, C[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C, C[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"687","brivanib-alaninate","FGFR inhibitor, VEGFR inhibitor","FGFR3",NA,NA,"C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N, C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N, C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N, C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N, C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N, C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"688","brl-15572","5-ht1d receptor antagonist","HTR1D",NA,NA,"OC(CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"689","BRL-15572","serotonin receptor antagonist","HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6",NA,NA,"O[C@@H](CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1 |&1:1|, O[C@@H](CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1 |&1:1|, O[C@@H](CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1 |&1:1|, O[C@@H](CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1 |&1:1|","Preclinical",0,0,0,0,0,0,0,0,1,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"690","BRL-26314","cholesterol inhibitor","LPL",NA,NA,"OC(=O)[C@@H](Cc1ccccc1)NCc1ccc(Cl)cc1 |&1:3,r|, OC(=O)[C@@H](Cc1ccccc1)NCc1ccc(Cl)cc1 |&1:3,r|, OC(=O)[C@@H](Cc1ccccc1)NCc1ccc(Cl)cc1 |&1:3,r|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"691","BRL-37344","adrenergic receptor agonist","ADRB1, ADRB2, ADRB3",NA,NA,"C[C@H](Cc1ccc(OCC(O)=O)cc1)NC[C@H](O)c1cccc(Cl)c1, C[C@H](Cc1ccc(OCC(O)=O)cc1)NC[C@H](O)c1cccc(Cl)c1, C[C@H](Cc1ccc(OCC(O)=O)cc1)NC[C@H](O)c1cccc(Cl)c1, C[C@H](Cc1ccc(OCC(O)=O)cc1)NC[C@H](O)c1cccc(Cl)c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0
"692","BRL-44408","adrenergic receptor antagonist","ADRA2A, ADRA2B, ADRA2C",NA,NA,"C[C@H]1N(CC2=NCCN2)Cc2ccccc12 |&1:1,t:4|, C[C@H]1N(CC2=NCCN2)Cc2ccccc12 |&1:1,t:4|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0
"693","BRL-50481","phosphodiesterase inhibitor","PDE7A, PDE7B",NA,NA,"CN(C)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O, CN(C)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O, CN(C)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O, CN(C)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"694","BRL-52537","opioid receptor agonist","OPRK1",NA,NA,"Clc1ccc(CC(=O)N2CCCC[C@@H]2CN2CCCC2)cc1Cl |&1:13|, Clc1ccc(CC(=O)N2CCCC[C@@H]2CN2CCCC2)cc1Cl |&1:13|, Clc1ccc(CC(=O)N2CCCC[C@@H]2CN2CCCC2)cc1Cl |&1:13|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"695","BRL-54443","serotonin receptor agonist","HTR1E, HTR1F",NA,NA,"CN1CCC(CC1)c1c[nH]c2ccc(O)cc12, CN1CCC(CC1)c1c[nH]c2ccc(O)cc12, CN1CCC(CC1)c1c[nH]c2ccc(O)cc12, CN1CCC(CC1)c1c[nH]c2ccc(O)cc12","Preclinical",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"696","brofaromine","monoamine oxidase inhibitor","MAOA","neurology/psychiatry","depression","COc1cc(Br)c2oc(cc2c1)C3CCNCC3","Phase 1",0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"697","brolitene","muscle relaxant","RYR1","rheumatology","lumbago","OCCNC(=O)\C=C\c1ccccc1, OCCNC(=O)\C=C\c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"698","bromfenac","cyclooxygenase inhibitor","PTGS1, PTGS2",NA,NA,"Nc1c(CC(O)=O)cccc1C(=O)c1ccc(Br)cc1, Nc1c(CC(O)=O)cccc1C(=O)c1ccc(Br)cc1","Withdrawn",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"699","bromocriptine","dopamine receptor agonist","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7","endocrinology, neurology/psychiatry","hyperprolactinemia, Parkinson's Disease, acromegaly","CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C |c:28|, CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C |c:28|, CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C |c:28|, CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C |c:28|","Launched",0,0,0,0,0,0,0,0,1,8,0,0,0,0,1,5,0,0,1,6,1,1,1,1
"700","bromodiphenhydramine","histamine receptor antagonist","HRH1","Allergies","allergic rhinitis","CN(C)CCO[C@H](c1ccccc1)c1ccc(Br)cc1 |&1:6,r|","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"701","bromopride","dopamine receptor antagonist","DRD2","gastroenterology","nausea, vomiting, gastroesophageal reflux disease (GERD)","CCN(CC)CCNC(=O)c1cc(Br)c(N)cc1OC, CCN(CC)CCNC(=O)c1cc(Br)c(N)cc1OC, CCN(CC)CCNC(=O)c1cc(Br)c(N)cc1OC","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1
"702","bromperidol","dopamine receptor antagonist","DRD2","neurology/psychiatry","schizophrenia","OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Br)cc1, OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Br)cc1, OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Br)cc1, OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Br)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1
"703","brompheniramine","histamine receptor antagonist","HRH1","allergy, otolaryngology","allergic rhinitis, common cold","CN(C)CC[C@@H](c1ccc(Br)cc1)c1ccccn1 |&1:5|","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"704","broxaterol","adrenergic receptor agonist","ADRB2",NA,NA,"CC(C)(C)NC[C@@H](O)c1cc(Br)no1 |&1:6,r|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
"705","brucine","glycine receptor antagonist","CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",NA,NA,"COc1cc2N3[C@H]4[C@@H]5[C@H](CC3=O)OCC=C3CN6CC[C@]4([C@@H]6C[C@H]53)c2cc1OC |t:15|, COc1cc2N3C4[C@@H]5C(CC3=O)OCC=C3CN6CC[C@]4([C@@H]6C[C@H]53)c2cc1OC","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,5,0,0,0,0,0,0
"706","BS-181","CDK inhibitor","CDK7",NA,NA,"CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12, CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12, CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12, CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12, CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12, CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12, CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"707","BTB06584","ATPase inhibitor","ATP5F1",NA,NA,"[O-][N+](=O)c1ccc(cc1OC(=O)c1ccc(Cl)cc1)S(=O)(=O)c1ccccc1, [O-][N+](=O)c1ccc(cc1OC(=O)c1ccc(Cl)cc1)S(=O)(=O)c1ccccc1, [O-][N+](=O)c1ccc(cc1OC(=O)c1ccc(Cl)cc1)S(=O)(=O)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"708","BTB1","mitotic kinesin inhibitor","KIF18A",NA,NA,"[O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)c1ccccc1, [O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)c1ccccc1, [O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"709","BTS-54505","dopamine reuptake inhibitor","SLC6A2, SLC6A3, SLC6A4",NA,NA,"CC(C)C[C@@H](N)C1(CCC1)c1ccc(Cl)cc1 |&1:4|, CC(C)C[C@@H](N)C1(CCC1)c1ccc(Cl)cc1 |&1:4|, CC(C)C[C@@H](N)C1(CCC1)c1ccc(Cl)cc1 |&1:4|, CC(C)C[C@@H](N)C1(CCC1)c1ccc(Cl)cc1 |&1:4|, CC(C)C[C@@H](N)C1(CCC1)c1ccc(Cl)cc1 |&1:4|","Withdrawn",1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"710","BTS-72664","GABA receptor antagonist","GABBR1",NA,NA,"C[C@@H](Oc1ccc(Cl)cc1)c1ccnc2ncnn12 |&1:1,r|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"711","BTT-3033","integrin inhibitor","ITGA2, ITGB1",NA,NA,"CN(c1ccc(NC(=O)Nc2ccccc2)cc1)S(=O)(=O)c1cnn(c1)-c1ccc(F)cc1, CN(c1ccc(NC(=O)Nc2ccccc2)cc1)S(=O)(=O)c1cnn(c1)-c1ccc(F)cc1, CN(c1ccc(NC(=O)Nc2ccccc2)cc1)S(=O)(=O)c1cnn(c1)-c1ccc(F)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"712","BU-224","imidazoline receptor ligand","MAOA, MAOB",NA,NA,"C1CN=C(N1)c1ccc2ccccc2n1 |c:2|, C1CN=C(N1)c1ccc2ccccc2n1 |c:2|, C1CN=C(N1)c1ccc2ccccc2n1 |c:2|","Preclinical",0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"713","bucladesine","adenosine receptor agonist, camp stimulant, adenosine receptor agonist, cAMP stimulant","PRKACA","dermatology","skin ulcer","CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15,17,24,25,&1:20|, CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15,17,24,25,&1:20|, CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15,17,24,25,&1:20|, CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15,17,24,25,&1:20|, CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15,17,24,25,&1:20|, CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15,17,24,25,&1:20|, CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15,17,24,25,&1:20|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"714","buclizine","histamine receptor antagonist","HRH1","neurology/psychiatry","migraine headache","CC(C)(C)c1ccc(CN2CCN(CC2)[C@@H](c2ccccc2)c2ccc(Cl)cc2)cc1 |&1:15|, CC(C)(C)c1ccc(CN2CCN(CC2)[C@@H](c2ccccc2)c2ccc(Cl)cc2)cc1 |&1:15|","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"715","budesonide","glucocorticoid receptor agonist","NR3C1","gastroenterology","Crohn's disease","CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|, CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|, CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|, CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|, CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|, CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|, CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|, CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|, CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"716","budipine","glutamate receptor antagonist","GRIN1","neurology/psychiatry","Parkinson's Disease","CC(C)(C)N1CCC(CC1)(c1ccccc1)c1ccccc1, CC(C)(C)N1CCC(CC1)(c1ccccc1)c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"717","bufexamac","cyclooxygenase inhibitor","HDAC10, HDAC6",NA,NA,"CCCCOc1ccc(CC(=O)NO)cc1, CCCCOc1ccc(CC(=O)NO)cc1, CCCCOc1ccc(CC(=O)NO)cc1, CCCCOc1ccc(CC(=O)NO)cc1","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"718","buflomedil","adrenergic receptor antagonist, calcium channel blocker","ADRA1A","cardiology","peripheral artery disease (PAD)","COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1, COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1, COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1, COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1, COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1, COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"719","bumetanide","solute carrier family member inhibitor","CFTR, GPR35, SLC12A1, SLC12A2, SLC12A4, SLC12A5","cardiology","edema, congestive heart failure","CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O","Launched",1,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"720","bunazosin","adrenergic receptor antagonist","ADRA1A","ophthalmology","glaucoma, intraocular pressure","CCCC(=O)N1CCCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n1, CCCC(=O)N1CCCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"721","buparlisib","PI3K inhibitor","PIK3CA, PIK3CG",NA,NA,"Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F, Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F, Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F, Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"722","buphenine","adrenergic receptor agonist","ADRB2","rheumatology","Raynaud's disease","CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1, CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"723","bupicomide","adrenergic receptor antagonist","ADRB1",NA,NA,"CCCCc1ccc(nc1)C(N)=O, CCCCc1ccc(nc1)C(N)=O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
"724","bupivacaine","sodium channel blocker","KCNA5, SCN10A","neurology/psychiatry","peripheral nerve block, caudal epidural block, lumbar epidural block","CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C |&1:9,r|","Launched",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"725","bupranolol","adrenergic receptor antagonist","ADRB1, ADRB2, ADRB3","cardiology, ophthalmology","hypertension, glaucoma","Cc1ccc(Cl)c(OC[C@@H](O)CNC(C)(C)C)c1 |&1:9,r|, Cc1ccc(Cl)c(OC[C@@H](O)CNC(C)(C)C)c1 |&1:9,r|, Cc1ccc(Cl)c(OC[C@@H](O)CNC(C)(C)C)c1 |&1:9,r|, Cc1ccc(Cl)c(OC[C@@H](O)CNC(C)(C)C)c1 |&1:9,r|, Cc1ccc(Cl)c(OC[C@@H](O)CNC(C)(C)C)c1 |&1:9,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,1,1,1,1
"726","bupropion","dopamine reuptake inhibitor","SLC6A2, SLC6A3","neurology/psychiatry","depression","C[C@@H](NC(C)(C)C)C(=O)c1cccc(Cl)c1 |&1:1,r|","Launched",1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"727","burixafor","cc chemokine receptor antagonist","CXCR4","hematologic malignancy","multiple myeloma","Nc1cc(nc(NC[C@H]2CC[C@H](CNCCCNC3CCCCC3)CC2)n1)N1CCN(CCP(O)(O)=O)CC1.Br.Br |r|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"728","buspirone","serotonin receptor agonist","DRD2, HTR1A","neurology/psychiatry","generalized anxiety disorder (GAD)","O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1, O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1, O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1, O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1","Launched",0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,1,1,1
"729","butabindide","tripeptidyl peptidase inhibitor","TPP2",NA,NA,"CCCCNC(=O)[C@@H]1Cc2ccccc2N1C(=O)[C@@H](N)CC, CCCCNC(=O)[C@@H]1Cc2ccccc2N1C(=O)[C@@H](N)CC","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"730","butaclamol","dopamine receptor antagonist","DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A",NA,NA,"CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc([C@@H]2C1)c34","Phase 2",0,0,0,0,0,0,0,0,1,2,0,0,0,0,1,5,0,0,0,0,0,0,0,0
"731","butalbital","GABA receptor antagonist","CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA2, GRIK2","neurology/psychiatry","headache, muscle relaxant","CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O, CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,1,16,0,0,1,2,0,0,1,1,1,1
"732","butein","EGFR inhibitor, SRC inhibitor","ACE",NA,NA,"Oc1ccc(C(=O)\C=C\c2ccc(O)c(O)c2)c(O)c1, Oc1ccc(C(=O)\C=C\c2ccc(O)c(O)c2)c(O)c1, Oc1ccc(C(=O)\C=C\c2ccc(O)c(O)c2)c(O)c1, Oc1ccc(C(=O)\C=C\c2ccc(O)c(O)c2)c(O)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"733","butenafine","fungal squalene epoxidase inhibitor","SQLE","infectious disease","tinea pedis, tinea cruris, tinea corporis","CN(Cc1ccc(cc1)C(C)(C)C)Cc1cccc2ccccc12, CN(Cc1ccc(cc1)C(C)(C)C)Cc1cccc2ccccc12, CN(Cc1ccc(cc1)C(C)(C)C)Cc1cccc2ccccc12, CN(Cc1ccc(cc1)C(C)(C)C)Cc1cccc2ccccc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"734","buthionine-sulfoximine","glutathione transferase inhibitor","GCLM",NA,NA,"CCCCS(=N)(=O)CC[C@H](N)C(O)=O |a:9,&1:4|, CCCCS(=N)(=O)CC[C@H](N)C(O)=O |a:9,&1:4|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"735","butylated-hydroxytoluene","carbonic anhydrase inhibitor","CA2",NA,NA,"Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"736","butylphthalide","potassium channel antagonist","KCNK2","neurology/psychiatry","stroke","CCCC[C@H]1OC(=O)c2ccccc12 |&1:4,r|, CCCC[C@H]1OC(=O)c2ccccc12 |&1:4,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"737","BVT-2733","11-beta hydroxysteroid dehydrogenase inhibitor","HSD17B1",NA,NA,"CN1CCN(CC1)C(=O)Cc1csc(NS(=O)(=O)c2cccc(Cl)c2C)n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"738","BVT-948","tyrosine phosphatase inhibitor","PTPN1, PTPN11, PTPN2",NA,NA,"CC1(C)C(=O)NC2=C1C(=O)C(=O)c1ccccc21 |c:6|, CC1(C)C(=O)NC2=C1C(=O)C(=O)c1ccccc21 |c:6|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"739","BW-A4C","lipoxygenase inhibitor","ALOX5",NA,NA,"CC(=O)N(O)C\C=C\c1cccc(Oc2ccccc2)c1, CC(=O)N(O)C\C=C\c1cccc(Oc2ccccc2)c1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"740","BW-B70C","lipoxygenase inhibitor","ALOX5",NA,NA,"C[C@@H](\C=C\c1cccc(Oc2ccc(F)cc2)c1)N(O)C(N)=O |&1:1,r|, C[C@@H](\C=C\c1cccc(Oc2ccc(F)cc2)c1)N(O)C(N)=O |&1:1,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"741","BW-180C","opioid receptor agonist","OPRD1, OPRM1",NA,NA,"CC(C)C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"742","BW-373U86","opioid receptor agonist","OPRD1",NA,NA,"CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(O)c1, CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(O)c1, CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(O)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"743","BW-616U","monoamine oxidase inhibitor","MAOA",NA,NA,"CNC(=O)c1ccc2C(=O)c3ccccc3S(=O)(=O)c2c1, CNC(=O)c1ccc2C(=O)c3ccccc3S(=O)(=O)c2c1","Preclinical",0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"744","BW-723C86","serotonin receptor agonist","HTR2A, HTR2B, HTR2C",NA,NA,"C[C@@H](N)Cc1c[nH]c2ccc(OCc3cccs3)cc12 |&1:1|, C[C@@H](N)Cc1c[nH]c2ccc(OCc3cccs3)cc12 |&1:1|, C[C@@H](N)Cc1c[nH]c2ccc(OCc3cccs3)cc12 |&1:1|","Preclinical",0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"745","BX-795","IKK inhibitor","CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1",NA,NA,"Ic1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCCNC(=O)c1cccs1, Ic1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCCNC(=O)c1cccs1, Ic1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCCNC(=O)c1cccs1, Ic1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCCNC(=O)c1cccs1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"746","BX-912","pyruvate dehydrogenase kinase inhibitor","CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1",NA,NA,"Brc1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCc1cnc[nH]1, Brc1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCc1cnc[nH]1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"747","BYK-204165","PARP inhibitor","PARP1",NA,NA,"Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12, Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12, Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12, Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12, Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12, Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12, Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"748","C-021","CC chemokine receptor antagonist","CCR4",NA,NA,"COc1cc2nc(nc(NC3CCCCCC3)c2cc1OC)N1CCC(CC1)N1CCCCC1, COc1cc2nc(nc(NC3CCCCCC3)c2cc1OC)N1CCC(CC1)N1CCCCC1, COc1cc2nc(nc(NC3CCCCCC3)c2cc1OC)N1CCC(CC1)N1CCCCC1, COc1cc2nc(nc(NC3CCCCCC3)c2cc1OC)N1CCC(CC1)N1CCCCC1, COc1cc2nc(nc(NC3CCCCCC3)c2cc1OC)N1CCC(CC1)N1CCCCC1, COc1cc2nc(nc(NC3CCCCCC3)c2cc1OC)N1CCC(CC1)N1CCCCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"749","C-1","protein kinase inhibitor","PRKCA",NA,NA,"O=S(=O)(N1CCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCNCC1)c1cccc2cnccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"750","cabazitaxel","microtubule inhibitor","TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8","oncology","prostate cancer","CO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C |t:51|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"751","cabergoline","dopamine receptor agonist","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR7","endocrinology","hyperprolactinemia","CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1, CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1, CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1, CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1, CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1, CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1","Launched",0,0,0,0,0,0,0,0,1,7,0,0,0,0,1,5,0,0,1,8,1,1,1,1
"752","cabozantinib","RET tyrosine kinase inhibitor, VEGFR inhibitor","KDR, MET, RET","oncology","medullary thyroid cancer (MTC)","COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"753","CaCCinh-A01","calcium-activated chloride channel inhibitor","CLCA1",NA,NA,"CC(C)(C)[C@H]1CCc2c(C1)sc(NC(=O)c1ccco1)c2C(O)=O |&1:4,r|, CC(C)(C)[C@H]1CCc2c(C1)sc(NC(=O)c1ccco1)c2C(O)=O |&1:4,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"754","caffeic-acid","HIV integrase inhibitor, lipoxygenase inhibitor, nitric oxide production inhibitor, tumor necrosis factor production inhibitor","ALOX5, MIF",NA,NA,"OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)\C=C\c1ccc(O)c(O)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"755","caffeic-acid-phenethyl-ester","HIV integrase inhibitor","RELA",NA,NA,"Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O, Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O, Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"756","caffeine","adenosine receptor antagonist, phosphodiesterase inhibitor","ADORA1, ADORA2A, ADORA2B, ADORA3, ATM, ITPR1, ITPR2, ITPR3, PDE10A, PDE11A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, PDE6A, PDE6B, PDE6C, PDE7A, PDE7B, PDE8A, PDE8B, PDE9A, PIK3CA, PIK3CB, PIK3CD, PRKDC, RYR1, RYR2, RYR3","neurology/psychiatry","fatigue, drowsiness","Cn1cnc2n(C)c(=O)n(C)c(=O)c12, Cn1cnc2n(C)c(=O)n(C)c(=O)c12, Cn1cnc2n(C)c(=O)n(C)c(=O)c12, Cn1cnc2n(C)c(=O)n(C)c(=O)c12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"757","calcifediol","vitamin D receptor agonist","VDR","endocrinology","hyperparathyroidism","C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"758","calcipotriol","vitamin D receptor agonist","VDR","dermatology","psoriasis","C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"759","calcitriol","vitamin D receptor agonist","VDR","endocrinology, orthopedics","hypocalcemia, hypoparathyroidism, osteoporosis","C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"760","Calhex-231","calcium sensing receptor negative allosteric modulator","CASR",NA,NA,"C[C@@H](N[C@H]1CCCC[C@@H]1NC(=O)c1ccc(Cl)cc1)c1cccc2ccccc12, C[C@@H](N[C@H]1CCCC[C@@H]1NC(=O)c1ccc(Cl)cc1)c1cccc2ccccc12, C[C@@H](N[C@H]1CCCC[C@@H]1NC(=O)c1ccc(Cl)cc1)c1cccc2ccccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"761","camicinal","motilin receptor agonist","MLNR",NA,NA,"C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(CC3)Nc3cccc(F)c3)cc2)CCN1, C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(CC3)Nc3cccc(F)c3)cc2)CCN1, C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(CC3)Nc3cccc(F)c3)cc2)CCN1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"762","CaMKII-IN-1","calcium/calmodulin dependent protein kinase inhibitor","AKT1, CAMK2A, CAMK4, MYLK",NA,NA,"Cc1c(Cl)cccc1S(=O)(=O)Nc1nc(NCCc2ccccc2)nc2CCN(Cc3ccccc3)Cc12, Cc1c(Cl)cccc1S(=O)(=O)Nc1nc(NCCc2ccccc2)nc2CCN(Cc3ccccc3)Cc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"763","camostat-mesilate","protease inhibitor","PRSS1","gastroenterology","pancreatitis","CN(C)C(=O)COC(=O)Cc1ccc(OC(=O)c2ccc(NC(N)=N)cc2)cc1, CN(C)C(=O)COC(=O)Cc1ccc(OC(=O)c2ccc(NC(N)=N)cc2)cc1, CN(C)C(=O)COC(=O)Cc1ccc(OC(=O)c2ccc(NC(N)=N)cc2)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"764","camphor-(1R)","TRPV activator","TRPV1",NA,NA,"CC1(C)[C@@H]2CC[C@]1(C)C(=O)C2, CC1(C)[C@@H]2CC[C@]1(C)C(=O)C2","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"765","camptothecin","topoisomerase inhibitor","TOP1",NA,NA,"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"766","camptothecin-20(s)-o-propionate","anticancer agent","TOP1","oncology","breast cancer","CCC(=O)O[C@]1(CC)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"767","canagliflozin","sodium/glucose cotransporter inhibitor","SLC5A1, SLC5A2","endocrinology","diabetes mellitus","Cc1ccc(cc1Cc1ccc(s1)-c1ccc(F)cc1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O, Cc1ccc(cc1Cc1ccc(s1)-c1ccc(F)cc1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O, Cc1ccc(cc1Cc1ccc(s1)-c1ccc(F)cc1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O","Launched",1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"768","candesartan","angiotensin receptor antagonist","AGTR1","cardiology","hypertension, congestive heart failure","CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"769","canertinib","EGFR inhibitor","AKT1, EGFR, ERBB2, ERBB4",NA,NA,"Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl, Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl, Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl, Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl, Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl, Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl, Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl, Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"770","canrenone","mineralocorticoid receptor antagonist","NR3C2",NA,NA,"C[C@]12CCC3C(C=CC4=CC(=O)CC[C@]34C)C1CC[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]21CCC(=O)O1 |c:6,t:8|","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"771","capadenoson","adenosine receptor agonist","ADORA1",NA,NA,"Nc1nc(SCc2csc(n2)-c2ccc(Cl)cc2)c(C#N)c(-c2ccc(OCCO)cc2)c1C#N, Nc1nc(SCc2csc(n2)-c2ccc(Cl)cc2)c(C#N)c(-c2ccc(OCCO)cc2)c1C#N, Nc1nc(SCc2csc(n2)-c2ccc(Cl)cc2)c(C#N)c(-c2ccc(OCCO)cc2)c1C#N","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"772","capecitabine","DNA synthesis inhibitor, thymidylate synthase inhibitor","TYMS","oncology","breast cancer, colorectal cancer","CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"773","capsaicin","TRPV agonist","CFTR, TRPV1","neurology/psychiatry, rheumatology","muscle pain, rheumatoid arthritis","COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O, COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O, COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"774","capsazepine","TRPV agonist","TRPV1, TRPV4",NA,NA,"Oc1cc2CCCN(Cc2cc1O)C(=S)NCCc1ccc(Cl)cc1, Oc1cc2CCCN(Cc2cc1O)C(=S)NCCc1ccc(Cl)cc1, Oc1cc2CCCN(Cc2cc1O)C(=S)NCCc1ccc(Cl)cc1, Oc1cc2CCCN(Cc2cc1O)C(=S)NCCc1ccc(Cl)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"775","captopril","angiotensin converting enzyme inhibitor","ACE, LTA4H, MMP2, MMP9","cardiology, endocrinology, nephrology","hypertension, congestive heart failure, myocardial infarction, diabetes mellitus, diabetic nephropathy","C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"776","caracemide","ribonucleotide reductase inhibitor","RRM1",NA,NA,"CNC(=O)ON(C(C)=O)C(=O)NC, CNC(=O)ON(C(C)=O)C(=O)NC, CNC(=O)ON(C(C)=O)C(=O)NC","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"777","caramiphen","cholinergic receptor antagonist","CHRM1, CHRM2","neurology/psychiatry","Parkinson's Disease","CCN(CC)CCOC(=O)C1(CCCC1)c1ccccc1, CCN(CC)CCOC(=O)C1(CCCC1)c1ccccc1, CCN(CC)CCOC(=O)C1(CCCC1)c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,1,1,1,1
"778","carazolol","adrenergic receptor antagonist","ADRB1, ADRB2, ADRB3","cardiology","angina pectoris, cardiac arrythmia, hypertension, myocardial infarction","CC(C)NC[C@@H](O)COc1cccc2[nH]c3ccccc3c12 |&1:5,r|, CC(C)NC[C@@H](O)COc1cccc2[nH]c3ccccc3c12 |&1:5,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,1,1,1,1
"779","carbachol","cholinergic receptor agonist","CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA2","ophthalmology","intraocular pressure","C[N+](C)(C)CCOC(N)=O, C[N+](C)(C)CCOC(N)=O, C[N+](C)(C)CCOC(N)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,6,0,0,1,1,1,1
"780","carbamazepine","carboxamide antiepileptic","SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A","neurology/psychiatry","seizures","NC(=O)N1c2ccccc2C=Cc2ccccc12 |c:11|, NC(=O)N1c2ccccc2C=Cc2ccccc12 |c:11|, NC(=O)N1c2ccccc2C=Cc2ccccc12 |c:11|, NC(=O)N1c2ccccc2C=Cc2ccccc12 |c:11|, NC(=O)N1c2ccccc2C=Cc2ccccc12 |c:11|","Launched",0,0,1,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"781","carbendazim","microtubule inhibitor, tubulin polymerization inhibitor","TP53, TUBB","infectious disease","fungicide","COC(=O)Nc1nc2ccccc2[nH]1, COC(=O)Nc1nc2ccccc2[nH]1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"782","carbenoxolone","11-beta hydroxysteroid dehydrogenase inhibitor","GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, HSD11B1, PANX1, PANX2, PANX3","gastroenterology, dental","peptic ulcer disease (PUD), mouth inflammation","CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)OC(=O)CCC(O)=O |t:18|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"783","carbetapentane","acetylcholine receptor antagonist","CHRM2","otolaryngology, pulmonary","common cold, nasal congestion, bronchitis","CCN(CC)CCOCCOC(=O)C1(CCCC1)c1ccccc1, CCN(CC)CCOCCOC(=O)C1(CCCC1)c1ccccc1, CCN(CC)CCOCCOC(=O)C1(CCCC1)c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,1
"784","carbetocin","oxytocin receptor agonist","OXTR","hematology","hemorrhage","CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(OC)cc2)NC(=O)CCCSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O, CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(OC)cc2)NC(=O)CCCSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"785","carbidopa","aromatic L-amino acid decarboxylase inhibitor","DDC","neurology/psychiatry","Parkinson's Disease","C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O, C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O, C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O, C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O, C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O, C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O, CC(Cc1ccc(O)c(O)c1)(NN)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"786","carbimazole","antithyroid agent","TPO","endocrinology","hyperthyroidism","CCOC(=O)n1ccn(C)c1=S, CCOC(=O)n1ccn(C)c1=S, CCOC(=O)n1ccn(C)c1=S, CCOC(=O)n1ccn(C)c1=S","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"787","carbinoxamine","histamine receptor antagonist","HRH1","allergy, ophthalmology, otolaryngology, dermatology","allergic rhinitis, conjunctivitis, vasomotor rhinitis, dermatographism","CN(C)CCO[C@@H](c1ccc(Cl)cc1)c1ccccn1 |&1:6|","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"788","carboprost","prostanoid receptor agonist","PTGER1","hematology","postpartum hemorrhage (pph)","O=C(O)CCC/C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@](O)(C)CCCCC","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"789","carboxyamidotriazole","calcium channel blocker","CXCL8",NA,NA,"NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N, NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N, NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N, NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"790","carboxylosartan","angiotensin antagonist","AGTR1",NA,NA,"CCCCc1nc(Cl)c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(Cl)c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"791","cardionogen-1","WNT signaling inhibitor","CTNNB1",NA,NA,"C1CCC(CC1)c1nn2c(nnc2s1)-c1ccco1, C1CCC(CC1)c1nn2c(nnc2s1)-c1ccco1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"792","carebastine","histamine receptor antagonist","HRH1",NA,NA,"CC(C)(C(O)=O)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1, CC(C)(C(O)=O)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1","Phase 1",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
"793","carfilzomib","proteasome inhibitor","PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9","hematologic malignancy","multiple myeloma","CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1, CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1, CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1, CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1, CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1, CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1, CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1, CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"794","carglumic-acid","carbamoyl phosphate synthase activator","CPS1","metabolism","hyperammonemia","NC(=O)N[C@@H](CCC(O)=O)C(O)=O, NC(=O)N[C@@H](CCC(O)=O)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"795","caricotamide","NADPH quinone oxidoreductase inhibitor","NQO2",NA,NA,"NC(=O)CN1C=CCC(=C1)C(N)=O |c:5,8|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"796","cariporide","sodium/hydrogen exchanger inhibitor","SLC9A1",NA,NA,"CC(C)c1ccc(cc1S(C)(=O)=O)C(=O)N=C(N)N","Phase 3",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"797","cariprazine","dopamine receptor antagonist","DRD2, DRD3","neurology/psychiatry","schizophrenia","CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 |r|, CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 |r|, CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 |r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,1,1,1,1
"798","carmofur","thymidylate synthase inhibitor","TYMS","oncology","breast cancer, colorectal cancer","CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"799","carmoterol","adrenergic receptor agonist","ADRB2",NA,NA,"COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
"800","carmoxirole","dopamine receptor agonist","DRD2",NA,NA,"OC(=O)c1ccc2[nH]cc(CCCCN3CCC(=CC3)c3ccccc3)c2c1 |c:17|, OC(=O)c1ccc2[nH]cc(CCCCN3CCC(=CC3)c3ccccc3)c2c1 |c:17|, OC(=O)c1ccc2[nH]cc(CCCCN3CCC(=CC3)c3ccccc3)c2c1 |c:17|, OC(=O)c1ccc2[nH]cc(CCCCN3CCC(=CC3)c3ccccc3)c2c1 |c:17|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0
"801","carmustine","DNA alkylating agent, DNA inhibitor","GSR","hematologic malignancy, oncology","non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, multiple myeloma, glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma","[O-][NH2+]N(CCCl)C(=O)NCCCl, [O-][NH2+]N(CCCl)C(=O)NCCCl, [O-][NH2+]N(CCCl)C(=O)NCCCl","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"802","caroxazone","monoamine oxidase inhibitor","MAOA, MAOB",NA,NA,"NC(=O)CN1Cc2ccccc2OC1=O, NC(=O)CN1Cc2ccccc2OC1=O, NC(=O)CN1Cc2ccccc2OC1=O","Withdrawn",0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"803","carprofen","cyclooxygenase inhibitor","PTGS2","rheumatology","osteoarthritis","C[C@@H](C(O)=O)c1ccc2c(c1)[nH]c1ccc(Cl)cc21 |&1:1,r|, C[C@@H](C(O)=O)c1ccc2c(c1)[nH]c1ccc(Cl)cc21 |&1:1,r|, C[C@@H](C(O)=O)c1ccc2c(c1)[nH]c1ccc(Cl)cc21 |&1:1,r|","Launched",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"804","carteolol","adrenergic receptor antagonist","ADRB1, ADRB2, ADRB3","ophthalmology","intraocular pressure, glaucoma, ocular hypertension","CC(C)(C)NCC(O)COc1cccc2NC(=O)CCc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,1,1,1,1
"805","carteolol hydrochloride","adrenergic receptor antagonist","ADRB1, ADRB2, ADRB3","Cardiology","angina pectoris","CC(C)(C)NC[C@@H](O)COc1cccc2NC(=O)CCc12 |&1:6,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,1,1,1,1
"806","carvedilol","adrenergic receptor antagonist","ADRB1, ADRB2, ADRB3","cardiology","myocardial infarction, hypertension, myocardial infarction, hypertension","COc1ccccc1OCCNC[C@@H](O)COc1cccc2[nH]c3ccccc3c12 |&1:13|, COc1ccccc1OCCNC[C@@H](O)COc1cccc2[nH]c3ccccc3c12 |&1:13|, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,1,1,1,1
"807","casin","GTPase inhibitor","CDC42",NA,NA,"OCCN[C@H]1CCCc2c1[nH]c1ccc(cc21)-c1ccccc1 |&1:4,r|, OCCN[C@H]1CCCc2c1[nH]c1ccc(cc21)-c1ccccc1 |&1:4,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"808","castanospermine","glucosidase inhibitor","GAA, GBA",NA,NA,"O[C@H]1CCN2C[C@H](O)[C@@H](O)[C@H](O)[C@@H]12, O[C@H]1CCN2C[C@H](O)[C@@H](O)[C@H](O)[C@@H]12, O[C@H]1CCN2C[C@H](O)[C@@H](O)[C@H](O)[C@@H]12","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"809","cathepsin-inhibitor-1","cathepsin inhibitor","CTSB, CTSL, CTSV",NA,NA,"Cn1nc(cc1C(=O)N[C@@H](Cc1cccc(Cl)c1)C(=O)NCC#N)C(C)(C)C, Cn1nc(cc1C(=O)N[C@@H](Cc1cccc(Cl)c1)C(=O)NCC#N)C(C)(C)C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"810","CAY10505","PI3K inhibitor","PIK3CG",NA,NA,"Fc1ccc(cc1)-c1ccc(\C=C2\SC(=O)NC2=O)o1, Fc1ccc(cc1)-c1ccc(\C=C2\SC(=O)NC2=O)o1, Fc1ccc(cc1)-c1ccc(\C=C2\SC(=O)NC2=O)o1, Fc1ccc(cc1)-c1ccc(\C=C2\SC(=O)NC2=O)o1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"811","CB-03-01","androgen receptor antagonist","AR",NA,NA,"CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO |t:12|, CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO |t:12|, CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO |t:12|, CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO |t:12|, CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO |t:12|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"812","cb-103","notch signaling inhibitor","NOTCH1","oncology","breast cancer","CC(C)(C)c1ccc(Oc2ccc(N)cn2)cc1","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"813","cb-1158","arginase inhibitor","ARG1, ARG2, IFNLR1","oncology","bladder cancer","C[C@H](N)C(=O)N1C[C@H](CCCB(O)O)[C@@](N)(C1)C(=O)O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"814","CB-5083","valosin-containing protein inhibitor","VCP",NA,NA,"Cc1cc2c(cccc2n1-c1nc2CCOCc2c(NCc2ccccc2)n1)C(N)=O, Cc1cc2c(cccc2n1-c1nc2CCOCc2c(NCc2ccccc2)n1)C(N)=O, Cc1cc2c(cccc2n1-c1nc2CCOCc2c(NCc2ccccc2)n1)C(N)=O, Cc1cc2c(cccc2n1-c1nc2CCOCc2c(NCc2ccccc2)n1)C(N)=O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"815","CB-839","glutaminase inhibitor","GLS",NA,NA,"FC(F)(F)Oc1cccc(CC(=O)Nc2ccc(CCCCc3nnc(NC(=O)Cc4ccccn4)s3)nn2)c1, FC(F)(F)Oc1cccc(CC(=O)Nc2ccc(CCCCc3nnc(NC(=O)Cc4ccccn4)s3)nn2)c1, FC(F)(F)Oc1cccc(CC(=O)Nc2ccc(CCCCc3nnc(NC(=O)Cc4ccccn4)s3)nn2)c1, FC(F)(F)Oc1cccc(CC(=O)Nc2ccc(CCCCc3nnc(NC(=O)Cc4ccccn4)s3)nn2)c1, FC(F)(F)Oc1cccc(CC(=O)Nc2ccc(CCCCc3nnc(NC(=O)Cc4ccccn4)s3)nn2)c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"816","CBiPES","glutamate receptor positive allosteric modulator","GRM2",NA,NA,"CCS(=O)(=O)N(Cc1cccnc1)c1cccc(c1)-c1ccc(cc1)C#N, CCS(=O)(=O)N(Cc1cccnc1)c1cccc(c1)-c1ccc(cc1)C#N, CCS(=O)(=O)N(Cc1cccnc1)c1cccc(c1)-c1ccc(cc1)C#N","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"817","cbp/p300-in-4","bromodomain inhibitor","CREBBP, EP300","genetics","duchenne muscular dystrophy (dmd)","CO[C@H]1CC[C@@H](CC1)n1c(nc2cc(ccc12)-c1c(C)noc1C)[C@@H]1CCCC(=O)N1c1ccc(F)c(F)c1",NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"818","CBS-1114","lipoxygenase inhibitor","ALOX5",NA,NA,"NC(=NNc1ccccc1)c1ccccc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"819","CC-115","DNA protein kinase inhibitor, mTOR inhibitor","MTOR",NA,NA,"CCN1C(=O)CN=C2NC=C(N=C12)c1ccc(nc1C)-c1nnc[nH]1 |c:9,t:6,11|, CCN1C(=O)CN=C2NC=C(N=C12)c1ccc(nc1C)-c1nnc[nH]1 |c:9,t:6,11|, CCN1C(=O)CN=C2NC=C(N=C12)c1ccc(nc1C)-c1nnc[nH]1 |c:9,t:6,11|, CCN1C(=O)CN=C2NC=C(N=C12)c1ccc(nc1C)-c1nnc[nH]1 |c:9,t:6,11|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"820","CC-223","mTOR inhibitor","MTOR",NA,NA,"CO[C@H]1CC[C@@H](CC1)N1C(=O)CNc2ncc(nc12)-c1ccc(nc1)C(C)(C)O |r|, CO[C@H]1CC[C@@H](CC1)N1C(=O)CNc2ncc(nc12)-c1ccc(nc1)C(C)(C)O |r|, CO[C@H]1CC[C@@H](CC1)N1C(=O)CNc2ncc(nc12)-c1ccc(nc1)C(C)(C)O |r|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"821","CC-401","JNK inhibitor","MAPK8",NA,NA,"C(CN1CCCCC1)Oc1cccc(c1)-c1n[nH]c2ccc(cc12)-c1nnc[nH]1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"822","cc-92480","ubiquitin ligase inhibitor","CRBN","hematologic malignancy","multiple myeloma","Fc1cc(ccc1N2CCN(Cc3ccc(COc4cccc5C(=O)N(Cc45)[C@H]6CCC(=O)NC6=O)cc3)CC2)C#N","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"823","CCG-1423","apoptosis stimulant","RHOC, SRF",NA,NA,"C[C@@H](ONC(=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(=O)Nc1ccc(Cl)cc1 |&1:1,r|, C[C@@H](ONC(=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(=O)Nc1ccc(Cl)cc1 |&1:1,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"824","CCG-50014","G protein signaling inhibitor","RGS4, RGS8",NA,NA,"Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"825","CCG-63802","G protein signaling inhibitor","RGS4",NA,NA,"Cc1cccc(Oc2nc3c(C)cccn3c(=O)c2\C=C(/C#N)c2nc3ccccc3s2)c1, Cc1cccc(Oc2nc3c(C)cccn3c(=O)c2\C=C(/C#N)c2nc3ccccc3s2)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"826","CCG-63808","G protein signaling inhibitor","RGS4",NA,NA,"Cc1cccn2c1nc(Oc1ccc(F)cc1)c(\C=C(/C#N)c1nc3ccccc3s1)c2=O, Cc1cccn2c1nc(Oc1ccc(F)cc1)c(\C=C(/C#N)c1nc3ccccc3s1)c2=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"827","CCMI","acetylcholine receptor allosteric modulator","CHRNA7",NA,NA,"Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1, Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1, Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1, Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1, Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
"828","ccr1 antagonist 9","ccr antagonist","CCR1","rheumatology","rheumatoid arthritis","O=C(C1=CN=CC2=C1C=NN2C3=CC=C(F)C=C3)NCC4=CC(S(=O)(C)=O)=NC=C4","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"829","ccr2 antagonist 3","potassium channel blocker","KCNJ3","cardiology","cardiac arrythmia","CC1=C(F)C=CC(C(N(C)[C@@H](C(C)C)CN2CC(O)C2)=O)=C1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"830","CCT-031374","WNT signaling inhibitor","CTNNB1",NA,NA,"O=C(CN1C2=NCCN2c2ccccc12)c1ccc(cc1)-c1ccccc1 |t:4|, O=C(CN1C2=NCCN2c2ccccc12)c1ccc(cc1)-c1ccccc1 |t:4|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"831","CCT018159","HSP inhibitor","HSP90AA1, HSP90AB1",NA,NA,"CCc1cc(-c2n[nH]c(C)c2-c2ccc3OCCOc3c2)c(O)cc1O, CCc1cc(-c2n[nH]c(C)c2-c2ccc3OCCOc3c2)c(O)cc1O, CCc1cc(-c2n[nH]c(C)c2-c2ccc3OCCOc3c2)c(O)cc1O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"832","CCT129202","Aurora kinase inhibitor","AURKA, AURKB, AURKC",NA,NA,"CN(C)c1ccc(cc1)-c1nc2ncc(Cl)c(N3CCN(CC(=O)Nc4nccs4)CC3)c2[nH]1, CN(C)c1ccc(cc1)-c1nc2ncc(Cl)c(N3CCN(CC(=O)Nc4nccs4)CC3)c2[nH]1, CN(C)c1ccc(cc1)-c1nc2ncc(Cl)c(N3CCN(CC(=O)Nc4nccs4)CC3)c2[nH]1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"833","CCT137690","Aurora kinase inhibitor","AURKA, AURKB, AURKC",NA,NA,"CN1CCN(CC1)c1ccc(cc1)-c1nc2ncc(Br)c(N3CCN(Cc4cc(C)on4)CC3)c2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2ncc(Br)c(N3CCN(Cc4cc(C)on4)CC3)c2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2ncc(Br)c(N3CCN(Cc4cc(C)on4)CC3)c2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2ncc(Br)c(N3CCN(Cc4cc(C)on4)CC3)c2[nH]1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"834","CC4","nicotinic receptor agonist","CHRNB2",NA,NA,"O=c1cccc2[C@@H]3C[C@@H](CN(CCN4C[C@@H]5C[C@H](C4)c4cccc(=O)n4C5)C3)Cn12, O=c1cccc2[C@@H]3C[C@@H](CN(CCN4C[C@@H]5C[C@H](C4)c4cccc(=O)n4C5)C3)Cn12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
"835","CD-1530","retinoid receptor agonist","RARG",NA,NA,"OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"836","CD-437","retinoid receptor agonist","RARG",NA,NA,"OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"837","CDK1-5-inhibitor","CDK inhibitor, glycogen synthase kinase inhibitor","CDK1, CDK5, GSK3B",NA,NA,"Nc1[nH]nc2nc3ccccc3nc12, Nc1[nH]nc2nc3ccccc3nc12, Nc1[nH]nc2nc3ccccc3nc12, Nc1[nH]nc2nc3ccccc3nc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"838","CDK9-IN-6","CDK inhibitor","CDK9",NA,NA,"COC[C@H](C)N[C@H]1CC[C@@H](CC1)Nc1cc(c(Cl)cn1)-c1cccc(NCC2(CCOCC2)C#N)n1, COC[C@H](C)N[C@H]1CC[C@@H](CC1)Nc1cc(c(Cl)cn1)-c1cccc(NCC2(CCOCC2)C#N)n1, COC[C@H](C)N[C@H]1CC[C@@H](CC1)Nc1cc(c(Cl)cn1)-c1cccc(NCC2(CCOCC2)C#N)n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"839","CDPPB","glutamate receptor positive allosteric modulator","GRM5",NA,NA,"O=C(Nc1cc(nn1-c1ccccc1)-c1ccccc1)c1cccc(c1)C#N, O=C(Nc1cc(nn1-c1ccccc1)-c1ccccc1)c1cccc(c1)C#N","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"840","ce-245677","tie tyrosine kinase inhibitor","NTRK1, NTRK2, TEK","oncology","breast cancer","O=C(NC1=CC=C(Cl)C=C1Cl)NC2=CC(C(C3=CN(C(C)C)C4=NC=NC(N)=C43)=O)=CC=C2OC","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"841","cebranopadol","opioid receptor agonist","OPRL1, OPRM1",NA,NA,"CN(C)[C@]1(CC[C@@]2(CC1)OCCc1c2[nH]c2ccc(F)cc12)c1ccccc1 |r|, CN(C)[C@]1(CC[C@@]2(CC1)OCCc1c2[nH]c2ccc(F)cc12)c1ccccc1 |r|, CN(C)[C@]1(CC[C@@]2(CC1)OCCc1c2[nH]c2ccc(F)cc12)c1ccccc1 |r|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"842","cediranib","KIT inhibitor, VEGFR inhibitor","CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB",NA,NA,"COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1, COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1, COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1, COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1, COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"843","cefadroxil","bacterial cell wall synthesis inhibitor","SLC15A1, SLC15A2, SLC22A6, SLC22A8","infectious disease, otolaryngology, infectious disease, otolaryngology","urinary tract infections, skin infections, tonsillitis, pharyngitis, urinary tract infections, skin infections, tonsillitis, pharyngitis","CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccc(O)cc1)C2=O)C(O)=O |t:1|, CC1=C(N2[C@H](SC1)[C@H](NC(=O)C(N)c1ccc(O)cc1)C2=O)C(O)=O","Launched",1,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"844","cefazolin","bacterial cell wall synthesis inhibitor","PON1","infectious disease","urinary tract infections, skin infections, bacterial septicemia, endocarditis, surgical prophylaxis, bone and joint infections","Cc1nnc(SCC2=C(N3[C@H](SC2)[C@H](NC(=O)Cn2cnnn2)C3=O)C(O)=O)s1 |t:7|, Cc1nnc(SCC2=C(N3[C@H](SC2)[C@H](NC(=O)Cn2cnnn2)C3=O)C(O)=O)s1 |t:7|, Cc1nnc(SCC2=C(N3[C@H](SC2)[C@H](NC(=O)Cn2cnnn2)C3=O)C(O)=O)s1 |t:7|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"845","cefdinir","bacterial cell wall synthesis inhibitor","MPO","infectious disease, otolaryngology, pulmonary","pneumonia, tonsillitis, pharyngitis, bronchitis, skin infections, otitis, sinusitis","Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:19|, Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:19|, Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:19|, Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:19|, Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:19|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"846","cefepime","penicillin binding protein inhibitor, bacterial cell wall synthesis inhibitor","A1BG","infectious disease, Infectious disease","pneumonia, urinary tract infections, skin infections, intra-abdominal infections, gram-negative bacterial infections","CO\N=C(\C(=O)N[C@H]1[C@H]2SCC(C[N+]3(C)CCCC3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |&1:7,&2:8,c:19|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N+]3(C)CCCC3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:19|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"847","cefotetan","bacterial cell wall synthesis inhibitor, penicillin binding protein inhibitor","PBP","infectious disease, Infectious disease","urinary tract infections, respiratory tract infections, skin infections, gynecologic infections, chlamydia, intra-abdominal infections, bone and joint infections, surgical prophylaxis, gram-positive bacterial infections","CO[C@]1(NC(=O)C2SC(S2)=C(C(N)=O)C(O)=O)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |a:2,&1:17,c:30|, CO[C@]1(NC(=O)C2SC(S2)=C(C(N)=O)C(O)=O)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |a:2,&1:17,c:30|, CO[C@]1(NC(=O)C2SC(S2)=C(C(N)=O)C(O)=O)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |a:2,&1:17,c:30|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"848","cefradine","bacterial cell wall synthesis inhibitor","CYP3A4","infectious disease, otolaryngology","respiratory tract infections, otitis, skin infections, urinary tract infections, tonsillitis, pharyngitis, pneumonia","CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C1=CCC=CC1)C2=O)C(O)=O |c:17,t:1,14|, CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C1=CCC=CC1)C2=O)C(O)=O |c:17,t:1,14|, CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C1=CCC=CC1)C2=O)C(O)=O |c:17,t:1,14|, CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C1=CCC=CC1)C2=O)C(O)=O |c:17,t:1,14|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"849","celecoxib","cyclooxygenase inhibitor","CA12, PDPK1, PTGS2","rheumatology, endocrinology","osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, primary dysmenorrhea (PD)","Cc1ccc(cc1)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)(F)F, Cc1ccc(cc1)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)(F)F, Cc1ccc(cc1)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)(F)F, Cc1ccc(cc1)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)(F)F","Launched",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"850","celiprolol","adrenergic receptor antagonist","ADRA2A, ADRB1, ADRB2","genetics","Ehlers-Danlos syndrome (EDS)","CCN(CC)C(=O)Nc1ccc(OC[C@@H](O)CNC(C)(C)C)c(c1)C(C)=O |&1:14|, CCN(CC)C(=O)Nc1ccc(OC[C@@H](O)CNC(C)(C)C)c(c1)C(C)=O |&1:14|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,1,1,1,1
"851","cenisertib","aurora kinase inhibitor","AURKB, KDR","oncology","pancreatic cancer","[H][C@@]1([C@H]([C@H]2C(N)=O)NC3=NC(NC4=CC=C(C(C)=C4)N5CCN(CC5)C)=NC=C3F)C[C@]2(C=C1)[H]","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"852","CEP-32496","RAF inhibitor","BRAF, RAF1",NA,NA,"COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC, COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC, COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC, COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC, COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC, COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC, COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"853","CEP-33779","JAK inhibitor","JAK2",NA,NA,"CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"854","CEP-37440","ALK tyrosine kinase receptor inhibitor","ALK",NA,NA,"CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"855","ceralasertib","atr kinase inhibitor","ATR","Oncology","breast cancer","C[C@@H]1COCCN1c1cc(nc(n1)-c1ccnc2[nH]ccc12)C1(CC1)[S@](C)(=N)=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"856","ceritinib","ALK tyrosine kinase receptor inhibitor","ALK, FLT3, IGF1R, INSR, TSSK1B","oncology","non-small cell lung cancer (NSCLC)","CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"857","cerulenin","fatty acid synthase inhibitor","FASN","infectious disease","fungal infection","C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O, C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O, C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O, C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"858","ceruletide","CCK receptor agonist","CCKAR",NA,NA,"[H][C@](NC(=O)[C@H](Cc1ccc(OS(O)(=O)=O)cc1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)([C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"859","cetaben","ACAT inhibitor, cholesterol inhibitor","PPARA",NA,NA,"CCCCCCCCCCCCCCCCNc1ccc(cc1)C(O)=O, CCCCCCCCCCCCCCCCNc1ccc(cc1)C(O)=O, CCCCCCCCCCCCCCCCNc1ccc(cc1)C(O)=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"860","cetilistat","triacylglycerol lipase inhibitor","PNLIP",NA,NA,"CCCCCCCCCCCCCCCCOc1nc2ccc(C)cc2c(=O)o1, CCCCCCCCCCCCCCCCOc1nc2ccc(C)cc2c(=O)o1, CCCCCCCCCCCCCCCCOc1nc2ccc(C)cc2c(=O)o1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"861","cetirizine","histamine receptor antagonist","HRH1","allergy","allergic rhinitis","OC(=O)COCCN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:13|, OC(=O)COCCN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:13|, OC(=O)COCCN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:13|, OC(=O)COCCN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:13|","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"862","cetrorelix","gonadotropin releasing factor hormone receptor antagonist","GNRHR, LHCGR","endocrinology","premature luteinizing hormone surges","CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O, CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O, CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"863","cevimeline","acetylcholine receptor agonist","CHRM3","rheumatology","sjogren's syndrome","C[C@H]1O[C@]2(CS1)CN1CCC2CC1 |&1:1,3|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,1
"864","cevipabulin","microtubule stimulant, tubulin polymerization inhibitor, microtubule stimulant, tubulin polymerization inhibitor","TUBB",NA,NA,"CNCCCOc1cc(F)c(c(F)c1)-c1c(Cl)nc2ncnn2c1NC(C)C(F)(F)F, [H][C@@](C)(Nc1c(c(Cl)nc2ncnn12)-c1c(F)cc(OCCCNC)cc1F)C(F)(F)F","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"865","CE3F4","rap guanine nucleotide exchange factor inhibitor","RAPGEF3",NA,NA,"C[C@H]1CCc2c(Br)c(F)c(Br)cc2N1C=O |&1:1,r|, C[C@H]1CCc2c(Br)c(F)c(Br)cc2N1C=O |&1:1,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"866","CFTRinh-172","chloride channel blocker","CFTR",NA,NA,"OC(=O)c1ccc(\C=C2\SC(=S)N(C2=O)c2cccc(c2)C(F)(F)F)cc1, OC(=O)c1ccc(\C=C2\SC(=S)N(C2=O)c2cccc(c2)C(F)(F)F)cc1, OC(=O)c1ccc(\C=C2\SC(=S)N(C2=O)c2cccc(c2)C(F)(F)F)cc1, OC(=O)c1ccc(\C=C2\SC(=S)N(C2=O)c2cccc(c2)C(F)(F)F)cc1, OC(=O)c1ccc(\C=C2\SC(=S)N(C2=O)c2cccc(c2)C(F)(F)F)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"867","CF102","adenosine receptor agonist","ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,"CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)nc(Cl)nc12, CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)nc(Cl)nc12, CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)nc(Cl)nc12, CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)nc(Cl)nc12","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"868","CGH2466","adenosine receptor antagonist","ADORA1, ADORA2B, ADORA3",NA,NA,"Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1, Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1, Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1, Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1, Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"869","CGK-733","ATM kinase inhibitor, ATR kinase inhibitor","ATM, ATR",NA,NA,"[O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|, [O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|, [O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|, [O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|, [O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|, [O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"870","CGM097","MDM inhibitor","MDM2",NA,NA,"COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"871","CGP-12177","adrenergic receptor agonist","ADRB1, ADRB2, ADRB3",NA,NA,"CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(=O)[nH]c12 |&1:6|, CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(=O)[nH]c12 |&1:6|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0
"872","CGP-13501","GABA receptor modulator","GABBR1",NA,NA,"CC(C)(C)c1cc(CC(C)(C)C=O)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(CC(C)(C)C=O)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(CC(C)(C)C=O)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(CC(C)(C)C=O)cc(c1O)C(C)(C)C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"873","CGP-20712A","adrenergic receptor antagonist","ADRB1, ADRB3",NA,NA,"CS(O)(=O)=O.Cn1cc(nc1-c1ccc(OC[C@H](O)CNCCOc2ccc(O)c(c2)C(N)=O)cc1)C(F)(F)F |&1:17,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0
"874","CGP-37157","mitochondrial Na+/Ca2+ exchanger antagonist, sodium/calcium exchange inhibitor","SLC8A1",NA,NA,"Clc1ccc2NC(=O)CS[C@@H](c3ccccc3Cl)c2c1 |&1:10,r|, Clc1ccc2NC(=O)CS[C@@H](c3ccccc3Cl)c2c1 |&1:10,r|, Clc1ccc2NC(=O)CS[C@@H](c3ccccc3Cl)c2c1 |&1:10,r|, Clc1ccc2NC(=O)CS[C@@H](c3ccccc3Cl)c2c1 |&1:10,r|, Clc1ccc2NC(=O)CS[C@@H](c3ccccc3Cl)c2c1 |&1:10,r|","Preclinical",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"875","CGP-37849","glutamate receptor antagonist","GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,"C\C(CP(O)(O)=O)=C/[C@@H](N)C(O)=O |&1:8,r|, C\C(CP(O)(O)=O)=C/[C@@H](N)C(O)=O |&1:8,r|, C\C(CP(O)(O)=O)=C/[C@@H](N)C(O)=O |&1:8,r|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"876","CGP-52411","EGFR inhibitor","EGFR",NA,NA,"O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12, O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12, O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12, O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"877","CGP-53353","EGFR inhibitor, PKC inhibitor","EGFR, PRKCB",NA,NA,"Fc1ccc(Nc2cc3C(=O)NC(=O)c3cc2Nc2ccc(F)cc2)cc1, Fc1ccc(Nc2cc3C(=O)NC(=O)c3cc2Nc2ccc(F)cc2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"878","CGP-54626","GABA receptor antagonist","GABBR1, GABBR2, KCTD12, KCTD16, KCTD8",NA,NA,"C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1 |a:1,4,&1:7|, C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1 |a:1,4,&1:7|, C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1 |a:1,4,&1:7|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"879","CGP-55845","GABA receptor antagonist","GABBR1, GABBR2, KCTD12, KCTD16, KCTD8",NA,NA,"C[C@H](NC[C@H](O)CP(O)(=O)Cc1ccccc1)c1ccc(Cl)c(Cl)c1, C[C@H](NC[C@H](O)CP(O)(=O)Cc1ccccc1)c1ccc(Cl)c(Cl)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"880","CGP-57380","MAP kinase inhibitor","AURKB, LCK, MKNK1, MKNK2, SGK1",NA,NA,"Nc1ncnc2n[nH]c(Nc3ccc(F)cc3)c12, Nc1ncnc2n[nH]c(Nc3ccc(F)cc3)c12, Nc1ncnc2n[nH]c(Nc3ccc(F)cc3)c12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"881","CGP-60474","CDK inhibitor","CDK1, CDK2",NA,NA,"OCCCNc1cc(ccn1)-c1ccnc(Nc2cccc(Cl)c2)n1, OCCCNc1cc(ccn1)-c1ccnc(Nc2cccc(Cl)c2)n1, OCCCNc1cc(ccn1)-c1ccnc(Nc2cccc(Cl)c2)n1, OCCCNc1cc(ccn1)-c1ccnc(Nc2cccc(Cl)c2)n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"882","CGP-71683","neuropeptide receptor antagonist","NPY5R",NA,NA,"Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12 |r|, Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12 |r|, Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12 |r|, Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12 |r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"883","CGP-74514","CDK inhibitor","CDK1",NA,NA,"CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc12, CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc12, CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc12, CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"884","CGP-7930","GABA receptor modulator","GABBR1",NA,NA,"CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"885","CGS-15943","adenosine receptor antagonist","ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,"Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"886","CGS-20625","benzodiazepine receptor agonist, GABA benzodiazepine site receptor partial agonist","GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6",NA,NA,"COc1ccc(cc1)-n1[nH]c2c3CCCCCc3ncc2c1=O, COc1ccc(cc1)-n1[nH]c2c3CCCCCc3ncc2c1=O, COc1ccc(cc1)-n1[nH]c2c3CCCCCc3ncc2c1=O, COc1ccc(cc1)-n1[nH]c2c3CCCCCc3ncc2c1=O, COc1ccc(cc1)-n1[nH]c2c3CCCCCc3ncc2c1=O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,1,6,0,0,0,0,0,0,0,0,0,0
"887","CGS-21680","adenosine receptor agonist","ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,"CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)nc(NCCc3ccc(CCC(O)=O)cc3)nc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"888","CGS-9896","GABA receptor antagonist","GABRA1, GABRB2, GABRG2",NA,NA,"Clc1ccc(cc1)-n1[nH]c2c(cnc3ccccc23)c1=O, Clc1ccc(cc1)-n1[nH]c2c(cnc3ccccc23)c1=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0
"889","CH-5183284","fibroblast growth factor inhibitor","FGFR1, FGFR2, FGFR3",NA,NA,"Cc1nc2ccc(cc2[nH]1)-n1ncc(C(=O)c2cc3ccccc3[nH]2)c1N, Cc1nc2ccc(cc2[nH]1)-n1ncc(C(=O)c2cc3ccccc3[nH]2)c1N, Cc1nc2ccc(cc2[nH]1)-n1ncc(C(=O)c2cc3ccccc3[nH]2)c1N, Cc1nc2ccc(cc2[nH]1)-n1ncc(C(=O)c2cc3ccccc3[nH]2)c1N","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"890","CHC","monocarboxylate transporter inhibitor","SLC16A1",NA,NA,"OC(=O)C(=C\c1ccc(O)cc1)\C#N, OC(=O)C(=C\c1ccc(O)cc1)\C#N","Preclinical",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"891","chenodeoxycholic-acid","11-beta hydroxysteroid dehydrogenase inhibitor, FXR agonist","HSD11B1, NR1H4","cardiology, gastroenterology","cerebral cholesterosis, gallstones","C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"892","CHF5074","gamma secretase modulator","PSEN1",NA,NA,"OC(=O)C1(CC1)c1ccc(c(F)c1)-c1ccc(Cl)c(Cl)c1, OC(=O)C1(CC1)c1ccc(c(F)c1)-c1ccc(Cl)c(Cl)c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"893","chicago-sky-blue-6b","glutamate inhibitor, macrophage migration inhibiting factor inhibitor","MIF",NA,NA,"COc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(OC)c1 |c:12,40|, COc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(OC)c1 |c:12,40|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"894","chidamide","HDAC inhibitor","HDAC10, HDAC3","hematologic malignancy","peripheral T-cell lymphoma (PTCL)","Nc1ccc(F)cc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1, Nc1ccc(F)cc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1, Nc1ccc(F)cc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1, Nc1ccc(F)cc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"895","CHIR-124","CHK inhibitor","CHEK1",NA,NA,"Clc1ccc2[nH]c(=O)c(-c3nc4ccccc4[nH]3)c(N[C@@H]3CN4CCC3CC4)c2c1, Clc1ccc2[nH]c(=O)c(-c3nc4ccccc4[nH]3)c(N[C@@H]3CN4CCC3CC4)c2c1, Clc1ccc2[nH]c(=O)c(-c3nc4ccccc4[nH]3)c(N[C@@H]3CN4CCC3CC4)c2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"896","CHIR-98014","glycogen synthase kinase inhibitor","GSK3A, GSK3B",NA,NA,"Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O, Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O, Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O, Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"897","CHIR-99021","glycogen synthase kinase inhibitor","CDK1, GSK3A, GSK3B, MAPK1",NA,NA,"Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"898","chloramphenicol","bacterial 50S ribosomal subunit inhibitor","CD55","infectious disease, endocrinology","meningitis, fever, cholera","OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O, OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O, OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O, OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O, OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"899","chlorisondamine-diiodide","acetylcholine receptor antagonist","CHRNA1",NA,NA,"C[N+](C)(C)CC[N+]1(C)Cc2c(C1)c(Cl)c(Cl)c(Cl)c2Cl, C[N+](C)(C)CC[N+]1(C)Cc2c(C1)c(Cl)c(Cl)c(Cl)c2Cl","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
"900","chlormadinone-acetate","5 alpha reductase inhibitor","PGR","endocrinology","hypermenorrhea, amenorrhea, oligomenorrhea, polymenorrhea","CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"901","chlormerodrin","sodium/potassium/chloride transporter inhibitor","ALDH5A1, SLC12A1","urology","urinary frequency","COC(CNC(=O)N)C[Hg]Cl","Withdrawn",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"902","chlormezanone","GABA receptor modulator","GABRA1",NA,NA,"CN1[C@@H](c2ccc(Cl)cc2)S(=O)(=O)CCC1=O |&1:2,r|, CN1[C@@H](c2ccc(Cl)cc2)S(=O)(=O)CCC1=O |&1:2,r|, CN1[C@@H](c2ccc(Cl)cc2)S(=O)(=O)CCC1=O |&1:2,r|, CN1[C@@H](c2ccc(Cl)cc2)S(=O)(=O)CCC1=O |&1:2,r|, CN1[C@@H](c2ccc(Cl)cc2)S(=O)(=O)CCC1=O |&1:2,r|","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0
"903","chlorogenic-acid","antioxidant","SLC37A4","neurology/psychiatry, pulmonary, allergy","headache, chest congestion, allergic rhinitis","O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O, O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O, O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O, O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"904","chloroprocaine","sodium channel blocker","ATP1A1, CHRNA10, GRIN3A, HTR3A, SCN10A, SLC6A3","neurology/psychiatry","local anesthetic","CCN(CC)CCOC(=O)c1ccc(N)cc1Cl","Launched",1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,1
"905","chloropyramine","histamine receptor antagonist","HRH1","cardiology, ophthalmology, allergy, pulmonary","edema, conjunctivitis, allergic rhinitis, asthma","CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1, CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1, CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1, CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1, CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1, CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"906","chloroquine","antimalarial agent","MRGPRX1","infectious disease","malaria, amebiasis","CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12 |&1:8|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"907","chlorothiazide","diuretic","CA1, CA2, CA4, SLC12A3","cardiology","hypertension","NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O |c:12|, NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O |c:12|, NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O |c:12|, NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O |c:12|","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"908","chlorotrianisene","estrogenic hormone","ESR1, ESR2","endocrinology, oncology","menopause, prostate cancer","COc1ccc(cc1)C(Cl)=C(c1ccc(OC)cc1)c1ccc(OC)cc1, COc1ccc(cc1)C(Cl)=C(c1ccc(OC)cc1)c1ccc(OC)cc1, COc1ccc(cc1)C(Cl)=C(c1ccc(OC)cc1)c1ccc(OC)cc1, COc1ccc(cc1)C(Cl)=C(c1ccc(OC)cc1)c1ccc(OC)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"909","chloroxine","opioid receptor antagonist","OPRK1","gastroenterology, infectious disease, dermatology","diarrhea, inflammatory bowel disease, giardiasis, dandruff","Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"910","chlorproguanil","dihydrofolate reductase inhibitor","DHFR","infectious disease","malaria","CC(C)NC(=N)N=C(N)Nc1ccc(Cl)c(Cl)c1, CC(C)NC(=N)N=C(N)Nc1ccc(Cl)c(Cl)c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"911","chlorpromazine","dopamine receptor antagonist","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CALM1, CHRM1, CHRM3, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HRH4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7, KCNH2, ORM1, ORM2, SMPD1, TRPC5","neurology/psychiatry, gastroenterology, hematology, infectious disease","schizophrenia, nausea, vomiting, acute intermittent porphyria (AIP), tetanus","CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12","Launched",0,0,0,0,0,0,0,0,1,6,1,2,0,0,1,5,1,2,1,6,1,1,1,1
"912","chlorpropamide","ATP channel blocker","ABCC8, KCNJ10","endocrinology","diabetes mellitus","CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1, CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1, CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1, CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1, CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"913","chlorprothixene","dopamine receptor antagonist","CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, HRH1, HTR2A, HTR2B, HTR2C","neurology/psychiatry","schizophrenia, bipolar disorder","CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12, CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12, CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12, CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12, CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12, CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12, CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12","Launched",0,0,0,0,0,0,0,0,1,3,1,1,0,0,1,3,1,5,0,0,1,1,1,1
"914","chlorpyrifos","acetylcholinesterase inhibitor","ACHE",NA,NA,"CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl, CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl, CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"915","chlorthalidone","carbonic anhydrase inhibitor","CA1, CA12, CA14, CA2, CA4, CA7, SLC12A1","cardiology, gastroenterology, rheumatology, nephrology","hypertension, edema, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis (AGN), chronic renal failure","NS(=O)(=O)c1cc(ccc1Cl)[C@@]1(O)NC(=O)c2ccccc12 |&1:11,r|, NS(=O)(=O)c1cc(ccc1Cl)[C@@]1(O)NC(=O)c2ccccc12 |&1:11,r|, NS(=O)(=O)c1cc(ccc1Cl)[C@@]1(O)NC(=O)c2ccccc12 |&1:11,r|","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"916","chlorzoxazone","bacterial 30S ribosomal subunit inhibitor","KCNMA1, KCNN4","neurology/psychiatry","muscle relaxant","Clc1ccc2oc(=O)[nH]c2c1, Clc1ccc2oc(=O)[nH]c2c1, Clc1ccc2oc(=O)[nH]c2c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"917","cholic-acid","bile acid","ADH1C, CES1, COX4I1, COX5A, COX5B, COX6A2, COX6B1, COX6C, COX7A1, COX7B, COX7C, COX8A, ESRRG, FABP6, FECH, GPBAR1, MT-CO1, MT-CO2, MT-CO3, PLA2G1B","gastroenterology, neurology/psychiatry, genetics","bile acid synthesis disorders, peroxisomal disorders, Zellweger syndrome","C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"918","choline","acetylcholine precursor","ACHE, BCHE, CHRNA2, PCYT1A, PCYT1B, PHOSPHO1, PLD1, PLD2",NA,NA,"C[N+](C)(C)CCO, C[N+](C)(C)CCO, C[N+](C)(C)CCO","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
"919","CHPG","glutamate receptor agonist","GRM5",NA,NA,"N[C@@H](C(O)=O)c1cc(O)ccc1Cl |&1:1,r|, N[C@@H](C(O)=O)c1cc(O)ccc1Cl |&1:1,r|, N[C@@H](C(O)=O)c1cc(O)ccc1Cl |&1:1,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"920","CHR-6494","serine/threonine kinase inhibitor","GSG2",NA,NA,"CCCNc1ccc2ncc(-c3ccc4n[nH]cc4c3)n2n1, CCCNc1ccc2ncc(-c3ccc4n[nH]cc4c3)n2n1, CCCNc1ccc2ncc(-c3ccc4n[nH]cc4c3)n2n1, CCCNc1ccc2ncc(-c3ccc4n[nH]cc4c3)n2n1, CCCNc1ccc2ncc(-c3ccc4n[nH]cc4c3)n2n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"921","chrysin","breast cancer resistance protein inhibitor","AKR1B1, CDK6, CYP19A1, CYP1B1",NA,NA,"Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccccc1, Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccccc1, Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccccc1, Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccccc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"922","chrysophanic-acid","EGFR inhibitor","EGFR, MTOR",NA,NA,"Cc1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1, Cc1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"923","chs-828","nampt inhibitor","A1BG, NAMPT","Oncology","lung cancer","Clc1ccc(OCCCCCC\N=C(\NC#N)Nc2ccncc2)cc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"924","CH223191","aryl hydrocarbon receptor antagonist","AHR",NA,NA,"Cc1ccccc1\N=N\c1ccc(NC(=O)c2ccnn2C)c(C)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"925","CH5132799","PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,"CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1, CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1, CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1, CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"926","CH55","retinoid receptor binder","RARA, RARB",NA,NA,"CC(C)(C)c1cc(cc(c1)C(C)(C)C)C(=O)\C=C\c1ccc(cc1)C(O)=O, CC(C)(C)c1cc(cc(c1)C(C)(C)C)C(=O)\C=C\c1ccc(cc1)C(O)=O, CC(C)(C)c1cc(cc(c1)C(C)(C)C)C(=O)\C=C\c1ccc(cc1)C(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"927","CI-966","GAT inhibitor","SLC6A1",NA,NA,"OC(=O)C1=CCCN(CCOC(c2ccc(cc2)C(F)(F)F)c2ccc(cc2)C(F)(F)F)C1 |t:3|, OC(=O)C1=CCCN(CCOC(c2ccc(cc2)C(F)(F)F)c2ccc(cc2)C(F)(F)F)C1 |t:3|, OC(=O)C1=CCCN(CCOC(c2ccc(cc2)C(F)(F)F)c2ccc(cc2)C(F)(F)F)C1 |t:3|, OC(=O)C1=CCCN(CCOC(c2ccc(cc2)C(F)(F)F)c2ccc(cc2)C(F)(F)F)C1 |t:3|","Phase 1",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"928","CI-976","ACAT inhibitor","ACAT1, CES1",NA,NA,"CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC, CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC, CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC, CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC, CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC, CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC, CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"929","cianidanol","fatty acid synthase inhibitor","PTGS1",NA,NA,"O[C@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1ccc(O)c(O)c1, O[C@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1ccc(O)c(O)c1","Withdrawn",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"930","ciclesonide","glucocorticoid receptor agonist","NR3C1, SERPINA6","allergy","allergic rhinitis","CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C)C1CCCCC1 |c:24,t:20|, CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C)C1CCCCC1 |c:24,t:20|, CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C)C1CCCCC1 |c:24,t:20|, CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C)C1CCCCC1 |c:24,t:20|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"931","ciclopirox","membrane integrity inhibitor","ATP1A1","infectious disease","onychomycosis","Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"932","cicloprofen","cyclooxygenase inhibitor","PTGS1, PTGS2",NA,NA,"C[C@@H](C(O)=O)c1ccc-2c(Cc3ccccc-23)c1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc-2c(Cc3ccccc-23)c1 |&1:1,r|","Preclinical",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"933","CID-16020046","G protein-coupled receptor antagonist","GPR55",NA,NA,"Cc1ccc(cc1)-c1n[nH]c2C(=O)N([C@H](c12)c1cccc(O)c1)c1ccc(cc1)C(O)=O |&1:14,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"934","CID-2011756","protein kinase inhibitor","PKD1",NA,NA,"Clc1cccc(c1)-c1ccc(o1)C(=O)Nc1ccc(CN2CCOCC2)cc1, Clc1cccc(c1)-c1ccc(o1)C(=O)Nc1ccc(CN2CCOCC2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"935","CID-2745687","G protein-coupled receptor antagonist","GPR35",NA,NA,"COC(=O)c1cnn(c1\C=N\NC(=S)NC(C)(C)C)-c1ccc(F)cc1F, COC(=O)c1cnn(c1\C=N\NC(=S)NC(C)(C)C)-c1ccc(F)cc1F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"936","CID-5458317","MAP kinase phosphatase inhibitor","MAPK3",NA,NA,"OC1=c2ccccc2=C(NC2CCCCC2)\C1=C/c1ccccc1 |c:1,t:8|, OC1=c2ccccc2=C(NC2CCCCC2)\C1=C/c1ccccc1 |c:1,t:8|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"937","ciglitazone","PPAR receptor agonist","PPARG",NA,NA,"CC1(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)CCCCC1 |r|, CC1(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)CCCCC1 |r|, CC1(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)CCCCC1 |r|, CC1(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)CCCCC1 |r|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"938","cilastatin","dehydropeptidase inhibitor","DPEP1",NA,NA,"CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O, CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"939","cilazapril","angiotensin converting enzyme inhibitor","ACE","cardiology","hypertension, congestive heart failure","CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCCN2CCC[C@H](N2C1=O)C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCCN2CCC[C@H](N2C1=O)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"940","cilengitide","integrin antagonist","ITGAV, ITGB3",NA,NA,"CC(C)[C@@H]1N(C)C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O, CC(C)[C@@H]1N(C)C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O, CC(C)[C@@H]1N(C)C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O, CC(C)[C@@H]1N(C)C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"941","cilnidipine","calcium channel blocker","CACNA1B","cardiology","hypertension","COCCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1, COCCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1 |&1:14,r,c:7,12|, COCCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1 |&1:14,r,c:7,12|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"942","cilomilast","phosphodiesterase inhibitor","PDE4A, PDE4B, PDE4D",NA,NA,"COc1ccc(cc1OC1CCCC1)C1(CCC(CC1)C(O)=O)C#N, COc1ccc(cc1OC1CCCC1)[C@]1(CC[C@@H](CC1)C(O)=O)C#N |r|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"943","cilostamide","phosphodiesterase inhibitor","PDE3A, PDE3B",NA,NA,"CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1, CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1, CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"944","cilostazol","phosphodiesterase inhibitor","PDE3A, PDE3B","cardiology","claudication","O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1, O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1, O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1, O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1, O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1, O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1, O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"945","CIM-0216","transient receptor potential channel agonist","TRPM3",NA,NA,"Cc1cc(NC(=O)[C@@H](N2CCCc3ccccc23)c2ccccc2)no1 |&1:7,r|, Cc1cc(NC(=O)[C@@H](N2CCCc3ccccc23)c2ccccc2)no1 |&1:7,r|, Cc1cc(NC(=O)[C@@H](N2CCCc3ccccc23)c2ccccc2)no1 |&1:7,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"946","cimaterol","adrenergic receptor agonist","ADRB1, ADRB2, ADRB3",NA,NA,"CC(C)NC[C@@H](O)c1ccc(N)c(c1)C#N |&1:5,r|, CC(C)NC[C@@H](O)c1ccc(N)c(c1)C#N |&1:5,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0
"947","cimetidine","histamine receptor antagonist","HRH2, SLC29A4, SLC47A1, SLC47A2","gastroenterology, hematologic malignancy, endocrinology","duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma","CN\C(NCCSCc1[nH]cnc1C)=N/C#N, CN\C(NCCSCc1[nH]cnc1C)=N/C#N, CN\C(NCCSCc1[nH]cnc1C)=N/C#N, CN\C(NCCSCc1[nH]cnc1C)=N/C#N, CN\C(NCCSCc1[nH]cnc1C)=N/C#N, CN\C(NCCSCc1[nH]cnc1C)=N/C#N","Launched",1,3,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"948","cimetropium","acetylcholine receptor antagonist","CHRM1","gastroenterology","irritable bowel syndrome","C[N@@+]1(CC2CC2)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1 |a:6,8,10,11,13,17,&1:1,TLB:0:1:7.8.9:11.13,THB:2:1:7.8.9:11.13,12:11:1:7.8.9,12:13:1:7.8.9,14:8:1:11.13|, C[N@@+]1(CC2CC2)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1 |a:6,8,10,11,13,17,&1:1,TLB:0:1:7.8.9:11.13,THB:2:1:7.8.9:11.13,12:11:1:7.8.9,12:13:1:7.8.9,14:8:1:11.13|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,1
"949","cinacalcet","calcium channel activator","CASR","endocrinology, nephrology, oncology","hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia","C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12, C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12, C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12, C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12, C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12, C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12, C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12, C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"950","cinaciguat","guanylate cyclase activator","GUCY1A3, GUCY1B3",NA,NA,"OC(=O)CCCCN(CCc1ccccc1OCc1ccc(CCc2ccccc2)cc1)Cc1ccc(cc1)C(O)=O, OC(=O)CCCCN(CCc1ccccc1OCc1ccc(CCc2ccccc2)cc1)Cc1ccc(cc1)C(O)=O, OC(=O)CCCCN(CCc1ccccc1OCc1ccc(CCc2ccccc2)cc1)Cc1ccc(cc1)C(O)=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"951","cinalukast","leukotriene receptor antagonist","CYSLTR1",NA,NA,"CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O, CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O, CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"952","cinanserin","serotonin receptor antagonist","HTR2A",NA,NA,"CN(C)CCCSc1ccccc1NC(=O)\C=C\c1ccccc1, CN(C)CCCSc1ccccc1NC(=O)\C=C\c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"953","cinchocaine","sodium channel blocker","CALM1, SCN10A, SCN5A","neurology/psychiatry","local anesthetic","CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1, CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1, CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1","Launched",0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"954","cinchonine","P glycoprotein inhibitor","CYP2D6",NA,NA,"O[C@H]([C@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"955","cinnamaldehyde","aldose reductase inhibitor, TRPV agonist","TRPA1",NA,NA,"O=C\C=C\c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"956","CINPA-1","CAR antagonist","NR1H4, NR1I3, PPARG",NA,NA,"CCOC(=O)Nc1ccc2CCc3ccccc3N(C(=O)CN(CC)CC)c2c1, CCOC(=O)Nc1ccc2CCc3ccccc3N(C(=O)CN(CC)CC)c2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"957","cipemastat","metalloproteinase inhibitor","ADAM17, MMP1, MMP13, MMP2, MMP3, MMP8, MMP9",NA,NA,"CN1C(=O)N(C[C@@H]([C@@H](CC2CCCC2)C(=O)N2CCCCC2)C(=O)NO)C(=O)C1(C)C","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"958","ciprofibrate","PPAR receptor agonist","PPARA","endocrinology","hyperlipidemia","CC(C)(Oc1ccc(cc1)[C@H]1CC1(Cl)Cl)C(O)=O |&1:10,r|, CC(C)(Oc1ccc(cc1)[C@H]1CC1(Cl)Cl)C(O)=O |&1:10,r|, CC(C)(Oc1ccc(cc1)[C@H]1CC1(Cl)Cl)C(O)=O |&1:10,r|, CC(C)(Oc1ccc(cc1)[C@H]1CC1(Cl)Cl)C(O)=O |&1:10,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"959","ciprofloxacin","bacterial DNA gyrase inhibitor","TOP2A","otolaryngology","otitis","OC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O, OC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O, OC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O, OC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"960","ciproxifan","histamine receptor antagonist","ADRA2A, ADRA2C, HRH3, HRH4, HTR3A",NA,NA,"O=C(C1CC1)c1ccc(OCCCc2cnc[nH]2)cc1, O=C(C1CC1)c1ccc(OCCCc2cnc[nH]2)cc1","Preclinical",0,0,0,0,0,0,0,0,1,1,1,2,0,0,0,0,0,0,1,2,0,0,0,0
"961","CIQ","glutamate receptor potentiator","GRIN2C, GRIN2D",NA,NA,"COc1ccc(OC[C@H]2N(CCc3cc(OC)c(OC)cc23)C(=O)c2cccc(Cl)c2)cc1 |&1:8,r|, COc1ccc(OC[C@H]2N(CCc3cc(OC)c(OC)cc23)C(=O)c2cccc(Cl)c2)cc1 |&1:8,r|, COc1ccc(OC[C@H]2N(CCc3cc(OC)c(OC)cc23)C(=O)c2cccc(Cl)c2)cc1 |&1:8,r|, COc1ccc(OC[C@H]2N(CCc3cc(OC)c(OC)cc23)C(=O)c2cccc(Cl)c2)cc1 |&1:8,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"962","cirazoline","adrenergic receptor agonist","ADRA1A",NA,NA,"C(Oc1ccccc1C1CC1)C1=NCCN1 |t:13|, C(Oc1ccccc1C1CC1)C1=NCCN1 |t:13|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
"963","cis-ACPD","glutamate receptor agonist","GRM2, GRM3, GRM6, GRM7, GRM8",NA,NA,"[H][C@]1(CC[C@@](N)(C1)C(O)=O)C(O)=O |&1:1,4,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"964","cis-exo-camphanediol-2,3","nitric oxide stimulant","NOS3",NA,NA,"CC1(C)[C@H]2CC[C@]1(C)[C@@H](O)[C@H]2O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"965","cis-urocanic-acid","serotonin receptor agonist","HTR2A",NA,NA,"OC(=O)\C=C\c1cnc[nH]1, OC(=O)\C=C\c1cnc[nH]1, OC(=O)\C=C\c1cnc[nH]1, OC(=O)\C=C/c1cnc[nH]1","Phase 2",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"966","cisapride","serotonin receptor agonist","HTR2A, HTR3A, HTR4, KCNH2",NA,NA,"COC1CN(CCCOc2ccc(F)cc2)CCC1NC(=O)c1cc(Cl)c(N)cc1OC, CO[C@H]1CN(CCCOc2ccc(F)cc2)CC[C@H]1NC(=O)c1cc(Cl)c(N)cc1OC, CO[C@H]1CN(CCCOc2ccc(F)cc2)CC[C@H]1NC(=O)c1cc(Cl)c(N)cc1OC, CO[C@H]1CN(CCCOc2ccc(F)cc2)CC[C@H]1NC(=O)c1cc(Cl)c(N)cc1OC","Withdrawn",0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"967","cisatracurium","acetylcholine receptor antagonist","CHRNA2","neurology/psychiatry, critical care","muscle relaxant, endotracheal intubation","COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC, COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC, COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,1
"968","cisplatin","DNA alkylating agent, DNA synthesis inhibitor","XIAP","oncology","testicular carcinoma, ovarian cancer, bladder cancer","N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"969","citalopram","selective serotonin reuptake inhibitor (SSRI)","ADRA1A, CHRM1, HRH1, SLC6A2, SLC6A3, SLC6A4","neurology/psychiatry","depression","CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1 |&1:6|, CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1 |&1:6|, CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1 |&1:6|","Launched",1,3,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,1,1,1
"970","CITCO","constitutive androstane receptor (CAR) agonist","NR1I3",NA,NA,"Clc1ccc(cc1)-c1nc2sccn2c1\C=N\OCc1ccc(Cl)c(Cl)c1, Clc1ccc(cc1)-c1nc2sccn2c1\C=N\OCc1ccc(Cl)c(Cl)c1, Clc1ccc(cc1)-c1nc2sccn2c1\C=N\OCc1ccc(Cl)c(Cl)c1, Clc1ccc(cc1)-c1nc2sccn2c1\C=N\OCc1ccc(Cl)c(Cl)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"971","citicoline","glutathione transferase stimulant, membrane permeability enhancer","ACHE, SLC1A2","neurology/psychiatry, ophthalmology","stroke, Alzheimer's disease, senile dementia, Parkinson's Disease, attention-deficit/hyperactivity disorder (ADHD), glaucoma","C[N+](C)(C)CCOP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(N)nc1=O |a:16,18,19,21,&1:7,&2:11|, C[N+](C)(C)CCOP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(N)nc1=O |a:16,18,19,21,&1:7,&2:11|, C[N+](C)(C)CCOP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(N)nc1=O |a:16,18,19,21,&1:7,&2:11|, C[N+](C)(C)CCOP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(N)nc1=O |a:16,18,19,21,&1:7,&2:11|","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"972","citric-acid","coagulation factor inhibitor","AKR1B1, ANG, APRT, BHMT, C8G, CA4, CPB1, CS, CTDSP1, GNMT, HGS, HS3ST3A1, IL4I1, ITPA, LSM6, MDH2, MIF, PDE5A, PKD2L1, PLEKHA1, RNASE1, RNASE3, SRC, TNFSF13B, UCK2",NA,NA,"OC(=O)CC(O)(CC(O)=O)C(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"973","CJ-033466","serotonin receptor agonist","HTR4",NA,NA,"CC(C)CN1CCC(CNC(=O)c2cc(Cl)c(N)n3cc(C)nc23)CC1, CC(C)CN1CCC(CNC(=O)c2cc(Cl)c(N)n3cc(C)nc23)CC1","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"974","CK-636","actin related protein inhibitor","ACTR2, ACTR3, ARPC1B, ARPC2, ARPC3, ARPC4, ARPC5",NA,NA,"Cc1[nH]c2ccccc2c1CCNC(=O)c1cccs1, Cc1[nH]c2ccccc2c1CCNC(=O)c1cccs1, Cc1[nH]c2ccccc2c1CCNC(=O)c1cccs1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"975","CKD-712","NFkB pathway inhibitor","JAK2, STAT1",NA,NA,"Oc1cc2CCN[C@@H](Cc3cccc4ccccc34)c2cc1O |&1:7|, Oc1cc2CCN[C@@H](Cc3cccc4ccccc34)c2cc1O |&1:7|, Oc1cc2CCN[C@@H](Cc3cccc4ccccc34)c2cc1O |&1:7|, Oc1cc2CCN[C@@H](Cc3cccc4ccccc34)c2cc1O |&1:7|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"976","CKI-7","casein kinase inhibitor","CSNK1G2",NA,NA,"NCCNS(=O)(=O)c1ccc(Cl)c2ccncc12, NCCNS(=O)(=O)c1ccc(Cl)c2ccncc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"977","CL-218872","benzodiazepine receptor agonist","GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2",NA,NA,"Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F, Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F, Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,1,6,0,0,0,0,0,0,0,0,0,0
"978","cladribine","adenosine deaminase inhibitor, ribonucleotide reductase inhibitor","ADA, PNP, POLA1, POLE, POLE2, POLE3, POLE4, RRM1, RRM2, RRM2B","hematologic malignancy","hairy cell leukemia","Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1, Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1, Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1, Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1, Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1, Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"979","clarithromycin","bacterial 50S ribosomal subunit inhibitor","CYP3A4","otolaryngology, pulmonary, infectious disease","pharyngitis, tonsillitis, sinusitis, bronchitis, pneumonia, skin infections, otitis","CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"980","clascoterone","androgen receptor antagonist","AR","dermatology","acne vulgaris (av)","CCC(=O)OC1(CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C)C(=O)CO","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"981","clebopride","dopamine receptor antagonist","ACHE, DRD2","gastroenterology","nausea","COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1, COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1, COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1
"982","clemastine","histamine receptor antagonist","HRH1","allergy","allergic rhinitis, urticaria","CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1, CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1, CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1, CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1, CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"983","clenbuterol","adrenergic receptor agonist","ABCC8, ADRB2, KCNJ11","pulmonary","chronic obstructive pulmonary disease (COPD), asthma","CC(C)(C)NC[C@@H](O)c1cc(Cl)c(N)c(Cl)c1 |r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"984","cleviprex","calcium channel blocker","CACNA1C, CACNA1D, CACNA1F, CACNA1S","cardiology","hypertension","CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:17,r,c:10,15|, CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:17,r,c:10,15|, CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:17,r,c:10,15|, CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:17,r,c:10,15|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"985","clidinium","acetylcholine receptor antagonist","CHRM1, CHRM3","gastroenterology","peptic ulcer disease (PUD), irritable bowel syndrome, enterocolitis","C[N+]12CCC(CC1)[C@@H](C2)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:7,THB:9:7:2.3:5.6|, C[N+]12CCC(CC1)[C@@H](C2)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:7,THB:9:7:2.3:5.6|, C[N+]12CCC(CC1)[C@@H](C2)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:7,THB:9:7:2.3:5.6|, C[N+]12CCC(CC1)[C@@H](C2)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:7,THB:9:7:2.3:5.6|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,1,1,1,1
"986","clinofibrate","lipase clearing factor inhibitor","LPL","endocrinology","hypertriglyceridemia","CCC(C)(Oc1ccc(cc1)C1(CCCCC1)c1ccc(O[C@](C)(CC)C(O)=O)cc1)C(O)=O |&1:22,&2:2,r|, CCC(C)(Oc1ccc(cc1)C1(CCCCC1)c1ccc(O[C@](C)(CC)C(O)=O)cc1)C(O)=O |&1:22,&2:2,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"987","clioquinol","chelating agent","OPRK1",NA,NA,"Oc1c(I)cc(Cl)c2cccnc12, Oc1c(I)cc(Cl)c2cccnc12, Oc1c(I)cc(Cl)c2cccnc12, Oc1c(I)cc(Cl)c2cccnc12","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"988","clobenpropit","histamine receptor antagonist","HRH1, HRH2, HRH3, HRH4",NA,NA,"Clc1ccc(CNC(=N)SCCCc2cnc[nH]2)cc1, Clc1ccc(CNC(=N)SCCCc2cnc[nH]2)cc1, Clc1ccc(CNC(=N)SCCCc2cnc[nH]2)cc1, Clc1ccc(CNC(=N)SCCCc2cnc[nH]2)cc1, Clc1ccc(CNC(=N)SCCCc2cnc[nH]2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,0,0,0,0
"989","clobetasol-propionate","glucocorticoid receptor agonist","NR3C1, PLA2G1B","dermatology","corticosteroid-responsive dermatoses","CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl |c:17,t:13|, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl |c:17,t:13|, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl |c:17,t:13|, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl |c:17,t:13|, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl |c:17,t:13|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"990","clobetasone-butyrate","corticosteroid agonist","NR3C1","dermatology","eczema, psoriasis, dermatitis","CCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)C(=O)C[C@]12C)C(=O)CCl |c:18,t:14|, CCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)C(=O)C[C@]12C)C(=O)CCl |c:18,t:14|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"991","clocortolone-pivalate","steroid","NR3C1, PLA2G1B","dermatology","corticosteroid-responsive dermatoses","C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C |c:12,t:8|, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C |c:12,t:8|, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C |c:12,t:8|, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C |c:12,t:8|, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C |c:12,t:8|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"992","clodronic-acid","bone resorption inhibitor","SLC25A4, SLC25A5, SLC25A6","orthopedics, endocrinology, hematologic malignancy","osteoporosis, hyperparathyroidism, hypercalcemia, multiple myeloma","OP(O)(=O)C(Cl)(Cl)P(O)(O)=O, OP(O)(=O)C(Cl)(Cl)P(O)(O)=O, OP(O)(=O)C(Cl)(Cl)P(O)(O)=O","Launched",1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"993","clofarabine","ribonucleotide reductase inhibitor","POLA1, POLD1, POLE, RRM1, RRM2, RRM2B","hematologic malignancy","acute lymphoblastic leukemia (ALL)","Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"994","clofedanol","histamine receptor antagonist","HRH1","pulmonary","cough suppressant","CN(C)CC[C@@](O)(c1ccccc1)c1ccccc1Cl |&1:5,r|","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"995","clofibrate","PPAR receptor agonist","LPL, PPARA","endocrinology, cardiology","hyperlipidemia, cholesterol","CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1, CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1, CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1, CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"996","clofibric-acid","PPAR receptor agonist","PPARA","endocrinology","hyperlipidemia","CC(C)(Oc1ccc(Cl)cc1)C(O)=O, CC(C)(Oc1ccc(Cl)cc1)C(O)=O, CC(C)(Oc1ccc(Cl)cc1)C(O)=O, CC(C)(Oc1ccc(Cl)cc1)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"997","clofilium","potassium channel blocker","KCNA5, KCNH1",NA,NA,"CCCCCCC[N+](CC)(CC)CCCCc1ccc(Cl)cc1, CCCCCCC[N+](CC)(CC)CCCCc1ccc(Cl)cc1, CCCCCCC[N+](CC)(CC)CCCCc1ccc(Cl)cc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"998","clomethiazole","GABA receptor antagonist, GABA receptor modulator","GABRA1","neurology/psychiatry","Parkinson's Disease, sedative, muscle relaxant","Cc1ncsc1CCCl, Cc1ncsc1CCCl, Cc1ncsc1CCCl","Launched",0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1
"999","clomifene","estrogen receptor antagonist","ESR1","obstetrics/gynecology","infertility","CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1000","clomipramine","serotonin transporter (SERT) inhibitor","GSTP1, HTR2A, HTR2B, HTR2C, SLC6A2, SLC6A3, SLC6A4","neurology/psychiatry","obsessive compulsive disorder (OCD)","CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12","Launched",1,3,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1001","clonidine","adrenergic receptor agonist","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C","cardiology, neurology/psychiatry","hypertension, attention-deficit/hyperactivity disorder (ADHD)","Clc1cccc(Cl)c1NC1=NCCN1 |t:10|, Clc1cccc(Cl)c1NC1=NCCN1 |t:10|, Clc1cccc(Cl)c1NC1=NCCN1 |t:10|, Clc1cccc(Cl)c1NC1=NCCN1 |t:10|, Clc1cccc(Cl)c1NC1=NCCN1 |t:10|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,6,1,1,1,1
"1002","clonixin","cyclooxygenase inhibitor","PTGS1, PTGS2","rheumatology, infectious disease","rheumatoid arthritis, soft tissue infection","Cc1c(Cl)cccc1Nc1ncccc1C(O)=O","Preclinical",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1003","clopidogrel","purinergic receptor antagonist","P2RY12","cardiology, neurology/psychiatry","myocardial infarction, stroke, peripheral artery disease (PAD), acute coronary syndrome (ACS)","COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl, COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl, COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl, COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl, COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl, COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl, COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1004","cloprostenol-(+/-)","prostaglandin receptor agonist","PTGDR, PTGER1, PTGER3, PTGFR, TBXA2R","obstetrics/gynecology","endometriosis","O[C@@H](COc1cccc(Cl)c1)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O, O[C@@H](COc1cccc(Cl)c1)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1005","cloranolol","adrenergic receptor antagonist","ADRB1, ADRB2, ADRB3","cardiology","hypertension","CC(C)(C)NC[C@@H](O)COc1cc(Cl)ccc1Cl |&1:6|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,1,1,1,1
"1006","clorgiline","monoamine oxidase inhibitor","MAOA",NA,NA,"CN(CCCOc1ccc(Cl)cc1Cl)CC#C, CN(CCCOc1ccc(Cl)cc1Cl)CC#C, CN(CCCOc1ccc(Cl)cc1Cl)CC#C, CN(CCCOc1ccc(Cl)cc1Cl)CC#C","Phase 2",0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1007","clorotepine","adrenergic receptor antagonist, dopamine receptor antagonist","ADRA1A, ADRA1B, ADRA1D, DRD2, HRH1, HTR2C, HTR6","neurology/psychiatry","psychosis","CN1CCN(CC1)[C@H]1Cc2ccccc2Sc2ccc(Cl)cc12 |&1:7|, CN1CCN(CC1)[C@H]1Cc2ccccc2Sc2ccc(Cl)cc12 |&1:7|","Launched",0,0,0,0,0,0,0,0,1,2,1,1,0,0,1,1,0,0,1,3,1,1,1,1
"1008","clorprenaline","adrenergic receptor agonist","ADRB1, ADRB2","pulmonary","asthma","CC(C)NC[C@@H](O)c1ccccc1Cl |&1:5|, CC(C)NC[C@@H](O)c1ccccc1Cl |&1:5|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,1,1,1,1
"1009","clotrimazole","cytochrome P450 inhibitor, imidazoline receptor ligand","CYP3A4, KCNN4, NR1I2, NR1I3, TRPM2, TRPM4, TRPM8","infectious disease","vulvovaginal candidiasis, oropharyngeal candidiasis","Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1010","cloxyquin","potassium channel activator","KCNK18",NA,NA,"Oc1ccc(Cl)c2cccnc12, Oc1ccc(Cl)c2cccnc12, Oc1ccc(Cl)c2cccnc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1011","clozapine","dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CALY, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HRH4, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR5A, HTR6, HTR7","neurology/psychiatry","schizophrenia","CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12 |t:8|, CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12 |t:8|, CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12 |t:8|, CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12 |t:8|, CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12 |t:8|","Launched",0,0,0,0,0,0,0,0,1,12,1,2,0,0,1,5,1,5,1,6,1,1,1,1
"1012","CL316243","adrenergic receptor agonist","ADRB3, UCP1, UCP2, UCP3",NA,NA,"C[C@H](Cc1ccc2OC(Oc2c1)(C(O)=O)C(O)=O)NC[C@H](O)c1cccc(Cl)c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
"1013","CMPD-1","p38 MAPK inhibitor","GNRHR, MAPK14",NA,NA,"Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1, Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1, Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1014","cndac (hydrochloride)","antineoplastic agent","ATP8A2, BRCA2, RAD51D","hematologic malignancy","acute myeloid leukemia (aml)","Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2C#N)c(=O)n1.Cl |a:5,7,10,12|","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1015","CNQX","glutamate receptor antagonist","GRIA1, GRIA2, GRIA3, GRIA4",NA,NA,"[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1C#N, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1C#N, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1C#N","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1016","CNX-2006","EGFR inhibitor","EGFR",NA,NA,"COc1cc(NC2CN(CCF)C2)ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F, COc1cc(NC2CN(CCF)C2)ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1017","CNX-774","Bruton's tyrosine kinase (BTK) inhibitor","BTK",NA,NA,"CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1018","CO-101244","glutamate receptor antagonist","GRIN2B",NA,NA,"Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1, Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1, Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1, Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1019","CO-102862","sodium channel blocker","SCN4A, SCN9A",NA,NA,"NC(=O)N\N=C\c1ccc(Oc2ccc(F)cc2)cc1, NC(=O)N\N=C\c1ccc(Oc2ccc(F)cc2)cc1, NC(=O)N\N=C\c1ccc(Oc2ccc(F)cc2)cc1","Phase 1",0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1020","cobicistat","cytochrome P450 inhibitor","CYP3A4, CYP3A43, CYP3A5, CYP3A7","infectious disease","human immunodeficiency virus (HIV-1)","CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1, CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1, CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1, CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1021","cobimetinib","MEK inhibitor","MAP2K1","oncology","melanoma","OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1, OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1, OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1, OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1, OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1, OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1, OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1, OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1022","colchicine","microtubule inhibitor","GLRA1, GLRA2, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8","rheumatology, endocrinology","gout, fever","COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC, COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC, COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC, COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1023","colforsin","adenylyl cyclase activator","ADCY2, ADCY5",NA,NA,"CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C |a:4,5,13,15,17,22,25,&1:7|, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C |a:4,5,13,15,17,22,25,&1:7|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1024","compound-w","beta-secretase inhibitor","BACE1",NA,NA,"OC(=O)c1cc(Oc2ccc(cc2)[N+]([O-])=O)cc(Oc2ccc(cc2)[N+]([O-])=O)c1, OC(=O)c1cc(Oc2ccc(cc2)[N+]([O-])=O)cc(Oc2ccc(cc2)[N+]([O-])=O)c1, OC(=O)c1cc(Oc2ccc(cc2)[N+]([O-])=O)cc(Oc2ccc(cc2)[N+]([O-])=O)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1025","compound-401","DNA dependent protein kinase inhibitor","MTOR, PRKDC",NA,NA,"O=c1cc(nc2c3ccccc3ccn12)N1CCOCC1, O=c1cc(nc2c3ccccc3ccn12)N1CCOCC1, O=c1cc(nc2c3ccccc3ccn12)N1CCOCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1026","conivaptan","vasopressin receptor antagonist","AVPR1A, AVPR2","endocrinology","hyponatremia","Cc1nc-2c(CCN(C(=O)c3ccc(NC(=O)c4ccccc4-c4ccccc4)cc3)c3ccccc-23)[nH]1, Cc1nc-2c(CCN(C(=O)c3ccc(NC(=O)c4ccccc4-c4ccccc4)cc3)c3ccccc-23)[nH]1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1027","copanlisib","PI3K inhibitor","PIK3CA, PIK3CB, PIK3CD, PIK3CG","hematologic malignancy","follicular lymphoma","COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12 |c:35,t:18|, COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12 |c:35,t:18|, COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12 |c:35,t:18|, COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12 |c:35,t:18|, COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12 |c:35,t:18|, COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12 |c:35,t:18|, COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12 |c:35,t:18|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1028","COR-170","cannabinoid receptor inverse agonist","CNR2",NA,NA,"CCCCCn1cc(C(=O)NC23CC4CC(CC(C4)C2)C3)c(=O)c2cc(ccc12)-c1ccccc1, CCCCCn1cc(C(=O)NC23CC4CC(CC(C4)C2)C3)c(=O)c2cc(ccc12)-c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1029","corosolic-acid","PKC inhibitor, protein tyrosine kinase inhibitor","HSD11B1, PTPN1",NA,NA,"C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1030","corticosterone","mineralocorticoid receptor agonist","HSD11B1, NCOA1, NR3C2",NA,NA,"C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:9|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1031","cortisone","glucocorticoid receptor agonist","NR3C1","gastroenterology, rheumatology, dermatology, gastroenterology, rheumatology, dermatology","ulcerative colitis, rheumatoid arthritis, psoriasis, joint inflammation, eczema, ulcerative colitis, rheumatoid arthritis, psoriasis, joint inflammation, eczema","C[C@]12CC(=O)C3C(CCC4=CC(=O)CC[C@]34C)C1CC[C@]2(O)C(=O)CO, C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|, C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1032","cortisone-acetate","glucocorticoid receptor agonist","NR3C1","pulmonary, rheumatology, allergy, dermatology, ophthalmology, gastroenterology, infectious disease","asthma, rheumatoid arthritis, urticaria, osteoarthritis, psoriasis, allergic rhinitis, conjunctivitis, ulcerative colitis, meningitis","CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C |t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C |t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C |t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C |t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C |t:15|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1033","cortodoxone","androgen receptor antagonist","AR",NA,NA,"C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:8|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1034","cot-inhibitor-1","MAPK-interacting kinase inhibitor","MAP3K8",NA,NA,"Fc1ccc(Nc2c(cnc3c(Cl)cc(NCc4cn(CCN5CCCCCC5)nn4)cc23)C#N)cc1Cl, Fc1ccc(Nc2c(cnc3c(Cl)cc(NCc4cn(CCN5CCCCCC5)nn4)cc23)C#N)cc1Cl","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1035","cot-inhibitor-2","MAPK-interacting kinase inhibitor","MAP3K8",NA,NA,"CCN1CCC(CC1)n1cc(CNc2cc(Cl)c3ncc(C#N)c(Nc4ccc(F)c(Cl)c4)c3c2)nn1, CCN1CCC(CC1)n1cc(CNc2cc(Cl)c3ncc(C#N)c(Nc4ccc(F)c(Cl)c4)c3c2)nn1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1036","coumarin","vitamin K antagonist","CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP2A6","gastroenterology, pulmonary","ulcerative colitis, asthma, celiac disease","O=c1ccc2ccccc2o1, O=c1ccc2ccccc2o1, O=c1ccc2ccccc2o1, O=c1ccc2ccccc2o1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1037","CP-316819","glycogen phosphorylase inhibitor","PYGL",NA,NA,"CON(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1, CON(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1, CON(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1038","CP-339818","potassium channel blocker","KCNA3",NA,NA,"CCCCC\N=c1/ccn(Cc2ccccc2)c2ccccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1039","CP-376395","corticotropin releasing factor receptor antagonist","CRHR1",NA,NA,"CCC(CC)Nc1cc(C)nc(Oc2c(C)cc(C)cc2C)c1C, CCC(CC)Nc1cc(C)nc(Oc2c(C)cc(C)cc2C)c1C, CCC(CC)Nc1cc(C)nc(Oc2c(C)cc(C)cc2C)c1C","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1040","CP-471474","matrix metalloprotease inhibitor","MMP1, MMP13, MMP2, MMP3, MMP9",NA,NA,"CC(C)(NS(=O)(=O)c1ccc(Oc2ccc(F)cc2)cc1)C(=O)NO, CC(C)(NS(=O)(=O)c1ccc(Oc2ccc(F)cc2)cc1)C(=O)NO, CC(C)(NS(=O)(=O)c1ccc(Oc2ccc(F)cc2)cc1)C(=O)NO","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1041","CP-532623","cholesteryl ester transfer protein inhibitor","CETP",NA,NA,"CC[C@@H]1C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(C)=O)c2cc(ccc2N1C(=O)OC(C)C)C(F)(F)F","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1042","CP-640186","acetyl-CoA carboxylase inhibitor","ACACA, ACACB",NA,NA,"O=C([C@@H]1CCCN(C1)C1CCN(CC1)C(=O)c1c2ccccc2cc2ccccc12)N1CCOCC1, O=C([C@@H]1CCCN(C1)C1CCN(CC1)C(=O)c1c2ccccc2cc2ccccc12)N1CCOCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1043","CP-673451","PDGFR tyrosine kinase receptor inhibitor","KIT, PDGFRA, PDGFRB",NA,NA,"COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1044","CP-724714","EGFR inhibitor, protein tyrosine kinase inhibitor","ERBB2",NA,NA,"COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1, COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1, COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1, COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1, COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1045","CP-775146","PPAR receptor agonist","PPARA",NA,NA,"CC(C)c1ccc(CC(=O)N2CCC[C@H](C2)c2cccc(OC(C)(C)C(O)=O)c2)cc1, CC(C)c1ccc(CC(=O)N2CCC[C@H](C2)c2cccc(OC(C)(C)C(O)=O)c2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1046","CP-91149","glycogen phosphorylase inhibitor","PYGL",NA,NA,"CN(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1, CN(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1, CN(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1, CN(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1047","CP-93129","serotonin receptor agonist","HTR1A",NA,NA,"O=c1ccc2[nH]cc(C3=CCNCC3)c2[nH]1 |t:8|, O=c1ccc2[nH]cc(C3=CCNCC3)c2[nH]1 |t:8|, O=c1ccc2[nH]cc(C3=CCNCC3)c2[nH]1 |t:8|","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1048","CP-94253","serotonin receptor agonist","HTR1B",NA,NA,"CCCOc1ccc2[nH]cc(C3=CCNCC3)c2n1 |t:11|, CCCOc1ccc2[nH]cc(C3=CCNCC3)c2n1 |t:11|","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1049","CP-945,598","cannabinoid receptor antagonist","CNR1",NA,NA,"CCNC1(CCN(CC1)c1ncnc2n(c(nc12)-c1ccccc1Cl)-c1ccc(Cl)cc1)C(N)=O, CCNC1(CCN(CC1)c1ncnc2n(c(nc12)-c1ccccc1Cl)-c1ccc(Cl)cc1)C(N)=O, CCNC1(CCN(CC1)c1ncnc2n(c(nc12)-c1ccccc1Cl)-c1ccc(Cl)cc1)C(N)=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1050","CP-99994","tachykinin antagonist","TACR1",NA,NA,"COc1ccccc1CN[C@H]1CCCN[C@H]1c1ccccc1, COc1ccccc1CN[C@H]1CCCN[C@H]1c1ccccc1, COc1ccccc1CN[C@H]1CCCN[C@H]1c1ccccc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1051","CPA-inhibitor","carboxypeptidase inhibitor","CPA1, CPA2",NA,NA,"ON(C[C@@H](Cc1ccccc1)C(O)=O)C(=O)Cc1ccccc1 |&1:3,r|, ON(C[C@@H](Cc1ccccc1)C(O)=O)C(=O)Cc1ccccc1 |&1:3,r|, ON(C[C@@H](Cc1ccccc1)C(O)=O)C(=O)Cc1ccccc1 |&1:3,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1052","CPCCOEt","glutamate receptor antagonist","GRM1",NA,NA,"CCOC(=O)[C@]12C[C@H]1\C(=N/O)c1ccccc1O2 |&1:5,7,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1053","CPI-0610","bromodomain inhibitor","BRD4",NA,NA,"Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 |t:10|, Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 |t:10|, Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 |t:10|, Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 |t:10|, Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 |t:10|, Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 |t:10|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1054","CPI-1189","tumor necrosis factor release inhibitor","TNF",NA,NA,"CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C, CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C, CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C, CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1055","CPI-169","histone lysine methyltransferase inhibitor","EZH2",NA,NA,"CCS(=O)(=O)N1CCC(CC1)[C@@H](C)n1c(C)c(C(=O)NCc2c(OC)cc(C)[nH]c2=O)c2ccccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1056","CPI-203","bromodomain inhibitor","BRD4",NA,NA,"Cc1nnc2[C@H](CC(N)=O)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:10|, Cc1nnc2[C@H](CC(N)=O)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:10|, Cc1nnc2[C@H](CC(N)=O)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:10|, Cc1nnc2[C@H](CC(N)=O)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:10|, Cc1nnc2[C@H](CC(N)=O)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:10|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1057","CPI-360","histone lysine methyltransferase inhibitor","EZH2",NA,NA,"COc1cc(C)[nH]c(=O)c1CNC(=O)c1c(C)n([C@H](C)C2CCOCC2)c2ccccc12, COc1cc(C)[nH]c(=O)c1CNC(=O)c1c(C)n([C@H](C)C2CCOCC2)c2ccccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1058","CPI-613","pyruvate dehydrogenase inhibitor","PDHA1",NA,NA,"OC(=O)CCCC[C@@H](CCSCc1ccccc1)SCc1ccccc1 |&1:7,r|, OC(=O)CCCC[C@@H](CCSCc1ccccc1)SCc1ccccc1 |&1:7,r|, OC(=O)CCCC[C@@H](CCSCc1ccccc1)SCc1ccccc1 |&1:7,r|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1059","CPP","glutamate receptor antagonist","GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,"OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1, OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1, OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1060","CPSI-1306-(+/-)","macrophage migration inhibiting factor inhibitor","MIF",NA,NA,"Fc1ccc(C2=NO[C@@H](CC(=O)N3CCOCC3)C2)c(F)c1 |&1:8,r,t:5|, Fc1ccc(C2=NO[C@@H](CC(=O)N3CCOCC3)C2)c(F)c1 |&1:8,r,t:5|, Fc1ccc(C2=NO[C@@H](CC(=O)N3CCOCC3)C2)c(F)c1 |&1:8,r,t:5|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1061","crenolanib","PDGFR tyrosine kinase receptor inhibitor","CSF1R, FLT3, KIT, PDGFRA, PDGFRB",NA,NA,"CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1062","cridanimod","progesterone receptor agonist","PGR","infectious disease","influenza A virus infection","OC(=O)Cn1c2ccccc2c(=O)c2ccccc12, OC(=O)Cn1c2ccccc2c(=O)c2ccccc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1063","crisaborole","phosphodiesterase inhibitor","PDE4A, PDE4B, PDE4C, PDE4D","dermatology","dermatitis","OB1OCc2cc(Oc3ccc(cc3)C#N)ccc12, OB1OCc2cc(Oc3ccc(cc3)C#N)ccc12, OB1OCc2cc(Oc3ccc(cc3)C#N)ccc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1064","crizotinib","ALK tyrosine kinase receptor inhibitor","ALK, MET","oncology","non-small cell lung cancer (NSCLC)","C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1065","crizotinib-(S)","MTH1 inhibitor","NUDT1",NA,NA,"C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1066","crocin","microtubule inhibitor","BCL2, BIRC5, CCND1, TPPP","endocrinology","hyperglycemia","O[C@@H]([C@H](O)[C@H]1O)[C@H](O[C@H]1OC(/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C(O[C@@H]([C@@H]([C@@H](O)[C@@H]2O)O)O[C@@H]2CO[C@@H]([C@@H]([C@@H](O)[C@@H]3O)O)O[C@@H]3CO)=O)=O)CO[C@@H]([C@@H]([C@@H](O)[C@@H]4O)O)O[C@@H]4CO","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1067","cromoglicic-acid","immunosuppressant","KCNMA1, S100P","pulmonary, ophthalmology, allergy, gastroenterology","asthma, conjunctivitis, urticaria, ulcerative colitis","OC(COc1cccc2oc(cc(=O)c12)C(O)=O)COc1cccc2oc(cc(=O)c12)C(O)=O, OC(COc1cccc2oc(cc(=O)c12)C(O)=O)COc1cccc2oc(cc(=O)c12)C(O)=O, OC(COc1cccc2oc(cc(=O)c12)C(O)=O)COc1cccc2oc(cc(=O)c12)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1068","cryptotanshinone","acetylcholinesterase inhibitor, STAT inhibitor","STAT3",NA,NA,"C[C@H]1COC2=C1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc21 |c:4|, C[C@H]1COC2=C1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc21 |c:4|, C[C@H]1COC2=C1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc21 |c:4|, C[C@H]1COC2=C1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc21 |c:4|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1069","CR8-(R)","CDK inhibitor","CCNA2",NA,NA,"CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1070","CS-110266","dopamine receptor agonist","SLC6A3",NA,NA,"C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1, C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1, C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1, C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1, C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1, C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1","Preclinical",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1071","CS-917","fructose biphosphate inhibitor","FBP1",NA,NA,"CC(C)Cc1sc(N)nc1-c1ccc(o1)P(O)(O)=O, CC(C)Cc1sc(N)nc1-c1ccc(o1)P(O)(O)=O, CC(C)Cc1sc(N)nc1-c1ccc(o1)P(O)(O)=O, CC(C)Cc1sc(N)nc1-c1ccc(o1)P(O)(O)=O, CC(C)Cc1sc(N)nc1-c1ccc(o1)P(O)(O)=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1072","CT-7758","integrin antagonist","ITGA4",NA,NA,"OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1 |c:26|, OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1 |c:26|, OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1 |c:26|, OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1 |c:26|, OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1 |c:26|, OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1 |c:26|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1073","CTEP","glutamate receptor antagonist","GRM5",NA,NA,"Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(OC(F)(F)F)cc1, Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(OC(F)(F)F)cc1, Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(OC(F)(F)F)cc1, Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(OC(F)(F)F)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1074","CTS-1027","metalloproteinase inhibitor","MMP1, MMP13, MMP2, MMP3, MMP9",NA,NA,"ONC(=O)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1, ONC(=O)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1, ONC(=O)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1, ONC(=O)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1, ONC(=O)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1075","CTS21166","beta-secretase inhibitor","BACE1",NA,NA,"CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(O)=O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(O)=O, CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(O)=O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(O)=O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1076","CU-CPT-4a","toll-like receptor inhibitor","TLR3",NA,NA,"OC(=O)[C@@H](Cc1ccccc1)NC(=O)c1sc2cc(F)ccc2c1Cl, OC(=O)[C@@H](Cc1ccccc1)NC(=O)c1sc2cc(F)ccc2c1Cl","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1077","CU-T12-9","toll-like receptor agonist","TLR1, TLR2",NA,NA,"CNc1ccc(cc1-n1cnc(c1)-c1ccc(cc1)C(F)(F)F)[N+]([O-])=O, CNc1ccc(cc1-n1cnc(c1)-c1ccc(cc1)C(F)(F)F)[N+]([O-])=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1078","CUDC-101","EGFR inhibitor","EGFR, ERBB2",NA,NA,"COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCCCCC(=O)NO, COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCCCCC(=O)NO, COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCCCCC(=O)NO","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1079","CUDC-427","apoptosis inhibitor","XIAP",NA,NA,"CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1sc(nc1-c1ccccc1)-c1ncco1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1sc(nc1-c1ccccc1)-c1ncco1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1sc(nc1-c1ccccc1)-c1ncco1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1sc(nc1-c1ccccc1)-c1ncco1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1080","CUDC-907","PI3K inhibitor","HDAC2, PIK3R1",NA,NA,"COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1, COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1, COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1, COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1, COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1081","CUR-61414","smoothened receptor antagonist","DHH, IHH, SMO",NA,NA,"COc1cccc(CN([C@H]2C[C@H](N(Cc3ccc4OCOc4c3)C2)C(=O)N2CCNCC2)C(=O)CC(C)(C)C)c1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1082","curcumin","cyclooxygenase inhibitor, histone acetyltransferase inhibitor, lipoxygenase inhibitor, NFkB pathway inhibitor","APP, CA1, CA12, CA14, CA2, CA4, CA6, CA9, CHRM3, CYP3A4, DNMT3B, EP300, MMP13, MMP9, NOS2, PTGS1, PTGS2, XDH",NA,NA,"COc1cc(\C=C\C(O)=CC(=O)\C=C\c2ccc(O)c(OC)c2)ccc1O, COc1cc(\C=C\C(O)=CC(=O)\C=C\c2ccc(O)c(OC)c2)ccc1O, COc1cc(\C=C\C(O)=CC(=O)\C=C\c2ccc(O)c(OC)c2)ccc1O, COc1cc(\C=C\C(O)=CC(=O)\C=C\c2ccc(O)c(OC)c2)ccc1O, COc1cc(\C=C\C(O)=CC(=O)\C=C\c2ccc(O)c(OC)c2)ccc1O, COc1cc(\C=C\C(O)=CC(=O)\C=C\c2ccc(O)c(OC)c2)ccc1O, COc1cc(\C=C\C(O)=CC(=O)\C=C\c2ccc(O)c(OC)c2)ccc1O","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
"1083","curcumol","JAK inhibitor","JAK1, JAK2, JAK3",NA,NA,"CC(C)[C@@H]1C[C@@]23O[C@]1(O)CC(=C)[C@@H]2CC[C@@H]3C, CC(C)[C@@H]1C[C@@]23O[C@]1(O)CC(=C)[C@@H]2CC[C@@H]3C, CC(C)[C@@H]1C[C@@]23O[C@]1(O)CC(=C)[C@@H]2CC[C@@H]3C, CC(C)[C@@H]1C[C@@]23O[C@]1(O)CC(=C)[C@@H]2CC[C@@H]3C, CC(C)[C@@H]1C[C@@]23O[C@]1(O)CC(=C)[C@@H]2CC[C@@H]3C","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1084","cutamesine","sigma receptor agonist","SIGMAR1",NA,NA,"COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC, COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC, COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC, COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC, COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1085","CV-1808","adenosine receptor agonist","ADORA2A",NA,NA,"Nc1nc(Nc2ccccc2)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1nc(Nc2ccccc2)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1nc(Nc2ccccc2)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1nc(Nc2ccccc2)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1086","CVT-10216","aldehyde dehydrogenase inhibitor","ALDH2",NA,NA,"CS(=O)(=O)Nc1ccc(cc1)-c1coc2cc(OCc3cccc(c3)C(O)=O)ccc2c1=O, CS(=O)(=O)Nc1ccc(cc1)-c1coc2cc(OCc3cccc(c3)C(O)=O)ccc2c1=O, CS(=O)(=O)Nc1ccc(cc1)-c1coc2cc(OCc3cccc(c3)C(O)=O)ccc2c1=O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1087","CW-008","PKA activator","PRKACA",NA,NA,"COc1ccn2ncc(-c3nc4n[nH]c(NC(=O)c5ccc(F)cc5)c4cc3F)c2c1, COc1ccn2ncc(-c3nc4n[nH]c(NC(=O)c5ccc(F)cc5)c4cc3F)c2c1, COc1ccn2ncc(-c3nc4n[nH]c(NC(=O)c5ccc(F)cc5)c4cc3F)c2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1088","CX-4945","casein kinase inhibitor","CSNK2A1, CSNK2A2, DAPK3, HIPK3",NA,NA,"OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21, OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21, OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21, OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21, OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1089","cyamemazine","serotonin receptor antagonist","HTR1A, HTR2A, HTR2C, HTR7","neurology/psychiatry","schizophrenia, anxiety","C[C@@H](CN(C)C)CN1c2ccccc2Sc2ccc(cc12)C#N |&1:1,r|, C[C@@H](CN(C)C)CN1c2ccccc2Sc2ccc(cc12)C#N |&1:1,r|","Launched",0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1090","cyanocobalamin","methylmalonyl CoA mutase stimulant, vitamin B","MUT","hematology, infectious disease, gastroenterology","anemia, fish tapeworm infestation, celiac disease","C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(\C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)O[P@@](O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12 |a:1,8,10,15,30,36,42,48,54,63,74,75,79,80,&1:70,c:16,20,24,t:22,26,29|, C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(\C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)O[P@@](O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12 |a:1,8,10,15,30,36,42,48,54,63,74,75,79,80,&1:70,c:16,20,24,t:22,26,29|, C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(\C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)O[P@@](O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12 |a:1,8,10,15,30,36,42,48,54,63,74,75,79,80,&1:70,c:16,20,24,t:22,26,29|, C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(\C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)O[P@@](O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12 |a:1,8,10,15,30,36,42,48,54,63,74,75,79,80,&1:70,c:16,20,24,t:22,26,29|, C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(\C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)O[P@@](O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12 |a:1,8,10,15,30,36,42,48,54,63,74,75,79,80,&1:70,c:16,20,24,t:22,26,29|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1091","cyanopindolol","adrenergic receptor antagonist","ADRB1, HTR1A, HTR1D",NA,NA,"CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(cc12)C#N |&1:6|, CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(cc12)C#N |&1:6|, CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(cc12)C#N |&1:6|","Phase 2",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,1,1,0,0,0,0
"1092","cyclizine","histamine receptor modulator","HRH1, SULT1E1","gastroenterology, neurology/psychiatry","nausea, vomiting, vertigo, motion sickness","CN1CCN(CC1)C(c1ccccc1)c1ccccc1, CN1CCN(CC1)C(c1ccccc1)c1ccccc1, CN1CCN(CC1)C(c1ccccc1)c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"1093","cyclobenzaprine","adrenergic receptor agonist, serotonin receptor agonist","HTR2A","neurology/psychiatry","spasms","CN(C)CCC=C1c2ccccc2C=Cc2ccccc12 |c:14|, CN(C)CCC=C1c2ccccc2C=Cc2ccccc12 |c:14|, CN(C)CCC=C1c2ccccc2C=Cc2ccccc12 |c:14|","Launched",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1094","cycloheximide","protein synthesis inhibitor","RPL3",NA,NA,"C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1, C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1, C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1, C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1095","cyclophosphamide","DNA alkylating agent","CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP3A7","hematologic malignancy, oncology","Hodgkin's lymphoma, small lymphocytic lymphoma (SLL), breast cancer, neuroblastoma, Burkitt's lymphoma, multiple myeloma, chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), true histiocytic lymphoma (THL), retinoblastoma, ovarian cancer","ClCCN(CCCl)[P@@]1(=O)NCCCO1 |r|, ClCCN(CCCl)[P@@]1(=O)NCCCO1 |r|, ClCCN(CCCl)[P@@]1(=O)NCCCO1 |r|, ClCCN(CCCl)[P@@]1(=O)NCCCO1 |r|, ClCCN(CCCl)[P@@]1(=O)NCCCO1 |r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1096","cyclopiazonic-acid","ATPase inhibitor","ATP2A1",NA,NA,"CC(=O)C1=C(O)[C@@H]2[C@@H]3[C@@H](Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O |a:6,7,8,&1:3,c:3|, CC(=O)C1=C(O)[C@@H]2[C@@H]3[C@@H](Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O |a:6,7,8,&1:3,c:3|, CC(=O)C1=C(O)[C@@H]2[C@@H]3[C@@H](Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O |a:6,7,8,&1:3,c:3|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1097","cycloserine-(D)","bacterial cell wall synthesis inhibitor","GRIN1","infectious disease","tuberculosis, tuberculosis","N[C@@H]1CONC1=O, N[C@@H]1CONC1=O, N[C@@H]1CONC1=O, N[C@@H]1CONC1=O, N[C@@H]1CONC1=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1098","cyclosporin-A","calcineurin inhibitor","ABCB11, CAMLG, FPR1, PPIA, PPIF, PPP3CA, PPP3R2, SLC10A1, SLCO1B1, SLCO1B3","rheumatology, dermatology","rheumatoid arthritis, psoriasis","CC[C@H]1NC(=O)[C@@H]([C@@H](O)[C@@H](C)C\C=C\C)N(C)C(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@@H](C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C |&1:2,&2:6,&3:7,&4:9,&5:19,&6:27,&7:36,&8:45,&9:50,&10:55,&11:64,&12:68,r|, CC[C@H]1NC(=O)[C@@H]([C@@H](O)[C@@H](C)C\C=C\C)N(C)C(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@@H](C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C |&1:2,&2:6,&3:7,&4:9,&5:19,&6:27,&7:36,&8:45,&9:50,&10:55,&11:64,&12:68,r|, CC[C@H]1NC(=O)[C@@H]([C@@H](O)[C@@H](C)C\C=C\C)N(C)C(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@@H](C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C |&1:2,&2:6,&3:7,&4:9,&5:19,&6:27,&7:36,&8:45,&9:50,&10:55,&11:64,&12:68,r|, CC[C@H]1NC(=O)[C@@H]([C@@H](O)[C@@H](C)C\C=C\C)N(C)C(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@@H](C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C |&1:2,&2:6,&3:7,&4:9,&5:19,&6:27,&7:36,&8:45,&9:50,&10:55,&11:64,&12:68,r|, CC[C@H]1NC(=O)[C@@H]([C@@H](O)[C@@H](C)C\C=C\C)N(C)C(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@@H](C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C |&1:2,&2:6,&3:7,&4:9,&5:19,&6:27,&7:36,&8:45,&9:50,&10:55,&11:64,&12:68,r|, CC[C@H]1NC(=O)[C@@H]([C@@H](O)[C@@H](C)C\C=C\C)N(C)C(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@@H](C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C |&1:2,&2:6,&3:7,&4:9,&5:19,&6:27,&7:36,&8:45,&9:50,&10:55,&11:64,&12:68,r|, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C","Launched",1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1099","cyclothiazide","glutamate receptor modulator","CA2, GRIA1, GRIA2, GRIA3, GRIA4, SLC12A3","cardiology","hypertension","NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)[C@H]2C[C@H]3C[C@@H]2C=C3)cc1Cl |&1:9,&2:14,&3:16,&4:18,r,c:21|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)[C@H]2C[C@H]3C[C@@H]2C=C3)cc1Cl |&1:9,&2:14,&3:16,&4:18,r,c:21|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)[C@H]2C[C@H]3C[C@@H]2C=C3)cc1Cl |&1:9,&2:14,&3:16,&4:18,r,c:21|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)[C@H]2C[C@H]3C[C@@H]2C=C3)cc1Cl |&1:9,&2:14,&3:16,&4:18,r,c:21|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)[C@H]2C[C@H]3C[C@@H]2C=C3)cc1Cl |&1:9,&2:14,&3:16,&4:18,r,c:21|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)[C@H]2C[C@H]3C[C@@H]2C=C3)cc1Cl |&1:9,&2:14,&3:16,&4:18,r,c:21|","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1100","cyclovalone","breast cancer resistance protein inhibitor","ABCG2","gastroenterology","bile stimulation","COc1cc(\C=C2/CCC\C(=C/c3ccc(O)c(OC)c3)C2=O)ccc1O, COc1cc(\C=C2/CCC\C(=C/c3ccc(O)c(OC)c3)C2=O)ccc1O, COc1cc(\C=C2/CCC\C(=C/c3ccc(O)c(OC)c3)C2=O)ccc1O, COc1cc(\C=C2/CCC\C(=C/c3ccc(O)c(OC)c3)C2=O)ccc1O, COc1cc(\C=C2/CCC\C(=C/c3ccc(O)c(OC)c3)C2=O)ccc1O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1101","CYC116","Aurora kinase inhibitor","AURKA, AURKB, KDR",NA,NA,"Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1102","CYM-50260","sphingosine 1-phosphate receptor agonist","S1PR4",NA,NA,"FCc1ccc(OCCOc2ccc(Cl)cc2Cl)c(Cl)n1, FCc1ccc(OCCOc2ccc(Cl)cc2Cl)c(Cl)n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1103","CYM-50358","sphingosine 1-phosphate receptor antagonist","S1PR4",NA,NA,"Cc1cc(CN)cc(C)c1NC(=O)c1ccc(o1)-c1cc(Cl)ccc1Cl, Cc1cc(CN)cc(C)c1NC(=O)c1ccc(o1)-c1cc(Cl)ccc1Cl","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1104","CYM-50769","neuropeptide receptor antagonist","NPBWR1",NA,NA,"COc1ccc(Oc2c(Cl)cnn(C3c4ccccc4-c4ccccc34)c2=O)cc1, COc1ccc(Oc2c(Cl)cnn(C3c4ccccc4-c4ccccc34)c2=O)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1105","CYM-5442","sphingosine 1-phosphate receptor agonist","S1PR1",NA,NA,"CCOc1ccc(cc1OCC)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCO |&1:22|, CCOc1ccc(cc1OCC)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCO |&1:22|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1106","CYM-5520","sphingosine 1-phosphate receptor agonist","S1PR2",NA,NA,"Cc1cc(C(=O)Cn2cc(ccc2=O)C#N)c(C)n1Cc1ccccc1, Cc1cc(C(=O)Cn2cc(ccc2=O)C#N)c(C)n1Cc1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1107","CYM-5541","sphingosine 1-phosphate receptor agonist","S1PR3",NA,NA,"O=C(N(C1CCCCC1)C1CCCCC1)c1cc(on1)C1CC1, O=C(N(C1CCCCC1)C1CCCCC1)c1cc(on1)C1CC1, O=C(N(C1CCCCC1)C1CCCCC1)c1cc(on1)C1CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1108","cyproheptadine","histamine receptor antagonist","ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, HRH1, HTR2A, HTR2C, HTR6, HTR7","allergy, otolaryngology, ophthalmology, dermatology","allergic rhinitis, vasomotor rhinitis, conjunctivitis, urticaria, dermatographism","CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|","Launched",0,0,0,0,0,0,0,0,1,4,1,1,0,0,0,0,1,3,1,3,1,1,1,1
"1109","cyproterone-acetate","androgen receptor antagonist","ADORA1, AR","oncology","prostate cancer","CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1110","cysteamine","tissue transglutaminase inhibitor","NPY2R, SST","metabolism","cystinosis","NCCS, NCCS","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1111","CYT-997","tubulin polymerization inhibitor","TUBB",NA,NA,"CCC[C@H](Nc1nc(ncc1C)-c1ccc(NC(=O)NCC)c(OC)c1)c1cccnc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1112","cytarabine","ribonucleotide reductase inhibitor","POLA1, POLB, POLD1, POLE","hematologic malignancy","acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)","Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1113","cytisine","acetylcholine receptor agonist","CHRNA2, CHRNA3, CHRNA4, CHRNA6, CHRNA7, CHRNB2, CHRNB4","neurology/psychiatry","nicotinism","O=c1cccc2[C@H]3CNC[C@H](C3)Cn12, O=c1cccc2[C@H]3CNC[C@H](C3)Cn12, O=c1cccc2[C@H]3CNC[C@H](C3)Cn12, O=c1cccc2[C@H]3CNC[C@H](C3)Cn12, O=c1cccc2[C@H]3CNC[C@H](C3)Cn12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,7,0,0,1,1,1,1
"1114","cytochalasin-B","microtubule inhibitor","ACTB",NA,NA,"C[C@H]1[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]22OC(=O)\C=C\[C@H](O)CCC[C@@H](C)C\C=C\[C@H]2[C@H](O)C1=C |t:20,30|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1115","cyt387","JAK inhibitor","JAK1, JAK2, JAK3",NA,NA,"O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1116","CY208-243","dopamine receptor agonist","CALY",NA,NA,"CN1Cc2ccccc2[C@H]2[C@H]1Cc1c[nH]c3cccc2c13, CN1Cc2ccccc2[C@H]2[C@H]1Cc1c[nH]c3cccc2c13, CN1Cc2ccccc2[C@H]2[C@H]1Cc1c[nH]c3cccc2c13","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1117","CZC-54252","leucine rich repeat kinase inhibitor","LRRK2",NA,NA,"COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2NS(C)(=O)=O)n1)N1CCOCC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2NS(C)(=O)=O)n1)N1CCOCC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2NS(C)(=O)=O)n1)N1CCOCC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2NS(C)(=O)=O)n1)N1CCOCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1118","CZC24832","PI3K inhibitor","PIK3CG",NA,NA,"CC(C)(C)NS(=O)(=O)c1cncc(c1)-c1cc(F)c2nc(N)nn2c1, CC(C)(C)NS(=O)(=O)c1cncc(c1)-c1cc(F)c2nc(N)nn2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1119","C34","toll-like receptor inhibitor","TLR4",NA,NA,"CC(C)O[C@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1NC(C)=O, CC(C)O[C@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1NC(C)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1120","C646","histone acetyltransferase inhibitor","EP300",NA,NA,"CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1121","d,l-3-hydroxybutyric acid","hydroxycarboxylic acid receptor agonist","HCAR2, HDAC2, HDAC3",NA,NA,"C[C@@H](O)CC(O)=O |&1:1|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1122","D-phenylalanine","enkephalinase inhibitor","CCBL1, CRH, HCAR3",NA,NA,"N[C@H](Cc1ccccc1)C(O)=O, N[C@H](Cc1ccccc1)C(O)=O, N[C@H](Cc1ccccc1)C(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1123","D-serine","glutamate receptor agonist","GLRA1, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SERPINB3",NA,NA,"N[C@H](CO)C(O)=O, N[C@H](CO)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1124","D-4476","TGF beta receptor inhibitor","CSNK1A1, CSNK1D, TGFB1",NA,NA,"NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCCOc2c1)-c1ccccn1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1125","D-64131","microtubule inhibitor","TUBB",NA,NA,"COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1, COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1, COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1, COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1, COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1, COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1126","DAA-1106","benzodiazepine receptor agonist","TSPO",NA,NA,"COc1ccc(OC)c(CN(C(C)=O)c2cc(F)ccc2Oc2ccccc2)c1, COc1ccc(OC)c(CN(C(C)=O)c2cc(F)ccc2Oc2ccccc2)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1127","dabigatran","thrombin inhibitor","F2","neurology/psychiatry, hematology","stroke, systemic embolism, pulmonary embolism (PE), deep vein thrombosis (DVT)","Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1, Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1, Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1, Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1, Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1, Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1, Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1128","dabigatran-etexilate","thrombin inhibitor","F2","neurology/psychiatry, hematology","stroke, systemic embolism, pulmonary embolism (PE), deep vein thrombosis (DVT)","CCCCCCOC(=O)\N=C(\N)c1ccc(NCc2nc3cc(ccc3n2C)C(=O)N(CCC(=O)OCC)c2ccccn2)cc1, CCCCCCOC(=O)\N=C(\N)c1ccc(NCc2nc3cc(ccc3n2C)C(=O)N(CCC(=O)OCC)c2ccccn2)cc1, CCCCCCOC(=O)\N=C(\N)c1ccc(NCc2nc3cc(ccc3n2C)C(=O)N(CCC(=O)OCC)c2ccccn2)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1129","dabrafenib","RAF inhibitor","BRAF, LIMK1, NEK11, RAF1, SIK1","oncology","melanoma","CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1130","dabuzalgron","adrenergic receptor agonist","ADRB3","urology","urinary incontinence","Cc1c(OCC2=NCCN2)ccc(Cl)c1NS(C)(=O)=O |t:5|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"1131","dacarbazine","DNA alkylating agent","PGD, POLA2","oncology, hematologic malignancy","melanoma, Hodgkin's lymphoma","CN(C)\N=N\c1nc[nH]c1C(N)=O, CN(C)\N=N\c1nc[nH]c1C(N)=O, CN(C)\N=N\c1nc[nH]c1C(N)=O, CN(C)\N=N\c1nc[nH]c1C(N)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1132","dacinostat","HDAC inhibitor","HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",NA,NA,"OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1133","dacomitinib","EGFR inhibitor","EGFR, ERBB2, ERBB4",NA,NA,"COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1134","dactinomycin","RNA polymerase inhibitor","POLR2A","oncology","testicular carcinoma, Wilm's tumor, rhabdomyosarcoma, Ewing's sarcoma, gestational trophoblastic disease (GTD)","CC(C)[C@H]1NC(=O)[C@@H](NC(=O)c2ccc(C)c3oc4c(C)c(=O)c(N)c(C(=O)N[C@H]5[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]6CCCN6C(=O)[C@H](NC5=O)C(C)C)c4nc23)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C1=O, CC(C)[C@H]1NC(=O)[C@@H](NC(=O)c2ccc(C)c3oc4c(C)c(=O)c(N)c(C(=O)N[C@H]5[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]6CCCN6C(=O)[C@H](NC5=O)C(C)C)c4nc23)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C1=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1135","daidzein","estrogen receptor agonist","ESRRA, ESRRB, ESRRG, TRPC5",NA,NA,"Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1136","daidzin","antioxidant","ALDH2",NA,NA,"OC[C@H]1O[C@@H](Oc2ccc3c(c2)occ(-c2ccc(O)cc2)c3=O)[C@H](O)[C@@H](O)[C@@H]1O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1137","dalargin","opioid receptor agonist","OPRM1",NA,NA,"CC(C)C[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=N)C(O)=O |a:23,41,&1:4,&2:8,&3:28|, CC(C)C[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=N)C(O)=O |a:23,41,&1:4,&2:8,&3:28|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1138","dalbavancin","bacterial cell wall synthesis inhibitor","PNLIP","infectious disease","skin infections","CN[C@@H]1c2ccc(O)c(Oc3cc(O)c(Cl)c(c3)[C@@H]3NC(=O)[C@@H](Cc4ccc(Oc5cc6cc(Oc7ccc(cc7Cl)[C@@H](O)[C@@H]7NC(=O)[C@H](NC(=O)[C@@H]6NC3=O)c3ccc(O)c(c3)-c3c(O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]6O)cc(O)cc3[C@H](NC7=O)C(=O)NCCCN(C)C)c5O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3NC(=O)CCCCCCCCC(C)C)C(O)=O)cc4)NC1=O)c2, CN[C@@H]1c2ccc(O)c(Oc3cc(O)c(Cl)c(c3)[C@@H]3NC(=O)[C@@H](Cc4ccc(Oc5cc6cc(Oc7ccc(cc7Cl)[C@@H](O)[C@@H]7NC(=O)[C@H](NC(=O)[C@@H]6NC3=O)c3ccc(O)c(c3)-c3c(O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]6O)cc(O)cc3[C@H](NC7=O)C(=O)NCCCN(C)C)c5O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3NC(=O)CCCCCCCCC(C)C)C(O)=O)cc4)NC1=O)c2","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1139","dalcetrapib","cholesteryl ester transfer protein inhibitor","CETP",NA,NA,"CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C, CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C, CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1140","dalfampridine","potassium channel blocker","KCNA1, KCNA10, KCNA2, KCNA3, KCNA4, KCNA5, KCNA6, KCNA7, KCNB1, KCNB2, KCNC1, KCNC2, KCNC3, KCNC4, KCND1, KCND2, KCND3, KCNF1, KCNG1, KCNG2, KCNG3, KCNG4, KCNH1, KCNH2, KCNH3, KCNH4, KCNH5, KCNH6, KCNH7, KCNH8, KCNJ13, KCNJ5, KCNQ1, KCNQ2, KCNQ3, KCNQ4, KCNQ5, KCNS1, KCNS2, KCNS3, KCNV1, KCNV2","neurology/psychiatry","multiple sclerosis","Nc1ccncc1, Nc1ccncc1, Nc1ccncc1, Nc1ccncc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1141","daltroban","thromboxane receptor antagonist","TBXA2R",NA,NA,"OC(=O)Cc1ccc(CCNS(=O)(=O)c2ccc(Cl)cc2)cc1, OC(=O)Cc1ccc(CCNS(=O)(=O)c2ccc(Cl)cc2)cc1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1142","daminozide","KDM2A inhibitor","KDM2A, KDM7A, PHF8",NA,NA,"CN(C)NC(=O)CCC(O)=O, CN(C)NC(=O)CCC(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1143","danazol","estrogen receptor antagonist, progesterone receptor agonist","AR, CCL2, ESR1, GNRHR, GNRHR2, PGR","obstetrics/gynecology, cardiology","endometriosis, angioedema","C[C@]12CC[C@H]3[C@@H](CCC4=Cc5oncc5C[C@]34C)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=Cc5oncc5C[C@]34C)[C@@H]1CC[C@@]2(O)C#C |t:8|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1144","danirixin","CC chemokine receptor antagonist","CXCR2",NA,NA,"Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(c1O)S(=O)(=O)[C@H]1CCCNC1, Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(c1O)S(=O)(=O)[C@H]1CCCNC1, Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(c1O)S(=O)(=O)[C@H]1CCCNC1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1145","dantrolene","calcium channel blocker","RYR1, RYR3","neurology/psychiatry, endocrinology","spasms, malignant hyperthermia (MH)","[O-][N+](=O)c1ccc(cc1)-c1ccc(\C=N\N2CC(=O)NC2=O)o1, [O-][N+](=O)c1ccc(cc1)-c1ccc(\C=N\N2CC(=O)NC2=O)o1, [O-][N+](=O)c1ccc(cc1)-c1ccc(\C=N\N2CC(=O)NC2=O)o1, [O-][N+](=O)c1ccc(cc1)-c1ccc(\C=N\N2CC(=O)NC2=O)o1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1146","danusertib","Aurora kinase inhibitor, growth factor receptor inhibitor","AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK",NA,NA,"CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1, CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1, CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1, CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1, CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1147","dapagliflozin","sodium/glucose cotransporter inhibitor","SLC5A1, SLC5A2","endocrinology","diabetes mellitus","CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1, CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1, CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1, CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1","Launched",1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1148","dapiprazole","adrenergic receptor antagonist","ADRA1A, ADRA1B, ADRA1D","ophthalmology","mydriasis","Cc1ccccc1N1CCN(CCc2nnc3CCCCn23)CC1, Cc1ccccc1N1CCN(CCc2nnc3CCCCn23)CC1, Cc1ccccc1N1CCN(CCc2nnc3CCCCn23)CC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,1,1,1,1
"1149","dapivirine","non-nucleoside reverse transcriptase inhibitor","CYP3A4, CYP3A5",NA,NA,"Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1, Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1, Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1, Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1, Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1150","dapoxetine","selective serotonin reuptake inhibitor (SSRI)","HTR1A, HTR1B, HTR2C, SLC6A4","urology","premature ejaculation (PE)","CN(C)[C@@H](CCOc1cccc2ccccc12)c1ccccc1, CN(C)[C@@H](CCOc1cccc2ccccc12)c1ccccc1, CN(C)[C@@H](CCOc1cccc2ccccc12)c1ccccc1, CN(C)[C@@H](CCOc1cccc2ccccc12)c1ccccc1","Launched",1,1,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1151","daprodustat","hypoxia inducible factor inhibitor","EGLN1",NA,NA,"OC(=O)CNC(=O)c1c(O)n(C2CCCCC2)c(=O)n(C2CCCCC2)c1=O, OC(=O)CNC(=O)c1c(O)n(C2CCCCC2)c(=O)n(C2CCCCC2)c1=O, OC(=O)CNC(=O)c1c(O)n(C2CCCCC2)c(=O)n(C2CCCCC2)c1=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1152","dapsone","bacterial antifolate","DHFR","dermatology, infectious disease","dermatitis herpetiformis (DH), leprosy","Nc1ccc(cc1)S(=O)(=O)c1ccc(N)cc1, Nc1ccc(cc1)S(=O)(=O)c1ccc(N)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1153","darapladib","phospholipase inhibitor","PLA2G7",NA,NA,"CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1, CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1, CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1, CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1, CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1, CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1, CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1, CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1154","darglitazone","PPAR receptor antagonist","PPARG",NA,NA,"Cc1oc(nc1CCC(=O)c1ccc(CC2SC(=O)NC2=O)cc1)-c1ccccc1, Cc1oc(nc1CCC(=O)c1ccc(CC2SC(=O)NC2=O)cc1)-c1ccccc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1155","darifenacin","acetylcholine receptor antagonist","CHRM1, CHRM2, CHRM3, CHRM4, CHRM5","urology","urinary incontinence","NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1, NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1, NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,5,0,0,1,1,1,1
"1156","darolutamide","androgen receptor antagonist","AR","oncology","breast cancer, prostate cancer","C[C@@H](Cn1ccc(n1)c2ccc(c(c2)Cl)C#N)NC(=O)c3cc([nH]n3)C(C)O, C[C@@H](Cn1ccc(n1)-c1ccc(C#N)c(Cl)c1)NC(=O)c1cc(n[nH]1)[C@@H](C)O |a:1,&1:25|, C[C@@H](Cn1ccc(n1)-c1ccc(C#N)c(Cl)c1)NC(=O)c1cc(n[nH]1)[C@@H](C)O |a:1,&1:25|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1157","darunavir","HIV protease inhibitor","CYP3A4","infectious disease","human immunodeficiency virus (HIV-1)","CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1, CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1, CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1, CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1, CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1158","darusentan","endothelin receptor antagonist","EDNRA",NA,NA,"COc1cc(OC)nc(O[C@H](C(O)=O)C(OC)(c2ccccc2)c2ccccc2)n1, COc1cc(OC)nc(O[C@H](C(O)=O)C(OC)(c2ccccc2)c2ccccc2)n1, COc1cc(OC)nc(O[C@H](C(O)=O)C(OC)(c2ccccc2)c2ccccc2)n1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1159","dasatinib","Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, SRC inhibitor, tyrosine kinase inhibitor","ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1","hematologic malignancy","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1160","DAU-5884","acetylcholine receptor antagonist","CHRM3",NA,NA,"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)N1Cc2ccccc2NC1=O, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)N1Cc2ccccc2NC1=O, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)N1Cc2ccccc2NC1=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
"1161","daunorubicin","RNA synthesis inhibitor, topoisomerase inhibitor","TOP2A, TOP2B","hematologic malignancy","acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)","COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1162","dauricine","nfkb pathway inhibitor","GORASP1, PTGR1","oncology","colorectal cancer","COc1cc2CCN(C)[C@H](Cc3ccc(Oc4cc(C[C@H]5N(C)CCc6cc(OC)c(OC)cc56)ccc4O)cc3)c2cc1OC","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1163","dazmegrel","thromboxane synthase inhibitor","TBXAS1",NA,NA,"Cc1c(Cn2ccnc2)c2ccccc2n1CCC(O)=O, Cc1c(Cn2ccnc2)c2ccccc2n1CCC(O)=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1164","dazoxiben","thromboxane synthase inhibitor","TBXAS1",NA,NA,"OC(=O)c1ccc(OCCn2ccnc2)cc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1165","DBeQ","ATPase inhibitor","CASP3",NA,NA,"C(Nc1nc(NCc2ccccc2)c2ccccc2n1)c1ccccc1, C(Nc1nc(NCc2ccccc2)c2ccccc2n1)c1ccccc1, C(Nc1nc(NCc2ccccc2)c2ccccc2n1)c1ccccc1, C(Nc1nc(NCc2ccccc2)c2ccccc2n1)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1166","DBPR108","dipeptidyl peptidase inhibitor","DPP4",NA,NA,"CC(C)(CC(=O)N1CCCC1)NCC(=O)N1C[C@@H](F)C[C@H]1C#N, CC(C)(CC(=O)N1CCCC1)NCC(=O)N1C[C@@H](F)C[C@H]1C#N, CC(C)(CC(=O)N1CCCC1)NCC(=O)N1C[C@@H](F)C[C@H]1C#N, CC(C)(CC(=O)N1CCCC1)NCC(=O)N1C[C@@H](F)C[C@H]1C#N","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1167","DC-260126","free fatty acid receptor antagonist","FFAR1",NA,NA,"CCCCc1ccc(NS(=O)(=O)c2ccc(F)cc2)cc1, CCCCc1ccc(NS(=O)(=O)c2ccc(F)cc2)cc1, CCCCc1ccc(NS(=O)(=O)c2ccc(F)cc2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1168","DCC-2618","KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","KIT, PDGFRA",NA,NA,"Cn1cc(cn1)-c1cc(Oc2cc(F)c(NC(=O)C3(CC3)C(=O)Nc3ccccc3)cc2F)ccn1, Cn1cc(cn1)-c1cc(Oc2cc(F)c(NC(=O)C3(CC3)C(=O)Nc3ccccc3)cc2F)ccn1, Cn1cc(cn1)-c1cc(Oc2cc(F)c(NC(=O)C3(CC3)C(=O)Nc3ccccc3)cc2F)ccn1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1169","DCEBIO","potassium channel activator","KCNN2, KCNN3, KCNN4",NA,NA,"CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O, CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O, CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O, CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O, CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O, CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O, CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1170","DCPIB","chloride channel blocker, gap junction modulator, glutamate inhibitor","SLC1A2",NA,NA,"CCCC[C@]1(Cc2cc(OCCCC(O)=O)c(Cl)c(Cl)c2C1=O)C1CCCC1 |&1:4,r|","Preclinical",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1171","DDR1-IN-1","discoidin domain receptor inhibitor","DDR1, DDR2",NA,NA,"CCN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Oc3ccc4NC(=O)Cc4c3)c2)CC1, CCN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Oc3ccc4NC(=O)Cc4c3)c2)CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1172","debrisoquin","adrenergic neuron blocker","SLC6A2","cardiology","hypertension","NC(=N)N1CCc2ccccc2C1, NC(=N)N1CCc2ccccc2C1, NC(=N)N1CCc2ccccc2C1","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1173","decamethonium","acetylcholine receptor agonist","ACHE, CHRNA2","neurology/psychiatry","muscle relaxant","C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,1
"1174","decernotinib","protein tyrosine kinase inhibitor, JAK inhibitor","JAK2, JAK3","Immunology","rheumatoid arthritis","CC[C@@](C)(Nc1ccnc(n1)-c1c[nH]c2ncccc12)C(=O)NCC(F)(F)F |&1:2,r|, CC[C@@](C)(Nc1ccnc(n1)-c1c[nH]c2ncccc12)C(=O)NCC(F)(F)F |&1:2,r|, CC[C@@](C)(Nc1ccnc(n1)-c1c[nH]c2ncccc12)C(=O)NCC(F)(F)F","Phase 2/Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1175","decitabine","DNA methyltransferase inhibitor","DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML)","Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1176","decoglurant","glutamate receptor modulator","GRM2, GRM3","neurology/psychiatry","depression","NC1=NC=C(C#CC2=C3N=C(C4=CC=C(C(F)(F)F)C=C4)C=C(C(F)(F)F)N3N=C2)C=C1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1177","defactinib","focal adhesion kinase inhibitor","PTK2",NA,NA,"CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1178","deferasirox","chelating agent","CYP3A4","hematology","transfusional hemosiderosis, thalassemia, iron overload","OC(=O)c1ccc(cc1)-n1nc(nc1-c1ccccc1O)-c1ccccc1O, OC(=O)c1ccc(cc1)-n1nc(nc1-c1ccccc1O)-c1ccccc1O, OC(=O)c1ccc(cc1)-n1nc(nc1-c1ccccc1O)-c1ccccc1O, OC(=O)c1ccc(cc1)-n1nc(nc1-c1ccccc1O)-c1ccccc1O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1179","deferiprone","chelating agent","UGT1A6","hematology","transfusional hemosiderosis, thalassemia, iron overload","Cc1c(O)c(=O)ccn1C, Cc1c(O)c(=O)ccn1C, Cc1c(O)c(=O)ccn1C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1180","deflazacort","glucocorticoid receptor agonist","NR3C1","rheumatology","joint inflammation","CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C |c:23,t:8,19|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1181","deforolimus","mTOR inhibitor","MTOR",NA,NA,"CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O |c:14,33,t:29,31|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1182","degarelix","gonadotropin releasing factor hormone receptor antagonist","GNRHR","oncology","prostate cancer","CC(C)CC(NC(=O)C(Cc1ccc(NC(N)=O)cc1)NC(=O)C(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)NC(=O)C(CO)NC(=O)C(Cc1cccnc1)NC(=O)C(Cc1ccc(Cl)cc1)NC(=O)C(Cc1ccc2ccccc2c1)NC(C)=O)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O, CC(C)C[C@H](NC(=O)[C@@H](Cc1ccc(NC(N)=O)cc1)NC(=O)[C@H](Cc1ccc(NC(=O)[C@@H]2CC(=O)NC(=O)N2)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1183","dehydrocorydaline","acetylcholinesterase inhibitor","ACHE",NA,NA,"COc1ccc2c(C)c3-c4cc(OC)c(OC)cc4CC[n+]3cc2c1OC, COc1ccc2c(C)c3-c4cc(OC)c(OC)cc4CC[n+]3cc2c1OC, COc1ccc2c(C)c3-c4cc(OC)c(OC)cc4CC[n+]3cc2c1OC, COc1ccc2c(C)c3-c4cc(OC)c(OC)cc4CC[n+]3cc2c1OC","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1184","dehydroepiandrosterone","protein synthesis stimulant","ESR1, ESR2, G6PD, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, HSD17B1, NR1I2, NR1I3, PPARA, SIGMAR1, SULT2A1, SULT2B1","endocrinology","menopause","C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O |t:7|, C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O |t:7|, C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O |t:7|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,1,16,0,0,0,0,0,0,1,1,1,1
"1185","dehydroepiandrosterone-sulfate","androgen receptor agonist, estrogen receptor agonist","AR, ESR1, ESR2","endocrinology","menopause","C[C@]12CC[C@H]3[C@@H](CC=C4C[C@H](CC[C@]34C)OS(O)(=O)=O)[C@@H]1CCC2=O |t:7|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1186","delanzomib","proteasome inhibitor","CMA1, CTSG, CYP3A4, ELANE",NA,NA,"CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1187","delapril","angiotensin converting enzyme inhibitor","ACE","cardiology","hypertension","CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N(CC(O)=O)C1Cc2ccccc2C1, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N(CC(O)=O)C1Cc2ccccc2C1, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N(CC(O)=O)C1Cc2ccccc2C1, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N(CC(O)=O)C1Cc2ccccc2C1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1188","delavirdine","non-nucleoside reverse transcriptase inhibitor","CYP3A4","infectious disease","human immunodeficiency virus (HIV-1)","CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1, CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1, CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1, CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1, CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1189","delivert","angiotensin receptor agonist","AGTR1, AGTR2","critical care","sepsis","CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@@H]1C(=O)N[C@H](Cc1ccccc1)C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@@H]1C(=O)N[C@H](Cc1ccccc1)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1190","delphinidin","membrane permeability inhibitor","GLO1",NA,NA,"Oc1cc(O)c2cc(O)c([o+]c2c1)-c1cc(O)c(O)c(O)c1, Oc1cc(O)c2cc(O)c([o+]c2c1)-c1cc(O)c(O)c(O)c1, Oc1cc(O)c2cc(O)c([o+]c2c1)-c1cc(O)c(O)c(O)c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1191","delta-tocotrienol","HMGCR inhibitor","HMGCR",NA,NA,"CC(C)=CCC\C(C)=C\CC\C(C)=C\CC[C@]1(C)CCc2cc(O)cc(C)c2O1, CC(C)=CCC\C(C)=C\CC\C(C)=C\CC[C@]1(C)CCc2cc(O)cc(C)c2O1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1192","deltarasin","phosphodiesterase inhibitor","KRAS",NA,NA,"C(Oc1ccc(cc1)-c1nc2ccccc2n1Cc1ccccc1)[C@H](C1CCNCC1)n1c(nc2ccccc12)-c1ccccc1, C(Oc1ccc(cc1)-c1nc2ccccc2n1Cc1ccccc1)[C@H](C1CCNCC1)n1c(nc2ccccc12)-c1ccccc1, C(Oc1ccc(cc1)-c1nc2ccccc2n1Cc1ccccc1)[C@H](C1CCNCC1)n1c(nc2ccccc12)-c1ccccc1, C(Oc1ccc(cc1)-c1nc2ccccc2n1Cc1ccccc1)[C@H](C1CCNCC1)n1c(nc2ccccc12)-c1ccccc1, C(Oc1ccc(cc1)-c1nc2ccccc2n1Cc1ccccc1)[C@H](C1CCNCC1)n1c(nc2ccccc12)-c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1193","demecarium","acetylcholinesterase inhibitor","ACHE, BCHE","ophthalmology","intraocular pressure, glaucoma","CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1194","deoxycholic-acid","biliverdin reductase A activator, G protein-coupled receptor agonist","FPR1, GPBAR1","endocrinology","submental fat","C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1195","deoxycorticosterone-acetate","progestogen hormone","NR3C2",NA,NA,"CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1196","deoxyepinephrine","adrenergic receptor agonist, dopamine receptor agonist","ADRA1A, DRD1, DRD2",NA,NA,"CNCCc1ccc(O)c(O)c1, CNCCc1ccc(O)c(O)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,1,1,0,0,0,0
"1197","deprodone propionate","anti-inflammatory agent","ALOX5AP, CHRNB4","dermatology","eczema","CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,1
"1198","deptropine","histamine receptor antagonist","HRH1",NA,NA,"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC1c2ccccc2CCc2ccccc12 |r,THB:0:1:3.4:6.7.8|","Preclinical",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
"1199","dequalinium","PKC inhibitor","KCNN1, KCNN3","infectious disease","first-aid antiseptic","Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12, Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12, Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12, Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12, Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12, Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1200","deracoxib","cyclooxygenase inhibitor","PTGS2","rheumatology","osteoarthritis","COc1ccc(cc1F)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)F, COc1ccc(cc1F)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)F","Launched",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1201","deserpidine","angiotensin converting enzyme inhibitor","ACE, SLC18A2","cardiology","hypertension","CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1202","desipramine","tricyclic antidepressant","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR1A, HTR2A, HTR2C, SLC6A2, SLC6A4, SMPD1","neurology/psychiatry","depression","CNCCCN1c2ccccc2CCc2ccccc12, CNCCCN1c2ccccc2CCc2ccccc12","Launched",1,2,0,0,0,0,0,0,1,3,1,1,0,0,1,1,1,5,1,8,1,1,1,1
"1203","deslanoside","Na/K-ATPase inhibitor","ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B1, ATP1B2, ATP1B3, FXYD2","cardiology","congestive heart failure, cardiac arrythmia","C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |t:66|, C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |t:66|, C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |t:66|, C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |t:66|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1204","desloratadine","histamine receptor antagonist","HRH1","allergy","allergic rhinitis, urticaria","Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1, Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1, Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1, Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1, Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1, Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1, Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"1205","desmethylclozapine","acetylcholine receptor agonist","HTR2C",NA,NA,"Clc1ccc2Nc3ccccc3C(=Nc2c1)N1CCNCC1 |c:13|, Clc1ccc2Nc3ccccc3C(=Nc2c1)N1CCNCC1 |c:13|","Phase 2",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1206","desmopressin-acetate","vasopressin receptor agonist","AVPR1A, AVPR1B, AVPR2, OXTR","endocrinology, urology","central diabetes insipidus, nocturnal enuresis","NC(=O)CC[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)CCSSC[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O |r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1207","desogestrel","progesterone receptor agonist","ESR1, PGR","endocrinology","contraceptive","CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:10|, CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:10|, CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:10|, CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:10|, CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:10|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1208","desonide","glucocorticoid receptor agonist","NR3C1, PLA2G1B","gastroenterology","Crohn's disease","CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1209","desoximetasone","glucocorticoid receptor agonist","NR3C1, PLA2G1B","dermatology","corticosteroid-responsive dermatoses","C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO |c:11,t:7|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1210","desoxycorticosterone-pivalate","corticosteroid agonist","NR3C2","endocrinology","Addison's disease","CC(C)(C)C(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:17|, CC(C)(C)C(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:17|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1211","desoxycortone","mineralocorticoid receptor agonist","NR3C1, NR3C2",NA,NA,"C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:8|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1212","desoxypeganine","acetylcholinesterase inhibitor, monoamine oxidase inhibitor","ACHE",NA,NA,"C1CN2Cc3ccccc3N=C2C1 |c:11|, C1CN2Cc3ccccc3N=C2C1 |c:11|, C1CN2Cc3ccccc3N=C2C1 |c:11|, C1CN2Cc3ccccc3N=C2C1 |c:11|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1213","desvenlafaxine","serotonin‚Äìnorepinephrine reuptake inhibitor (SNRI), serotonin‚Äö√§√¨norepinephrine reuptake inhibitor (snri)","SLC6A2, SLC6A3, SLC6A4","neurology/psychiatry","depression","CN(C)C[C@@H](c1ccc(O)cc1)C1(O)CCCCC1 |&1:4|, CN(C)C[C@@H](c1ccc(O)cc1)C1(O)CCCCC1 |&1:4|, CN(C)C[C@@H](c1ccc(O)cc1)C1(O)CCCCC1 |&1:4|, CN(C)C[C@@H](c1ccc(O)cc1)C1(O)CCCCC1 |&1:4|, CN(C)C[C@@H](c1ccc(O)cc1)C1(O)CCCCC1 |&1:4|, CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1, CN(C)C[C@@H](c1ccc(O)cc1)C1(O)CCCCC1 |&1:4|","Launched",1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1214","detomidine","adrenergic receptor agonist","ADRA2A","neurology/psychiatry","sedative","Cc1cccc(Cc2cnc[nH]2)c1C, Cc1cccc(Cc2cnc[nH]2)c1C, Cc1cccc(Cc2cnc[nH]2)c1C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"1215","deucravacitinib","tyrosine kinase inhibitor","TYK2","gastroenterology","crohn's disease","[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc3cccc(c3OC)c4ncn(C)n4","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1216","deutetrabenazine","vesicular monoamine transporter inhibitor","SLC18A2","neurology/psychiatry","huntington's disease","[2H]C([2H])([2H])OC1=CC2=C(C=C1OC([2H])([2H])[2H])[C@@H]1CC(=O)[C@@H](CC(C)C)CN1CC2","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1217","dexamethasone","glucocorticoid receptor agonist","ANXA1, NOS2, NR0B1, NR3C1, NR3C2","endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology, endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology","hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis, hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (dh), nephrotic syndrome, psoriasis","C[C@@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1218","dexamethasone palmitate","glucocorticoid receptor agonist","NR3C1","rheumatology","rheumatoid arthritis","CCCCCCCCCCCCCCCC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1219","dexbrompheniramine","histamine receptor antagonist","HRH1","allergy","allergic rhinitis","Brc1ccc(cc1)[C@@H](c2ncccc2)CCN(C)C","Withdrawn",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"1220","dexfosfoserine","membrane integrity inhibitor","CFTR, GRM4, GRM6, GRM7, GRM8, KCNC4, PDPK1, PIM1, PRKACA, PRKCQ, PYGL, PYGM, REG1A, RHO, SERPINB3, SMAD2, TAOK2",NA,NA,"N[C@@H](COP(O)(O)=O)C(O)=O, N[C@@H](COP(O)(O)=O)C(O)=O, N[C@@H](COP(O)(O)=O)C(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1221","dexlansoprazole","ATPase inhibitor","ATP4A","gastroenterology","gastroesophageal reflux disease (GERD), erosive esophagitis (EE)","Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1, Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1, Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1, Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1222","dexloxiglumide","CCK receptor antagonist","CCKAR",NA,NA,"CCCCCN(CCCOC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccc(Cl)c(Cl)c1, CCCCCN(CCCOC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccc(Cl)c(Cl)c1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1223","dexmedetomidine","adrenergic receptor agonist","ADRA2A, ADRA2B, ADRA2C","neurology/psychiatry","sedative","C[C@H](c1cnc[nH]1)c1cccc(C)c1C, C[C@H](c1cnc[nH]1)c1cccc(C)c1C, C[C@H](c1cnc[nH]1)c1cccc(C)c1C, C[C@H](c1cnc[nH]1)c1cccc(C)c1C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,1,1,1,1
"1224","dexniguldipine","calmodulin antagonist","ADORA3",NA,NA,"COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1225","dexrazoxane","chelating agent, topoisomerase inhibitor","TOP2A, TOP2B","cardiology","cardiomyopathy","C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1226","dextromethorphan","glutamate receptor antagonist, sigma receptor agonist","CHRNA2, CHRNA3, CHRNA4, CHRNA7, CHRNB2, CHRNB4, CYBA, CYBB, GRIN3A, NCF1, NCF2, NCF4, OPRD1, OPRK1, OPRM1, PGRMC1, RAC1, RAC2, SIGMAR1, SLC6A2, SLC6A4","pulmonary","cough suppressant","COc1ccc2C[C@H]3[C@H]4CCCC[C@@]4(CCN3C)c2c1, COc1ccc2C[C@H]3[C@H]4CCCC[C@@]4(CCN3C)c2c1, COc1ccc2C[C@H]3[C@H]4CCCC[C@@]4(CCN3C)c2c1","Launched",1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,6,0,0,1,1,1,1
"1227","DFB","glutamate receptor agonist","GRM5",NA,NA,"Fc1cccc(\C=N\N=C\c2cccc(F)c2)c1, Fc1cccc(\C=N\N=C\c2cccc(F)c2)c1, Fc1cccc(\C=N\N=C\c2cccc(F)c2)c1, Fc1cccc(\C=N\N=C\c2cccc(F)c2)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1228","DG-172","PPAR receptor inverse agonist","PPARD",NA,NA,"CN1CCN(CC1)c1ccc(\C=C(/C#N)c2ccccc2Br)cc1, CN1CCN(CC1)c1ccc(\C=C(/C#N)c2ccccc2Br)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1229","DH-97","melatonin receptor antagonist","MTNR1B",NA,NA,"CCCCC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12, CCCCC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12, CCCCC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1230","diacerein","interleukin inhibitor","IL1B","rheumatology","osteoarthritis","CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O, CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O, CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O, CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O, CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1231","diadenosine-tetraphosphate","adenosine kinase inhibitor","P2RY13, P2RY2",NA,NA,"Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:10,12,32,34,35,37,49,51,&1:15,&2:19,&3:23,&4:27|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1232","diarylpropionitrile","estrogen receptor agonist","ESR2",NA,NA,"Oc1ccc(C[C@@H](C#N)c2ccc(O)cc2)cc1 |&1:6,r|, Oc1ccc(C[C@@H](C#N)c2ccc(O)cc2)cc1 |&1:6,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1233","diazoxide","potassium channel activator","ATP1A1, CA1, CA2, KCNJ11, KCNJ8, KCNMA1, SLC12A3","endocrinology","hypoglycemia","CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1 |t:1|, CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1 |t:1|, CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1 |t:1|, CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1 |t:1|, CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1 |t:1|","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1234","diclofenac","cyclooxygenase inhibitor","AKR1C3, ALOX5, ASIC1, ASIC3, KCNQ2, KCNQ3, PLA2G2A, PPARG, PTGS1, PTGS2, SCN4A","rheumatology, neurology/psychiatry","rheumatoid arthritis, osteoarthritis, migraine headache","OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl, OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl, OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl, OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl, OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl","Launched",0,0,1,1,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1235","diclofenamide","carbonic anhydrase inhibitor","CA1, CA12, CA2, CA4, CA7","ophthalmology, neurology/psychiatry","glaucoma, epilepsy","NS(=O)(=O)c1cc(Cl)c(Cl)c(c1)S(N)(=O)=O, NS(=O)(=O)c1cc(Cl)c(Cl)c(c1)S(N)(=O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1236","diclofensine","dopamine reuptake inhibitor","DRD1, MAOA, MAOB",NA,NA,"COc1ccc2[C@@H](CN(C)Cc2c1)c1ccc(Cl)c(Cl)c1 |&1:6|, COc1ccc2[C@@H](CN(C)Cc2c1)c1ccc(Cl)c(Cl)c1 |&1:6|","Phase 3",0,0,0,0,0,0,1,2,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0
"1237","dicoumarol","NADPH inhibitor","CRYZ, NQO1, VKORC1","hematology","deep vein thrombosis (DVT)","Oc1c(Cc2c(O)c3ccccc3oc2=O)c(=O)oc2ccccc12, Oc1c(Cc2c(O)c3ccccc3oc2=O)c(=O)oc2ccccc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1238","dicycloverine","acetylcholine receptor antagonist","CHRM1, CHRM2, CHRM3","gastroenterology","irritable bowel syndrome","CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1, CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1, CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,1,1,1,1
"1239","didanosine","nucleoside reverse transcriptase inhibitor","PNP","infectious disease","human immunodeficiency virus (HIV-1)","OC[C@@H]1CC[C@@H](O1)n1cnc2c1[nH]cnc2=O, OC[C@@H]1CC[C@@H](O1)n1cnc2c1[nH]cnc2=O, OC[C@@H]1CC[C@@H](O1)n1cnc2c1[nH]cnc2=O, OC[C@@H]1CC[C@@H](O1)n1cnc2c1[nH]cnc2=O, OC[C@@H]1CC[C@@H](O1)n1cnc2c1[nH]cnc2=O, OC[C@@H]1CC[C@@H](O1)n1cnc2c1[nH]cnc2=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1240","didox","ribonucleotide reductase inhibitor","RRM1","oncology","breast cancer","ONC(=O)c1ccc(O)c(O)c1, ONC(=O)c1ccc(O)c(O)c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1241","dienestrol","estrogen receptor agonist","ESR1","endocrinology","menopause","C\C=C(\C(=C\C)\c1ccc(O)cc1)/c1ccc(O)cc1, C\C=C(\C(=C\C)\c1ccc(O)cc1)/c1ccc(O)cc1, C\C=C(\C(=C\C)\c1ccc(O)cc1)/c1ccc(O)cc1, C\C=C(\C(=C\C)\c1ccc(O)cc1)/c1ccc(O)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1242","dienogest","progesterone receptor agonist","PGR","endocrinology, obstetrics/gynecology","contraceptive, endometriosis","C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N |c:4,10|, C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N |c:4,10|, C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N |c:4,10|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1243","diethylcarbamazine","lipoxygenase inhibitor","ALOX5, PTGS1","infectious disease","filariasis","CCN(CC)C(=O)N1CCN(C)CC1, CCN(CC)C(=O)N1CCN(C)CC1, CCN(CC)C(=O)N1CCN(C)CC1","Launched",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1244","diethylstilbestrol","estrogen receptor agonist","ESR1, ESR2, ESRRB, ESRRG",NA,NA,"CC\C(=C(\CC)c1ccc(O)cc1)c1ccc(O)cc1, CC\C(=C(\CC)c1ccc(O)cc1)c1ccc(O)cc1, CC\C(=C(\CC)c1ccc(O)cc1)c1ccc(O)cc1, CC\C(=C(\CC)c1ccc(O)cc1)c1ccc(O)cc1","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1245","difamilast","phosphodiesterase inhibitor","PDE4A","dermatology","dermatitis","CCOc1ccccc1C(=O)NCc2coc(n2)c3ccc(OC(F)F)c(OC(C)C)c3","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1246","difelikefalin","opioid receptor agonist","OPRK1","nephrology","uremic pruritus","CC(C)C[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@H](N)Cc1ccccc1)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O |a:4,8,19,31|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1247","diflorasone diacetate","glucocorticoid receptor agonist","NR3C1","Dermatology, dermatology","psoriasis, corticosteroid-responsive dermatoses","[H][C@@]12C[C@H](C)[C@](OC(C)=O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C |r,c:35,t:31|, [H][C@@]12C[C@H](C)[C@](OC(C)=O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C |r,c:35,t:31|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1248","diflunisal","prostanoid receptor antagonist","PTGS1, PTGS2","rheumatology","rheumatoid arthritis, osteoarthritis","OC(=O)c1cc(ccc1O)-c1ccc(F)cc1F, OC(=O)c1cc(ccc1O)-c1ccc(F)cc1F","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1249","difluprednate","glucocorticoid receptor agonist","NR3C1","ophthalmology","endogenous uveitis","CCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)COC(C)=O |c:18,t:14|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1250","digitoxigenin","ATPase inhibitor","ATP1A1",NA,NA,"C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:25|, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:25|, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:25|, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:25|, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:25|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1251","digitoxin","ATPase inhibitor","ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B1, ATP1B2, ATP1B3, FXYD2","cardiology","congestive heart failure, cardiac arrythmia","C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CC[C@@H]5[C@@H]4CC[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C |t:45|, C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CC[C@@H]5[C@@H]4CC[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C |t:45|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1252","digoxin","ATPase inhibitor","ATP1A1","cardiology","congestive heart failure, atrial fibrillation (AF)","[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@]([H])(CC[C@]3([H])[C@]2([H])C[C@@H](O)[C@@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |t:60|, [H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@]([H])(CC[C@]3([H])[C@]2([H])C[C@@H](O)[C@@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |t:60|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1253","dihomo-gamma-linolenic-acid","prostanoid receptor agonist","PTGS1, PTGS2",NA,NA,"CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O","Phase 2",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1254","dihydrexidine","dopamine receptor agonist","DRD1, DRD2, DRD3, DRD4, DRD5",NA,NA,"Oc1cc2CC[C@H]3NCc4ccccc4[C@@H]3c2cc1O, Oc1cc2CC[C@H]3NCc4ccccc4[C@@H]3c2cc1O, Oc1cc2CC[C@H]3NCc4ccccc4[C@@H]3c2cc1O, Oc1cc2CC[C@H]3NCc4ccccc4[C@@H]3c2cc1O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,5,0,0,0,0,0,0,0,0
"1255","dihydroergocristine","adrenergic receptor antagonist, prolactin inhibitor","ADRA1A, ADRB1, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR3A, HTR4, HTR5A, HTR6, HTR7","neurology/psychiatry","senile dementia, cerebrovascular insufficiency","CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O","Launched",0,0,0,0,0,0,0,0,1,7,0,0,0,0,1,5,0,0,1,2,1,1,1,1
"1256","dihydroergotamine","serotonin receptor agonist","ADRA2A, DRD2, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR7","neurology/psychiatry","migraine headache","CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O","Launched",0,0,0,0,0,0,0,0,1,6,0,0,0,0,1,1,0,0,1,1,1,1,1,1
"1257","dihydrotachysterol","vitamin analog","VDR","orthopedics, endocrinology","rickets, hypocalcemia, osteomalacia","CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2\C(CCC[C@@]12C)=C\C=C1/C[C@@H](O)CC[C@@H]1C |&1:3,&2:7,&3:9,&4:12,&5:17,&6:23,&7:27,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1258","dihydroxyphenylglycine","glutamate receptor agonist","GRM1, GRM5",NA,NA,"N[C@@H](C(O)=O)c1cc(O)cc(O)c1 |&1:1,r|, N[C@@H](C(O)=O)c1cc(O)cc(O)c1 |&1:1,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1259","dilazep","adenosine reuptake inhibitor","SLC29A1","cardiology","coronary heart disease","COc1cc(cc(OC)c1OC)C(=O)OCCCN1CCCN(CCCOC(=O)c2cc(OC)c(OC)c(OC)c2)CC1, COc1cc(cc(OC)c1OC)C(=O)OCCCN1CCCN(CCCOC(=O)c2cc(OC)c(OC)c(OC)c2)CC1, COc1cc(cc(OC)c1OC)C(=O)OCCCN1CCCN(CCCOC(=O)c2cc(OC)c(OC)c(OC)c2)CC1","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1260","diltiazem","calcium channel blocker","CACNA1C, CACNA1S, CACNA2D1, CACNG1, HTR3A, KCNA5","cardiology","hypertension, angina pectoris","COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O, COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O, COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O, COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O, COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O, COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O","Launched",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1261","dimaprit","histamine receptor agonist","HRH2, HRH3, HRH4",NA,NA,"CN(C)CCCSC(N)=N, CN(C)CCCSC(N)=N, CN(C)CCCSC(N)=N, CN(C)CCCSC(N)=N","Preclinical",0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0
"1262","dimemorfan","sigma receptor agonist","SIGMAR1","pulmonary","cough suppressant","CN1CC[C@@]23CCCC[C@@H]2[C@@H]1Cc1ccc(C)cc31, CN1CC[C@@]23CCCC[C@@H]2[C@@H]1Cc1ccc(C)cc31, CN1CC[C@@]23CCCC[C@@H]2[C@@H]1Cc1ccc(C)cc31","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1263","dimenhydrinate","histamine receptor antagonist","HRH1","neurology/psychiatry, gastroenterology","motion sickness, nausea, vomiting","Cn1c2nc(Cl)[nH]c2c(=O)n(C)c1=O.CN(C)CCOC(c1ccccc1)c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"1264","dimercaptosuccinic-acid","chelating agent","DNMT1","neurology/psychiatry","metal toxicity","OC(=O)[C@@H](S)[C@@H](S)C(O)=O, OC(=O)[C@@H](S)[C@@H](S)C(O)=O, OC(=O)[C@@H](S)[C@@H](S)C(O)=O, OC(=O)[C@@H](S)[C@@H](S)C(O)=O, OC(=O)[C@@H](S)[C@@H](S)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1265","dimethindene-(S)-(+)","acetylcholine receptor antagonist","HRH1",NA,NA,"C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |c:2|, C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |c:2|, C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |c:2|, C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |c:2|, C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |c:2|","Preclinical",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
"1266","dimethyl-fumarate","nuclear factor erythroid derived, like (NRF2) activator","KEAP1","neurology/psychiatry","multiple sclerosis","COC(=O)\C=C\C(=O)OC, COC(=O)\C=C\C(=O)OC, COC(=O)\C=C\C(=O)OC, COC(=O)\C=C\C(=O)OC, COC(=O)\C=C\C(=O)OC, COC(=O)\C=C\C(=O)OC","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1267","dimetindene","cholinergic receptor antagonist, histamine receptor antagonist","HRH1","allergy","allergic rhinitis","C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |&1:1,r,c:2|","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"1268","diminazene-aceturate","angiotensin converting enzyme activator","AOC1, PRDX5, PRSS1",NA,NA,"NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1269","dimpylate","acetylcholinesterase inhibitor","ACHE","infectious disease","flea control","CCOP(=S)(OCC)Oc1cc(C)nc(n1)C(C)C, CCOP(=S)(OCC)Oc1cc(C)nc(n1)C(C)C, CCOP(=S)(OCC)Oc1cc(C)nc(n1)C(C)C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1270","dinaciclib","CDK inhibitor","CDK1, CDK2, CDK5, CDK9",NA,NA,"CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO, CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO, CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO, CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO, CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO, CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO, CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1271","dinoprost","prostacyclin analog","PTGDR, PTGDR2, PTGER1, PTGER2, PTGER3, PTGER4, PTGFR, TBXA2R","obstetrics/gynecology","labor induction","CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1272","dinoprostone","prostanoid receptor agonist","CATSPER1, CATSPER2, CATSPER3, CATSPER4, PTGDR, PTGDR2, PTGER1, PTGER2, PTGER3, PTGER4, PTGFR, TBXA2R",NA,NA,"CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1273","dioscin","apoptosis stimulant","CXCR3",NA,NA,"C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@H](CC[C@]5(C)[C@H]4CC[C@]23C)O[C@@H]2O[C@H](CO)[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@H](O)[C@H]2O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](O)[C@H]2O)O[C@]11CC[C@@H](C)CO1 |t:8|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1274","diosmetin","aryl hydrocarbon receptor agonist","CYP1B1","dermatology","cosmetic","COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O)cc2o1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1275","diosmin","aryl hydrocarbon receptor agonist, capillary stabilizing agent","AHR","cardiology, hematology, dermatology","chronic venous insufficiency (CVI), edema, deep vein thrombosis (DVT), statis dermatitis, heavy leg syndrome","COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1276","diphemanil","acetylcholine receptor antagonist","CHRM3","neurology/psychiatry","spasms","C[N+]1(C)CCC(CC1)=C(c1ccccc1)c1ccccc1, C[N+]1(C)CCC(CC1)=C(c1ccccc1)c1ccccc1, C[N+]1(C)CCC(CC1)=C(c1ccccc1)c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,1
"1277","diphenhydramine","histamine receptor antagonist","HRH1","neurology/psychiatry","headache","CN(C)CCOC(c1ccccc1)c1ccccc1, CN(C)CCOC(c1ccccc1)c1ccccc1, CN(C)CCOC(c1ccccc1)c1ccccc1, CN(C)CCOC(c1ccccc1)c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"1278","diphenidol","acetylcholine receptor agonist","CHRM1, CHRM2, CHRM3, CHRM4","neurology/psychiatry","vertigo","OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1, OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1, OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1, OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1, OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,1,1,1,1
"1279","diphenyleneiodonium","nitric oxide synthase inhibitor","NOS2, NOS3",NA,NA,"[I]1c2ccccc2-c2ccccc12 |^1:0|, [I]1c2ccccc2-c2ccccc12 |^1:0|, [I]1c2ccccc2-c2ccccc12 |^1:0|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1280","diphenylpyraline","dopamine reuptake inhibitor","HRH1, SLC6A3","allergy","allergic rhinitis","CN1CCC(CC1)OC(c1ccccc1)c1ccccc1, CN1CCC(CC1)OC(c1ccccc1)c1ccccc1, CN1CCC(CC1)OC(c1ccccc1)c1ccccc1, CN1CCC(CC1)OC(c1ccccc1)c1ccccc1","Launched",1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"1281","dipraglurant","glutamate receptor negative allosteric modulator","GRM5",NA,NA,"Fc1ccc2nc(CCC#Cc3ccccn3)cn2c1, Fc1ccc2nc(CCC#Cc3ccccn3)cn2c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1282","DIPT","dopamine reuptake inhibitor, serotonin reuptake inhibitor","HTR1A, HTR2A, HTR2C",NA,NA,"CC(C)N(CCc1c[nH]c2ccccc12)C(C)C","Launched",0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1283","dipyridamole","phosphodiesterase inhibitor","ADA, PDE10A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, PDE6A, PDE6B, PDE6C, PDE6D, PDE6G, PDE6H, PDE7A, PDE7B, PDE8A, PDE8B, PDE9A, SLC29A1","cardiology","coronary artery disease (CAD), peripheral artery disease (PAD), hypertension","OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1284","disopyramide","sodium channel blocker","CHRM1, CHRM2, CHRM3, KCND2, KCND3, KCNH2, SCN5A","cardiology","ventricular tachycardia (VT), ventricular arrhythmias","CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C |&1:6|, CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C |&1:6|, CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C |&1:6|, CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C |&1:6|, CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C |&1:6|","Launched",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,1,1,1,1
"1285","disulfiram","aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist","ALDH2, DBH","neurology/psychiatry","abstinence from alcohol","CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1286","ditiocarb-sodium-trihydrate","immunostimulant","CA1, CA2, CA4",NA,NA,"CCN(CC)C(S)=S, CCN(CC)C(S)=S","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1287","ditolylguanidine","sigma receptor agonist","GRIN1, GRIN2A, GRIN2B, SIGMAR1",NA,NA,"Cc1ccccc1NC(=N)Nc1ccccc1C, Cc1ccccc1NC(=N)Nc1ccccc1C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1288","dizocilpine-(+)","glutamate receptor antagonist","GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,"C[C@]12N[C@H](Cc3ccccc13)c1ccccc21, C[C@]12N[C@H](Cc3ccccc13)c1ccccc21, C[C@]12N[C@H](Cc3ccccc13)c1ccccc21, C[C@]12N[C@H](Cc3ccccc13)c1ccccc21, C[C@]12N[C@H](Cc3ccccc13)c1ccccc21, C[C@]12N[C@H](Cc3ccccc13)c1ccccc21","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1289","dl-tboa","excitatory amino acid transporter inhibitor","EAAT1, EAAT2, EAAT3",NA,NA,"N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O |&1:1,2|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1290","DMAB-anabaseine","adrenergic receptor agonist","CHRNA7",NA,NA,"CN(C)c1ccc(\C=C2/CCCN=C2c2cccnc2)cc1 |c:12|, CN(C)c1ccc(\C=C2/CCCN=C2c2cccnc2)cc1 |c:12|, CN(C)c1ccc(\C=C2/CCCN=C2c2cccnc2)cc1 |c:12|, CN(C)c1ccc(\C=C2/CCCN=C2c2cccnc2)cc1 |c:12|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
"1291","DMeOB","glutamate receptor modulator","GRM5",NA,NA,"COc1cccc(\C=N\N=C\c2cccc(OC)c2)c1, COc1cccc(\C=N\N=C\c2cccc(OC)c2)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1292","DMH1","ALK tyrosine kinase receptor inhibitor","ACVR1",NA,NA,"CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1293","DMH4","VEGFR inhibitor","KDR",NA,NA,"C(CN1CCOCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccccc1, C(CN1CCOCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccccc1, C(CN1CCOCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1294","DMP-777","elastase inhibitor","MPO",NA,NA,"CCC[C@@H](NC(=O)N1[C@@H](Oc2ccc(cc2)C(=O)N2CCN(C)CC2)C(CC)(CC)C1=O)c1ccc2OCOc2c1, CCC[C@@H](NC(=O)N1[C@@H](Oc2ccc(cc2)C(=O)N2CCN(C)CC2)C(CC)(CC)C1=O)c1ccc2OCOc2c1, CCC[C@@H](NC(=O)N1[C@@H](Oc2ccc(cc2)C(=O)N2CCN(C)CC2)C(CC)(CC)C1=O)c1ccc2OCOc2c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1295","dm4","tubulin inhibitor","CD19, MSLN, SDC1, TUBB","hematologic malignancy","multiple myeloma","CO[C@@H]1\C=C\C=C(/C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)S)[C@]3(C)O[C@H]3[C@H](C)[C@@H]4C[C@@]1(O)NC(=O)O4",NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1296","DNQX","glutamate receptor antagonist","GRIA1, GRIA2, GRIK1, GRIN1, GRIN2A, GRIN2B",NA,NA,"[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1297","dobutamine","adrenergic receptor agonist","ADRB1, ADRB2","cardiology","congestive heart failure","CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,1,1,1,1
"1298","docebenone","lipoxygenase inhibitor","ALOX5",NA,NA,"CC1=C(C)C(=O)C(CCCCC#CCCCC#CCO)=C(C)C1=O |c:1,t:19|, CC1=C(C)C(=O)C(CCCCC#CCCCC#CCO)=C(C)C1=O |c:1,t:19|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1299","docetaxel","tubulin polymerization inhibitor","BCL2, MAP2, MAP4, MAPT, NR1I2, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8","oncology","breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)","CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C |t:53|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C |t:53|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C |t:53|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C |t:53|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C |t:53|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C |t:53|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C |t:53|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C |t:53|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1300","doconexent","PPAR receptor agonist","FFAR1, PTGS1, PTGS2",NA,NA,"CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O, CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1301","docosanol","lipase clearing factor inhibitor","TLR7","dental","cold sore","CCCCCCCCCCCCCCCCCCCCCCO, CCCCCCCCCCCCCCCCCCCCCCO, CCCCCCCCCCCCCCCCCCCCCCO, CCCCCCCCCCCCCCCCCCCCCCO","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1302","dofequidar","MRP inhibitor, P glycoprotein inhibitor","ABCB1",NA,NA,"OC(COc1cccc2ncccc12)CN1CCN(CC1)C(=O)C(c1ccccc1)c1ccccc1, OC(COc1cccc2ncccc12)CN1CCN(CC1)C(=O)C(c1ccccc1)c1ccccc1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1303","dofequidar fumarate","mrp inhibitor","ABCB1, ABCC1",NA,NA,"O[C@@H](COc1cccc2ncccc12)CN1CCN(CC1)C(=O)C(c1ccccc1)c1ccccc1 |&1:1,r|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1304","dofetilide","potassium channel blocker","KCNH1, KCNH2, KCNJ12, KCNK2",NA,NA,"CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1305","dolasetron","serotonin receptor antagonist","HTR3A","gastroenterology","nausea, vomiting","O=C(O[C@H]1C[C@H]2C[C@H]3C[C@@H](C1)N2CC3=O)c1c[nH]c2ccccc12, O=C(O[C@H]1C[C@H]2C[C@H]3C[C@@H](C1)N2CC3=O)c1c[nH]c2ccccc12, O=C(O[C@H]1C[C@H]2C[C@H]3C[C@@H](C1)N2CC3=O)c1c[nH]c2ccccc12","Launched",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1306","dolastatin-10","tubulin polymerization inhibitor","TUBB",NA,NA,"CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C, CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C, CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C, CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C, CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C, CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C, CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1307","dolutegravir","HIV integrase inhibitor","CYP3A4, CYP3A5, CYP3A7, POU2F2, UGT1A1","infectious disease","human immunodeficiency virus (HIV-1)","C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1308","domperidone","dopamine receptor antagonist","DRD2, DRD3","infectious disease","fescue toxicosis","Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1, Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1, Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1, Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1, Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,1,1,1,1
"1309","donepezil","acetylcholinesterase inhibitor","ACHE","neurology/psychiatry","Alzheimer's disease","COc1cc2C[C@@H](CC3CCN(Cc4ccccc4)CC3)C(=O)c2cc1OC |r|, COc1cc2C[C@@H](CC3CCN(Cc4ccccc4)CC3)C(=O)c2cc1OC |r|, COc1cc2C[C@@H](CC3CCN(Cc4ccccc4)CC3)C(=O)c2cc1OC |r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1310","donitriptan","serotonin receptor agonist","HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR5A, HTR6",NA,NA,"NCCc1c[nH]c2ccc(OCC(=O)N3CCN(CC3)c3ccc(cc3)C#N)cc12, NCCc1c[nH]c2ccc(OCC(=O)N3CCN(CC3)c3ccc(cc3)C#N)cc12, NCCc1c[nH]c2ccc(OCC(=O)N3CCN(CC3)c3ccc(cc3)C#N)cc12, NCCc1c[nH]c2ccc(OCC(=O)N3CCN(CC3)c3ccc(cc3)C#N)cc12","Phase 2",0,0,0,0,0,0,0,0,1,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1311","dopamine","dopamine receptor agonist","DBH, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR7, SLC6A2, SLC6A3, SLC6A4","cardiology, neurology/psychiatry","ventricular arrhythmias, depression, headache, tremors","NCCc1ccc(O)c(O)c1, NCCc1ccc(O)c(O)c1, NCCc1ccc(O)c(O)c1, NCCc1ccc(O)c(O)c1","Launched",1,3,0,0,0,0,0,0,1,2,0,0,0,0,1,5,0,0,0,0,1,1,1,1
"1312","doramapimod","p38 MAPK inhibitor","MAPK11, MAPK12, MAPK13, MAPK14",NA,NA,"Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1313","doripenem","bacterial cell wall synthesis inhibitor","DPEP1","infectious disease","intra-abdominal infections, urinary tract infections, pyelonephritis","C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O |c:20|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O |c:20|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O |c:20|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O |c:20|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O |c:20|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O |c:20|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1314","dorsomorphin","AMPK inhibitor","ACVR1, BMPR1A, BMPR1B, EPHA2, FKBP1A, FLT1, FLT3, KDR, LCK, MKNK1, PRKAA1, RPS6KA1, SRC",NA,NA,"C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1, C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1, C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1, C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1, C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1, C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1, C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1315","dorzagliatin","glucokinase activator","GCK","endocrinology","diabetes mellitus","CC(C)C[C@H](N1CC(=CC1=O)Oc2ccccc2Cl)C(=O)Nc3ccn(C[C@@H](O)CO)n3","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1316","dorzolamide","carbonic anhydrase inhibitor","CA1, CA12, CA14, CA2, CA4, CA7","ophthalmology","intraocular pressure, glaucoma","CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(cc12)S(N)(=O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1317","dosulepin","norepinephrine reuptake inhibitor, serotonin‚Äìnorepinephrine reuptake inhibitor (SNRI), tricyclic antidepressant","CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, SLC6A2, SLC6A4","neurology/psychiatry","depression","CN(C)CC\C=C1/c2ccccc2CSc2ccccc12, CN(C)CC\C=C1/c2ccccc2CSc2ccccc12, CN(C)CC\C=C1/c2ccccc2CSc2ccccc12","Launched",1,2,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,5,0,0,1,1,1,1
"1318","dotinurad","urate transporter inhibitor","SLC22A12","nephrology","hyperuricemia","C1N(C2=CC=CC=C2S1(=O)=O)C(=O)C3=CC(=C(C(=C3)Cl)O)Cl","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1319","dovitinib","EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB",NA,NA,"CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1320","doxazosin","adrenergic receptor antagonist","ADRA1A, ADRA1B, ADRA1D","urology, cardiology","benign prostatic hyperplasia (BPH), hypertension","COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)[C@H]1COc2ccccc2O1 |&1:23,r|, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)[C@H]1COc2ccccc2O1 |&1:23,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,1,1,1,1
"1321","doxepin","histamine receptor antagonist","HRH1, SLC6A2, SLC6A4","neurology/psychiatry","depression, anxiety","CN(C)CC\C=C1\c2ccccc2COc2ccccc12, CN(C)CC\C=C1\c2ccccc2COc2ccccc12, CN(C)CC\C=C1\c2ccccc2COc2ccccc12","Launched",1,2,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"1322","doxercalciferol","vitamin D receptor agonist","VDR","nephrology, endocrinology","chronic kidney disease (CKD), hyperparathyroidism","CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1/C[C@@H](O)C[C@H](O)C1=C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1323","doxifluridine","thymidylate synthase inhibitor","TYMS","oncology","colorectal cancer","C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1324","doxofylline","adenosine receptor antagonist","ADORA1, PDE4A, PDE4B, PDE4C, PDE4D","pulmonary","asthma","Cn1c2ncn(CC3OCCO3)c2c(=O)n(C)c1=O, Cn1c2ncn(CC3OCCO3)c2c(=O)n(C)c1=O, Cn1c2ncn(CC3OCCO3)c2c(=O)n(C)c1=O, Cn1c2ncn(CC3OCCO3)c2c(=O)n(C)c1=O, Cn1c2ncn(CC3OCCO3)c2c(=O)n(C)c1=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1325","doxorubicin","topoisomerase inhibitor, dna polymerase inhibitor","TOP2A","hematologic malignancy, oncology","acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Wilm's tumor, breast cancer, ovarian cancer, Hodgkin's lymphoma, bladder cancer, multiple myeloma","COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1326","doxycycline","bacterial 30S ribosomal subunit inhibitor, metalloproteinase inhibitor","MMP8","dental","periodontitis","C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)c2c(O)cccc12 |a:1,2,3,5,6,18,&1:12,&2:22,c:22,t:11|, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)c2c(O)cccc12 |a:1,2,3,5,6,18,&1:12,&2:22,c:22,t:11|, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)c2c(O)cccc12 |a:1,2,3,5,6,18,&1:12,&2:22,c:22,t:11|, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)c2c(O)cccc12 |a:1,2,3,5,6,18,&1:12,&2:22,c:22,t:11|, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)c2c(O)cccc12 |a:1,2,3,5,6,18,&1:12,&2:22,c:22,t:11|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1327","doxylamine","histamine receptor antagonist","HRH1","neurology/psychiatry","sedative","CN(C)CCOC(C)(c1ccccc1)c1ccccn1, CN(C)CCOC(C)(c1ccccc1)c1ccccn1","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"1328","doxylamine succinate","histamine receptor antagonist","HRH1","Allergies","allergic conjunctivitis","CN(C)CCO[C@@](C)(c1ccccc1)c1ccccn1 |&1:6,r|","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"1329","DPCPX","adenosine receptor antagonist","ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,"CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C1CCCC1, CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C1CCCC1, CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C1CCCC1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1330","DPI-201106","sodium channel activator","ADRB2",NA,NA,"O[C@@H](COc1cccc2[nH]c(cc12)C#N)CN1CCN(CC1)C(c1ccccc1)c1ccccc1 |&1:1,r|, O[C@@H](COc1cccc2[nH]c(cc12)C#N)CN1CCN(CC1)C(c1ccccc1)c1ccccc1 |&1:1,r|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
"1331","DPO-1","potassium channel blocker","KCNA5",NA,NA,"CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1P(=O)(c1ccccc1)c1ccccc1, CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1P(=O)(c1ccccc1)c1ccccc1, CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1P(=O)(c1ccccc1)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1332","DPPE","histamine receptor antagonist","ABCB1, HRH1",NA,NA,"CCN(CC)CCOc1ccc(Cc2ccccc2)cc1, CCN(CC)CCOc1ccc(Cc2ccccc2)cc1, CCN(CC)CCOc1ccc(Cc2ccccc2)cc1","Phase 3",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
"1333","DQP-1105","glutamate receptor antagonist","GRIN2C, GRIN2D",NA,NA,"Cc1ccc2[nH]c(=O)c(C3=NN([C@@H](C3)c3ccc(Br)cc3)C(=O)CCC(O)=O)c(-c3ccccc3)c2c1 |&1:12,r,t:9|, Cc1ccc2[nH]c(=O)c(C3=NN([C@@H](C3)c3ccc(Br)cc3)C(=O)CCC(O)=O)c(-c3ccccc3)c2c1 |&1:12,r,t:9|, Cc1ccc2[nH]c(=O)c(C3=NN([C@@H](C3)c3ccc(Br)cc3)C(=O)CCC(O)=O)c(-c3ccccc3)c2c1 |&1:12,r,t:9|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1334","DR-2313","PARP inhibitor","PARP1, PARP3",NA,NA,"Cc1nc(=O)c2CSCCc2[nH]1, Cc1nc(=O)c2CSCCc2[nH]1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1335","DR-4485","serotonin receptor antagonist","HTR7",NA,NA,"Clc1ccc(cc1)C1=CCN(CCCC[C@@]23CCCc4c2c(NC3=O)ccc4Cl)CC1 |&1:15,t:8|, Clc1ccc(cc1)C1=CCN(CCCC[C@@]23CCCc4c2c(NC3=O)ccc4Cl)CC1 |&1:15,t:8|, Clc1ccc(cc1)C1=CCN(CCCC[C@@]23CCCc4c2c(NC3=O)ccc4Cl)CC1 |&1:15,t:8|","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1336","DRF053-(R)","CDK inhibitor","CSNK1A1",NA,NA,"CC[C@H](CO)Nc1nc(Nc2cccc(c2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(Nc2cccc(c2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(Nc2cccc(c2)-c2ccccn2)c2ncn(C(C)C)c2n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1337","droloxifene","selective estrogen receptor modulator (SERM)","ESR1",NA,NA,"CC\C(=C(\c1ccc(OCCN(C)C)cc1)c1cccc(O)c1)c1ccccc1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1338","dromostanolone-propionate","androgen receptor modulator","AR","oncology","breast cancer","CCC(=O)O[C@H]1CC[C@H]2[C@H]3CC[C@H]4CC(=O)[C@@H](C)C[C@@]4(C)[C@@H]3CC[C@@]12C |&1:5,&2:8,&3:9,&4:12,&5:16,&6:19,&7:21,&8:24,r|, CCC(=O)O[C@H]1CC[C@H]2[C@H]3CC[C@H]4CC(=O)[C@@H](C)C[C@@]4(C)[C@@H]3CC[C@@]12C |&1:5,&2:8,&3:9,&4:12,&5:16,&6:19,&7:21,&8:24,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1339","dronedarone","adrenergic receptor antagonist","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, KCNA5, KCNH2, KCNK2, SCN1A","cardiology","atrial fibrillation (AF)","CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12, CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12, CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12, CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12, CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12","Launched",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,7,1,1,1,1
"1340","droperidol","dopamine receptor antagonist","ADRA1A, DRD2, DRD3, DRD4, HTR2A","gastroenterology","nausea, vomiting","Fc1ccc(cc1)C(=O)CCCN1CCC(=CC1)n1c2ccccc2[nH]c1=O |c:16|, Fc1ccc(cc1)C(=O)CCCN1CCC(=CC1)n1c2ccccc2[nH]c1=O |c:16|, Fc1ccc(cc1)C(=O)CCCN1CCC(=CC1)n1c2ccccc2[nH]c1=O |c:16|","Launched",0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,3,0,0,1,1,1,1,1,1
"1341","drospirenone","mineralocorticoid receptor antagonist","AR, NR3C2, PGR","endocrinology","contraceptive","C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1 |t:10|, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1 |t:10|, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1 |t:10|, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1 |t:10|, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1 |t:10|, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1 |t:10|, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1 |t:10|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1342","droxicam","cyclooxygenase inhibitor","PTGS1","rheumatology","rheumatoid arthritis, osteoarthritis","CN1c2c(oc(=O)n(-c3ccccn3)c2=O)-c2ccccc2S1(=O)=O, CN1c2c(oc(=O)n(-c3ccccn3)c2=O)-c2ccccc2S1(=O)=O","Launched",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1343","droxidopa","norepinephrine precursor","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH","cardiology, neurology/psychiatry","hypertension, Parkinson's Disease","N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(O)=O, N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(O)=O, N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(O)=O, N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(O)=O, N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,9,1,1,1,1
"1344","droxinostat","HDAC inhibitor","HDAC6, HDAC8",NA,NA,"Cc1cc(Cl)ccc1OCCCC(=O)NO, Cc1cc(Cl)ccc1OCCCC(=O)NO, Cc1cc(Cl)ccc1OCCCC(=O)NO, Cc1cc(Cl)ccc1OCCCC(=O)NO","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1345","ds-1971a","voltage-gated sodium channel blocker","SCN9A","neurology/psychiatry","peripheral neuropathy","O=S(C1=CC(Cl)=C(O[C@@H]2[C@@H](C3=CC=NN3C)CCCC2)C=C1F)(NC4=NC=NC=C4)=O","Phase 2",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1346","DSR-6434","toll-like receptor agonist","TLR7",NA,NA,"CCCCNc1nc(N)c2[nH]c(=O)n(Cc3ccc(OCCN(C)C)nc3)c2n1, CCCCNc1nc(N)c2[nH]c(=O)n(Cc3ccc(OCCN(C)C)nc3)c2n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1347","dtp3","dual specificity protein kinase inhibitor","MAP2K7","hematologic malignancy","multiple myeloma","CC(=O)N[C@H](Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](Cc2ccccc2)C(=O)N",NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1348","DU-728","structural glycoprotein antagonist","ITGA2B, ITGB3",NA,NA,"N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O, N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1349","duloxetine","norepinephrine reuptake inhibitor, serotonin‚Äìnorepinephrine reuptake inhibitor (SNRI)","HTR2A, HTR2C, HTR6, SLC6A2, SLC6A3, SLC6A4","neurology/psychiatry","depression, generalized anxiety disorder (GAD), muscle pain, peripheral neuropathy","CNCC[C@H](Oc1cccc2ccccc12)c1cccs1, CNCC[C@H](Oc1cccc2ccccc12)c1cccs1, CNCC[C@H](Oc1cccc2ccccc12)c1cccs1, CNCC[C@H](Oc1cccc2ccccc12)c1cccs1, CNCC[C@H](Oc1cccc2ccccc12)c1cccs1, CNCC[C@H](Oc1cccc2ccccc12)c1cccs1, CNCC[C@H](Oc1cccc2ccccc12)c1cccs1","Launched",1,3,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1350","DUP-697","cyclooxygenase inhibitor","PTGS2",NA,NA,"CS(=O)(=O)c1ccc(cc1)-c1cc(Br)sc1-c1ccc(F)cc1, CS(=O)(=O)c1ccc(cc1)-c1cc(Br)sc1-c1ccc(F)cc1, CS(=O)(=O)c1ccc(cc1)-c1cc(Br)sc1-c1ccc(F)cc1","Phase 1",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1351","dusquetide (tfa)","immunostimulant","SQSTM1","dental","mucositis","C[C@@H](C(N)=O)NC([C@H]1N(C([C@H](C(C)C)NC([C@H]([C@@H](C)CC)NC([C@H](CCCNC(N)=N)N)=O)=O)=O)CCC1)=O.OC(C(F)(F)F)=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1352","dutasteride","5 alpha reductase inhibitor","SRD5A1, SRD5A2, SRD5A3","urology","benign prostatic hyperplasia (BPH)","C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)Nc1cc(ccc1C(F)(F)F)C(F)(F)F |c:12|, C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)Nc1cc(ccc1C(F)(F)F)C(F)(F)F |c:12|, C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)Nc1cc(ccc1C(F)(F)F)C(F)(F)F |c:12|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1353","duvelisib","PI3K inhibitor","PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,"C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1, C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1, C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1, C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1354","dxd","topoisomerase inhibitor","TOP1","oncology","breast cancer","CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](NC(=O)CO)c(c3Cn1c2=O)c45",NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1355","dyclonine","sodium channel blocker","SCN10A, SCN5A","neurology/psychiatry","local anesthetic","CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1","Launched",0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1356","dydrogesterone","progesterone receptor agonist","PGR","obstetrics/gynecology","infertility","CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C |c:8,t:10|, CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C |c:8,t:10|, CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C |c:8,t:10|, CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C |c:8,t:10|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1357","dynasore","dynamin inhibitor","DNM1, DNM1L, DNM2",NA,NA,"Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O, Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O, Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O, Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O, Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O, Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1358","dynole-34-2","dynamin inhibitor","DNM1",NA,NA,"CCCCCCCCNC(=O)C(=C\c1cn(CCCN(C)C)c2ccccc12)\C#N, CCCCCCCCNC(=O)C(=C\c1cn(CCCN(C)C)c2ccccc12)\C#N","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1359","dyphylline","adenosine receptor antagonist, phosphodiesterase inhibitor","PDE4A","pulmonary","asthma, bronchitis, emphysema","Cn1c2ncn(C[C@@H](O)CO)c2c(=O)n(C)c1=O |&1:7,r|, Cn1c2ncn(C[C@@H](O)CO)c2c(=O)n(C)c1=O |&1:7,r|, Cn1c2ncn(C[C@@H](O)CO)c2c(=O)n(C)c1=O |&1:7,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1360","DY131","estrogen-related receptor agonist","ESRRB, ESRRG",NA,NA,"CCN(CC)c1ccc(\C=N\NC(=O)c2ccc(O)cc2)cc1, CCN(CC)c1ccc(\C=N\NC(=O)c2ccc(O)cc2)cc1, CCN(CC)c1ccc(\C=N\NC(=O)c2ccc(O)cc2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1361","E-2012","gamma secretase modulator","APH1A, APH1B, PSENEN",NA,NA,"COc1cc(\C=C2/CCCN([C@@H](C)c3ccc(F)cc3)C2=O)ccc1-n1cnc(C)c1, COc1cc(\C=C2/CCCN([C@@H](C)c3ccc(F)cc3)C2=O)ccc1-n1cnc(C)c1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1362","E-4031","potassium channel blocker","KCNH1, KCNH2",NA,NA,"Cc1cccc(CCN2CCC(CC2)C(=O)c2ccc(NS(C)(=O)=O)cc2)n1, Cc1cccc(CCN2CCC(CC2)C(=O)c2ccc(NS(C)(=O)=O)cc2)n1, Cc1cccc(CCN2CCC(CC2)C(=O)c2ccc(NS(C)(=O)=O)cc2)n1, Cc1cccc(CCN2CCC(CC2)C(=O)c2ccc(NS(C)(=O)=O)cc2)n1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1363","E-64","calpain inhibitor, cysteine protease inhibitor","CTSS",NA,NA,"CC(C)C[C@H](NC(=O)[C@H]1O[C@@H]1C(O)=O)C(=O)NCCCCNC(N)=N, CC(C)C[C@H](NC(=O)[C@H]1O[C@@H]1C(O)=O)C(=O)NCCCCNC(N)=N","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1364","eact","calcium-activated chloride channel inhibitor","ANO1",NA,NA,"COCCN(C(=O)c1cc(OC)c(OC)c(OC)c1)c1nc(cs1)-c1ccccc1, COCCN(C(=O)c1cc(OC)c(OC)c(OC)c1)c1nc(cs1)-c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1365","EB-47","PARP inhibitor","PARP1",NA,NA,"Nc1ncnc2n(cnc12)[C@H]1O[C@H]([C@H](O)[C@@H]1O)C(=O)N1CCN(CC(=O)Nc2cccc3C(=O)NCc23)CC1, Nc1ncnc2n(cnc12)[C@H]1O[C@H]([C@H](O)[C@@H]1O)C(=O)N1CCN(CC(=O)Nc2cccc3C(=O)NCc23)CC1, Nc1ncnc2n(cnc12)[C@H]1O[C@H]([C@H](O)[C@@H]1O)C(=O)N1CCN(CC(=O)Nc2cccc3C(=O)NCc23)CC1, Nc1ncnc2n(cnc12)[C@H]1O[C@H]([C@H](O)[C@@H]1O)C(=O)N1CCN(CC(=O)Nc2cccc3C(=O)NCc23)CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1366","ebastine","histamine receptor antagonist","CYP3A4, HRH1","allergy","allergic rhinitis, urticaria","CC(C)(C)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1, CC(C)(C)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1, CC(C)(C)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1, CC(C)(C)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"1367","EBPC","aldose reductase inhibitor","AKR1B1",NA,NA,"CCOC(=O)[C@@H]1CN(Cc2ccccc2)C(=O)C1=O |&1:5,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1368","ebrotidine","histamine receptor antagonist","HRH2",NA,NA,"NC(=N)Nc1nc(CSCCN\C=N\S(=O)(=O)c2ccc(Br)cc2)cs1, NC(=N)Nc1nc(CSCCN\C=N\S(=O)(=O)c2ccc(Br)cc2)cs1, NC(=N)Nc1nc(CSCCN\C=N\S(=O)(=O)c2ccc(Br)cc2)cs1, NC(=N)Nc1nc(CSCCN\C=N\S(=O)(=O)c2ccc(Br)cc2)cs1, NC(=N)Nc1nc(CSCCN\C=N\S(=O)(=O)c2ccc(Br)cc2)cs1","Withdrawn",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
"1369","ebselen","cyclooxygenase inhibitor, glutathione peroxidase agonist, H+/K+-ATPase inhibitor, nitric oxide synthase inhibitor","ALB",NA,NA,"O=c1n([se]c2ccccc12)-c1ccccc1, O=c1n([se]c2ccccc12)-c1ccccc1, O=c1n([se]c2ccccc12)-c1ccccc1, O=c1n([se]c2ccccc12)-c1ccccc1","Phase 2/Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1370","EC-144","HSP inhibitor","HSP90AA1, HSP90AB1",NA,NA,"COc1c(C)cnc(Cn2cc(C#CCC(C)(C)O)c3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cc(C#CCC(C)(C)O)c3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cc(C#CCC(C)(C)O)c3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cc(C#CCC(C)(C)O)c3c(Cl)nc(N)nc23)c1C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1371","EC-23","retinoid receptor agonist","RARA, RARB, RARG",NA,NA,"CC1(C)CCC(C)(C)c2cc(ccc12)C#Cc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C#Cc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C#Cc1ccc(cc1)C(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1372","ecabet","gastrin inhibitor, urease inhibitor","NOXO1","ophthalmology","dry eye syndrome","CC(C)c1cc2CC[C@H]3[C@@](C)(CCC[C@]3(C)c2cc1S(O)(=O)=O)C(O)=O, CC(C)c1cc2CC[C@H]3[C@@](C)(CCC[C@]3(C)c2cc1S(O)(=O)=O)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1373","econazole","lanosterol demethylase inhibitor, sterol demethylase inhibitor","NPY1R, NPY2R, TRPM2, TRPV5","infectious disease","tinea pedis, tinea cruris, tinea corporis, tinea versicolor, cutaneous candidiasis","Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1374","ecothiopate","acetylcholinesterase inhibitor","BCHE","ophthalmology","glaucoma","[I-].O=P(OCC)(OCC)SCC[N+](C)(C)C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1375","ec5026","epoxide hydolase inhibitor","EPHX2","neurology/psychiatry","pain relief","CC[C@H](C)C(=O)N1CCC(CC1)NC(=O)Nc1ccc(OC(F)(F)F)c(F)c1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1376","edaglitazone","PPAR receptor agonist","PPARG",NA,NA,"Cc1oc(nc1CCOc1ccc(C[C@@H]2SC(=O)NC2=O)c2sccc12)-c1ccccc1 |&1:14,r|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1377","edaravone","nootropic agent","BCL2","neurology/psychiatry","stroke","Cc1cc(=O)n([nH]1)-c1ccccc1, Cc1cc(=O)n([nH]1)-c1ccccc1, Cc1cc(=O)n([nH]1)-c1ccccc1, Cc1cc(=O)n([nH]1)-c1ccccc1, Cc1cc(=O)n([nH]1)-c1ccccc1, Cc1cc(=O)n([nH]1)-c1ccccc1, Cc1cc(=O)n([nH]1)-c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1378","edoxaban","coagulation factor inhibitor","F10","neurology/psychiatry, hematology, cardiology","stroke, pulmonary embolism (PE), systemic embolism, deep vein thrombosis (DVT), atrial fibrillation (AF)","CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)Nc2ccc(Cl)cn2)[C@@H](C1)NC(=O)c1nc2CCN(C)Cc2s1, CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)Nc2ccc(Cl)cn2)[C@@H](C1)NC(=O)c1nc2CCN(C)Cc2s1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1379","edrophonium","acetylcholinesterase inhibitor","ACHE, BCHE","neurology/psychiatry","myasthenia gravis","CC[N+](C)(C)c1cccc(O)c1, CC[N+](C)(C)c1cccc(O)c1, CC[N+](C)(C)c1cccc(O)c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1380","EED226","polycomb protein inhibitor","EED",NA,NA,"CS(=O)(=O)c1ccc(cc1)-c1cnc(NCc2ccco2)n2cnnc12, CS(=O)(=O)c1ccc(cc1)-c1cnc(NCc2ccco2)n2cnnc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1381","efaproxiral","hemoglobin oxygen release stimulant","HBA1, HBB",NA,NA,"Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(O)=O)cc2)c1, Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(O)=O)cc2)c1, Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(O)=O)cc2)c1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1382","efaroxan","adrenergic receptor antagonist","ADORA2A",NA,NA,"CCC1(Cc2ccccc2O1)C1=NCCN1, CCC1(Cc2ccccc2O1)C1=NCCN1, CCC1(Cc2ccccc2O1)C1=NCCN1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1383","efatutazone","PPAR receptor agonist","PPARG",NA,NA,"Cc1cc(Oc2ccc3nc(COc4ccc(C[C@H]5SC(=O)NC5=O)cc4)n(C)c3c2)cc(C)c1N |r|, Cc1cc(Oc2ccc3nc(COc4ccc(C[C@H]5SC(=O)NC5=O)cc4)n(C)c3c2)cc(C)c1N |r|, Cc1cc(Oc2ccc3nc(COc4ccc(C[C@H]5SC(=O)NC5=O)cc4)n(C)c3c2)cc(C)c1N |r|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1384","efavirenz","HIV protease inhibitor","CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4","infectious disease","human immunodeficiency virus (HIV-1)","FC(F)(F)[C@]1(OC(=O)Nc2ccc(Cl)cc12)C#CC1CC1, FC(F)(F)[C@]1(OC(=O)Nc2ccc(Cl)cc12)C#CC1CC1, FC(F)(F)[C@]1(OC(=O)Nc2ccc(Cl)cc12)C#CC1CC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1385","efinaconazole","lanosterol demethylase inhibitor, fungal lanosterol demethylase inhibitor","CYP51A1","infectious disease, Infectious disease","onychomycosis, fungal infection","C[C@@H](N1CCC(=C)CC1)[C@@](O)(Cn1cncn1)c1ccc(F)cc1F |a:1,&1:9|, C[C@@H](N1CCC(=C)CC1)[C@](O)(Cn1cncn1)c1ccc(F)cc1F","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1386","eflornithine","ornithine decarboxylase inhibitor","ARG2, ODC1","dermatology","facial hair reduction","NCCCC(N)(C(F)F)C(O)=O |&1:4|, NCCCC(N)(C(F)F)C(O)=O |&1:4|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1387","EGF816","EGFR inhibitor","EGFR",NA,NA,"CN(C)C\C=C\C(=O)N1CCCC[C@H](C1)n1c(NC(=O)c2ccnc(C)c2)nc2cccc(Cl)c12, CN(C)C\C=C\C(=O)N1CCCC[C@H](C1)n1c(NC(=O)c2ccnc(C)c2)nc2cccc(Cl)c12, CN(C)C\C=C\C(=O)N1CCCC[C@H](C1)n1c(NC(=O)c2ccnc(C)c2)nc2cccc(Cl)c12","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1388","eglumetad","glutamate receptor agonist","GRM2, GRM3, GRM6, GRM8",NA,NA,"N[C@]1(CC[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CC[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CC[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1389","EG00229","neuropilin receptor antagonist","NRP1",NA,NA,"NC(=N)NCCC[C@H](NC(=O)c1sccc1NS(=O)(=O)c1cccc2nsnc12)C(O)=O, NC(=N)NCCC[C@H](NC(=O)c1sccc1NS(=O)(=O)c1cccc2nsnc12)C(O)=O, NC(=N)NCCC[C@H](NC(=O)c1sccc1NS(=O)(=O)c1cccc2nsnc12)C(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1390","EHop-016","Ras GTPase inhibitor","RAC1, RAC3",NA,NA,"CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12, CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12, CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12, CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12, CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12, CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12, CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12, CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1391","EIPA","sodium/hydrogen exchanger inhibitor, transient receptor potential polycystic inhibitor","ADRA2A, ASIC1, PKD2L1",NA,NA,"CCN(C(C)C)c1nc(N)c(nc1Cl)C(=O)N=C(N)N, CCN(C(C)C)c1nc(N)c(nc1Cl)C(=O)N=C(N)N","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
"1392","EIT-hydrobromide","nitric oxide synthase inhibitor","NOS2, NOS3",NA,NA,"CCSC(N)=N, CCSC(N)=N","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1393","EI1","histone lysine methyltransferase inhibitor","EZH2",NA,NA,"CCC(CC)n1ccc2c(cc(cc12)C#N)C(=O)NCc1c(C)cc(C)[nH]c1=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1394","elacridar","P glycoprotein inhibitor","ABCB1",NA,NA,"COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1395","elacytarabine","antineoplastic agent","DCK",NA,NA,"CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@H]([C@@H](O)[C@@H]1O)n1ccc(N)nc1=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1396","elafibranor","PPAR receptor agonist","PPARA, PPARD, PPARG",NA,NA,"CSc1ccc(cc1)C(=O)\C=C\c1cc(C)c(OC(C)(C)C(O)=O)c(C)c1, CSc1ccc(cc1)C(=O)\C=C\c1cc(C)c(OC(C)(C)C(O)=O)c(C)c1, CSc1ccc(cc1)C(=O)\C=C\c1cc(C)c(OC(C)(C)C(O)=O)c(C)c1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1397","elagolix","gonadotropin releasing factor hormone receptor antagonist","GNRHR",NA,NA,"COc1cccc(c1F)-c1c(C)n(Cc2c(F)cccc2C(F)(F)F)c(=O)n(C[C@H](NCCCC(O)=O)c2ccccc2)c1=O, COc1cccc(c1F)-c1c(C)n(Cc2c(F)cccc2C(F)(F)F)c(=O)n(C[C@H](NCCCC(O)=O)c2ccccc2)c1=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1398","eldecalcitol","bone formation stimulant","VDR",NA,NA,"[H][C@@]12CC[C@H]([C@H](C)CCCC(C)(C)O)[C@@]1(C)CCC\C2=C/C=C1/C[C@@H](O)[C@@H](OCCCO)[C@H](O)C1=C","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1399","elenbecestat","beta secretase inhibitor","BACE1","neurology/psychiatry","alzheimer's disease","FC1=CC=C(NC(C2=NC=C(C(F)F)N=C2)=O)C=C1[C@@]3(N=C(N)SC4)[C@@]4([H])[C@@H](C)OC3","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1400","elesclomol","oxidative stress inducer","HSPA1A",NA,NA,"CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1, CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1, CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1, CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1401","eletriptan","serotonin receptor agonist","HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR7","neurology/psychiatry","migraine headache","CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12, CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12, CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12, CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12, CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12, CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12","Launched",0,0,0,0,0,0,0,0,1,7,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1402","elexacaftor","cystic fibrosis transmembrane conductance regulator inhibitor","CFTR","pulmonary","cystic fibrosis","CC1(C)C[C@H](C)CN1C2=C(C(NS(C3=CN(C)N=C3C)(=O)=O)=O)C=CC(N4C=CC(OCC(C)(C(F)(F)F)C)=N4)=N2","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1403","eliglustat","glycosyl transferase inhibitor","UGCG","hematology","Gaucher disease","CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1, CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1, CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1, CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1, CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1, CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1404","elinogrel","purinergic receptor antagonist","P2RY12",NA,NA,"CNc1cc2[nH]c(=O)n(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(Cl)s4)cc3)c(=O)c2cc1F, CNc1cc2[nH]c(=O)n(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(Cl)s4)cc3)c(=O)c2cc1F","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1405","eliprodil","glutamate receptor antagonist","GRIN1, GRIN2B",NA,NA,"O[C@@H](CN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(Cl)cc1 |&1:1,r|, O[C@@H](CN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(Cl)cc1 |&1:1,r|, O[C@@H](CN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(Cl)cc1 |&1:1,r|, O[C@@H](CN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(Cl)cc1 |&1:1,r|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1406","ellagic-acid","glutathione transferase inhibitor, non-nucleoside reverse transcriptase inhibitor","CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CSNK2A1, GSK3B, PRKACA, PRKCA, PRKCB, SQLE, SYK",NA,NA,"Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O, Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O, Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O, Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O, Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1407","ELN-441958","bradykinin receptor antagonist","BDKRB1",NA,NA,"Clc1cccc2CN(C(=O)c12)c1cccc(c1)C(=O)N1CCC2(CC1)CCN(CC2)c1ccncc1, Clc1cccc2CN(C(=O)c12)c1cccc(c1)C(=O)N1CCC2(CC1)CCN(CC2)c1ccncc1, Clc1cccc2CN(C(=O)c12)c1cccc(c1)C(=O)N1CCC2(CC1)CCN(CC2)c1ccncc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1408","eltanolone","GABA receptor positive allosteric modulator","GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB2, GABRG2",NA,NA,"CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,1,8,0,0,0,0,0,0,0,0,0,0
"1409","eltoprazine","serotonin receptor agonist","HTR1A, HTR1B",NA,NA,"C1CN(CCN1)c1cccc2OCCOc12, C1CN(CCN1)c1cccc2OCCOc12, C1CN(CCN1)c1cccc2OCCOc12, C1CN(CCN1)c1cccc2OCCOc12","Phase 2",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1410","eltrombopag","thrombopoietin receptor agonist","MPL","hematology, infectious disease, hematology, infectious disease","anemia, hepatitis C, thrombocytopenia, anemia, hepatitis c, thrombocytopenia","CC1=NN(C(=O)\C1=N/Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1 |t:1|, CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1411","elubrixin","cc chemokine receptor antagonist","CXCR2","pulmonary","cystic fibrosis","Oc1c(NC(=O)Nc2cccc(F)c2Cl)ccc(Cl)c1S(=O)(=O)N1CCNCC1.Cc1ccc(cc1)S(=O)(=O)O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1412","eluxadoline","opioid receptor agonist, opioid receptor antagonist","OPRD1, OPRK1, OPRM1","gastroenterology","irritable bowel syndrome","COc1ccc(CN([C@@H](C)c2nc(c[nH]2)-c2ccccc2)C(=O)[C@@H](N)Cc2c(C)cc(cc2C)C(N)=O)cc1C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1413","embelin","HCV inhibitor, XIAP inhibitor","XIAP",NA,NA,"CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|, CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|, CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|, CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|, CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|, CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|, CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|, CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1414","EMD-1214063","hepatocyte growth factor receptor inhibitor","MET",NA,NA,"CN1CCC(COc2cnc(nc2)-c2cccc(Cn3nc(ccc3=O)-c3cccc(c3)C#N)c2)CC1, CN1CCC(COc2cnc(nc2)-c2cccc(Cn3nc(ccc3=O)-c3cccc(c3)C#N)c2)CC1, CN1CCC(COc2cnc(nc2)-c2cccc(Cn3nc(ccc3=O)-c3cccc(c3)C#N)c2)CC1, CN1CCC(COc2cnc(nc2)-c2cccc(Cn3nc(ccc3=O)-c3cccc(c3)C#N)c2)CC1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1415","EMD-386088","serotonin receptor agonist","HTR6",NA,NA,"Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1 |t:13|, Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1 |t:13|, Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1 |t:13|, Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1 |t:13|","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1416","EMD-53998","phosphodiesterase inhibitor","TNNC1",NA,NA,"COc1ccc(cc1OC)C(=O)N1CCCc2cc(ccc12)C1=NNC(=O)S[C@@H]1C |r,t:25|, COc1ccc(cc1OC)C(=O)N1CCCc2cc(ccc12)C1=NNC(=O)S[C@@H]1C |r,t:25|, COc1ccc(cc1OC)C(=O)N1CCCc2cc(ccc12)C1=NNC(=O)S[C@@H]1C |r,t:25|, COc1ccc(cc1OC)C(=O)N1CCCc2cc(ccc12)C1=NNC(=O)S[C@@H]1C |r,t:25|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1417","EMD-66684","angiotensin receptor antagonist","AGTR1",NA,NA,"CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1418","emedastine","histamine receptor antagonist","HRH1","ophthalmology","conjunctivitis","CCOCCn1c(nc2ccccc12)N1CCCN(C)CC1, CCOCCn1c(nc2ccccc12)N1CCCN(C)CC1, CCOCCn1c(nc2ccccc12)N1CCCN(C)CC1","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"1419","emetine","protein synthesis inhibitor","RPS2",NA,NA,"CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1420","emodin","11-beta hydroxysteroid dehydrogenase inhibitor","CSNK2A1",NA,NA,"Cc1cc(O)c2C(=O)c3c(O)cc(O)cc3C(=O)c2c1, Cc1cc(O)c2C(=O)c3c(O)cc(O)cc3C(=O)c2c1, Cc1cc(O)c2C(=O)c3c(O)cc(O)cc3C(=O)c2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1421","empagliflozin","sodium/glucose cotransporter inhibitor","SLC5A1, SLC5A2","endocrinology","diabetes mellitus","OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(Cl)c(Cc2ccc(O[C@H]3CCOC3)cc2)c1, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(Cl)c(Cc2ccc(O[C@H]3CCOC3)cc2)c1, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(Cl)c(Cc2ccc(O[C@H]3CCOC3)cc2)c1","Launched",1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1422","emricasan","caspase inhibitor","CASP1, CASP3, CASP7",NA,NA,"C[C@H](NC(=O)C(=O)Nc1ccccc1C(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)COc1c(F)c(F)cc(F)c1F, C[C@H](NC(=O)C(=O)Nc1ccccc1C(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)COc1c(F)c(F)cc(F)c1F, C[C@H](NC(=O)C(=O)Nc1ccccc1C(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)COc1c(F)c(F)cc(F)c1F, C[C@H](NC(=O)C(=O)Nc1ccccc1C(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)COc1c(F)c(F)cc(F)c1F","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1423","enalapril","angiotensin converting enzyme inhibitor","ACE","cardiology","hypertension, congestive heart failure, left ventricular systolic dysfunction (LVSD)","CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1424","enalaprilat","angiotensin converting enzyme inhibitor","ACE","cardiology","hypertension","C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1425","enarodustat","hypoxia inducible factor prolyl hydroxylase inhibitor","EGLN1","hematology","anemia","OC(=O)CNC(=O)c1c(O)cc(CCc2ccccc2)n3ncnc13","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1426","enasidenib","isocitrate dehydrogenase inhibitor","IDH1","hematologic malignancy","acute myeloid leukemia (AML)","CC(C)(O)CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F, CC(C)(O)CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F, CC(C)(O)CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F, CC(C)(O)CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F, CC(C)(O)CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1427","enciprazine","GABA receptor modulator","GABRA1",NA,NA,"COc1ccccc1N1CCN(C[C@@H](O)COc2cc(OC)c(OC)c(OC)c2)CC1 |&1:13,r|, COc1ccccc1N1CCN(C[C@@H](O)COc2cc(OC)c(OC)c(OC)c2)CC1 |&1:13,r|, COc1ccccc1N1CCN(C[C@@H](O)COc2cc(OC)c(OC)c(OC)c2)CC1 |&1:13,r|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0
"1428","encorafenib","RAF inhibitor, serine/threonine kinase inhibitor","BRAF, CCND1","oncology","melanoma","COC(=O)N[C@@H](C)CNc1nccc(n1)-c1cn(nc1-c1cc(Cl)cc(NS(C)(=O)=O)c1F)C(C)C, C[C@@H](CNc1nccc(n1)c2cn(nc2c3cc(cc(c3F)NS(=O)(=O)C)Cl)C(C)C)NC(=O)OC","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1429","endo-IWR-1","PARP inhibitor","TNKS, TNKS2",NA,NA,"O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1430","endoxifen","estrogen receptor antagonist","ESR1",NA,NA,"CC\C(=C(/c1ccc(O)cc1)c1ccc(OCCNC)cc1)c1ccccc1, CC\C(=C(/c1ccc(O)cc1)c1ccc(OCCNC)cc1)c1ccccc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1431","enflurane","membrane permeability inhibitor","GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9","neurology/psychiatry","anesthetic","FC(F)OC(F)(F)[C@@H](F)Cl |&1:7,r|, FC(F)OC(F)(F)[C@@H](F)Cl |&1:7,r|, FC(F)OC(F)(F)[C@@H](F)Cl |&1:7,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,1,16,0,0,0,0,0,0,1,1,1,1
"1432","enilconazole","sterol demethylase inhibitor","CYP19A1, CYP1A2, CYP2B6, CYP2C9, CYP2J2, CYP3A4, CYP3A5, NR1I2, PPARA, PTGER2","infectious disease","skin infections","Clc1ccc([C@@H](Cn2ccnc2)OCC=C)c(Cl)c1 |&1:5|, Clc1ccc([C@@H](Cn2ccnc2)OCC=C)c(Cl)c1 |&1:5|, Clc1ccc([C@@H](Cn2ccnc2)OCC=C)c(Cl)c1 |&1:5|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1433","eniluracil","dihydropyrimidine dehydrogenase inhibitor","AOX1, DPYD, XDH",NA,NA,"O=c1[nH]cc(C#C)c(=O)[nH]1, O=c1[nH]cc(C#C)c(=O)[nH]1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1434","ENMD-2076","Aurora kinase inhibitor, FLT3 inhibitor, VEGFR inhibitor","AURKA, FLT3, KDR, PDGFRA, PTK2, SRC",NA,NA,"CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(\C=C\c2ccccc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(\C=C\c2ccccc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(\C=C\c2ccccc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(\C=C\c2ccccc2)n1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1435","enocitabine","DNA synthesis inhibitor","CMPK1, RRM1, TYMS","hematologic malignancy","acute myeloid leukemia (AML)","CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1, CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1436","enoxacin","topoisomerase inhibitor","TOP2A","infectious disease","urinary tract infections, gonorrhea","CCn1cc(C(O)=O)c(=O)c2cc(F)c(nc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(nc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(nc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(nc12)N1CCNCC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1437","enoximone","phosphodiesterase inhibitor","PDE3A","cardiology","congestive heart failure","CSc1ccc(cc1)C(=O)c1[nH]c(=O)[nH]c1C, CSc1ccc(cc1)C(=O)c1[nH]c(=O)[nH]c1C, CSc1ccc(cc1)C(=O)c1[nH]c(=O)[nH]c1C, CSc1ccc(cc1)C(=O)c1[nH]c(=O)[nH]c1C, CSc1ccc(cc1)C(=O)c1[nH]c(=O)[nH]c1C, CSc1ccc(cc1)C(=O)c1[nH]c(=O)[nH]c1C, CSc1ccc(cc1)C(=O)c1[nH]c(=O)[nH]c1C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1438","enoxolone","gap junction modulator","HSD11B1","gastroenterology, otolaryngology","peptic ulcer disease (PUD), common cold","CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O |t:19|, CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O |t:19|, CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O |t:19|, CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O |t:19|, CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O |t:19|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1439","enprofylline","phosphodiesterase inhibitor","ADORA1, ADORA2A, ADORA2B, ADORA3, PDE4A, PDE4B",NA,NA,"CCCn1c2nc[nH]c2c(=O)[nH]c1=O, CCCn1c2nc[nH]c2c(=O)[nH]c1=O, CCCn1c2nc[nH]c2c(=O)[nH]c1=O, CCCn1c2nc[nH]c2c(=O)[nH]c1=O, CCCn1c2nc[nH]c2c(=O)[nH]c1=O, CCCn1c2nc[nH]c2c(=O)[nH]c1=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1440","ensartinib","alk inihibitor","ALK","oncology","non-small cell lung cancer (nsclc)","C[C@@H](Oc1cc(nnc1N)C(=O)Nc2ccc(cc2)C(=O)N3C[C@@H](C)N[C@@H](C)C3)c4c(Cl)ccc(F)c4Cl","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1441","entacapone","catechol O methyltransferase inhibitor","COMT","neurology/psychiatry","Parkinson's Disease","CCN(CC)C(=O)C(=C\c1cc(O)c(O)c(c1)[N+]([O-])=O)\C#N, CCN(CC)C(=O)C(=C\c1cc(O)c(O)c(c1)[N+]([O-])=O)\C#N, CCN(CC)C(=O)C(=C\c1cc(O)c(O)c(c1)[N+]([O-])=O)\C#N, CCN(CC)C(=O)C(=C\c1cc(O)c(O)c(c1)[N+]([O-])=O)\C#N, CCN(CC)C(=O)C(=C\c1cc(O)c(O)c(c1)[N+]([O-])=O)\C#N","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1442","entinostat","HDAC inhibitor","HDAC1, HDAC2, HDAC3, HDAC9",NA,NA,"Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1443","entrectinib","ALK tyrosine kinase receptor inhibitor, proto-oncogene tyrosine protein kinase inhibitor","ALK, NTRK1, NTRK2, NTRK3, ROS1","oncology","non-small cell lung cancer (NSCLC)","CN1CCN(CC1)c1ccc(C(=O)Nc2[nH]nc3ccc(Cc4cc(F)cc(F)c4)cc23)c(NC2CCOCC2)c1, CN1CCN(CC1)c1ccc(C(=O)Nc2[nH]nc3ccc(Cc4cc(F)cc(F)c4)cc23)c(NC2CCOCC2)c1, CN1CCN(CC1)c1ccc(C(=O)Nc2[nH]nc3ccc(Cc4cc(F)cc(F)c4)cc23)c(NC2CCOCC2)c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1444","enzalutamide","androgen receptor antagonist","AR","oncology","prostate cancer","CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C1(C)C)c1ccc(C#N)c(c1)C(F)(F)F, CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C1(C)C)c1ccc(C#N)c(c1)C(F)(F)F","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1445","enzastaurin","PKC inhibitor","AKT1, GSK3B, PRKCA, PRKCB, PRKCD, PRKCG",NA,NA,"Cn1cc(C2=C(C(=O)NC2=O)c2cn(C3CCN(Cc4ccccn4)CC3)c3ccccc23)c2ccccc12 |t:4|, Cn1cc(C2=C(C(=O)NC2=O)c2cn(C3CCN(Cc4ccccn4)CC3)c3ccccc23)c2ccccc12 |t:4|, Cn1cc(C2=C(C(=O)NC2=O)c2cn(C3CCN(Cc4ccccn4)CC3)c3ccccc23)c2ccccc12 |t:4|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1446","EN460","endoplasmic reticulum oxidation inhibitor","ERO1A",NA,NA,"OC(=O)c1cc(ccc1Cl)N1N=C(\C(=C\c2ccc(o2)-c2ccccc2)C1=O)C(F)(F)F |c:12|, OC(=O)c1cc(ccc1Cl)N1N=C(\C(=C\c2ccc(o2)-c2ccccc2)C1=O)C(F)(F)F |c:12|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1447","EO-1428","p38 MAPK inhibitor","MAPK11, MAPK14",NA,NA,"Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl, Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl, Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl, Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1448","epacadostat","indoleamine 2,3-dioxygenase inhibitor","IDO1",NA,NA,"NS(=O)(=O)NCCNc1nonc1C(NO)=Nc1ccc(F)c(Br)c1, NS(=O)(=O)NCCNc1nonc1C(NO)=Nc1ccc(F)c(Br)c1, NS(=O)(=O)NCCNc1nonc1C(NO)=Nc1ccc(F)c(Br)c1, NS(=O)(=O)NCCNc1nonc1C(NO)=Nc1ccc(F)c(Br)c1, NS(=O)(=O)NCCNc1nonc1C(NO)=Nc1ccc(F)c(Br)c1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1449","epalrestat","aldose reductase inhibitor","AKR1B1","nephrology","diabetic nephropathy","C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1, C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1, C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1, C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1, C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1450","eperisone","acetylcholine receptor antagonist","CYP2J2","neurology/psychiatry","amyotrophic lateral sclerosis (ALS), spasms, head injury, spinal injury","CCc1ccc(cc1)C(=O)[C@@H](C)CN1CCCCC1 |r|, CCc1ccc(cc1)C(=O)[C@@H](C)CN1CCCCC1 |r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1451","ephedrine","adrenergic receptor agonist","ACHE, ADRA1A, ADRB2, SLC18A2, SLC6A2","cardiology, pulmonary, neurology/psychiatry, endocrinology","hypotension, asthma, narcolepsy, obesity","CN[C@@H](C)[C@H](O)c1ccccc1, CN[C@@H](C)[C@H](O)c1ccccc1","Launched",1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,1,1,1,1
"1452","ephedrine-(racemic)","adrenergic receptor agonist","ADRA1A, ADRA2A, ADRB1, ADRB2, ATF1, ATF2, ATF3, ATF4, ATF5, ATF6, ATF7, FOS, IL2, JDP2, JUN, NFATC1, SLC6A2, SLC6A3, SLC6A4, TNF","cardiology, pulmonary, neurology/psychiatry, endocrinology","hypotension, asthma, narcolepsy, obesity","CN[C@@H](C)[C@@H](O)c1ccccc1 |&1:2,&2:4|, CN[C@@H](C)[C@@H](O)c1ccccc1 |&1:2,&2:4|","Launched",1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,4,1,1,1,1
"1453","epi-001","ppar receptor modulator","AR","oncology","prostate cancer","OCC(O)COC1=CC=C(C(C)(C2=CC=C(OCC(O)CCl)C=C2)C)C=C1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1454","epiandrosterone","steroid","G6PD",NA,NA,"C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1455","epicatechin-gallate-(-)","bacterial DNA gyrase inhibitor","BACE1, FASN",NA,NA,"Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1ccc(O)c(O)c1, Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1ccc(O)c(O)c1, Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1ccc(O)c(O)c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1456","epigallocatechin-gallate-(-)","bacterial DNA gyrase inhibitor","ELANE, EP300, FASN, KAT2B, MMP14, MMP2",NA,NA,"Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1, Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1, Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1, Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1, Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1","Phase 2/Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1457","epinastine","histamine receptor antagonist","HRH1","ophthalmology","conjunctivitis","NC1=NC[C@H]2N1c1ccccc1Cc1ccccc21 |&1:4,t:1|, NC1=NC[C@H]2N1c1ccccc1Cc1ccccc21 |&1:4,t:1|","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"1458","epinephrine","adrenergic receptor agonist, carbonic anhydrase activator, neurotransmitter","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, TNF","cardiology, allergy, pulmonary","cardiac arrest, anaphylactic shock, asthma","CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,9,1,1,1,1
"1459","epirizole","cyclooxygenase inhibitor","PTGS1, PTGS2","neurology/psychiatry","pain relief","COc1cc(C)nn1-c1nc(C)cc(OC)n1, COc1cc(C)nn1-c1nc(C)cc(OC)n1","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1460","epirubicin","topoisomerase inhibitor","CHD1, TOP2A","oncology","breast cancer","COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1461","epitiostanol","androgen receptor agonist","AR","oncology","breast cancer","C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@@H]5S[C@@H]5C[C@]34C)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@@H]5S[C@@H]5C[C@]34C)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@@H]5S[C@@H]5C[C@]34C)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@@H]5S[C@@H]5C[C@]34C)[C@@H]1CC[C@@H]2O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1462","eplerenone","cytochrome P450 inhibitor","NR3C2","cardiology","congestive heart failure, hypertension","COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1463","epomediol","cholesterol inhibitor","CYP7A1","neurology/psychiatry","itching","CC1(C)OC2(C)[C@@H](O)C[C@H]1C[C@@H]2O |&1:11,&2:9,&3:6,r,THB:12:11:1.3:8.6,7:6:1.3:11.10|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1464","epoprostenol","prostacyclin analog","P2RY12, PTGER1, PTGER4, PTGIR, PTGIS","cardiology","hypertension","CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2O\C(C[C@H]12)=C/CCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2O\C(C[C@H]12)=C/CCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2O\C(C[C@H]12)=C/CCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2O\C(C[C@H]12)=C/CCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2O\C(C[C@H]12)=C/CCCC(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1465","epothilone-B","microtubule stabilizing agent, tubulin polymerization inhibitor","TUBB",NA,NA,"C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1466","epothilone-D","microtubule stabilizing agent, tubulin polymerization inhibitor","TUBB",NA,NA,"C[C@H]1CCC\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1 |c:6|, C[C@H]1CCC\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1 |c:6|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1467","EPPTB","trace amine associated receptor antagonist","TAAR1",NA,NA,"CCOc1cccc(NC(=O)c2ccc(N3CCCC3)c(c2)C(F)(F)F)c1, CCOc1cccc(NC(=O)c2ccc(N3CCCC3)c(c2)C(F)(F)F)c1, CCOc1cccc(NC(=O)c2ccc(N3CCCC3)c(c2)C(F)(F)F)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1468","eprobemide","monoamine oxidase inhibitor","MAOA","neurology/psychiatry","depression","Clc1ccc(cc1)C(=O)NCCCN1CCOCC1, Clc1ccc(cc1)C(=O)NCCCN1CCOCC1, Clc1ccc(cc1)C(=O)NCCCN1CCOCC1","Launched",0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1469","eprodisate","amyloid protein inhibitor, antiamyloidogenic agent","SAA1",NA,NA,"OS(=O)(=O)CCCS(O)(=O)=O, OS(=O)(=O)CCCS(O)(=O)=O, OS(=O)(=O)CCCS(O)(=O)=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1470","eprosartan","angiotensin receptor antagonist","AGTR1","cardiology","hypertension","CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O, CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O, CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O, CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O, CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O, CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1471","eptifibatide","platelet aggregation inhibitor","ITGA2B, ITGB3","cardiology","acute coronary syndrome (acs), percutaneous coronary intervention (pci), acute coronary syndrome (ACS), percutaneous coronary intervention (PCI)","NC(=N)NCCCC[C@@H]1NC(=O)CCSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(O)=O)NC(=O)CNC1=O)C(N)=O, NC(=N)NCCCC[C@@H]1NC(=O)CCSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(O)=O)NC(=O)CNC1=O)C(N)=O, NC(=N)NCCCCC1NC(=O)CCSSCC(NC(=O)C2CCCN2C(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(CC(O)=O)NC(=O)CNC1=O)C(N)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1472","EPZ-5676","histone lysine methyltransferase inhibitor","DOT1L",NA,NA,"CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1473","EPZ004777","histone lysine methyltransferase inhibitor","DOT1L",NA,NA,"CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1474","EPZ005687","histone lysine methyltransferase inhibitor","EZH2",NA,NA,"Cc1cc(C)c(CNC(=O)c2cc(cc3n(ncc23)C2CCCC2)-c2ccc(CN3CCOCC3)cc2)c(=O)[nH]1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1475","EPZ011989","histone lysine methyltransferase inhibitor","EZH2",NA,NA,"CCN([C@H]1CC[C@@H](CC1)N(C)CCOC)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C#CCN1CCOCC1 |r|, CCN([C@H]1CC[C@@H](CC1)N(C)CCOC)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C#CCN1CCOCC1 |r|, CCN([C@H]1CC[C@@H](CC1)N(C)CCOC)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C#CCN1CCOCC1 |r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1476","EPZ015666","protein arginine N-methyltransferase inhibitor","PRMT5",NA,NA,"O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1, O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1, O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1, O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1, O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1, O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1, O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1, O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1, O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1477","EPZ020411","protein arginine N-methyltransferase inhibitor","PRMT6",NA,NA,"CNCCN(C)Cc1c[nH]nc1-c1ccc(O[C@H]2C[C@@H](C2)OCCC2CCOCC2)cc1 |r|, CNCCN(C)Cc1c[nH]nc1-c1ccc(O[C@H]2C[C@@H](C2)OCCC2CCOCC2)cc1 |r|, CNCCN(C)Cc1c[nH]nc1-c1ccc(O[C@H]2C[C@@H](C2)OCCC2CCOCC2)cc1 |r|, CNCCN(C)Cc1c[nH]nc1-c1ccc(O[C@H]2C[C@@H](C2)OCCC2CCOCC2)cc1 |r|, CNCCN(C)Cc1c[nH]nc1-c1ccc(O[C@H]2C[C@@H](C2)OCCC2CCOCC2)cc1 |r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1478","equilin","estrogen receptor agonist","HSD17B1",NA,NA,"C[C@@]12CC[C@H]3C(=CCc4cc(O)ccc34)[C@@H]1CCC2=O |&1:1,&2:4,&3:15,r,c:5|, C[C@@]12CC[C@H]3C(=CCc4cc(O)ccc34)[C@@H]1CCC2=O |&1:1,&2:4,&3:15,r,c:5|, C[C@@]12CC[C@H]3C(=CCc4cc(O)ccc34)[C@@H]1CCC2=O |&1:1,&2:4,&3:15,r,c:5|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1479","equol","estrogen receptor agonist","ESR1, ESR2",NA,NA,"Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1, Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1, Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1480","ER-27319","mediator release inhibitor, SYK inhibitor","SYK",NA,NA,"Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1481","ER-50891","retinoid receptor antagonist","RARA",NA,NA,"CC(C)c1cccc2c(cc(nc12)-c1ccc([nH]1)-c1ccc(cc1)C(O)=O)-c1ccccc1, CC(C)c1cccc2c(cc(nc12)-c1ccc([nH]1)-c1ccc(cc1)C(O)=O)-c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1482","erastin","ion channel antagonist","VDAC2",NA,NA,"CCOc1ccccc1-n1c(nc2ccccc2c1=O)[C@@H](C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1 |&1:20,r|, CCOc1ccccc1-n1c(nc2ccccc2c1=O)[C@@H](C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1 |&1:20,r|, CCOc1ccccc1-n1c(nc2ccccc2c1=O)[C@@H](C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1 |&1:20,r|, CCOc1ccccc1-n1c(nc2ccccc2c1=O)[C@@H](C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1 |&1:20,r|, CCOc1ccccc1-n1c(nc2ccccc2c1=O)[C@@H](C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1 |&1:20,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1483","erbstatin-analog","EGFR inhibitor, tyrosine kinase inhibitor","EGFR",NA,NA,"COC(=O)\C=C\c1cc(O)ccc1O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1484","ercalcitriol","vitamin D receptor agonist","VDR",NA,NA,"C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1485","erdafitinib","FGFR inhibitor","FGFR1, FGFR2, FGFR3, FGFR4",NA,NA,"COc1cc(OC)cc(c1)N(CCNC(C)C)c1ccc2ncc(nc2c1)-c1cnn(C)c1, COc1cc(OC)cc(c1)N(CCNC(C)C)c1ccc2ncc(nc2c1)-c1cnn(C)c1, COc1cc(OC)cc(c1)N(CCNC(C)C)c1ccc2ncc(nc2c1)-c1cnn(C)c1, COc1cc(OC)cc(c1)N(CCNC(C)C)c1ccc2ncc(nc2c1)-c1cnn(C)c1, COc1cc(OC)cc(c1)N(CCNC(C)C)c1ccc2ncc(nc2c1)-c1cnn(C)c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1486","ergocalciferol","vitamin analog","VDR","endocrinology, orthopedics","hypoparathyroidism, rickets, hypophosphatemia","CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1487","ergoloid mesylate","serotonin receptor antagonist","ADRA1A, ADRB1, DRD1, HTR1A","neurology/psychiatry","senile dementia","C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C","Launched",0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,2,1,1,1,1
"1488","ergonovine","adrenergic receptor agonist, serotonin receptor agonist","ADRA1A, HTR1E","hematology","postpartum hemorrhage (PPH)","C[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:22|","Launched",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"1489","ergotamine","adrenergic receptor antagonist","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, DRD1, DRD2, DRD5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, SLC6A2","neurology/psychiatry","migraine headache","CN1C[C@@H](C=C2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O |c:4|, CN1C[C@@H](C=C2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O |c:4|","Launched",1,1,0,0,0,0,0,0,1,10,0,0,0,0,1,3,0,0,1,5,1,1,1,1
"1490","ERK5-IN-1","MAP kinase inhibitor","MAPK7",NA,NA,"COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCN(C)CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1491","erlotinib","EGFR inhibitor","EGFR, NR1I2","oncology","non-small cell lung cancer (NSCLC), pancreatic cancer","COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1492","erteberel","estrogen receptor agonist","ESR1, ESR2",NA,NA,"Oc1ccc(cc1)[C@@H]1Oc2ccc(O)cc2[C@@H]2CCC[C@H]12, Oc1ccc(cc1)[C@@H]1Oc2ccc(O)cc2[C@@H]2CCC[C@H]12, Oc1ccc(cc1)[C@@H]1Oc2ccc(O)cc2[C@@H]2CCC[C@H]12","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1493","ertugliflozin","sodium/glucose cotransporter inhibitor","SLC5A2","endocrinology","diabetes mellitus","CCOc1ccc(Cc2cc(ccc2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)cc1","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1494","erythromycin","NFkB pathway inhibitor","MLNR","infectious disease","listeria, respiratory tract infections, skin infections, syphilis, amebiasis, pelvic inflammatory disease, chlamydia, diphtheria, erythrasma","CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1495","erythromycin-estolate","bacterial 50S ribosomal subunit inhibitor","ABCB1, ALB, CYP3A4, CYP51A1, KCNH2, MLNR, SLC47A1","infectious disease","listeria, respiratory tract infections, skin infections, syphilis, amebiasis, pelvic inflammatory disease, chlamydia, diphtheria, erythrasma","CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2OC(=O)CC)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2OC(=O)CC)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1496","erythromycin-ethylsuccinate","cytochrome P450 inhibitor, protein synthesis inhibitor","ABCB1, ALB, CYP3A4, CYP51A1, KCNH2, MLNR, SLC47A1","infectious disease","listeria, respiratory tract infections, skin infections, syphilis, amebiasis, pelvic inflammatory disease, chlamydia, diphtheria, erythrasma","CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C, CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C, CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C, CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1497","escitalopram","selective serotonin reuptake inhibitor (SSRI)","SLC6A4","neurology/psychiatry","depression, generalized anxiety disorder (GAD)","CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1, CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1, CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1, CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1, OC(=O)C(O)=O.CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1 |&1:12,r|","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1498","eseroline-(-)","acetylcholinesterase inhibitor","OPRD1, OPRM1",NA,NA,"CN1CC[C@]2(C)[C@H]1N(C)c1ccc(O)cc21","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1499","ESI-09","EPAC inhibitor","RAPGEF3, RAPGEF4",NA,NA,"CC(C)(C)c1cc(no1)C(=O)C(=N\Nc1cccc(Cl)c1)\C#N, CC(C)(C)c1cc(no1)C(=O)C(=N\Nc1cccc(Cl)c1)\C#N, CC(C)(C)c1cc(no1)C(=O)C(=N\Nc1cccc(Cl)c1)\C#N","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1500","eslicarbazepine-acetate","sodium channel blocker","SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A","neurology/psychiatry","seizures","CC(=O)O[C@H]1Cc2ccccc2N(C(N)=O)c2ccccc12, CC(=O)O[C@H]1Cc2ccccc2N(C(N)=O)c2ccccc12","Launched",0,0,1,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1501","esmolol","adrenergic receptor antagonist","ADRB1","cardiology","ventricular tachycardia (VT), hypertension","COC(=O)CCc1ccc(OC[C@@H](O)CNC(C)C)cc1 |&1:12,r|, COC(=O)CCc1ccc(OC[C@@H](O)CNC(C)C)cc1 |&1:12,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"1502","esomeprazole","ATPase inhibitor","ATP4A","gastroenterology","gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, peptic ulcer disease (PUD)","COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1503","estetrol","selective estrogen receptor modulator (SERM)","ESR1",NA,NA,"C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1[C@@H](O)[C@@H](O)[C@@H]2O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1504","estradiol","estrogen receptor agonist","ESR1, ESR2, GPER1, KCNMA1, NR1I2","endocrinology","contraceptive","C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1505","estradiol-acetate","estrogen receptor agonist","ESR1","endocrinology, obstetrics/gynecology","menopause, vaginal atrophy","CC(=O)Oc1ccc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1506","estradiol-benzoate","contraceptive agent","ESR1",NA,NA,"C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)c5ccccc5)ccc34)[C@@H]1CC[C@@H]2O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1507","estradiol-cypionate","estrogen receptor agonist","ESR1","endocrinology","hypoestrogenism, menopause","C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1508","estradiol-valerate","estrogen receptor agonist","ESR1","oncology, endocrinology, obstetrics/gynecology","prostate cancer, hypoestrogenism, menopause, vaginal atrophy","CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C, CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C, CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C, CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C, CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C, CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C, CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1509","estramustine","DNA alkylating agent","ESR1, ESR2, MAP1A, MAP2","oncology, Oncology","prostate cancer, breast cancer","C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1510","estramustine-phosphate","DNA synthesis inhibitor, microtubule inhibitor","ESR1, ESR2, MAP1A, MAP2","oncology","prostate cancer","C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2OP(O)(O)=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2OP(O)(O)=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2OP(O)(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1511","estriol","estrogen receptor agonist","ESR1, ESR2","endocrinology, obstetrics/gynecology, infectious disease","menopause, vaginal atrophy, urinary tract infections","C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@@H](O)[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@@H](O)[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@@H](O)[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@@H](O)[C@@H]2O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1512","estrone","estrogen receptor agonist, estrogenic hormone","ESR1, ESR2","endocrinology","menopause","C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1513","estropipate","estrogen receptor agonist","ESR1, ESR2","orthopedics, endocrinology, obstetrics/gynecology, orthopedics, endocrinology, obstetrics/gynecology","osteoporosis, menopause, vaginal atrophy, hypoestrogenism, osteoporosis, menopause, vaginal atrophy, hypoestrogenism","C[C@]12CC[C@H]3[C@@H](CCc4cc(OS(O)(=O)=O)ccc34)[C@@H]1CCC2=O, C[C@]12CCC3C(CCc4cc(OS(O)(=O)=O)ccc34)C1CCC2=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1514","etacrynic-acid","sodium/potassium/chloride transporter inhibitor","ATP1A1, SLC12A1","cardiology, gastroenterology, nephrology, rheumatology","hypertension, congestive heart failure, edema, hepatic cirrhosis, chronic renal failure, nephrotic syndrome","CCC(=C)C(=O)c1ccc(OCC(O)=O)c(Cl)c1Cl, CCC(=C)C(=O)c1ccc(OCC(O)=O)c(Cl)c1Cl, CCC(=C)C(=O)c1ccc(OCC(O)=O)c(Cl)c1Cl","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1515","etazolate","phosphodiesterase inhibitor","GABRB3, PDE4A",NA,NA,"CCOC(=O)c1cnc2n(CC)ncc2c1NN=C(C)C, CCOC(=O)c1cnc2n(CC)ncc2c1NN=C(C)C, CCOC(=O)c1cnc2n(CC)ncc2c1NN=C(C)C","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0
"1516","ETC-159","beta catenin inhibitor, porcupine inhibitor","PORCN",NA,NA,"Cn1c2ncn(CC(=O)Nc3ccc(nn3)-c3ccccc3)c2c(=O)n(C)c1=O, Cn1c2ncn(CC(=O)Nc3ccc(nn3)-c3ccccc3)c2c(=O)n(C)c1=O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1517","etelcalcetide","calcium-sensing receptor agonist","CASR","endocrinology","hyperparathyroidism","C[C@H](C(=O)N[C@H](CCCNC(=N)N)C(=O)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@@H](C(=O)O)N)NC(=O)C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1518","ethanolamine-oleate","immunostimulant","F12, FABP4, FFAR1, FFAR4, PLD2","gastroenterology","esophageal varices","NCCO.CCCCCCCC\C=C/CCCCCCCC(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1519","ethinyl-estradiol","estrogen receptor agonist, estrogenic hormone","ESR1, ESR2, NR1I2","endocrinology","contraceptive","C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1520","ethisterone","progestogen hormone","TYR","endocrinology","amenorrhea","C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)C#C |t:8|, CC12CCC3C(CCC4=CC(=O)CCC34C)C1CCC2(O)C#C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1521","ethosuximide","succinimide antiepileptic","CACNA1G, CACNA1H, CACNA1I","neurology/psychiatry","epilepsy","CC[C@@]1(C)CC(=O)NC1=O |&1:2,r|, CC[C@@]1(C)CC(=O)NC1=O |&1:2,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1522","ethotoin","hydantoin antiepileptic","SCN5A","neurology/psychiatry","seizures","CCN1C(=O)N[C@@H](C1=O)c1ccccc1 |r|, CCN1C(=O)N[C@@H](C1=O)c1ccccc1 |r|, CCN1C(=O)N[C@@H](C1=O)c1ccccc1 |r|","Launched",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1523","ethoxzolamide","carbonic anhydrase inhibitor","CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9","ophthalmology, gastroenterology","glaucoma, duodenal ulcer disease","CCOc1ccc2nc(sc2c1)S(N)(=O)=O, CCOc1ccc2nc(sc2c1)S(N)(=O)=O, CCOc1ccc2nc(sc2c1)S(N)(=O)=O, CCOc1ccc2nc(sc2c1)S(N)(=O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1524","ethyl pyruvate","tnf production inhibitor","HMGB1, TNF","gastroenterology","pancreatitis","CC(C(OCC)=O)=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1525","eticlopride","dopamine receptor antagonist","DRD2, DRD3, DRD4",NA,NA,"CCN1CCC[C@H]1CNC(=O)c1c(O)c(CC)cc(Cl)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(O)c(CC)cc(Cl)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(O)c(CC)cc(Cl)c1OC","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0
"1526","etidocaine","sodium channel blocker","A1BG","neurology/psychiatry","anesthetic","CCCN(CC)C(CC)C(=O)Nc1c(C)cccc1C","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1527","etidronic-acid","bone resorption inhibitor","ATP6V1A, PTPRS","endocrinology, orthopedics","Paget's disease, heterotopic ossification","CC(O)(P(O)(O)=O)P(O)(O)=O, CC(O)(P(O)(O)=O)P(O)(O)=O, CC(O)(P(O)(O)=O)P(O)(O)=O, CC(O)(P(O)(O)=O)P(O)(O)=O, CC(O)(P(O)(O)=O)P(O)(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1528","etifoxine","GABA receptor modulator","GABRA1, GABRA2, GABRA3, GABRA5","neurology/psychiatry","anxiety","CCNC1=Nc2ccc(Cl)cc2[C@@](C)(O1)c1ccccc1 |&1:12,r,t:3|, CCNC1=Nc2ccc(Cl)cc2[C@@](C)(O1)c1ccccc1 |&1:12,r,t:3|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,1,1,1,1
"1529","etilefrine","adrenergic receptor agonist","ADRA1A, ADRB1","neurology/psychiatry, otolaryngology, endocrinology, pulmonary","headache, nasal congestion, fever, cough suppressant, common cold","CCNCC(O)c1cccc(O)c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,1,1,1,1
"1530","etilevodopa","dopamine receptor agonist","DRD3",NA,NA,"CCOC(=O)[C@@H](N)Cc1ccc(O)c(O)c1, CCOC(=O)[C@@H](N)Cc1ccc(O)c(O)c1, CCOC(=O)[C@@H](N)Cc1ccc(O)c(O)c1, CCOC(=O)[C@@H](N)Cc1ccc(O)c(O)c1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0
"1531","etizolam","benzodiazepine receptor agonist","GABRA1","neurology/psychiatry","insomnia, anxiety","CCc1cc2c(s1)-n1c(C)nnc1CN=C2c1ccccc1Cl |c:16|, CCc1cc2c(s1)-n1c(C)nnc1CN=C2c1ccccc1Cl |c:16|, CCc1cc2c(s1)-n1c(C)nnc1CN=C2c1ccccc1Cl |c:16|, CCc1cc2c(s1)-n1c(C)nnc1CN=C2c1ccccc1Cl |c:16|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1
"1532","etodolac","cyclooxygenase inhibitor","PTGS2","rheumatology","osteoarthritis, rheumatoid arthritis","CCc1cccc2c3CCO[C@@](CC)(CC(O)=O)c3[nH]c12 |&1:11,r|, CCc1cccc2c3CCO[C@@](CC)(CC(O)=O)c3[nH]c12 |&1:11,r|, CCc1cccc2c3CCO[C@@](CC)(CC(O)=O)c3[nH]c12 |&1:11,r|","Launched",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1533","etofenamate","cyclooxygenase inhibitor","PTGS1, PTGS2","neurology/psychiatry, rheumatology","muscle pain, joint pain","OCCOCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F, OCCOCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1534","etofibrate","PPAR receptor agonist","PPARA","endocrinology","hypertriglyceridemia","CC(C)(Oc1ccc(Cl)cc1)C(=O)OCCOC(=O)c1cccnc1, CC(C)(Oc1ccc(Cl)cc1)C(=O)OCCOC(=O)c1cccnc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1535","etofylline","adenosine receptor antagonist","ADORA1","pulmonary","asthma, bronchitis","Cn1c2ncn(CCO)c2c(=O)n(C)c1=O, Cn1c2ncn(CCO)c2c(=O)n(C)c1=O, Cn1c2ncn(CCO)c2c(=O)n(C)c1=O, Cn1c2ncn(CCO)c2c(=O)n(C)c1=O, Cn1c2ncn(CCO)c2c(=O)n(C)c1=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1536","etofylline-clofibrate","platelet aggregation inhibitor","PPARA","endocrinology","hyperlipidemia","Cn1c2ncn(CCOC(=O)C(C)(C)Oc3ccc(Cl)cc3)c2c(=O)n(C)c1=O, Cn1c2ncn(CCOC(=O)C(C)(C)Oc3ccc(Cl)cc3)c2c(=O)n(C)c1=O, Cn1c2ncn(CCOC(=O)C(C)(C)Oc3ccc(Cl)cc3)c2c(=O)n(C)c1=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1537","etomidate","GABA receptor modulator","ADRA2B, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ","neurology/psychiatry","general anaesthetic","CCOC(=O)c1cncn1[C@H](C)c1ccccc1, CCOC(=O)c1cncn1[C@H](C)c1ccccc1, CCOC(=O)c1cncn1[C@H](C)c1ccccc1, CCOC(=O)c1cncn1[C@H](C)c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,1,16,0,0,0,0,1,1,1,1,1,1
"1538","etomoxir","carnitine palmitoyltransferase inhibitor","CPT1A",NA,NA,"CCOC(=O)[C@@]1(CCCCCCOc2ccc(Cl)cc2)CO1, CCOC(=O)[C@@]1(CCCCCCOc2ccc(Cl)cc2)CO1, CCOC(=O)[C@@]1(CCCCCCOc2ccc(Cl)cc2)CO1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1539","etonogestrel","progesterone receptor agonist","ESR1, PGR","endocrinology","contraceptive","[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H] |c:23|, CCC12CC(=C)C3C(CCC4=CC(=O)CCC34)C1CC[C@@]2(O)C#C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1540","etoposide","topoisomerase inhibitor","TOP2A, TOP2B","oncology","non-small cell lung cancer (NSCLC)","COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1541","etoposide-phosphate","topoisomerase inhibitor","TOP2A","oncology","testicular carcinoma, small cell lung cancer","COc1cc(cc(OC)c1OP(O)(O)=O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1OP(O)(O)=O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1OP(O)(O)=O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1542","etoricoxib","cyclooxygenase inhibitor","PTGS2","rheumatology","rheumatoid arthritis, psoriatic arthritis, osteoarthritis, gout, ankylosing spondylitis","Cc1ccc(cn1)-c1ncc(Cl)cc1-c1ccc(cc1)S(C)(=O)=O, Cc1ccc(cn1)-c1ncc(Cl)cc1-c1ccc(cc1)S(C)(=O)=O, Cc1ccc(cn1)-c1ncc(Cl)cc1-c1ccc(cc1)S(C)(=O)=O","Launched",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1543","ETP-45658","PI3K inhibitor","PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,"Cn1ncc2c(nc(nc12)-c1cccc(O)c1)N1CCOCC1, Cn1ncc2c(nc(nc12)-c1cccc(O)c1)N1CCOCC1, Cn1ncc2c(nc(nc12)-c1cccc(O)c1)N1CCOCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1544","etravirine","non-nucleoside reverse transcriptase inhibitor","CYP2C19, CYP2C9, CYP3A4","infectious disease","human immunodeficiency virus (HIV-1)","Cc1cc(cc(C)c1Oc1nc(Nc2ccc(cc2)C#N)nc(N)c1Br)C#N, Cc1cc(cc(C)c1Oc1nc(Nc2ccc(cc2)C#N)nc(N)c1Br)C#N, Cc1cc(cc(C)c1Oc1nc(Nc2ccc(cc2)C#N)nc(N)c1Br)C#N, Cc1cc(cc(C)c1Oc1nc(Nc2ccc(cc2)C#N)nc(N)c1Br)C#N","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1545","etretinate","protein synthesis inhibitor","RARA, RXRG",NA,NA,"CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\c1c(C)cc(OC)c(C)c1C, CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\c1c(C)cc(OC)c(C)c1C, CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\c1c(C)cc(OC)c(C)c1C, CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\c1c(C)cc(OC)c(C)c1C, CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\c1c(C)cc(OC)c(C)c1C","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1546","etripamil","calcium channel blocker","CACNA1C","cardiology","ventricular tachycardia (vt)","COC(=O)c1cccc(CCN(C)CCC[C@](C#N)(C(C)C)c2ccc(OC)c(OC)c2)c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1547","eucalyptol","acetylcholinesterase inhibitor","ACHE","dental","gingivitis","CC12CCC(CC1)C(C)(C)O2, CC12CCC(CC1)C(C)(C)O2","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1548","eugenol","androgen receptor antagonist","AR","dental","toothache","COc1cc(CC=C)ccc1O, COc1cc(CC=C)ccc1O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1549","EUK-134","catalase stimulant","APP, SOD2",NA,NA,"COc1cccc2C=[N+]3CC[N+]4=Cc5cccc(OC)c5O[Mn]34(Cl)Oc12 |t:7,11|, COc1cccc2C=[N+]3CC[N+]4=Cc5cccc(OC)c5O[Mn]34(Cl)Oc12 |t:7,11|, COc1cccc2C=[N+]3CC[N+]4=Cc5cccc(OC)c5O[Mn]34(Cl)Oc12 |t:7,11|, COc1cccc2C=[N+]3CC[N+]4=Cc5cccc(OC)c5O[Mn]34(Cl)Oc12 |t:7,11|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1550","evacetrapib","cholesteryl ester transfer protein inhibitor","CETP",NA,NA,"Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1, Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1, Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1, Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1551","evans-blue","glutamate receptor negative allosteric modulator","GRIA1, PTPN1",NA,NA,"Cc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(C)c1 |c:11,39|, Cc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(C)c1 |c:11,39|, Cc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(C)c1 |c:11,39|, Cc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(C)c1 |c:11,39|, Cc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(C)c1 |c:11,39|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1552","evatanepag","prostaglandin inhibitor","PTGER2, PTGER4",NA,NA,"CC(C)(C)c1ccc(CN(Cc2cccc(OCC(O)=O)c2)S(=O)(=O)c2cccnc2)cc1, CC(C)(C)c1ccc(CN(Cc2cccc(OCC(O)=O)c2)S(=O)(=O)c2cccnc2)cc1, CC(C)(C)c1ccc(CN(Cc2cccc(OCC(O)=O)c2)S(=O)(=O)c2cccnc2)cc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1553","everolimus","mTOR inhibitor","MTOR","oncology, neurology/psychiatry, genetics, urology","breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma","CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1554","evodiamine","ATPase inhibitor, TRPV agonist","TRPV1",NA,NA,"CN1[C@H]2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12 |&1:2,r|, CN1[C@H]2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12 |&1:2,r|, CN1[C@H]2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12 |&1:2,r|, CN1[C@H]2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12 |&1:2,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1555","evogliptin","dipeptidyl peptidase inhibitor","DPP4","endocrinology","diabetes mellitus","CC(C)(C)OC[C@H]1N(CCNC1=O)C(=O)C[C@H](N)Cc2cc(F)c(F)cc2F","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1556","EVP-6124","acetylcholine receptor agonist","CHRNA7",NA,NA,"Clc1cccc2cc(sc12)C(=O)N[C@H]1CN2CCC1CC2, Clc1cccc2cc(sc12)C(=O)N[C@H]1CN2CCC1CC2, Clc1cccc2cc(sc12)C(=O)N[C@H]1CN2CCC1CC2, Clc1cccc2cc(sc12)C(=O)N[C@H]1CN2CCC1CC2","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
"1557","EW-7197","TGF beta receptor inhibitor","ACVR1B, TGFBR1",NA,NA,"Cc1cccc(n1)-c1nc(CNc2ccccc2F)[nH]c1-c1ccc2ncnn2c1, Cc1cccc(n1)-c1nc(CNc2ccccc2F)[nH]c1-c1ccc2ncnn2c1, Cc1cccc(n1)-c1nc(CNc2ccccc2F)[nH]c1-c1ccc2ncnn2c1, Cc1cccc(n1)-c1nc(CNc2ccccc2F)[nH]c1-c1ccc2ncnn2c1, Cc1cccc(n1)-c1nc(CNc2ccccc2F)[nH]c1-c1ccc2ncnn2c1, Cc1cccc(n1)-c1nc(CNc2ccccc2F)[nH]c1-c1ccc2ncnn2c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1558","EX-527","SIRT inhibitor","SIRT1",NA,NA,"NC(=O)[C@H]1CCCc2c1[nH]c1ccc(Cl)cc21 |&1:3,r|, NC(=O)[C@H]1CCCc2c1[nH]c1ccc(Cl)cc21 |&1:3,r|, NC(=O)[C@H]1CCCc2c1[nH]c1ccc(Cl)cc21 |&1:3,r|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1559","examorelin","growth hormone releasing factor agonist","GHRHR, GHSR",NA,NA,"C[C@H](NC(=O)[C@@H](Cc1c(C)[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1560","exatecan-mesylate","topoisomerase inhibitor","TOP1",NA,NA,"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1561","exemestane","aromatase inhibitor","CYP19A1","oncology","breast cancer","C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O |c:13,t:9|, C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O |c:13,t:9|, C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O |c:13,t:9|, C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O |c:13,t:9|, C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O |c:13,t:9|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1562","exenatide","GLP receptor agonist","GLP1R","endocrinology","diabetes mellitus","[H]N[C@@H](Cc1c[nH]cn1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O |r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1563","exherin","cadherin antagonist","CDH2",NA,NA,"CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O, CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O, CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O, CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O, CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1564","exifone","nootropic agent","TYR",NA,NA,"Oc1ccc(C(=O)c2cc(O)c(O)c(O)c2)c(O)c1O, Oc1ccc(C(=O)c2cc(O)c(O)c(O)c2)c(O)c1O","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1565","exisulind","phosphodiesterase inhibitor","PDE5A",NA,NA,"CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)S(C)(=O)=O |c:1|, CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)S(C)(=O)=O |c:1|, CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)S(C)(=O)=O |c:1|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1566","exo-IWR-1","WNT signaling inhibitor negative control","TNKS",NA,NA,"O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@H]3C[C@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@H]3C[C@H](C=C3)[C@H]2C1=O |c:29|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1567","ezatiostat","glutathione transferase inhibitor","GSTP1",NA,NA,"CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1, CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1, CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1, CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1, CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1568","ezetimibe","cholesterol inhibitor, niemann-pick c1-like 1 protein antagonist, cholesterol inhibitor, Niemann-Pick C1-like 1 protein antagonist","ANPEP, NPC1L1, SOAT1","endocrinology, metabolism, endocrinology, metabolism","hyperlipidemia, hypercholesterolemia, sitosterolemia, hyperlipidemia, hypercholesterolemia, sitosterolemia","O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, OC(CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1569","ezutromid","utrophin enhancer","UTRN",NA,NA,"CCN(CC)c1ccc(cc1)-n1nc2cc(C)c(N)cc2n1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1570","E7449","PARP inhibitor","PARP1, PARP2, TNKS, TNKS2",NA,NA,"O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1571","F-11440","serotonin receptor agonist","HTR1A",NA,NA,"Cn1c(=O)cnn(CCCCN2CCN(CC2)c2ncccn2)c1=O, Cn1c(=O)cnn(CCCCN2CCN(CC2)c2ncccn2)c1=O","Phase 2",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1572","fadrozole","aromatase inhibitor","CYP11B1, CYP19A1","oncology","breast cancer","N#Cc1ccc(cc1)[C@H]1CCCc2cncn12 |&1:8|, N#Cc1ccc(cc1)[C@H]1CCCc2cncn12 |&1:8|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1573","fagomine","glucosidase inhibitor","GLB1",NA,NA,"OC[C@H]1NCC[C@@H](O)[C@@H]1O, OC[C@H]1NCC[C@@H](O)[C@@H]1O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1574","falecalcitriol","vitamin D receptor agonist","VDR","endocrinology","hyperparathyroidism","C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1575","famotidine","histamine receptor antagonist","HRH2","gastroenterology","heartburn","NC(=N)Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1, NC(=N)Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1, NC(=N)Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"1576","fananserin","dopamine receptor antagonist, serotonin receptor antagonist","HTR2A",NA,NA,"Fc1ccc(cc1)N1CCN(CCCN2c3cccc4cccc(c34)S2(=O)=O)CC1, Fc1ccc(cc1)N1CCN(CCCN2c3cccc4cccc(c34)S2(=O)=O)CC1, Fc1ccc(cc1)N1CCN(CCCN2c3cccc4cccc(c34)S2(=O)=O)CC1","Phase 2",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1577","fapi-4","fibroblast activation protein inhibitor","FAP","oncology","breast cancer","O=C(NCC(N1CC(F)(F)C[C@]1(C#N)[H])=O)C2=CC=NC3=CC=C(OCCCN4CCN(C(CN5CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC5)=O)CC4)C=C32",NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1578","farnesyl-thiosalicylic-acid-amide","Ras GTPase inhibitor","HRAS",NA,NA,"CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(N)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(N)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(N)=O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1579","fasudil","rho associated kinase inhibitor","PKIA, PRKACA, ROCK1, ROCK2","neurology/psychiatry","cerebral vasospasm","O=S(=O)(N1CCCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCCNCC1)c1cccc2cnccc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1580","febuxostat","xanthine oxidase inhibitor","XDH","nephrology","hyperuricemia","CC(C)COc1ccc(cc1C#N)-c1nc(C)c(s1)C(O)=O, CC(C)COc1ccc(cc1C#N)-c1nc(C)c(s1)C(O)=O, CC(C)COc1ccc(cc1C#N)-c1nc(C)c(s1)C(O)=O, CC(C)COc1ccc(cc1C#N)-c1nc(C)c(s1)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1581","fedovapagon","vasopressin receptor agonist","AVPR2","urology","benign prostatic hyperplasia (bph)","CN(C)C(=O)[C@@H]1CCCN1C(=O)NCc2ccc(cc2C)C(=O)N3CCCCc4ccccc34","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1582","fedratinib","FLT3 inhibitor, JAK inhibitor","BRD4, JAK1, JAK2, JAK3, TYK2","hematologic malignancy","myelofibrosis","Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1583","felbamate","glutamate receptor antagonist","GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B","neurology/psychiatry","epilepsy","NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1584","felbinac","cyclooxygenase inhibitor","CTSL","rheumatology, neurology/psychiatry","rheumatoid arthritis, muscle pain","OC(=O)Cc1ccc(cc1)-c1ccccc1, OC(=O)Cc1ccc(cc1)-c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1585","felbinac-ethyl","cyclooxygenase inhibitor","PTGS1, PTGS2",NA,NA,"CCOC(=O)Cc1ccc(cc1)-c1ccccc1","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1586","felodipine","calcium channel blocker","CFTR","null, cardiology","angina pectoris, hypertension","CCOC(=O)[C@H]1[C@H](C(C(=O)OC)=C(C)N=C1C)c1cccc(Cl)c1Cl |&2:6,r,c:14,t:11|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:12,r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:12,r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:12,r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:12,r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:12,r,c:5,10|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1587","fenbendazole","tubulin polymerization inhibitor","TUBB","infectious disease","gastrointestinal parasites, gastrointestinal roundworms","COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1, COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1, COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1, COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1588","fenbufen","cyclooxygenase inhibitor","PTGS1, PTGS2","neurology/psychiatry","pain relief","OC(=O)CCC(=O)c1ccc(cc1)-c1ccccc1, OC(=O)CCC(=O)c1ccc(cc1)-c1ccccc1","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1589","fenclonine-(+/-)","tryptophan hydroxylase inhibitor","PAH, TPH1, TPH2",NA,NA,"N[C@@H](Cc1ccc(Cl)cc1)C(O)=O |&1:1|, N[C@@H](Cc1ccc(Cl)cc1)C(O)=O |&1:1|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1590","fendiline","calcium channel blocker","HTR2B",NA,NA,"C[C@@H](NCCC(c1ccccc1)c1ccccc1)c1ccccc1 |&1:1|, C[C@@H](NCCC(c1ccccc1)c1ccccc1)c1ccccc1 |&1:1|, C[C@@H](NCCC(c1ccccc1)c1ccccc1)c1ccccc1 |&1:1|, C[C@@H](NCCC(c1ccccc1)c1ccccc1)c1ccccc1 |&1:1|, C[C@@H](NCCC(c1ccccc1)c1ccccc1)c1ccccc1 |&1:1|, C[C@@H](NCCC(c1ccccc1)c1ccccc1)c1ccccc1 |&1:1|","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1591","fenigam","benzodiazepine receptor agonist","GABBR1, GABBR2","neurology/psychiatry","posttraumatic stress disorder, anxiety, depression","NC[C@@H](CC(O)=O)c1ccccc1 |&1:2,r|, NC[C@@H](CC(O)=O)c1ccccc1 |&1:2,r|, NC[C@@H](CC(O)=O)c1ccccc1 |&1:2,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1592","fenobam","glutamate receptor antagonist","GRM5",NA,NA,"CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1 |c:5|, CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1 |c:5|, CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1 |c:5|, CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1 |c:5|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1593","fenofibrate","PPAR receptor agonist","MMP25, PPARA","endocrinology","hypercholesterolemia, hypertriglyceridemia","CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1, CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1, CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1, CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1594","fenofibric-acid","cytochrome P450 inhibitor","CLCN1, PPARA","cardiology","dyslipidemia","CC(C)(Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1)C(O)=O, CC(C)(Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1)C(O)=O, CC(C)(Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1595","fenoldopam","dopamine receptor agonist","DRD1, DRD4","cardiology","hypertension","Oc1ccc(cc1)[C@H]1CNCCc2c(Cl)c(O)c(O)cc12 |&1:7|, Oc1ccc(cc1)[C@H]1CNCCc2c(Cl)c(O)c(O)cc12 |&1:7|, Oc1ccc(cc1)[C@H]1CNCCc2c(Cl)c(O)c(O)cc12 |&1:7|, Oc1ccc(cc1)C1CNCCc2c(Cl)c(O)c(O)cc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,1,1,1,1
"1596","fenoldopam hydrochloride","dopamine receptor agonist","DRD1","Cardiovascular","hypertension","Oc1ccc(cc1)C1CNCCc2c(Cl)c(O)c(O)cc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1
"1597","fenoprofen","prostaglandin inhibitor","PTGS1, SLC5A8","rheumatology","rheumatoid arthritis, osteoarthritis, rheumatoid arthritis, osteoarthritis","C[C@@H](C(O)=O)c1cccc(Oc2ccccc2)c1 |&1:1|, CC(C(O)=O)c1cccc(Oc2ccccc2)c1","Launched",1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1598","fenoterol","adrenergic receptor agonist","ADRB2",NA,NA,"C[C@@H](Cc1ccc(O)cc1)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:1,12,r|","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
"1599","fenretinide","apoptosis stimulant, retinoid receptor agonist","RARA",NA,NA,"C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1600","fentiazac","cyclooxygenase inhibitor","PTGS1, PTGS2","neurology/psychiatry, rheumatology","muscle pain, joint pain","OC(=O)Cc1sc(nc1-c1ccc(Cl)cc1)-c1ccccc1, OC(=O)Cc1sc(nc1-c1ccc(Cl)cc1)-c1ccccc1","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1601","FERb-033","EGFR inhibitor","ERBB2",NA,NA,"O\N=C\c1ccc(c(Cl)c1O)-c1ccc(O)c(F)c1, O\N=C\c1ccc(c(Cl)c1O)-c1ccc(O)c(F)c1, O\N=C\c1ccc(c(Cl)c1O)-c1ccc(O)c(F)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1602","ferulic-acid","antioxidant","CA1, CA12, CA14, CA2, CA4, CA6, CA9",NA,NA,"COc1cc(\C=C\C(O)=O)ccc1O, COc1cc(\C=C\C(O)=O)ccc1O, COc1cc(\C=C\C(O)=O)ccc1O, COc1cc(\C=C\C(O)=O)ccc1O, COc1cc(\C=C\C(O)=O)ccc1O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1603","fesoterodine","acetylcholine receptor antagonist","CHRM1, CHRM2, CHRM3, CHRM4, CHRM5","urology","urinary incontinence","CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1OC(=O)C(C)C)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1OC(=O)C(C)C)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1OC(=O)C(C)C)C(C)C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,5,0,0,1,1,1,1
"1604","fexaramine","FXR agonist","NR1H4",NA,NA,"COC(=O)\C=C\c1cccc(c1)N(Cc1ccc(cc1)-c1ccc(cc1)N(C)C)C(=O)C1CCCCC1, COC(=O)\C=C\c1cccc(c1)N(Cc1ccc(cc1)-c1ccc(cc1)N(C)C)C(=O)C1CCCCC1, COC(=O)\C=C\c1cccc(c1)N(Cc1ccc(cc1)-c1ccc(cc1)N(C)C)C(=O)C1CCCCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1605","fexofenadine","histamine receptor antagonist","HRH1","allergy","allergic rhinitis, urticaria","CC(C)(C(O)=O)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:12|, CC(C)(C(O)=O)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:12|, CC(C)(C(O)=O)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:12|, CC(C)(C(O)=O)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:12|, CC(C)(C(O)=O)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:12|","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"1606","FG-2216","hypoxia inducible factor prolyl hydroxylase inhibitor","EGLN1, EGLN2, HIF1A",NA,NA,"OC(=O)CNC(=O)c1nc(Cl)c2ccccc2c1O, OC(=O)CNC(=O)c1nc(Cl)c2ccccc2c1O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1607","FG-4592","hypoxia inducible factor prolyl hydroxylase inhibitor","EGLN1, EGLN2, EGLN3",NA,NA,"Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12, Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12, Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12, Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12, Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12, Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1608","FGIN-1-27","inositol monophosphatase inhibitor","TSPO",NA,NA,"CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccccc12)-c1ccc(F)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccccc12)-c1ccc(F)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccccc12)-c1ccc(F)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccccc12)-c1ccc(F)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1609","FGIN-1-43","benzodiazepine receptor agonist","TSPO",NA,NA,"CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1610","FH-535","PPAR receptor antagonist, WNT signaling inhibitor","PPARD, PPARG",NA,NA,"Cc1cc(ccc1NS(=O)(=O)c1cc(Cl)ccc1Cl)[N+]([O-])=O, Cc1cc(ccc1NS(=O)(=O)c1cc(Cl)ccc1Cl)[N+]([O-])=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1611","fidarestat","aldose reductase inhibitor","AKR1B1",NA,NA,"NC(=O)[C@H]1C[C@]2(NC(=O)NC2=O)c2cc(F)ccc2O1 |&1:3,&2:5,r|, NC(=O)[C@H]1C[C@]2(NC(=O)NC2=O)c2cc(F)ccc2O1 |&1:3,&2:5,r|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1612","filanesib","kinesin inhibitor, kinesin-like spindle protein inhibitor","KIF11",NA,NA,"CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F |c:7|, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F |c:7|, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F |c:7|, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F |c:7|, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F |c:7|, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F |c:7|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1613","filgotinib","JAK inhibitor","JAK1, JAK2, JAK3, TYK2",NA,NA,"O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1, O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1, O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1, O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1, O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1614","fimasartan","angiotensin receptor antagonist","AGTR1","cardiology","hypertension, congestive heart failure","CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1615","finasteride","5 alpha reductase inhibitor","AKR1D1, SRD5A1, SRD5A2","endocrinology","androgenetic alopecia","CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C |c:18|, CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C |c:18|, CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C |c:18|, CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C |c:18|, CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C |c:18|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1616","finerenone","mineralocorticoid receptor antagonist","NR3C2","nephrology","chronic kidney disease (ckd)","CCOc1ncc(C)c2NC(C)=C([C@@H](c3ccc(cc3OC)C#N)c12)C(N)=O |a:13,c:11|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1617","fingolimod","immunosuppressant, sphingosine 1-phosphate receptor agonist","S1PR1, S1PR5","neurology/psychiatry","multiple sclerosis","CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1618","FIPI","phospholipase inhibitor","PLD1, PLD2",NA,NA,"Fc1ccc2[nH]c(cc2c1)C(=O)NCCN1CCC(CC1)n1c2ccccc2[nH]c1=O, Fc1ccc2[nH]c(cc2c1)C(=O)NCCN1CCC(CC1)n1c2ccccc2[nH]c1=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1619","firategrast","integrin antagonist","ITGA4",NA,NA,"CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1, CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1, CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1, CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1, CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1, CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1, CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1, CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1620","firocoxib","cyclooxygenase inhibitor","PTGS2","rheumatology","osteoarthritis","CC1(C)OC(=O)C(OCC2CC2)=C1c1ccc(cc1)S(C)(=O)=O |c:12|, CC1(C)OC(=O)C(OCC2CC2)=C1c1ccc(cc1)S(C)(=O)=O |c:12|","Launched",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1621","fisetin","Aurora kinase inhibitor","CDK6, FASN",NA,NA,"Oc1ccc2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1ccc2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1ccc2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1ccc2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1622","FIT","opioid receptor agonist","OPRD1",NA,NA,"CCC(=O)N(C1CCN(CCc2ccc(cc2)N=C=S)CC1)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1623","FK-33-824","opioid receptor agonist","OPRM1",NA,NA,"C[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)N[C@H](CO)CC[S@@](C)=O |a:1,5,23,34,&1:39|, C[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)N[C@H](CO)CC[S@@](C)=O |a:1,5,23,34,&1:39|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1624","FK-3311","cyclooxygenase inhibitor","PTGS2",NA,NA,"CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1, CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1, CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1","Phase 2",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1625","FK-866","niacinamide phosphoribosyltransferase inhibitor","NAMPT",NA,NA,"O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1, O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1, O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1626","FK-888","tachykinin antagonist","TACR1, TACR2",NA,NA,"CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1627","flavoxate","acetylcholine receptor antagonist","CHRM1, CHRM2","urology","urinary incontinence, interstitial cystitis (IC), urethritis, prostatitis","Cc1c(oc2c(cccc2c1=O)C(=O)OCCN1CCCCC1)-c1ccccc1, Cc1c(oc2c(cccc2c1=O)C(=O)OCCN1CCCCC1)-c1ccccc1, Cc1c(oc2c(cccc2c1=O)C(=O)OCCN1CCCCC1)-c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,1,1,1,1
"1628","flecainide","sodium channel blocker","KCNA5, KCNA7, SCN5A","cardiology","ventricular tachycardia (VT), atrial fibrillation (AF), ventricular arrhythmias","FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1, FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1, FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1, FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1, FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1, FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1","Launched",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1629","fleroxacin","topoisomerase inhibitor","TOP2A","infectious disease, gastroenterology","gonorrhea, enteritis, diarrhea, respiratory tract infections","CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1630","flesinoxan","serotonin receptor agonist","HTR1A","cardiology","hypertension","O=C(NCCN1CCN(C2=C3OC[C@@H](CO)OC3=CC=C2)CC1)C4=CC=C(F)C=C4","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1631","flibanserin","serotonin receptor agonist","DRD4, HTR1A, HTR2A","neurology/psychiatry","hypoactive sexual desire disorder","FC(F)(F)c1cccc(c1)N1CCN(CCn2c3ccccc3[nH]c2=O)CC1, FC(F)(F)c1cccc(c1)N1CCN(CCn2c3ccccc3[nH]c2=O)CC1","Launched",0,0,0,0,0,0,0,0,1,2,0,0,0,0,1,1,0,0,0,0,1,1,1,1
"1632","flindokalner","potassium channel agonist","KCNMA1, KCNN4, KCNQ2, KCNQ4, KCNQ5",NA,NA,"COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(ccc12)C(F)(F)F, COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(ccc12)C(F)(F)F, COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(ccc12)C(F)(F)F, COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(ccc12)C(F)(F)F","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1633","floctafenine","cyclooxygenase inhibitor","PTGS1, PTGS2","neurology/psychiatry","pain relief","OC[C@@H](O)COC(=O)c1ccccc1Nc1ccnc2c(cccc12)C(F)(F)F |&1:2,r|, OC[C@@H](O)COC(=O)c1ccccc1Nc1ccnc2c(cccc12)C(F)(F)F |&1:2,r|, OC[C@@H](O)COC(=O)c1ccccc1Nc1ccnc2c(cccc12)C(F)(F)F |&1:2,r|","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1634","flopropione","serotonin receptor antagonist","HTR1A","neurology/psychiatry","spasms","CCC(=O)c1c(O)cc(O)cc1O, CCC(=O)c1c(O)cc(O)cc1O, CCC(=O)c1c(O)cc(O)cc1O, CCC(=O)c1c(O)cc(O)cc1O, CCC(=O)c1c(O)cc(O)cc1O","Launched",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1635","florbetaben","beta amyloid plaque binder","APP","neurology/psychiatry","alzheimer's disease","CNC1=CC=C(\C=C\C2=CC=C(OCCOCCOCCF)C=C2)C=C1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1636","florbetapir","beta amyloid plaque binder","APP","neurology/psychiatry","alzheimer's disease","CNC1=CC=C(\C=C\C2=CC=C(OCCOCCOCCF)N=C2)C=C1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1637","flortaucipir f18","pet imaging agent","MAOA, MAOB, MAPT","neurology/psychiatry","alzheimer's disease","C1=CC2=C(C=C1C3=CN=C(C=C3)F)NC4=C2C=NC=C4","Launched",0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1638","floxuridine","DNA synthesis inhibitor","TYMS","oncology","colorectal cancer","OC[C@H]1OC(C[C@H]1O)n1cc(F)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(F)c(=O)[nH]c1=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1639","flubendazole","tubulin polymerization inhibitor","TUBB","infectious disease","gastrointestinal parasites","COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccc(F)cc1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccc(F)cc1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccc(F)cc1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccc(F)cc1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccc(F)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1640","fluconazole","sterol demethylase inhibitor","CYP51A1","infectious disease","esophageal candidiasis, meningitis","OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F, OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F, OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1641","flucytosine","other antifungal","DNMT1","infectious disease","bacterial septicemia, endocarditis, urinary tract infections, meningitis","Nc1nc(=O)[nH]cc1F, Nc1nc(=O)[nH]cc1F, Nc1nc(=O)[nH]cc1F, Nc1nc(=O)[nH]cc1F","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1642","fludarabine","ribonucleotide reductase inhibitor","ADA, DCK, POLA1, RRM1, RRM2","hematologic malignancy","chronic lymphocytic leukemia (CLL)","Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1643","fludarabine-phosphate","ribonucleotide reductase inhibitor","POLA1, POLD1, POLE, RRM1, RRM2, RRM2B","hematologic malignancy","chronic lymphocytic leukemia (CLL)","Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1644","fludroxycortide","glucocorticoid receptor agonist","NR3C1, SERPINA6","infectious disease, dermatology","skin infections, psoriasis","CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |t:11|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1645","flufenamic-acid","chloride channel blocker","AKR1C3, ANO1, AR, GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, PANX1, PANX2, PANX3, PKD2L1, PTGS1, PTGS2, TRPC5, TRPM2, TRPM5",NA,NA,"OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F, OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F, OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F","Preclinical",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1646","flumatinib","Bcr-Abl kinase inhibitor","ABL1, PDGFRB",NA,NA,"CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1647","flumazenil","benzodiazepine receptor antagonist","GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ","neurology/psychiatry","sedative","CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21, CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21, CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21, CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21, CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21","Launched",0,0,0,0,0,0,0,0,0,0,0,0,1,16,0,0,0,0,0,0,1,1,1,1
"1648","flumethasone","glucocorticoid receptor agonist","NR3C1, PLA2G1B","otolaryngology, infectious disease, dermatology","otitis, ear infections, corticosteroid-responsive dermatoses","C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:12,t:8|, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:12,t:8|, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:12,t:8|, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:12,t:8|, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:12,t:8|, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:12,t:8|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1649","flumethasone pivalate","glucocorticoid receptor agonist","NR3C1","Dermatology","dermatitis","C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(=O)C(C)(C)C |c:12,t:8|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1650","flumethasone-pivalate","glucocorticoid receptor agonist","NR3C1, SERPINA6","allergy","allergic rhinitis","C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(=O)C(C)(C)C |c:12,t:8|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1651","flunarizine","calcium channel blocker","CACNA1G, CACNA1H, CACNA1I, CALM1, HRH1","neurology/psychiatry, cardiology","migraine headache, vertigo, peripheral artery disease (PAD)","Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"1652","flunisolide","cytochrome P450 inhibitor","NR3C1","allergy","allergic rhinitis","CC1(C)O[C@@H]2CC3C4C[C@H](F)C5=CC(=O)C=CC5(C)C4C(O)CC3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:15,t:11|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1653","fluocinolone-acetonide","glucocorticoid receptor agonist","NR3C1, SERPINA6","dermatology","seborrheic dermatitis","CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:15,t:11|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:15,t:11|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:15,t:11|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:15,t:11|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:15,t:11|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1654","fluocinonide","glucocorticoid receptor agonist","NR3C1, SERPINA6, SMO","dermatology","seborrheic dermatitis, eczema","CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |c:25,t:21|, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |c:25,t:21|, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |c:25,t:21|, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |c:25,t:21|, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |c:25,t:21|, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |c:25,t:21|, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |c:25,t:21|, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1CC1C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1655","fluorofenidone","nadph oxidase inhibitor","NOX1","pulmonary","idiopathic pulmonary fibrosis (ipf)","CC1=CN(C(=O)C=C1)c2cccc(F)c2","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1656","fluoxetine","selective serotonin reuptake inhibitor (SSRI)","ANO1, HTR2B, SLC6A4","neurology/psychiatry","depression, obsessive compulsive disorder (OCD), bulimia nervosa, panic disorders, bipolar disorder","CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1, CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1, CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1, CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1","Launched",1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1657","fluoxetine hydrochloride","serotonin transporter (sert) inhibitor","SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN5A, SCN7A, SCN8A, SCN9A, SLC6A4","Neurology","depression","CNCC[C@@H](Oc1ccc(cc1)C(F)(F)F)c1ccccc1 |&1:4,r|","Launched",1,1,1,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1658","flupentixol","dopamine receptor antagonist","ADRA1A, CHRM1, DRD1, DRD2, DRD3, DRD5, HTR2A","neurology/psychiatry","schizophrenia, depression","OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1","Launched",0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,4,1,1,1,1,1,1,1,1
"1659","fluphenazine","dopamine receptor antagonist","CALM1, DRD1, DRD2, DRD5, HRH1, HTR2A, HTR6, HTR7","neurology/psychiatry","schizophrenia","OCCN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, OCCN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, OCCN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, OCCN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1","Launched",0,0,0,0,0,0,0,0,1,3,1,1,0,0,1,3,0,0,0,0,1,1,1,1
"1660","fluphenazine-decanoate","dopamine receptor antagonist","DRD2, HTR1B, HTR4","neurology/psychiatry","schizophrenia","CCCCCCCCCC(=O)OCCN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, CCCCCCCCCC(=O)OCCN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1","Launched",0,0,0,0,0,0,0,0,1,2,0,0,0,0,1,1,0,0,0,0,1,1,1,1
"1661","flupirtine","glutamate receptor antagonist","ADRA2A, KCNQ1, KCNQ2","neurology/psychiatry","pain relief","CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N, CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N, CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N, CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N, CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N, CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"1662","fluprazine","serotonin receptor agonist","HTR1A, HTR1B",NA,NA,"NC(=O)NCCN1CCN(CC1)c1cccc(c1)C(F)(F)F, NC(=O)NCCN1CCN(CC1)c1cccc(c1)C(F)(F)F","Phase 1",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1663","fluprednisolone","glucocorticoid receptor agonist","NR3C1","ophthalmology","contact dermatitis","C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)C[C@@H](C4=CC(=O)C=C[C@]34C)F)O","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1664","fluralaner","GABA receptor antagonist, gaba gated chloride channel blocker","GABRD","infectious disease","mites","Cc1cc(ccc1C(=O)NCC(=O)NCC(F)(F)F)C1=NO[C@](C1)(c1cc(Cl)cc(Cl)c1)C(F)(F)F |&1:22,r,t:20|, Cc1cc(ccc1C(=O)NCC(=O)NCC(F)(F)F)C2=NOC(C2)(c3cc(cc(c3)Cl)Cl)C(F)(F)F","Launched",0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1
"1665","flurandrenolide","glucocorticoid receptor agonist","NR3C1","nephrology, nephrology, infectious disease, dermatology","chronic kidney disease (ckd), chronic kidney disease (ckd), skin infections, psoriasis","CC1(C)O[C@@H]2CC3C4C[C@H](F)C5=CC(=O)CC[C@]5(C)C4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1666","flurbiprofen-(S)-(+)","cyclooxygenase inhibitor","PTGS1, PTGS2","rheumatology","rheumatoid arthritis, osteoarthritis","C[C@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1, C[C@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1, C[C@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1667","flurizan","gamma secretase inhibitor","APH1B, BACE1, IKBKG, PSEN1, PSEN2, PTGS1, PTGS2",NA,NA,"C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1, C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1, C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1, C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1","Phase 3",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1668","fluspirilene","dopamine receptor antagonist","CACNG1, DRD2, HRH1, HTR1A, HTR1D, HTR1E, HTR2A","neurology/psychiatry","schizophrenia","Fc1ccc(cc1)C(CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1)c1ccc(F)cc1, Fc1ccc(cc1)C(CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1)c1ccc(F)cc1, Fc1ccc(cc1)C(CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1)c1ccc(F)cc1, Fc1ccc(cc1)C(CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1)c1ccc(F)cc1","Launched",0,0,0,0,0,0,0,0,1,4,1,1,0,0,1,1,0,0,0,0,1,1,1,1
"1669","flutamide","androgen receptor antagonist","AHR, AR","oncology","prostate cancer","CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1670","flutemetamol","pet imaging agent","APP","neurology/psychiatry","alzheimer's disease","CNC1=C(F)C=C(C=C1)C1=NC2=C(S1)C=C(O)C=C2","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1671","fluticasone furoate","glucocorticoid receptor agonist","NR3C1, NR3C2, PGR","pulmonary","asthma","CC1CC2C3CC(C4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)SCF)OC(=O)C5=CC=CO5)C)O)F)C)F","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1672","fluticasone-propionate","glucocorticoid receptor agonist","NR3C1, NR3C2, PGR, PLA2G4A","dermatology","corticosteroid-responsive dermatoses","CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF |c:18,t:14|, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF |c:18,t:14|, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF |c:18,t:14|, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF |c:18,t:14|, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF |c:18,t:14|, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF |c:18,t:14|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1673","fluvastatin","HMGCR inhibitor","HMGCR","endocrinology, cardiology","hypercholesterolemia, congenital heart defects","CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1674","fluvoxamine","selective serotonin reuptake inhibitor (SSRI)","SLC6A4","neurology/psychiatry","obsessive compulsive disorder (OCD)","COCCCC\C(=N/OCCN)c1ccc(cc1)C(F)(F)F, COCCCC\C(=N/OCCN)c1ccc(cc1)C(F)(F)F, COCCCC\C(=N/OCCN)c1ccc(cc1)C(F)(F)F, COCCCC\C(=N/OCCN)c1ccc(cc1)C(F)(F)F, COCCCC\C(=N/OCCN)c1ccc(cc1)C(F)(F)F","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1675","folic-acid","folate receptor ligand","FOLR2, FOLR3, SLC19A1, SLC46A1","hematology","megaloblastic anemia","Nc1nc(=O)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2[nH]1, Nc1nc(=O)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2[nH]1","Launched",1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1676","foliglurax (monohydrochloride)","glutamate receptor modulator","GRM4","neurology/psychiatry","parkinson's disease","O/N=C1C=C(C2=CC3=C(C=CS3)C=N2)OC4=CC=C(CCCN5CCOCC5)C=C\14.Cl",NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1677","fomepizole","alcohol dehydrogenase inhibitor","ADH1A, ADH1B, ADH1C, AKR1A1, CAT","critical care","poison antidote","Cc1cn[nH]c1, Cc1cn[nH]c1, Cc1cn[nH]c1, Cc1cn[nH]c1, Cc1cn[nH]c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1678","fondaparinux","coagulation factor inhibitor","F10, SERPINC1","hematology","deep vein thrombosis (DVT)","[H][C@@]1(O[C@@H]2[C@@H](COS(O)(=O)=O)O[C@H](O[C@@]3([H])[C@H](O)[C@@H](OS(O)(=O)=O)[C@H](O[C@@]4([H])[C@H](O)[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@@H]4COS(O)(=O)=O)O[C@H]3C(O)=O)[C@H](NS(O)(=O)=O)[C@H]2OS(O)(=O)=O)O[C@@H]([C@@H](O[C@@]2([H])O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]2NS(O)(=O)=O)[C@H](O)[C@H]1O)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1679","foretinib","VEGFR inhibitor","FLT1, FLT4, KDR, MET",NA,NA,"COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1, COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1, COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1, COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1, COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1, COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1, COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1, COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1680","formestane","aromatase inhibitor","CYP19A1","oncology","breast cancer","C[C@]12CC[C@H]3[C@@H](CC[C@H]4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O |a:1,4,5,15,17,&1:8|, C[C@]12CC[C@H]3[C@@H](CC[C@H]4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O |a:1,4,5,15,17,&1:8|, C[C@]12CC[C@H]3[C@@H](CC[C@H]4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O |a:1,4,5,15,17,&1:8|, C[C@]12CC[C@H]3[C@@H](CC[C@H]4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O |a:1,4,5,15,17,&1:8|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1681","formononetin","alcohol dehydrogenase inhibitor","ADH1C, SLC5A2",NA,NA,"COc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, COc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, COc1ccc(cc1)-c1coc2cc(O)ccc2c1=O","Preclinical",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1682","formoterol","adrenergic receptor agonist","ADRB2","pulmonary","asthma, chronic obstructive pulmonary disease (COPD), bronchospasm","COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1, COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1, COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1, COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1, COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1, COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1, COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"1683","forodesine","purinergic receptor antagonist","PNP","hematologic malignancy","peripheral T-cell lymphoma (PTCL)","OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O, OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O, OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O, OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O, OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1684","foropafant","platelet activating factor receptor antagonist","PTAFR",NA,NA,"CC(C)c1cc(C(C)C)c(-c2csc(n2)N(CCN(C)C)Cc2cccnc2)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(-c2csc(n2)N(CCN(C)C)Cc2cccnc2)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(-c2csc(n2)N(CCN(C)C)Cc2cccnc2)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(-c2csc(n2)N(CCN(C)C)Cc2cccnc2)c(c1)C(C)C","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1685","forskolin","adenylyl cyclase activator","ADCY2, ADCY5, GNAS",NA,NA,"CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1686","fosaprepitant-dimeglumine","tachykinin antagonist","TACR1","gastroenterology","nausea, vomiting","C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1687","fosbretabulin","tubulin polymerization inhibitor, ve-cadherin antagonist, tubulin polymerization inhibitor, VE-cadherin antagonist","CDH5",NA,NA,"COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1688","foscenvivint","wnt signaling inhibitor","CCND1, CTNNB1","oncology","hepatocellular carcinoma (hcc)","[H][C@]12[C@H](C)N(Cc3cccc4cccnc34)C(=O)[C@H](Cc3ccc(OP(O)(O)=O)cc3)N1C(=O)CN(C)N2C(=O)NCc1ccccc1","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1689","fosdagrocorat","glucocorticoid receptor agonist","NR3C1","rheumatology","rheumatoid arthritis","FC(F)(F)[C@]1(OP(O)(O)=O)C[C@]2([H])[C@](C3=CC=C(C(NC(C=CC=N4)=C4C)=O)C=C3CC2)(CC1)CC5=CC=CC=C5","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1690","fosfestrol","synthetic estrogen","ESR1, ESR2","oncology","prostate cancer","CC\C(=C(\CC)c1ccc(OP(O)(O)=O)cc1)c1ccc(OP(O)(O)=O)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1691","fosfosal","phosphodiesterase inhibitor","PTGS1, PTGS2","neurology/psychiatry","pain relief","OC(=O)c1ccccc1OP(O)(O)=O, OC(=O)c1ccccc1OP(O)(O)=O, OC(=O)c1ccccc1OP(O)(O)=O","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1692","fosifloxuridine nafalbenamide","thymidylate synthase inhibitor","TYMS","oncology","colorectal cancer","C[C@H](N[P@@](=O)(OC[C@H]1O[C@H](C[C@@H]1O)n1cc(F)c(=O)[nH]c1=O)Oc1cccc2ccccc12)C(=O)OCc1ccccc1 |&1:3|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1693","fosinopril","angiotensin converting enzyme inhibitor","ACE","cardiology","hypertension, congestive heart failure","CCC(=O)O[C@@H](OP(=O)(CCCCc1ccccc1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C |a:5,24,26,&1:7|, CCC(=O)O[C@@H](OP(=O)(CCCCc1ccccc1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C |a:5,24,26,&1:7|, CCC(=O)O[C@@H](OP(=O)(CCCCc1ccccc1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C |a:5,24,26,&1:7|, CCC(=O)O[C@@H](OP(=O)(CCCCc1ccccc1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C |a:5,24,26,&1:7|, CCC(=O)O[C@@H](OP(=O)(CCCCc1ccccc1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C |a:5,24,26,&1:7|, CCC(=O)O[C@@H](OP(=O)(CCCCc1ccccc1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C |a:5,24,26,&1:7|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1694","fosinoprilat","angiotensin converting enzyme inhibitor","ACE","cardiology","hypertension","OC(=O)[C@@H]1C[C@H](CN1C(=O)C[P@](O)(=O)CCCCc1ccccc1)C1CCCCC1 |a:3,5,&1:11|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1695","fosphenytoin","sodium channel blocker","SCN5A","neurology/psychiatry","epilepsy, seizures","OP(O)(=O)OCN1C(=O)NC(C1=O)(c1ccccc1)c1ccccc1, OP(O)(=O)OCN1C(=O)NC(C1=O)(c1ccccc1)c1ccccc1, OP(O)(=O)OCN1C(=O)NC(C1=O)(c1ccccc1)c1ccccc1","Launched",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1696","fostamatinib","SYK inhibitor","SYK","hematology","chronic immune thrombocytopenia (ITP)","COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)N(COP(O)(O)=O)c4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)N(COP(O)(O)=O)c4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)N(COP(O)(O)=O)c4n3)n2)cc(OC)c1OC","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1697","foxy-5","WNT5a peptide mimetic","WNT5A",NA,NA,"CSCC[C@H](NC=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O, CSCC[C@H](NC=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O, CSCC[C@H](NC=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1698","FPL-64176","calcium channel activator","CACNA1C, CACNA1S",NA,NA,"COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1, COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1, COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1, COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1, COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1699","FPS-ZM1","RAGE receptor antagonist","AGER",NA,NA,"Clc1ccc(cc1)C(=O)N(Cc1ccccc1)C1CCCCC1, Clc1ccc(cc1)C(=O)N(Cc1ccccc1)C1CCCCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1700","FR-139317","endothelin receptor antagonist","EDNRA",NA,NA,"CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O, CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O, CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O, CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1701","FR-180204","MAP kinase inhibitor","MAPK1, MAPK3",NA,NA,"Nc1[nH]nc2nnc(cc12)-c1c(nn2ccccc12)-c1ccccc1, Nc1[nH]nc2nnc(cc12)-c1c(nn2ccccc12)-c1ccccc1, Nc1[nH]nc2nnc(cc12)-c1c(nn2ccccc12)-c1ccccc1, Nc1[nH]nc2nnc(cc12)-c1c(nn2ccccc12)-c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1702","frakefamide","opioid receptor agonist","OPRD1","neurology/psychiatry","depression","C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc2ccc(F)cc2)C(=O)N[C@@H](Cc3ccccc3)C(=O)N, C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O.OC(=O)C(F)(F)F |a:1,5,18,30|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1703","FRAX486","serine/threonine kinase inhibitor","PAK1, PAK2, PAK3, PAK4",NA,NA,"CCn1c2nc(Nc3ccc(N4CCNCC4)c(F)c3)ncc2cc(-c2ccc(Cl)cc2Cl)c1=O, CCn1c2nc(Nc3ccc(N4CCNCC4)c(F)c3)ncc2cc(-c2ccc(Cl)cc2Cl)c1=O, CCn1c2nc(Nc3ccc(N4CCNCC4)c(F)c3)ncc2cc(-c2ccc(Cl)cc2Cl)c1=O, CCn1c2nc(Nc3ccc(N4CCNCC4)c(F)c3)ncc2cc(-c2ccc(Cl)cc2Cl)c1=O, CCn1c2nc(Nc3ccc(N4CCNCC4)c(F)c3)ncc2cc(-c2ccc(Cl)cc2Cl)c1=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1704","freselestat","elastase inhibitor","CELA1, ELANE",NA,NA,"CC(C)[C@@H](NC(=O)Cn1c(ncc(N)c1=O)-c1ccccc1)[C@@H](O)c1nnc(o1)C(C)(C)C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1705","frovatriptan","serotonin receptor agonist","HTR1A, HTR1B, HTR1D","neurology/psychiatry","migraine headache","CN[C@@H]1CCc2[nH]c3ccc(cc3c2C1)C(N)=O","Launched",0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1706","fruquintinib","VEGFR inhibitor","KDR","oncology","colorectal cancer","CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12, CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12, CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12, CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1707","ftorafur","thymidylate synthase inhibitor","TYMS","oncology","colorectal cancer","Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O, Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O, Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O, Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O, Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1708","fulacimstat","chymotrypsin inhibitor","CTRL","endocrinology","diabetes mellitus","CN1C(=O)Oc2cc(ccc12)N3C=C(C(=O)O)C(=O)N([C@@H]4CCc5c4cccc5C(F)(F)F)C3=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1709","fulvestrant","estrogen receptor antagonist","ESR1, ESR2, GPER1","oncology","breast cancer","C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1710","fumagillin","methionine aminopeptidase inhibitor","METAP2","infectious disease, Infectious disease","microsporidiosis, fungal infection","CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O |a:2,3,6,10,13,&1:9|, CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O |a:2,3,6,10,13,&1:9|, CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O |a:2,3,6,10,13,&1:9|, CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O |a:2,3,6,10,13,&1:9|, [H][C@@]1([C@H](OC)[C@@H](CC[C@]11CO1)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O)[C@@]1(C)O[C@@H]1CC=C(C)C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1711","furamidine","protein arginine N-methyltransferase inhibitor","PRMT1",NA,NA,"NC(=N)c1ccc(cc1)-c1ccc(o1)-c1ccc(cc1)C(N)=N, NC(=N)c1ccc(cc1)-c1ccc(o1)-c1ccc(cc1)C(N)=N","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1712","furegrelate","thromboxane synthase inhibitor","TBXAS1",NA,NA,"OC(=O)c1cc2cc(Cc3cccnc3)ccc2o1, OC(=O)c1cc2cc(Cc3cccnc3)ccc2o1, OC(=O)c1cc2cc(Cc3cccnc3)ccc2o1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1713","furosemide","diuretic","CA2, GPR35, SLC12A1, SLC12A2","cardiology, rheumatology","edema, hypertension, congestive heart failure, nephrotic syndrome","NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl, NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl, NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl, NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl, NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl, NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl","Launched",1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1714","furprofen","prostagladin inhibitor","PTGS2","neurology/psychiatry","pain relief","C[C@@H](C(O)=O)c1ccc(cc1)C(=O)c1ccco1 |&1:1,r|",NA,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1715","F351","TGF beta receptor inhibitor","TGFB1",NA,NA,"Cc1ccc(=O)n(c1)-c1ccc(O)cc1, Cc1ccc(=O)n(c1)-c1ccc(O)cc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1716","g-caryophyllene","acetylcholinesterase inhibitor","ACHE",NA,NA,"C\C1=C/CCC(=C)[C@H]2CC(C)(C)[C@@H]2CC1 |c:1|, C\C1=C/CCC(=C)[C@H]2CC(C)(C)[C@@H]2CC1 |c:1|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1717","G-1","G protein-coupled receptor agonist","GPER1",NA,NA,"CC(=O)c1ccc2N[C@H]([C@H]3CC=C[C@H]3c2c1)c1cc2OCOc2cc1Br |c:11|, CC(=O)c1ccc2N[C@H]([C@H]3CC=C[C@H]3c2c1)c1cc2OCOc2cc1Br |c:11|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1718","G-15","estrogen receptor antagonist","GPER1",NA,NA,"Brc1cc2OCOc2cc1[C@H]1Nc2ccccc2[C@H]2C=CC[C@@H]12 |&1:10,18,22,c:22|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1719","gabapentin","calcium channel blocker","ADORA1, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CACNG2, CACNG3, CACNG4, CACNG5, CACNG6, CACNG7, CACNG8, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B","infectious disease, neurology/psychiatry","virus herpes simplex (HSV), shingles, seizures, restless leg syndrome","NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1720","gabapentin-enacarbil","adrenergic receptor agonist","CACNA1G","neurology/psychiatry","restless leg syndrome, postherpetic neuralgia","CC(C)C(=O)O[C@@H](C)OC(=O)NCC1(CC(O)=O)CCCCC1 |&1:6,r|, CC(C)C(=O)O[C@@H](C)OC(=O)NCC1(CC(O)=O)CCCCC1 |&1:6,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1721","gabazine","GABA receptor antagonist","GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRG2",NA,NA,"COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1, COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1, COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1, COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1, COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,1,7,0,0,0,0,0,0,0,0,0,0
"1722","gabexate","serine protease inhibitor","PRSS1, TPSAB1","gastroenterology","pancreatitis","CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1, CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1, CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1, CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1, CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1, CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1, CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1723","gaboxadol","benzodiazepine receptor agonist","GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRD, GABRR1, GABRR2, GABRR3",NA,NA,"O=c1[nH]oc2CNCCc12, O=c1[nH]oc2CNCCc12, O=c1[nH]oc2CNCCc12, O=c1[nH]oc2CNCCc12, O=c1[nH]oc2CNCCc12","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,1,10,0,0,0,0,0,0,0,0,0,0
"1724","gadopentetic-acid","contrast agent","PGD","radiology","contrast agent","OC(=O)CN1CCN2CCN(CC(O)=O)CC(=O)O[Gd](OC(=O)C1)OC(=O)C2","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1725","galantamine","acetylcholinesterase inhibitor","ACHE, BCHE, CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG","neurology/psychiatry","senile dementia","COc1ccc2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3Oc1c24 |c:12|, COc1ccc2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3Oc1c24 |c:12|, COc1ccc2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3Oc1c24 |c:12|, COc1ccc2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3Oc1c24 |c:12|, COc1ccc2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3Oc1c24 |c:12|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,16,0,0,1,1,1,1
"1726","galeterone","androgen receptor modulator","AR, CYP17A1",NA,NA,"[H][C@@]12CC=C(n3cnc4ccccc34)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C |t:3,27|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1727","gallamine-triethiodide","acetylcholine receptor antagonist","CHRM2, CHRNA1","neurology/psychiatry","muscle relaxant","CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC, CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC, CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC, CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC, CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC, CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,1,1,1,1
"1728","gallic-acid","beta amyloid protein neurotoxicity inhibitor, PPAR receptor agonist","CA1, CA12, CA14, CA2, CA4, CA6, CA9, SELP",NA,NA,"OC(=O)c1cc(O)c(O)c(O)c1, OC(=O)c1cc(O)c(O)c(O)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1729","gallopamil","L-type calcium channel blocker","ATP2A2","cardiology","hypertension, cardiac arrythmia","COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2cc(OC)c(OC)c(OC)c2)cc1OC |&1:13|, COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2cc(OC)c(OC)c(OC)c2)cc1OC |&1:13|, COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2cc(OC)c(OC)c(OC)c2)cc1OC |&1:13|, COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2cc(OC)c(OC)c(OC)c2)cc1OC |&1:13|, COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2cc(OC)c(OC)c(OC)c2)cc1OC |&1:13|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1730","gambogic-acid","caspase activator","BCL2",NA,NA,"CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C |c:22,33|, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C |c:22,33|, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C |c:22,33|, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C |c:22,33|, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C |c:22,33|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1731","gamma-aminobutyric-acid","benzodiazepine receptor agonist","GABBR1, GABBR2, GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2, GATM, KCTD12, KCTD16, KCTD8, SLC6A1",NA,NA,"NCCCC(O)=O, NCCCC(O)=O, NCCCC(O)=O, NCCCC(O)=O","Preclinical",1,1,0,0,0,0,0,0,0,0,0,0,1,6,0,0,0,0,0,0,0,0,0,0
"1732","gamma-linolenic-acid","cyclooxygenase inhibitor, prostanoid receptor agonist","PTGS1, PTGS2",NA,NA,"CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O","Phase 2",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1733","ganaxolone","GABA receptor modulator","GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6",NA,NA,"CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,1,6,0,0,0,0,0,0,0,0,0,0
"1734","ganetespib","HSP inhibitor","HSP90AA1",NA,NA,"CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O, CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O, CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O, CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O, CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O, CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O, CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1735","GANT-58","GLI antagonist","GLI1",NA,NA,"c1cc(ccn1)-c1sc(c(c1-c1ccncc1)-c1ccncc1)-c1ccncc1, c1cc(ccn1)-c1sc(c(c1-c1ccncc1)-c1ccncc1)-c1ccncc1, c1cc(ccn1)-c1sc(c(c1-c1ccncc1)-c1ccncc1)-c1ccncc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1736","GANT-61","GLI antagonist","GLI1, GLI2",NA,NA,"CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1, CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1, CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1, CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1, CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1, CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1, CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1, CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1, CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1737","garenoxacin","topoisomerase inhibitor","TOP2A","infectious disease","respiratory tract infections","C[C@H]1NCc2cc(ccc12)-c1ccc2c(c1OC(F)F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1NCc2cc(ccc12)-c1ccc2c(c1OC(F)F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1NCc2cc(ccc12)-c1ccc2c(c1OC(F)F)n(cc(C(O)=O)c2=O)C1CC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1738","gavestinel","glutamate receptor antagonist","GLRB, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B",NA,NA,"OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1, OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1, OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1, OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1739","gavorestat","aldose reductase inhibitor","AKR1B1",NA,NA,"OC(=O)Cc1nn(Cc2nc3cc(ccc3s2)C(F)(F)F)c(=O)c2cscc12",NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1740","GBR-12935","dopamine reuptake inhibitor","AGTR1, SLC6A3",NA,NA,"C(CN1CCN(CCOC(c2ccccc2)c2ccccc2)CC1)Cc1ccccc1, C(CN1CCN(CCOC(c2ccccc2)c2ccccc2)CC1)Cc1ccccc1","Preclinical",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1741","GBR-13069","dopamine reuptake inhibitor","SLC6A3",NA,NA,"Fc1ccc(cc1)C(OCCN1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1","Preclinical",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1742","GDC-0068","AKT inhibitor","AKT1, AKT2, AKT3, PRKG1",NA,NA,"CC(C)NC[C@@H](C(=O)N1CCN(CC1)c1ncnc2[C@H](O)C[C@@H](C)c12)c1ccc(Cl)cc1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1743","GDC-0152","XIAP inhibitor","BIRC2, BIRC3, BIRC7, XIAP",NA,NA,"CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1744","GDC-0349","Pim kinase inhibitor","PIK3CA",NA,NA,"CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1745","GDC-0810","selective estrogen receptor destabilizer","ESR1",NA,NA,"CC\C(=C(\c1ccc(\C=C\C(O)=O)cc1)c1ccc2n[nH]cc2c1)c1ccc(F)cc1Cl, CC\C(=C(\c1ccc(\C=C\C(O)=O)cc1)c1ccc2n[nH]cc2c1)c1ccc(F)cc1Cl, CC\C(=C(\c1ccc(\C=C\C(O)=O)cc1)c1ccc2n[nH]cc2c1)c1ccc(F)cc1Cl","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1746","GDC-0834","Bruton's tyrosine kinase (BTK) inhibitor","BTK",NA,NA,"CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|, CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|, CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|, CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|, CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|, CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|, CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|, CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1747","GDC-0879","RAF inhibitor","BRAF",NA,NA,"OCCn1cc(c(n1)-c1ccncc1)-c1ccc2\C(CCc2c1)=N\O, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2\C(CCc2c1)=N\O, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2\C(CCc2c1)=N\O, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2\C(CCc2c1)=N\O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1748","GDC-0941","PI3K inhibitor","PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,"CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1, CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1, CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1, CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1, CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1, CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1, CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1, CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1749","GDC-0980","mTOR inhibitor, PI3K inhibitor","FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK",NA,NA,"C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1750","GDC-0994","MAP kinase inhibitor","MAPK1, MAPK3",NA,NA,"Cn1nccc1Nc1nccc(n1)-c1ccn([C@@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1 |&1:17,r|, Cn1nccc1Nc1nccc(n1)-c1ccn([C@@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1 |&1:17,r|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1751","gedunin","HSP inhibitor","HSP90AA1",NA,NA,"CC(=O)O[C@@H]1C[C@H]2C(C)(C)C(=O)C=C[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](OC(=O)[C@H]4O[C@@]34[C@]12C)c1ccoc1 |c:12|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1752","gefitinib","EGFR inhibitor","EGFR","oncology","non-small cell lung cancer (NSCLC)","COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1753","geldanamycin","HSP inhibitor","HSP90AA1",NA,NA,"CO[C@H]1C[C@H](C)CC2=C(OC)C(=O)C=C(NC(=O)\C(C)=C\C=C\[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,t:13,19,21,32|, CO[C@H]1C[C@H](C)CC2=C(OC)C(=O)C=C(NC(=O)\C(C)=C\C=C\[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,t:13,19,21,32|, CO[C@H]1C[C@H](C)CC2=C(OC)C(=O)C=C(NC(=O)\C(C)=C\C=C\[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,t:13,19,21,32|, CO[C@H]1C[C@H](C)CC2=C(OC)C(=O)C=C(NC(=O)\C(C)=C\C=C\[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,t:13,19,21,32|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1754","gemcabene","ppar receptor agonist","APOB, LPA, PCSK9, PPARA, PPARG","endocrinology","hypercholesterolemia","CC(C)(CCCCOCCCCC(C)(C)C(O)=O)C(O)=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1755","gemcitabine","ribonucleotide reductase inhibitor","CMPK1, RRM1, RRM2, TYMS","oncology","ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer","Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1756","gemcitabine-elaidate","apoptosis inhibitor, DNA synthesis inhibitor","CMPK1, RRM1, TYMS",NA,NA,"CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O, CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O, CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O, CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O, CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1757","gemfibrozil","lipoprotein lipase activator","LPL, PPARA, SLCO1B1, SLCO1B3, SLCO2B1","endocrinology, cardiology","hyperlipidemia, coronary heart disease","Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1, Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1, Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1, Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1, Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1","Launched",1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1758","gemilukast","leukotriene receptor antagonist","CYSLTR1, CYSLTR2","pulmonary","asthma","O=C(O)CCCN1C(C)=C(CCCC(O)=O)C2=C1C(C#CC3=CC=C(OCCCCC4=CC=CC(F)=C4C)C=C3)=CC=C2F","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1759","geniposide","GLP receptor agonist","GLP1R",NA,NA,"COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO |c:25,t:4|, COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO |c:25,t:4|, COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO |c:25,t:4|, COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO |c:25,t:4|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1760","genistein","tyrosine kinase inhibitor","CFTR, ESR1, ESR2, ESRRA, ESRRB, ESRRG, NCOA1, NCOA2, PPARG, PTK2B, TOP2A, TRPC5",NA,NA,"Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O, Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O, Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O, Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O, Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O, Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O","Phase 2/Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1761","gentamycin","bacterial 50S ribosomal subunit inhibitor","HSPA8","infectious disease, critical care","bone and joint infections, endocarditis, pelvic inflammatory disease, meningitis, pneumonia, urinary tract infections, sepsis","CN[C@H](C)[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1762","gentiopicrin","glutamate receptor downregulator","GRIN2B",NA,NA,"OC[C@H]1O[C@@H](O[C@@H]2OC=C3C(=O)OCC=C3[C@H]2C=C)[C@H](O)[C@@H](O)[C@@H]1O |c:14,t:8|, OC[C@H]1O[C@@H](O[C@@H]2OC=C3C(=O)OCC=C3[C@H]2C=C)[C@H](O)[C@@H](O)[C@@H]1O |c:14,t:8|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1763","genz-123346","glucosylceramidase inhibitor","UGCG",NA,NA,"CCCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1, CCCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1764","genz-644282","topoisomerase inhibitor","TOP1",NA,NA,"CNCCn1c2c3cc4OCOc4cc3ncc2c2cc(OC)c(OC)cc2c1=O, CNCCn1c2c3cc4OCOc4cc3ncc2c2cc(OC)c(OC)cc2c1=O, CNCCn1c2c3cc4OCOc4cc3ncc2c2cc(OC)c(OC)cc2c1=O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1765","gestrinone","progesterone receptor antagonist","AR, ESR1, PGR","obstetrics/gynecology","endometriosis","CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C |c:3,5,11|, CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C |c:3,5,11|, CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C |c:3,5,11|, CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C |c:3,5,11|, CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C |c:3,5,11|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1766","GF109203X","PKC inhibitor","PDPK1, PIM1, PRKCI, PRKCZ",NA,NA,"CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|, CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|, CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|, CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|, CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|, CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|, CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1767","GGsTop","gamma glutamyltransferase Inhibitor","GGT1",NA,NA,"COP(=O)(CC[C@@H](N)C(O)=O)Oc1cccc(CC(O)=O)c1 |&1:2,&2:6,r|, COP(=O)(CC[C@@H](N)C(O)=O)Oc1cccc(CC(O)=O)c1 |&1:2,&2:6,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1768","GGTI-298","GGTase inhibitor","CDKN1A",NA,NA,"COC(=O)[C@H](CC(C)C)NC(=O)c1ccc(NC[C@@H](N)CS)cc1-c1cccc2ccccc12, COC(=O)[C@H](CC(C)C)NC(=O)c1ccc(NC[C@@H](N)CS)cc1-c1cccc2ccccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1769","gilteritinib","FLT3 inhibitor","FLT3",NA,NA,"CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(CC3)N3CCN(C)CC3)c(OC)c2)nc1NC1CCOCC1, CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(CC3)N3CCN(C)CC3)c(OC)c2)nc1NC1CCOCC1, CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(CC3)N3CCN(C)CC3)c(OC)c2)nc1NC1CCOCC1, CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(CC3)N3CCN(C)CC3)c(OC)c2)nc1NC1CCOCC1, CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(CC3)N3CCN(C)CC3)c(OC)c2)nc1NC1CCOCC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1770","gimeracil","dihydropyrimidine dehydrogenase inhibitor","DPYD","oncology","gastric adenocarcinoma","Oc1cc(=O)[nH]cc1Cl, Oc1cc(=O)[nH]cc1Cl","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1771","ginkgolide-A","GABA receptor antagonist","GLRA1, GLRB",NA,NA,"C[C@@H]1C(=O)O[C@H]2C[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1772","ginkgolide-B","platelet activating factor receptor antagonist","GLRA1, GLRA2, GLRA3, GLRB, HTR3A, HTR3B",NA,NA,"C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O, C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O, C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O, C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O, C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O, C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O","Phase 3",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1773","ginsenoside rg1","solute carrier family member inhibitor","SLCO1B3","neurology/psychiatry","alzheimer's disease","[H][C@]12C(C)(C)[C@@H](O)CC[C@]1(C)[C@]3([H])[C@@]([C@@](CC[C@]4([H])[C@@](CC/C=C(C)/C)(C)O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)(C)[C@]4([H])[C@H](O)C3)(C)C[C@@H]2O[C@]6([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O","Preclinical",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1774","ginsenoside-C-K","NFkB pathway inhibitor, nitric oxide synthase inhibitor","PTGS2",NA,NA,"CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C","Phase 1",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1775","ginsenoside-RE3","angiogenesis inhibitor, apoptosis stimulant","KCNH2",NA,NA,"CC(C)=CCC[C@@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C |a:9,12,14,15,18,19,23,25,27,30,32,34,36,38,41,43,45,50,53,&1:6|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1776","givinostat","HDAC inhibitor","HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",NA,NA,"CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1777","GKA-50","glucokinase activator","GCK",NA,NA,"COC[C@H](C)Oc1cc(O[C@@H](C)Cc2ccccc2)cc(c1)C(=O)Nc1ccc(cn1)C(O)=O, COC[C@H](C)Oc1cc(O[C@@H](C)Cc2ccccc2)cc(c1)C(=O)Nc1ccc(cn1)C(O)=O, COC[C@H](C)Oc1cc(O[C@@H](C)Cc2ccccc2)cc(c1)C(=O)Nc1ccc(cn1)C(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1778","GKT137831","NADPH oxidase inhibitor","NOX1, NOX4",NA,NA,"CN(C)c1cccc(c1)-c1n(C)c(=O)cc2[nH]n(-c3ccccc3Cl)c(=O)c12, CN(C)c1cccc(c1)-c1n(C)c(=O)cc2[nH]n(-c3ccccc3Cl)c(=O)c12, CN(C)c1cccc(c1)-c1n(C)c(=O)cc2[nH]n(-c3ccccc3Cl)c(=O)c12, CN(C)c1cccc(c1)-c1n(C)c(=O)cc2[nH]n(-c3ccccc3Cl)c(=O)c12","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1779","GK921","transglutaminase inhibitor","TGM2",NA,NA,"C(CN1CCCC1)Oc1nc2cccnc2nc1C#Cc1ccccc1, C(CN1CCCC1)Oc1nc2cccnc2nc1C#Cc1ccccc1, C(CN1CCCC1)Oc1nc2cccnc2nc1C#Cc1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1780","glafenine","cystic fibrosis transmembrane conductance regulator inhibitor, DeltaF508-CFTR Correctors, deltaf508-cftr correctors, cystic fibrosis transmembrane conductance regulator inhibitor","CFTR","Pulmonology","pain relief","OC[C@@H](O)COC(=O)c1ccccc1Nc1ccnc2cc(Cl)ccc12 |&1:2|, OC[C@@H](O)COC(=O)c1ccccc1Nc1ccnc2cc(Cl)ccc12 |&1:2|, OC[C@@H](O)COC(=O)c1ccccc1Nc1ccnc2cc(Cl)ccc12 |r|, OCC(O)COC(=O)c1ccccc1Nc1ccnc2cc(Cl)ccc12","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1781","glasdegib","hedgehog pathway inhibitor","SMO","hematologic malignancy","acute myeloid leukemia (AML)","CN1CC[C@H](C[C@@H]1c1nc2ccccc2[nH]1)NC(=O)Nc1ccc(cc1)C#N, CN1CC[C@H](C[C@@H]1c1nc2ccccc2[nH]1)NC(=O)Nc1ccc(cc1)C#N, CN1CC[C@H](C[C@@H]1c1nc2ccccc2[nH]1)NC(=O)Nc1ccc(cc1)C#N, CN1CC[C@H](C[C@@H]1c1nc2ccccc2[nH]1)NC(=O)Nc1ccc(cc1)C#N, CN1CC[C@H](C[C@@H]1c1nc2ccccc2[nH]1)NC(=O)Nc1ccc(cc1)C#N","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1782","glimepiride","insulin secretagogue","ABCC8, KCNJ1, KCNJ11","endocrinology","diabetes mellitus","CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O |r,c:2|, CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O |r,c:2|, CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O |r,c:2|, CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O |r,c:2|, CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O |r,c:2|, CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O |r,c:2|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1783","glipizide","sulfonylurea","ABCC8, KCNJ10, KCNJ11, PPARG","endocrinology","diabetes mellitus, hyperglycemia","Cc1cnc(cn1)C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, Cc1cnc(cn1)C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, Cc1cnc(cn1)C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1784","gliquidone","sulfonylurea","ABCC8, KCNJ10, KCNJ8","endocrinology","diabetes mellitus","COc1ccc2c(c1)C(=O)N(CCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1)C(=O)C2(C)C, COc1ccc2c(c1)C(=O)N(CCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1)C(=O)C2(C)C, COc1ccc2c(c1)C(=O)N(CCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1)C(=O)C2(C)C, COc1ccc2c(c1)C(=O)N(CCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1)C(=O)C2(C)C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1785","GLPG0492","androgen receptor modulator","AR",NA,NA,"CN1C(=O)N(C(=O)[C@@]1(CO)c1ccccc1)c1ccc(C#N)c(c1)C(F)(F)F, CN1C(=O)N(C(=O)[C@@]1(CO)c1ccccc1)c1ccc(C#N)c(c1)C(F)(F)F, CN1C(=O)N(C(=O)[C@@]1(CO)c1ccccc1)c1ccc(C#N)c(c1)C(F)(F)F","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1786","GLPG0492-R-enantiomer","androgen receptor modulator","AR",NA,NA,"CN1C(=O)N(C(=O)[C@]1(CO)c1ccccc1)c1ccc(C#N)c(c1)C(F)(F)F, CN1C(=O)N(C(=O)[C@]1(CO)c1ccccc1)c1ccc(C#N)c(c1)C(F)(F)F, CN1C(=O)N(C(=O)[C@]1(CO)c1ccccc1)c1ccc(C#N)c(c1)C(F)(F)F","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1787","glpg0974","free fatty acid receptor antagonist","FFAR2","gastroenterology","ulcerative colitis","C[C@@]1(CCN1C(=O)c1csc2ccccc12)C(=O)N(CCCC(O)=O)Cc1cccc(Cl)c1 |a:1|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1788","glucosamine","glycosylated protein precursor","IL1B","neurology/psychiatry, rheumatology","muscle pain, rheumatoid arthritis, joint pain, backache","N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1789","glutathione","antioxidant","ESD, GGT1, GLO1, GLRX, GLRX2, GPX1, GPX2, GPX3, GPX4, GPX5, GPX6, GPX7, GPX8, GSR, GSS, GSTA1, GSTA2, GSTA3, GSTA4, GSTA5, GSTK1, GSTM1, GSTM2, GSTM3, GSTM4, GSTM5, GSTO1, GSTO2, GSTP1, GSTT1, GSTZ1, HAGH, HPGDS, LTC4S, MGST1, MGST2, MGST3, TXNDC12",NA,NA,"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O, N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1790","glutathione disulfide","glutathione reductase (nadph) activators","GSR, GSTM2, MGST1","ophthalmology","ocular hypertension","C(CC(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1791","glyburide","ATP channel blocker, insulin secretagogue, sulfonylurea","ABCA1, ABCB11, ABCC8, ABCC9, CFTR, CPT1A, KCNJ1, KCNJ11, KCNJ5, KCNJ8, SLCO2B1","endocrinology","diabetes mellitus, hyperglycemia","COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1792","glycitein","tumor necrosis factor release inhibitor","TNF",NA,NA,"COc1cc2c(cc1O)occ(-c1ccc(O)cc1)c2=O, COc1cc2c(cc1O)occ(-c1ccc(O)cc1)c2=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1793","glycol salicylate","prostaglandin inhibitor","PTGS1, PTGS2","neurology/psychiatry","muscle pain","C1=CC=C(C(=C1)C(=O)OCCO)O","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1794","glycopyrrolate","acetylcholine receptor antagonist","CHRM1, CHRM2, CHRM3, CHRM4, CHRM5","gastroenterology","peptic ulcer disease (PUD)","C[N+]1(C)CC[C@@H](C1)OC(=O)[C@@](O)(C1CCCC1)c1ccccc1 |&1:5,&2:10|, C[N+]1(C)CC[C@@H](C1)OC(=O)[C@@](O)(C1CCCC1)c1ccccc1 |&1:5,&2:10|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,5,0,0,1,1,1,1
"1795","GM-1485","immunophilin ligand","FKBP1A",NA,NA,"CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1796","GMX1778","NAMPT inhibitor","NAMPT",NA,NA,"Clc1ccc(OCCCCCCN\C(NC#N)=N\c2ccncc2)cc1, Clc1ccc(OCCCCCCN\C(NC#N)=N\c2ccncc2)cc1, Clc1ccc(OCCCCCCN\C(NC#N)=N\c2ccncc2)cc1","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1797","gne-477","mtor inhibitor","MTOR, PIK3CA","oncology","renal cell carcinoma (rcc)","NC1=NC=C(C2=NC(N3CCOCC3)=C4C(C(C)=C(CN5CCN(S(=O)(C)=O)CC5)S4)=N2)C=N1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1798","GNF-2","Bcr-Abl kinase inhibitor","ABL1, BCR",NA,NA,"NC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1, NC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1, NC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1, NC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1799","GNF-5","Bcr-Abl kinase inhibitor","ABL1, BCR",NA,NA,"OCCNC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1, OCCNC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1, OCCNC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1800","GNF-5837","growth factor receptor inhibitor","NTRK1, NTRK2, NTRK3",NA,NA,"Cc1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)cc1Nc1ccc2\C(=C\c3ccc[nH]3)C(=O)Nc2c1, Cc1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)cc1Nc1ccc2\C(=C\c3ccc[nH]3)C(=O)Nc2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1801","GNF-7","glucokinase inhibitor, protein kinase inhibitor","GCK, TNK2",NA,NA,"CN1C(=O)N(Cc2cnc(Nc3ccc(C)nc3)nc12)c1cc(NC(=O)c2cccc(c2)C(F)(F)F)ccc1C, CN1C(=O)N(Cc2cnc(Nc3ccc(C)nc3)nc12)c1cc(NC(=O)c2cccc(c2)C(F)(F)F)ccc1C, CN1C(=O)N(Cc2cnc(Nc3ccc(C)nc3)nc12)c1cc(NC(=O)c2cccc(c2)C(F)(F)F)ccc1C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1802","GNTI","opioid receptor antagonist","OPRK1, OPRM1",NA,NA,"NC(=N)Nc1ccc2[nH]c3[C@@H]4Oc5c6c(C[C@H]7N(CC8CC8)CC[C@@]46[C@@]7(O)Cc3c2c1)ccc5O, NC(=N)Nc1ccc2[nH]c3[C@@H]4Oc5c6c(C[C@H]7N(CC8CC8)CC[C@@]46[C@@]7(O)Cc3c2c1)ccc5O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1803","go-6983","protein kinase inhibitor","PRKCA, PRKCB, PRKCD, PRKCG, PRKCZ",NA,NA,"COc1ccc2n(CCCN(C)C)cc(C3=C(C(=O)NC3=O)c3c[nH]c4ccccc34)c2c1 |t:15|, COc1ccc2n(CCCN(C)C)cc(C3=C(C(=O)NC3=O)c3c[nH]c4ccccc34)c2c1 |t:15|, COc1ccc2n(CCCN(C)C)cc(C3=C(C(=O)NC3=O)c3c[nH]c4ccccc34)c2c1 |t:15|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1804","golgicide-A","ARF inhibitor","GBF1",NA,NA,"Fc1cc(F)c2N[C@@H]([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1 |a:8,12,&1:7,c:10|, Fc1cc(F)c2N[C@@H]([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1 |a:8,12,&1:7,c:10|, Fc1cc(F)c2N[C@@H]([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1 |a:8,12,&1:7,c:10|, Fc1cc(F)c2N[C@@H]([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1 |a:8,12,&1:7,c:10|, Fc1cc(F)c2N[C@@H]([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1 |a:8,12,&1:7,c:10|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1805","golvatinib","VEGFR inhibitor","KDR, MET",NA,NA,"CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1, CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1, CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1, CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1806","gonadorelin","gonadotropin releasing factor hormone receptor agonist","GNRHR","obstetrics/gynecology","cystic ovaries, reproductive synchrony","CC(C)C[C@H](NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1807","goserelin-acetate","gonadotropin releasing factor hormone receptor agonist","GNRHR, LHCGR","oncology, obstetrics/gynecology","prostate cancer, breast cancer, endometriosis","CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O, CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1808","gossypol","BCL inhibitor, MCL1 inhibitor","BCL2",NA,NA,"CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1809","GPBAR-A","G protein-coupled receptor agonist","GPBAR1",NA,NA,"Fc1ccccc1-c1ccnc2OCC(=O)N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)Cc12, Fc1ccccc1-c1ccnc2OCC(=O)N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)Cc12, Fc1ccccc1-c1ccnc2OCC(=O)N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)Cc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1810","GPI-1046","FKBP inhibitor","FKBP1A",NA,NA,"CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(=O)OCCCc1cccnc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1811","GPP-78","NAMPT inhibitor","NAMPT",NA,NA,"O=C(CCCCCCCn1cc(nn1)-c1cccnc1)Nc1ccccc1-c1ccccc1, O=C(CCCCCCCn1cc(nn1)-c1cccnc1)Nc1ccccc1-c1ccccc1, O=C(CCCCCCCn1cc(nn1)-c1cccnc1)Nc1ccccc1-c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1812","GPR120-modulator-1","G protein-coupled receptor modulator","FFAR4",NA,NA,"Cc1cc(OCc2nc(cs2)-c2ccccc2Cl)ccc1OCC(O)=O, Cc1cc(OCc2nc(cs2)-c2ccccc2Cl)ccc1OCC(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1813","GP1a","cannabinoid receptor agonist","CNR2",NA,NA,"Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1, Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1, Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1, Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1, Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1, Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1814","GP2a","cannabinoid receptor agonist","CNR2",NA,NA,"Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NC2CCCCC2)c1, Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NC2CCCCC2)c1, Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NC2CCCCC2)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1815","GR-103691","dopamine receptor antagonist","DRD3",NA,NA,"COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(cc2)-c2ccc(cc2)C(C)=O)CC1, COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(cc2)-c2ccc(cc2)C(C)=O)CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0
"1816","GR-113808","serotonin receptor antagonist","HTR4",NA,NA,"Cn1cc(C(=O)OCC2CCN(CCNS(C)(=O)=O)CC2)c2ccccc12, Cn1cc(C(=O)OCC2CCN(CCNS(C)(=O)=O)CC2)c2ccccc12","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1817","GR-127935","serotonin receptor antagonist","HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6",NA,NA,"COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1N1CCN(C)CC1, COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1N1CCN(C)CC1, COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1N1CCN(C)CC1, COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1N1CCN(C)CC1, COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1N1CCN(C)CC1","Preclinical",0,0,0,0,0,0,0,0,1,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1818","GR-144053","integrin antagonist","ITGA2B, ITGB3",NA,NA,"NC(=N)c1ccc(cc1)N1CCN(CC1)C1CCN(CC(O)=O)CC1, NC(=N)c1ccc(cc1)N1CCN(CC1)C1CCN(CC(O)=O)CC1, NC(=N)c1ccc(cc1)N1CCN(CC1)C1CCN(CC(O)=O)CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1819","GR-159897","tachykinin antagonist","TAC1, TACR2",NA,NA,"COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1, COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1, COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1, COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1, COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1820","GR-235","estrogen receptor agonist, FXR antagonist, progesterone receptor agonist","NR1H4",NA,NA,"[H][C@@]12CC(=O)C(=CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C |t:20|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1821","GR-79236","adenosine receptor agonist","ADORA1, ADORA2A",NA,NA,"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@H]3CCC[C@@H]3O)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@H]3CCC[C@@H]3O)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@H]3CCC[C@@H]3O)ncnc12","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1822","granisetron","serotonin receptor antagonist","HTR3A","gastroenterology","nausea, vomiting","CN1[C@H]2CCC[C@@H]1C[C@@H](C2)NC(=O)c1nn(C)c2ccccc12 |&1:2,&2:6,&3:8|, CN1[C@H]2CCC[C@@H]1C[C@@H](C2)NC(=O)c1nn(C)c2ccccc12 |&1:2,&2:6,&3:8|, CN1[C@H]2CCC[C@@H]1C[C@@H](C2)NC(=O)c1nn(C)c2ccccc12 |&1:2,&2:6,&3:8|","Launched",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1823","grapiprant","prostaglandin inhibitor","PTGER4","rheumatology","osteoarthritis","CCc1nc2c(C)nc(C)cc2n1-c1ccc(CCNC(=O)NS(=O)(=O)c2ccc(C)cc2)cc1, CCc1nc2c(C)nc(C)cc2n1-c1ccc(CCNC(=O)NS(=O)(=O)c2ccc(C)cc2)cc1, CCc1nc2c(C)nc(C)cc2n1-c1ccc(CCNC(=O)NS(=O)(=O)c2ccc(C)cc2)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1824","griseofulvin","tubulin polymerization inhibitor","KRT12","infectious disease","ringworm, tinea pedis","COC1=CC(=O)C[C@@H](C)[C@]11Oc2c(C1=O)c(OC)cc(OC)c2Cl |t:2|, COC1=CC(=O)C[C@@H](C)[C@]11Oc2c(C1=O)c(OC)cc(OC)c2Cl |t:2|, COC1=CC(=O)C[C@@H](C)[C@]11Oc2c(C1=O)c(OC)cc(OC)c2Cl |t:2|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1825","GR125487","serotonin receptor antagonist","HTR4",NA,NA,"COc1[nH]c2ccc(F)cc2c1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1, COc1[nH]c2ccc(F)cc2c1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1, COc1[nH]c2ccc(F)cc2c1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1, COc1[nH]c2ccc(F)cc2c1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1826","GR46611","serotonin receptor agonist","HTR1D",NA,NA,"COc1ccc(CNC(=O)\C=C\c2ccc3[nH]cc(CCN(C)C)c3c2)cc1, COc1ccc(CNC(=O)\C=C\c2ccc3[nH]cc(CCN(C)C)c3c2)cc1, COc1ccc(CNC(=O)\C=C\c2ccc3[nH]cc(CCN(C)C)c3c2)cc1, COc1ccc(CNC(=O)\C=C\c2ccc3[nH]cc(CCN(C)C)c3c2)cc1","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1827","GS-143","ubiquitin ligase inhibitor","BTRC, NFKBIA",NA,NA,"OC(=O)c1ccc(cc1)N1N=C(Cc2ccccc2)\C(=C/c2ccc(o2)-c2ccccc2F)C1=O |t:11|, OC(=O)c1ccc(cc1)N1N=C(Cc2ccccc2)\C(=C/c2ccc(o2)-c2ccccc2F)C1=O |t:11|, OC(=O)c1ccc(cc1)N1N=C(Cc2ccccc2)\C(=C/c2ccc(o2)-c2ccccc2F)C1=O |t:11|, OC(=O)c1ccc(cc1)N1N=C(Cc2ccccc2)\C(=C/c2ccc(o2)-c2ccccc2F)C1=O |t:11|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1828","GS-39783","GABA receptor modulator","GABBR1",NA,NA,"CSc1nc(NC2CCCC2)c(c(NC2CCCC2)n1)[N+]([O-])=O, CSc1nc(NC2CCCC2)c(c(NC2CCCC2)n1)[N+]([O-])=O, CSc1nc(NC2CCCC2)c(c(NC2CCCC2)n1)[N+]([O-])=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1829","GS-6201","adenosine receptor antagonist","ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,"CCCn1c(=O)n(CC)c2nc([nH]c2c1=O)-c1cnn(Cc2cccc(c2)C(F)(F)F)c1, CCCn1c(=O)n(CC)c2nc([nH]c2c1=O)-c1cnn(Cc2cccc(c2)C(F)(F)F)c1, CCCn1c(=O)n(CC)c2nc([nH]c2c1=O)-c1cnn(Cc2cccc(c2)C(F)(F)F)c1, CCCn1c(=O)n(CC)c2nc([nH]c2c1=O)-c1cnn(Cc2cccc(c2)C(F)(F)F)c1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1830","GS-9620","toll-like receptor agonist","TLR7",NA,NA,"CCCCOc1nc(N)c2NC(=O)CN(Cc3cccc(CN4CCCC4)c3)c2n1, CCCCOc1nc(N)c2NC(=O)CN(Cc3cccc(CN4CCCC4)c3)c2n1, CCCCOc1nc(N)c2NC(=O)CN(Cc3cccc(CN4CCCC4)c3)c2n1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1831","GS-9973","SYK inhibitor","SYK",NA,NA,"C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1832","GSK-J1","histone demethylase inhibitor","KDM6B",NA,NA,"OC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, OC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, OC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, OC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1833","GSK-J4","histone lysine demethylase inhibitor","KDM6A, KDM6B",NA,NA,"CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1834","GSK-LSD-1","histone lysine demethylase inhibitor","KDM1A",NA,NA,"C1[C@@H](NC2CCNCC2)[C@@H]1c1ccccc1, C1[C@@H](NC2CCNCC2)[C@@H]1c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1835","GSK-3-inhibitor-IX","glycogen synthase kinase inhibitor, lipoxygenase inhibitor","GSK3A, GSK3B",NA,NA,"O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1836","gsk-626616","dual specificity protein kinase inhibitor","DYRK3","hematology","anemia","Clc1cccc(Cl)c1\N=C/2\NC(=O)\C(=C\c3ccc4nccnc4c3)\S2","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1837","GSK0660","PPAR receptor antagonist","PPARD",NA,NA,"COC(=O)c1sccc1S(=O)(=O)Nc1ccc(Nc2ccccc2)cc1OC, COC(=O)c1sccc1S(=O)(=O)Nc1ccc(Nc2ccccc2)cc1OC, COC(=O)c1sccc1S(=O)(=O)Nc1ccc(Nc2ccccc2)cc1OC","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1838","GSK1059615","PI3K inhibitor","PIK3CG",NA,NA,"O=C1NC(=O)\C(S1)=C\c1ccc2nccc(-c3ccncc3)c2c1, O=C1NC(=O)\C(S1)=C\c1ccc2nccc(-c3ccncc3)c2c1, O=C1NC(=O)\C(S1)=C\c1ccc2nccc(-c3ccncc3)c2c1, O=C1NC(=O)\C(S1)=C\c1ccc2nccc(-c3ccncc3)c2c1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1839","GSK1070916","Aurora kinase inhibitor","AURKA, AURKB, AURKC, CYP2D6, CYP3A4",NA,NA,"CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1, CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1, CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1, CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1840","GSK1292263","glucose dependent insulinotropic receptor agonist","GRPR",NA,NA,"CC(C)c1noc(n1)N1CCC(COc2ccc(nc2)-c2ccc(cc2)S(C)(=O)=O)CC1, CC(C)c1noc(n1)N1CCC(COc2ccc(nc2)-c2ccc(cc2)S(C)(=O)=O)CC1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1841","GSK1562590","urotensin receptor antagonist","UTS2R",NA,NA,"CN([C@@H](CN1CCCC1)c1ccc(cc1)-c1cccc(c1)C(N)=O)C(=O)CN1C(=O)COc2cc(Cl)c(Cl)cc12, CN([C@@H](CN1CCCC1)c1ccc(cc1)-c1cccc(c1)C(N)=O)C(=O)CN1C(=O)COc2cc(Cl)c(Cl)cc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1842","GSK163090","serotonin receptor antagonist","HTR1A, HTR1B, HTR1D",NA,NA,"Cc1ccc2c(cccc2n1)N1CCN(CCc2cccc(c2)N2CCNC2=O)CC1, Cc1ccc2c(cccc2n1)N1CCN(CCc2cccc(c2)N2CCNC2=O)CC1, Cc1ccc2c(cccc2n1)N1CCN(CCc2cccc(c2)N2CCNC2=O)CC1","Phase 2",0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1843","GSK1838705A","insulin growth factor receptor inhibitor","ALK, IGF1R, INSR, RPS6KA1",NA,NA,"CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1844","GSK1904529A","IGF-1 inhibitor, insulin growth factor receptor inhibitor, insulin receptor ligand","IGF1R, INSR",NA,NA,"CCc1cc(Nc2nccc(n2)-c2c(nc3ccccn23)-c2ccc(OC)c(c2)C(=O)Nc2c(F)cccc2F)c(OC)cc1N1CCC(CC1)N1CCN(CC1)S(C)(=O)=O, CCc1cc(Nc2nccc(n2)-c2c(nc3ccccn23)-c2ccc(OC)c(c2)C(=O)Nc2c(F)cccc2F)c(OC)cc1N1CCC(CC1)N1CCN(CC1)S(C)(=O)=O, CCc1cc(Nc2nccc(n2)-c2c(nc3ccccn23)-c2ccc(OC)c(c2)C(=O)Nc2c(F)cccc2F)c(OC)cc1N1CCC(CC1)N1CCN(CC1)S(C)(=O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1845","GSK2110183","AKT inhibitor","AKT1, AKT2, AKT3",NA,NA,"Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1, Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1, Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1, Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1, Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1846","GSK2126458","mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,"COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1, COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1, COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1, COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1, COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1, COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1, COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1847","GSK2190915","lipoxygenase inhibitor","ALOX5AP",NA,NA,"CCOc1ccc(cn1)-c1ccc(Cn2c(CC(C)(C)C(O)=O)c(SC(C)(C)C)c3cc(OCc4ccc(C)cn4)ccc23)cc1, CCOc1ccc(cn1)-c1ccc(Cn2c(CC(C)(C)C(O)=O)c(SC(C)(C)C)c3cc(OCc4ccc(C)cn4)ccc23)cc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1848","GSK2193874","transient receptor potential channel antagonist","TRPV4",NA,NA,"FC(F)(F)c1cccc(c1)-c1nc2cc(Br)ccc2c(C(=O)NC2(CC2)c2ccccc2)c1CN1CCC(CC1)N1CCCCC1, FC(F)(F)c1cccc(c1)-c1nc2cc(Br)ccc2c(C(=O)NC2(CC2)c2ccccc2)c1CN1CCC(CC1)N1CCCCC1, FC(F)(F)c1cccc(c1)-c1nc2cc(Br)ccc2c(C(=O)NC2(CC2)c2ccccc2)c1CN1CCC(CC1)N1CCCCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1849","GSK2194069","fatty acid synthase inhibitor","FASN",NA,NA,"O=C(C1CC1)N1CC[C@@H](Cc2n[nH]c(=O)n2-c2ccc(cc2)-c2ccc3occc3c2)C1, O=C(C1CC1)N1CC[C@@H](Cc2n[nH]c(=O)n2-c2ccc(cc2)-c2ccc3occc3c2)C1, O=C(C1CC1)N1CC[C@@H](Cc2n[nH]c(=O)n2-c2ccc(cc2)-c2ccc3occc3c2)C1, O=C(C1CC1)N1CC[C@@H](Cc2n[nH]c(=O)n2-c2ccc(cc2)-c2ccc3occc3c2)C1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1850","gsk2245035","toll-like receptor agonist","TLR7","pulmonary","asthma","O=C1NC2=C(N=C(N=C2N1CCCCCN3CCCCC3)O[C@H](CCC)C)N","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1851","GSK2256294A","epoxide hydolase inhibitor","EPHX2",NA,NA,"CNc1nc(C)nc(N[C@H]2CCC[C@H](C2)C(=O)NCc2ccc(cc2C(F)(F)F)C#N)n1, CNc1nc(C)nc(N[C@H]2CCC[C@H](C2)C(=O)NCc2ccc(cc2C(F)(F)F)C#N)n1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1852","GSK2330672","bile acid transporter inhibitor","SLC10A2",NA,NA,"CCCC[C@]1(CC)CS(=O)(=O)c2cc(CNC(CC(O)=O)CC(O)=O)c(OC)cc2[C@H](N1)c1ccccc1, CCCC[C@]1(CC)CS(=O)(=O)c2cc(CNC(CC(O)=O)CC(O)=O)c(OC)cc2[C@H](N1)c1ccccc1","Phase 2",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1853","GSK2334470","phosphoinositide dependent kinase inhibitor","AURKA, AURKB, PDPK1",NA,NA,"CNc1nc(cc(n1)-c1ccc2c(N)[nH]nc2c1)N1C[C@H](CC[C@H]1C)C(=O)NC1CCCCC1, CNc1nc(cc(n1)-c1ccc2c(N)[nH]nc2c1)N1C[C@H](CC[C@H]1C)C(=O)NC1CCCCC1, CNc1nc(cc(n1)-c1ccc2c(N)[nH]nc2c1)N1C[C@H](CC[C@H]1C)C(=O)NC1CCCCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1854","GSK256066","phosphodiesterase inhibitor","PDE4A",NA,NA,"COc1cccc(Nc2c(cnc3c(C)cc(cc23)S(=O)(=O)c2cccc(c2)C(=O)N(C)C)C(N)=O)c1, COc1cccc(Nc2c(cnc3c(C)cc(cc23)S(=O)(=O)c2cccc(c2)C(=O)N(C)C)C(N)=O)c1, COc1cccc(Nc2c(cnc3c(C)cc(cc23)S(=O)(=O)c2cccc(c2)C(=O)N(C)C)C(N)=O)c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1855","GSK2578215A","leucine rich repeat kinase inhibitor","LRRK2",NA,NA,"Fc1cc(ccn1)-c1ccc(OCc2ccccc2)c(c1)C(=O)Nc1cccnc1, Fc1cc(ccn1)-c1ccc(OCc2ccccc2)c(c1)C(=O)Nc1cccnc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1856","GSK2606414","protein kinase inhibitor","EIF2AK3, MYLK2",NA,NA,"Cn1cc(-c2ccc3N(CCc3c2)C(=O)Cc2cccc(c2)C(F)(F)F)c2c(N)ncnc12, Cn1cc(-c2ccc3N(CCc3c2)C(=O)Cc2cccc(c2)C(F)(F)F)c2c(N)ncnc12, Cn1cc(-c2ccc3N(CCc3c2)C(=O)Cc2cccc(c2)C(F)(F)F)c2c(N)ncnc12, Cn1cc(-c2ccc3N(CCc3c2)C(=O)Cc2cccc(c2)C(F)(F)F)c2c(N)ncnc12, Cn1cc(-c2ccc3N(CCc3c2)C(=O)Cc2cccc(c2)C(F)(F)F)c2c(N)ncnc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1857","GSK2636771","PI3K inhibitor","PIK3CB",NA,NA,"Cc1nc2c(cc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1)C(O)=O, Cc1nc2c(cc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1)C(O)=O, Cc1nc2c(cc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1)C(O)=O, Cc1nc2c(cc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1)C(O)=O, Cc1nc2c(cc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1)C(O)=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1858","GSK269962","rho associated kinase inhibitor","ROCK1, ROCK2",NA,NA,"CCn1c(nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc12)-c1nonc1N, CCn1c(nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc12)-c1nonc1N, CCn1c(nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc12)-c1nonc1N, CCn1c(nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc12)-c1nonc1N","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1859","GSK2801","bromodomain inhibitor","BAZ2A, BAZ2B",NA,NA,"CCCOc1ccn2c(cc(-c3ccccc3S(C)(=O)=O)c2c1)C(C)=O, CCCOc1ccn2c(cc(-c3ccccc3S(C)(=O)=O)c2c1)C(C)=O, CCCOc1ccn2c(cc(-c3ccccc3S(C)(=O)=O)c2c1)C(C)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1860","GSK2816126","histone lysine methyltransferase inhibitor","EZH2",NA,NA,"CC[C@H](C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCNCC1)C(=O)NCc1c(C)cc(C)[nH]c1=O, CC[C@H](C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCNCC1)C(=O)NCc1c(C)cc(C)[nH]c1=O, CC[C@H](C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCNCC1)C(=O)NCc1c(C)cc(C)[nH]c1=O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1861","GSK2830371","protein phosphatase inhibitor","PPM1D",NA,NA,"Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1, Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1, Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1862","GSK2837808A","lactate dehydrogenase inhibitor","LDHA",NA,NA,"COc1ncc(-c2ccc3c(Nc4cc(Oc5cc(F)cc(F)c5)cc(c4)C(O)=O)c(cnc3c2)S(=O)(=O)NC2CC2)c(OC)n1, COc1ncc(-c2ccc3c(Nc4cc(Oc5cc(F)cc(F)c5)cc(c4)C(O)=O)c(cnc3c2)S(=O)(=O)NC2CC2)c(OC)n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1863","GSK2879552","histone lysine demethylase inhibitor","KDM1A",NA,NA,"OC(=O)c1ccc(CN2CCC(CN[C@@H]3C[C@H]3c3ccccc3)CC2)cc1, OC(=O)c1ccc(CN2CCC(CN[C@@H]3C[C@H]3c3ccccc3)CC2)cc1, OC(=O)c1ccc(CN2CCC(CN[C@@H]3C[C@H]3c3ccccc3)CC2)cc1, OC(=O)c1ccc(CN2CCC(CN[C@@H]3C[C@H]3c3ccccc3)CC2)cc1, OC(=O)c1ccc(CN2CCC(CN[C@@H]3C[C@H]3c3ccccc3)CC2)cc1","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1864","gsk2983559 (free acid)","ripk inhibitor","RIPK2","gastroenterology","inflammatory bowel disease","CC(C)(C)S(C(C(OCCOP(O)(O)=O)=CC1=NC=N2)=CC1=C2NC3=CC(N=CS4)=C4C=C3)(=O)=O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1865","GSK37647","free fatty acid receptor agonist","FFAR4",NA,NA,"COc1ccc(cc1)S(=O)(=O)Nc1c(C)cc(C)cc1C, COc1ccc(cc1)S(=O)(=O)Nc1c(C)cc(C)cc1C, COc1ccc(cc1)S(=O)(=O)Nc1c(C)cc(C)cc1C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1866","GSK3787","PPAR receptor antagonist","PPARD",NA,NA,"FC(F)(F)c1ccc(nc1)S(=O)(=O)CCNC(=O)c1ccc(Cl)cc1, FC(F)(F)c1ccc(nc1)S(=O)(=O)CCNC(=O)c1ccc(Cl)cc1, FC(F)(F)c1ccc(nc1)S(=O)(=O)CCNC(=O)c1ccc(Cl)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1867","GSK429286A","rho associated kinase inhibitor","ROCK1",NA,NA,"CC1=C([C@@H](CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2c[nH]nc2cc1F |&1:3,r,t:1|, CC1=C([C@@H](CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2c[nH]nc2cc1F |&1:3,r,t:1|, CC1=C([C@@H](CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2c[nH]nc2cc1F |&1:3,r,t:1|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1868","GSK461364","PLK inhibitor","PLK1",NA,NA,"C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F, C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F, C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F, C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1869","GSK503","histone lysine methyltransferase inhibitor","EZH2",NA,NA,"CC(C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCN(C)CC1)C(=O)NCc1c(C)cc(C)[nH]c1=O, CC(C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCN(C)CC1)C(=O)NCc1c(C)cc(C)[nH]c1=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1870","GSK650394","serum/glucocorticoid regulated kinase inhibitor","SGK1, SGK2",NA,NA,"OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1871","GSK690693","AKT inhibitor","AKT1, AKT2, AKT3, PAK4, PAK6, PAK7, PRKCQ, PRKG1, PRKX",NA,NA,"CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N, CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N, CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N, CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N, CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N, CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N, CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1872","GSK9027","glucocorticoid receptor agonist","NR3C1",NA,NA,"Fc1ccc(cc1)-n1ncc2cc(ccc12)-c1ccc(NS(=O)(=O)Cc2ccccc2)cc1C(F)(F)F, Fc1ccc(cc1)-n1ncc2cc(ccc12)-c1ccc(NS(=O)(=O)Cc2ccccc2)cc1C(F)(F)F, Fc1ccc(cc1)-n1ncc2cc(ccc12)-c1ccc(NS(=O)(=O)Cc2ccccc2)cc1C(F)(F)F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1873","GSK923295","centromere associated protein inhibitor","CENPE",NA,NA,"CC(C)Oc1ccc(cc1Cl)C(=O)N[C@H](CNC(=O)CN(C)C)Cc1ccc(cc1)-c1cn2cccc([C@H](C)O)c2n1, CC(C)Oc1ccc(cc1Cl)C(=O)N[C@H](CNC(=O)CN(C)C)Cc1ccc(cc1)-c1cn2cccc([C@H](C)O)c2n1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1874","GTP-14564","FLT3 inhibitor, tyrosine kinase inhibitor","CSF1R, FLT3, KIT, PDGFRB",NA,NA,"c1ccc(cc1)-c1[nH]nc2c3ccccc3oc12, c1ccc(cc1)-c1[nH]nc2c3ccccc3oc12, c1ccc(cc1)-c1[nH]nc2c3ccccc3oc12, c1ccc(cc1)-c1[nH]nc2c3ccccc3oc12, c1ccc(cc1)-c1[nH]nc2c3ccccc3oc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1875","GTS21","cholinergic receptor agonist","CHRNA7",NA,NA,"COc1ccc(\C=C2/CCCN=C2c2cccnc2)c(OC)c1 |c:11|, COc1ccc(\C=C2/CCCN=C2c2cccnc2)c(OC)c1 |c:11|","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
"1876","guaiacol","local anesthetic","CA2","pulmonary","cough suppressant","COc1ccccc1O, COc1ccccc1O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1877","guanaben-acetate","adrenergic receptor agonist","ADRA2A, ADRA2B, ADRA2C","cardiology","hypertension","NC(=N)N\N=C\c1c(Cl)cccc1Cl, NC(=N)N\N=C\c1c(Cl)cccc1Cl, NC(=N)N\N=C\c1c(Cl)cccc1Cl, NC(=N)N\N=C\c1c(Cl)cccc1Cl, NC(=N)N\N=C\c1c(Cl)cccc1Cl, NC(=N)N\N=C\c1c(Cl)cccc1Cl","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,1,1,1,1
"1878","guanethidine","adrenergic inhibitor","SLC6A2","cardiology","hypertension","NC(=N)NCCN1CCCCCCC1, NC(=N)NCCN1CCCCCCC1, NC(=N)NCCN1CCCCCCC1, NC(=N)NCCN1CCCCCCC1, NC(=N)NCCN1CCCCCCC1","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1879","guanfacine","adrenergic receptor agonist","ADRA2A, ADRA2B, ADRA2C","cardiology","hypertension","NC(=N)NC(=O)Cc1c(Cl)cccc1Cl, NC(=N)NC(=O)Cc1c(Cl)cccc1Cl, NC(=N)NC(=O)Cc1c(Cl)cccc1Cl, NC(=N)NC(=O)Cc1c(Cl)cccc1Cl, NC(=N)NC(=O)Cc1c(Cl)cccc1Cl","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,1,1,1,1
"1880","guanidine","HSP inhibitor","ALDH2, DLG4, GAMT, RNASE1","neurology/psychiatry","Lambert-Eaton myasthenic syndrome (LEMS)","NC(N)=N, NC(N)=N, NC(N)=N","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1881","guanidinoethyldisulfide-bicarbonate","nitric oxide synthase inhibitor","NOS2",NA,NA,"NC(=N)NCCSSCCNC(N)=N","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1882","guanidinopropionic-acid","creatine kinase inhibitor","CKM",NA,NA,"NC(=N)NCCC(O)=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1883","Gue-1654","oxoeicosanoid receptor modulator","OXER1",NA,NA,"CSc1nc2ccc3nc(NC(=O)C(c4ccccc4)c4ccccc4)sc3c2s1, CSc1nc2ccc3nc(NC(=O)C(c4ccccc4)c4ccccc4)sc3c2s1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1884","gusacitinib","jak inhibitor","CLDN23, IL13, IL36G, JAK1, SYK","dermatology","dermatitis","OC1CCN(CC1)c2ccc(Nc3nc(nc4C=NNC(=O)c34)N5CCC(CC#N)CC5)cc2","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1885","guvacine","GABA uptake inhibitor","SLC6A1, SLC6A11, SLC6A12, SLC6A13",NA,NA,"OC(=O)C1=CCCNC1 |t:3|, OC(=O)C1=CCCNC1 |t:3|, OC(=O)C1=CCCNC1 |t:3|, OC(=O)C1=CCCNC1 |t:3|","Preclinical",1,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1886","GW-0742","PPAR receptor agonist","PPARD",NA,NA,"Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1887","GW-1100","G protein-coupled receptor agonist","FFAR1",NA,NA,"CCOC(=O)c1ccc(cc1)-n1cc(Cc2cnc(OCC)nc2)c(=O)nc1SCc1ccc(F)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1888","GW-1929","PPAR receptor agonist","PPARG",NA,NA,"CN(CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c2ccccc2)C(O)=O)cc1)c1ccccn1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1889","GW-2580","cFMS kinase inhibitor","CSF1R",NA,NA,"COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1, COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1, COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1890","GW-311616","elastase inhibitor, leukocyte elastase inhibitor","ELANE",NA,NA,"CC(C)[C@H]1[C@H]2[C@@H](CCN2C(=O)\C=C\CN2CCCCC2)N(C1=O)S(C)(=O)=O, CC(C)[C@H]1[C@H]2[C@@H](CCN2C(=O)\C=C\CN2CCCCC2)N(C1=O)S(C)(=O)=O, CC(C)[C@H]1[C@H]2[C@@H](CCN2C(=O)\C=C\CN2CCCCC2)N(C1=O)S(C)(=O)=O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1891","GW-3965","LXR agonist","NR1H2, NR1H3",NA,NA,"OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1892","GW-405833","cannabinoid receptor agonist","CNR2",NA,NA,"COc1ccc2n(C(=O)c3cccc(Cl)c3Cl)c(C)c(CCN3CCOCC3)c2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1893","GW-4064","FXR agonist","NR1H4",NA,NA,"CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl, CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl, CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl, CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl, CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl, CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1894","GW-438014A","neuropeptide receptor antagonist","NPY5R",NA,NA,"O=C(Nc1nc2ccccc2n1CCc1ccccc1)c1ccccc1, O=C(Nc1nc2ccccc2n1CCc1ccccc1)c1ccccc1, O=C(Nc1nc2ccccc2n1CCc1ccccc1)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1895","GW-441756","growth factor receptor inhibitor","NTRK1",NA,NA,"Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12, Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1896","GW-501516","PPAR receptor agonist","PPARA, PPARD",NA,NA,"Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1897","GW-5074","leucine rich repeat kinase inhibitor, RAF inhibitor","NTRK1, RAF1",NA,NA,"Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br, Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br, Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br, Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br, Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br, Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1898","GW-542573X","calcium channel activator","KCNN1",NA,NA,"COc1ccccc1NC(=O)OCC1CCN(CC1)C(=O)OC(C)(C)C, COc1ccccc1NC(=O)OCC1CCN(CC1)C(=O)OC(C)(C)C, COc1ccccc1NC(=O)OCC1CCN(CC1)C(=O)OC(C)(C)C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1899","GW-583340","EGFR inhibitor","EGFR, ERBB2",NA,NA,"CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1900","GW-627368","prostanoid receptor antagonist","PTGER4",NA,NA,"CCOc1c2CN(C(=O)c2c(OCC)c2ccccc12)c1ccc(CC(=O)NS(=O)(=O)c2ccccc2)cc1, CCOc1c2CN(C(=O)c2c(OCC)c2ccccc12)c1ccc(CC(=O)NS(=O)(=O)c2ccccc2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1901","GW-6471","PPAR receptor antagonist","PPARA",NA,NA,"CCC(=O)NC[C@H](Cc1ccc(OCCc2nc(oc2C)-c2ccccc2)cc1)N\C(C)=C/C(=O)c1ccc(cc1)C(F)(F)F, CCC(=O)NC[C@H](Cc1ccc(OCCc2nc(oc2C)-c2ccccc2)cc1)N\C(C)=C/C(=O)c1ccc(cc1)C(F)(F)F, CCC(=O)NC[C@H](Cc1ccc(OCCc2nc(oc2C)-c2ccccc2)cc1)N\C(C)=C/C(=O)c1ccc(cc1)C(F)(F)F, CCC(=O)NC[C@H](Cc1ccc(OCCc2nc(oc2C)-c2ccccc2)cc1)N\C(C)=C/C(=O)c1ccc(cc1)C(F)(F)F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1902","GW-7647","PPAR receptor agonist","PPARA",NA,NA,"CC(C)(Sc1ccc(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)cc1)C(O)=O, CC(C)(Sc1ccc(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)cc1)C(O)=O, CC(C)(Sc1ccc(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)cc1)C(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1903","GW-788388","ALK tyrosine kinase receptor inhibitor","LCK, MAPK14, TGFBR1",NA,NA,"O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1, O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1, O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1, O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1904","GW-803430","melanin inhibitor","KCNH2, MCHR1",NA,NA,"COc1cc(ccc1OCCN1CCCC1)-n1cnc2cc(sc2c1=O)-c1ccc(Cl)cc1, COc1cc(ccc1OCCN1CCCC1)-n1cnc2cc(sc2c1=O)-c1ccc(Cl)cc1, COc1cc(ccc1OCCN1CCCC1)-n1cnc2cc(sc2c1=O)-c1ccc(Cl)cc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1905","GW-842166","cannabinoid receptor agonist","CNR2",NA,NA,"FC(F)(F)c1nc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1, FC(F)(F)c1nc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1, FC(F)(F)c1nc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1906","GW-843682X","PLK inhibitor","PLK1, PLK3",NA,NA,"COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC, COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC, COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC, COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC, COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1907","GW-9508","free fatty acid receptor agonist, G protein-coupled receptor agonist","FFAR1, FFAR4",NA,NA,"OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1, OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1, OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1, OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1908","GW-9662","PPAR receptor antagonist","NCOA2, PPARG, RXRA",NA,NA,"[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccccc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccccc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1909","gw7604","selective estrogen receptor destabilizer","ESR1","oncology","breast cancer","O=C(O)/C=C/C1=CC=C(/C(C2=CC=C(O)C=C2)=C(C3=CC=CC=C3)/CC)C=C1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1910","GYKI-52466","glutamate receptor antagonist","GRIA1, GRIA2, GRIA3, GRIA4",NA,NA,"CC1=NN=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1 |t:1,3|, CC1=NN=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1 |t:1,3|, CC1=NN=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1 |t:1,3|, CC1=NN=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1 |t:1,3|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1911","GZD824","Bcr-Abl kinase inhibitor","ABL1, BCR",NA,NA,"CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1912","G007-LK","tankyrase inhibitor","TNKS, TNKS2",NA,NA,"CS(=O)(=O)c1ccc(nc1)-c1nnc(\C=C\c2nnc(o2)-c2ccc(cc2)C#N)n1-c1ccccc1Cl, CS(=O)(=O)c1ccc(nc1)-c1nnc(\C=C\c2nnc(o2)-c2ccc(cc2)C#N)n1-c1ccccc1Cl","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1913","h-ile-pro-pro-oh (hydrochloride)","angiotensin converting enzyme inhibitor","ACE","cardiology","hypertension","O=C(N1[C@@H](CCC1)C(N2[C@@H](CCC2)C(O)=O)=O)[C@H]([C@@H](C)CC)N.Cl",NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1914","h-val-pro-pro-oh (tfa)","angiotensin converting enzyme inhibitor","ACE","cardiology","hypertension","N[C@@H](C(C)C)C(N1CCC[C@H]1C(N2CCC[C@H]2C(O)=O)=O)=O.OC(C(F)(F)F)=O",NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1915","H-89","PKA inhibitor","GSG2, PKIA, PRKACA",NA,NA,"Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1916","HA-130","autotaxin inhibitor","ENPP2",NA,NA,"OB(O)c1cccc(COc2ccc(\C=C3/SC(=O)N(Cc4ccc(F)cc4)C3=O)cc2)c1, OB(O)c1cccc(COc2ccc(\C=C3/SC(=O)N(Cc4ccc(F)cc4)C3=O)cc2)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1917","HA-966-(R)-(+)","glutamate receptor agonist","GRIA1",NA,NA,"N[C@@H]1CCN(O)C1=O, N[C@@H]1CCN(O)C1=O, N[C@@H]1CCN(O)C1=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1918","HA-966-(S)-(-)","glutamate receptor antagonist","GRIA1",NA,NA,"N[C@H]1CCN(O)C1=O, N[C@H]1CCN(O)C1=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1919","halcinonide","glucocorticoid receptor agonist","NR3C1","dermatology","corticosteroid-responsive dermatoses","CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl |t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl |t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl |t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl |t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl |t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl |t:10|, CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)CCC5(C)C4(F)C(O)CC3(C)[C@@]2(O1)C(=O)CCl","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1920","halobetasol-propionate","glucocorticoid receptor agonist","NR3C1, PLA2G1B","dermatology","corticosteroid-responsive dermatoses","CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl |c:18,t:14|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1921","halofantrine","antimalarial agent","KCNN4","infectious disease","malaria","CCCCN(CCCC)CC[C@@H](O)c1cc2c(Cl)cc(Cl)cc2c2cc(ccc12)C(F)(F)F |&1:11|, CCCCN(CCCC)CC[C@@H](O)c1cc2c(Cl)cc(Cl)cc2c2cc(ccc12)C(F)(F)F |&1:11|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1922","halofuginone","collagenase inhibitor","COL1A1, MMP2","rheumatology","scleroderma","O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(Br)c(Cl)cc2c1=O, O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(Br)c(Cl)cc2c1=O, O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(Br)c(Cl)cc2c1=O, O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(Br)c(Cl)cc2c1=O, O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(Br)c(Cl)cc2c1=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1923","halopemide","phospholipase inhibitor","PLD1, PLD2",NA,NA,"Fc1ccc(cc1)C(=O)NCCN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O, Fc1ccc(cc1)C(=O)NCCN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O, Fc1ccc(cc1)C(=O)NCCN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O, Fc1ccc(cc1)C(=O)NCCN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O, Fc1ccc(cc1)C(=O)NCCN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1924","haloperidol","dopamine receptor antagonist","DRD1, DRD2, DRD3, DRD4, DRD5, GRIN2B, HRH1, HTR1A, HTR1D, HTR2A, HTR2B, HTR7, KCNH1","neurology/psychiatry","schizophrenia, Tourette's disorder","OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1, OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1, OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1, OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1, OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1","Launched",0,0,0,0,0,0,0,0,1,5,1,1,0,0,1,5,0,0,0,0,1,1,1,1
"1925","haloperidol-decanoate","psychoactive drug","DRD2, DRD3, DRD4, HTR2A","neurology/psychiatry","schizophrenia","CCCCCCCCCC(=O)OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1, CCCCCCCCCC(=O)OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1","Launched",0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,3,0,0,0,0,1,1,1,1
"1926","halothane","glutamate receptor antagonist","GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, KCNK10, KCNK12, KCNK13, KCNK15, KCNK18, KCNK2, KCNK3, KCNK9","neurology/psychiatry","general anaesthetic","FC(F)(F)[C@@H](Cl)Br |&1:4,r|, FC(F)(F)[C@@H](Cl)Br |&1:4,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,1,16,0,0,0,0,0,0,1,1,1,1
"1927","harmane","monoamine oxidase inhibitor","MAOA, MAOB",NA,NA,"Cc1nccc2c3ccccc3[nH]c12","Preclinical",0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1928","ha14-1","bcl inhibitor","BCL2","Oncology","acute myeloid leukemia (aml)","CCOC(=O)C(C#N)C1c2cc(Br)ccc2OC(N)=C1C(=O)OCC","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1929","HA14-1","BCL inhibitor","BCL2",NA,NA,"CCOC(=O)[C@@H](C#N)[C@H]1C(C(=O)OCC)=C(N)Oc2ccc(Br)cc12 |&1:5,8,r,t:14|, CCOC(=O)[C@@H](C#N)[C@H]1C(C(=O)OCC)=C(N)Oc2ccc(Br)cc12 |&1:5,8,r,t:14|, CCOC(=O)[C@@H](C#N)[C@H]1C(C(=O)OCC)=C(N)Oc2ccc(Br)cc12 |&1:5,8,r,t:14|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1930","HC-030031","TRPA1 channel blocker","TRPA1",NA,NA,"CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1, CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1, CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1, CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1, CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1, CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1931","HC-067047","transient receptor potential channel antagonist","TRPV4",NA,NA,"Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1932","heclin","ubiquitin ligase inhibitor","NEDD4, SMURF2, WWP1",NA,NA,"CCc1ccc(\C=C\C(=O)Nc2ccc(cc2)C(C)=O)o1, CCc1ccc(\C=C\C(=O)Nc2ccc(cc2)C(C)=O)o1, CCc1ccc(\C=C\C(=O)Nc2ccc(cc2)C(C)=O)o1, CCc1ccc(\C=C\C(=O)Nc2ccc(cc2)C(C)=O)o1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1933","HEMADO","adenosine receptor agonist","ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,"CCCCC#Cc1nc(NC)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1, CCCCC#Cc1nc(NC)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1, CCCCC#Cc1nc(NC)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1934","hemin","heme oxygenase activators, enzyme inducer, enzyme inducer, heme oxygenase activators","HMOX1, HMOX2","Neurology, hematology, cardiology, hematology, cardiology, Neurology","multiple sclerosis, acute intermittent porphyria (aip), hypertension, ventricular tachycardia (vt), acute intermittent porphyria (AIP), hypertension, ventricular tachycardia (VT), multiple sclerosis","CC1=C(CCC(O)=O)\C2=C\c3c(CCC(O)=O)c(C)c4\C=C5/N=C(/C=c6/c(C=C)c(C)\c(=C\C1=N2)n6[Fe](O)n34)C(C)=C5C=C |c:1,20,34,45,t:8,22,24,31|, CC1=C(CCC(O)=O)\C2=C\c3c(CCC(O)=O)c(C)c4\C=C5/N=C(/C=c6/c(C=C)c(C)\c(=C\C1=N2)n6[Fe](O)n34)C(C)=C5C=C |c:1,20,34,45,t:8,22,24,31|, CC1=C(CCC(O)=O)\C2=C\c3c(CCC(O)=O)c(C)c4\C=C5/N=C(/C=c6/c(C=C)c(C)\c(=C\C1=N2)n6[Fe](O)n34)C(C)=C5C=C |c:1,20,34,45,t:8,22,24,31|, [Fe+3].Cc1c(C=C)c2cc3[nH]c(cc4[nH]c(cc5nc(cc1n2)c(C=C)c5C)c(C)c4CCC(O)=O)c(CCC(O)=O)c3C, [Fe+3].Cc1c(C=C)c2cc3[nH]c(cc4[nH]c(cc5nc(cc1n2)c(C=C)c5C)c(C)c4CCC(O)=O)c(CCC(O)=O)c3C","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1935","hesperadin","Aurora kinase inhibitor","AURKB",NA,NA,"CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1936","hesperetin","ACAT inhibitor","DGAT1, MTTP, SOAT1, SOAT2",NA,NA,"COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1937","hesperidin","flavanone glycoside","AURKB, CACNA1B",NA,NA,"COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1938","hexachlorophene","potassium channel activator","GLUD1, SDHD","infectious disease","gram-positive bacterial infections","Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1939","hexafluronium bromide","acetylcholinesterase inhibitor","BCHE","neurology/psychiatry","muscle relaxant","[Br-].[Br-].c1cccc3c1c2c(cccc2)C3[N+](CCCCCC[N+](C6c4ccccc4c5ccccc56)(C)C)(C)C","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1940","hexamethonium","cholinergic receptor antagonist","CHRNA2, CHRNA3, CHRNA4, CHRNA6",NA,NA,"C[N+](C)(C)CCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCC[N+](C)(C)C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0
"1941","hexamethylenebisacetamide","AKT inhibitor, differentiation inducer, NFKB pathway inhibitor","AKT1",NA,NA,"CC(=O)NCCCCCCNC(C)=O, CC(=O)NCCCCCCNC(C)=O, CC(=O)NCCCCCCNC(C)=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1942","hexestrol","synthetic estrogen","AKR1C1, ESR1, ESR2","endocrinology","hypoestrogenism","CC[C@@H]([C@@H](CC)c1ccc(O)cc1)c1ccc(O)cc1, CC[C@@H]([C@@H](CC)c1ccc(O)cc1)c1ccc(O)cc1, CC[C@@H]([C@@H](CC)c1ccc(O)cc1)c1ccc(O)cc1, CC[C@@H]([C@@H](CC)c1ccc(O)cc1)c1ccc(O)cc1, CC[C@@H]([C@@H](CC)c1ccc(O)cc1)c1ccc(O)cc1 |&1:2,&2:3,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1943","hexoprenaline","adrenergic receptor agonist","ADRB2","pulmonary","asthma","O[C@@H](CNCCCCCCNC[C@@H](O)c1ccc(O)c(O)c1)c1ccc(O)c(O)c1 |&1:1,&2:12|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"1944","hexylcaine","sodium channel blocker","SCN5A","neurology/psychiatry","local anesthetic","C[C@@H](CNC1CCCCC1)OC(=O)c1ccccc1 |&1:1|, C[C@@H](CNC1CCCCC1)OC(=O)c1ccccc1 |&1:1|","Launched",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1945","hexylresorcinol","local anesthetic","TYR","infectious disease","skin infections, first-aid antiseptic","CCCCCCc1ccc(O)cc1O, CCCCCCc1ccc(O)cc1O, CCCCCCc1ccc(O)cc1O, CCCCCCc1ccc(O)cc1O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1946","higenamine","adrenergic receptor agonist","ADRB2",NA,NA,"Oc1ccc(C[C@H]2NCCc3cc(O)c(O)cc23)cc1 |&1:6|, Oc1ccc(C[C@H]2NCCc3cc(O)c(O)cc23)cc1 |&1:6|, Oc1ccc(C[C@H]2NCCc3cc(O)c(O)cc23)cc1 |&1:6|, Oc1ccc(C[C@H]2NCCc3cc(O)c(O)cc23)cc1 |&1:6|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
"1947","histamine","histamine receptor agonist","HRH1, HRH2, HRH3, HRH4","allergy","allergic rhinitis","NCCc1cnc[nH]1, NCCc1cnc[nH]1, NCCc1cnc[nH]1, NCCc1cnc[nH]1, NCCc1cnc[nH]1, NCCc1cnc[nH]1, NCCc1cnc[nH]1","Launched",0,0,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,1,1,1,1
"1948","HJC-0350","GTPase inhibitor","RAPGEF4",NA,NA,"Cc1cc(C)n(c1)S(=O)(=O)c1c(C)cc(C)cc1C, Cc1cc(C)n(c1)S(=O)(=O)c1c(C)cc(C)cc1C, Cc1cc(C)n(c1)S(=O)(=O)c1c(C)cc(C)cc1C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1949","HKI-357","EGFR inhibitor","EGFR",NA,NA,"CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1950","HLCL-61","protein arginine N-methyltransferase inhibitor","PRMT5",NA,NA,"CCn1c2ccccc2c2cc(CNCc3ccccc3OC)ccc12, CCn1c2ccccc2c2cc(CNCc3ccccc3OC)ccc12, CCn1c2ccccc2c2cc(CNCc3ccccc3OC)ccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1951","hmn-176","plk inhibitor","NFYA, PLK1","oncology","breast cancer","O=S(C1=CC=C(OC)C=C1)(NC2=CC=CC=C2/C=C/C3=CC=N(C=C3)=O)=O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1952","HMN-214","PLK inhibitor","PLK1",NA,NA,"COc1ccc(cc1)S(=O)(=O)N(C(C)=O)c1ccccc1\C=C\c1cc[n+]([O-])cc1, COc1ccc(cc1)S(=O)(=O)N(C(C)=O)c1ccccc1\C=C\c1cc[n+]([O-])cc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1953","homatropine","acetylcholine receptor antagonist","CHRM1","ophthalmology","uveal tract inflammation, pupil dilation","CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](O)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](O)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](O)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](O)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](O)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,1
"1954","homatropine-methylbromide","acetylcholine receptor antagonist","CHRM5","ophthalmology","uveal tract inflammation","C[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](O)c1ccccc1 |a:3,6,8,&1:13,THB:10:8:1:4.5|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,1
"1955","homoharringtonine","protein synthesis inhibitor","RPL3","hematologic malignancy","chronic myeloid leukemia (CML)","COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC |c:39|, COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC |c:39|, COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC |c:39|, COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC |c:39|, COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC |c:39|, COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC |c:39|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1956","homoquinolinic-acid","glutamate receptor agonist","GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,"OC(=O)Cc1cccnc1C(O)=O, OC(=O)Cc1cccnc1C(O)=O, OC(=O)Cc1cccnc1C(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1957","honokiol","AKT inhibitor","ALOX5, PTGS1, PTGS2",NA,NA,"Oc1ccc(cc1CC=C)-c1cc(CC=C)ccc1O, Oc1ccc(cc1CC=C)-c1cc(CC=C)ccc1O, Oc1ccc(cc1CC=C)-c1cc(CC=C)ccc1O","Phase 3",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1958","HTH-01-015","protein kinase inhibitor","NUAK1",NA,NA,"CN1c2cc3ccccc3cc2C(=O)N(C)c2c(C)nc(Nc3cnn(c3)C3CCNCC3)nc12, CN1c2cc3ccccc3cc2C(=O)N(C)c2c(C)nc(Nc3cnn(c3)C3CCNCC3)nc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1959","HTMT","histamine receptor agonist","HRH4",NA,NA,"C[C@@H](CCCCC(=O)Nc1ccc(cc1)C(F)(F)F)NCCc1cnc[nH]1 |&1:1|, C[C@@H](CCCCC(=O)Nc1ccc(cc1)C(F)(F)F)NCCc1cnc[nH]1 |&1:1|","Preclinical",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
"1960","huperzine-A","acetylcholinesterase inhibitor","ACHE",NA,NA,"C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|, C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|, C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|, C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|, C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|, C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1961","hydralazine","vasodilator, myeloperoxidase inhibitor","MPO","cardiology","hypertension","N\N=C1/N=NCc2ccccc12 |c:3|, NNc1nncc2ccccc12, NNc1nncc2ccccc12, NNc1nncc2ccccc12, N\N=c1/[nH]ncc2ccccc12, N\N=c1/[nH]ncc2ccccc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1962","hydrochlorothiazide","thiazide diuretic","CA1, CA12, CA2, CA4, CA9, KCNMA1, SLC12A3","cardiology","hypertension, congestive heart failure","NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl, NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl, NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl, NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1963","hydrocortisone","glucocorticoid receptor agonist","ANXA1, NOS2, NR3C1, NR3C2","dermatology, neurology/psychiatry","eczema, psoriasis, seborrheic dermatitis, itching","C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1964","hydrocortisone buteprate","glucocorticoid receptor modulator","ANXA1, NR3C1","dermatology","dermatosis","CCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)COC(=O)CC","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1965","hydrocortisone-acetate","glucocorticoid receptor agonist","NR3C1","dermatology","corticosteroid-responsive dermatoses","CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |t:15|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1966","hydrocortisone-butyrate","glucocorticoid receptor agonist","NR3C1","dermatology","corticosteroid-responsive dermatoses, eczema","CCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)CO |t:13|, CCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)CO |t:13|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1967","hydrocortisone-valerate","glucocorticoid receptor agonist","NR3C1","dermatology","corticosteroid-responsive dermatoses","CCCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)CO |t:14|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1968","hydroflumethiazide","sodium/potassium/chloride transporter inhibitor","ATP1A1, CA1, CA12, CA2, CA4, CA9, KCNMA1, SLC12A1, SLC12A3","cardiology, gastroenterology, rheumatology, nephrology","edema, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, chronic renal failure, acute glomerulonephritis (AGN), hypertension","NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1C(F)(F)F, NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1C(F)(F)F, NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1C(F)(F)F","Launched",1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1969","hydroquinone","melanin inhibitor","TYR","dermatology","dyschromia","Oc1ccc(O)cc1, Oc1ccc(O)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1970","hydroxyamphetamine","trace amine associated receptor agonist","TAAR1","ophthalmology","mydriasis","C[C@@H](N)Cc1ccc(O)cc1 |&1:1|, C[C@@H](N)Cc1ccc(O)cc1 |&1:1|, C[C@@H](N)Cc1ccc(O)cc1 |&1:1|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1971","hydroxychloroquine","antimalarial agent","TLR7, TLR9","infectious disease","malaria","CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12, CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12, CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1972","hydroxychloroquine sulfate","angiotensin converting enzyme inhibitor","ACE2","Infectious disease","human immunodeficiency virus (hiv-1)","CCN(CCO)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12 |&1:9,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1973","hydroxyfasudil","rho associated kinase inhibitor","PKIA, PRKACA, ROCK1",NA,NA,"O=c1[nH]ccc2c(cccc12)S(=O)(=O)N1CCCNCC1, O=c1[nH]ccc2c(cccc12)S(=O)(=O)N1CCCNCC1, O=c1[nH]ccc2c(cccc12)S(=O)(=O)N1CCCNCC1, O=c1[nH]ccc2c(cccc12)S(=O)(=O)N1CCCNCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1974","hydroxyprogesterone","progesterone receptor agonist","PGR","obstetrics/gynecology","spontaneous preterm birth","CC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)CC[C@]4(C)C3CC[C@]12C, CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:11|, CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:11|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1975","hydroxyprogesterone-acetate","progesterone receptor agonist","PGR",NA,NA,"CC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:11|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1976","hydroxytacrine-maleate-(R,S)","cholinesterase inhibitor","ACHE",NA,NA,"Nc1c2[C@@H](O)CCCc2nc2ccccc12 |&1:3|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1977","hydroxytyrosol","lipoxygenase inhibitor","ALOX5","oncology","breast cancer","OC1=CC=C(CCO)C=C1O","Phase 2/Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1978","hydroxyurea","ribonucleotide reductase inhibitor","RRM1, RRM2, RRM2B","hematologic malignancy, oncology","chronic myeloid leukemia (CML), head and neck squamous cell carcinoma (HNSCC)","NC(=O)NO, NC(=O)NO, NC(=O)NO, NC(=O)NO, NC(=O)NO, NC(=O)NO, NC(=O)NO","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1979","hydroxyzine","antihistamine","HRH1","neurology/psychiatry, allergy, dermatology","anxiety, urticaria, itching, dermatosis","OCCOCCN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:12|, OCCOCCN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:12|, OCCOCCN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:12|","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"1980","hymecromone","monoamine oxidase inhibitor","MAOA, MAOB",NA,NA,"Cc1cc(=O)oc2cc(O)ccc12, Cc1cc(=O)oc2cc(O)ccc12, Cc1cc(=O)oc2cc(O)ccc12, Cc1cc(=O)oc2cc(O)ccc12","Phase 2",0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1981","hyoscyamine","acetylcholine receptor antagonist","CHRM1, CHRM2, CHRM3, CHRM4","gastroenterology, urology, neurology/psychiatry, allergy","peptic ulcer disease (PUD), acute abdominal visceral spasm, ulcerative colitis, interstitial cystitis (IC), enterocolitis, irritable bowel syndrome, tremors, allergic rhinitis","CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,1,1,1,1
"1982","hyperin","aldose reductase inhibitor","ACE, AKR1B1",NA,NA,"OC[C@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:27,&4:29,&5:31,r|, OC[C@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:27,&4:29,&5:31,r|, OC[C@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:27,&4:29,&5:31,r|, OC[C@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:27,&4:29,&5:31,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1983","hypoestoxide","IKK inhibitor","IKBKB, IL1B, TNF",NA,NA,"CC(=O)O[C@@H]1C[C@]2(C)O[C@H]2CC[C@]2(C)O[C@H]2C[C@@H]2CC(=O)C(=C)[C@@H]1C2(C)C","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1984","hypoxanthine","PARP inhibitor","PNP",NA,NA,"O=c1nc[nH]c2nc[nH]c12, O=c1nc[nH]c2nc[nH]c12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1985","H2L-5765834","lysophosphatidic acid receptor antagonist","LPAR1, LPAR3",NA,NA,"OC(=O)c1ccc2C(=O)N(C(=O)c2c1)c1cccc(Oc2ccc(cc2)[N+]([O-])=O)c1, OC(=O)c1ccc2C(=O)N(C(=O)c2c1)c1cccc(Oc2ccc(cc2)[N+]([O-])=O)c1, OC(=O)c1ccc2C(=O)N(C(=O)c2c1)c1cccc(Oc2ccc(cc2)[N+]([O-])=O)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1986","h3b-6527","fgfr inhibitor","FGFR4","oncology","hepatocellular carcinoma (hcc)","CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)c(NC(=O)C=C)c1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1987","I-BET-762","bromodomain inhibitor","BRD2, BRD3, BRD4",NA,NA,"CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|, CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|, CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|, CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|, CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|, CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|, CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|, CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1988","I-BET151","bromodomain inhibitor","BRD2, BRD3, BRD4",NA,NA,"COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C, COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C, COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C, COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C, COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C, COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1989","I-BRD9","bromodomain inhibitor","BRD9",NA,NA,"CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1, CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1, CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1, CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1, CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1, CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1, CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1990","I-CBP-112","bromodomain inhibitor","CREBBP, EP300",NA,NA,"CCC(=O)N1CCOc2c(C1)cc(cc2OC[C@H]1CCCN(C)C1)-c1ccc(OC)c(OC)c1, CCC(=O)N1CCOc2c(C1)cc(cc2OC[C@H]1CCCN(C)C1)-c1ccc(OC)c(OC)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1991","IB-MECA","adenosine receptor agonist","ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,"CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)ncnc12, CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)ncnc12, CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)ncnc12","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1992","ibandronate","bone resorption inhibitor","FDPS","orthopedics","osteoporosis","CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O, CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O, CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O, CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1993","IBC-293","hydroxycarboxylic acid receptor agonist","HCAR3",NA,NA,"CC(C)n1nnc2cc(ccc12)C(O)=O, CC(C)n1nnc2cc(ccc12)C(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1994","IBMX","phosphodiesterase inhibitor","ADORA1, PDE2A, PDE3B, PDE4D, PDE5A, PDE6G, PDE7A, PDE8A, PDE9A",NA,NA,"CC(C)Cn1c2nc[nH]c2c(=O)n(C)c1=O, CC(C)Cn1c2nc[nH]c2c(=O)n(C)c1=O, CC(C)Cn1c2nc[nH]c2c(=O)n(C)c1=O, CC(C)Cn1c2nc[nH]c2c(=O)n(C)c1=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1995","ibotenic-acid","glutamate receptor agonist","GRIN1",NA,NA,"N[C@@H](C(O)=O)c1cc(=O)[nH]o1 |&1:1,r|, N[C@@H](C(O)=O)c1cc(=O)[nH]o1 |&1:1,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1996","ibrolipim","lipoprotein lipase activator","LPL",NA,NA,"CCOP(=O)(Cc1ccc(cc1)C(=O)Nc1ccc(Br)cc1C#N)OCC, CCOP(=O)(Cc1ccc(cc1)C(=O)Nc1ccc(Br)cc1C#N)OCC, CCOP(=O)(Cc1ccc(cc1)C(=O)Nc1ccc(Br)cc1C#N)OCC","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"1997","ibrutinib","Bruton's tyrosine kinase (BTK) inhibitor","BLK, BMX, BTK","hematologic malignancy","chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)","Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1998","ibudilast","leukotriene receptor antagonist, phosphodiesterase inhibitor","IL1B, IL6, PDE3A, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A","pulmonary, neurology/psychiatry","asthma, stroke","CC(C)C(=O)c1c(nn2ccccc12)C(C)C, CC(C)C(=O)c1c(nn2ccccc12)C(C)C, CC(C)C(=O)c1c(nn2ccccc12)C(C)C, CC(C)C(=O)c1c(nn2ccccc12)C(C)C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"1999","ibuprofen-(S)","cyclooxygenase inhibitor","ASIC1, PTGS1, PTGS2, SLC5A8","neurology/psychiatry","pain relief","CC(C)Cc1ccc(cc1)[C@H](C)C(O)=O, CC(C)Cc1ccc(cc1)[C@H](C)C(O)=O, CC(C)Cc1ccc(cc1)[C@H](C)C(O)=O","Launched",1,1,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2000","ibuprofen-piconol","cyclooxygenase inhibitor","PTGS1, PTGS2","neurology/psychiatry","pain relief","CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)OCc1ccccn1 |&1:10,r|, CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)OCc1ccccn1 |&1:10,r|, CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)OCc1ccccn1 |&1:10,r|, CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)OCc1ccccn1 |&1:10,r|","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2001","ibuproxam","cyclooxygenase inhibitor, prostaglandin inhibitor","ALOX5","endocrinology, rheumatology, neurology/psychiatry","fever, joint inflammation, pain relief","CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NO |r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2002","ibutamoren","growth hormone secretagogue receptor agonist","GHR, GHSR",NA,NA,"CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CN(c3ccccc23)S(C)(=O)=O)CC1, CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CN(c3ccccc23)S(C)(=O)=O)CC1, CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CN(c3ccccc23)S(C)(=O)=O)CC1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2003","ibutilide","potassium channel blocker","CACNA1C, KCNH2","cardiology","atrial fibrillation (AF)","CCCCCCCN(CC)CCC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:13|, CCCCCCCN(CC)CCC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:13|, CCCCCCCN(CC)CCC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:13|, CCCCCCCN(CC)CCC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:13|, CCCCCCCN(CC)CCC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:13|, CCCCCCCN(CC)CCC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:13|, CCCCCCCN(CC)CCC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:13|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2004","ic-87114","pi3k inhibitor","PIK3C2B, PIK3CD, PIK3CG","hematologic malignancy","acute myeloid leukemia (aml)","Cc1ccccc1-n1c(Cn2cnc3c(N)ncnc23)nc2cccc(C)c2c1=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2005","ICA-069673","voltage-gated potassium channel activator","KCNQ2, KCNQ3",NA,NA,"Fc1ccc(cc1F)C(=O)Nc1cnc(Cl)nc1, Fc1ccc(cc1F)C(=O)Nc1cnc(Cl)nc1, Fc1ccc(cc1F)C(=O)Nc1cnc(Cl)nc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2006","ICA-110381","voltage-gated potassium channel activator","KCNQ2",NA,NA,"Clc1ccc(cc1)C(=O)Nc1ccc(Cl)nc1, Clc1ccc(cc1)C(=O)Nc1ccc(Cl)nc1, Clc1ccc(cc1)C(=O)Nc1ccc(Cl)nc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2007","ICA-121431","sodium channel blocker","SCN1A, SCN3A",NA,NA,"O=C(Nc1ccc(cc1)S(=O)(=O)Nc1nccs1)C(c1ccccc1)c1ccccc1, O=C(Nc1ccc(cc1)S(=O)(=O)Nc1nccs1)C(c1ccccc1)c1ccccc1, O=C(Nc1ccc(cc1)S(=O)(=O)Nc1nccs1)C(c1ccccc1)c1ccccc1, O=C(Nc1ccc(cc1)S(=O)(=O)Nc1nccs1)C(c1ccccc1)c1ccccc1","Preclinical",0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2008","icariin","phosphodiesterase inhibitor","PDE5A",NA,NA,"COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2009","icaritin","PPAR receptor antagonist","PDE5A",NA,NA,"COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O)cc(O)c2c(=O)c1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O)cc(O)c2c(=O)c1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O)cc(O)c2c(=O)c1O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2010","icatibant-acetate","bradykinin receptor antagonist","BDKRB2","cardiology","angioedema","N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O, N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O, N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O, N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2011","ICG-001","beta-catenin inhibitor","CTNNB1",NA,NA,"Oc1ccc(C[C@@H]2N3[C@H](CN(Cc4cccc5ccccc45)C2=O)N(CCC3=O)C(=O)NCc2ccccc2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2012","ICI-118,551","adrenergic receptor antagonist","ADRB2, ADRB3",NA,NA,"CC(C)N[C@@H](C)[C@H](O)COc1ccc(C)c2CCCc12, CC(C)N[C@@H](C)[C@H](O)COc1ccc(C)c2CCCc12, CC(C)N[C@@H](C)[C@H](O)COc1ccc(C)c2CCCc12","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0
"2013","ICI-162846","histamine receptor antagonist","HRH2",NA,NA,"NC(=O)CCCCn1ccc(NC(=N)NCC(F)(F)F)n1, NC(=O)CCCCn1ccc(NC(=N)NCC(F)(F)F)n1","Phase 1",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
"2014","ICI-192605","thromboxane receptor antagonist","TBXA2R",NA,NA,"OC(=O)CC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)c1ccccc1Cl, OC(=O)CC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)c1ccccc1Cl, OC(=O)CC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)c1ccccc1Cl","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2015","ICI-199441","opioid receptor agonist","CYP2D6, OPRD1, OPRK1, OPRM1, UTS2R",NA,NA,"CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccc(Cl)c(Cl)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2016","ICI-215,001","adrenergic receptor agonist","ADRB3",NA,NA,"O[C@@H](CNCCOc1ccc(OCC(O)=O)cc1)COc1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
"2017","ICI-89406","adrenergic receptor antagonist","ADRB1, ADRB2",NA,NA,"O[C@@H](CNCCNC(=O)Nc1ccccc1)COc1ccccc1C#N |&1:1,r|, O[C@@H](CNCCNC(=O)Nc1ccccc1)COc1ccccc1C#N |&1:1,r|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0
"2018","icilin","TRPV agonist","TRPA1, TRPM8",NA,NA,"Oc1ccccc1N1CC=C(NC1=O)c1cccc(c1)[N+]([O-])=O |c:10|, Oc1ccccc1N1CC=C(NC1=O)c1cccc(c1)[N+]([O-])=O |c:10|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2019","icomucret","mucin production enhancer","LTB4R2",NA,NA,"CCCCC[C@H](O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2020","icosapent","platelet aggregation inhibitor","ACSL3, ACSL4, FADS1, FFAR1, PPARD, PPARG, PTGS1, PTGS2, SLC8A1, TRPV1","endocrinology","hypertriglyceridemia","CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O, CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O, CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O, CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O, CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O","Launched",1,1,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2021","icotinib","EGFR inhibitor","EGFR","oncology","non-small cell lung cancer (NSCLC)","C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1, C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1, C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1, C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2022","iCRT-14","beta catenin inhibitor, WNT signaling inhibitor","CTNNB1, TCF4",NA,NA,"Cc1cc(\C=C2/SC(=O)N(C2=O)c2ccccc2)c(C)n1-c1cccnc1, Cc1cc(\C=C2/SC(=O)N(C2=O)c2ccccc2)c(C)n1-c1cccnc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2023","IC261","casein kinase inhibitor","CSNK1A1, CSNK1D, CSNK1E, CSNK1G2",NA,NA,"COc1cc(OC)c(\C=C2\C(=O)Nc3ccccc23)c(OC)c1, COc1cc(OC)c(\C=C2\C(=O)Nc3ccccc23)c(OC)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2024","ID-1101","insulin sensitizer","INS",NA,NA,"C[C@H](O)[C@H](C)[C@H](N)C(O)=O, C[C@H](O)[C@H](C)[C@H](N)C(O)=O, C[C@H](O)[C@H](C)[C@H](N)C(O)=O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2025","idalopirdine","serotonin receptor antagonist","HTR6",NA,NA,"FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1, FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1, FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1, FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1, FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1","Phase 3",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2026","idarubicin","topoisomerase inhibitor","TOP2A","hematologic malignancy","acute myeloid leukemia (AML)","C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O, C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O, C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O, C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O, C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O, C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2027","idasanutlin","MDM inhibitor","MDM2, TP53",NA,NA,"COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O, COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O, COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O, COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O, COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O, COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O, COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O, COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O, COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2028","idazoxan","adrenergic receptor antagonist","ADRA2A, PTGS2",NA,NA,"C1CN=C(N1)[C@H]1COc2ccccc2O1 |r,c:2|, C1CN=C(N1)[C@H]1COc2ccccc2O1 |r,c:2|, C1CN=C(N1)[C@H]1COc2ccccc2O1 |r,c:2|","Phase 3",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
"2029","idelalisib","PI3K inhibitor","PIK3CA, PIK3CB, PIK3CD, PIK3CG","hematologic malignancy","chronic lymphocytic leukemia (CLL)","CC[C@H](Nc1ncnc2nc[nH]c12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1, CC[C@H](Nc1ncnc2nc[nH]c12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1, CC[C@H](Nc1ncnc2nc[nH]c12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1, CC[C@H](Nc1ncnc2nc[nH]c12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1, CC[C@H](Nc1ncnc2nc[nH]c12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2030","ido1-in-5","indoleamine 2,3-dioxygenase inhibitor","IDO1","oncology","renal cell carcinoma (rcc)","FC1=CC=C(C(N[C@H](C)C2=CC=C(N(C(C3CCOCC3)=O)CC4)C4=C2)=O)C=C1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2031","IDO5L","indoleamine 2,3-dioxygenase inhibitor","IDO1",NA,NA,"Nc1nonc1\C(NO)=N/c1ccc(F)c(Cl)c1, Nc1nonc1\C(NO)=N/c1ccc(F)c(Cl)c1, Nc1nonc1\C(NO)=N/c1ccc(F)c(Cl)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2032","IDRA-21","glutamate receptor positive allosteric modulator","GRIA1, GRIA2, GRIA3, GRIA4",NA,NA,"C[C@H]1Nc2ccc(Cl)cc2S(=O)(=O)N1 |&1:1,r|, C[C@H]1Nc2ccc(Cl)cc2S(=O)(=O)N1 |&1:1,r|, C[C@H]1Nc2ccc(Cl)cc2S(=O)(=O)N1 |&1:1,r|, C[C@H]1Nc2ccc(Cl)cc2S(=O)(=O)N1 |&1:1,r|, C[C@H]1Nc2ccc(Cl)cc2S(=O)(=O)N1 |&1:1,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2033","idronoxil","XIAP inhibitor","ENOX2, SPHK1",NA,NA,"Oc1ccc(cc1)C1=Cc2ccc(O)cc2OC1 |t:8|, Oc1ccc(cc1)C1=Cc2ccc(O)cc2OC1 |t:8|, Oc1ccc(cc1)C1=Cc2ccc(O)cc2OC1 |t:8|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2034","IEM1460","glutamate receptor antagonist","GRIA2",NA,NA,"C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2, C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2, C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2, C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2, C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2035","IEM1754","glutamate receptor antagonist","GRIA1",NA,NA,"NCCCCCNCC12CC3CC(CC(C3)C1)C2, NCCCCCNCC12CC3CC(CC(C3)C1)C2, NCCCCCNCC12CC3CC(CC(C3)C1)C2, NCCCCCNCC12CC3CC(CC(C3)C1)C2","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2036","ifenprodil","adrenergic receptor antagonist, glutamate receptor antagonist","GRIN2B",NA,NA,"C[C@@H]([C@H](O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1 |&1:1,2|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2037","ifenprodil tartrate","glutamate receptor antagonist","GIRK, GRIN2B, NR1A, NR2B","Pulmonology","acute resperatory distress syndrome","CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2038","ifosfamide","DNA alkylating agent","CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP3A4, CYP3A5, CYP3A7, PTGS1","oncology, urology","testicular carcinoma, hemorrhagic cystitis","ClCCN[P@@]1(=O)OCCCN1CCCl |r|, ClCCN[P@@]1(=O)OCCCN1CCCl |r|, ClCCN[P@@]1(=O)OCCCN1CCCl |r|","Launched",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2039","igmesine","sigma receptor agonist","SIGMAR1",NA,NA,"CCC(C\C=C\c1ccccc1)(N(C)CC1CC1)c1ccccc1 |&1:2|, CCC(C\C=C\c1ccccc1)(N(C)CC1CC1)c1ccccc1 |&1:2|, CCC(C\C=C\c1ccccc1)(N(C)CC1CC1)c1ccccc1 |&1:2|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2040","iguratimod","cyclooxygenase inhibitor, NFkB pathway inhibitor","PTGS2","rheumatology","rheumatoid arthritis","CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1, CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1","Launched",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2041","IKK-16","IKK inhibitor","IKBKB",NA,NA,"O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2042","IKK-2-inhibitor","IKK inhibitor, SYK inhibitor","IKBKB",NA,NA,"NC(=O)c1sc(cc1N)-c1ccsc1, NC(=O)c1sc(cc1N)-c1ccsc1, NC(=O)c1sc(cc1N)-c1ccsc1, NC(=O)c1sc(cc1N)-c1ccsc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2043","IKK-2-inhibitor-V","IKK inhibitor, NFkB pathway inhibitor","IKBKB",NA,NA,"Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F, Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F, Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F, Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F, Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F, Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2044","ilomastat","matrix metalloprotease inhibitor","ACAN, ADAM28, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP8, MMP9",NA,NA,"CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2045","iloperidone","dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR6, HTR7","neurology/psychiatry","schizophrenia","COc1cc(ccc1OCCCN1CCC(CC1)c1noc2cc(F)ccc12)C(C)=O, COc1cc(ccc1OCCCN1CCC(CC1)c1noc2cc(F)ccc12)C(C)=O","Launched",0,0,0,0,0,0,0,0,1,4,1,1,0,0,1,4,0,0,1,2,1,1,1,1
"2046","iloprost","platelet aggregation inhibitor, prostanoid receptor agonist","PTGDR, PTGER1, PTGER2, PTGER3, PTGER4, PTGFR, PTGIR, TBXA2R","pulmonary","pulmonary arterial hypertension (PAH)","CC#CC[C@@H](C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/CCCC(O)=O |a:6,10,11,14,18,&1:4|, CC#CC[C@@H](C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/CCCC(O)=O |a:6,10,11,14,18,&1:4|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2047","ilorasertib","aurora kinase inhibitor","AURKC, KDR, VEGFA","hematologic malignancy","chronic myelomonocytic leukemia (cmmol)","Nc1ncc(c2cnn(CCO)c2)c3scc(c4ccc(NC(=O)Nc5cccc(F)c5)cc4)c13","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2048","imatinib","Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2049","imepitoin","gaba receptor agonist","GABRA2","neurology/psychiatry","epilepsy","C1COCCN1C2=NC(=O)N(C2)C3=CC=C(C=C3)Cl","Launched",0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1
"2050","imetit","histamine receptor agonist","HRH3, HRH4",NA,NA,"NC(=N)SCCc1cnc[nH]1, NC(=N)SCCc1cnc[nH]1","Preclinical",0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0
"2051","imidafenacin","acetylcholine receptor antagonist","CHRM1, CHRM3","neurology/psychiatry","spasms","Cc1nccn1CCC(C(N)=O)(c1ccccc1)c1ccccc1, Cc1nccn1CCC(C(N)=O)(c1ccccc1)c1ccccc1, Cc1nccn1CCC(C(N)=O)(c1ccccc1)c1ccccc1, Cc1nccn1CCC(C(N)=O)(c1ccccc1)c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,1,1,1,1
"2052","imidapril","angiotensin converting enzyme inhibitor","ACE","cardiology","hypertension, congestive heart failure","CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@@H](CN(C)C1=O)C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@@H](CN(C)C1=O)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2053","imiloxan","adrenergic receptor antagonist","ADRA2A, ADRA2B",NA,NA,"CCn1ccnc1C[C@H]1COc2ccccc2O1 |&1:8|, CCn1ccnc1C[C@H]1COc2ccccc2O1 |&1:8|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0
"2054","imipramine","norepinephrine reputake inhibitor, serotonin reuptake inhibitor","ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD5, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7, KCND2, KCND3, KCNH1, KCNH2, SLC6A2, SLC6A3, SLC6A4","neurology/psychiatry, urology","depression, nocturnal enuresis","CN(C)CCCN1c2ccccc2CCc2ccccc12, CN(C)CCCN1c2ccccc2CCc2ccccc12, CN(C)CCCN1c2ccccc2CCc2ccccc12, CN(C)CCCN1c2ccccc2CCc2ccccc12, CN(C)CCCN1c2ccccc2CCc2ccccc12, CN(C)CCCN1c2ccccc2CCc2ccccc12","Launched",1,3,0,0,0,0,0,0,1,5,1,1,0,0,1,3,1,5,1,3,1,1,1,1
"2055","imiquimod","interferon inducer, toll-like receptor agonist","TLR7, TLR8","dermatology, infectious disease, oncology","actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)","CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2056","immepip","histamine receptor agonist","HRH3, HRH4",NA,NA,"C(C1CCNCC1)c1cnc[nH]1, C(C1CCNCC1)c1cnc[nH]1","Preclinical",0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0
"2057","immethridine","histamine receptor agonist","HRH3",NA,NA,"C(c1cnc[nH]1)c1ccncc1, C(c1cnc[nH]1)c1ccncc1, C(c1cnc[nH]1)c1ccncc1","Phase 1",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
"2058","impentamine","histamine receptor antagonist","HRH3",NA,NA,"NCCCCCc1cnc[nH]1, NCCCCCc1cnc[nH]1, NCCCCCc1cnc[nH]1","Preclinical",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
"2059","imrecoxib","cyclooxygenase inhibitor","PTGS2","rheumatology","osteoarthritis","CCCN1CC(=C(C1=O)c1ccc(C)cc1)c1ccc(cc1)S(C)(=O)=O |c:5|","Phase 1",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2060","im156","ampk activator","NDUFS1, PRKAA2","oncology","breast cancer","NC(Nc1ccc(OC(F)(F)F)cc1)=NC(=N)N1CCCC1.CC(=O)O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2061","INC-280","c-Met inhibitor","MET",NA,NA,"CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1, CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1, CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1, CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1, CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2062","INCA-6","calcineurin inhibitor","NFATC1",NA,NA,"O=C1C=CC(=O)C2=C1C1c3ccccc3C2c2ccccc12 |c:2,6|, O=C1C=CC(=O)C2=C1C1c3ccccc3C2c2ccccc12 |c:2,6|, O=C1C=CC(=O)C2=C1C1c3ccccc3C2c2ccccc12 |c:2,6|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2063","INCB-3284","CC chemokine receptor antagonist","CCR2",NA,NA,"COc1ccc(cn1)[C@]1(O)CC[C@@H](CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F, COc1ccc(cn1)[C@]1(O)CC[C@@H](CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2064","indacaterol","adrenergic receptor agonist","ADRB1, ADRB2","pulmonary","chronic obstructive pulmonary disease (COPD)","CCc1cc2CC(Cc2cc1CC)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12, CCc1cc2CC(Cc2cc1CC)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,1,1,1,1
"2065","indalpine","selective serotonin reuptake inhibitor (SSRI)","SLC6A4",NA,NA,"C(Cc1c[nH]c2ccccc12)C1CCNCC1, C(Cc1c[nH]c2ccccc12)C1CCNCC1","Withdrawn",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2066","indapamide","thiazide diuretic","CA2, HTR3A, KCNQ1","cardiology","hypertension, congestive heart failure","C[C@H]1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O |&1:1,r|, C[C@H]1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O |&1:1,r|, C[C@H]1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O |&1:1,r|, C[C@H]1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O |&1:1,r|","Launched",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2067","indatraline","norepinephrine transporter inhibitor","MAOA, MAOB",NA,NA,"CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1, CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1, CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1, CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1, CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1","Preclinical",0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2068","indeglitazar","PPAR receptor agonist","NCOA1, PPARA, PPARD, PPARG",NA,NA,"COc1ccc(cc1)S(=O)(=O)n1cc(CCC(O)=O)c2cc(OC)ccc12","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2069","indinavir","HIV protease inhibitor","CYP3A4, CYP3A5, CYP3A7","infectious disease","human immunodeficiency virus (HIV-1)","CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12, CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12, CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12, CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12, CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12, CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12, CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12, CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2070","indiplon","benzodiazepine receptor agonist","GABRA1",NA,NA,"CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1, CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1, CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1, CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1, CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0
"2071","indirubin","CDK inhibitor, glycogen synthase kinase inhibitor","CDK1, CDK5, GSK3A",NA,NA,"O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O, O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O, O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O, O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O","Phase 2/Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2072","indirubin-3-monoxime","CDK inhibitor, glycogen synthase kinase inhibitor","CDK1, CDK2, CDK5, CDK5R1, GSK3B",NA,NA,"O\N=C1\C(\Nc2ccccc\12)=C1\C(=O)Nc2ccccc12, O\N=C1\C(\Nc2ccccc\12)=C1\C(=O)Nc2ccccc12, O\N=C1\C(\Nc2ccccc\12)=C1\C(=O)Nc2ccccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2073","indisulam","CDK inhibitor","CA1, CA12, CA14, CA2, CA6, CA7, CA9",NA,NA,"NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12, NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12, NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12, NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2074","indobufen","cyclooxygenase inhibitor, platelet aggregation inhibitor","PTGS1, PTGS2","hematology","thrombosis","CC[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:2,r|, CC[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:2,r|","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2075","indocyanine-green","contrast agent","SLCO1B1","cardiology","vascular imaging agent","CC1(C)\C(=C/C=C/C=C/C=C/C2=[N+](CCCCS(O)(=O)=O)c3ccc4ccccc4c3C2(C)C)N(CCCCS(O)(=O)=O)c2ccc3ccccc3c12 |c:11|, CC1(C)\C(=C/C=C/C=C/C=C/C2=[N+](CCCCS(O)(=O)=O)c3ccc4ccccc4c3C2(C)C)N(CCCCS(O)(=O)=O)c2ccc3ccccc3c12 |c:11|, CC1(C)\C(=C/C=C/C=C/C=C/C2=[N+](CCCCS(O)(=O)=O)c3ccc4ccccc4c3C2(C)C)N(CCCCS(O)(=O)=O)c2ccc3ccccc3c12 |c:11|, CC1(C)\C(=C/C=C/C=C/C=C/C2=[N+](CCCCS(O)(=O)=O)c3ccc4ccccc4c3C2(C)C)N(CCCCS(O)(=O)=O)c2ccc3ccccc3c12 |c:11|, CC1(C)\C(=C/C=C/C=C/C=C/C2=[N+](CCCCS(O)(=O)=O)c3ccc4ccccc4c3C2(C)C)N(CCCCS(O)(=O)=O)c2ccc3ccccc3c12 |c:11|","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2076","indole-3-carbinol","aryl hydrocarbon receptor agonist, indoleamine 2,3-dioxygenase inhibitor","AHR",NA,NA,"OCc1c[nH]c2ccccc12, OCc1c[nH]c2ccccc12, OCc1c[nH]c2ccccc12","Phase 2/Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2077","indomethacin","cyclooxygenase inhibitor","GLO1, PLA2G2A, PPARA, PPARG, PTGDR2, PTGR2, PTGS1, PTGS2, SLC46A1","rheumatology, orthopedics","rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, bursitis, tendinitis","COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1","Launched",1,1,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2078","indoprofen","cyclooxygenase inhibitor, prostanoid receptor antagonist","CXCR1, CXCR2, PTGS1, PTGS2",NA,NA,"C[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:1,r|, C[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:1,r|, C[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:1,r|, C[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:1,r|, C[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:1,r|","Withdrawn",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2079","indoramin","adrenergic receptor antagonist","ADRA1A, ADRA1B, ADRA1D, ADRA2B, ADRA2C","urology, cardiology","benign prostatic hyperplasia (BPH), hypertension","O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1, O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1, O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,5,1,1,1,1
"2080","indotecan","topoisomerase inhibitor","CHEK1, PDLIM7, TOP1","oncology","soft tissue sarcoma (sts)","COc1cc2c3C(=O)c4cc5OCOc5cc4-c3n(CCCN3CCOCC3)c(=O)c2cc1OC","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2081","indoximod","indoleamine 2,3-dioxygenase inhibitor","IDO1",NA,NA,"Cn1cc(C[C@@H](N)C(O)=O)c2ccccc12, Cn1cc(C[C@@H](N)C(O)=O)c2ccccc12, Cn1cc(C[C@@H](N)C(O)=O)c2ccccc12, Cn1cc(C[C@@H](N)C(O)=O)c2ccccc12","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2082","ingenol","PKC activator","PRKCD, PRKCE","dermatology","keratosis","[H][C@]12C=C(CO)[C@@H](O)[C@]3(O)[C@@H](O)C(C)=C[C@]3([C@H](C)C[C@@H]3[C@H]1C3(C)C)C2=O |c:13,t:2|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2083","ingenol-mebutate","PKC activator","PRKCA, PRKCB, PRKCD, PRKCE, PRKCG","dermatology","actinic keratosis (AK)","C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C |c:9,t:18|, C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C |c:9,t:18|, C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C |c:9,t:18|, C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C |c:9,t:18|, C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C |c:9,t:18|, C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C |c:9,t:18|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2084","INH1","Hec1 inhibitor","NDC80",NA,NA,"Cc1ccc(-c2csc(NC(=O)c3ccccc3)n2)c(C)c1, Cc1ccc(-c2csc(NC(=O)c3ccccc3)n2)c(C)c1, Cc1ccc(-c2csc(NC(=O)c3ccccc3)n2)c(C)c1, Cc1ccc(-c2csc(NC(=O)c3ccccc3)n2)c(C)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2085","iniparib","PARP inhibitor","PARP1",NA,NA,"NC(=O)c1ccc(I)c(c1)[N+]([O-])=O, NC(=O)c1ccc(I)c(c1)[N+]([O-])=O, NC(=O)c1ccc(I)c(c1)[N+]([O-])=O, NC(=O)c1ccc(I)c(c1)[N+]([O-])=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2086","inosine","neurotrophic agent","PARP1, PNP",NA,NA,"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c1[nH]cnc2=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c1[nH]cnc2=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c1[nH]cnc2=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c1[nH]cnc2=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2087","inositol","insulin sensitizer","CDIPT","obstetrics/gynecology","polycystic ovary syndrom (PCOS)","O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O, O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2088","INT-767","FXR agonist","GPBAR1",NA,NA,"CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOS(O)(=O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12, CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOS(O)(=O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12, CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOS(O)(=O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2089","integrin-antagonist-1","integrin antagonist","ITGAV, ITGB6",NA,NA,"Cc1cc(C)n(n1)-c1cccc(c1)[C@@H](CN1CC[C@@H](CCc2ccc3CCCNc3n2)C1)CC(O)=O, Cc1cc(C)n(n1)-c1cccc(c1)[C@@H](CN1CC[C@@H](CCc2ccc3CCCNc3n2)C1)CC(O)=O, Cc1cc(C)n(n1)-c1cccc(c1)[C@@H](CN1CC[C@@H](CCc2ccc3CCCNc3n2)C1)CC(O)=O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2090","iodipamide","radiopaque medium","ALB","radiology","contrast agent","OC(=O)c1c(I)cc(I)c(NC(=O)CCCCC(=O)Nc2c(I)cc(I)c(C(O)=O)c2I)c1I, OC(=O)c1c(I)cc(I)c(NC(=O)CCCCC(=O)Nc2c(I)cc(I)c(C(O)=O)c2I)c1I","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2091","iodophenpropit","histamine receptor antagonist","HRH3, HRH4",NA,NA,"Ic1ccc(CCNC(=N)SCCCc2cnc[nH]2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0
"2092","iomazenil","radiopaque medium","TSPO","neurology/psychiatry","epilepsy","CCOC(=O)c1c2n(cn1)-c3cccc(c3C(=O)N(C2)C)I","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2093","IOWH032","CFTR channel antagonist","CFTR",NA,NA,"Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1, Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1, Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1, Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2094","IOX1","histone demethylase inhibitor","EGLN1, KDM3A, KDM4C, KDM6B",NA,NA,"OC(=O)c1ccc(O)c2ncccc12, OC(=O)c1ccc(O)c2ncccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2095","IOX2","hypoxia inducible factor inhibitor","EGLN1, KDM2A, KDM5C",NA,NA,"OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O, OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O, OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O, OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O, OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2096","IPA-3","p21 activated kinase inhibitor","PAK1",NA,NA,"Oc1ccc2ccccc2c1SSc1c(O)ccc2ccccc12, Oc1ccc2ccccc2c1SSc1c(O)ccc2ccccc12, Oc1ccc2ccccc2c1SSc1c(O)ccc2ccccc12, Oc1ccc2ccccc2c1SSc1c(O)ccc2ccccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2097","ipidacrine","acetylcholinesterase inhibitor","ACHE",NA,NA,"Nc1c2CCCc2nc2CCCCc12, Nc1c2CCCc2nc2CCCCc12, Nc1c2CCCc2nc2CCCCc12","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2098","ipragliflozin-L-proline","sodium/glucose cotransporter inhibitor","SLC5A2","endocrinology","diabetes mellitus","OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(F)c(Cc2cc3ccccc3s2)c1, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(F)c(Cc2cc3ccccc3s2)c1, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(F)c(Cc2cc3ccccc3s2)c1","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2099","ipratropium","acetylcholine receptor antagonist","CHRM1, CHRM2, CHRM3, CHRM4, CHRM5","pulmonary","bronchospasm, chronic obstructive pulmonary disease (COPD), bronchitis, emphysema","CC(C)[N@@+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |a:5,8,10,&1:3,&2:15,TLB:4:3:6.7:9.10.11,THB:1:3:6.7:9.10.11,12:10:3:6.7|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,5,0,0,1,1,1,1
"2100","iproniazid","monoamine oxidase inhibitor","MAOA, MAOB",NA,NA,"CC(C)NNC(=O)c1ccncc1, CC(C)NNC(=O)c1ccncc1, CC(C)NNC(=O)c1ccncc1","Withdrawn",0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2101","ipsapirone","serotonin receptor agonist","HTR1A",NA,NA,"O=C1N(CCCCN2CCN(CC2)c2ncccn2)S(=O)(=O)c2ccccc12, O=C1N(CCCCN2CCN(CC2)c2ncccn2)S(=O)(=O)c2ccccc12","Phase 3",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2102","irbesartan","angiotensin receptor antagonist","AGTR1, JUN, SLC10A1","cardiology, nephrology","hypertension, diabetic nephropathy","CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |t:4|, CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |t:4|, CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |t:4|, CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |t:4|, CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |t:4|","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2103","irinotecan","topoisomerase inhibitor","TOP1, TOP1MT","oncology","colorectal cancer","CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2104","IRL-2500","endothelin receptor antagonist","EDNRB",NA,NA,"CN([C@H](Cc1ccc(cc1)-c1ccccc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O)C(=O)c1cc(C)cc(C)c1, CN([C@H](Cc1ccc(cc1)-c1ccccc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O)C(=O)c1cc(C)cc(C)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2105","irosustat","steroid sulfatase inhibitor","CA2, STS",NA,NA,"NS(=O)(=O)Oc1ccc2c3CCCCCc3c(=O)oc2c1, NS(=O)(=O)Oc1ccc2c3CCCCCc3c(=O)oc2c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2106","irsogladine","phosphodiesterase inhibitor","PDE4A","gastroenterology","peptic ulcer disease (PUD)","Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl, Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl, Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl, Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl, Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2107","isamoltane","adrenergic receptor antagonist","HTR1A, HTR1B",NA,NA,"CC(C)NC[C@@H](O)COc1ccccc1-n1cccc1 |&1:5|, CC(C)NC[C@@H](O)COc1ccccc1-n1cccc1 |&1:5|","Phase 1",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2108","isavuconazole","cytochrome P450 inhibitor, fungal lanosterol demethylase inhibitor","CYP3A4, CYP51A1","Infectious disease","fungal infection","C[C@@H](c1nc(cs1)-c1ccc(cc1)C#N)[C@@](O)(Cn1cncn1)c1cc(F)ccc1F |a:1,&1:15|, C[C@@H](c1nc(cs1)-c1ccc(cc1)C#N)[C@](O)(Cn1cncn1)c1cc(F)ccc1F","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2109","ISO-1","macrophage migration inhibiting factor inhibitor","MIF",NA,NA,"COC(=O)C[C@H]1CC(=NO1)c1ccc(O)cc1 |&1:5,r,c:7|, COC(=O)C[C@H]1CC(=NO1)c1ccc(O)cc1 |&1:5,r,c:7|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2110","isobutyramide","gene expression stimulant","HBE1, HBG1",NA,NA,"CC(C)C(N)=O, CC(C)C(N)=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2111","isocarboxazid","monoamine oxidase inhibitor","MAOA, MAOB","neurology/psychiatry","depression","Cc1cc(no1)C(=O)NNCc1ccccc1, Cc1cc(no1)C(=O)NNCc1ccccc1, Cc1cc(no1)C(=O)NNCc1ccccc1, Cc1cc(no1)C(=O)NNCc1ccccc1, Cc1cc(no1)C(=O)NNCc1ccccc1","Launched",0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2112","isoconazole","fungal lanosterol demethylase inhibitor","CYP17A1","infectious disease","gram-positive bacterial infections","Clc1ccc([C@@H](Cn2ccnc2)OCc2c(Cl)cccc2Cl)c(Cl)c1 |&1:5|, Clc1ccc([C@@H](Cn2ccnc2)OCc2c(Cl)cccc2Cl)c(Cl)c1 |&1:5|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2113","isoflurane","inhaled anaesthetic","GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9","neurology/psychiatry","general anaesthetic","FC(F)O[C@@H](Cl)C(F)(F)F |&1:4,r|, FC(F)O[C@@H](Cl)C(F)(F)F |&1:4,r|, FC(F)O[C@@H](Cl)C(F)(F)F |&1:4,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,1,16,0,0,0,0,0,0,1,1,1,1
"2114","isoflurophate","cholinesterase inhibitor","ACHE, BCHE","ophthalmology","glaucoma","CC(C)OP(F)(=O)OC(C)C, CC(C)OP(F)(=O)OC(C)C, CC(C)OP(F)(=O)OC(C)C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2115","isoguvacine","benzodiazepine receptor agonist","GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRR1, GABRR2, GABRR3",NA,NA,"OC(=O)C1=CCNCC1 |t:3|, OC(=O)C1=CCNCC1 |t:3|, OC(=O)C1=CCNCC1 |t:3|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,1,9,0,0,0,0,0,0,0,0,0,0
"2116","isoliquiritigenin","guanylate cyclase activator","GABBR1",NA,NA,"Oc1ccc(\C=C\C(=O)c2ccc(O)cc2O)cc1, Oc1ccc(\C=C\C(=O)c2ccc(O)cc2O)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2117","isoniazid","FABI inhibitor","CYP1A2, CYP2C19, CYP2C8, CYP2E1, CYP3A4","infectious disease","tuberculosis","NNC(=O)c1ccncc1, NNC(=O)c1ccncc1, NNC(=O)c1ccncc1, NNC(=O)c1ccncc1, NNC(=O)c1ccncc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2118","isoprenaline","adrenergic receptor agonist","ADRB1, ADRB2, ADRB3","cardiology, pulmonary","bradycardia, heart block, asthma","CC(C)NC[C@@H](O)c1ccc(O)c(O)c1 |&1:5|, CC(C)NC[C@@H](O)c1ccc(O)c(O)c1 |&1:5|, CC(C)NC[C@@H](O)c1ccc(O)c(O)c1 |&1:5|, CC(C)NC[C@@H](O)c1ccc(O)c(O)c1 |&1:5|, CC(C)NC[C@@H](O)c1ccc(O)c(O)c1 |&1:5|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,1,1,1,1
"2119","isopropamide-iodide","acetylcholine receptor antagonist","CHRM3, CHRM4","gastroenterology","peptic ulcer disease (PUD), gastrointestinal acidosis","CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C, CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C, CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C, CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C, CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,1,1,1,1
"2120","isosorbide-dinitrate","nitric oxide stimulant","GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3, NPR1","cardiology","angina pectoris, coronary artery disease (CAD)","[O-][N+](=O)O[C@@H]1CO[C@@H]2[C@H](CO[C@H]12)O[N+]([O-])=O, [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@H](CO[C@H]12)O[N+]([O-])=O, [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@H](CO[C@H]12)O[N+]([O-])=O, [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@H](CO[C@H]12)O[N+]([O-])=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2121","isosorbide-mononitrate","nitric oxide stimulant","GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3","cardiology","angina pectoris, coronary artery disease (CAD)","O[C@H]1CO[C@@H]2[C@@H](CO[C@H]12)O[N+]([O-])=O, O[C@H]1CO[C@@H]2[C@@H](CO[C@H]12)O[N+]([O-])=O, O[C@H]1CO[C@@H]2[C@@H](CO[C@H]12)O[N+]([O-])=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2122","isotretinoin","retinoid receptor agonist","RARA, RARB, RARG","dermatology","acne vulgaris (AV)","C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O |c:4|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2123","isoxicam","cyclooxygenase inhibitor","PTGS1, PTGS2",NA,NA,"CN1C(C(=O)Nc2cc(C)on2)=C(O)c2ccccc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2cc(C)on2)=C(O)c2ccccc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2cc(C)on2)=C(O)c2ccccc2S1(=O)=O |t:12|","Withdrawn",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2124","isoxsuprine","adrenergic receptor agonist","ADRB2","rheumatology, cardiology","Raynaud's disease, arteriosclerosis, Buerger's disease","C[C@@H](COc1ccccc1)N[C@H](C)[C@@H](O)c1ccc(O)cc1 |&1:13,&2:11,&3:1|, C[C@@H](COc1ccccc1)N[C@H](C)[C@@H](O)c1ccc(O)cc1 |&1:13,&2:11,&3:1|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"2125","ispinesib","kinesin inhibitor","KIF11",NA,NA,"CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2126","isradipine","calcium channel blocker","CACNA1D, CACNA1F, CACNA2D1","cardiology","hypertension","COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc2nonc12)C(=O)OC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc2nonc12)C(=O)OC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc2nonc12)C(=O)OC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc2nonc12)C(=O)OC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc2nonc12)C(=O)OC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc2nonc12)C(=O)OC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc2nonc12)C(=O)OC(C)C |r,c:4,9|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2127","ISRIB","eukaryotic translation initiation factor inhibitor, PERK inhibitor","EIF2A, EIF2AK3",NA,NA,"Clc1ccc(OCC(=O)N[C@H]2CC[C@@H](CC2)NC(=O)COc2ccc(Cl)cc2)cc1 |r|, Clc1ccc(OCC(=O)N[C@H]2CC[C@@H](CC2)NC(=O)COc2ccc(Cl)cc2)cc1 |r|, Clc1ccc(OCC(=O)N[C@H]2CC[C@@H](CC2)NC(=O)COc2ccc(Cl)cc2)cc1 |r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2128","istaroxime","ATPase inhibitor","ATP1A1",NA,NA,"C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2129","istradefylline","adenosine receptor antagonist","ADORA1, ADORA2A, ADORA2B, ADORA3","neurology/psychiatry","Parkinson's Disease, dyskinesia","CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2130","isuzinaxib","nadph oxidase inhibitor","NOX1, NOX4","nephrology","diabetic nephropathy","CCCc1c([nH]n(-c2ccccn2)c1=O)-c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2131","ISX-9","neural stem cell inducer","NEUROD1",NA,NA,"O=C(NC1CC1)c1cc(on1)-c1cccs1, O=C(NC1CC1)c1cc(on1)-c1cccs1, O=C(NC1CC1)c1cc(on1)-c1cccs1, O=C(NC1CC1)c1cc(on1)-c1cccs1, O=C(NC1CC1)c1cc(on1)-c1cccs1, O=C(NC1CC1)c1cc(on1)-c1cccs1, O=C(NC1CC1)c1cc(on1)-c1cccs1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2132","itacitinib","JAK inhibitor","JAK1",NA,NA,"Fc1c(ccnc1C(F)(F)F)C(=O)N1CCC(CC1)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12, Fc1c(ccnc1C(F)(F)F)C(=O)N1CCC(CC1)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12, Fc1c(ccnc1C(F)(F)F)C(=O)N1CCC(CC1)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2133","ITD-1","TGF beta receptor inhibitor","TGFBR2",NA,NA,"CCOC(=O)C1=C(C)NC2=C([C@@H]1c1ccc(cc1)-c1ccccc1)C(=O)CC(C)(C)C2 |&1:11,r,c:5,9|, CCOC(=O)C1=C(C)NC2=C([C@@H]1c1ccc(cc1)-c1ccccc1)C(=O)CC(C)(C)C2 |&1:11,r,c:5,9|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2134","ITE","aryl hydrocarbon receptor agonist","AHR",NA,NA,"COC(=O)c1csc(n1)C(=O)c1c[nH]c2ccccc12, COC(=O)c1csc(n1)C(=O)c1c[nH]c2ccccc12, COC(=O)c1csc(n1)C(=O)c1c[nH]c2ccccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2135","ITI214","phosphodiesterase inhibitor","PDE1A",NA,NA,"CN1C2=N[C@@H]3CCC[C@@H]3N2c2nn(Cc3ccc(cc3)-c3cccc(F)n3)c(Nc3ccccc3)c2C1=O |t:2|, CN1C2=N[C@@H]3CCC[C@@H]3N2c2nn(Cc3ccc(cc3)-c3cccc(F)n3)c(Nc3ccccc3)c2C1=O |t:2|, CN1C2=N[C@@H]3CCC[C@@H]3N2c2nn(Cc3ccc(cc3)-c3cccc(F)n3)c(Nc3ccccc3)c2C1=O |t:2|, CN1C2=N[C@@H]3CCC[C@@H]3N2c2nn(Cc3ccc(cc3)-c3cccc(F)n3)c(Nc3ccccc3)c2C1=O |t:2|","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2136","itopride","dopamine receptor antagonist","CHRM3, DRD2","gastroenterology, neurology/psychiatry","dyspepsia, gastroparesis, heartburn, nausea, vomiting, anorexia","COc1ccc(cc1OC)C(=O)NCc1ccc(OCCN(C)C)cc1, COc1ccc(cc1OC)C(=O)NCc1ccc(OCCN(C)C)cc1, COc1ccc(cc1OC)C(=O)NCc1ccc(OCCN(C)C)cc1, COc1ccc(cc1OC)C(=O)NCc1ccc(OCCN(C)C)cc1, COc1ccc(cc1OC)C(=O)NCc1ccc(OCCN(C)C)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,1
"2137","ITX3","GEF inhibitor","TRIO",NA,NA,"Cc1cc(\C=c2\sc3nc4ccccc4n3c2=O)c(C)n1-c1ccccc1, Cc1cc(\C=c2\sc3nc4ccccc4n3c2=O)c(C)n1-c1ccccc1, Cc1cc(\C=c2\sc3nc4ccccc4n3c2=O)c(C)n1-c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2138","IT1t","CC chemokine receptor antagonist","CXCR4",NA,NA,"CC1(C)CN2C(CS\C(NC3CCCCC3)=N\C3CCCCC3)=CSC2=N1 |c:24,28|, CC1(C)CN2C(CS\C(NC3CCCCC3)=N\C3CCCCC3)=CSC2=N1 |c:24,28|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2139","IU1","ubiquitin C-terminal hydrolase inhibitor","USP14",NA,NA,"Cc1cc(C(=O)CN2CCCC2)c(C)n1-c1ccc(F)cc1, Cc1cc(C(=O)CN2CCCC2)c(C)n1-c1ccc(F)cc1, Cc1cc(C(=O)CN2CCCC2)c(C)n1-c1ccc(F)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2140","ivabradine","HCN channel blocker, potassium channel blocker, sodium channel blocker","HCN1, HCN3, HCN4","cardiology","angina pectoris","COc1cc2C[C@H](CN(C)CCCN3CCc4cc(OC)c(OC)cc4CC3=O)c2cc1OC, COc1cc2C[C@H](CN(C)CCCN3CCc4cc(OC)c(OC)cc4CC3=O)c2cc1OC","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2141","ivacaftor","CFTR channel potentiator","CFTR","pulmonary","cystic fibrosis","CC(C)(C)c1cc(c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O)C(C)(C)C, CC(C)(C)c1cc(c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O)C(C)(C)C, CC(C)(C)c1cc(c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O)C(C)(C)C, CC(C)(C)c1cc(c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O)C(C)(C)C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2142","ivermectin","benzodiazepine receptor agonist","CHRNA7, P2RX7","infectious disease","gastrointestinal roundworms, lungworms, cattle grubs, mites, lice, horn flies","CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,1
"2143","ivosidenib","isocitrate dehydrogenase inhibitor","IDH1","hematologic malignancy","acute myeloid leukemia (AML)","Fc1cncc(c1)N([C@H](C(=O)NC1CC(F)(F)C1)c1ccccc1Cl)C(=O)[C@@H]1CCC(=O)N1c1cc(ccn1)C#N, Fc1cncc(c1)N([C@H](C(=O)NC1CC(F)(F)C1)c1ccccc1Cl)C(=O)[C@@H]1CCC(=O)N1c1cc(ccn1)C#N, Fc1cncc(c1)N([C@H](C(=O)NC1CC(F)(F)C1)c1ccccc1Cl)C(=O)[C@@H]1CCC(=O)N1c1cc(ccn1)C#N","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2144","IWP-L6","porcupine inhibitor","PORCN",NA,NA,"O=C(CSc1nc2CCSc2c(=O)n1-c1ccccc1)Nc1ccc(cn1)-c1ccccc1, O=C(CSc1nc2CCSc2c(=O)n1-c1ccccc1)Nc1ccc(cn1)-c1ccccc1, O=C(CSc1nc2CCSc2c(=O)n1-c1ccccc1)Nc1ccc(cn1)-c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2145","ixabepilone","microtubule stabilizing agent","TUBB","oncology","breast cancer","C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1, C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1, C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2146","JAK3-inhibitor-V","JAK inhibitor","JAK3",NA,NA,"C=CC(=O)c1ccc2ccccc2c1, C=CC(=O)c1ccc2ccccc2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2147","JDTic","opioid receptor antagonist","OPRK1",NA,NA,"CC(C)[C@@H](CN1CC[C@](C)([C@@H](C)C1)c1cccc(O)c1)NC(=O)[C@H]1Cc2ccc(O)cc2CN1, CC(C)[C@@H](CN1CC[C@](C)([C@@H](C)C1)c1cccc(O)c1)NC(=O)[C@H]1Cc2ccc(O)cc2CN1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2148","JHW-007","dopamine reuptake inhibitor","SLC6A3",NA,NA,"CCCCN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccc(F)cc1)c1ccc(F)cc1, CCCCN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccc(F)cc1)c1ccc(F)cc1","Preclinical",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2149","JIB04","histone lysine demethylase inhibitor","KDM4E",NA,NA,"Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2150","JLK-6","gamma secretase inhibitor","PSEN1",NA,NA,"COc1oc(=O)c2cc(N)ccc2c1Cl","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2151","JNJ-10191584","histamine receptor antagonist","HRH4",NA,NA,"CN1CCN(CC1)C(=O)c1nc2ccc(Cl)cc2[nH]1, CN1CCN(CC1)C(=O)c1nc2ccc(Cl)cc2[nH]1, CN1CCN(CC1)C(=O)c1nc2ccc(Cl)cc2[nH]1, CN1CCN(CC1)C(=O)c1nc2ccc(Cl)cc2[nH]1","Preclinical",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
"2152","JNJ-10397049","orexin receptor antagonist","HCRTR1, HCRTR2",NA,NA,"CC1(C)OC[C@H](NC(=O)Nc2ccc(Br)cc2Br)[C@@H](O1)c1ccccc1, CC1(C)OC[C@H](NC(=O)Nc2ccc(Br)cc2Br)[C@@H](O1)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2153","JNJ-16259685","glutamate receptor antagonist","GRM1",NA,NA,"CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1 |r|, CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1 |r|, CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1 |r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2154","JNJ-1661010","FAAH inhibitor","FAAH",NA,NA,"O=C(Nc1ccccc1)N1CCN(CC1)c1nc(ns1)-c1ccccc1, O=C(Nc1ccccc1)N1CCN(CC1)c1nc(ns1)-c1ccccc1, O=C(Nc1ccccc1)N1CCN(CC1)c1nc(ns1)-c1ccccc1, O=C(Nc1ccccc1)N1CCN(CC1)c1nc(ns1)-c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2155","JNJ-17203212","TRPV antagonist","TRPV1",NA,NA,"FC(F)(F)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2C(F)(F)F)nc1, FC(F)(F)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2C(F)(F)F)nc1, FC(F)(F)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2C(F)(F)F)nc1, FC(F)(F)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2C(F)(F)F)nc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2156","JNJ-26481585","HDAC inhibitor","HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, MDM2",NA,NA,"Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12, Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12, Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12, Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12, Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2157","JNJ-27141491","CC chemokine receptor antagonist","CCR2",NA,NA,"CC[C@@H](c1ccc(F)c(F)c1)n1c(C(=O)OC)c([nH]c1=S)-c1ccno1, CC[C@@H](c1ccc(F)c(F)c1)n1c(C(=O)OC)c([nH]c1=S)-c1ccno1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2158","JNJ-37822681","dopamine receptor antagonist","DRD2",NA,NA,"Fc1ccc(CN2CCC(CC2)Nc2ccc(nn2)C(F)(F)F)cc1F, Fc1ccc(CN2CCC(CC2)Nc2ccc(nn2)C(F)(F)F)cc1F, Fc1ccc(CN2CCC(CC2)Nc2ccc(nn2)C(F)(F)F)cc1F","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0
"2159","JNJ-38877605","tyrosine kinase inhibitor","MET",NA,NA,"Cn1cc(cn1)-c1ccc2nnc(n2n1)C(F)(F)c1ccc2ncccc2c1, Cn1cc(cn1)-c1ccc2nnc(n2n1)C(F)(F)c1ccc2ncccc2c1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2160","JNJ-40411813","glutamate receptor positive allosteric modulator","GRM2",NA,NA,"CCCCn1ccc(N2CCC(CC2)c2ccccc2)c(Cl)c1=O, CCCCn1ccc(N2CCC(CC2)c2ccccc2)c(Cl)c1=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2161","JNJ-42041935","hypoxia inducible factor prolyl hydroxylase inhibitor","PDK2",NA,NA,"OC(=O)c1cnn(c1)-c1nc2cc(Cl)c(OC(F)(F)F)cc2[nH]1, OC(=O)c1cnn(c1)-c1nc2cc(Cl)c(OC(F)(F)F)cc2[nH]1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2162","JNJ-42165279","FAAH inhibitor","FAAH",NA,NA,"FC1(F)Oc2ccc(CN3CCN(CC3)C(=O)Nc3cnccc3Cl)cc2O1, FC1(F)Oc2ccc(CN3CCN(CC3)C(=O)Nc3cnccc3Cl)cc2O1, FC1(F)Oc2ccc(CN3CCN(CC3)C(=O)Nc3cnccc3Cl)cc2O1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2163","JNJ-47965567","purinergic receptor antagonist","P2RX7",NA,NA,"O=C(NCC1(CCOCC1)N1CCN(CC1)c1ccccc1)c1cccnc1Sc1ccccc1, O=C(NCC1(CCOCC1)N1CCN(CC1)c1ccccc1)c1cccnc1Sc1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2164","jnj-5207852","histamine receptor antagonist","HRH3","neurology/psychiatry","epilepsy","C(COc1ccc(CN2CCCCC2)cc1)CN1CCCCC1","Phase 2",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"2165","JNJ-63533054","G protein-coupled receptor agonist","GPR139",NA,NA,"C[C@H](NC(=O)CNC(=O)c1cccc(Cl)c1)c1ccccc1, C[C@H](NC(=O)CNC(=O)c1cccc(Cl)c1)c1ccccc1, C[C@H](NC(=O)CNC(=O)c1cccc(Cl)c1)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2166","JNJ-7706621","CDK inhibitor","AURKA, AURKB, CDK1, CDK2",NA,NA,"Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F, Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F, Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F, Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F, Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F, Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F, Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F, Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2167","JNJ-7777120","histamine receptor antagonist","HRH4",NA,NA,"CN1CCN(CC1)C(=O)c1cc2cc(Cl)ccc2[nH]1, CN1CCN(CC1)C(=O)c1cc2cc(Cl)ccc2[nH]1, CN1CCN(CC1)C(=O)c1cc2cc(Cl)ccc2[nH]1, CN1CCN(CC1)C(=O)c1cc2cc(Cl)ccc2[nH]1","Preclinical",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
"2168","JQ1-(+)","bromodomain inhibitor","BRD4, BRDT",NA,NA,"Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|, Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|, Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|, Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|, Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|, Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|, Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2169","JTC-801","opioid receptor antagonist","OPRL1",NA,NA,"CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2170","JTE-013","lysophospholipid receptor antagonist","P2RY10, S1PR2",NA,NA,"CC(C)c1cc(NNC(=O)Nc2cc(Cl)nc(Cl)c2)nc2n(C)nc(C)c12, CC(C)c1cc(NNC(=O)Nc2cc(Cl)nc(Cl)c2)nc2n(C)nc(C)c12, CC(C)c1cc(NNC(=O)Nc2cc(Cl)nc(Cl)c2)nc2n(C)nc(C)c12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2171","JTE-607","cytokine production inhibitor","IL10, IL1B, IL6, TNF",NA,NA,"CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O, CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O, CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O, CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O, CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2172","JTE-907","cannabinoid receptor inverse agonist","CNR2",NA,NA,"CCCCCOc1c(OC)ccc2cc(C(=O)NCc3ccc4OCOc4c3)c(=O)[nH]c12, CCCCCOc1c(OC)ccc2cc(C(=O)NCc3ccc4OCOc4c3)c(=O)[nH]c12, CCCCCOc1c(OC)ccc2cc(C(=O)NCc3ccc4OCOc4c3)c(=O)[nH]c12","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2173","JW-55","tankyrase inhibitor","TNKS, TNKS2",NA,NA,"COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1, COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1, COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1, COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1, COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1, COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1, COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1, COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2174","JW-642","monoacylglycerol lipase inhibitor","MGLL",NA,NA,"FC(F)(F)C(OC(=O)N1CCN(Cc2cccc(Oc3ccccc3)c2)CC1)C(F)(F)F, FC(F)(F)C(OC(=O)N1CCN(Cc2cccc(Oc3ccccc3)c2)CC1)C(F)(F)F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2175","JW-67","WNT pathway inhibitor","APC, AXIN1, GSK3B",NA,NA,"O=C1Nc2ccccc2C11OCC2(CO1)COC1(OC2)C(=O)Nc2ccccc12, O=C1Nc2ccccc2C11OCC2(CO1)COC1(OC2)C(=O)Nc2ccccc12, O=C1Nc2ccccc2C11OCC2(CO1)COC1(OC2)C(=O)Nc2ccccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2176","JW-74","tankyrase inhibitor, WNT signaling inhibitor","TNKS, TNKS2",NA,NA,"COc1ccc(cc1)-n1c(SCc2nc(no2)-c2ccc(C)cc2)nnc1-c1ccncc1, COc1ccc(cc1)-n1c(SCc2nc(no2)-c2ccc(C)cc2)nnc1-c1ccncc1, COc1ccc(cc1)-n1c(SCc2nc(no2)-c2ccc(C)cc2)nnc1-c1ccncc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2177","JX-401","p38 MAPK inhibitor","MAPK14",NA,NA,"COc1cc(SC)ccc1C(=O)N1CCC(Cc2ccccc2)CC1, COc1cc(SC)ccc1C(=O)N1CCC(Cc2ccccc2)CC1, COc1cc(SC)ccc1C(=O)N1CCC(Cc2ccccc2)CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2178","JZL-184","monoacylglucerol lipase inhibitor","MGLL",NA,NA,"OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1, OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1, OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2179","JZL-195","FAAH inhibitor, monoacylglycerol lipase inhibitor","FAAH, MGLL",NA,NA,"[O-][N+](=O)c1ccc(OC(=O)N2CCN(Cc3cccc(Oc4ccccc4)c3)CC2)cc1, [O-][N+](=O)c1ccc(OC(=O)N2CCN(Cc3cccc(Oc4ccccc4)c3)CC2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2180","K-Ras(G12C)-inhibitor-12","K-Ras inhibitor","KRAS",NA,NA,"Oc1cc(Cl)c(I)cc1NCC(=O)N1CCN(CC1)C(=O)C=C, Oc1cc(Cl)c(I)cc1NCC(=O)N1CCN(CC1)C(=O)C=C, Oc1cc(Cl)c(I)cc1NCC(=O)N1CCN(CC1)C(=O)C=C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2181","K-strophanthidin","ATPase inhibitor","ATP1A1",NA,NA,"C[C@]12CC[C@H]3[C@@H](CC[C@]4(O)C[C@@H](O)CC[C@]34C=O)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:27|, C[C@]12CC[C@H]3[C@@H](CC[C@]4(O)C[C@@H](O)CC[C@]34C=O)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:27|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2182","k-80003","retinoid receptor antagonist","RXRA","cardiology","atherosclerosis","CC(C)c1ccc(\C=C/2\C(=C(CC(=O)O)c3cc(F)ccc23)C)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2183","K-858","kinesin-like spindle protein inhibitor","KIF11",NA,NA,"CC(=O)NC1=NN(C(C)=O)[C@@](C)(S1)c1ccccc1 |&1:10,r,t:4|, CC(=O)NC1=NN(C(C)=O)[C@@](C)(S1)c1ccccc1 |&1:10,r,t:4|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2184","kaempferol","bone resorption inhibitor, estrogen-related receptor inverse agonist","AKR1B1, ALOX15B, ALOX5, AR, CYP1B1, GLO1, HSD17B1, UGT3A1",NA,NA,"Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2185","kainic-acid","kainate receptor agonist","GRIA1, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5",NA,NA,"CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O, CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2186","karenitecin","topoisomerase inhibitor","TOP1",NA,NA,"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4c(CC[Si](C)(C)C)c3Cn1c2=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2187","kartogenin","chondrocyte differentiation stimulator","FLNA",NA,NA,"OC(=O)c1ccccc1C(=O)Nc1ccc(cc1)-c1ccccc1, OC(=O)c1ccccc1C(=O)Nc1ccc(cc1)-c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2188","KB-R7943","sodium/calcium exchange inhibitor","SLC8A1, TRPC3, TRPC5, TRPC6",NA,NA,"NC(=N)SCCc1ccc(OCc2ccc(cc2)[N+]([O-])=O)cc1, NC(=N)SCCc1ccc(OCc2ccc(cc2)[N+]([O-])=O)cc1, NC(=N)SCCc1ccc(OCc2ccc(cc2)[N+]([O-])=O)cc1","Preclinical",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2189","KB-SRC-4","SRC inhibitor","SRC",NA,NA,"Nc1ncnc2n(nc(-c3ccc(Cl)cc3)c12)-c1cccc(c1)-c1cnnn1Cc1cccc(c1)-c1ccccc1, Nc1ncnc2n(nc(-c3ccc(Cl)cc3)c12)-c1cccc(c1)-c1cnnn1Cc1cccc(c1)-c1ccccc1, Nc1ncnc2n(nc(-c3ccc(Cl)cc3)c12)-c1cccc(c1)-c1cnnn1Cc1cccc(c1)-c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2190","kb-0742 (dihydrochloride)","cdk9 inhibitor","CDK9","oncology","prostate cancer","N[C@@H]1C[C@@H](NC2=CC(C(CC)CC)=NC3=CC=NN23)CC1.[H]Cl.[H]Cl","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2191","KBG","neprilysin inhibitor","MME",NA,NA,"O[C@H]1O[C@@H]2CO[C@@H](O[C@H]2[C@H](O)[C@H]1O)c1ccccc1 |a:3,8,9,11,&1:1,&2:6|, O[C@H]1O[C@@H]2CO[C@@H](O[C@H]2[C@H](O)[C@H]1O)c1ccccc1 |a:3,8,9,11,&1:1,&2:6|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2192","KD-023","ACAT inhibitor","ACACA, ACACB",NA,NA,"CCCCCCCCCCCCCCOc1ccc(o1)C(O)=O, CCCCCCCCCCCCCCOc1ccc(o1)C(O)=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2193","KD025","rho associated kinase inhibitor","ROCK2",NA,NA,"CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3n[nH]cc3c2)c2ccccc2n1, CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3n[nH]cc3c2)c2ccccc2n1, CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3n[nH]cc3c2)c2ccccc2n1, CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3n[nH]cc3c2)c2ccccc2n1, CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3n[nH]cc3c2)c2ccccc2n1, CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3n[nH]cc3c2)c2ccccc2n1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2194","kenpaullone","CDK inhibitor, glycogen synthase kinase inhibitor","CCNB1, CDK1, CDK5, GSK3B",NA,NA,"Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2195","ketanserin","serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA1D, DRD1, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR5A, HTR7, SLC18A1, SLC18A2","cardiology","hypertension","Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1","Launched",1,2,0,0,0,0,0,0,1,8,0,0,0,0,1,2,0,0,1,3,1,1,1,1
"2196","ketoconazole","sterol demethylase inhibitor","KCNA10","dermatology","seborrheic dermatitis","CC(=O)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1 |&1:15,18|, CC(=O)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1 |&1:15,18|, CC(=O)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1 |&1:15,18|, CC(=O)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1 |&1:15,18|, CC(=O)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1 |&1:15,18|, CC(=O)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1 |&1:15,18|, CC(=O)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1 |&1:15,18|, CC(=O)N1CCN(CC1)c1ccc(OCC2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2197","ketoprofen","cyclooxygenase inhibitor","PTGS1, PTGS2, SLC5A8","rheumatology","rheumatoid arthritis, osteoarthritis","C[C@@H](C(O)=O)c1cccc(c1)C(=O)c1ccccc1 |&1:1,r|, C[C@@H](C(O)=O)c1cccc(c1)C(=O)c1ccccc1 |&1:1,r|, C[C@@H](C(O)=O)c1cccc(c1)C(=O)c1ccccc1 |&1:1,r|","Launched",1,1,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2198","ketorolac","cyclooxygenase inhibitor","PTGS1, PTGS2","neurology/psychiatry","pain relief","OC(=O)[C@H]1CCn2c1ccc2C(=O)c1ccccc1 |&1:3,r|, OC(=O)[C@H]1CCn2c1ccc2C(=O)c1ccccc1 |&1:3,r|, OC(=O)[C@H]1CCn2c1ccc2C(=O)c1ccccc1 |&1:3,r|","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2199","ketotifen","histamine receptor antagonist, histamine receptor agonist, leukotriene receptor antagonist, phosphodiesterase inhibitor","HRH1","neurology/psychiatry, pulmonary","itching, asthma","CN1CCC(CC1)=C1c2ccsc2C(O)=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccsc2C(O)=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccsc2C(O)=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccsc2C(O)=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccsc2C(O)=Cc2ccccc12 |c:16|, CN1CCC(=C2c3ccccc3CC(=O)c4sccc24)CC1","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"2200","KF-38789","P selectin inhibitor","SELP",NA,NA,"COc1ccc([C@H]2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1 |&1:6,r,c:8|, COc1ccc([C@H]2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1 |&1:6,r,c:8|, COc1ccc([C@H]2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1 |&1:6,r,c:8|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2201","KG-5","RAF inhibitor","BRAF, FLT3, KIT, PDGFRB",NA,NA,"CSc1nc(N)cc(Oc2ccc(cc2)-c2nnc(Nc3cccc(c3)C(F)(F)F)[nH]2)n1, CSc1nc(N)cc(Oc2ccc(cc2)-c2nnc(Nc3cccc(c3)C(F)(F)F)[nH]2)n1, CSc1nc(N)cc(Oc2ccc(cc2)-c2nnc(Nc3cccc(c3)C(F)(F)F)[nH]2)n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2202","KH-CB19","CDC inhibitor","CLK1, CLK3, DYRK1A",NA,NA,"CCOC(=O)c1c(C(C=N)C#N)c2ccc(Cl)c(Cl)c2n1C, CCOC(=O)c1c(C(C=N)C#N)c2ccc(Cl)c(Cl)c2n1C, CCOC(=O)c1c(C(C=N)C#N)c2ccc(Cl)c(Cl)c2n1C, CCOC(=O)c1c(C(C=N)C#N)c2ccc(Cl)c(Cl)c2n1C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2203","KHK-IN-1","hexokinase inhibitor","KHK",NA,NA,"CSc1ccccc1Nc1nc(nc2c(NCC3CC3)ncnc12)N1CCNCC1, CSc1ccccc1Nc1nc(nc2c(NCC3CC3)ncnc12)N1CCNCC1, CSc1ccccc1Nc1nc(nc2c(NCC3CC3)ncnc12)N1CCNCC1, CSc1ccccc1Nc1nc(nc2c(NCC3CC3)ncnc12)N1CCNCC1, CSc1ccccc1Nc1nc(nc2c(NCC3CC3)ncnc12)N1CCNCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2204","KHS-101","neural stem cell inducer","TACC3",NA,NA,"CC(C)CNc1ccnc(NCc2csc(n2)-c2ccccc2)n1, CC(C)CNc1ccnc(NCc2csc(n2)-c2ccccc2)n1, CC(C)CNc1ccnc(NCc2csc(n2)-c2ccccc2)n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2205","KI-16425","lysophosphatidic acid receptor antagonist","LPAR1, LPAR3",NA,NA,"C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(CSCCC(O)=O)cc1)c1ccccc1Cl |&1:1,r|, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(CSCCC(O)=O)cc1)c1ccccc1Cl |&1:1,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2206","KI-20227","c-Fms inhibitor","CSF1R, KDR, KIT, PDGFRB",NA,NA,"COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)N[C@@H](C)c1nccs1 |&1:27,r|, COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)N[C@@H](C)c1nccs1 |&1:27,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2207","KI-8751","KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","KDR",NA,NA,"COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2208","kifunensine","mannosidase inhibitor","MAN1B1, MAN2A1",NA,NA,"OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12, OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12, OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12, OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2209","ki16198","lipoprotein antagonist","LPA",NA,NA,"COC(=O)CCSCc1ccc(cc1)-c1onc(C)c1NC(=O)O[C@@H](C)c1ccccc1Cl |&1:24,r|, COC(=O)CCSCc1ccc(cc1)-c1onc(C)c1NC(=O)O[C@@H](C)c1ccccc1Cl |&1:24,r|, COC(=O)CCSCc1ccc(cc1)-c1onc(C)c1NC(=O)O[C@@H](C)c1ccccc1Cl |&1:24,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2210","KL-001","proteasome inhibitor","CRY1, CRY2",NA,NA,"CS(=O)(=O)N(C[C@@H](O)Cn1c2ccccc2c2ccccc12)Cc1ccco1 |&1:6,r|, CS(=O)(=O)N(C[C@@H](O)Cn1c2ccccc2c2ccccc12)Cc1ccco1 |&1:6,r|, CS(=O)(=O)N(C[C@@H](O)Cn1c2ccccc2c2ccccc12)Cc1ccco1 |&1:6,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2211","KML29","monoacylglucerol lipase inhibitor","MGLL",NA,NA,"OC(C1CCN(CC1)C(=O)OC(C(F)(F)F)C(F)(F)F)(c1ccc2OCOc2c1)c1ccc2OCOc2c1, OC(C1CCN(CC1)C(=O)OC(C(F)(F)F)C(F)(F)F)(c1ccc2OCOc2c1)c1ccc2OCOc2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2212","KN-62","calcium/calmodulin dependent protein kinase inhibitor, purinergic receptor antagonist","AKT1, CAMK2A, CHEK1, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, P2RX7, PRKCA, ROCK1, RPS6KB1, SGK1",NA,NA,"CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(CC1)c1ccccc1)S(=O)(=O)c1cccc2cnccc12 |&1:2,r|, CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(CC1)c1ccccc1)S(=O)(=O)c1cccc2cnccc12 |&1:2,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2213","KN-93","calcium/calmodulin dependent protein kinase inhibitor","CAMK2A",NA,NA,"COc1ccc(cc1)S(=O)(=O)N(CCO)c1ccccc1CN(C)C\C=C\c1ccc(Cl)cc1, COc1ccc(cc1)S(=O)(=O)N(CCO)c1ccccc1CN(C)C\C=C\c1ccc(Cl)cc1, COc1ccc(cc1)S(=O)(=O)N(CCO)c1ccccc1CN(C)C\C=C\c1ccc(Cl)cc1, COc1ccc(cc1)S(=O)(=O)N(CCO)c1ccccc1CN(C)C\C=C\c1ccc(Cl)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2214","kojic acid","nfkb pathway inhibitor","NFKB1",NA,NA,"OCc1cc(=O)c(O)co1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2215","Ko143","BCRP inhibitor","ABCB1, ABCC1",NA,NA,"COc1ccc2c3C[C@@H]4N([C@@H](CC(C)C)c3[nH]c2c1)C(=O)[C@H](CCC(=O)OC(C)(C)C)NC4=O, COc1ccc2c3C[C@@H]4N([C@@H](CC(C)C)c3[nH]c2c1)C(=O)[C@H](CCC(=O)OC(C)(C)C)NC4=O, COc1ccc2c3C[C@@H]4N([C@@H](CC(C)C)c3[nH]c2c1)C(=O)[C@H](CCC(=O)OC(C)(C)C)NC4=O, COc1ccc2c3C[C@@H]4N([C@@H](CC(C)C)c3[nH]c2c1)C(=O)[C@H](CCC(=O)OC(C)(C)C)NC4=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2216","KPT-185","exportin antagonist","XPO1",NA,NA,"COc1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)OC(C)C)n1, COc1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)OC(C)C)n1, COc1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)OC(C)C)n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2217","KPT-276","exportin antagonist","XPO1",NA,NA,"FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)N2CC(F)(F)C2)n1, FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)N2CC(F)(F)C2)n1, FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)N2CC(F)(F)C2)n1, FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)N2CC(F)(F)C2)n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2218","KRCA-0008","ALK inihibitor","ALK",NA,NA,"COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccc(cc2OC)N2CCN(CC2)C(C)=O)n1)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccc(cc2OC)N2CCN(CC2)C(C)=O)n1)N1CCN(CC1)C(C)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2219","KRN-633","VEGFR inhibitor","FLT1, FLT4, KDR",NA,NA,"CCCNC(=O)Nc1ccc(Oc2ncnc3cc(OC)c(OC)cc23)cc1Cl, CCCNC(=O)Nc1ccc(Oc2ncnc3cc(OC)c(OC)cc23)cc1Cl, CCCNC(=O)Nc1ccc(Oc2ncnc3cc(OC)c(OC)cc23)cc1Cl","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2220","KS-176","BCRP inhibitor","ABCG2",NA,NA,"OCCc1ccc(NC(=O)c2ccccc2NC(=O)c2ccc(cc2)[N+]([O-])=O)cc1, OCCc1ccc(NC(=O)c2ccccc2NC(=O)c2ccc(cc2)[N+]([O-])=O)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2221","KU-0063794","mTOR inhibitor","MTOR",NA,NA,"COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2222","KU-55933","ATM kinase inhibitor","ATM, PRKDC",NA,NA,"O=c1cc(oc(c1)-c1cccc2Sc3ccccc3Sc12)N1CCOCC1, O=c1cc(oc(c1)-c1cccc2Sc3ccccc3Sc12)N1CCOCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2223","KU-60019","ATM kinase inhibitor","ATM",NA,NA,"C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1, C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1, C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1, C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1, C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2224","kuromanin","ribosyl cyclase inhibitor","CD38",NA,NA,"OC[C@H]1O[C@@H](Oc2cc3c(O)cc(O)cc3[o+]c2-c2ccc(O)c(O)c2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2cc3c(O)cc(O)cc3[o+]c2-c2ccc(O)c(O)c2)[C@H](O)[C@@H](O)[C@@H]1O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2225","KW-2449","Abl kinase inhibitor, Aurora kinase inhibitor, FLT3 inhibitor","ABL1, AURKA, AURKB, FLT3",NA,NA,"O=C(N1CCNCC1)c1ccc(\C=C\c2[nH]nc3ccccc23)cc1, O=C(N1CCNCC1)c1ccc(\C=C\c2[nH]nc3ccccc23)cc1, O=C(N1CCNCC1)c1ccc(\C=C\c2[nH]nc3ccccc23)cc1, O=C(N1CCNCC1)c1ccc(\C=C\c2[nH]nc3ccccc23)cc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2226","KW-3902","adenosine receptor antagonist","ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,"CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C12C[C@@H]3C[C@H]1C[C@H](C2)C3 |&1:23,&2:21,&3:19,r|, CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C12C[C@@H]3C[C@H]1C[C@H](C2)C3 |&1:23,&2:21,&3:19,r|, CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C12C[C@@H]3C[C@H]1C[C@H](C2)C3 |&1:23,&2:21,&3:19,r|, CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C12C[C@@H]3C[C@H]1C[C@H](C2)C3 |&1:23,&2:21,&3:19,r|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2227","KX2-391","SRC inhibitor, tubulin polymerization inhibitor","SRC",NA,NA,"O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1, O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1, O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1, O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2228","kynurenic-acid","glutamate receptor antagonist","GPR35, GRIN1, GRIN2A, GRIN2B",NA,NA,"OC(=O)c1cc(=O)c2ccccc2[nH]1, OC(=O)c1cc(=O)c2ccccc2[nH]1, OC(=O)c1cc(=O)c2ccccc2[nH]1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2229","KY02111","WNT pathway inhibitor","DKK1",NA,NA,"COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC, COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC, COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC, COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC, COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2230","K02288","bone morphogenic protein inhibitor","BMP1",NA,NA,"COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1, COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1, COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1, COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1, COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1, COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2231","K145","sphingosine kinase inhibitor","SPHK2",NA,NA,"CCCCOc1ccc(CC\C=C2/SC(=O)N(CCN)C2=O)cc1, CCCCOc1ccc(CC\C=C2/SC(=O)N(CCN)C2=O)cc1, CCCCOc1ccc(CC\C=C2/SC(=O)N(CCN)C2=O)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2232","L-arginine","nitric oxide precursor","ARG2, ASL, ASS1, AZIN2, GPRC6A, NOS2, NOS3, SLC7A1, SLC7A3, SLC7A4","cardiology, neurology/psychiatry, urology, obstetrics/gynecology, otolaryngology","congestive heart failure, hypertension, coronary artery disease (CAD), claudication, senile dementia, erectile dysfunction, infertility, common cold","N[C@@H](CCCNC(N)=N)C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O","Launched",1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2233","L-aspartic-acid","metallic radical formation stimulant","ACY1, ACY3, ADSS, ADSSL1, ASNS, ASPA, ASPH, ASRGL1, ASS1, CAD, DARS, DARS2, GOT1, GOT2, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, LYZ, PAICS, RNASE1, SLC1A1, SLC25A12, SLC25A13",NA,NA,"N[C@@H](CC(O)=O)C(O)=O, N[C@@H](CC(O)=O)C(O)=O, N[C@@H](CC(O)=O)C(O)=O","Launched",1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2234","L-citrulline","nitric oxide stimulant","ASS1, DDAH1, DDAH2, GPRC6A, NOS1, NOS2, NOS3, OTC, PADI1, PADI2, PADI3, PADI4, PADI6","cardiology, urology","hypertension, erectile dysfunction","N[C@@H](CCCNC(N)=O)C(O)=O |&1:1,r|, N[C@@H](CCCNC(N)=O)C(O)=O |&1:1,r|, N[C@@H](CCCNC(N)=O)C(O)=O |&1:1,r|, N[C@@H](CCCNC(N)=O)C(O)=O |&1:1,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2235","L-cysteinesulfinic-acid","glutamate receptor agonist","GRM1, GRM5, GSR, HMGCS2, PAPOLA, PRDX2",NA,NA,"N[C@@H](C[S@@](O)=O)C(O)=O |a:1,&1:3|, N[C@@H](C[S@@](O)=O)C(O)=O |a:1,&1:3|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2236","L-glutamic-acid","glutamate receptor agonist","AADAT, AASS, ABAT, ALDH18A1, ASNS, BCAT1, BCAT2, CCBL2, DNPEP, EARS2, ENPEP, EPRS, FOLH1, FPGS, FTCD, GAD1, GAD2, GATB, GCLC, GCLM, GGCX, GLS, GLS2, GLUD1, GLUD2, GLUL, GMPS, GOT1, GOT2, GPT, GPT2, GRIA1, GRIA2, GRIA3, GRIA4, GRID1, GRID2, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, GRM1, GRM2, GRM3, GRM4, GRM6, GRM7, GRM8, LGSN, NADSYN1, NAGS, OPLAH, PFAS, PGCP, PSAT1, SLC1A1, SLC1A2, SLC1A3, SLC1A6, SLC1A7, SLC25A18, SLC25A22, SLC7A11, TAT",NA,NA,"N[C@@H](CCC(O)=O)C(O)=O, N[C@@H](CCC(O)=O)C(O)=O","Launched",1,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2237","L-lysine","serotonin receptor agonist","GPRC6A, KARS, SLC7A1, SLC7A2, SLC7A3, SLC7A4",NA,NA,"NCCCC[C@H](N)C(O)=O","Phase 2",1,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2238","L-methionine","voltage-gated calcium channel ligand","BHMT, BHMT2, METAP2, MTR, MTRR","pulmonary, allergy, neurology/psychiatry","asthma, allergic rhinitis, depression, Parkinson's Disease, schizophrenia","CSCC[C@H](N)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2239","L-mimosine","dopamine beta hydroxylase inhibitor, eukaryotic translation initiation factor inhibitor","DBH, EIF5A",NA,NA,"N[C@@H](CN1CC(=O)C(=O)C=C1)C(O)=O |c:9|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2240","L-monomethylarginine","nitric oxide synthase inhibitor","NOS1, NOS2",NA,NA,"CN[C@@H](CCCNC(N)=N)C(O)=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2241","L-NAME","nitric oxide synthase inhibitor","NOS3",NA,NA,"COC(=O)[C@@H](N)CCCNC(N)=N[N+]([O-])=O, COC(=O)[C@@H](N)CCCNC(N)=N[N+]([O-])=O, COC(=O)[C@@H](N)CCCNC(N)=N[N+]([O-])=O","Phase 2/Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2242","L-NIL","nitric oxide synthase inhibitor","NOS1, NOS2, NOS3",NA,NA,"CC(=N)NCCCC[C@H](N)C(O)=O, CC(=N)NCCCC[C@H](N)C(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2243","L-proline","glutamate receptor agonist","EPRS, L3HYPDH, P3H1, P3H2, P3H3, P4HA1, P4HA2, PARS2, PPIA, PPIB, PPIC, PPIF, PPIG, PPIH, PRODH, PROSC, PYCR1, PYCR2, PYCRL, SLC6A14, SLC6A7",NA,NA,"OC(=O)[C@@H]1CCCN1","Launched",1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2244","L-quisqualic-acid","glutamate receptor agonist","FOLH1, GRIA2, GRIK1, GRIK2, GRM1, GRM2, GRM3, GRM5, GRM7, GRM8",NA,NA,"N[C@@H](Cn1oc(=O)[nH]c1=O)C(O)=O, N[C@@H](Cn1oc(=O)[nH]c1=O)C(O)=O, N[C@@H](Cn1oc(=O)[nH]c1=O)C(O)=O, N[C@@H](Cn1oc(=O)[nH]c1=O)C(O)=O, N[C@@H](Cn1oc(=O)[nH]c1=O)C(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2245","L-152804","neuropeptide receptor antagonist","NPY5R",NA,NA,"CC1(C)CC(=O)C([C@@H]2C3=C(CC(C)(C)CC3=O)Oc3ccccc23)C(=O)C1 |&1:7,r,t:8|, CC1(C)CC(=O)C([C@@H]2C3=C(CC(C)(C)CC3=O)Oc3ccccc23)C(=O)C1 |&1:7,r,t:8|, CC1(C)CC(=O)C([C@@H]2C3=C(CC(C)(C)CC3=O)Oc3ccccc23)C(=O)C1 |&1:7,r,t:8|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2246","L-161982","prostanoid receptor antagonist","PTGER4",NA,NA,"CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(cc1)-c1ccccc1S(=O)(=O)NC(=O)c1sccc1C, CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(cc1)-c1ccccc1S(=O)(=O)NC(=O)c1sccc1C, CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(cc1)-c1ccccc1S(=O)(=O)NC(=O)c1sccc1C, CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(cc1)-c1ccccc1S(=O)(=O)NC(=O)c1sccc1C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2247","L-165041","PPAR receptor agonist","PPARD",NA,NA,"CCCc1c(O)c(ccc1OCCCOc1ccc(OCC(O)=O)cc1)C(C)=O, CCCc1c(O)c(ccc1OCCCOc1ccc(OCC(O)=O)cc1)C(C)=O, CCCc1c(O)c(ccc1OCCCOc1ccc(OCC(O)=O)cc1)C(C)=O, CCCc1c(O)c(ccc1OCCCOc1ccc(OCC(O)=O)cc1)C(C)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2248","L-168049","glucagon receptor antagonist","GCGR",NA,NA,"CCCOc1ccc(Br)cc1-c1cc([nH]c1-c1ccncc1)-c1ccc(Cl)cc1, CCCOc1ccc(Br)cc1-c1cc([nH]c1-c1ccncc1)-c1ccc(Cl)cc1, CCCOc1ccc(Br)cc1-c1cc([nH]c1-c1ccncc1)-c1ccc(Cl)cc1, CCCOc1ccc(Br)cc1-c1cc([nH]c1-c1ccncc1)-c1ccc(Cl)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2249","L-365260","CCK receptor antagonist","CCKAR, CCKBR, KCNQ1",NA,NA,"CN1c2ccccc2C(=N[C@@H](NC(=O)Nc2cccc(C)c2)C1=O)c1ccccc1 |c:9|, CN1c2ccccc2C(=N[C@@H](NC(=O)Nc2cccc(C)c2)C1=O)c1ccccc1 |c:9|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2250","L-368899","oxytocin receptor antagonist","AVPR1A, AVPR2, OXTR",NA,NA,"Cc1ccccc1N1CCN(CC1)S(=O)(=O)C[C@]12CC[C@H](C[C@@H]1NC(=O)[C@@H](N)CCS(C)(=O)=O)C2(C)C","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2251","L-655,708","GABA receptor inverse agonist","GABRA1, GABRA2, GABRA3, GABRA5, GABRG2",NA,NA,"CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21, CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21, CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21, CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21, CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,1,5,0,0,0,0,0,0,0,0,0,0
"2252","L-655240","thromboxane receptor antagonist","PTGES",NA,NA,"Cc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(F)cc12, Cc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(F)cc12","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2253","L-689560","glutamate receptor antagonist","GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,"OC(=O)[C@H]1C[C@H](NC(=O)Nc2ccccc2)c2c(Cl)cc(Cl)cc2N1, OC(=O)[C@H]1C[C@H](NC(=O)Nc2ccccc2)c2c(Cl)cc(Cl)cc2N1, OC(=O)[C@H]1C[C@H](NC(=O)Nc2ccccc2)c2c(Cl)cc(Cl)cc2N1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2254","L-690330","inositol monophosphatase inhibitor","IMPA1",NA,NA,"CC(Oc1ccc(O)cc1)(P(O)(O)=O)P(O)(O)=O, CC(Oc1ccc(O)cc1)(P(O)(O)=O)P(O)(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2255","L-693403","sigma receptor agonist, sigma receptor antagonist","DRD2, SIGMAR1",NA,NA,"C(N1CCC2(CCc3ccccc23)CC1)c1ccccc1, C(N1CCC2(CCc3ccccc23)CC1)c1ccccc1, C(N1CCC2(CCc3ccccc23)CC1)c1ccccc1, C(N1CCC2(CCc3ccccc23)CC1)c1ccccc1, C(N1CCC2(CCc3ccccc23)CC1)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0
"2256","L-694247","serotonin receptor agonist","HTR1A, HTR1B, HTR1D",NA,NA,"CS(=O)(=O)Nc1ccc(Cc2noc(n2)-c2ccc3[nH]cc(CCN)c3c2)cc1, CS(=O)(=O)Nc1ccc(Cc2noc(n2)-c2ccc3[nH]cc(CCN)c3c2)cc1","Preclinical",0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2257","L-701252","glutamate receptor antagonist","GRIN1",NA,NA,"Oc1c(C(=O)C2CC2)c(=O)[nH]c2cc(Cl)ccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2258","L-701324","glutamate receptor antagonist","GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,"Oc1c(-c2cccc(Oc3ccccc3)c2)c(=O)[nH]c2cc(Cl)ccc12, Oc1c(-c2cccc(Oc3ccccc3)c2)c(=O)[nH]c2cc(Cl)ccc12, Oc1c(-c2cccc(Oc3ccccc3)c2)c(=O)[nH]c2cc(Cl)ccc12, Oc1c(-c2cccc(Oc3ccccc3)c2)c(=O)[nH]c2cc(Cl)ccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2259","L-732,138","tachykinin antagonist","TACR1, TACR2",NA,NA,"CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)OCc1cc(cc(c1)C(F)(F)F)C(F)(F)F, CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)OCc1cc(cc(c1)C(F)(F)F)C(F)(F)F, CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)OCc1cc(cc(c1)C(F)(F)F)C(F)(F)F, CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)OCc1cc(cc(c1)C(F)(F)F)C(F)(F)F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2260","L-733060","tachykinin antagonist","TACR1",NA,NA,"FC(F)(F)c1cc(CO[C@H]2CCCN[C@H]2c2ccccc2)cc(c1)C(F)(F)F, FC(F)(F)c1cc(CO[C@H]2CCCN[C@H]2c2ccccc2)cc(c1)C(F)(F)F, FC(F)(F)c1cc(CO[C@H]2CCCN[C@H]2c2ccccc2)cc(c1)C(F)(F)F, FC(F)(F)c1cc(CO[C@H]2CCCN[C@H]2c2ccccc2)cc(c1)C(F)(F)F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2261","L-741742","dopamine receptor antagonist","DRD3, DRD4, SCN1A, SCN3A",NA,NA,"Cc1c(noc1-c1ccc(Cl)cc1)C1CCN(CCc2ccccc2)CC1, Cc1c(noc1-c1ccc(Cl)cc1)C1CCN(CCc2ccccc2)CC1","Preclinical",0,0,1,2,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0
"2262","L-745870","dopamine receptor antagonist","DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR6, HTR7",NA,NA,"Clc1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1, Clc1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1, Clc1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1","Preclinical",0,0,0,0,0,0,0,0,1,4,0,0,0,0,1,4,0,0,0,0,0,0,0,0
"2263","L-755507","adrenergic receptor agonist","ADRB1, ADRB2, ADRB3",NA,NA,"CCCCCCNC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1, CCCCCCNC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1, CCCCCCNC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0
"2264","L-760735","tachykinin antagonist","TACR1",NA,NA,"C[C@@H](O[C@H]1OCCN(Cc2n[nH]nc2CN(C)C)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(Cc2n[nH]nc2CN(C)C)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2265","L-778123","farnesyltransferase inhibitor","FNTA, FNTB, PGGT1B",NA,NA,"Clc1cccc(c1)N1CCN(Cc2cncn2Cc2ccc(cc2)C#N)CC1=O, Clc1cccc(c1)N1CCN(Cc2cncn2Cc2ccc(cc2)C#N)CC1=O, Clc1cccc(c1)N1CCN(Cc2cncn2Cc2ccc(cc2)C#N)CC1=O, Clc1cccc(c1)N1CCN(Cc2cncn2Cc2ccc(cc2)C#N)CC1=O, Clc1cccc(c1)N1CCN(Cc2cncn2Cc2ccc(cc2)C#N)CC1=O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2266","L-798106","prostanoid receptor antagonist","PTGER3",NA,NA,"COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1, COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1, COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2267","L-838417","GABA receptor partial agonist","GABRA1, GABRA2, GABRA3, GABRA5",NA,NA,"Cn1ncnc1COc1nn2c(nnc2cc1C(C)(C)C)-c1cc(F)ccc1F, Cn1ncnc1COc1nn2c(nnc2cc1C(C)(C)C)-c1cc(F)ccc1F, Cn1ncnc1COc1nn2c(nnc2cc1C(C)(C)C)-c1cc(F)ccc1F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,0,0
"2268","labetalol","adrenergic receptor antagonist","ADRA1D, ADRB1, ADRB2","cardiology","hypertension","C[C@@H](CCc1ccccc1)NC[C@@H](O)c1ccc(O)c(c1)C(N)=O |&1:1,&2:12,r|, C[C@@H](CCc1ccccc1)NC[C@@H](O)c1ccc(O)c(c1)C(N)=O |&1:1,&2:12,r|, C[C@@H](CCc1ccccc1)NC[C@@H](O)c1ccc(O)c(c1)C(N)=O |&1:1,&2:12,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,1,1,1,1
"2269","lacidipine","calcium channel blocker","CACNA1C","cardiology","hypertension","CCOC(=O)C1=C(C)NC(C)=C(C1c1ccccc1\C=C\C(=O)OC(C)(C)C)C(=O)OCC |c:5,10|, CCOC(=O)C1=C(C)NC(C)=C(C1c1ccccc1\C=C\C(=O)OC(C)(C)C)C(=O)OCC |c:5,10|, CCOC(=O)C1=C(C)NC(C)=C(C1c1ccccc1\C=C\C(=O)OC(C)(C)C)C(=O)OCC |c:5,10|, CCOC(=O)C1=C(C)NC(C)=C(C1c1ccccc1\C=C\C(=O)OC(C)(C)C)C(=O)OCC |c:5,10|, CCOC(=O)C1=C(C)NC(C)=C(C1c1ccccc1\C=C\C(=O)OC(C)(C)C)C(=O)OCC |c:5,10|, CCOC(=O)C1=C(C)NC(C)=C(C1c1ccccc1\C=C\C(=O)OC(C)(C)C)C(=O)OCC |c:5,10|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2270","laflunimus","prostagladin inhibitor","PTGS1, PTGS2",NA,NA,"Cc1cc(NC(=O)[C@@H](C#N)C(=O)C2CC2)ccc1C(F)(F)F |&1:7,r|","Phase 2",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2271","lafutidine","histamine receptor antagonist","HRH2","gastroenterology","duodenal ulcer disease, peptic ulcer disease (PUD), duodenal ulcer disease, peptic ulcer disease (pud)","O=C(C[S@@](=O)Cc1ccco1)NC\C=C/COc1cc(CN2CCCCC2)ccn1 |&1:3|, O=C(CS(=O)Cc1ccco1)NC\C=C/COc1cc(CN2CCCCC2)ccn1","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"2272","lamotrigine","serotonin receptor antagonist, sodium channel blocker","SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A","neurology/psychiatry","epilepsy, bipolar disorder","Nc1nnc(c(N)n1)-c1cccc(Cl)c1Cl, Nc1nnc(c(N)n1)-c1cccc(Cl)c1Cl, Nc1nnc(c(N)n1)-c1cccc(Cl)c1Cl, Nc1nnc(c(N)n1)-c1cccc(Cl)c1Cl","Launched",0,0,1,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2273","landiolol","adrenergic receptor antagonist","ADRB1","cardiology","cardiac arrythmia","CC1(C)OC[C@@H](COC(=O)CCc2ccc(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)cc2)O1, CC1(C)OC[C@@H](COC(=O)CCc2ccc(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)cc2)O1, CC1(C)OC[C@@H](COC(=O)CCc2ccc(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)cc2)O1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"2274","lanraplenib","protein tyrosine kinase inhibitor","A1BG, LAT, TNK1","rheumatology","lupus","Nc1cncc(n1)c2cn3ccnc3c(Nc4ccc(cc4)N5CCN(CC5)C6COC6)n2","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2275","lanreotide","somatostatin receptor agonist","SSTR2, SSTR3, SSTR5","endocrinology","acromegaly","CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccc3ccccc3c2)CSSC[C@@H](C(=O)N[C@H](C(N)=O)[C@@H](C)O)NC1=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2276","lansoprazole","ATPase inhibitor","ATP4A, ATP4B","gastroenterology","heartburn","Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1 |&1:14,r|, Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1 |r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2277","lapatinib","EGFR inhibitor","EGFR, ERBB2","oncology","breast cancer","CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2278","laquinimod","immunosuppressant","CXCL2",NA,NA,"CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1, CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1, CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1, CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1, CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2279","laropiprant","prostanoid receptor antagonist","PTGDR, PTGDR2, PTGER1, PTGER2, PTGER3, PTGFR, PTGIR, TBXA2R","cardiology","cholesterol","CS(=O)(=O)c1cc(F)cc2c3CC[C@H](CC(O)=O)c3n(Cc3ccc(Cl)cc3)c12, CS(=O)(=O)c1cc(F)cc2c3CC[C@H](CC(O)=O)c3n(Cc3ccc(Cl)cc3)c12, CS(=O)(=O)c1cc(F)cc2c3CC[C@H](CC(O)=O)c3n(Cc3ccc(Cl)cc3)c12, CS(=O)(=O)c1cc(F)cc2c3CC[C@H](CC(O)=O)c3n(Cc3ccc(Cl)cc3)c12, CS(=O)(=O)c1cc(F)cc2c3CC[C@H](CC(O)=O)c3n(Cc3ccc(Cl)cc3)c12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2280","larotrectinib","tropomyosin receptor kinase inhibitor, alk tyrosine kinase receptor inhibitor","NTRK1, NTRK2, NTRK3","hematologic malignancy","myeloproliferative neoplasms","O[C@H]1CCN(C1)C(=O)Nc1cnn2ccc(nc12)N1CCC[C@@H]1c1cc(F)ccc1F, O[C@H]1CCN(C1)C(=O)Nc1cnn2ccc(nc12)N1CCC[C@@H]1c1cc(F)ccc1F, O[C@H]1CCN(C1)C(=O)Nc2cnn3ccc(nc23)N4CCC[C@@H]4c5cc(F)ccc5F","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2281","lasofoxifene","selective estrogen receptor modulator (SERM)","ESR1, ESR2","orthopedics, oncology","osteoporosis, breast cancer","O[C@@H]([C@H](O)C(O)=O)C(O)=O.Oc1ccc2[C@H]([C@H](CCc2c1)c1ccccc1)c1ccc(OCCN2CCCC2)cc1, O[C@@H]([C@H](O)C(O)=O)C(O)=O.Oc1ccc2[C@H]([C@H](CCc2c1)c1ccccc1)c1ccc(OCCN2CCCC2)cc1, Oc1ccc2[C@H]([C@H](CCc2c1)c3ccccc3)c4ccc(OCCN5CCCC5)cc4","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2282","las101057","adenosine receptor antagonist","ADORA2B","pulmonary","asthma","Fc1cnccc1-c1ncc(NC(=O)C2CC2)nc1-c1cccnc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2283","latanoprost","prostanoid receptor agonist","PTGFR","ophthalmology","ocular hypertension, glaucoma","CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1, CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1, CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2284","latanoprostene bunod","prostanoid receptor agonist","GUCY1A1, PTGFR","ophthalmology","intraocular pressure","C1[C@H]([C@@H]([C@H]([C@H]1O)C/C=C\CCCC(=O)OCCCCO[N+](=O)[O-])CC[C@H](CCC2=CC=CC=C2)O)O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2285","latrepirdine","glutamate receptor antagonist","HRH1, HTR6",NA,NA,"CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1","Phase 3",0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0
"2286","latrunculin-B","actin polymerization inhibitor","ACTA1, MKL1, SPIRE2",NA,NA,"C[C@H]1CC[C@@H]2C[C@H](C[C@@](O)(O2)[C@@H]2CSC(=O)N2)OC(=O)\C=C(C)/CC\C=C/1 |c:27,t:22|, C[C@H]1CC[C@@H]2C[C@H](C[C@@](O)(O2)[C@@H]2CSC(=O)N2)OC(=O)\C=C(C)/CC\C=C/1 |c:27,t:22|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2287","lauric-acid","bacterial permeability inducer","GPR84, HNF4A, LTF, LY96, PLA2G2A, TLR4",NA,NA,"CCCCCCCCCCCC(O)=O, CCCCCCCCCCCC(O)=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2288","lazabemide","monoamine oxidase inhibitor","MAOB",NA,NA,"NCCNC(=O)c1ccc(Cl)cn1, NCCNC(=O)c1ccc(Cl)cn1, NCCNC(=O)c1ccc(Cl)cn1, NCCNC(=O)c1ccc(Cl)cn1","Phase 3",0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2289","lb-100","protein phosphatase inhibitor","PPP5C","Neurology","depression","CN1CCN(CC1)C(=O)C1C2CCC(O2)C1C(O)=O, CN1CCN(CC1)C(=O)[C@H]1[C@H]2CC[C@H](O2)[C@@H]1C(O)=O |&1:15,&2:9|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2290","LCL-161","XIAP inhibitor","BIRC2, XIAP",NA,NA,"CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2291","LCQ908","diacylglycerol O acyltransferase inhibitor","DGAT1",NA,NA,"OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1 |r|, OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1 |r|, OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1 |r|, OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1 |r|, OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1 |r|, OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1 |r|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2292","LDC1267","protein tyrosine kinase inhibitor","AXL, MERTK, TYRO3",NA,NA,"CCOc1cn(nc1C(=O)Nc1ccc(Oc2ccnc3cc(OC)c(OC)cc23)c(F)c1)-c1ccc(F)cc1C, CCOc1cn(nc1C(=O)Nc1ccc(Oc2ccnc3cc(OC)c(OC)cc23)c(F)c1)-c1ccc(F)cc1C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2293","LDN-209929","haspin kinase inhibitor","GSG2",NA,NA,"COc1ccc2nc3ccc(Cl)cc3c(SCCCN)c2c1, COc1ccc2nc3ccc(Cl)cc3c(SCCCN)c2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2294","LDN-212854","bone morphogenic protein inhibitor","ABL1, ACVR1, RIPK2",NA,NA,"C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2295","LDN-27219","tissue transglutaminase inhibitor","TGM2",NA,NA,"NNC(=O)CSc1nc2scc(-c3ccccc3)c2c(=O)n1-c1ccccc1, NNC(=O)CSc1nc2scc(-c3ccccc3)c2c(=O)n1-c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2296","LDN193189","bone morphogenic protein inhibitor","ACVR1, BMPR1A",NA,NA,"C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2297","LE-135","retinoid receptor agonist","RARB",NA,NA,"CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C |t:9|, CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C |t:9|, CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C |t:9|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2298","leflunomide","dihydroorotate dehydrogenase inhibitor, PDGFR tyrosine kinase receptor inhibitor","AHR, DHODH, PTK2B","rheumatology","rheumatoid arthritis","Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F, Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F, Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F, Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2299","lemborexant","orexin receptor antagonist","HCRTR1, HCRTR2",NA,NA,"Cc1ncc(OC[C@]2(C[C@H]2C(=O)Nc2ccc(F)cn2)c2cccc(F)c2)c(C)n1, Cc1ncc(OC[C@]2(C[C@H]2C(=O)Nc2ccc(F)cn2)c2cccc(F)c2)c(C)n1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2300","lenalidomide","anticancer agent","TNF","hematologic malignancy","multiple myeloma, mantle cell lymphoma (MCL), myelodysplastic diseases (MDS)","Nc1cccc2C(=O)N(Cc12)[C@H]1CCC(=O)NC1=O |&1:11,r|, Nc1cccc2C(=O)N(Cc12)[C@H]1CCC(=O)NC1=O |&1:11,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2301","lenvatinib","FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FLT4, KDR","oncology","thyroid cancer","COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O, COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O, COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O, COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O, COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O, COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2302","leptomycin b","exportin antagonist","XPO1","Oncology","anticancer antibiotic","CC\C(\C=C\[C@@H]1OC(=O)C=C[C@@H]1C)=C\[C@H](C)C\C=C\C(\C)=C\[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C\C(O)=O |c:9|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2303","lercanidipine","calcium channel blocker","CACNA2D1","cardiology","hypertension","COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(c1ccccc1)c1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(c1ccccc1)c1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(c1ccccc1)c1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(c1ccccc1)c1ccccc1 |c:4,9|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2304","lerisetron","serotonin receptor antagonist","HTR3A",NA,NA,"C(c1ccccc1)n1c(nc2ccccc12)N1CCNCC1, C(c1ccccc1)n1c(nc2ccccc12)N1CCNCC1, C(c1ccccc1)n1c(nc2ccccc12)N1CCNCC1","Phase 3",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2305","lesinurad","uric acid diuretic","SLC22A12","rheumatology","gout","OC(=O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12, OC(=O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2306","lestaurtinib","FLT3 inhibitor, growth factor receptor inhibitor, JAK inhibitor","FLT3, NTRK1, NTRK2, NTRK3","Oncology","acute myeloid leukemia (aml)","C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13","Phase 2/Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2307","letrozole","aromatase inhibitor","CYP19A1","oncology","breast cancer","N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1, N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1, N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2308","leucomethylene-blue","nitric oxide production inhibitor, tau aggregation inhibitor","MAPT",NA,NA,"CN(C)c1ccc2Nc3ccc(cc3Sc2c1)N(C)C","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2309","leuprolide","gonadotropin releasing factor hormone receptor agonist","GNRHR","oncology","prostate cancer","CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1, CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2310","levalbuterol","adrenergic receptor agonist","ADRB2","pulmonary","bronchospasm","CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1, CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1, CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"2311","levallorphan","opioid receptor antagonist","CHRNA2, OPRM1","pulmonary","respiratory depression","Oc1ccc2C[C@@H]3[C@@H]4CCCC[C@]4(CCN3CC=C)c2c1, Oc1ccc2C[C@@H]3[C@@H]4CCCC[C@]4(CCN3CC=C)c2c1, Oc1ccc2C[C@@H]3[C@@H]4CCCC[C@]4(CCN3CC=C)c2c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,1
"2312","levamisole","acetylcholine receptor agonist","ALPL",NA,NA,"C1CN2C[C@@H](N=C2S1)c1ccccc1 |c:5|, C1CN2C[C@@H](N=C2S1)c1ccccc1 |c:5|, C1CN2C[C@@H](N=C2S1)c1ccccc1 |c:5|, C1CN2C[C@@H](N=C2S1)c1ccccc1 |c:5|","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2313","levcromakalim","potassium channel activator","KCNJ5",NA,NA,"CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N, CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N, CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N, CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N, CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2314","levetiracetam","calcium channel blocker","CACNA1B, SCN1A, SV2A","neurology/psychiatry","seizures","CC[C@H](N1CCCC1=O)C(N)=O, CC[C@H](N1CCCC1=O)C(N)=O, CC[C@H](N1CCCC1=O)C(N)=O, CC[C@H](N1CCCC1=O)C(N)=O, CC[C@H](N1CCCC1=O)C(N)=O, CC[C@H](N1CCCC1=O)C(N)=O, CC[C@H](N1CCCC1=O)C(N)=O","Launched",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2315","levo-phencynonate","acetylcholine receptor antagonist","CHRM1",NA,NA,"CN1C[C@@H]2CCC[C@H](C1)[C@H]2OC(=O)[C@@](O)(C1CCCC1)c1ccccc1 |&1:7,&2:3,&3:9,&4:13|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
"2316","levobetaxolol","adrenergic receptor antagonist","ADRB1, ADRB2","ophthalmology","intraocular pressure, glaucoma","CC(C)NC[C@H](O)COc1ccc(CCOCC2CC2)cc1, CC(C)NC[C@H](O)COc1ccc(CCOCC2CC2)cc1, CC(C)NC[C@H](O)COc1ccc(CCOCC2CC2)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,1,1,1,1
"2317","levobunolol","adrenergic receptor antagonist","ADRB1, ADRB2, ADRB3","ophthalmology","glaucoma, ocular hypertension","CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12, CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12, CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12, CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,1,1,1,1
"2318","levobupivacaine","voltage-gated potassium channel blocker","KCNA5","Anesthesia","local anesthetic","CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2319","levocabastine","histamine receptor antagonist","HRH1, NTSR2","ophthalmology","conjunctivitis","C[C@@H]1CN(CC[C@]1(C(O)=O)c1ccccc1)[C@H]1CC[C@](CC1)(C#N)c1ccc(F)cc1","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"2320","levocarnitine-propionate","carnitine palmitoyltransferase inhibitor","CRAT","neurology/psychiatry, endocrinology","peripheral neuropathy, carnitine deficiency","CCC(=O)O[C@H](CC(O)=O)C[N+](C)(C)C, CCC(=O)O[C@H](CC(O)=O)C[N+](C)(C)C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2321","levocetirizine","histamine receptor antagonist","HRH1","allergy","allergic rhinitis, urticaria","OC(=O)COCCN1CCN(CC1)[C@H](c1ccccc1)c1ccc(Cl)cc1, OC(=O)COCCN1CCN(CC1)[C@H](c1ccccc1)c1ccc(Cl)cc1, OC(=O)COCCN1CCN(CC1)[C@H](c1ccccc1)c1ccc(Cl)cc1, OC(=O)COCCN1CCN(CC1)[C@H](c1ccccc1)c1ccc(Cl)cc1","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"2322","levodopa","dopamine precursor, dopamine analog","DDC, DRD1, DRD2, DRD3, DRD4, DRD5, GPR143","neurology/psychiatry","Parkinson's Disease","N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O, N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O, N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O, N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O, COC(=O)C(N)Cc1ccc(O)c(O)c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,5,0,0,0,0,1,1,1,1
"2323","levofloxacin","bacterial DNA gyrase inhibitor","TOP2A","infectious disease, otolaryngology, pulmonary, urology","pneumonia, sinusitis, bronchitis, skin infections, prostatitis, urinary tract infections, pyelonephritis, anthrax, plague","C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O, C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2324","levomepromazine","dopamine receptor antagonist","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR2A, HTR2C","neurology/psychiatry, gastroenterology","psychosis, schizophrenia, bipolar disorder, nausea, insomnia","COc1ccc2Sc3ccccc3N(C[C@H](C)CN(C)C)c2c1, COc1ccc2Sc3ccccc3N(C[C@H](C)CN(C)C)c2c1, COc1ccc2Sc3ccccc3N(C[C@H](C)CN(C)C)c2c1","Launched",0,0,0,0,0,0,0,0,1,2,1,1,0,0,1,5,1,5,1,6,1,1,1,1
"2325","levomequitazine","histamine receptor antagonist","HRH1",NA,NA,"C([C@H]1CN2CCC1CC2)N1c2ccccc2Sc2ccccc12 |&1:1,r|, C([C@H]1CN2CCC1CC2)N1c2ccccc2Sc2ccccc12 |&1:1,r|, C([C@H]1CN2CCC1CC2)N1c2ccccc2Sc2ccccc12 |&1:1,r|, C([C@H]1CN2CCC1CC2)N1c2ccccc2Sc2ccccc12 |&1:1,r|, C([C@H]1CN2CCC1CC2)N1c2ccccc2Sc2ccccc12 |&1:1,r|","Phase 2",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
"2326","levonordefrin","vasodilator","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, SLC6A2","hematology","hemorrhage","C[C@H](N)[C@H](O)c1ccc(O)c(O)c1, C[C@H](N)[C@H](O)c1ccc(O)c(O)c1","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,6,1,1,1,1
"2327","levonorgestrel","estrogen receptor agonist, glucocorticoid receptor antagonist, progesterone receptor agonist, progesterone receptor antagonist","PGR","endocrinology","contraceptive","CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2328","levosimendan","calcium sensitizer","KCNJ11, KCNJ8, PDE3A, TNNC1","cardiology","congestive heart failure","C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1 |c:6|, C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1 |c:6|, C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1 |c:6|, C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1 |c:6|, C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1 |c:6|, C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1 |c:6|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2329","levosulpiride","dopamine receptor antagonist","CA1, CA12, CA7, DRD2, DRD3","neurology/psychiatry, gastroenterology, urology","schizophrenia, psychosis, anxiety, vertigo, dyspepsia, irritable bowel syndrome, premature ejaculation (PE)","CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O, CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O, CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O, CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O, CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O, CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,1,1,1,1
"2330","levothyroxine","thyroid hormone stimulant","THRA, THRB","endocrinology","myxedema coma","N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2331","LFM-A13","Bruton's tyrosine kinase (BTK) inhibitor","BTK",NA,NA,"CC(=O)[C@@H](C#N)C(=O)Nc1cc(Br)ccc1Br |&1:3,r|, CC(=O)[C@@H](C#N)C(=O)Nc1cc(Br)ccc1Br |&1:3,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2332","LGK-974","porcupine inhibitor","PORCN",NA,NA,"Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C, Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C, Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C, Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C, Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C, Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2333","LH846","casein kinase inhibitor","CSNK1D",NA,NA,"Cc1cc2sc(NC(=O)Cc3ccccc3)nc2cc1Cl, Cc1cc2sc(NC(=O)Cc3ccccc3)nc2cc1Cl, Cc1cc2sc(NC(=O)Cc3ccccc3)nc2cc1Cl","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2334","liarozole","cytochrome P450 inhibitor","CYP19A1, CYP26A1",NA,NA,"Clc1cccc(c1)[C@H](c1ccc2nc[nH]c2c1)n1ccnc1 |&1:7,r|","Phase 2/Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2335","licarbazepine","voltage-gated sodium channel blocker","SCN5A",NA,NA,"NC(=O)N1c2ccccc2C[C@@H](O)c2ccccc12 |&1:11,r|, NC(=O)N1c2ccccc2C[C@@H](O)c2ccccc12 |&1:11,r|, NC(=O)N1c2ccccc2C[C@@H](O)c2ccccc12 |&1:11,r|, NC(=O)N1c2ccccc2C[C@@H](O)c2ccccc12 |&1:11,r|, NC(=O)N1c2ccccc2C[C@@H](O)c2ccccc12 |&1:11,r|","Phase 3",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2336","licochalcone-A","topoisomerase inhibitor","PTPN1",NA,NA,"COc1cc(O)c(cc1\C=C\C(=O)c1ccc(O)cc1)C(C)(C)C=C","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2337","licofelone","cyclooxygenase inhibitor, lipoxygenase inhibitor","ALOX5, PLA2G2E, PTGS2",NA,NA,"CC1(C)Cc2c(c(c(CC(O)=O)n2C1)-c1ccc(Cl)cc1)-c1ccccc1, CC1(C)Cc2c(c(c(CC(O)=O)n2C1)-c1ccc(Cl)cc1)-c1ccccc1, CC1(C)Cc2c(c(c(CC(O)=O)n2C1)-c1ccc(Cl)cc1)-c1ccccc1, CC1(C)Cc2c(c(c(CC(O)=O)n2C1)-c1ccc(Cl)cc1)-c1ccccc1","Phase 3",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2338","lidocaine","histamine receptor agonist","EGFR, SCN10A, SCN5A, SCN9A","neurology/psychiatry, dermatology, hematology","itching, eczema, hemorrhage","CCN(CC)CC(=O)Nc1c(C)cccc1C, CCN(CC)CC(=O)Nc1c(C)cccc1C, CCN(CC)CC(=O)Nc1c(C)cccc1C, CCN(CC)CC(=O)Nc1c(C)cccc1C","Launched",0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2339","lidoflazine","calcium channel blocker","SCN1A, SCN3A, SLC29A1","cardiology","coronary artery disease (CAD)","Cc1cccc(C)c1NC(=O)CN1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1, Cc1cccc(C)c1NC(=O)CN1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1, Cc1cccc(C)c1NC(=O)CN1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1","Launched",1,1,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2340","ligandrol","androgen receptor modulator","AR, SARM1","endocrinology","cachexia","O[C@H]([C@H]1CCCN1c2ccc(C#N)c(c2)C(F)(F)F)C(F)(F)F","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2341","ligustilide","tumor necrosis factor production inhibitor","TNF",NA,NA,"CCC\C=C1/OC(=O)C2=C1CCC=C2 |c:8,13|, CCC\C=C1/OC(=O)C2=C1CCC=C2 |c:8,13|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2342","limaprost-alfadex","prostanoid receptor agonist","PTGER1","cardiology","claudication","CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O, CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O, CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O, CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2343","LIMKi-3","LIM kinase inhibitor","LIMK1",NA,NA,"CC(C)C(=O)Nc1ncc(s1)-c1cc(nn1-c1c(Cl)cccc1Cl)C(F)F, CC(C)C(=O)Nc1ncc(s1)-c1cc(nn1-c1c(Cl)cccc1Cl)C(F)F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2344","linaclotide","guanylate cyclase activator","GUCY2C","gastroenterology","irritable bowel syndrome, constipation, irritable bowel syndrome, constipation","[H][C@@]12CCCN1C(=O)[C@H](CC(N)=O)NC(=O)[C@]1([H])CSSC[C@H](N)C(=O)N[C@@]3([H])CSSC[C@]([H])(NC(=O)[C@H](C)NC2=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CSSC[C@]([H])(NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CCC(O)=O)NC3=O)C(=O)N1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O, C[C@@H](O)C1NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CSSC[C@H](NC(=O)CNC1=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCC(O)=O)NC3=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N2","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2345","linagliptin","dipeptidyl peptidase inhibitor","DPP4","endocrinology","diabetes mellitus","CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1, CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1, CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1, CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1, CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1, CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1, CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2346","linezolid","bacterial 50S ribosomal subunit inhibitor","MAOA, MAOB","infectious disease","pneumonia, skin infections","CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1","Launched",0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2347","linifanib","PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK",NA,NA,"Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3n[nH]c(N)c23)c1, Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3n[nH]c(N)c23)c1, Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3n[nH]c(N)c23)c1, Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3n[nH]c(N)c23)c1, Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3n[nH]c(N)c23)c1, Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3n[nH]c(N)c23)c1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2348","linoleic-acid","oxidative stress inducer","FABP4, FFAR1, FFAR4, HNF4A, KCNB1, PPARG, TRPM8",NA,NA,"CCCCC\C=C/C\C=C/CCCCCCCC(O)=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2349","linopirdine","potassium channel blocker","KCNQ2, KCNQ3, KCNQ4, KCNQ5",NA,NA,"O=C1N(c2ccccc2C1(Cc1ccncc1)Cc1ccncc1)c1ccccc1, O=C1N(c2ccccc2C1(Cc1ccncc1)Cc1ccncc1)c1ccccc1, O=C1N(c2ccccc2C1(Cc1ccncc1)Cc1ccncc1)c1ccccc1, O=C1N(c2ccccc2C1(Cc1ccncc1)Cc1ccncc1)c1ccccc1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2350","linsitinib","IGF-1 inhibitor","IGF1R, INSR, INSRR",NA,NA,"C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2351","liothyronine","thyroid hormone stimulant","THRA, THRB","endocrinology","hypothyroidism, myxedema coma","N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2352","liraglutide","GLP receptor agonist","GLP1R","endocrinology","weight-loss aid, diabetes mellitus, weight-loss aid, diabetes mellitus","CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(Cc1ccccc1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O, CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2353","lisinopril","angiotensin converting enzyme inhibitor","ACE, ACE2","cardiology, endocrinology","hypertension, congestive heart failure, diabetes mellitus","NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2354","lisuride","dopamine receptor agonist","ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6","neurology/psychiatry","Parkinson's Disease","CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:23|, CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:23|, CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:23|","Launched",0,0,0,0,0,0,0,0,1,7,0,0,0,0,1,5,0,0,1,4,1,1,1,1
"2355","lithocholic-acid","FXR antagonist, vitamin D receptor agonist","GPBAR1, NR1H4, NR1I2, VDR",NA,NA,"C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2356","litronesib","kinesin-like spindle protein inhibitor","KIF11",NA,NA,"CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 |c:19|, CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 |c:19|, CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 |c:19|, CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 |c:19|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2357","lixivaptan","vasopressin receptor antagonist","AVPR2",NA,NA,"Cc1ccc(F)cc1C(=O)Nc1ccc(C(=O)N2Cc3cccn3Cc3ccccc23)c(Cl)c1, Cc1ccc(F)cc1C(=O)Nc1ccc(C(=O)N2Cc3cccn3Cc3ccccc23)c(Cl)c1, Cc1ccc(F)cc1C(=O)Nc1ccc(C(=O)N2Cc3cccn3Cc3ccccc23)c(Cl)c1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2358","LM-22A4","tropomyosin receptor kinase inhibitor","NTRK2",NA,NA,"OCCNC(=O)c1cc(cc(c1)C(=O)NCCO)C(=O)NCCO, OCCNC(=O)c1cc(cc(c1)C(=O)NCCO)C(=O)NCCO, OCCNC(=O)c1cc(cc(c1)C(=O)NCCO)C(=O)NCCO","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2359","LMI070","survival motor neuron protein modulator","SMN1",NA,NA,"CC1(C)CC(CC(C)(C)N1)Oc1ccc(nn1)-c1ccc(cc1O)-c1cn[nH]c1, CC1(C)CC(CC(C)(C)N1)Oc1ccc(nn1)-c1ccc(cc1O)-c1cn[nH]c1","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2360","LMK-235","HDAC inhibitor","HDAC4, HDAC5",NA,NA,"Cc1cc(C)cc(c1)C(=O)NOCCCCCC(=O)NO, Cc1cc(C)cc(c1)C(=O)NOCCCCCC(=O)NO, Cc1cc(C)cc(c1)C(=O)NOCCCCCC(=O)NO","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2361","lmp744 hydrochloride","topoisomerase inhibitor","TOP1","oncology","ovarian cancer","COc1cc2c3C(=O)c4cc5OCOc5cc4-c3n(CCCNCCO)c(=O)c2cc1OC.Cl","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2362","LM11A-31","neurotrophic agent","NGFR",NA,NA,"CC[C@@H](C)[C@@H](N)C(=O)NCCN1CCOCC1 |&1:2,&2:4,r|, CC[C@@H](C)[C@@H](N)C(=O)NCCN1CCOCC1 |&1:2,&2:4,r|, CC[C@@H](C)[C@@H](N)C(=O)NCCN1CCOCC1 |&1:2,&2:4,r|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2363","lobeline","acetylcholine receptor antagonist","CHRNA10, CHRNA9, SLC18A2","neurology/psychiatry","smoking cessation","CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1, CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1, CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1, CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1, CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1, CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,1,1,1,1
"2364","lofepramine","norepinephrine reuptake inhibitor, serotonin‚Äìnorepinephrine reuptake inhibitor (SNRI)","HTR1A, SLC6A2, SLC6A4","neurology/psychiatry","depression","CN(CCCN1c2ccccc2CCc2ccccc12)CC(=O)c1ccc(Cl)cc1, CN(CCCN1c2ccccc2CCc2ccccc12)CC(=O)c1ccc(Cl)cc1, CN(CCCN1c2ccccc2CCc2ccccc12)CC(=O)c1ccc(Cl)cc1","Launched",1,2,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2365","lomeguatrib","O6-alkylguanine-DNA alkyltransferase inhibitor","MGMT",NA,NA,"Nc1nc(OCc2cc(Br)cs2)c2[nH]cnc2n1, Nc1nc(OCc2cc(Br)cs2)c2[nH]cnc2n1, Nc1nc(OCc2cc(Br)cs2)c2[nH]cnc2n1, Nc1nc(OCc2cc(Br)cs2)c2[nH]cnc2n1, Nc1nc(OCc2cc(Br)cs2)c2[nH]cnc2n1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2366","lomerizine","calcium channel blocker","CACNA1B, SCN5A","neurology/psychiatry","migraine headache","COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC, COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC, COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC, COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC, COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC, COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC, COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC, COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC","Launched",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2367","lometrexol","glycinamide ribonucleotide formyltransferase inhibitor","GART",NA,NA,"Nc1nc(=O)c2C[C@@H](CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2368","lomitapide","microsomal trigylceride transfer protein inhibitor","MTTP","endocrinology","hypercholesterolemia","FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)c2ccccc2-c2ccc(cc2)C(F)(F)F)c2ccccc2-c2ccccc12, FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)c2ccccc2-c2ccc(cc2)C(F)(F)F)c2ccccc2-c2ccccc12, FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)c2ccccc2-c2ccc(cc2)C(F)(F)F)c2ccccc2-c2ccccc12, FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)c2ccccc2-c2ccc(cc2)C(F)(F)F)c2ccccc2-c2ccccc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2369","lonafarnib","farnesyltransferase inhibitor","FNTA, HRAS, KRAS, NRAS",NA,NA,"NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1, NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1, NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1, NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1, NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1, NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1, NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2370","lonapalene","lipoxygenase inhibitor","ALOX5","dermatology","psoriasis","COc1c(OC)c(OC(=O)C)c2cc(Cl)ccc2c1OC(=O)C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2371","lonidamine","glucokinase inhibitor","GCK",NA,NA,"OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12, OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12, OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12, OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12, OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2372","loperamide","opioid receptor agonist","CACNA1A, CALM1, OPRD1, OPRK1, OPRM1, POMC","gastroenterology","diarrhea","CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1, CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1, CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1, CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1, CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1, CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1, CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1, CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2373","loratadine","histamine receptor antagonist","HRH1","allergy, neurology/psychiatry","allergic rhinitis, itching","CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12, CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12, CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12, CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12, CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"2374","loreclezole","benzodiazepine receptor agonist","GABRB2, GABRB3",NA,NA,"Cl\C(=C/n1cncn1)c1ccc(Cl)cc1Cl, Cl\C(=C/n1cncn1)c1ccc(Cl)cc1Cl","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0
"2375","lorediplon","GABA receptor modulator","GABRA1",NA,NA,"CN(C(C)=O)c1cc(ccc1F)-c1ccnc2c(cnn12)C(=O)c1cccs1, CN(C(C)=O)c1cc(ccc1F)-c1ccnc2c(cnn12)C(=O)c1cccs1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0
"2376","lorglumide","CCK receptor antagonist","CCKAR, CCKBR",NA,NA,"CCCCCN(CCCCC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:13,r|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2377","lorlatinib","ALK tyrosine kinase receptor inhibitor","ALK","oncology","non-small cell lung cancer (NSCLC)","C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N, C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N, C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N, C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N, C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N, C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2378","lornoxicam","cyclooxygenase inhibitor","PTGS1, PTGS2","rheumatology, neurology/psychiatry","osteoarthritis, sciata","CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O |t:12|","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2379","losartan","angiotensin receptor antagonist","AGTR1","cardiology, nephrology","hypertension, diabetic nephropathy, hypertension","CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2380","losmapimod","p38 MAPK inhibitor","MAPK14",NA,NA,"Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1, Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1, Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1, Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1, Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1, Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2381","loteprednol","glucocorticoid receptor agonist, phospholipase inhibitor","NR3C1","ophthalmology","conjunctivitis","CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl |c:17,t:13|, CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl |c:17,t:13|, CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl |c:17,t:13|, CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl |c:17,t:13|, CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl |c:17,t:13|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2382","lotilaner","gaba receptor antagonist","GABRA1","infectious disease","flea control","CC1=C(SC(=C1)C2=NO[C@@](C2)(C3=CC(=C(C(=C3)Cl)Cl)Cl)C(F)(F)F)C(=O)NCC(=O)NCC(F)(F)F","Launched",0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1
"2383","lovastatin","HMGCR inhibitor","HDAC2, HMGCR, ITGAL, NR1I2","cardiology, endocrinology","coronary heart disease, myocardial infarction, hypercholesterolemia","CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2384","loxapine","dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HRH2, HRH4, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR5A, HTR6, HTR7, SLC6A2, SLC6A3, SLC6A4","neurology/psychiatry","schizophrenia","CN1CCN(CC1)C1=Nc2ccccc2Oc2ccc(Cl)cc12 |t:8|, CN1CCN(CC1)C1=Nc2ccccc2Oc2ccc(Cl)cc12 |t:8|, CN1CCN(CC1)C1=Nc2ccccc2Oc2ccc(Cl)cc12 |t:8|","Launched",1,3,0,0,0,0,0,0,1,10,1,3,0,0,1,5,1,5,1,6,1,1,1,1
"2385","loxistatin-acid","cysteine peptidase inhibitor","CTSB",NA,NA,"CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O, CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O, CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2386","loxoprofen","cyclooxygenase inhibitor, prostanoid receptor antagonist","PTGS2","neurology/psychiatry","pain relief","C[C@@H](C(O)=O)c1ccc(C[C@H]2CCCC2=O)cc1 |&1:1,&2:10,r|, C[C@@H](C(O)=O)c1ccc(C[C@H]2CCCC2=O)cc1 |&1:1,&2:10,r|, C[C@@H](C(O)=O)c1ccc(C[C@H]2CCCC2=O)cc1 |&1:1,&2:10,r|, C[C@@H](C(O)=O)c1ccc(C[C@H]2CCCC2=O)cc1 |&1:1,&2:10,r|","Launched",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2387","LPA2-antagonist-1","lysophosphatidic acid receptor antagonist","LPAR2",NA,NA,"C[C@@H](CN1CCN(CC1)S(=O)(=O)c1ccc(Cl)c(Cl)c1)Nc1ncnc2c(C)csc12, C[C@@H](CN1CCN(CC1)S(=O)(=O)c1ccc(Cl)c(Cl)c1)Nc1ncnc2c(C)csc12, C[C@@H](CN1CCN(CC1)S(=O)(=O)c1ccc(Cl)c(Cl)c1)Nc1ncnc2c(C)csc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2388","LRRK2-IN-1","leucine rich repeat kinase inhibitor","LRRK2",NA,NA,"COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2389","LSN-2463359","glutamate receptor positive allosteric modulator","GRM5",NA,NA,"CC(C)NC(=O)c1ccc(cn1)C#Cc1ccncc1, CC(C)NC(=O)c1ccc(cn1)C#Cc1ccncc1, CC(C)NC(=O)c1ccc(cn1)C#Cc1ccncc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2390","lta4h-in-1","leukotriene inhibitor","LTA4H","gastroenterology","inflammatory bowel disease","N[C@@H](CC(=O)O)Cn1nnc(n1)c2ccc(Oc3ncc(Cl)cc3F)cc2","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2391","LTB4","leukocyte activator","LTB4R, LTB4R2",NA,NA,"CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2392","Lu-AA-47070","adenosine receptor antagonist","ADORA2A",NA,NA,"CC(C)(C)CC(=O)Nc1c(F)cc(cc1F)C(=O)\N=c1/sccn1COP(O)(O)=O, CC(C)(C)CC(=O)Nc1c(F)cc(cc1F)C(=O)\N=c1/sccn1COP(O)(O)=O, CC(C)(C)CC(=O)Nc1c(F)cc(cc1F)C(=O)\N=c1/sccn1COP(O)(O)=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2393","lubiprostone","chloride channel activator","CLCN2","gastroenterology","constipation, irritable bowel syndrome","CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O, CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O, CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2394","lucanthone","endonuclease inhibitor","APEX1, TOP1, TOP2A",NA,NA,"CCN(CC)CCNc1ccc(C)c2sc3ccccc3c(=O)c12","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2395","lucitanib","FGFR inhibitor, VEGFR inhibitor","FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET",NA,NA,"CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2396","LUF-5834","adenosine receptor agonist","ADORA2A, ADORA2B",NA,NA,"Nc1nc(SCc2ncc[nH]2)c(C#N)c(-c2ccc(O)cc2)c1C#N, Nc1nc(SCc2ncc[nH]2)c(C#N)c(-c2ccc(O)cc2)c1C#N","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2397","lumacaftor","CFTR channel agonist","CFTR","pulmonary","cystic fibrosis","Cc1ccc(NC(=O)C2(CC2)c2ccc3OC(F)(F)Oc3c2)nc1-c1cccc(c1)C(O)=O, Cc1ccc(NC(=O)C2(CC2)c2ccc3OC(F)(F)Oc3c2)nc1-c1cccc(c1)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2398","lumateperone","dopamine receptor modulator, serotonin receptor antagonist","DRD2, HTR2A",NA,NA,"CN1CCN2[C@H]3CCN(CCCC(=O)c4ccc(F)cc4)C[C@H]3c3cccc1c23, CN1CCN2[C@H]3CCN(CCCC(=O)c4ccc(F)cc4)C[C@H]3c3cccc1c23, CN1CCN2[C@H]3CCN(CCCC(=O)c4ccc(F)cc4)C[C@H]3c3cccc1c23, CN1CCN2[C@H]3CCN(CCCC(=O)c4ccc(F)cc4)C[C@H]3c3cccc1c23","Launched",0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0
"2399","lumefantrine","antimalarial agent","ATP1A1","infectious disease","malaria","CCCCN(CCCC)C[C@@H](O)c1cc(Cl)cc2\C(=C/c3ccc(Cl)cc3)c3cc(Cl)ccc3-c12 |&1:10,r|, CCCCN(CCCC)C[C@@H](O)c1cc(Cl)cc2\C(=C/c3ccc(Cl)cc3)c3cc(Cl)ccc3-c12 |&1:10,r|, CCCCN(CCCC)C[C@@H](O)c1cc(Cl)cc2\C(=C/c3ccc(Cl)cc3)c3cc(Cl)ccc3-c12 |&1:10,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2400","lumiracoxib","cyclooxygenase inhibitor","PTGS1, PTGS2",NA,NA,"Cc1ccc(Nc2c(F)cccc2Cl)c(CC(O)=O)c1, Cc1ccc(Nc2c(F)cccc2Cl)c(CC(O)=O)c1, Cc1ccc(Nc2c(F)cccc2Cl)c(CC(O)=O)c1, Cc1ccc(Nc2c(F)cccc2Cl)c(CC(O)=O)c1","Withdrawn",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2401","lupanine","sodium channel blocker, sodium channel blocker, insulin secretagogue, insulin secretagogue","INS","Endocrinology","diabetes mellitus","[H][C@@]12CCCCN1C[C@@H]1C[C@H]2CN2C(=O)CCC[C@]12[H], [H][C@@]12CCCCN1C[C@@H]1C[C@H]2CN2C(=O)CCC[C@]12[H], O=C1CCCC2C3CC(CN12)[C@@H]1CCCCN1C3","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2402","lurasidone","dopamine receptor antagonist, serotonin receptor antagonist","ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7","neurology/psychiatry","schizophrenia","O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)c1nsc2ccccc12, O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)c1nsc2ccccc12, O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)c1nsc2ccccc12, O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)c1nsc2ccccc12, O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)c1nsc2ccccc12","Launched",0,0,0,0,0,0,0,0,1,3,0,0,0,0,1,1,0,0,1,2,1,1,1,1
"2403","luteolin","glucosidase inhibitor","TOP1",NA,NA,"Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccc(O)c(O)c1, Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccc(O)c(O)c1, Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccc(O)c(O)c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2404","luzindole","melatonin receptor antagonist","MTNR1A, MTNR1B",NA,NA,"CC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12, CC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12, CC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2405","LXR-623","LXR agonist","AR, NR1H2, NR1H3, NR1I2, NR3C1",NA,NA,"Fc1ccc(cc1)-c1n(Cc2ccc(F)cc2Cl)nc2c(cccc12)C(F)(F)F, Fc1ccc(cc1)-c1n(Cc2ccc(F)cc2Cl)nc2c(cccc12)C(F)(F)F","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2406","LX1031","tryptophan hydroxylase inhibitor","TPH1",NA,NA,"COc1cccc(c1)-c1ccc(cc1)[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F, COc1cccc(c1)-c1ccc(cc1)[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2407","LX7101","LIM kinase inhibitor, rho associated kinase inhibitor","LIMK2, ROCK1, ROCK2",NA,NA,"CN(C)C(=O)Oc1cccc(NC(=O)C2(CN)CCN(CC2)c2ncnc3[nH]cc(C)c23)c1, CN(C)C(=O)Oc1cccc(NC(=O)C2(CN)CCN(CC2)c2ncnc3[nH]cc(C)c23)c1, CN(C)C(=O)Oc1cccc(NC(=O)C2(CN)CCN(CC2)c2ncnc3[nH]cc(C)c23)c1, CN(C)C(=O)Oc1cccc(NC(=O)C2(CN)CCN(CC2)c2ncnc3[nH]cc(C)c23)c1","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2408","lylamine","cannabinoid receptor agonist","CNR1",NA,NA,"CC(C)c1ccc2c(CC[C@H]3[C@](C)(CN)CCC[C@]23C)c1, CC(C)c1ccc2c(CC[C@H]3[C@](C)(CN)CCC[C@]23C)c1, CC(C)c1ccc2c(CC[C@H]3[C@](C)(CN)CCC[C@]23C)c1, CC(C)c1ccc2c(CC[C@H]3[C@](C)(CN)CCC[C@]23C)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2409","lypressin","vasopressin receptor agonist","AVPR1A, AVPR1B, AVPR2","endocrinology","central diabetes insipidus","NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O, NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O, NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2410","LY2090314","glycogen synthase kinase inhibitor","GSK3B",NA,NA,"Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1 |t:11|, Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1 |t:11|, Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1 |t:11|, Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1 |t:11|, Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1 |t:11|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2411","LY2109761","TGF beta receptor inhibitor","TGFBR1, TGFBR2",NA,NA,"C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c2CCCn2nc1-c1ccccn1, C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c2CCCn2nc1-c1ccccn1, C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c2CCCn2nc1-c1ccccn1, C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c2CCCn2nc1-c1ccccn1, C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c2CCCn2nc1-c1ccccn1, C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c2CCCn2nc1-c1ccccn1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2412","LY2140023","glutamate receptor agonist","GRM3",NA,NA,"N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2413","LY215490","glutamate receptor antagonist","GRIA1, GRIA2, GRIA3, GRIA4, GRIK1",NA,NA,"OC(=O)[C@@H]1C[C@H]2C[C@@H](CCc3nn[nH]n3)CC[C@H]2CN1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2414","LY2157299","TGF beta receptor inhibitor","TGFBR1",NA,NA,"Cc1cccc(n1)-c1nn2CCCc2c1-c1ccnc2ccc(cc12)C(N)=O, Cc1cccc(n1)-c1nn2CCCc2c1-c1ccnc2ccc(cc12)C(N)=O, Cc1cccc(n1)-c1nn2CCCc2c1-c1ccnc2ccc(cc12)C(N)=O, Cc1cccc(n1)-c1nn2CCCc2c1-c1ccnc2ccc(cc12)C(N)=O","Phase 2/Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2415","LY2183240","FAAH inhibitor, FAAH reuptake inhibitor","FAAH",NA,NA,"CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1, CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1, CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1, CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1, CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2416","LY2228820","p38 MAPK inhibitor","MAPK14",NA,NA,"CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1nc([nH]c1-c1ccc(F)cc1)C(C)(C)C, CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1nc([nH]c1-c1ccc(F)cc1)C(C)(C)C, CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1nc([nH]c1-c1ccc(F)cc1)C(C)(C)C, CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1nc([nH]c1-c1ccc(F)cc1)C(C)(C)C, CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1nc([nH]c1-c1ccc(F)cc1)C(C)(C)C","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2417","LY223982","leukotriene receptor antagonist","LTB4R",NA,NA,"COc1ccc(\C=C\CCCCOc2ccc(cc2CCC(O)=O)C(=O)c2cccc(c2)C(O)=O)cc1, COc1ccc(\C=C\CCCCOc2ccc(cc2CCC(O)=O)C(=O)c2cccc(c2)C(O)=O)cc1, COc1ccc(\C=C\CCCCOc2ccc(cc2CCC(O)=O)C(=O)c2cccc(c2)C(O)=O)cc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2418","LY225910","CCK receptor antagonist","CCKBR",NA,NA,"CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O, CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O, CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O, CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O, CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O, CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2419","LY2365109","glycine transporter inhibitor","SLC6A9",NA,NA,"CN(CCOc1ccc(cc1C(C)(C)C)-c1ccc2OCOc2c1)CC(O)=O, CN(CCOc1ccc(cc1C(C)(C)C)-c1ccc2OCOc2c1)CC(O)=O","Preclinical",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2420","LY2452473","androgen receptor modulator","AR",NA,NA,"CC(C)OC(=O)N[C@@H]1Cc2c(C1)c1cc(ccc1n2Cc1ccccn1)C#N","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2421","LY255283","leukotriene receptor antagonist","LTB4R, LTB4R2",NA,NA,"CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nn[nH]n1, CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nn[nH]n1, CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nn[nH]n1, CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nn[nH]n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2422","ly2562175","fxr agonist","NR1H4","gastroenterology","non-alcoholic steatohepatitis (nash)","Cn1cc(C(O)=O)c2ccc(cc12)N1CCC(CC1)OCc1c(onc1-c1c(Cl)cccc1Cl)C1CC1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2423","LY2584702","ribosomal protein inhibitor","RPS6KB1",NA,NA,"Cn1cc(nc1C1CCN(CC1)c1ncnc2n[nH]cc12)-c1ccc(F)c(c1)C(F)(F)F, Cn1cc(nc1C1CCN(CC1)c1ncnc2n[nH]cc12)-c1ccc(F)c(c1)C(F)(F)F","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2424","LY2603618","CHK inhibitor","CHEK1",NA,NA,"Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2425","LY2606368","CHK inhibitor","CHEK1",NA,NA,"COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)[nH]n1, COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)[nH]n1, COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)[nH]n1, COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)[nH]n1, COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)[nH]n1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2426","LY2608204","glucokinase activator","GCK",NA,NA,"O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2427","LY266097","serotonin receptor antagonist","HTR2B",NA,NA,"COc1ccc(C[C@H]2NCCc3c2[nH]c2ccc(C)cc32)c(Cl)c1OC |&1:7|, COc1ccc(C[C@H]2NCCc3c2[nH]c2ccc(C)cc32)c(Cl)c1OC |&1:7|, COc1ccc(C[C@H]2NCCc3c2[nH]c2ccc(C)cc32)c(Cl)c1OC |&1:7|","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2428","LY2784544","JAK inhibitor","JAK2, JAK3",NA,NA,"Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2429","LY2801653","MET inhibitor","MET",NA,NA,"Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1, Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1, Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1, Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2430","LY2811376","beta-secretase inhibitor","BACE1",NA,NA,"C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1 |c:6|, C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1 |c:6|, C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1 |c:6|, C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1 |c:6|, C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1 |c:6|, C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1 |c:6|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2431","LY2857785","CDK inhibitor","CDK9",NA,NA,"CC(C)c1n(C)nc2ccc(cc12)-c1ccnc(N[C@H]2CC[C@@H](CC2)NC2CCOCC2)n1 |r|, CC(C)c1n(C)nc2ccc(cc12)-c1ccnc(N[C@H]2CC[C@@H](CC2)NC2CCOCC2)n1 |r|, CC(C)c1n(C)nc2ccc(cc12)-c1ccnc(N[C@H]2CC[C@@H](CC2)NC2CCOCC2)n1 |r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2432","LY2874455","FGFR antagonist","FGFR1, FGFR2, FGFR3, FGFR4, KDR",NA,NA,"C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl, C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl, C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl, C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl, C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl, C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl, C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl, C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2433","LY288513","CCK receptor antagonist","CCKBR",NA,NA,"Brc1ccc(NC(=O)N2NC(=O)[C@H]([C@@H]2c2ccccc2)c2ccccc2)cc1, Brc1ccc(NC(=O)N2NC(=O)[C@H]([C@@H]2c2ccccc2)c2ccccc2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2434","LY2886721","beta-secretase inhibitor","BACE1",NA,NA,"NC1=N[C@]2(COC[C@H]2CS1)c1cc(NC(=O)c2ccc(F)cn2)ccc1F |t:1|","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2435","ly2922470","g protein-coupled receptor agonist","FFAR1","endocrinology","diabetes mellitus","COc1cccc2CCCN(Cc3ccc(COc4ccc(cc4)[C@H](CC(O)=O)C#CC)s3)c12","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2436","LY294002","DNA dependent protein kinase inhibitor, mTOR inhibitor, phosphodiesterase inhibitor, PI3K inhibitor, PLK inhibitor","AKT1, CHEK1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIM1, PLK1, PRKCA, PRKDC, ROCK1, RPS6KB1, SGK1",NA,NA,"O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2437","ly2940094","nociceptin/orphanin fq (nop) receptor antagonist","OPRL1","neurology/psychiatry","depression","Cc1nn(cc1CN1CCC2(CC1)OCC(F)(F)c1cc(Cl)sc21)-c1ncccc1CO","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2438","LY2979165","glutamate receptor agonist","GRM2",NA,NA,"C[C@H](N)C(=O)N[C@]1(C[C@@H](Sc2nnc[nH]2)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, C[C@H](N)C(=O)N[C@]1(C[C@@H](Sc2nnc[nH]2)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, C[C@H](N)C(=O)N[C@]1(C[C@@H](Sc2nnc[nH]2)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, C[C@H](N)C(=O)N[C@]1(C[C@@H](Sc2nnc[nH]2)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, C[C@H](N)C(=O)N[C@]1(C[C@@H](Sc2nnc[nH]2)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, C[C@H](N)C(=O)N[C@]1(C[C@@H](Sc2nnc[nH]2)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2439","LY3000328","cathepsin inhibitor","CTSS",NA,NA,"CNC(=O)O[C@H]1COc2ccc(cc2[C@@H]1NC(=O)c1ccc(F)cc1)N1CCN(CC1)C1COC1, CNC(=O)O[C@H]1COc2ccc(cc2[C@@H]1NC(=O)c1ccc(F)cc1)N1CCN(CC1)C1COC1, CNC(=O)O[C@H]1COc2ccc(cc2[C@@H]1NC(=O)c1ccc(F)cc1)N1CCN(CC1)C1COC1, CNC(=O)O[C@H]1COc2ccc(cc2[C@@H]1NC(=O)c1ccc(F)cc1)N1CCN(CC1)C1COC1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2440","LY3009120","RAF inhibitor","BRAF, RAF1",NA,NA,"CNc1ncc2cc(c(C)nc2n1)-c1cc(NC(=O)NCCC(C)(C)C)c(F)cc1C, CNc1ncc2cc(c(C)nc2n1)-c1cc(NC(=O)NCCC(C)(C)C)c(F)cc1C, CNc1ncc2cc(c(C)nc2n1)-c1cc(NC(=O)NCCC(C)(C)C)c(F)cc1C","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2441","LY3023414","mTOR inhibitor, PI3K inhibitor","MTOR",NA,NA,"CO[C@@H](C)Cn1c2c(cnc3ccc(cc23)-c2cncc(c2)C(C)(C)O)n(C)c1=O, CO[C@@H](C)Cn1c2c(cnc3ccc(cc23)-c2cncc(c2)C(C)(C)O)n(C)c1=O, CO[C@@H](C)Cn1c2c(cnc3ccc(cc23)-c2cncc(c2)C(C)(C)O)n(C)c1=O, CO[C@@H](C)Cn1c2c(cnc3ccc(cc23)-c2cncc(c2)C(C)(C)O)n(C)c1=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2442","LY303511","casein kinase inhibitor, mTOR inhibitor, PI3K inhibitor","BRD2, BRD3, BRD4",NA,NA,"O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2443","LY310762","serotonin receptor antagonist","HTR1D",NA,NA,"CC1(C)C(=O)N(CCN2CCC(CC2)C(=O)c2ccc(F)cc2)c2ccccc12, CC1(C)C(=O)N(CCN2CCC(CC2)C(=O)c2ccc(F)cc2)c2ccccc12, CC1(C)C(=O)N(CCN2CCC(CC2)C(=O)c2ccc(F)cc2)c2ccccc12, CC1(C)C(=O)N(CCN2CCC(CC2)C(=O)c2ccc(F)cc2)c2ccccc12","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2444","LY320135","cannabinoid receptor antagonist","CNR1",NA,NA,"COc1ccc(cc1)-c1oc2cc(OC)ccc2c1C(=O)c1ccc(cc1)C#N, COc1ccc(cc1)-c1oc2cc(OC)ccc2c1C(=O)c1ccc(cc1)C#N, COc1ccc(cc1)-c1oc2cc(OC)ccc2c1C(=O)c1ccc(cc1)C#N","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2445","LY344864","serotonin receptor agonist","HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR7",NA,NA,"CN(C)[C@@H]1CCc2[nH]c3ccc(NC(=O)c4ccc(F)cc4)cc3c2C1, CN(C)[C@@H]1CCc2[nH]c3ccc(NC(=O)c4ccc(F)cc4)cc3c2C1, CN(C)[C@@H]1CCc2[nH]c3ccc(NC(=O)c4ccc(F)cc4)cc3c2C1","Preclinical",0,0,0,0,0,0,0,0,1,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2446","LY364947","p38 MAPK inhibitor, TGF beta receptor inhibitor","TGFBR1",NA,NA,"c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2447","LY393558","serotonin receptor antagonist","HTR1B, HTR1D, HTR2A, HTR2B",NA,NA,"CC(C)N1Cc2cc(ccc2N(CCN2CCC(=CC2)c2c[nH]c3cc(F)ccc23)S1(=O)=O)S(C)(=O)=O |c:18|, CC(C)N1Cc2cc(ccc2N(CCN2CCC(=CC2)c2c[nH]c3cc(F)ccc23)S1(=O)=O)S(C)(=O)=O |c:18|","Preclinical",0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2448","LY404187","glutamate receptor positive allosteric modulator","GRIA1, GRIA2, GRIA3, GRIA4",NA,NA,"CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(cc1)C#N |&1:8,r|, CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(cc1)C#N |&1:8,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2449","LY456236","glutamate receptor antagonist","GRM1",NA,NA,"COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1, COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1, COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1, COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2450","m-chlorophenylbiguanide","serotonin receptor agonist","HTR3A, HTR3B",NA,NA,"NC(N)=NC(=N)Nc1cccc(Cl)c1, NC(N)=NC(=N)Nc1cccc(Cl)c1","Preclinical",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2451","M-14157","ATP-sensitive potassium channel antagonist","KCNQ1",NA,NA,"CCCCCC(O)CCCC(O)=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2452","M-25","smoothened receptor antagonist","DHH, IHH, SMO",NA,NA,"CCCC(CCC)C(=O)NCc1ccc2n(ncc2c1)-c1ccccc1OC, CCCC(CCC)C(=O)NCc1ccc2n(ncc2c1)-c1ccccc1OC","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2453","m-3M3FBS","phospholipase activator","PLCB2, PLCB3, PLCD1, PLCG1, PLCG2",NA,NA,"Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1cccc(c1)C(F)(F)F, Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1cccc(c1)C(F)(F)F, Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1cccc(c1)C(F)(F)F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2454","M-344","HDAC inhibitor","HDAC8",NA,NA,"CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2455","mabuterol","adrenergic receptor agonist","ADRB2","pulmonary","asthma","CC(C)(C)NC[C@@H](O)c1cc(Cl)c(N)c(c1)C(F)(F)F |&1:6|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"2456","macimorelin","ghrelin receptor agonist","GHSR","endocrinology","cachexia","CC(C)(C(=O)N[C@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@H](CC3=CNC4=CC=CC=C43)NC=O)N","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2457","macitentan","endothelin receptor antagonist","EDNRA, EDNRB","endocrinology","contraceptive","CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2458","maduramicin acid","other antibiotic","PPP2CA, PTEN","infectious disease","coccidiosis","CO[C@H]1C[C@@H](O[C@H]2C[C@@H](O[C@H]2[C@]3(C)CC[C@@H](O3)[C@]4(C)CC[C@]5(C[C@H](O)[C@@H](C)[C@H](O5)[C@@H](C)[C@@H]6O[C@](O)(CC(O)=O)[C@@H](C)[C@H](OC)[C@H]6OC)O4)[C@H]7O[C@](C)(O)[C@H](C)C[C@@H]7C)O[C@@H](C)[C@@H]1OC","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2459","mafenide","carbonic anhydrase inhibitor","CA12, CA14, CA2, CA4, CA6, CA9","infectious disease","first-aid antibiotic, skin infections","NCc1ccc(cc1)S(N)(=O)=O, NCc1ccc(cc1)S(N)(=O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2460","magnolol","PPAR receptor agonist","GABRA1, PPARG",NA,NA,"Oc1ccc(CC=C)cc1-c1cc(CC=C)ccc1O, Oc1ccc(CC=C)cc1-c1cc(CC=C)ccc1O, Oc1ccc(CC=C)cc1-c1cc(CC=C)ccc1O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0
"2461","malathion","cholinesterase inhibitor","ACHE","infectious disease","lice","CCOC(=O)C[C@@H](SP(=S)(OC)OC)C(=O)OCC |&1:6,r|, CCOC(=O)C[C@@H](SP(=S)(OC)OC)C(=O)OCC |&1:6,r|, CCOC(=O)C[C@@H](SP(=S)(OC)OC)C(=O)OCC |&1:6,r|, CCOC(=O)C[C@@H](SP(=S)(OC)OC)C(=O)OCC |&1:6,r|, CCOC(=O)C[C@@H](SP(=S)(OC)OC)C(=O)OCC |&1:6,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2462","manidipine","calcium channel blocker","CACNA1C, CACNA1D","cardiology","hypertension","COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN1CCN(CC1)C(c1ccccc1)c1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN1CCN(CC1)C(c1ccccc1)c1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN1CCN(CC1)C(c1ccccc1)c1ccccc1 |r,c:4,9|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2463","mapracorat","glucocorticoid receptor agonist","CXCL8, MYOC, NR3C1","ophthalmology","cataracts","Cc1ccc2c(NC[C@](O)(CC(C)(C)c3cc(F)cc4CCOc34)C(F)(F)F)cccc2n1 |a:8|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2464","maprotiline","norepinephrine reputake inhibitor, tricyclic antidepressant","SLC6A2","neurology/psychiatry","depression, dysthymic disorder","CNCCC[C@@]12CC[C@@H](c3ccccc13)c1ccccc21 |r|, CNCCC[C@@]12CC[C@@H](c3ccccc13)c1ccccc21 |r|","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2465","map4343","microtubule stimulant","MAP2","neurology/psychiatry","depression","[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@H](CC[C@]12C)OC |t:19|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2466","maraviroc","CC chemokine receptor antagonist","CCR5","infectious disease","human immunodeficiency virus (HIV-1)","CC(C)c1nnc(C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1, CC(C)c1nnc(C)n1C1CC2CCC(C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2467","maribavir","cytomegalovirus inhibitor, protein kinase inhibitor","PYGM",NA,NA,"CC(C)Nc1nc2cc(Cl)c(Cl)cc2n1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O, CC(C)Nc1nc2cc(Cl)c(Cl)cc2n1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O, CC(C)Nc1nc2cc(Cl)c(Cl)cc2n1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2468","marimastat","matrix metalloprotease inhibitor","MMP1, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP19, MMP2, MMP20, MMP21, MMP23A, MMP24, MMP25, MMP26, MMP27, MMP28, MMP3, MMP7, MMP8, MMP9",NA,NA,"CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C, CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C, CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C, CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C, CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C, CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2469","maropitant","neurokinin receptor antagonist","TACR1","gastroenterology","vomiting","COc1ccc(cc1CN[C@H]1C2CCN(CC2)[C@H]1C(c1ccccc1)c1ccccc1)C(C)(C)C, COc1ccc(cc1CN[C@H]1C2CCN(CC2)[C@H]1C(c1ccccc1)c1ccccc1)C(C)(C)C, COc1ccc(cc1CN[C@H]1C2CCN(CC2)[C@H]1C(c1ccccc1)c1ccccc1)C(C)(C)C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2470","masitinib","KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, SRC inhibitor","FGFR3, KIT, PDGFRA, PDGFRB","dermatology","mastocytoma","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2471","masoprocol","lipoxygenase inhibitor","ALOX5","dermatology","actinic keratosis (AK)","C[C@@H](Cc1ccc(O)c(O)c1)[C@@H](C)Cc1ccc(O)c(O)c1 |&1:1,&2:11,r|, C[C@@H](Cc1ccc(O)c(O)c1)[C@@H](C)Cc1ccc(O)c(O)c1 |&1:1,&2:11,r|, C[C@@H](Cc1ccc(O)c(O)c1)[C@@H](C)Cc1ccc(O)c(O)c1 |&1:1,&2:11,r|, C[C@@H](Cc1ccc(O)c(O)c1)[C@@H](C)Cc1ccc(O)c(O)c1 |&1:1,&2:11,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2472","matrine","opioid receptor agonist","OPRK1",NA,NA,"O=C1CCC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2473","mavacoxib","cyclooxygenase inhibitor","PTGS2","rheumatology","joint inflammation","C1=CC(=CC=C1C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F)F","Launched",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2474","mavoglurant","glutamate receptor antagonist","GRM5",NA,NA,"COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#Cc1cccc(C)c1, COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#Cc1cccc(C)c1, COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#Cc1cccc(C)c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2475","maxacalcitol","vitamin D receptor agonist","VDR","endocrinology","hyperparathyroidism","C[C@H](OCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2476","mb-07344","thyroid hormone receptor agonist","THRB","endocrinology","hypercholesterolemia","CC(C)c1cc(Cc2c(C)cc(OCP(O)(O)=O)cc2C)ccc1O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2477","MBX-2982","glucose dependent insulinotropic receptor agonist","GPR119",NA,NA,"CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1, CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1, CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1, CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1, CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1, CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1, CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2478","MCC950","NOD like receptor inhibitor","NLRP3",NA,NA,"CC(C)(O)c1coc(c1)S(=O)(=O)NC(=O)Nc1c2CCCc2cc2CCCc12, CC(C)(O)c1coc(c1)S(=O)(=O)NC(=O)Nc1c2CCCc2cc2CCCc12, CC(C)(O)c1coc(c1)S(=O)(=O)NC(=O)Nc1c2CCCc2cc2CCCc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2479","MCOPPB","nociceptin/orphanin FQ receptor agonist","OPRL1",NA,NA,"CC1(CCCCCCC1)N1CCC(CC1)n1c(nc2ccccc12)[C@@H]1CCCNC1, CC1(CCCCCCC1)N1CCC(CC1)n1c(nc2ccccc12)[C@@H]1CCCNC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2480","mCPP","serotonin receptor agonist","HTR1A, HTR1D, HTR1E, HTR2A, HTR2B, HTR2C, HTR6",NA,NA,"Clc1cccc(c1)N1CCNCC1, Clc1cccc(c1)N1CCNCC1","Phase 2",0,0,0,0,0,0,0,0,1,7,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2481","MC1568","HDAC inhibitor","HDAC2",NA,NA,"Cn1c(\C=C\C(=O)NO)ccc1\C=C\C(=O)c1cccc(F)c1, Cn1c(\C=C\C(=O)NO)ccc1\C=C\C(=O)c1cccc(F)c1, Cn1c(\C=C\C(=O)NO)ccc1\C=C\C(=O)c1cccc(F)c1, Cn1c(\C=C\C(=O)NO)ccc1\C=C\C(=O)c1cccc(F)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2482","MD-920","NFkB pathway inhibitor","AADACL2",NA,NA,"C[C@@]12[C@H]3[C@H](C(O)=O)[C@@]45CC(=C)[C@@](O)(C4)CC[C@H]5[C@]3(OC1=O)C=C[C@@H]2O |c:25|, C[C@@]12[C@H]3[C@H](C(O)=O)[C@@]45CC(=C)[C@@](O)(C4)CC[C@H]5[C@]3(OC1=O)C=C[C@@H]2O |c:25|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2483","mdivi-1","dynamin inhibitor","DNM1",NA,NA,"COc1cc(c(Cl)cc1Cl)-n1c(=S)[nH]c2ccccc2c1=O, COc1cc(c(Cl)cc1Cl)-n1c(=S)[nH]c2ccccc2c1=O, COc1cc(c(Cl)cc1Cl)-n1c(=S)[nH]c2ccccc2c1=O, COc1cc(c(Cl)cc1Cl)-n1c(=S)[nH]c2ccccc2c1=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2484","MDL-11939","serotonin receptor antagonist","HTR2A, HTR2B, HTR2C",NA,NA,"O[C@@H](C1CCN(CCc2ccccc2)CC1)c1ccccc1 |&1:1,r|, O[C@@H](C1CCN(CCc2ccccc2)CC1)c1ccccc1 |&1:1,r|, O[C@@H](C1CCN(CCc2ccccc2)CC1)c1ccccc1 |&1:1,r|","Phase 2",0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2485","MDL-29951","glutamate receptor antagonist","FBP1",NA,NA,"OC(=O)CCc1c([nH]c2cc(Cl)cc(Cl)c12)C(O)=O, OC(=O)CCc1c([nH]c2cc(Cl)cc(Cl)c12)C(O)=O, OC(=O)CCc1c([nH]c2cc(Cl)cc(Cl)c12)C(O)=O, OC(=O)CCc1c([nH]c2cc(Cl)cc(Cl)c12)C(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2486","MDL-72832","serotonin receptor agonist","HTR1A",NA,NA,"O=C1CC2(CCCC2)CC(=O)N1CCCCNC[C@H]1COc2ccccc2O1 |&1:18|, O=C1CC2(CCCC2)CC(=O)N1CCCCNC[C@H]1COc2ccccc2O1 |&1:18|","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2487","MDL-73005EF","serotonin receptor antagonist","HTR1A",NA,NA,"O=C1CC2(CCCC2)CC(=O)N1CCNC[C@H]1COc2ccccc2O1 |&1:16|, O=C1CC2(CCCC2)CC(=O)N1CCNC[C@H]1COc2ccccc2O1 |&1:16|","Phase 1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2488","mdr-652","trpv agonist","TRPV1","neurology/psychiatry","chronic pain","O=C(NC1=CC=C(CO)C(F)=C1)NCC2=C(C3=CC=CC(Cl)=C3)N=C(C(C)(C)C)S2","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2489","ME-0328","PPAR receptor antagonist","PARP3",NA,NA,"C[C@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1, C[C@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1, C[C@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2490","mebendazole","tubulin polymerization inhibitor","TUBA1A, TUBB, TUBB4B","infectious disease","pinworm, whipworm, hookworm, ascariasis","COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccccc1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2491","mebeverine","acetylcholine receptor antagonist","CHRM1","gastroenterology","irritable bowel syndrome","CCN(CCCCOC(=O)c1ccc(OC)c(OC)c1)[C@@H](C)Cc1ccc(OC)cc1 |&1:20|, CCN(CCCCOC(=O)c1ccc(OC)c(OC)c1)[C@@H](C)Cc1ccc(OC)cc1 |&1:20|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,1
"2492","mecamylamine","acetylcholine receptor antagonist","CHRNA1, CHRNA2, CHRNA3, CHRNA4, CHRNA6, CHRNA7, CHRNB4","cardiology","hypertension","CNC1(C)C2CCC(C2)C1(C)C, CNC1(C)C2CCC(C2)C1(C)C, CNC1(C)C2CCC(C2)C1(C)C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,7,0,0,1,1,1,1
"2493","mecamylamine hydrochloride","nicotinic receptor antagonist","CHRNA7","Neurology","depression","CN[C@@]1(C)[C@H]2CC[C@H](C2)C1(C)C |&1:2,&2:4,7,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,1
"2494","meclinertant","neurotensin receptor antagonist","NTSR1, NTSR2",NA,NA,"COc1cccc(OC)c1-c1cc(nn1-c1ccnc2cc(Cl)ccc12)C(=O)NC1(C2CC3CC(C2)CC1C3)C(O)=O, COc1cccc(OC)c1-c1cc(nn1-c1ccnc2cc(Cl)ccc12)C(=O)NC1(C2CC3CC(C2)CC1C3)C(O)=O, COc1cccc(OC)c1-c1cc(nn1-c1ccnc2cc(Cl)ccc12)C(=O)NC1(C2CC3CC(C2)CC1C3)C(O)=O","Phase 2/Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2495","meclizine","constitutive androstane receptor (CAR) agonist","NR1I3","gastroenterology, neurology/psychiatry","nausea, vomiting, motion sickness","Cc1cccc(CN2CCN(CC2)[C@@H](c2ccccc2)c2ccc(Cl)cc2)c1 |&1:13|, Cc1cccc(CN2CCN(CC2)[C@@H](c2ccccc2)c2ccc(Cl)cc2)c1 |&1:13|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2496","meclofenamic-acid","cyclooxygenase inhibitor, prostanoid receptor antagonist","ALOX5, CNR1, KCNQ2, KCNQ3, PTGS1, PTGS2","rheumatology, neurology/psychiatry, endocrinology","joint pain, muscle pain, rheumatoid arthritis, primary dysmenorrhea (PD)","Cc1ccc(Cl)c(Nc2ccccc2C(O)=O)c1Cl, Cc1ccc(Cl)c(Nc2ccccc2C(O)=O)c1Cl","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2497","medetomidine","adrenergic receptor agonist","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C","neurology/psychiatry","sedative","C[C@@H](c1cnc[nH]1)c1cccc(C)c1C |r|, C[C@@H](c1cnc[nH]1)c1cccc(C)c1C |r|, C[C@@H](c1cnc[nH]1)c1cccc(C)c1C |r|, C[C@@H](c1cnc[nH]1)c1cccc(C)c1C |r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,6,1,1,1,1
"2498","medica-16","ATP citrase lyase inhibitor","FFAR1",NA,NA,"CC(C)(CCCCCCCCCCC(C)(C)CC(O)=O)CC(O)=O, CC(C)(CCCCCCCCCCC(C)(C)CC(O)=O)CC(O)=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2499","medroxyprogesterone","progesterone receptor agonist","PGR","endocrinology","contraceptive","C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2500","medroxyprogesterone-acetate","progesterone receptor agonist","ESR1, PGR","endocrinology","contraceptive","C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:28|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2501","medrysone","glucocorticoid receptor agonist","NR3C1","ophthalmology","conjunctivitis, episcleritis, conjunctivitis, episcleritis","C[C@H]1C[C@H]2[C@@H]3CC[C@H](C(C)=O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|, C[C@H]1C[C@H]2[C@@H]3CC[C@H](C(C)=O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|, C[C@H]1C[C@H]2[C@@H]3CC[C@H](C(C)=O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|, C[C@H]1CC2C3CCC(C(C)=O)C3(C)CC(O)C2C2(C)CCC(=O)C=C12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2502","mefenamic-acid","cyclooxygenase inhibitor","KCNQ1, PTGS1, PTGS2, TRPM3","endocrinology","primary dysmenorrhea (PD)","Cc1cccc(Nc2ccccc2C(O)=O)c1C, Cc1cccc(Nc2ccccc2C(O)=O)c1C, Cc1cccc(Nc2ccccc2C(O)=O)c1C","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2503","megestrol","progesterone receptor agonist","PGR","oncology","breast cancer","CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)O[C@@]1(CCC2C3C=C(C)C4=CC(=O)CCC4(C)C3CCC12C)C(C)=O, CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:9,12|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2504","megestrol-acetate","progesterone receptor agonist","NR3C1, PGR","neurology/psychiatry, endocrinology","anorexia, cachexia","CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2505","meglitinide","potassium channel blocker","CCR2",NA,NA,"COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)C(O)=O, COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)C(O)=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2506","meglutol","HMGCR inhibitor","HMGCR",NA,NA,"CC(O)(CC(O)=O)CC(O)=O, CC(O)(CC(O)=O)CC(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2507","meisoindigo","STAT inhibitor","STAT3",NA,NA,"CN1C(=O)\C(=C2\C(=O)Nc3ccccc23)c2ccccc12, CN1C(=O)\C(=C2\C(=O)Nc3ccccc23)c2ccccc12, CN1C(=O)\C(=C2\C(=O)Nc3ccccc23)c2ccccc12, CN1C(=O)\C(=C2\C(=O)Nc3ccccc23)c2ccccc12, CN1C(=O)\C(=C2\C(=O)Nc3ccccc23)c2ccccc12","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2508","MEK1-2-inhibitor","MEK inhibitor","MAP2K2",NA,NA,"Nc1ccc(SC(=N)C(C#N)c2ccccc2C(F)(F)F)cc1, Nc1ccc(SC(=N)C(C#N)c2ccccc2C(F)(F)F)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2509","melatonin","melatonin receptor agonist, nitric oxide synthase inhibitor","ASMT, CALM1, CALR, EPX, ESR1, HTR2B, MPO, MTNR1A, MTNR1B, NQO2, RORB","neurology/psychiatry","sleep cycle support","COc1ccc2[nH]cc(CCNC(C)=O)c2c1, COc1ccc2[nH]cc(CCNC(C)=O)c2c1, COc1ccc2[nH]cc(CCNC(C)=O)c2c1, COc1ccc2[nH]cc(CCNC(C)=O)c2c1","Launched",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2510","meldonium","gamma butyrobetaine hydroxylase inhibitor","BBOX1","cardiology","coronary artery disease (CAD)","C[N+](C)(C)NCCC(O)=O, C[N+](C)(C)NCCC(O)=O, C[N+](C)(C)NCCC(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2511","melevodopa","dopamine precursor, dopamine receptor agonist, dopamine precursor, dopamine receptor agonist","DDC","neurology/psychiatry","Parkinson's Disease","COC(=O)[C@@H](N)Cc1ccc(O)c(O)c1, COC(=O)[C@@H](N)Cc1ccc(O)c(O)c1, COC(=O)C(N)Cc1ccc(O)c(O)c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2512","meloxicam","cyclooxygenase inhibitor","PTGS1, PTGS2","rheumatology","osteoarthritis, rheumatoid arthritis, osteoarthritis, rheumatoid arthritis","CN1C(C(=O)Nc2ncc(C)s2)=C(O)c2ccccc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ncc(C)s2)=C(O)c2ccccc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2ncc(C)s2)=C(O)c2ccccc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2ncc(C)s2)=C(O)c2ccccc2S1(=O)=O |t:12|","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2513","melperone","dopamine receptor antagonist, serotonin receptor antagonist","DRD2, HTR2A","neurology/psychiatry","psychosis","CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1, CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1, CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1","Launched",0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,1,1,1
"2514","melphalan-n-oxide","hypoxia inducible factor inhibitor","HIF1A",NA,NA,"N[C@@H](Cc1ccc(cc1)[N+]([O-])(CCCl)CCCl)C(O)=O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2515","menadiol sodium sulfate","vitamin k","F10, F2, F7, F9, GGCX, PROC, PROS1","hematology","hemorrhage","Oc2c1ccccc1c(O)c(c2)C","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2516","menadione","mitochondrial DNA polymerase inhibitor, phosphatase inhibitor","AOX1, BGLAP, F10, F2, F7, F9, GGCX, NQO1, NQO2, PROC, PROS1, PROZ, VKORC1, VKORC1L1","gastroenterology, neurology/psychiatry, dermatology, rheumatology","ulcerative colitis, diarrhea, headache, varicose veins, rheumatoid arthritis","CC1=CC(=O)c2ccccc2C1=O |t:1|, CC1=CC(=O)c2ccccc2C1=O |t:1|, CC1=CC(=O)c2ccccc2C1=O |t:1|, CC1=CC(=O)c2ccccc2C1=O |t:1|, CC1=CC(=O)c2ccccc2C1=O |t:1|, CC1=CC(=O)c2ccccc2C1=O |t:1|, CC1=CC(=O)c2ccccc2C1=O |t:1|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2517","menadione-bisulfite","vitamin K","GGCX, VKORC1, VKORC1L1",NA,NA,"C[C@]1(CC(=O)c2ccccc2C1=O)S(O)(=O)=O |&1:1|, C[C@]1(CC(=O)c2ccccc2C1=O)S(O)(=O)=O |&1:1|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2518","menaquinone-7","osteoclast inhibitor","TNFRSF11B","cardiology","arteriosclerosis","CC(=CCC\C(=C\CC\C(=C\CC\C(=C\CC\C(=C\CC\C(=C\CC\C(=C\CC1=C(C)C(=O)c2ccccc2C1=O)\C)\C)\C)\C)\C)\C)C","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2519","mepacrine","cytokine production inhibitor, NFkB pathway inhibitor, TP53 activator","PLA2G1B","infectious disease","giardiasis","CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 |&1:8|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2520","mepazine","MALT1 inhibitor (JH)","MALT1",NA,NA,"CN1CCC[C@@H](CN2c3ccccc3Sc3ccccc23)C1 |&1:5,r|, CN1CCC[C@@H](CN2c3ccccc3Sc3ccccc23)C1 |&1:5,r|, CN1CCC[C@@H](CN2c3ccccc3Sc3ccccc23)C1 |&1:5,r|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2521","mephentermine","adrenergic receptor agonist","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3","cardiology","hypotension","CNC(C)(C)Cc1ccccc1, CNC(C)(C)Cc1ccccc1, CNC(C)(C)Cc1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,9,1,1,1,1
"2522","mephenytoin","hydantoin antiepileptic","SCN5A","neurology/psychiatry","seizures","CC[C@]1(NC(=O)N(C)C1=O)c1ccccc1 |&1:2,r|, CC[C@]1(NC(=O)N(C)C1=O)c1ccccc1 |&1:2,r|, CC[C@]1(NC(=O)N(C)C1=O)c1ccccc1 |&1:2,r|, CC[C@]1(NC(=O)N(C)C1=O)c1ccccc1 |&1:2,r|","Launched",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2523","meptazinol","opioid receptor agonist","BCHE","neurology/psychiatry","pain relief","CC[C@]1(CCCCN(C)C1)c1cccc(O)c1 |&1:2|, CC[C@]1(CCCCN(C)C1)c1cccc(O)c1 |&1:2|, CC[C@]1(CCCCN(C)C1)c1cccc(O)c1 |&1:2|, CC[C@]1(CCCCN(C)C1)c1cccc(O)c1 |&1:2|, CC[C@]1(CCCCN(C)C1)c1cccc(O)c1 |&1:2|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2524","mepyramine","histamine receptor antagonist","HRH1","otolaryngology, obstetrics/gynecology","common cold, menstrual pain","COc1ccc(CN(CCN(C)C)c2ccccn2)cc1, COc1ccc(CN(CCN(C)C)c2ccccn2)cc1, COc1ccc(CN(CCN(C)C)c2ccccn2)cc1, COc1ccc(CN(CCN(C)C)c2ccccn2)cc1, COc1ccc(CN(CCN(C)C)c2ccccn2)cc1, COc1ccc(CN(CCN(C)C)c2ccccn2)cc1","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"2525","merbarone","topoisomerase inhibitor","TOP2A",NA,NA,"Oc1[nH]c(=S)[nH]c(=O)c1C(=O)Nc1ccccc1, Oc1[nH]c(=S)[nH]c(=O)c1C(=O)Nc1ccccc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2526","mercaptopurine","immunosuppressant, protein synthesis inhibitor, purine antagonist","HPRT1, IMPDH1, IMPDH2, PPAT","hematologic malignancy","acute lymphoblastic leukemia (ALL)","S=c1nc[nH]c2nc[nH]c12, S=c1nc[nH]c2nc[nH]c12, S=c1nc[nH]c2nc[nH]c12, S=c1nc[nH]c2nc[nH]c12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2527","merimepodib","inosine monophosphate dehydrogenase inhibitor","IMPDH1",NA,NA,"COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1, COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1, COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1, COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1, COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1, COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1, COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2528","mesalazine","cyclooxygenase inhibitor, lipoxygenase inhibitor, prostanoid receptor antagonist","ALOX5, CHUK, IKBKB, MPO, PPARG, PTGS1, PTGS2","gastroenterology","ulcerative colitis, inflammatory bowel disease","Nc1ccc(O)c(c1)C(O)=O, Nc1ccc(O)c(c1)C(O)=O, Nc1ccc(O)c(c1)C(O)=O, Nc1ccc(O)c(c1)C(O)=O, Nc1ccc(O)c(c1)C(O)=O, Nc1ccc(O)c(c1)C(O)=O","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2529","mesoridazine","dopamine receptor antagonist","DRD2, HTR2A","neurology/psychiatry","schizophrenia","CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc(cc12)[S@@](C)=O |a:23,&1:6|, CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc(cc12)[S@@](C)=O |a:23,&1:6|, CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc(cc12)[S@@](C)=O |a:23,&1:6|, CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc(cc12)[S@@](C)=O |a:23,&1:6|, CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc(cc12)[S@@](C)=O |a:23,&1:6|, CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc(cc12)[S@@](C)=O |a:23,&1:6|, CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc(cc12)[S@@](C)=O |a:23,&1:6|","Launched",0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,1,1,1
"2530","mestinon","cholinesterase inhibitor","ACHE, BCHE","neurology/psychiatry","myasthenia gravis","CN(C)C(=O)Oc1ccc[n+](C)c1, CN(C)C(=O)Oc1ccc[n+](C)c1, CN(C)C(=O)Oc1ccc[n+](C)c1, CN(C)C(=O)Oc1ccc[n+](C)c1, CN(C)C(=O)Oc1ccc[n+](C)c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2531","mestranol","estrogen receptor agonist","ESR1","endocrinology","contraceptive","COc1ccc2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@@H]3CCc2c1, COc1ccc2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@@H]3CCc2c1, COc1ccc2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@@H]3CCc2c1, COc1ccc2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@@H]3CCc2c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2532","mesulergine","dopamine receptor agonist","HTR2A, HTR2B, HTR2C, HTR3A, HTR3B, HTR6, HTR7",NA,NA,"CN(C)S(=O)(=O)N[C@H]1C[C@H]2[C@@H](Cc3cn(C)c4cccc2c34)N(C)C1, CN(C)S(=O)(=O)N[C@H]1C[C@H]2[C@@H](Cc3cn(C)c4cccc2c34)N(C)C1","Phase 2",0,0,0,0,0,0,0,0,1,7,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2533","metaflumizone","sodium channel blocker","SCN8A","infectious disease","flea control","FC(F)(F)OC1=CC=C(NC(=O)NN=C(CC2=CC=C(C=C2)C#N)C3=CC=CC(=C3)C(F)(F)F)C=C1","Withdrawn",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2534","metamizole","cyclooxygenase inhibitor, opioid receptor agonist","PTGS1",NA,NA,"CN(CS(O)(=O)=O)c1c(C)n(C)n(-c2ccccc2)c1=O, CN(CS(O)(=O)=O)c1c(C)n(C)n(-c2ccccc2)c1=O","Withdrawn",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2535","metaproterenol","adrenergic receptor agonist","ADRB2","pulmonary","bronchospasm, asthma, bronchitis, emphysema, bronchospasm, asthma, bronchitis, emphysema","CC(C)NCC(O)c1cc(O)cc(O)c1, CC(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:5|, CC(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:5|, CC(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:5|, CC(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:5|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"2536","metaraminol","adrenergic receptor agonist","ADRA1A","cardiology","hypotension","C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"2537","metarrestin","rna polymerase inhibitor","EEF1A2","oncology","pancreatic cancer","O[C@H]1CC[C@@H](CC1)n1cnc2n(Cc3ccccc3)c(c(-c3ccccc3)c2c1=N)-c1ccccc1 |r|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2538","metatinib","Bcr-Abl kinase inhibitor","ABL1, BCR",NA,NA,"Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl, Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl, Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl, Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2539","metazosin","adrenergic receptor antagonist","ADRA1A",NA,NA,"CO[C@@H](C)C(=O)N1CCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n1 |&1:2,r|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
"2540","metenkephalin","immunostimulant","OPRD1",NA,NA,"CSCC[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O |&1:4,&2:8,&3:27,r|, CSCC[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O |&1:4,&2:8,&3:27,r|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2541","metergoline","dopamine receptor agonist, serotonin receptor antagonist, dopamine receptor agonist, serotonin receptor antagonist","HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7","neurology/psychiatry, endocrinology, neurology/psychiatry, endocrinology","seasonal affective disorder, anxiety, hyperprolactinemia, seasonal affective disorder, anxiety, hyperprolactinemia","CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@H]2[C@H]1Cc1cn(C)c3cccc2c13, CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@H]2[C@H]1Cc1cn(C)c3cccc2c13, CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@H]2[C@H]1Cc1cn(C)c3cccc2c13, CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@H]2[C@H]1Cc1cn(C)c3cccc2c13, CN1CC(CNC(=O)OCc2ccccc2)C[C@@H]2C1Cc1cn(C)c3cccc2c13","Launched",0,0,0,0,0,0,0,0,1,11,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2542","metformin","insulin sensitizer","ACACB, PRKAB1","endocrinology","diabetes mellitus","CN(C)C(=N)N=C(N)N, CN(C)C(=N)N=C(N)N, CN(C)C(=N)N=C(N)N, CN(C)C(=N)N=C(N)N, CN(C)C(=N)N=C(N)N, CN(C)C(=N)N=C(N)N","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2543","methacholine","acetylcholine receptor agonist","CHRM2, CHRM4","pulmonary","bronchial hyperresponsiveness diagnostic","C[C@@H](C[N+](C)(C)C)OC(C)=O |&1:1|, C[C@@H](C[N+](C)(C)C)OC(C)=O |&1:1|, C[C@@H](C[N+](C)(C)C)OC(C)=O |&1:1|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,1,1,1,1
"2544","methanesulfonyl-fluoride","acetylcholinesterase inhibitor","ACHE",NA,NA,"CS(F)(=O)=O, CS(F)(=O)=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2545","methantheline","acetylcholine receptor antagonist","CHRM1, HRH2","gastroenterology, neurology/psychiatry, urology","peptic ulcer disease (PUD), irritable bowel syndrome, pancreatitis, dyskinesia, neurogenic bladder","CC[N+](C)(CC)CCOC(=O)C1c2ccccc2Oc2ccccc12, CC[N+](C)(CC)CCOC(=O)C1c2ccccc2Oc2ccccc12","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1
"2546","methapyrilene","histamine receptor antagonist","HRH1",NA,NA,"CN(C)CCN(Cc1cccs1)c1ccccn1, CN(C)CCN(Cc1cccs1)c1ccccn1, CN(C)CCN(Cc1cccs1)c1ccccn1","Withdrawn",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
"2547","metharbital","GABA receptor modulator","CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA2, GRIK2","neurology/psychiatry","epilepsy","CCC1(CC)C(=O)NC(=O)N(C)C1=O, CCC1(CC)C(=O)NC(=O)N(C)C1=O, CCC1(CC)C(=O)NC(=O)N(C)C1=O, CCC1(CC)C(=O)NC(=O)N(C)C1=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,1,16,0,0,1,2,0,0,1,1,1,1
"2548","methazolamide","carbonic anhydrase inhibitor","CA1, CA12, CA14, CA2, CA4, CA7","ophthalmology","glaucoma, intraocular pressure, glaucoma, intraocular pressure","CC(=O)N=c1sc(nn1C)S(N)(=O)=O, CC(=O)\N=c1/sc(nn1C)S(N)(=O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2549","methimazole","antithyroid agent","TPO","endocrinology","hyperthyroidism","Cn1cc[nH]c1=S, Cn1cc[nH]c1=S, Cn1cc[nH]c1=S, Cn1cc[nH]c1=S","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2550","methiopril","angiotensin converting enzyme inhibitor","ACE",NA,NA,"C[C@@H]1CCC[C@@H](N1C(=O)CCSC(C)=O)C(O)=O |&1:1,5,r|, CC1CCCC(N1C(=O)CCSC(C)=O)C(O)=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2551","methocarbamol","muscle relaxant","CA1","neurology/psychiatry","muscle relaxant","COc1ccccc1OC[C@@H](O)COC(N)=O |&1:10,r|, COc1ccccc1OC[C@@H](O)COC(N)=O |&1:10,r|, COc1ccccc1OC[C@@H](O)COC(N)=O |&1:10,r|, COc1ccccc1OC[C@@H](O)COC(N)=O |&1:10,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2552","methotrexate","dihydrofolate reductase inhibitor","DHFR","oncology, hematologic malignancy, dermatology, rheumatology","gestational choriocarcinoma, hydatidiform mole, acute lymphoblastic leukemia (ALL), psoriasis, rheumatoid arthritis","CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2553","methoxamine","adrenergic receptor agonist","ADRA1A, ADRA1B, ADRA1D","cardiology","hypotension","COc1ccc(OC)c(c1)C(O)C(C)N, COc1ccc(OC)c(c1)C(O)C(C)N, COc1ccc(OC)c(c1)C(O)C(C)N, COc1ccc(OC)c(c1)C(O)C(C)N, COc1ccc(OC)c(c1)C(O)C(C)N","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,1,1,1,1
"2554","methoxsalen","DNA synthesis inhibitor","CYP1A1, CYP1A2, CYP2A13, CYP2A6, CYP3A4","dermatology","psoriasis","COc1c2occc2cc2ccc(=O)oc12, COc1c2occc2cc2ccc(=O)oc12, COc1c2occc2cc2ccc(=O)oc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2555","methoxyamine","DNA repair enzyme inhibitor","APEX1",NA,NA,"CON, CON","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2556","methoxyflurane","membrane permeability inhibitor","ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, MT-ND1","neurology/psychiatry","general anaesthetic","COC(F)(F)C(Cl)Cl, COC(F)(F)C(Cl)Cl, COC(F)(F)C(Cl)Cl, COC(F)(F)C(Cl)Cl, COC(F)(F)C(Cl)Cl, COC(F)(F)C(Cl)Cl","Launched",0,0,0,0,0,0,0,0,0,0,0,0,1,16,0,0,0,0,0,0,1,1,1,1
"2557","methscopolamine","acetylcholine receptor antagonist","CHRM1, CHRM2, CHRM3","gastroenterology","peptic ulcer disease (PUD)","C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,1,1,1,1
"2558","methsuximide","T-type calcium channel blocker","CACNA1G, CACNA1H, CACNA1I","neurology/psychiatry","seizures","CN1C(=O)C[C@@](C)(C1=O)c1ccccc1 |&1:5,r|, CN1C(=O)C[C@@](C)(C1=O)c1ccccc1 |&1:5,r|, CN1C(=O)C[C@@](C)(C1=O)c1ccccc1 |&1:5,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2559","methyclothiazide","chloride reabsorption inhibitor","SLC12A1, SLC12A3","cardiology","hypertension, edema","CN1[C@@H](CCl)Nc2cc(Cl)c(cc2S1(=O)=O)S(N)(=O)=O |&1:2,r|, CN1[C@@H](CCl)Nc2cc(Cl)c(cc2S1(=O)=O)S(N)(=O)=O |&1:2,r|, CN1[C@@H](CCl)Nc2cc(Cl)c(cc2S1(=O)=O)S(N)(=O)=O |&1:2,r|","Launched",1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2560","methyl-aminolevulinate","oxidizing agent","FCGR1A, FECH","dermatology","actinic keratosis (AK)","COC(=O)CCC(=O)CN, COC(=O)CCC(=O)CN","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2561","methylatropine-nitrate","acetylcholine receptor antagonist","CHRM1",NA,NA,"C[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |&1:3,6,8,&2:13|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
"2562","methyldopa","adrenergic receptor agonist","ADRA2A, ADRA2B, ADRA2C, DDC","cardiology","hypertension","C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,1,1,1,1
"2563","methylene-blue","guanylyl cyclase inhibitor, nitric oxide production inhibitor","ACHE","hematology","methemoglobinemia","CN(C)c1ccc2nc3ccc(cc3sc2c1)=[N+](C)C, CN(C)c1ccc2nc3ccc(cc3sc2c1)=[N+](C)C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2564","methylergometrine","dopamine receptor antagonist, serotonin receptor antagonist","DRD1, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C","hematology, neurology/psychiatry","postpartum hemorrhage (PPH), migraine headache","CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:23|, CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:23|, CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:23|","Launched",0,0,0,0,0,0,0,0,1,5,0,0,0,0,1,1,0,0,0,0,1,1,1,1
"2565","methyllycaconitine","acetylcholine receptor antagonist","CHRNA7",NA,NA,"CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14, CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14, CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14, CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
"2566","methylnaltrexone","opioid receptor antagonist","OPRD1, OPRK1, OPRM1","gastroenterology","constipation","[H][C@]12Oc3c4c(C[C@]5([H])[C@](O)(CCC1=O)[C@]24CC[N@+]5(C)CC1CC1)ccc3O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2567","methylprednisolone","glucocorticoid receptor agonist","NR3C1","endocrinology, rheumatology, dermatology, infectious disease, allergy, hematology, neurology/psychiatry, gastroenterology","hypercalcemia, thyroiditis, ankylosing spondylitis, bursitis, osteoarthritis, psoriatic arthritis, seborrheic dermatitis, mycosis, allergic rhinitis, psoriasis, anemia, multiple sclerosis, ulcerative colitis, enteritis","C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12 |c:23,t:27|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12 |c:23,t:27|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12 |c:23,t:27|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12 |c:23,t:27|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12 |c:23,t:27|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12 |c:23,t:27|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12 |c:23,t:27|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2568","methylprednisolone-aceponate","anti-inflammatory agent, glucocorticoid receptor agonist","NR3C1","endocrinology, rheumatology, infectious disease, allergy, pulmonary, gastroenterology, dermatology, neurology/psychiatry, hematology","congenital adrenal hyperplasia, thyroiditis, hypercalcemia, rheumatoid arthritis, bursitis, epicondylitis, allergic rhinitis, asthma, ulcerative colitis, enteritis, osteoarthritis, psoriasis, multiple sclerosis, anemia","CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)COC(C)=O |c:17,t:13|, CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)COC(C)=O |c:17,t:13|, CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)COC(C)=O |c:17,t:13|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2569","methysergide","serotonin receptor antagonist","HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7","neurology/psychiatry","headache","CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3cn(C)c4cccc(C2=C1)c34 |c:24|, CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3cn(C)c4cccc(C2=C1)c34 |c:24|, CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3cn(C)c4cccc(C2=C1)c34 |c:24|","Launched",0,0,0,0,0,0,0,0,1,10,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2570","metirosine","tyrosine hydroxylase inhibitor","TH","cardiology","hypertension","C[C@](N)(Cc1ccc(O)cc1)C(O)=O, C[C@](N)(Cc1ccc(O)cc1)C(O)=O, C[C@](N)(Cc1ccc(O)cc1)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2571","metitepine","serotonin receptor antagonist, anti-HCVE2","HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7","Infectious disease","antiviral","CSc1ccc2Sc3ccccc3C[C@@H](N3CCN(C)CC3)c2c1 |&1:14,r|, CSc1ccc2Sc3ccccc3C[C@@H](N3CCN(C)CC3)c2c1 |&1:14,r|, CSc1ccc2Sc3ccccc3C[C@@H](N3CCN(C)CC3)c2c1 |&1:14,r|, CSc1ccc2Sc3ccccc3CC(N3CCN(C)CC3)c2c1","Preclinical",0,0,0,0,0,0,0,0,1,11,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2572","metixene","acetylcholine receptor antagonist","CHRM5","neurology/psychiatry","Parkinson's Disease","CN1CCC[C@@H](CC2c3ccccc3Sc3ccccc23)C1 |&1:5|, CN1CCC[C@@H](CC2c3ccccc3Sc3ccccc23)C1 |&1:5|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,1
"2573","metoclopramide","dopamine receptor antagonist, serotonin receptor antagonist","CHRM1, DRD2, HTR3A, HTR3B, HTR4","gastroenterology","gastroparesis, nausea, vomiting","CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC, CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC","Launched",0,0,0,0,0,0,0,0,1,3,0,0,0,0,1,1,1,1,0,0,1,1,1,1
"2574","metocurine","acetylcholine receptor antagonist","CHRM2, CHRNA2","neurology/psychiatry","muscle relaxant","COc1ccc2C[C@@H]3c4c(CC[N+]3(C)C)cc(OC)c(OC)c4Oc3ccc(C[C@H]4c5cc(Oc1c2)c(OC)cc5CC[N+]4(C)C)cc3","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,1,1,1,1
"2575","metolazone","carbonic anhydrase inhibitor","SLC12A3","cardiology","edema, hypertension","C[C@H]1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O |&1:1,r|, C[C@H]1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O |&1:1,r|, C[C@H]1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O |&1:1,r|, C[C@H]1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O |&1:1,r|, C[C@H]1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O |&1:1,r|","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2576","metomidate","cytochrome p450 inhibitor","CYP1B1, CYP3A4","radiology","pet imaging","O=C(OC)c1cncn1C(c2ccccc2)C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2577","metoprine","histamine n-methyltransferase inhibitor","DHFR, HNMT","oncology","renal cell carcinoma (rcc)","CC1=C(C(N)=NC(N)=N1)C2=CC=C(C(Cl)=C2)Cl","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2578","metoprolol","adrenergic receptor antagonist","ADRB1, ADRB2","cardiology","hypertension, angina pectoris, myocardial infarction","COCCc1ccc(OC[C@@H](O)CNC(C)C)cc1 |&1:10|, COCCc1ccc(OC[C@@H](O)CNC(C)C)cc1 |&1:10|, COCCc1ccc(OC[C@@H](O)CNC(C)C)cc1 |&1:10|, COCCc1ccc(OC[C@@H](O)CNC(C)C)cc1 |&1:10|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,1,1,1,1
"2579","metoxibutropate","cyclooxygenase inhibitor","PTGS1, PTGS2",NA,NA,"COc1ccccc1OC(=O)[C@@H](C)c1ccc(CC(C)C)cc1 |&1:11,r|, COc1ccccc1OC(=O)[C@@H](C)c1ccc(CC(C)C)cc1 |&1:11,r|","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2580","metrifonate","acetylcholinesterase inhibitor","ACHE",NA,NA,"COP(=O)(OC)[C@@H](O)C(Cl)(Cl)Cl |&1:6,r|, COP(=O)(OC)[C@@H](O)C(Cl)(Cl)Cl |&1:6,r|, COP(=O)(OC)[C@@H](O)C(Cl)(Cl)Cl |&1:6,r|, COP(=O)(OC)[C@@H](O)C(Cl)(Cl)Cl |&1:6,r|, COP(=O)(OC)[C@@H](O)C(Cl)(Cl)Cl |&1:6,r|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2581","metronidazole","DNA inhibitor","CYP2C9, CYP3A4","dermatology","rosacea","Cc1ncc(n1CCO)[N+]([O-])=O, Cc1ncc(n1CCO)[N+]([O-])=O, Cc1ncc(n1CCO)[N+]([O-])=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2582","metyrapone","cytochrome P450 inhibitor","CYP11B1","nephrology","adrenal diagnostic agent","CC(C)(C(=O)c1cccnc1)c1cccnc1, CC(C)(C(=O)c1cccnc1)c1cccnc1, CC(C)(C(=O)c1cccnc1)c1cccnc1, CC(C)(C(=O)c1cccnc1)c1cccnc1, CC(C)(C(=O)c1cccnc1)c1cccnc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2583","mevastatin","HMGCR inhibitor","HMGCR",NA,NA,"CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2584","mexiletine","sodium channel blocker","PLAU, SCN4A, SCN5A","cardiology","ventricular arrhythmias, ventricular tachycardia (VT)","C[C@@H](N)COc1c(C)cccc1C |&1:1|, C[C@@H](N)COc1c(C)cccc1C |&1:1|, C[C@@H](N)COc1c(C)cccc1C |&1:1|, C[C@@H](N)COc1c(C)cccc1C |&1:1|, C[C@@H](N)COc1c(C)cccc1C |&1:1|, C[C@@H](N)COc1c(C)cccc1C |&1:1|, C[C@@H](N)COc1c(C)cccc1C |&1:1|","Launched",0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2585","ME0328","PARP inhibitor","PARP3",NA,NA,"C[C@@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1 |&1:1,r|, C[C@@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1 |&1:1,r|, C[C@@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1 |&1:1,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2586","MF-101","estrogen receptor agonist","CYP19A1, XDH",NA,NA,"Oc1ccc(cc1)[C@@H]1CC(=O)c2ccc(O)cc2O1, Oc1ccc(cc1)[C@@H]1CC(=O)c2ccc(O)cc2O1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2587","MG-132","proteasome inhibitor","PSMB1",NA,NA,"CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2588","MG-624","acetylcholine receptor antagonist","CHRNA7",NA,NA,"CC[N+](CC)(CC)CCOc1ccc(\C=C\c2ccccc2)cc1, CC[N+](CC)(CC)CCOc1ccc(\C=C\c2ccccc2)cc1, CC[N+](CC)(CC)CCOc1ccc(\C=C\c2ccccc2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
"2589","MGCD-265","VEGFR inhibitor","AXL, MET",NA,NA,"Cn1cnc(c1)-c1cc2nccc(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)c2s1, Cn1cnc(c1)-c1cc2nccc(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)c2s1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2590","mhp","sphingosine kinase inhibitor","SPHK1","dermatology","sunburn","OC(C=C1)=CC=C1C[C@@H](C(OC)=O)NC(CCCCC)=O",NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2591","MI-14","PI4K inhibitor","PI4KB",NA,NA,"CN(C)S(=O)(=O)c1cccc(c1)-c1c(C)nc2c(NCCNC(C)=O)cc(Cl)nn12, CN(C)S(=O)(=O)c1cccc(c1)-c1c(C)nc2c(NCCNC(C)=O)cc(Cl)nn12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2592","mianserin","serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA1D, HRH1, HRH2, HTR2A, HTR2B, HTR2C, HTR6, HTR7","neurology/psychiatry","depression","CN1CCN2C(C1)c1ccccc1Cc1ccccc21, CN1CCN2C(C1)c1ccccc1Cc1ccccc21, CN1CCN2C(C1)c1ccccc1Cc1ccccc21, CN1CCN2C(C1)c1ccccc1Cc1ccccc21","Launched",0,0,0,0,0,0,0,0,1,5,1,2,0,0,0,0,0,0,1,3,1,1,1,1
"2593","mianserin hydrochloride","5-ht2a receptor antagonist","HTR2A","Neurology","depression","CN1CCN2[C@@H](C1)c1ccccc1Cc1ccccc21 |&1:5,r|","Launched",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2594","mibampator","glutamate receptor modulator","GRIA1",NA,NA,"CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1, CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1, CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1, CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2595","mibefradil","T-type calcium channel blocker","ANO1, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CATSPER1, CATSPER2, CATSPER3, CATSPER4",NA,NA,"COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2596","miconazole","bacterial cell wall synthesis inhibitor","TRPM2, TRPV5","infectious disease, neurology/psychiatry","yeast infection, itching","Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1 |&1:7,r|, Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1 |&1:7,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2597","midafotel","glutamate receptor antagonist","GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,"OC(=O)[C@H]1CN(C\C=C\P(O)(O)=O)CCN1, OC(=O)[C@H]1CN(C\C=C\P(O)(O)=O)CCN1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2598","midostaurin","FLT3 inhibitor, KIT inhibitor, PKC inhibitor","FLT3, PRKCG","hematologic malignancy","acute myeloid leukemia (AML)","CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2599","mifepristone","glucocorticoid receptor antagonist, progesterone receptor antagonist","AR, NR1I2, NR3C1, PGR","endocrinology","hyperglycemia, diabetes mellitus","CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2600","mifobate","PPAR receptor antagonist","PPARG",NA,NA,"COP(=O)(OC)O[C@@H](c1ccc(Cl)cc1)P(=O)(OC)OC |&1:7,r|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2601","migalastat","alpha-galactosidase a inhibitor","GLA","endocrinology","fabry disease","C1[C@@H]([C@H]([C@H]([C@H](N1)CO)O)O)O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2602","miglitol","glucosidase inhibitor","GAA, GANAB, GANC, MGAM","endocrinology","diabetes mellitus","OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO, OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO, OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO, OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO, OCCN1C[C@@H](O)[C@@H](O)C(O)C1CO","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2603","miglustat","glycosyl transferase inhibitor","UGCG","hematology","Gaucher disease","CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO, CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2604","mik665","mcl1 inhibitor","MCL1","hematologic malignancy","multiple myeloma","COc1ccccc1-c1nccc(COc2ccccc2C[C@@H](Oc2ncnc3sc(c(-c4ccc(OCCN5CCN(C)CC5)c(Cl)c4C)c23)-c2ccc(F)cc2)C(O)=O)n1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2605","milacemide","monoamine oxidase inhibitor","MAOB",NA,NA,"CCCCCNCC(N)=O, CCCCCNCC(N)=O, CCCCCNCC(N)=O, CCCCCNCC(N)=O","Phase 3",0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2606","milnacipran","serotonin‚Äìnorepinephrine reuptake inhibitor (SNRI)","SLC6A2, SLC6A4","rheumatology","fibromyalgia","CCN(CC)C(=O)[C@]1(C[C@H]1CN)c1ccccc1 |r|","Launched",1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2607","milrinone","phosphodiesterase inhibitor","PDE2A, PDE3A, PDE3B, PDE5A","cardiology","congestive heart failure","Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N, Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N, Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N, Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N, Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N, Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2608","miltefosine","membrane integrity inhibitor","PLA2G1B","infectious disease","leishmaniasis","CCCCCCCCCCCCCCCCOP(O)(=O)OCC[N+](C)(C)C |&1:17|, CCCCCCCCCCCCCCCCOP(O)(=O)OCC[N+](C)(C)C |&1:17|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2609","mimosine","DNA replication inhibitor","CCL2, SHMT1, SHMT2, TYR",NA,NA,"N[C@@H](Cn1ccc(=O)c(O)c1)C(O)=O, N[C@@H](Cn1ccc(=O)c(O)c1)C(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2610","minaprine","serotonin reuptake inhibitor","ACHE, CHRM1, DRD1, DRD2, HTR2A, HTR2B, HTR2C, MAOA, SLC6A4",NA,NA,"Cc1cc(nnc1NCCN1CCOCC1)-c1ccccc1, Cc1cc(nnc1NCCN1CCOCC1)-c1ccccc1","Withdrawn",1,1,0,0,0,0,1,1,1,3,0,0,0,0,1,2,1,1,0,0,0,0,0,0
"2611","minodronic-acid","bone resorption inhibitor","FDPS, GGPS1","orthopedics","osteoporosis","OC(Cc1cnc2ccccn12)(P(O)(O)=O)P(O)(O)=O, OC(Cc1cnc2ccccn12)(P(O)(O)=O)P(O)(O)=O, OC(Cc1cnc2ccccn12)(P(O)(O)=O)P(O)(O)=O, OC(Cc1cnc2ccccn12)(P(O)(O)=O)P(O)(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2612","minoxidil","KATP activator, Kir6 channel (KATP) activator, vasodilator","ABCC9, KCNJ1, KCNJ10, KCNJ11, KCNJ8, PTGS1","endocrinology","androgenetic alopecia","Nc1cc(nc(N)[n+]1[O-])N1CCCCC1, Nc1cc(nc(N)[n+]1[O-])N1CCCCC1, Nc1cc(nc(N)[n+]1[O-])N1CCCCC1, Nc1cc(nc(N)[n+]1[O-])N1CCCCC1, Nc1cc(nc(N)[n+]1[O-])N1CCCCC1","Launched",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2613","mirabegron","adrenergic receptor agonist","ADRB1, ADRB2, ADRB3","urology","urinary incontinence","Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1, Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1, Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1, Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1, Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,1,1,1,1
"2614","mirin","MRE11A exonuclease inhibitor","MRE11A",NA,NA,"NC1=NC(=O)\C(S1)=C\c1ccc(O)cc1 |t:1|, NC1=NC(=O)\C(S1)=C\c1ccc(O)cc1 |t:1|, NC1=NC(=O)\C(S1)=C\c1ccc(O)cc1 |t:1|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2615","mirodenafil","phosphodiesterase inhibitor","PDE5A","urology","erectile dysfunction","CCCOc1ccc(cc1-c1nc2c(CCC)cn(CC)c2c(=O)[nH]1)S(=O)(=O)N1CCN(CCO)CC1, CCCOc1ccc(cc1-c1nc2c(CCC)cn(CC)c2c(=O)[nH]1)S(=O)(=O)N1CCN(CCO)CC1, CCCOc1ccc(cc1-c1nc2c(CCC)cn(CC)c2c(=O)[nH]1)S(=O)(=O)N1CCN(CCO)CC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2616","mirtazapine","adrenergic receptor antagonist, serotonin receptor antagonist","ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C","neurology/psychiatry","depression","CN1CCN2[C@@H](C1)c1ccccc1Cc1cccnc21 |&1:5,r|, CN1CCN2[C@@H](C1)c1ccccc1Cc1cccnc21 |&1:5,r|, CN1CCN2[C@@H](C1)c1ccccc1Cc1cccnc21 |&1:5,r|, CN1CCN2[C@@H](C1)c1ccccc1Cc1cccnc21 |&1:5,r|, CN1CCN2[C@@H](C1)c1ccccc1Cc1cccnc21 |&1:5,r|","Launched",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,1,3,1,1,1,1
"2617","misoprostol","prostanoid receptor agonist","PTGER2, PTGER3, PTGER4, PTGIR","gastroenterology","duodenal ulcer disease","CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC |a:10,11,16,&1:4|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2618","mitiglinide","insulin secretagogue","ABCC8, KCNJ10, PPARG","endocrinology","diabetes mellitus","OC(=O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)Cc1ccccc1, OC(=O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)Cc1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2619","mitoflaxone","antitumor agent","VWF",NA,NA,"OC(=O)Cc1cccc2c1oc(cc2=O)-c1ccccc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2620","mitoguazone","polyamine biosynthesis inhibitor","AMD1","oncology","follicular lymphoma","C\C(=N/NC(=N)N)\C=N\NC(=N)N","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2621","mitotane","antineoplastic agent","CYP11A1, CYP11B1, ESR1","oncology","adrenal cortical carcinoma","ClC(Cl)[C@@H](c1ccc(Cl)cc1)c1ccccc1Cl |&1:3,r|, ClC(Cl)[C@@H](c1ccc(Cl)cc1)c1ccccc1Cl |&1:3,r|, ClC(Cl)[C@@H](c1ccc(Cl)cc1)c1ccccc1Cl |&1:3,r|, ClC(Cl)[C@@H](c1ccc(Cl)cc1)c1ccccc1Cl |&1:3,r|, ClC(Cl)[C@@H](c1ccc(Cl)cc1)c1ccccc1Cl |&1:3,r|, ClC(Cl)[C@@H](c1ccc(Cl)cc1)c1ccccc1Cl |&1:3,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2622","mitoxantrone","topoisomerase inhibitor","TOP2A","neurology/psychiatry, oncology, hematologic malignancy","multiple sclerosis, prostate cancer, acute myeloid leukemia (AML)","OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2623","mivacurium","acetylcholine receptor antagonist","CHRNA2","critical care, neurology/psychiatry","endotracheal intubation, muscle relaxant","COc1cc2CC[N@@+](C)(CCCOC(=O)CC\C=C\CCC(=O)OCCC[N@@+]3(C)CCc4cc(OC)c(OC)cc4[C@H]3Cc3cc(OC)c(OC)c(OC)c3)[C@H](Cc3cc(OC)c(OC)c(OC)c3)c2cc1OC |a:41,55,&1:7,&2:27|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,1
"2624","mizolastine","histamine receptor antagonist","HRH1","allergy","urticaria, allergic rhinitis","CN(C1CCN(CC1)c1nc2ccccc2n1Cc1ccc(F)cc1)c1nc(=O)cc[nH]1, CN(C1CCN(CC1)c1nc2ccccc2n1Cc1ccc(F)cc1)c1nc(=O)cc[nH]1","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"2625","mizoribine","immunosuppressant, inosine monophosphate dehydrogenase inhibitor","IMPDH1","transplant, rheumatology","organ rejection, nephrotic syndrome","NC(=O)C1N=CN([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C1=O |c:4|, NC(=O)C1N=CN([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C1=O |c:4|, NC(=O)C1N=CN([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C1=O |c:4|, NC(=O)C1N=CN([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C1=O |c:4|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2626","MJ-15","cannabinoid receptor antagonist","CNR1",NA,NA,"Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NCc1cccnc1, Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NCc1cccnc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2627","MK-0354","niacin receptor agonist","HCAR2, HCAR3",NA,NA,"C1Cc2[nH]nc(-c3nn[nH]n3)c2C1, C1Cc2[nH]nc(-c3nn[nH]n3)c2C1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2628","mk-0429","integrin antagonist","ITGAV","nephrology","diabetic nephropathy","COc1ccc(cn1)[C@H](CC(=O)O)N2CCN(CCCc3ccc4CCCNc4n3)C2=O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2629","MK-0773","androgen receptor modulator","AR",NA,NA,"CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](C(=O)NCc5nc6ncccc6[nH]5)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=C(F)C1=O |t:35|, CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](C(=O)NCc5nc6ncccc6[nH]5)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=C(F)C1=O |t:35|, CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](C(=O)NCc5nc6ncccc6[nH]5)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=C(F)C1=O |t:35|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2630","MK-0812","CC chemokine receptor antagonist","CCR2",NA,NA,"CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCc2ncc(cc2C1)C(F)(F)F, CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCc2ncc(cc2C1)C(F)(F)F, CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCc2ncc(cc2C1)C(F)(F)F","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2631","MK-0893","glucagon receptor antagonist","GCGR",NA,NA,"COc1ccc2cc(ccc2c1)-c1cc(nn1[C@@H](C)c1ccc(cc1)C(=O)NCCC(O)=O)-c1cc(Cl)cc(Cl)c1, COc1ccc2cc(ccc2c1)-c1cc(nn1[C@@H](C)c1ccc(cc1)C(=O)NCCC(O)=O)-c1cc(Cl)cc(Cl)c1, COc1ccc2cc(ccc2c1)-c1cc(nn1[C@@H](C)c1ccc(cc1)C(=O)NCCC(O)=O)-c1cc(Cl)cc(Cl)c1, COc1ccc2cc(ccc2c1)-c1cc(nn1[C@@H](C)c1ccc(cc1)C(=O)NCCC(O)=O)-c1cc(Cl)cc(Cl)c1, COc1ccc2cc(ccc2c1)-c1cc(nn1[C@@H](C)c1ccc(cc1)C(=O)NCCC(O)=O)-c1cc(Cl)cc(Cl)c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2632","mk-0941","glucokinase activator","GCK","endocrinology","diabetes mellitus","CS(=O)(O)=O.O=C(NC1=NN(C)C=C1)C2=CC(O[C@@H](C)CO)=CC(OC3=CC=C(S(=O)(CC)=O)N=C3)=C2","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2633","MK-1775","WEE1 kinase inhibitor","WEE1",NA,NA,"CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1, CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1, CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1, CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1, CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2634","MK-2206","AKT inhibitor","AKT1, AKT2, AKT3",NA,NA,"NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2635","MK-2295","TRPV antagonist","TRPV1",NA,NA,"FC(F)(F)c1ccc(Nc2ncnc3cc(ccc23)-c2ncccc2C(F)(F)F)cc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2636","MK-2461","FGFR inhibitor, VEGFR inhibitor","FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, KDR, MERTK, MET, MST1R, NTRK1, NTRK2, PDGFRB",NA,NA,"CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(cc3c(=O)c2c1)-c1cnn(C)c1, CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(cc3c(=O)c2c1)-c1cnn(C)c1","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2637","MK-2894","prostaglandin inhibitor","PTGER4",NA,NA,"Cc1sc(C)c(C(=O)NC2(CC2)c2ccc(cc2)C(O)=O)c1Cc1ccc(cc1)C(F)(F)F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2638","MK-3207","calcitonin antagonist","CALCA",NA,NA,"Fc1cc(F)cc(c1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)Nc1ccc2C[C@]3(Cc2c1)C(=O)Nc1ncccc31, Fc1cc(F)cc(c1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)Nc1ccc2C[C@]3(Cc2c1)C(=O)Nc1ncccc31, Fc1cc(F)cc(c1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)Nc1ccc2C[C@]3(Cc2c1)C(=O)Nc1ncccc31","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2639","MK-3697","orexin receptor antagonist","HCRTR2",NA,NA,"COc1ccc(CNC(=O)c2cc(ncc2-c2nccs2)-c2cncc(C)c2)nc1OC, COc1ccc(CNC(=O)c2cc(ncc2-c2nccs2)-c2cncc(C)c2)nc1OC","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2640","MK-5046","bombesin receptor agonist","BRS3, GRPR, NMBR",NA,NA,"O[C@@](Cc1ncc(CC2(CC2)C(F)(F)F)[nH]1)(c1ccc(cc1)-n1cccn1)C(F)(F)F, O[C@@](Cc1ncc(CC2(CC2)C(F)(F)F)[nH]1)(c1ccc(cc1)-n1cccn1)C(F)(F)F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2641","MK-5108","Aurora kinase inhibitor","AURKA, AURKB, AURKC",NA,NA,"OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|, OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|, OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|, OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|, OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|, OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|, OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2642","MK-571","leukotriene receptor antagonist","ABCC2, CYSLTR1",NA,NA,"CN(C)C(=O)CCS[C@@H](SCCC(O)=O)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1 |&1:8|, CN(C)C(=O)CCS[C@@H](SCCC(O)=O)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1 |&1:8|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2643","MK-6096","orexin receptor antagonist","HCRTR1, HCRTR2",NA,NA,"C[C@@H]1CC[C@@H](COc2ccc(F)cn2)CN1C(=O)c1cc(C)ccc1-c1ncccn1, C[C@@H]1CC[C@@H](COc2ccc(F)cn2)CN1C(=O)c1cc(C)ccc1-c1ncccn1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2644","MK-8033","c-Met inhibitor","MET",NA,NA,"Cn1cc(cn1)-c1cnc2ccc3ccc(CS(=O)(=O)NCc4ccccn4)cc3c(=O)c2c1, Cn1cc(cn1)-c1cnc2ccc3ccc(CS(=O)(=O)NCc4ccccn4)cc3c(=O)c2c1, Cn1cc(cn1)-c1cnc2ccc3ccc(CS(=O)(=O)NCc4ccccn4)cc3c(=O)c2c1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2645","MK-8245","stearoyl-CoA desaturase inhibitor","SCD",NA,NA,"OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br, OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br, OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br, OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br, OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2646","MK-8745","Aurora kinase inhibitor","AURKA",NA,NA,"Fc1c(Cl)cccc1C(=O)N1CCN(Cc2cccc(Nc3nccs3)n2)CC1, Fc1c(Cl)cccc1C(=O)N1CCN(Cc2cccc(Nc3nccs3)n2)CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2647","mkc8866","ire1 inhibitor","ERN1","oncology","prostate cancer","COc1cc2c(C)c(CC(=O)N3CCOCC3)c(=O)oc2c(C=O)c1O",NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2648","MK2-IN-1","MAP kinase inhibitor","MAPKAPK2",NA,NA,"Clc1ccc(cc1)-c1ccc(o1)C(=O)N(Cc1ccccn1)c1ccc(cc1)N1CCNCC1, Clc1ccc(cc1)-c1ccc(o1)C(=O)N(Cc1ccccn1)c1ccc(cc1)N1CCNCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2649","MLN0128","mTOR inhibitor","MTOR, PIK3CA, PIK3CD, PIK3CG",NA,NA,"CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12, CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12, CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12, CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12, CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2650","MLN1117","PI3K inhibitor","PIK3CA",NA,NA,"Nc1nc2cc(ccc2o1)-c1ccc2ncc(C(=O)N3CCOCC3)n2c1, Nc1nc2cc(ccc2o1)-c1ccc2ncc(C(=O)N3CCOCC3)n2c1, Nc1nc2cc(ccc2o1)-c1ccc2ncc(C(=O)N3CCOCC3)n2c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2651","MLN8054","Aurora kinase inhibitor","AURKA",NA,NA,"OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1 |c:13|, OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1 |c:13|, OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1 |c:13|, OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1 |c:13|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2652","ML10302","serotonin receptor partial agonist","HTR3A, HTR3B, HTR4",NA,NA,"COc1cc(N)c(Cl)cc1C(=O)OCCN1CCCCC1, COc1cc(N)c(Cl)cc1C(=O)OCCN1CCCCC1, COc1cc(N)c(Cl)cc1C(=O)OCCN1CCCCC1","Preclinical",0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2653","ML141","GTPase inhibitor","CDC42",NA,NA,"COc1ccc(cc1)[C@H]1CC(=NN1c1ccc(cc1)S(N)(=O)=O)c1ccccc1 |&1:8,r,c:11|, COc1ccc(cc1)[C@H]1CC(=NN1c1ccc(cc1)S(N)(=O)=O)c1ccccc1 |&1:8,r,c:11|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2654","ML167","CLK inhibitor, DYRK inhibitor","CLK4, DYRK1B",NA,NA,"Cc1ccc(CNc2ncnc3ccc(cc23)-c2ccc(CO)o2)o1, Cc1ccc(CNc2ncnc3ccc(cc23)-c2ccc(CO)o2)o1, Cc1ccc(CNc2ncnc3ccc(cc23)-c2ccc(CO)o2)o1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2655","ML179","liver receptor homolog inverse agonist","NR5A2",NA,NA,"FC(F)(F)c1cccc(c1)N1CCN(CC1)c1cc(=O)n(C2CCCCC2)c(=O)[nH]1, FC(F)(F)c1cccc(c1)N1CCN(CC1)c1cc(=O)n(C2CCCCC2)c(=O)[nH]1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2656","ML193","G protein-coupled receptor antagonist","GPR55",NA,NA,"Cc1noc(NS(=O)(=O)c2ccc(NC(=O)c3cc(nc4c(C)cc(C)cc34)-c3ccccn3)cc2)c1C, Cc1noc(NS(=O)(=O)c2ccc(NC(=O)c3cc(nc4c(C)cc(C)cc34)-c3ccccn3)cc2)c1C, Cc1noc(NS(=O)(=O)c2ccc(NC(=O)c3cc(nc4c(C)cc(C)cc34)-c3ccccn3)cc2)c1C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2657","ML204","transient receptor potential channel antagonist","TRPC4, TRPC5",NA,NA,"Cc1cc(nc2ccccc12)N1CCCCC1, Cc1cc(nc2ccccc12)N1CCCCC1, Cc1cc(nc2ccccc12)N1CCCCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2658","ML213","potassium channel activator","KCNQ4",NA,NA,"Cc1cc(C)c(NC(=O)[C@@H]2C[C@H]3CC[C@@H]2C3)c(C)c1 |&1:11,14,&2:9,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2659","ML218","T-type calcium channel blocker","CACNA1G, CACNA1H, CACNA1I",NA,NA,"CC(C)(C)CCN1C[C@H]2[C@H](CNC(=O)c3cc(Cl)cc(Cl)c3)[C@H]2C1, CC(C)(C)CCN1C[C@H]2[C@H](CNC(=O)c3cc(Cl)cc(Cl)c3)[C@H]2C1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2660","ML228","hypoxia inducible factor activator","HIF1A",NA,NA,"C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1, C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1, C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1, C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1, C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1, C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1, C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2661","ML277","potassium channel activator","KCNQ1",NA,NA,"COc1ccc(cc1)-c1csc(NC(=O)[C@H]2CCCCN2S(=O)(=O)c2ccc(C)cc2)n1, COc1ccc(cc1)-c1csc(NC(=O)[C@H]2CCCCN2S(=O)(=O)c2ccc(C)cc2)n1, COc1ccc(cc1)-c1csc(NC(=O)[C@H]2CCCCN2S(=O)(=O)c2ccc(C)cc2)n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2662","ML281","serine/threonine kinase inhibitor","STK33",NA,NA,"CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2663","ML297","inward rectifier potassium channel activator","KCNJ3",NA,NA,"Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(n1)-c1ccccc1, Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(n1)-c1ccccc1, Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(n1)-c1ccccc1, Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(n1)-c1ccccc1, Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(n1)-c1ccccc1, Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(n1)-c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2664","ML298","phospholipase inhibitor","PLD2",NA,NA,"Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc(F)c(F)c2)CC1, Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc(F)c(F)c2)CC1, Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc(F)c(F)c2)CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2665","ML314","neurotensin agonist","NTSR1",NA,NA,"COc1ccccc1N1CCN(CC1)c1nc(nc2cc(OC)c(OC)cc12)C1CC1, COc1ccccc1N1CCN(CC1)c1nc(nc2cc(OC)c(OC)cc12)C1CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2666","ML323","ubiquitin specific protease inhibitor","USP1",NA,NA,"CC(C)c1ccccc1-c1ncc(C)c(NCc2ccc(cc2)-n2ccnn2)n1, CC(C)c1ccccc1-c1ncc(C)c(NCc2ccc(cc2)-n2ccnn2)n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2667","ML324","histone lysine demethylase inhibitor","KDM4A",NA,NA,"CN(C)CCCNC(=O)c1ccc(cc1)-c1cc(O)c2ncccc2c1, CN(C)CCCNC(=O)c1ccc(cc1)-c1cc(O)c2ncccc2c1, CN(C)CCCNC(=O)c1ccc(cc1)-c1cc(O)c2ncccc2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2668","ML3403","MAP kinase inhibitor","CYP3A4, MAPK11, MAPK12, MAPK14",NA,NA,"CSc1nc(c([nH]1)-c1ccc(F)cc1)-c1ccnc(N[C@@H](C)c2ccccc2)c1 |&1:20,r|, CSc1nc(c([nH]1)-c1ccc(F)cc1)-c1ccnc(N[C@@H](C)c2ccccc2)c1 |&1:20,r|, CSc1nc(c([nH]1)-c1ccc(F)cc1)-c1ccnc(N[C@@H](C)c2ccccc2)c1 |&1:20,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2669","ML347","ALK tyrosine kinase receptor inhibitor","ACVR1, ACVRL1, BMPR1A",NA,NA,"COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2670","ML348","lysophospholipase inhibitor","LYPLA1",NA,NA,"FC(F)(F)c1ccc(Cl)c(NC(=O)CN2CCN(CC2)C(=O)c2ccco2)c1, FC(F)(F)c1ccc(Cl)c(NC(=O)CN2CCN(CC2)C(=O)c2ccco2)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2671","ml355","lipoxygenase inhibitor","ALOX12","hematology","thrombosis","COc1cccc(CNc2ccc(cc2)S(=O)(=O)Nc3nc4ccccc4s3)c1O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2672","ML365","potassium channel blocker","KCNK3, KCNK9",NA,NA,"COc1ccccc1C(=O)Nc1cccc(NC(=O)c2cccc(C)c2)c1, COc1ccccc1C(=O)Nc1cccc(NC(=O)c2cccc(C)c2)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2673","ML786","RAF inhibitor","BRAF, RAF1",NA,NA,"CC(C)(N)c1cc(cc(c1)C(F)(F)F)C(=O)N[C@@H]1CCc2ccc(Oc3ccnc4NC(=O)CCc34)cc2C1, CC(C)(N)c1cc(cc(c1)C(F)(F)F)C(=O)N[C@@H]1CCc2ccc(Oc3ccnc4NC(=O)CCc34)cc2C1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2674","ML9","myosin light chain kinase inhibitor","TRPC6",NA,NA,"Clc1cccc2c(cccc12)S(=O)(=O)N1CCCNCC1, Clc1cccc2c(cccc12)S(=O)(=O)N1CCCNCC1, Clc1cccc2c(cccc12)S(=O)(=O)N1CCCNCC1, Clc1cccc2c(cccc12)S(=O)(=O)N1CCCNCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2675","MM-11253","retinoid receptor antagonist","RARG",NA,NA,"CC1(C)CCC(C)(C)c2cc(ccc12)C1(SCCS1)c1ccc2cc(ccc2c1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C1(SCCS1)c1ccc2cc(ccc2c1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C1(SCCS1)c1ccc2cc(ccc2c1)C(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2676","mmaf (hydrochloride)","tubulin polymerisation inhibitor","TPPP","oncology","breast cancer","CC(C)[C@H](NC)C(N[C@H](C(N([C@@H]([C@@H](C)CC)[C@H](OC)CC(N1CCC[C@@]1([H])[C@H](OC)[C@@H](C)C(N[C@H](C(O)=O)CC2=CC=CC=C2)=O)=O)C)=O)C(C)C)=O.Cl",NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2677","MM77","serotonin receptor antagonist","HTR1A",NA,NA,"COc1ccccc1N1CCN(CCCCN2C(=O)CCC2=O)CC1, COc1ccccc1N1CCN(CCCCN2C(=O)CCC2=O)CC1","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2678","MN-64","tankyrase inhibitor","TNKS",NA,NA,"CC(C)c1ccc(cc1)-c1cc(=O)c2ccccc2o1, CC(C)c1ccc(cc1)-c1cc(=O)c2ccccc2o1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2679","mobocertinib","egfr inhibitor","EGFR","oncology","non-small cell lung cancer (nsclc)","COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2ncc(C(=O)OC(C)C)c(n2)c3cn(C)c4ccccc34","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2680","mocetinostat","HDAC inhibitor","HDAC1, HDAC11, HDAC2, HDAC3",NA,NA,"Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2681","moclobemide","monoamine oxidase inhibitor","MAOA, MAOB","neurology/psychiatry","depression, anxiety","Clc1ccc(cc1)C(=O)NCCN1CCOCC1, Clc1ccc(cc1)C(=O)NCCN1CCOCC1, Clc1ccc(cc1)C(=O)NCCN1CCOCC1, Clc1ccc(cc1)C(=O)NCCN1CCOCC1","Launched",0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2682","moexipril","angiotensin converting enzyme inhibitor","ACE, ACE2","cardiology","hypertension","CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2683","mofegiline","monoamine oxidase inhibitor","MAOA, MAOB",NA,NA,"NC\C(CCc1ccc(F)cc1)=C\F, NC\C(CCc1ccc(F)cc1)=C\F, NC\C(CCc1ccc(F)cc1)=C\F, NC\C(CCc1ccc(F)cc1)=C\F","Phase 1",0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2684","mofezolac","cyclooxygenase inhibitor","PTGS1","rheumatology, orthopedics","rheumatoid arthritis, osteoporosis","COc1ccc(cc1)-c1noc(CC(O)=O)c1-c1ccc(OC)cc1","Launched",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2685","molidustat","hypoxia inducible factor inhibitor","EGLN2",NA,NA,"O=c1c(c[nH]n1-c1cc(ncn1)N1CCOCC1)-n1ccnn1, O=c1c(c[nH]n1-c1cc(ncn1)N1CCOCC1)-n1ccnn1, O=c1c(c[nH]n1-c1cc(ncn1)N1CCOCC1)-n1ccnn1, O=c1c(c[nH]n1-c1cc(ncn1)N1CCOCC1)-n1ccnn1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2686","molindone","dopamine receptor antagonist","DRD2, HRH1, HTR2A","neurology/psychiatry","schizophrenia","CCc1c(C)[nH]c2CC[C@@H](CN3CCOCC3)C(=O)c12 |r|, CCc1c(C)[nH]c2CC[C@@H](CN3CCOCC3)C(=O)c12 |r|","Launched",0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,1,1,1
"2687","molsidomine","guanylate cyclase stimulant","GUCY1A3","cardiology","coronary artery disease (CAD)","CCOC(=O)Nc1c[n+](no1)N1CCOCC1, CCOC(=O)Nc1c[n+](no1)N1CCOCC1, CCOC(=O)Nc1c[n+](no1)N1CCOCC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2688","mometasone","glucocorticoid receptor agonist","NR3C1","dermatology","corticosteroid-responsive dermatoses","C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl |c:11,t:7|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2689","mometasone-furoate","glucocorticoid receptor agonist","NR3C1","dermatology","corticosteroid-responsive dermatoses","C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl |c:11,t:7|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2690","monastrol","kinesin inhibitor","KIF11",NA,NA,"CCOC(=O)C1=C(C)NC(=S)N[C@@H]1c1cccc(O)c1 |r,c:5|, CCOC(=O)C1=C(C)NC(=S)N[C@@H]1c1cccc(O)c1 |r,c:5|, CCOC(=O)C1=C(C)NC(=S)N[C@@H]1c1cccc(O)c1 |r,c:5|, CCOC(=O)C1=C(C)NC(=S)N[C@@H]1c1cccc(O)c1 |r,c:5|, CCOC(=O)C1=C(C)NC(=S)N[C@@H]1c1cccc(O)c1 |r,c:5|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2691","monobenzone","melanin inhibitor","TYR","dermatology","skin depigmentation","Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2692","montelukast","leukotriene receptor antagonist","ALOX5, CYSLTR1","pulmonary, allergy","asthma, allergic rhinitis, exercise-induced bronchoconstriction (EIB)","CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1, CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1, CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1, CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1, CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1, CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1, CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1, CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2693","moracizine","sodium channel blocker","SCN5A","cardiology","ventricular arrhythmias","CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN3CCOCC3)c2c1, CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN3CCOCC3)c2c1, CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN3CCOCC3)c2c1","Withdrawn",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2694","morin","cytochrome P450 inhibitor","ADORA2A, ESR2, FASN, MCL1, SLC22A12",NA,NA,"Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O","Preclinical",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2695","morinidazole","other antibiotic","CYP51A1",NA,NA,"Cc1ncc(n1C[C@@H](O)CN1CCOCC1)[N+]([O-])=O |&1:7,r|, Cc1ncc(n1C[C@@H](O)CN1CCOCC1)[N+]([O-])=O |&1:7,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2696","mosapride","serotonin receptor agonist","HTR4","gastroenterology","hypertrophic gastritis (GHG), gastroesophageal reflux disease (GERD), dyspepsia, irritable bowel syndrome","CCOc1cc(N)c(Cl)cc1C(=O)NC[C@H]1CN(Cc2ccc(F)cc2)CCO1 |&1:15|, CCOc1cc(N)c(Cl)cc1C(=O)NC[C@H]1CN(Cc2ccc(F)cc2)CCO1 |&1:15|, CCOc1cc(N)c(Cl)cc1C(=O)NC[C@H]1CN(Cc2ccc(F)cc2)CCO1 |&1:15|","Launched",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2697","mosapride citrate","5-ht4 receptor agonist","5-HT4","Gastroenterology","gastroesophageal reflux disease (gerd)","CCOc1cc(N)c(Cl)cc1C(=O)NC[C@H]1CN(Cc2ccc(F)cc2)CCO1 |&1:15|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2698","motesanib","KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FLT1, FLT4, KDR, KIT",NA,NA,"CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2699","motolimod","toll-like receptor agonist","TLR8",NA,NA,"CCCN(CCC)C(=O)C1=Cc2ccc(cc2N=C(N)C1)-c1ccc(cc1)C(=O)N1CCCC1 |t:9,18|, CCCN(CCC)C(=O)C1=Cc2ccc(cc2N=C(N)C1)-c1ccc(cc1)C(=O)N1CCCC1 |t:9,18|, CCCN(CCC)C(=O)C1=Cc2ccc(cc2N=C(N)C1)-c1ccc(cc1)C(=O)N1CCCC1 |t:9,18|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2700","moxifloxacin","bacterial DNA gyrase inhibitor","TOP2A","otolaryngology, pulmonary, infectious disease","sinusitis, bronchitis, pneumonia, skin infections, intra-abdominal infections","COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1, COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1, COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1, COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2701","moxonidine","imidazoline receptor agonist","ADRA2A, ADRA2B, ADRA2C","cardiology","hypertension","COc1nc(C)nc(Cl)c1NC1=NCCN1 |t:12|, COc1nc(C)nc(Cl)c1NC1=NCCN1 |t:12|, COc1nc(C)nc(Cl)c1NC1=NCCN1 |t:12|, COc1nc(C)nc(Cl)c1NC1=NCCN1 |t:12|, COc1nc(C)nc(Cl)c1NC1=NCCN1 |t:12|, COc1nc(C)nc(Cl)c1NC1=NCCN1 |t:12|, COc1nc(C)nc(Cl)c1NC1=NCCN1 |t:12|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,1,1,1,1
"2702","mozavaptan","vasopressin receptor antagonist","AVPR1A, AVPR1B, AVPR2","endocrinology","hyponatremia","CN(C)[C@H]1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12 |&1:3,r|, CN(C)[C@H]1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12 |&1:3,r|, CN(C)[C@H]1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12 |&1:3,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2703","MPEP","glutamate receptor antagonist","GRM1, GRM4, GRM5",NA,NA,"Cc1cccc(n1)C#Cc1ccccc1, Cc1cccc(n1)C#Cc1ccccc1, Cc1cccc(n1)C#Cc1ccccc1, Cc1cccc(n1)C#Cc1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2704","MPI-0479605","mitotic kinase inhibitor","TTK",NA,NA,"Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2705","Mps-BAY-2a","monopolar spindle 1 kinase inhibitor","TTK",NA,NA,"CC(C)CNc1nc(cn2c(cnc12)-c1ccc(cc1)C(=O)NC1CC1)-c1cccc2ncccc12, CC(C)CNc1nc(cn2c(cnc12)-c1ccc(cc1)C(=O)NC1CC1)-c1cccc2ncccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2706","Mps1-IN-1","monopolar spindle 1 kinase inhibitor","TTK",NA,NA,"COc1cc(ccc1Nc1cc(Nc2ccccc2S(=O)(=O)C(C)C)c2cc[nH]c2n1)N1CCC(O)CC1, COc1cc(ccc1Nc1cc(Nc2ccccc2S(=O)(=O)C(C)C)c2cc[nH]c2n1)N1CCC(O)CC1, COc1cc(ccc1Nc1cc(Nc2ccccc2S(=O)(=O)C(C)C)c2cc[nH]c2n1)N1CCC(O)CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2707","MR-948","thromboxane synthase inhibitor","TBXAS1",NA,NA,"OCCc1ccc(OCCn2ccnc2)cc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2708","MRK-016","GABA receptor inverse agonist","GABRA1, GABRA2, GABRA3, GABRA5",NA,NA,"Cc1cc(no1)-c1nncc2c(c(OCc3ncnn3C)nn12)C(C)(C)C, Cc1cc(no1)-c1nncc2c(c(OCc3ncnn3C)nn12)C(C)(C)C, Cc1cc(no1)-c1nncc2c(c(OCc3ncnn3C)nn12)C(C)(C)C, Cc1cc(no1)-c1nncc2c(c(OCc3ncnn3C)nn12)C(C)(C)C","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,0,0
"2709","MRK-560","gamma secretase inhibitor","APP",NA,NA,"Fc1ccc(F)c(c1)[C@]1(CC[C@@H](CC1)NS(=O)(=O)C(F)(F)F)S(=O)(=O)c1ccc(Cl)cc1 |r|, Fc1ccc(F)c(c1)[C@]1(CC[C@@H](CC1)NS(=O)(=O)C(F)(F)F)S(=O)(=O)c1ccc(Cl)cc1 |r|, Fc1ccc(F)c(c1)[C@]1(CC[C@@H](CC1)NS(=O)(=O)C(F)(F)F)S(=O)(=O)c1ccc(Cl)cc1 |r|, Fc1ccc(F)c(c1)[C@]1(CC[C@@H](CC1)NS(=O)(=O)C(F)(F)F)S(=O)(=O)c1ccc(Cl)cc1 |r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2710","MRS-1220","adenosine receptor antagonist","ADORA2B, ADORA3",NA,NA,"Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2711","MRS-1334","adenosine receptor antagonist","ADORA3",NA,NA,"CCOC(=O)C1=C(C)NC(=C([C@@H]1C#Cc1ccccc1)C(=O)OCc1ccc(cc1)[N+]([O-])=O)c1ccccc1 |&1:11,r,c:5,9|, CCOC(=O)C1=C(C)NC(=C([C@@H]1C#Cc1ccccc1)C(=O)OCc1ccc(cc1)[N+]([O-])=O)c1ccccc1 |&1:11,r,c:5,9|, CCOC(=O)C1=C(C)NC(=C([C@@H]1C#Cc1ccccc1)C(=O)OCc1ccc(cc1)[N+]([O-])=O)c1ccccc1 |&1:11,r,c:5,9|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2712","MRS-2578","purinergic receptor antagonist","P2RY6",NA,NA,"S=C=Nc1cccc(NC(=S)NCCCCNC(=S)Nc2cccc(c2)N=C=S)c1, S=C=Nc1cccc(NC(=S)NCCCCNC(=S)Nc2cccc(c2)N=C=S)c1, S=C=Nc1cccc(NC(=S)NCCCCNC(=S)Nc2cccc(c2)N=C=S)c1, S=C=Nc1cccc(NC(=S)NCCCCNC(=S)Nc2cccc(c2)N=C=S)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2713","MRS-3777","adenosine receptor antagonist","ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,"C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12.C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12.C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12.C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2714","mrtx849","ras gtpase inhibitor","KRAS","oncology","gastric adenocarcinoma","CN1CCC[C@H]1COc2nc3CN(CCc3c(n2)N4CCN([C@@H](CC#N)C4)C(=O)C(=C)F)c5cccc6cccc(Cl)c56","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2715","msc2360844","pi3k inhibitor","PIK3CD","rheumatology","lupus","Fc1cccc2-c3c(CS(=O)(=O)c12)c(nn3-c1ccc(CN2CCOCC2)cc1)C(=O)N1CCOCC1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2716","MSX-122","CC chemokine receptor antagonist","CXCR4",NA,NA,"C(Nc1ncccn1)c1ccc(CNc2ncccn2)cc1, C(Nc1ncccn1)c1ccc(CNc2ncccn2)cc1, C(Nc1ncccn1)c1ccc(CNc2ncccn2)cc1, C(Nc1ncccn1)c1ccc(CNc2ncccn2)cc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2717","mtep","glutamate metabotropic receptor antagonist","GRM5","Neurology","parkinson's disease","Cc1nc(cs1)C#Cc1cccnc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2718","MTPG","glutamate receptor antagonist","GRM2, GRM3",NA,NA,"C[C@@](N)(C(O)=O)c1ccc(cc1)-c1nn[nH]n1 |&1:1|, C[C@@](N)(C(O)=O)c1ccc(cc1)-c1nn[nH]n1 |&1:1|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2719","mubritinib","protein tyrosine kinase inhibitor","EGFR, ERBB2",NA,NA,"FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2720","muscimol","benzodiazepine receptor agonist","GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRR1, GABRR2, GABRR3",NA,NA,"NCc1cc(=O)[nH]o1, NCc1cc(=O)[nH]o1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,1,9,0,0,0,0,0,0,0,0,0,0
"2721","mw-150","p38 mapk inhibitor","MAPK14","neurology/psychiatry","alzheimer's disease","CN1CCN(C2=NN=C(C3=CC=C4C=CC=CC4=C3)C(C5=CC=NC=C5)=C2)CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2722","MY-5445","phosphodiesterase inhibitor, platelet aggregation inhibitor","PDE5A",NA,NA,"Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1, Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1, Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1, Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2723","mycophenolate-mofetil","dehydrogenase inhibitor, inositol monophosphatase inhibitor","IMPDH1, IMPDH2","transplant","organ rejection","COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2724","mycophenolic-acid","dehydrogenase inhibitor, inositol monophosphatase inhibitor","IMPDH1, IMPDH2","transplant","organ rejection","COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2725","myricetin","androgen receptor agonist, cytochrome P450 inhibitor","PIK3CG",NA,NA,"Oc1cc(O)c2c(c1)oc(-c1cc(O)c(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1cc(O)c(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1cc(O)c(O)c(O)c1)c(O)c2=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2726","myricitrin","PKC inhibitor","NOS1, PRKCA",NA,NA,"C[C@@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2cc(O)c(O)c(O)c2)[C@H](O)[C@H](O)[C@H]1O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2727","M8-B","transient receptor potential channel antagonist","TRPM8",NA,NA,"COc1cc(CN(CCN)C(=O)c2cccs2)ccc1OCc1ccccc1, COc1cc(CN(CCN)C(=O)c2cccs2)ccc1OCc1ccccc1, COc1cc(CN(CCN)C(=O)c2cccs2)ccc1OCc1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2728","n-acetylcysteine amide","antioxidant","PSEN2","neurology/psychiatry","parkinson's disease","CC(=O)N[C@@H](CS)C(N)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2729","N-alpha-methylhistamine-dihydrochloride","histamine receptor agonist","HRH4",NA,NA,"CNCCc1cnc[nH]1, CNCCc1cnc[nH]1, CNCCc1cnc[nH]1","Phase 3",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
"2730","NAB-2","ubiquitin ligase transport promoter","NEDD4",NA,NA,"Cc1ccc(C)c(c1)-n1cnc2cc(ccc12)C(=O)NCc1ccccc1Cl, Cc1ccc(C)c(c1)-n1cnc2cc(ccc12)C(=O)NCc1ccccc1Cl, Cc1ccc(C)c(c1)-n1cnc2cc(ccc12)C(=O)NCc1ccccc1Cl","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2731","nabumetone","cyclooxygenase inhibitor","PTGS1, PTGS2","rheumatology","rheumatoid arthritis, osteoarthritis","COc1ccc2cc(CCC(C)=O)ccc2c1, COc1ccc2cc(CCC(C)=O)ccc2c1, COc1ccc2cc(CCC(C)=O)ccc2c1, COc1ccc2cc(CCC(C)=O)ccc2c1","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2732","nadide","free radical scavenger","AHCY, AKR1A1, ALDH2, BLVRA, DHPS, DLD, GALE, HMGCR, HSD17B1, HSD17B4, IMPDH2, MGAM, P2RY11, SORD, TRPM2",NA,NA,"NC(=O)c1ccc[n+](c1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:9,11,23,25,26,28,40,42,&1:14,&2:18|, NC(=O)c1ccc[n+](c1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:9,11,23,25,26,28,40,42,&1:14,&2:18|, NC(=O)c1ccc[n+](c1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:9,11,23,25,26,28,40,42,&1:14,&2:18|, NC(=O)c1ccc[n+](c1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:9,11,23,25,26,28,40,42,&1:14,&2:18|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2733","nadolol","adrenergic receptor antagonist","ADRB1, ADRB2, ADRB3","cardiology","angina pectoris, hypertension","CC(C)(C)NC[C@@H](O)COc1cccc2C[C@@H](O)[C@@H](O)Cc12 |a:16,18,&1:6|, CC(C)(C)NC[C@@H](O)COc1cccc2C[C@@H](O)[C@@H](O)Cc12 |a:16,18,&1:6|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,1,1,1,1
"2734","nafadotride","dopamine receptor antagonist","DRD2, DRD3, HTR1A",NA,NA,"CCCCN1CCC[C@@H]1CNC(=O)c1cc(C#N)c2ccccc2c1OC |&1:8,r|","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,2,0,0,0,0,0,0,0,0
"2735","nafamostat","serine protease inhibitor","ASIC1, ASIC2, ASIC3, C1R, PRSS1, TPSAB1, TRPM7","cardiology","anticoagulent","NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2cc(ccc2c1)C(N)=N, NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2cc(ccc2c1)C(N)=N, NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2cc(ccc2c1)C(N)=N, NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2cc(ccc2c1)C(N)=N, NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2cc(ccc2c1)C(N)=N","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2736","nafcillin","bacterial cell wall synthesis inhibitor","CYP1A2, CYP3A4, SLC22A6","infectious disease","gram-positive bacterial infections","CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2737","naftopidil","adrenergic receptor antagonist","ADRA1A","urology","benign prostatic hyperplasia (BPH)","COc1ccccc1N1CCN(C[C@@H](O)COc2cccc3ccccc23)CC1 |&1:13|, COc1ccccc1N1CCN(C[C@@H](O)COc2cccc3ccccc23)CC1 |&1:13|, COc1ccccc1N1CCN(C[C@@H](O)COc2cccc3ccccc23)CC1 |&1:13|, COc1ccccc1N1CCN(C[C@@H](O)COc2cccc3ccccc23)CC1 |&1:13|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"2738","nalbuphine","opioid receptor agonist, opioid receptor antagonist","OPRD1, OPRK1, OPRM1","neurology/psychiatry","pain relief","O[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CCC1)c45, O[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CCC1)c45, O[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CCC1)c45, O[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CCC1)c45","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2739","naldemedine","opioid receptor antagonist","OPRD1, OPRK1, OPRM1","gastroenterology","constipation","CC(C)(c1nc(no1)c2ccccc2)NC(=O)C3=C([C@H]4[C@@]56CCN([C@@H]([C@@]5(C3)O)Cc7c6c(c(cc7)O)O4)CC8CC8)O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2740","nalfurafine","opioid receptor agonist","OPRK1, OPRM1","nephrology","uremic pruritus","CN([C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45)C(=O)\C=C\c1ccoc1, CN([C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45)C(=O)\C=C\c1ccoc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2741","nalmefene","opioid receptor antagonist","OPRD1, OPRK1, OPRM1","pulmonary","respiratory depression","Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=C)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=C)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=C)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=C)CC[C@@]35O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2742","naloxegol","opioid receptor antagonist","OPRM1","gastroenterology","constipation","COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC=C)c45, COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC=C)c45","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2743","naloxone","opioid receptor antagonist","CREB1, ESR1, OPRD1, OPRK1, OPRM1, TLR4","pulmonary","respiratory depression","Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2744","naloxone-benzoylhydrazone","opioid receptor antagonist","OPRK1, OPRM1",NA,NA,"Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)\C(CC[C@@]35O)=N\NC(=O)c1ccccc1, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)\C(CC[C@@]35O)=N\NC(=O)c1ccccc1, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)\C(CC[C@@]35O)=N\NC(=O)c1ccccc1, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)\C(CC[C@@]35O)=N\NC(=O)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2745","naltrexone","opioid receptor antagonist","OPRD1, OPRK1, OPRM1, SIGMAR1","neurology/psychiatry","abstinence from alcohol","Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2746","naltriben","opioid receptor antagonist","OPRD1, OPRK1, OPRM1",NA,NA,"Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1oc2ccccc2c1C[C@@]35O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2747","naltrindole","opioid receptor antagonist","OPRD1, OPRK1, OPRM1",NA,NA,"Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2ccccc2c1C[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2ccccc2c1C[C@@]35O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2748","namitecan","topoisomerase inhibitor","TOP1","oncology","soft tissue sarcoma (sts)","CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4c(\C=N\OCCN)c3Cn1c2=O |a:2|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2749","NAN-190","serotonin receptor agonist","ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1F",NA,NA,"COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3C2=O)CC1, COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3C2=O)CC1","Preclinical",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,1,3,0,0,0,0
"2750","napabucasin","STAT inhibitor","STAT3",NA,NA,"CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2751","naphazoline","adrenergic receptor agonist","ADRA1A, ADRA2A","ophthalmology","eye irritation","C(C1=NCCN1)c1cccc2ccccc12 |t:1|, C(C1=NCCN1)c1cccc2ccccc12 |t:1|, C(C1=NCCN1)c1cccc2ccccc12 |t:1|, C(C1=NCCN1)c1cccc2ccccc12 |t:1|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,1,1,1,1
"2752","naproxen","cyclooxygenase inhibitor","PTGS1, PTGS2","neurology/psychiatry, rheumatology, dental, otolaryngology, endocrinology","pain relief, rheumatoid arthritis, headache, toothache, backache, muscle pain, common cold, fever","COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2753","naratriptan","serotonin receptor agonist","HTR1A, HTR1B, HTR1D, HTR1E, HTR1F","neurology/psychiatry","migraine headache","CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1, CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1, CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1","Launched",0,0,0,0,0,0,0,0,1,5,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2754","naringenin","aromatase inhibitor, TRPV antagonist","CYP19A1, CYP1B1, ESR2, GLO1, HSD17B1",NA,NA,"Oc1ccc(cc1)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1, Oc1ccc(cc1)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2755","naringin","cytochrome P450 inhibitor","SLCO1A2",NA,NA,"C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c3C(=O)C[C@H](Oc3c2)c2ccc(O)cc2)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c3C(=O)C[C@H](Oc3c2)c2ccc(O)cc2)[C@H](O)[C@H](O)[C@H]1O","Preclinical",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2756","NAS-181","serotonin receptor antagonist","HTR1B",NA,NA,"C(Oc1cccc2C=C(CN3CCOCC3)COc12)[C@H]1CNCCO1 |t:7|","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2757","nastorazepide","CCK receptor antagonist","CCKBR",NA,NA,"CC(C)(C)C(=O)CN1c2ccccc2N(C[C@@H](NC(=O)Nc2cccc(c2)C(O)=O)C1=O)C1CCCCC1, CC(C)(C)C(=O)CN1c2ccccc2N(C[C@@H](NC(=O)Nc2cccc(c2)C(O)=O)C1=O)C1CCCCC1, CC(C)(C)C(=O)CN1c2ccccc2N(C[C@@H](NC(=O)Nc2cccc(c2)C(O)=O)C1=O)C1CCCCC1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2758","nateglinide","insulin secretagogue","ABCC8, KCNJ10, KCNJ11, PPARG","endocrinology","diabetes mellitus","CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)C(O)=O, CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O, CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O, CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O, CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O, CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2759","NAV-26","voltage-gated sodium channel blocker","SCN9A",NA,NA,"FC(F)(F)Oc1ccc(CNC(=O)[C@H]2N(C3CCOCC3)C(=O)c3ccccc23)cc1 |&1:13,r|, FC(F)(F)Oc1ccc(CNC(=O)[C@H]2N(C3CCOCC3)C(=O)c3ccccc23)cc1 |&1:13,r|, FC(F)(F)Oc1ccc(CNC(=O)[C@H]2N(C3CCOCC3)C(=O)c3ccccc23)cc1 |&1:13,r|","Preclinical",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2760","navarixin","CC chemokine receptor antagonist","CXCR1, CXCR2",NA,NA,"CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1, CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1, CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2761","navitoclax","BCL inhibitor","BCL2, BCL2L1, BCL2L2",NA,NA,"CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2762","navoximod","indoleamine 2,3-dioxygenase inhibitor","IDO1","oncology","melanoma","O[C@H](CC1)CC[C@]1([H])[C@H](O)C[C@@H]2N3C(C4=C2C(F)=CC=C4)=CN=C3","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2763","NBI-27914","corticotropin releasing factor receptor antagonist","CRHR1",NA,NA,"CCCN(CC1CC1)c1nc(C)nc(Nc2c(Cl)cc(Cl)cc2Cl)c1Cl, CCCN(CC1CC1)c1nc(C)nc(Nc2c(Cl)cc(Cl)cc2Cl)c1Cl, CCCN(CC1CC1)c1nc(C)nc(Nc2c(Cl)cc(Cl)cc2Cl)c1Cl, CCCN(CC1CC1)c1nc(C)nc(Nc2c(Cl)cc(Cl)cc2Cl)c1Cl","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2764","NBI-74330-(+/-)","CC chemokine receptor antagonist","CXCR3",NA,NA,"CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(F)c(c1)C(F)(F)F |&1:20,r|, CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(F)c(c1)C(F)(F)F |&1:20,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2765","NBQX","glutamate receptor antagonist","GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIN1, GRIN2A, GRIN2B",NA,NA,"NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O, NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O, NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O, NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O, NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O, NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2766","NCS-382","GABA receptor antagonist","GABBR1, GABBR2, SLC52A2",NA,NA,"O[C@@H]1c2ccccc2CCC\C1=C/C(O)=O |&1:1|, O[C@@H]1c2ccccc2CCC\C1=C/C(O)=O |&1:1|","Preclinical",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2767","NDT-9513727","complement antagonist","C5AR1",NA,NA,"CCCCn1c(CN(Cc2ccc3OCOc3c2)Cc2ccc3OCOc3c2)c(nc1-c1ccccc1)-c1ccccc1, CCCCn1c(CN(Cc2ccc3OCOc3c2)Cc2ccc3OCOc3c2)c(nc1-c1ccccc1)-c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2768","NE-100","sigma receptor antagonist","SIGMAR1",NA,NA,"CCCN(CCC)CCc1ccc(OC)c(OCCc2ccccc2)c1, CCCN(CCC)CCc1ccc(OC)c(OCCc2ccccc2)c1, CCCN(CCC)CCc1ccc(OC)c(OCCc2ccccc2)c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2769","nebivolol","adrenergic receptor antagonist","ADRB1","cardiology","hypertension","O[C@H](CNC[C@@H](O)[C@@H]1CCc2cc(F)ccc2O1)[C@H]1CCc2cc(F)ccc2O1 |&1:1,5,7,18|, O[C@H](CNC[C@@H](O)[C@@H]1CCc2cc(F)ccc2O1)[C@H]1CCc2cc(F)ccc2O1 |&1:1,5,7,18|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"2770","nebracetam","acetylcholine receptor agonist","CHRM1",NA,NA,"NC[C@H]1CN(Cc2ccccc2)C(=O)C1 |&1:2|, NC[C@H]1CN(Cc2ccccc2)C(=O)C1 |&1:2|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
"2771","NECA","adenosine receptor agonist","ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,"CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12, CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12, CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12, CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2772","necrostatin-1","RIPK inhibitor","RIPK1",NA,NA,"CN1C(=S)N[C@@H](Cc2c[nH]c3ccccc23)C1=O |r|, CN1C(=S)N[C@@H](Cc2c[nH]c3ccccc23)C1=O |r|, CN1C(=S)N[C@@H](Cc2c[nH]c3ccccc23)C1=O |r|, CN1C(=S)N[C@@H](Cc2c[nH]c3ccccc23)C1=O |r|, CN1C(=S)N[C@@H](Cc2c[nH]c3ccccc23)C1=O |r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2773","necrostatin-2","necroptosis inhibitor, RIPK inhibitor","RIPK2",NA,NA,"CN1C(=O)N[C@H](Cc2c[nH]c3c(Cl)cccc23)C1=O, CN1C(=O)N[C@H](Cc2c[nH]c3c(Cl)cccc23)C1=O, CN1C(=O)N[C@H](Cc2c[nH]c3c(Cl)cccc23)C1=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2774","nedocromil","histamine receptor antagonist","CYSLTR1, CYSLTR2, FPR1, HSP90AA1, PTGDR","neurology/psychiatry, ophthalmology","itching, conjunctivitis","CCCc1c2oc(cc(=O)c2cc2c1n(CC)c(cc2=O)C(O)=O)C(O)=O, CCCc1c2oc(cc(=O)c2cc2c1n(CC)c(cc2=O)C(O)=O)C(O)=O, CCCc1c2oc(cc(=O)c2cc2c1n(CC)c(cc2=O)C(O)=O)C(O)=O, CCCc1c2oc(cc(=O)c2cc2c1n(CC)c(cc2=O)C(O)=O)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2775","nefazodone","adrenergic inhibitor, norepinephrine reuptake inhibitor, serotonin receptor antagonist, serotonin reuptake inhibitor","ADRA1A, ADRA1B, ADRA2A, CYP3A4, HTR1A, HTR2A, HTR2C, SLC6A2, SLC6A3, SLC6A4",NA,NA,"CCc1nn(CCCN2CCN(CC2)c2cccc(Cl)c2)c(=O)n1CCOc1ccccc1, CCc1nn(CCCN2CCN(CC2)c2cccc(Cl)c2)c(=O)n1CCOc1ccccc1, CCc1nn(CCCN2CCN(CC2)c2cccc(Cl)c2)c(=O)n1CCOc1ccccc1, CCc1nn(CCCN2CCN(CC2)c2cccc(Cl)c2)c(=O)n1CCOc1ccccc1","Withdrawn",1,3,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,1,3,0,0,0,0
"2776","nefiracetam","acetylcholine receptor agonist, benzodiazepine receptor agonist","CHRM1",NA,NA,"Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
"2777","nelarabine","DNA synthesis inhibitor, T cell inhibitor","POLA1","hematologic malignancy","acute lymphoblastic leukemia (ALL)","COc1nc(N)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, COc1nc(N)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, COc1nc(N)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2778","nelfinavir","HIV protease inhibitor","CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A7","infectious disease","human immunodeficiency virus (HIV-1)","Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C, Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C, Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C, Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C, Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C, Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C, Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C, Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2779","nemonapride","dopamine receptor antagonist","DRD2, DRD3, DRD4","neurology/psychiatry","schizophrenia","CNc1cc(OC)c(cc1Cl)C(=O)N[C@@H]1CCN(Cc2ccccc2)[C@@H]1C.CNc1cc(OC)c(cc1Cl)C(=O)N[C@H]1CCN(Cc2ccccc2)[C@H]1C, CNc1cc(OC)c(cc1Cl)C(=O)N[C@@H]1CCN(Cc2ccccc2)[C@@H]1C |&1:14,25|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0,1,1,1,1
"2780","nemorubicin","topoisomerase inhibitor","TOP1, TOP2A",NA,NA,"CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O, CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O, CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O, CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2781","neomycin","bacterial 30S ribosomal subunit inhibitor","CXCR4","infectious disease, gastroenterology","first-aid antibiotic, hepatic encephalopathy (HE), intra-abdominal infections","NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2782","neostigmine","acetylcholinesterase inhibitor","ACHE","neurology/psychiatry","myasthenia gravis","CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2783","nepafenac","cyclooxygenase inhibitor","PTGS1, PTGS2","ophthalmology","eye inflammation","NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N, NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2784","nepicastat","dopamine beta hydroxylase inhibitor","DBH",NA,NA,"NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1, NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1, NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1, NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2785","nepinalone","antitussive","SIGMAR1","pulmonary","cough suppressant","CC1(CCN2CCCCC2)C(=O)CCc3ccccc13","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2786","neratinib","EGFR inhibitor","EGFR, ERBB2, KDR","oncology","breast cancer","CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2787","neridronic-acid","bone resorption inhibitor","FDPS","endocrinology","brittle bone disease, Paget's disease","NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2788","netarsudil","rho associated kinase inhibitor","ROCK2","ophthalmology","ocular hypertension","Cc1ccc(C(=O)OCc2ccc(cc2)[C@@H](CN)C(=O)Nc3ccc4cnccc4c3)c(C)c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2789","netupitant","neurokinin receptor antagonist, tachykinin antagonist","TACR1","gastroenterology","nausea, vomiting","CN(C(=O)C(C)(C)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CN=C(C=C1C1=CC=CC=C1C)N1CC[N+](C)(COP(O)([O-])=O)CC1, CN(C(=O)C(C)(C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)c1cnc(cc1-c1ccccc1C)N1CCN(C)CC1, CN(C(=O)C(C)(C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)c1cnc(cc1-c1ccccc1C)N1CCN(C)CC1, CN(C(=O)C(C)(C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)c1cnc(cc1-c1ccccc1C)N1CCN(C)CC1, CN(C(=O)C(C)(C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)c1cnc(cc1-c1ccccc1C)N1CCN(C)CC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2790","neuropathiazol","neural stem cell inducer","BMP2, LIF",NA,NA,"CCOC(=O)c1ccc(cc1)N(C)c1csc(n1)-c1ccccc1, CCOC(=O)c1ccc(cc1)N(C)c1csc(n1)-c1ccccc1, CCOC(=O)c1ccc(cc1)N(C)c1csc(n1)-c1ccccc1, CCOC(=O)c1ccc(cc1)N(C)c1csc(n1)-c1ccccc1, CCOC(=O)c1ccc(cc1)N(C)c1csc(n1)-c1ccccc1, CCOC(=O)c1ccc(cc1)N(C)c1csc(n1)-c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2791","nevanimibe hydrochloride","acat inhibitor","ACAT1","endocrinology","congenital adrenal hyperplasia","CC(C)c1cccc(C(C)C)c1NC(=O)NCC1(CCCC1)c1ccc(cc1)N(C)C.Cl","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2792","nevirapine","non-nucleoside reverse transcriptase inhibitor","CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP3A4, CYP3A5","infectious disease","human immunodeficiency virus (HIV-1)","Cc1ccnc2N(C3CC3)c3ncccc3C(=O)Nc12, Cc1ccnc2N(C3CC3)c3ncccc3C(=O)Nc12, Cc1ccnc2N(C3CC3)c3ncccc3C(=O)Nc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2793","nexturastat-A","HDAC inhibitor","HDAC1, HDAC6",NA,NA,"CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1, CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1, CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1, CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1, CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2794","NFKB-activation-inhibitor-II","NFkB pathway inhibitor","RELA",NA,NA,"Cc1ccc(NCCCc2ccccc2)c(N)c1, Cc1ccc(NCCCc2ccccc2)c(N)c1, Cc1ccc(NCCCc2ccccc2)c(N)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2795","NG-nitro-arginine","nitric oxide synthase inhibitor","NOS1, NOS2, NOS3",NA,NA,"N[C@@H](CCCNC(N)=N[N+]([O-])=O)C(O)=O, N[C@@H](CCCNC(N)=N[N+]([O-])=O)C(O)=O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2796","NGB-2904","dopamine receptor antagonist","DRD3",NA,NA,"Clc1cccc(N2CCN(CCCCNC(=O)c3ccc-4c(Cc5ccccc-45)c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCNC(=O)c3ccc-4c(Cc5ccccc-45)c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCNC(=O)c3ccc-4c(Cc5ccccc-45)c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCNC(=O)c3ccc-4c(Cc5ccccc-45)c3)CC2)c1Cl","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0
"2797","NGD-94-1","dopamine receptor antagonist","DRD4",NA,NA,"C(N1CCN(CC1)c1ncccn1)c1cnc([nH]1)-c1ccccc1, C(N1CCN(CC1)c1ncccn1)c1cnc([nH]1)-c1ccccc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0
"2798","NGD-98-2","corticotropin releasing factor receptor antagonist","CRHR1",NA,NA,"CCC(CC)Nc1nc(C)c(nc1OC)-c1ccc(OC(F)(F)F)cc1OC, CCC(CC)Nc1nc(C)c(nc1OC)-c1ccc(OC(F)(F)F)cc1OC","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2799","NHI-2","lactate dehydrogenase inhibitor","LDHA",NA,NA,"COC(=O)c1cc2c(cc(cc2n1O)-c1ccccc1)C(F)(F)F, COC(=O)c1cc2c(cc(cc2n1O)-c1ccccc1)C(F)(F)F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2800","NI-57","bromodomain inhibitor","BRD1, BRPF1, BRPF3",NA,NA,"COc1cc(ccc1S(=O)(=O)Nc1ccc2n(C)c(=O)c(C)cc2c1)C#N, COc1cc(ccc1S(=O)(=O)Nc1ccc2n(C)c(=O)c(C)cc2c1)C#N, COc1cc(ccc1S(=O)(=O)Nc1ccc2n(C)c(=O)c(C)cc2c1)C#N, COc1cc(ccc1S(=O)(=O)Nc1ccc2n(C)c(=O)c(C)cc2c1)C#N","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2801","niacin","NAD precursor, vitamin B","DGAT2, HCAR1, HCAR2, HCAR3, NNMT, QPRT","endocrinology","hypertriglyceridemia","OC(=O)c1cccnc1, OC(=O)c1cccnc1, OC(=O)c1cccnc1, OC(=O)c1cccnc1, OC(=O)c1cccnc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2802","nialamide","monoamine oxidase inhibitor","COMT, MAOA, MAOB",NA,NA,"O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1, O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1, O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1","Withdrawn",0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2803","nicardipine","calcium channel blocker","ADORA3","cardiology","chronic stable angina, hypertension","COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(C)Cc1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(C)Cc1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(C)Cc1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(C)Cc1ccccc1 |r,c:4,9|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2804","nicardipine hydrochloride","potassium channel blocker","KCND2, KCND3","Cardiology","angina pectoris","COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(C)Cc1ccccc1 |r,c:4,9|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2805","nicergoline","adrenergic receptor antagonist","ADRA1A","rheumatology, neurology/psychiatry, cardiology, hematology","Raynaud's disease, migraine headache, atherosclerosis, thrombosis","CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13, CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13, CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13, CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"2806","niclosamide","DNA replication inhibitor, STAT inhibitor","STAT3","infectious disease","tapeworm","Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O, Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O, Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O, Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O, Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O, Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O, Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2807","nicorandil","nitric oxide donor, potassium channel activator","KCNJ11","cardiology","angina pectoris","[O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2808","nicotinamide","protein synthesis stimulant","BST1, LDHA, PARP1, SIRT5","dermatology","acne vulgaris (AV)","NC(=O)c1cccnc1, NC(=O)c1cccnc1, NC(=O)c1cccnc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2809","nicotinamide riboside","sirt activator","SIRT1","cardiology","cardiomyopathy","NC(=O)c1ccc[n+](c1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2810","nicotine","acetylcholine receptor agonist","CHAT, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB2, CHRNB3, CHRNB4, CYP19A1, TBXAS1, TRPA1","neurology/psychiatry","smoking cessation","CN1CCC[C@H]1c1cccnc1, CN1CCC[C@H]1c1cccnc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,11,0,0,1,1,1,1
"2811","nicotine bitartrate","nicotinic receptor agonist","NACHR","Smoking","smoking cessation","CN1CCCC1c1cccnc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2812","NIDA-41020","cannabinoid receptor antagonist","CNR1",NA,NA,"COc1ccc(cc1)-c1c(C)c(nn1-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, COc1ccc(cc1)-c1c(C)c(nn1-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, COc1ccc(cc1)-c1c(C)c(nn1-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2813","nidufexor","fxr agonist","NR1H4","gastroenterology","non-alcoholic steatohepatitis (nash)","Cn1nc(C(=O)N(Cc2ccccc2)Cc3ccc(cc3)C(=O)O)c4COc5ccc(Cl)cc5c14","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2814","nifedipine","calcium channel blocker","CACNA1C, CACNA1D, CACNA1F, CACNA1H, CACNA1S, CACNA2D1, CACNB2, CALM1, GLRA1, GLRA3, GLRB, KCNA1, KCNA5, NR1I2, TRPM3","cardiology","vasospastic angina, chronic stable angina","COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2815","nifenalol","adrenergic receptor antagonist","ADRB1, ADRB2",NA,NA,"CC(C)NC[C@@H](O)c1ccc(cc1)[N+]([O-])=O |&1:5,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0
"2816","niflumic-acid","cyclooxygenase inhibitor","ANO1, CLCN1, CLCNKA, CLCNKB, KCNQ1, PLA2G1B, PLA2G4A, PTGS1, PTGS2, UGT1A9","rheumatology, neurology/psychiatry","joint pain, muscle pain","OC(=O)c1cccnc1Nc1cccc(c1)C(F)(F)F, OC(=O)c1cccnc1Nc1cccc(c1)C(F)(F)F, OC(=O)c1cccnc1Nc1cccc(c1)C(F)(F)F","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2817","niguldipine-(S)-(+)","adrenergic receptor antagonist","ADRA1A",NA,NA,"COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
"2818","nilotinib","Abl kinase inhibitor, Bcr-Abl kinase inhibitor","ABL1, KIT","hematologic malignancy","chronic myeloid leukemia (CML)","Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)cc(c1)C(F)(F)F, Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)cc(c1)C(F)(F)F","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2819","nilutamide","androgen receptor antagonist","AR","oncology","prostate cancer","CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2820","nilvadipine","calcium channel blocker","CACNA1C, CACNA1D","cardiology","hypertension, cerebral artery occlusion","COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10,r,c:8,t:4|, COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10,r,c:8,t:4|, COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10,r,c:8,t:4|, COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10,r,c:8,t:4|, COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10,r,c:8,t:4|, COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10,r,c:8,t:4|, COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10,r,c:8,t:4|, COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10,r,c:8,t:4|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2821","nimesulide","cyclooxygenase inhibitor","LTF, PLA2G2E, PTGS1, PTGS2","rheumatology, obstetrics/gynecology","osteoarthritis, menstrual pain","CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O, CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O, CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O, CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O, CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O, CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2822","nimodipine","calcium channel blocker","CFTR, NR3C2","hematology","hemorrhage","COCCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C |r,c:7,12|, COCCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C |r,c:7,12|, COCCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C |r,c:7,12|, COCCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C |r,c:7,12|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2823","nintedanib","FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB","pulmonary","idiopathic pulmonary fibrosis (IPF)","COC(=O)c1ccc2\C(=C(\Nc3ccc(cc3)N(C)C(=O)CN3CCN(C)CC3)c3ccccc3)C(=O)Nc2c1, COC(=O)c1ccc2\C(=C(\Nc3ccc(cc3)N(C)C(=O)CN3CCN(C)CC3)c3ccccc3)C(=O)Nc2c1, COC(=O)c1ccc2\C(=C(\Nc3ccc(cc3)N(C)C(=O)CN3CCN(C)CC3)c3ccccc3)C(=O)Nc2c1, COC(=O)c1ccc2\C(=C(\Nc3ccc(cc3)N(C)C(=O)CN3CCN(C)CC3)c3ccccc3)C(=O)Nc2c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2824","niraparib","PARP inhibitor","PARP1","oncology","primary peritoneal cancer (PPC)","NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2825","nisoldipine","calcium channel blocker","A1BG, CACNA1C, CACNA1D, CACNA1F, CACNA1S","cardiology","hypertension","COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |c:4,9|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2826","nisoxetine","norepinephrine reuptake inhibitor","SLC6A2, SLC6A3, SLC6A4",NA,NA,"CNCC[C@@H](Oc1ccccc1OC)c1ccccc1 |&1:4,r|","Phase 1",1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2827","nitecapone","catechol O methyltransferase inhibitor","COMT",NA,NA,"CC(=O)C(=Cc1cc(O)c(O)c(c1)[N+]([O-])=O)C(C)=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2828","nitrendipine","calcium channel blocker","CACNA1D, CACNA2D1, KCNN4","cardiology","hypertension","CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |r,c:5,10|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2829","nitrocaramiphen","cholinergic receptor antagonist","CHRM1",NA,NA,"CCN(CC)CCOC(=O)C1(CCCC1)c1ccc(cc1)[N+]([O-])=O, CCN(CC)CCOC(=O)C1(CCCC1)c1ccc(cc1)[N+]([O-])=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
"2830","nitroxoline","cathepsin inhibitor","METAP2","infectious disease","urinary tract infections","Oc1ccc([N+]([O-])=O)c2cccnc12, Oc1ccc([N+]([O-])=O)c2cccnc12, Oc1ccc([N+]([O-])=O)c2cccnc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2831","nizatidine","histamine receptor antagonist","HRH2","gastroenterology","duodenal ulcer disease, erosive esophagitis (EE), ulcerative esophagitis (UE), gastroesophageal reflux disease (GERD)","CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O, CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O, CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O, CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O, CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O, CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"2832","NK-252","nuclear factor erythroid derived, like (NRF2) activator","NFE2L2",NA,NA,"O=C(NCc1ccccn1)Nc1nnc(o1)-c1ccco1, O=C(NCc1ccccn1)Nc1nnc(o1)-c1ccco1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2833","NKY-80","adenylyl cyclase inhibitor","ADCY5",NA,NA,"Nc1ncc2C(=O)C[C@@H](Cc2n1)c1ccco1 |&1:8,r|, Nc1ncc2C(=O)C[C@@H](Cc2n1)c1ccco1 |&1:8,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2834","NLG919","indoleamine 2,3-dioxygenase inhibitor","IDO1",NA,NA,"O[C@@H](C[C@H]1c2ccccc2-c2cncn12)C1CCCCC1 |&1:1,&2:3,r|, O[C@@H](C[C@H]1c2ccccc2-c2cncn12)C1CCCCC1 |&1:1,&2:3,r|, O[C@@H](C[C@H]1c2ccccc2-c2cncn12)C1CCCCC1 |&1:1,&2:3,r|, O[C@@H](C[C@H]1c2ccccc2-c2cncn12)C1CCCCC1 |&1:1,&2:3,r|, O[C@@H](C[C@H]1c2ccccc2-c2cncn12)C1CCCCC1 |&1:1,&2:3,r|, O[C@@H](C[C@H]1c2ccccc2-c2cncn12)C1CCCCC1 |&1:1,&2:3,r|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2835","NMDA","glutamate receptor agonist","GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,"CN[C@H](CC(O)=O)C(O)=O, CN[C@H](CC(O)=O)C(O)=O, CN[C@H](CC(O)=O)C(O)=O, CN[C@H](CC(O)=O)C(O)=O, CN[C@H](CC(O)=O)C(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2836","NMS-1286937","PLK inhibitor","FLT3, PLK1, PLK2, PLK3",NA,NA,"CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2837","NMS-873","ATPase inhibitor","VCP",NA,NA,"Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O, Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2838","NN-DNJ","glucosidase inhibitor","GBA",NA,NA,"CCCCCCCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2839","NNC-05-2090","GABA uptake inhibitor, GAT inhibitor","SLC6A12",NA,NA,"COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1","Preclinical",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2840","NNC-55-0396","T-type calcium channel blocker","CATSPER1, CATSPER2, CATSPER3, CATSPER4",NA,NA,"CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2841","NNC-63-0532","opioid receptor agonist","OPRL1",NA,NA,"COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O, COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O, COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O, COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O, COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O, COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2842","NNC-711","GABA uptake inhibitor","SIGMAR1, SLC6A1",NA,NA,"OC(=O)C1=CCCN(CCON=C(c2ccccc2)c2ccccc2)C1 |t:3|, OC(=O)C1=CCCN(CCON=C(c2ccccc2)c2ccccc2)C1 |t:3|, OC(=O)C1=CCCN(CCON=C(c2ccccc2)c2ccccc2)C1 |t:3|","Preclinical",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2843","NO-ASA","cyclooxygenase inhibitor","PTGS2",NA,NA,"CC(=O)Oc1ccccc1C(=O)Oc1cccc(CO[N+]([O-])=O)c1, CC(=O)Oc1ccccc1C(=O)Oc1cccc(CO[N+]([O-])=O)c1","Phase 2",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2844","nobiletin","MEK inhibitor","MAP2K1",NA,NA,"COc1ccc(cc1OC)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1, COc1ccc(cc1OC)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2845","nocodazole","tubulin polymerization inhibitor","HPGDS",NA,NA,"COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1cccs1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2846","nolatrexed","thymidylate synthase inhibitor","TYMS",NA,NA,"Cc1ccc2[nH]c(N)nc(=O)c2c1Sc1ccncc1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2847","nomegestrol-acetate","progesterone receptor agonist","PGR","endocrinology","contraceptive","CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O |t:9,12|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2848","nomifensine","dopamine reuptake inhibitor, noradrenaline uptake inhibitor","DRD2, SLC6A2, SLC6A3","Antidepressant","depression","CN1C[C@@H](c2ccccc2)c2cccc(N)c2C1 |&1:3|, CN1C[C@@H](c2ccccc2)c2cccc(N)c2C1 |&1:3|, CN1C[C@@H](c2ccccc2)c2cccc(N)c2C1 |&1:3|, CN1C[C@@H](c2ccccc2)c2cccc(N)c2C1 |&1:3|, CN1C[C@@H](c2ccccc2)c2cccc(N)c2C1 |&1:3,r|","Launched",1,2,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1
"2849","nonivamide","TRPV agonist","TRPV1","rheumatology, neurology/psychiatry","rheumatoid arthritis, muscle pain","CCCCCCCCC(=O)NCc1ccc(O)c(OC)c1, CCCCCCCCC(=O)NCc1ccc(O)c(OC)c1, CCCCCCCCC(=O)NCc1ccc(O)c(OC)c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2850","nor-binaltorphimine","opioid receptor antagonist","OPRD1, OPRK1, OPRM1",NA,NA,"Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2[C@@H]4Oc6c7c(C[C@H]8N(CC9CC9)CC[C@@]47[C@@]8(O)Cc2c1C[C@@]35O)ccc6O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2[C@@H]4Oc6c7c(C[C@H]8N(CC9CC9)CC[C@@]47[C@@]8(O)Cc2c1C[C@@]35O)ccc6O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2[C@@H]4Oc6c7c(C[C@H]8N(CC9CC9)CC[C@@]47[C@@]8(O)Cc2c1C[C@@]35O)ccc6O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2851","norepinephrine","adrenergic receptor agonist","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, SLC18A1, SLC18A2","cardiology, allergy, neurology/psychiatry","hypertension, urticaria, headache, seasonal affective disorder","NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1","Launched",1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,9,1,1,1,1
"2852","norethindrone","progesterone receptor agonist","PGR","obstetrics/gynecology","endometriosis","C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2853","norethindrone-acetate","progesterone receptor agonist","PGR","endocrinology, orthopedics, obstetrics/gynecology","menopause, osteoporosis, vaginal atrophy","CC(=O)O[C@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C#C |t:11|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2854","noretynodrel","progestogen hormone","PGR","endocrinology","contraceptive","C[C@]12CC[C@H]3[C@@H](CCC4=C3CCC(=O)C4)[C@@H]1CC[C@@]2(O)C#C |a:1,18,&1:4,&2:5,&3:15,c:8|, C[C@]12CC[C@H]3[C@@H](CCC4=C3CCC(=O)C4)[C@@H]1CC[C@@]2(O)C#C |a:1,18,&1:4,&2:5,&3:15,c:8|, C[C@]12CC[C@H]3[C@@H](CCC4=C3CCC(=O)C4)[C@@H]1CC[C@@]2(O)C#C |a:1,18,&1:4,&2:5,&3:15,c:8|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2855","norfloxacin","bacterial DNA gyrase inhibitor","TOP2A","infectious disease, urology","urinary tract infections, gonorrhea, prostatitis","CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2856","norfluoxetine","selective serotonin reuptake inhibitor (SSRI)","HTR2B",NA,NA,"NCC[C@@H](Oc1ccc(cc1)C(F)(F)F)c1ccccc1 |&1:3,r|, NCC[C@@H](Oc1ccc(cc1)C(F)(F)F)c1ccccc1 |&1:3,r|","Phase 1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2857","norgestimate","progesterone receptor agonist","ESR1, PGR","endocrinology","contraceptive","CC[C@]12CC[C@H]3[C@@H](CCC4=C\C(CC[C@H]34)=N\O)[C@@H]1CC[C@@]2(OC(C)=O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=C\C(CC[C@H]34)=N\O)[C@@H]1CC[C@@]2(OC(C)=O)C#C |t:9|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2858","norgestrel","progesterone receptor agonist","AR, ESR1, PGR, SRD5A1","endocrinology","contraceptive","CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |a:2,6,15,16,19,&1:5,t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |a:2,6,15,16,19,&1:5,t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |a:2,6,15,16,19,&1:5,t:9|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2859","nortriptyline","tricyclic antidepressant","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR6, KCNJ10, PGRMC1, SIGMAR1, SLC6A2, SLC6A4","neurology/psychiatry","depression","CNCCC=C1c2ccccc2CCc2ccccc12, CNCCC=C1c2ccccc2CCc2ccccc12","Launched",1,2,0,0,0,0,0,0,1,4,1,1,0,0,1,1,1,5,1,9,1,1,1,1
"2860","noscapine","bradykinin receptor antagonist, tubulin polymerization inhibitor","SIGMAR1","pulmonary","cough suppressant","COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12, COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12, COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12, COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12, COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2861","NPC-15199","ICAM1 antagonist","PPARG",NA,NA,"CC(C)C[C@@H](NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O, CC(C)C[C@@H](NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2862","NPPB","chloride channel blocker","ANO1, CLCN2, CLCN7, TRPA1",NA,NA,"OC(=O)c1cc(ccc1NCCCc1ccccc1)[N+]([O-])=O, OC(=O)c1cc(ccc1NCCCc1ccccc1)[N+]([O-])=O, OC(=O)c1cc(ccc1NCCCc1ccccc1)[N+]([O-])=O, OC(=O)c1cc(ccc1NCCCc1ccccc1)[N+]([O-])=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2863","NPS-2143","calcium receptor antagonist","CASR",NA,NA,"CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N, CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N, CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N, CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N, CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N, CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N, CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2864","NPY-5RA972","neuropeptide receptor antagonist","NPY5R",NA,NA,"CC(C)n1c2ccccc2c2c(C)c(NC(=O)N3CCOCC3)ccc12, CC(C)n1c2ccccc2c2c(C)c(NC(=O)N3CCOCC3)ccc12, CC(C)n1c2ccccc2c2c(C)c(NC(=O)N3CCOCC3)ccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2865","NQDI-1","caspase inhibitor","CASP3",NA,NA,"CCOC(=O)c1c2-c3ccccc3C(=O)c3cccc([nH]c1=O)c23, CCOC(=O)c1c2-c3ccccc3C(=O)c3cccc([nH]c1=O)c23","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2866","nrc-2694","anticancer agent","EGFR","oncology","non-small cell lung cancer (nsclc)","COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCN1CCOCC1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2867","NS-018","JAK inhibitor","JAK1, JAK2, JAK3, TYK2",NA,NA,"C[C@H](Nc1cc(cc(Nc2cnccn2)n1)-c1cnn(C)c1)c1ccc(F)cc1, C[C@H](Nc1cc(cc(Nc2cnccn2)n1)-c1cnn(C)c1)c1ccc(F)cc1, C[C@H](Nc1cc(cc(Nc2cnccn2)n1)-c1cnn(C)c1)c1ccc(F)cc1, C[C@H](Nc1cc(cc(Nc2cnccn2)n1)-c1cnn(C)c1)c1ccc(F)cc1","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2868","NS-11021","calcium-activated potassium channel activator","KCNMA1",NA,NA,"FC(F)(F)c1cc(NC(=S)Nc2ccc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F, FC(F)(F)c1cc(NC(=S)Nc2ccc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2869","NS-1643","voltage-gated potassium channel activator","KCNH2, KCNH6, KCNMA1",NA,NA,"Oc1ccc(cc1NC(=O)Nc1cc(ccc1O)C(F)(F)F)C(F)(F)F, Oc1ccc(cc1NC(=O)Nc1cc(ccc1O)C(F)(F)F)C(F)(F)F, Oc1ccc(cc1NC(=O)Nc1cc(ccc1O)C(F)(F)F)C(F)(F)F, Oc1ccc(cc1NC(=O)Nc1cc(ccc1O)C(F)(F)F)C(F)(F)F, Oc1ccc(cc1NC(=O)Nc1cc(ccc1O)C(F)(F)F)C(F)(F)F, Oc1ccc(cc1NC(=O)Nc1cc(ccc1O)C(F)(F)F)C(F)(F)F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2870","NS-19504","calcium-activated potassium channel activator","KCNMA1",NA,NA,"Nc1ncc(Cc2ccc(Br)cc2)s1, Nc1ncc(Cc2ccc(Br)cc2)s1, Nc1ncc(Cc2ccc(Br)cc2)s1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2871","NS-309","calcium-activated potassium channel activator","KCNN1, KCNN2, KCNN3, KCNN4",NA,NA,"O\N=C1/C(=O)Nc2c1ccc(Cl)c2Cl","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2872","NS-3623","voltage-gated potassium channel activator","KCNH2",NA,NA,"FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1, FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1, FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1, FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1, FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1, FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1, FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2873","NS-3861","acetylcholine receptor agonist","CHRNA3, CHRNB4",NA,NA,"CN1[C@@H]2CC[C@H]1C=C(C2)c1sccc1Br |&1:2,5,c:7|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0
"2874","NS-5806","voltage-gated potassium channel activator","KCND3",NA,NA,"FC(F)(F)c1cc(NC(=O)Nc2c(Br)cc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F, FC(F)(F)c1cc(NC(=O)Nc2c(Br)cc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F, FC(F)(F)c1cc(NC(=O)Nc2c(Br)cc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2875","NS-8","potassium channel agonist","KCNMA1",NA,NA,"Cc1c([nH]c(N)c1C#N)-c1ccccc1F","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2876","NS-8593","calcium-activated potassium channel modulator","KCNN1, KCNN2, KCNN3",NA,NA,"C1C[C@@H](Nc2nc3ccccc3[nH]2)c2ccccc2C1, C1C[C@@H](Nc2nc3ccccc3[nH]2)c2ccccc2C1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2877","NS-9283","acetylcholine receptor allosteric modulator","CHRNA4",NA,NA,"N#Cc1cccc(c1)-c1nc(no1)-c1cccnc1, N#Cc1cccc(c1)-c1nc(no1)-c1cccnc1, N#Cc1cccc(c1)-c1nc(no1)-c1cccnc1, N#Cc1cccc(c1)-c1nc(no1)-c1cccnc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
"2878","NSC-3852","HDAC inhibitor","HDAC1",NA,NA,"Oc1ccc(N=O)c2cccnc12, Oc1ccc(N=O)c2cccnc12, Oc1ccc(N=O)c2cccnc12, Oc1ccc(N=O)c2cccnc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2879","NSC-405020","matrix metalloprotease inhibitor","MMP1",NA,NA,"CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:3,r|, CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:3,r|, CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:3,r|, CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:3,r|, CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:3,r|, CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:3,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2880","NSC-4644","ACAT inhibitor, sterol regulatory element binding protein (SREBP) inhibitor","PYGM",NA,NA,"CC(=C)[C@@H]1CC[C@]2(CO)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12, CC(=C)[C@@H]1CC[C@]2(CO)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2881","NSC-5844","CC chemokine receptor agonist","CCR1",NA,NA,"Clc1ccc2c(NCCNc3ccnc4cc(Cl)ccc34)ccnc2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2882","NSC-625987","CDK inhibitor","CDK2, CDK4",NA,NA,"COc1ccc(OC)c2c1[nH]c1ccccc1c2=S","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2883","NSC-632839","ubiquitin specific protease inhibitor","SENP2, USP1, USP2, USP7",NA,NA,"Cc1ccc(\C=C2/CNC\C(=C/c3ccc(C)cc3)C2=O)cc1, Cc1ccc(\C=C2/CNC\C(=C/c3ccc(C)cc3)C2=O)cc1, Cc1ccc(\C=C2/CNC\C(=C/c3ccc(C)cc3)C2=O)cc1, Cc1ccc(\C=C2/CNC\C(=C/c3ccc(C)cc3)C2=O)cc1, Cc1ccc(\C=C2/CNC\C(=C/c3ccc(C)cc3)C2=O)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2884","NSC-636819","histone demethylase inhibitor","KDM4A, KDM4B",NA,NA,"[O-][N+](=O)c1cc(c(\C=C\c2ccc(Cl)c(Cl)c2)cc1\C=C\c1ccc(Cl)c(Cl)c1)[N+]([O-])=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2885","NSC-663284","CDC inhibitor","CDC25A, CDC25B, CDC25C",NA,NA,"ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2886","NSC-697923","ubiquitin-conjugating enzyme inhibitor","UBE2N",NA,NA,"Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O, Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O, Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O, Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O, Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2887","NSC-95397","CDC inhibitor","CDC25A, CDC25B",NA,NA,"OCCSC1=C(SCCO)C(=O)c2ccccc2C1=O |c:4|, OCCSC1=C(SCCO)C(=O)c2ccccc2C1=O |c:4|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2888","NSC-9965","acetylcholine receptor antagonist","CHRNA4, CHRNB2",NA,NA,"CO[C@H]1CC=C2CCN3CCC4=C(CC(=O)OC4)[C@]23C1 |t:4,11|, CO[C@H]1CC=C2CCN3CCC4=C(CC(=O)OC4)[C@]23C1 |t:4,11|, CO[C@H]1CC=C2CCN3CCC4=C(CC(=O)OC4)[C@]23C1 |t:4,11|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0
"2889","NTNCB","neuropeptide receptor antagonist","NPY5R",NA,NA,"[O-][N+](=O)c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNC[C@H]2CCc3ccccc3C2)CC1 |a:14,17,&1:21|, [O-][N+](=O)c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNC[C@H]2CCc3ccccc3C2)CC1 |a:14,17,&1:21|, [O-][N+](=O)c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNC[C@H]2CCc3ccccc3C2)CC1 |a:14,17,&1:21|, [O-][N+](=O)c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNC[C@H]2CCc3ccccc3C2)CC1 |a:14,17,&1:21|, [O-][N+](=O)c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNC[C@H]2CCc3ccccc3C2)CC1 |a:14,17,&1:21|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2890","NTRC-824","neurotensin receptor antagonist","NTSR2",NA,NA,"CC(C)C[C@H](NC(=O)Cn1cc(C(=O)C(F)(F)F)c2cc(NS(=O)(=O)c3ccc(C)cc3)ccc12)C(O)=O, CC(C)C[C@H](NC(=O)Cn1cc(C(=O)C(F)(F)F)c2cc(NS(=O)(=O)c3ccc(C)cc3)ccc12)C(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2891","nTZDpa","PPAR receptor agonist","PPARG",NA,NA,"OC(=O)c1c(Sc2ccccc2)c2cc(Cl)ccc2n1Cc1ccc(Cl)cc1, OC(=O)c1c(Sc2ccccc2)c2cc(Cl)ccc2n1Cc1ccc(Cl)cc1, OC(=O)c1c(Sc2ccccc2)c2cc(Cl)ccc2n1Cc1ccc(Cl)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2892","NT157","IGF-1 inhibitor","IGF1R",NA,NA,"Oc1cc(CNC(=S)\C=C\c2cc(O)c(O)c(Br)c2)cc(O)c1O, Oc1cc(CNC(=S)\C=C\c2cc(O)c(O)c(Br)c2)cc(O)c1O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2893","NU-1025","PARP inhibitor","PARP1",NA,NA,"Cc1nc(=O)c2cccc(O)c2[nH]1, Cc1nc(=O)c2cccc(O)c2[nH]1, Cc1nc(=O)c2cccc(O)c2[nH]1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2894","NU-2058","cyclin D inhibitor","CCNA2, CDK2",NA,NA,"Nc1nc(OCC2CCCCC2)c2[nH]cnc2n1, Nc1nc(OCC2CCCCC2)c2[nH]cnc2n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2895","NU-6027","CDK inhibitor","CCNA2, CDK2",NA,NA,"Nc1nc(N)c(N=O)c(OCC2CCCCC2)n1, Nc1nc(N)c(N=O)c(OCC2CCCCC2)n1, Nc1nc(N)c(N=O)c(OCC2CCCCC2)n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2896","NU-7026","DNA dependent protein kinase inhibitor, mTOR inhibitor, PI3K inhibitor","PRKDC",NA,NA,"O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1, O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1, O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1, O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1, O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2897","NU-7441","DNA dependent protein kinase inhibitor","PRKDC",NA,NA,"O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2898","nutlin-3","MDM inhibitor","MDM2, TP53",NA,NA,"COc1ccc(C2=N[C@H]([C@H](N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1 |&1:8,9,r,t:6|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2899","NVP-ADW742","insulin growth factor receptor inhibitor","IGF1R",NA,NA,"Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2900","NVP-AEW541","IGF-1 inhibitor","IGF1R, INSR",NA,NA,"Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1 |r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2901","NVP-AUY922","HSP inhibitor","HSP90AA1, HSP90AB1",NA,NA,"CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2902","NVP-BEZ235","mTOR inhibitor, PI3K inhibitor","ATR, MTOR, PIK3CA, PIK3CD, PIK3CG",NA,NA,"Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2903","NVP-BGJ398","FGFR inhibitor","FGFR1, FGFR2, FGFR3, FGFR4, KDR",NA,NA,"CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1, CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1, CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1, CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1, CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1, CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2904","NVP-BHG712","ephrin inhibitor","EPHB4",NA,NA,"Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2905","NVP-BSK805","JAK inhibitor","JAK2",NA,NA,"Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1, Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1, Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1, Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1, Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1, Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2906","NVP-BVU972","MET inhibitor","MET",NA,NA,"Cn1cc(cn1)-c1ccc2ncc(Cc3ccc4ncccc4c3)n2n1, Cn1cc(cn1)-c1ccc2ncc(Cc3ccc4ncccc4c3)n2n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2907","NVP-DPP728","dipeptidyl peptidase inhibitor","DPP4",NA,NA,"O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N, O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N, O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N, O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N, O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N, O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2908","NVP-HSP990","HSP inhibitor","HSP90AA1, HSP90AB1",NA,NA,"COc1cccc(n1)-c1cc(F)ccc1[C@H]1Cc2nc(N)nc(C)c2C(=O)N1, COc1cccc(n1)-c1cc(F)ccc1[C@H]1Cc2nc(N)nc(C)c2C(=O)N1, COc1cccc(n1)-c1cc(F)ccc1[C@H]1Cc2nc(N)nc(C)c2C(=O)N1, COc1cccc(n1)-c1cc(F)ccc1[C@H]1Cc2nc(N)nc(C)c2C(=O)N1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2909","NVP-TAE226","protein tyrosine kinase inhibitor","PTK2",NA,NA,"CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2910","NVP-TAE684","ALK tyrosine kinase receptor inhibitor","ALK, INSR",NA,NA,"COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2911","NVP-TNKS656","tankyrase inhibitor","TNKS2",NA,NA,"COc1ccc(cc1)C(=O)C1CCN(CC(=O)N(CC2CC2)Cc2nc(=O)c3COCCc3[nH]2)CC1, COc1ccc(cc1)C(=O)C1CCN(CC(=O)N(CC2CC2)Cc2nc(=O)c3COCCc3[nH]2)CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2912","NVP-231","ceramidase inhibitor","CERK",NA,NA,"O=C(Nc1nc2ccc(NC(=O)C34CC5CC(CC(C5)C3)C4)cc2s1)c1ccccc1, O=C(Nc1nc2ccc(NC(=O)C34CC5CC(CC(C5)C3)C4)cc2s1)c1ccccc1, O=C(Nc1nc2ccc(NC(=O)C34CC5CC(CC(C5)C3)C4)cc2s1)c1ccccc1, O=C(Nc1nc2ccc(NC(=O)C34CC5CC(CC(C5)C3)C4)cc2s1)c1ccccc1, O=C(Nc1nc2ccc(NC(=O)C34CC5CC(CC(C5)C3)C4)cc2s1)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2913","NVS-PAK1-1","p21 activated kinase inhibitor","PAK1",NA,NA,"CC(C)NC(=O)N1CC[C@@H](C1)NC1=Nc2cc(F)ccc2N(CC(F)F)c2ccc(Cl)cc12 |t:13|, CC(C)NC(=O)N1CC[C@@H](C1)NC1=Nc2cc(F)ccc2N(CC(F)F)c2ccc(Cl)cc12 |t:13|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2914","N6-cyclopentyladenosine","adenosine receptor agonist","ADORA1, ADORA2A, ADORA2B, ADORA3, SLC29A1",NA,NA,"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)ncnc12","Preclinical",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2915","N6022","alcohol dehydrogenase inhibitor","ADH5",NA,NA,"Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O, Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O, Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O, Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O, Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O, Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2916","OAC2","Oct activator","POU5F1",NA,NA,"O=C(Nc1ccc2[nH]ccc2c1)c1ccccc1, O=C(Nc1ccc2[nH]ccc2c1)c1ccccc1, O=C(Nc1ccc2[nH]ccc2c1)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2917","obatoclax","BCL inhibitor","BCL2",NA,NA,"COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2918","obeticholic-acid","FXR agonist","NR1H4","gastroenterology","primary biliary cholangitis","CC[C@H]1[C@@H](O)[C@H]2[C@H]3CC[C@@H]([C@@H](C)CCC(O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12 |&1:2,&2:3,&3:5,&4:6,&5:9,&6:10,&7:17,&8:21,&9:22,&10:26,&11:29,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2919","obidoxime","cholinesterase reactivator","ACHE","critical care, neurology/psychiatry","poison antidote, nerve gas poisoning","O\N=C\c1cc[n+](COC[n+]2ccc(\C=N\O)cc2)cc1, O\N=C\c1cc[n+](COC[n+]2ccc(\C=N\O)cc2)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2920","ochromycinone","STAT inhibitor","STAT3",NA,NA,"C[C@@H]1CC(=O)c2c(C1)ccc1C(=O)c3c(O)cccc3C(=O)c21","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2921","ocinaplon","GABA receptor modulator","GABRA1, GABRA2, GABRA3, GABRA5",NA,NA,"O=C(c1cnn2c(ccnc12)-c1ccncc1)c1ccccn1, O=C(c1cnn2c(ccnc12)-c1ccncc1)c1ccccn1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,0,0
"2922","oclacitinib","jak inhibitor","JAK2","dermatology","dermatitis","CNS(=O)(=O)C[C@@H]1CC[C@H](CC1)N(C)c2[nH]cnc3nccc23","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2923","octopamine","trace amine associated receptor agonist, neurotransmitter","ADRA2A, ADRA2B, ADRA2C, F10, TAAR1",NA,NA,"NC[C@@H](O)c1ccc(O)cc1 |&1:2,r|, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0
"2924","octreotide","somatostatin receptor agonist","SSTR2, SSTR3, SSTR5","gastroenterology, endocrinology, oncology","diarrhea, acromegaly, carcinoid tumors","C[C@@H](O)[C@@H](CO)NC(=O)[C@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 |&1:1,&2:3,&3:9,&4:14,&5:18,&6:30,&7:41,&8:55,&9:64,&10:65|, C[C@@H](O)[C@@H](CO)NC(=O)[C@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 |&1:1,&2:3,&3:9,&4:14,&5:18,&6:30,&7:41,&8:55,&9:64,&10:65|, C[C@@H](O)[C@@H](CO)NC(=O)[C@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 |&1:1,&2:3,&3:9,&4:14,&5:18,&6:30,&7:41,&8:55,&9:64,&10:65|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2925","OC000459","CRTH receptor antagonist","PTGDR2",NA,NA,"Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(O)=O, Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(O)=O, Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(O)=O, Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(O)=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2926","odanacatib","cathepsin inhibitor","CTSK",NA,NA,"CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N, CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N, CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N, CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2927","odm-203","fgfr inhibitor","FGFR1, FLT1","oncology","breast cancer","Cn1cc(cn1)c2ccc3c(c2)ncn3c4cc(NS(=O)(=O)C5CC5)cc(c4)c6ccc(F)cc6F","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2928","ODQ","guanylyl cyclase inhibitor","GUCY1A2, GUCY1A3, GUCY1B3",NA,NA,"O=c1onc2cnc3ccccc3n12, O=c1onc2cnc3ccccc3n12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2929","OF-1","bromodomain inhibitor","BRD1",NA,NA,"COc1cc2n(C)c(=O)n(C)c2cc1NS(=O)(=O)c1ccc(Br)cc1C, COc1cc2n(C)c(=O)n(C)c2cc1NS(=O)(=O)c1ccc(Br)cc1C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2930","OG-L002","histone lysine demethylase inhibitor","KDM1A",NA,NA,"N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1, N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1, N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1, N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1, N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1, N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2931","OICR-9429","WDR5/MLL interaction inhibitor","WDR5",NA,NA,"CN1CCN(CC1)c1ccc(cc1NC(=O)c1c[nH]c(=O)cc1C(F)(F)F)-c1cccc(CN2CCOCC2)c1, CN1CCN(CC1)c1ccc(cc1NC(=O)c1c[nH]c(=O)cc1C(F)(F)F)-c1cccc(CN2CCOCC2)c1, CN1CCN(CC1)c1ccc(cc1NC(=O)c1c[nH]c(=O)cc1C(F)(F)F)-c1cccc(CN2CCOCC2)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2932","olanzapine","dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, HRH1, HRH2, HRH4, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR5A, HTR6, HTR7","neurology/psychiatry","schizophrenia, bipolar disorder","CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12 |t:8|, CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12 |t:8|, CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12 |t:8|, CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12 |t:8|, CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12 |t:8|, CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12 |t:8|","Launched",0,0,0,0,0,0,0,0,1,12,1,3,1,16,1,5,1,5,1,8,1,1,1,1
"2933","olaparib","PARP inhibitor","PARP1, PARP2","oncology","ovarian cancer","Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2934","OLDA","TRPV agonist","GPR119",NA,NA,"CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2935","oleamide","cannabinoid receptor agonist","HTR7, PLA2G2A",NA,NA,"CCCCCCCC\C=C/CCCCCCCC(N)=O, CCCCCCCC\C=C/CCCCCCCC(N)=O, CCCCCCCC\C=C/CCCCCCCC(N)=O","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2936","oleanolic-acid","G protein-coupled receptor agonist","GPBAR1",NA,NA,"CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O |c:10|, CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O |c:10|, CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O |c:10|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2937","oleoylethanolamide","cannabinoid receptor agonist, glucose dependent insulinotropic receptor agonist, potassium channel blocker, PPAR receptor agonist","CNR1, GPR119, GPR55, PPARA",NA,NA,"CCCCCCCC\C=C/CCCCCCCC(=O)NCCO, CCCCCCCC\C=C/CCCCCCCC(=O)NCCO","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2938","oleuropein","estrogen receptor agonist, antioxidant","GPER1","null","fungal infection","COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)\C(=C\C)[C@@H]1CC(=O)OCCc1ccc(O)c(O)c1 |t:4|, COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@@H](O)[C@@H](O)[C@@H]2O)\C(=C/C)[C@@H]1CC(=O)OCCc1ccc(O)c(O)c1 |&1:7,&2:9,&3:11,&4:14,&5:16,&6:18,&7:23,r,t:4|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2939","oligomycin-A","ATP synthase inhibitor, ATPase inhibitor","ATP5A1",NA,NA,"[H][C@]12CC[C@@H](CC)\C=C\C=C\C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)\C=C\C(=O)O[C@]([H])([C@@H]1C)[C@H](C)[C@@]1(CC[C@H](C)[C@H](C[C@@H](C)O)O1)O2 |t:7,9,35|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2940","olinciguat","guanylyl cyclase activator","GUCY1A1, GUCY1A2","hematology","anemia","FC1=C(C=CC=C1)CN2C(C3=NOC=C3)=CC(C4=NC=C(F)C(NC[C@](C(N)=O)(O)C(F)(F)F)=N4)=N2","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2941","olmesartan","angiotensin receptor antagonist","AGTR1","cardiology","hypertension","CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2942","olmesartan-medoxomil","angiotensin receptor antagonist","AGTR1","cardiology","hypertension","CCCc1nc(c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2943","olmutinib","Bruton's tyrosine kinase (BTK) inhibitor, EGFR inhibitor","BTK, EGFR","oncology","non-small cell lung cancer (NSCLC)","CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3sccc3n2)cc1, CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3sccc3n2)cc1, CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3sccc3n2)cc1, CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3sccc3n2)cc1, CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3sccc3n2)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2944","olomoucine","CDK inhibitor","CDK1, CDK2, CDK5, MAPK1",NA,NA,"Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc12, Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2945","olopatadine","histamine receptor antagonist","HRH1, S100A1, S100A12, S100A13, S100A2, S100B","ophthalmology","conjunctivitis","CN(C)CC\C=C1\c2ccccc2COc2ccc(CC(O)=O)cc12, CN(C)CC\C=C1\c2ccccc2COc2ccc(CC(O)=O)cc12, CN(C)CC\C=C1\c2ccccc2COc2ccc(CC(O)=O)cc12, CN(C)CC\C=C1\c2ccccc2COc2ccc(CC(O)=O)cc12","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"2946","olprinone","phosphodiesterase inhibitor","PDE3A","cardiology","congestive heart failure","Cc1[nH]c(=O)c(cc1-c1ccc2nccn2c1)C#N, Cc1[nH]c(=O)c(cc1-c1ccc2nccn2c1)C#N, Cc1[nH]c(=O)c(cc1-c1ccc2nccn2c1)C#N, Cc1[nH]c(=O)c(cc1-c1ccc2nccn2c1)C#N","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2947","olsalazine","cyclooxygenase inhibitor","IFNG, TPMT","gastroenterology","ulcerative colitis","OC(=O)c1cc(ccc1O)\N=N\c1ccc(O)c(c1)C(O)=O, OC(=O)c1cc(ccc1O)\N=N\c1ccc(O)c(c1)C(O)=O, OC(=O)c1cc(ccc1O)\N=N\c1ccc(O)c(c1)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2948","oltipraz","nuclear factor erythroid derived, like (NRF2) activator","ANG",NA,NA,"Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2949","olutasidenib","isocitrate dehydrogenase inhibitor","IDH1","oncology","glioma","C[C@H](Nc1ccc(C#N)n(C)c1=O)c1cc2cc(Cl)ccc2[nH]c1=O","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2950","olvanil","TRPV agonist","CNR1, GPR119, TRPV1",NA,NA,"CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2951","omapatrilat","metalloproteinase inhibitor","ACE, MME",NA,NA,"[H][C@]12CCC[C@H](N1C(=O)[C@H](CCS2)NC(=O)[C@@H](S)Cc1ccccc1)C(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2952","omarigliptin","dipeptidyl peptidase inhibitor","DPP4","endocrinology","diabetes mellitus","CS(=O)(=O)n1cc2CN(Cc2n1)[C@H]1CO[C@@H]([C@@H](N)C1)c1cc(F)ccc1F, CS(=O)(=O)n1cc2CN(Cc2n1)[C@H]1CO[C@@H]([C@@H](N)C1)c1cc(F)ccc1F, CS(=O)(=O)n1cc2CN(Cc2n1)[C@H]1CO[C@@H]([C@@H](N)C1)c1cc(F)ccc1F, CS(=O)(=O)n1cc2CN(Cc2n1)[C@H]1CO[C@@H]([C@@H](N)C1)c1cc(F)ccc1F","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2953","OMDM-2","FAAH inhibitor","GPR119",NA,NA,"CCCCCCCC\C=C/CCCCCCCC(=O)N[C@@H](CO)Cc1ccc(O)cc1, CCCCCCCC\C=C/CCCCCCCC(=O)N[C@@H](CO)Cc1ccc(O)cc1, CCCCCCCC\C=C/CCCCCCCC(=O)N[C@@H](CO)Cc1ccc(O)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2954","omecamtiv-mecarbil","cardiac myosin activator","MYBPC3",NA,NA,"COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1, COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1, COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2955","omeprazole","ATPase inhibitor","ATP4A, CLCN2","gastroenterology","heartburn","COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|, COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|, COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|, COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|, COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2956","omeprazole-magnesium","proton pump inhibitor","ATP4A, ATP4B","gastroenterology","gastroesophageal reflux disease (GERD), heartburn","COc1ccc2n([Mg]n3c(nc4cc(OC)ccc34)[S@@](=O)Cc3ncc(C)c(OC)c3C)c(nc2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2957","omidenepag","prostanoid receptor agonist","PTGER2","ophthalmology","intraocular pressure","CC(C)OC(=O)CNC1=CC=CC(=N1)CN(CC2=CC=C(C=C2)N3C=CC=N3)S(=O)(=O)C4=CN=CC=C4","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2958","ONC201","AKT inhibitor, MAP kinase inhibitor","TNFSF10",NA,NA,"Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O |t:10,16|, Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O |t:10,16|, Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O |t:10,16|, Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O |t:10,16|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2959","onc206","dopamine receptor antagonist","DRD2","oncology","glioblastoma","Fc1ccc(CN2C3=NCCN3C3=C(CN(Cc4ccccc4)CC3)C2=O)c(F)c1 |t:7,13|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1
"2960","ondansetron","serotonin receptor antagonist, 5-ht3 receptor antagonist","HTR3A, HTR3B, HTR3C, HTR3D, HTR3E","Alcoholism, gastroenterology","abstinence from alcohol, nausea, vomiting","Cc1nccn1C[C@H]1CCc2c(C1=O)c1ccccc1n2C |r|, Cc1nccn1C[C@H]1CCc2c(C1=O)c1ccccc1n2C |r|, Cc1nccn1CC1CCc2c(C1=O)c1ccccc1n2C","Launched",0,0,0,0,0,0,0,0,1,5,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2961","ONO-AE3-208","prostanoid receptor antagonist","PTGER4",NA,NA,"C[C@@H](C(=O)Nc1cc(ccc1CCCC(O)=O)C#N)c1ccc(F)c2ccccc12 |&1:1,r|, C[C@@H](C(=O)Nc1cc(ccc1CCCC(O)=O)C#N)c1ccc(F)c2ccccc12 |&1:1,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2962","ONO-4059","Bruton's tyrosine kinase (BTK) inhibitor","BTK",NA,NA,"CC#CC(=O)N1CC[C@H](C1)n1c2ncnc(N)c2n(-c2ccc(Oc3ccccc3)cc2)c1=O, CC#CC(=O)N1CC[C@H](C1)n1c2ncnc(N)c2n(-c2ccc(Oc3ccccc3)cc2)c1=O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2963","ONO-4817","matrix metalloprotease inhibitor","MMP8",NA,NA,"CCOCOC[C@H](C[C@H](C)C(=O)NO)NC(=O)c1ccc(Oc2ccccc2)cc1, CCOCOC[C@H](C[C@H](C)C(=O)NO)NC(=O)c1ccc(Oc2ccccc2)cc1, CCOCOC[C@H](C[C@H](C)C(=O)NO)NC(=O)c1ccc(Oc2ccccc2)cc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2964","ONO-8130","prostanoid receptor antagonist","PTGER1",NA,NA,"CC(C)CN(c1cc2CCCc2cc1OCc1ccc(cc1)C(O)=O)S(=O)(=O)c1nc(C)cs1, CC(C)CN(c1cc2CCCc2cc1OCc1ccc(cc1)C(O)=O)S(=O)(=O)c1nc(C)cs1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2965","ON123300","CDK inhibitor","CDK4, NUAK1, PDGFRB",NA,NA,"CN1CCN(CC1)c1ccc(Nc2ncc3cc(C#N)c(=O)n(C4CCCC4)c3n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc3cc(C#N)c(=O)n(C4CCCC4)c3n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc3cc(C#N)c(=O)n(C4CCCC4)c3n2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2966","opaganib","angiogenesis inhibitor","DEGS1, DEGS2, SPHK2","Cardiology","atherosclerosis","Clc1ccc(cc1)[C@]12C[C@H]3C[C@H](C[C@](C3)(C1)C(=O)NCc1ccncc1)C2","Phase 2/Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2967","OPC-21268","vasopressin receptor antagonist","AVPR1A, AVPR2, OXTR",NA,NA,"CC(=O)NCCCOc1ccc(cc1)C(=O)N1CCC(CC1)N1C(=O)CCc2ccccc12, CC(=O)NCCCOc1ccc(cc1)C(=O)N1CCC(CC1)N1C(=O)CCc2ccccc12, CC(=O)NCCCOc1ccc(cc1)C(=O)N1CCC(CC1)N1C(=O)CCc2ccccc12, CC(=O)NCCCOc1ccc(cc1)C(=O)N1CCC(CC1)N1C(=O)CCc2ccccc12, CC(=O)NCCCOc1ccc(cc1)C(=O)N1CCC(CC1)N1C(=O)CCc2ccccc12","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2968","opicapone","catechol O methyltransferase inhibitor","COMT",NA,NA,"Cc1c(Cl)c(C)[n+]([O-])c(Cl)c1-c1noc(n1)-c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1c(Cl)c(C)[n+]([O-])c(Cl)c1-c1noc(n1)-c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1c(Cl)c(C)[n+]([O-])c(Cl)c1-c1noc(n1)-c1cc(O)c(O)c(c1)[N+]([O-])=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2969","or-1896","phosphodiesterase inhibitor","PDE3A, SMPD1","cardiology","congestive heart failure","C[C@@H]1CC(=O)NN=C1c1ccc(NC(C)=O)cc1 |c:6|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2970","OR-486","catechol O methyltransferase inhibitor","COMT",NA,NA,"Oc1cc(cc(c1O)[N+]([O-])=O)[N+]([O-])=O, Oc1cc(cc(c1O)[N+]([O-])=O)[N+]([O-])=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2971","orantinib","FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","AURKA, AURKB, EGFR, FGFR1, FGFR2, KDR, PDGFRA, PDGFRB",NA,NA,"Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2972","ORE1001","angiotensin converting enzyme inhibitor","ACE2",NA,NA,"CC(C)C[C@H](N[C@@H](Cc1cncn1Cc1cc(Cl)cc(Cl)c1)C(O)=O)C(O)=O, CC(C)C[C@H](N[C@@H](Cc1cncn1Cc1cc(Cl)cc(Cl)c1)C(O)=O)C(O)=O, CC(C)C[C@H](N[C@@H](Cc1cncn1Cc1cc(Cl)cc(Cl)c1)C(O)=O)C(O)=O","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2973","ORG-12962","serotonin receptor agonist","HTR2A, HTR2B, HTR2C",NA,NA,"FC(F)(F)c1ccc(nc1Cl)N1CCNCC1, FC(F)(F)c1ccc(nc1Cl)N1CCNCC1","Phase 2",0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2974","ORG-25543","glycine transporter inhibitor","GLRB, SLC6A5",NA,NA,"COc1cc(cc(OC)c1OCc1ccccc1)C(=O)NCC1(CCCC1)N(C)C, COc1cc(cc(OC)c1OCc1ccccc1)C(=O)NCC1(CCCC1)N(C)C","Preclinical",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2975","ORG-27569","cannabinoid receptor modulator","CNR1",NA,NA,"CCc1c([nH]c2ccc(Cl)cc12)C(=O)NCCc1ccc(cc1)N1CCCCC1, CCc1c([nH]c2ccc(Cl)cc12)C(=O)NCCc1ccc(cc1)N1CCCCC1, CCc1c([nH]c2ccc(Cl)cc12)C(=O)NCCc1ccc(cc1)N1CCCCC1, CCc1c([nH]c2ccc(Cl)cc12)C(=O)NCCc1ccc(cc1)N1CCCCC1, CCc1c([nH]c2ccc(Cl)cc12)C(=O)NCCc1ccc(cc1)N1CCCCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2976","ORG-9768","adrenergic receptor antagonist","ADRA2A",NA,NA,"CC1(CN)Cc2ccccc2C1, CC1(CN)Cc2ccccc2C1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
"2977","oridonin","BCL inhibitor","BCL2",NA,NA,"[H][C@@]1(O)[C@@]2([H])CC[C@]3([H])[C@@]1(C(=O)C2=C)[C@]1(O)OC[C@]32[C@@H](O)CCC(C)(C)[C@@]2([H])[C@@H]1O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2978","orlistat","lipase inhibitor","CNR1, DAGLA, DAGLB, FASN, LIPF, PNLIP","endocrinology","weight-loss aid","CCCCCCCCCCC[C@@H](C[C@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@@H](CC(C)C)NC=O, CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O, CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O, CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O, CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O, CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2979","ornithine","NFkB pathway modulator","GPRC6A",NA,NA,"Cl.NCCC[C@@H](N)C(O)=O |&1:5,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2980","orphanin-fq","opioid receptor agonist","OPRL1, OPRM1",NA,NA,"CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O, CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2981","orteronel","androgen biosynthesis inhibitor, androgen receptor antagonist, cytochrome P450 inhibitor","CYP17A1",NA,NA,"CNC(=O)c1ccc2cc(ccc2c1)[C@]1(O)CCn2cncc12, CNC(=O)c1ccc2cc(ccc2c1)[C@]1(O)CCn2cncc12, CNC(=O)c1ccc2cc(ccc2c1)[C@]1(O)CCn2cncc12","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2982","ORY-1001","histone lysine demethylase inhibitor","KDM1A",NA,NA,"NC1CCC(CC1)N[C@@H]1C[C@H]1c1ccccc1, NC1CCC(CC1)N[C@@H]1C[C@H]1c1ccccc1, NC1CCC(CC1)N[C@@H]1C[C@H]1c1ccccc1","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2983","oseltamivir-phosphate","neuraminidase inhibitor","CES1, NEU1, NEU2","infectious disease","influenza A virus infection","CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 |t:5|, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 |t:5|, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 |t:5|, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 |t:5|, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 |t:5|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2984","osemozotan","serotonin receptor agonist","HTR1A",NA,NA,"C(CNC[C@H]1COc2ccccc2O1)COc1ccc2OCOc2c1","Phase 2/Phase 3",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2985","OSI-027","mTOR inhibitor","MTOR",NA,NA,"COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12 |r|, COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12 |r|, COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12 |r|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2986","OSI-420","EGFR inhibitor","EGFR",NA,NA,"COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCO, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCO, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCO","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2987","OSI-930","KIT inhibitor, VEGFR inhibitor","FLT1, KDR, KIT",NA,NA,"FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1, FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1, FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1, FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1, FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2988","osimertinib","EGFR inhibitor","EGFR","oncology","non-small cell lung cancer (NSCLC)","COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12, COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12, COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12, COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12, COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12, COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12, COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2989","ospemifene","selective estrogen receptor modulator (SERM)","ESR1, ESR2","obstetrics/gynecology, endocrinology","vaginal atrophy, dyspareunia, menopause","OCCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, OCCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, OCCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2990","ostarine","androgen receptor modulator","AR",NA,NA,"C[C@](O)(COc1ccc(cc1)C#N)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F, C[C@](O)(COc1ccc(cc1)C#N)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2991","OT-R-antagonist-1","oxytocin receptor antagonist","AVPR1A, OXTR",NA,NA,"CO\N=C1\C[C@H](N(C1)C(=O)c1ccc(cc1)-c1ccccc1C)C(=O)NC[C@@H](O)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2992","otamixaban","coagulation factor inhibitor","F10",NA,NA,"COC(=O)[C@H](Cc1cccc(c1)C(N)=N)[C@@H](C)NC(=O)c1ccc(cc1)-c1cc[n+]([O-])cc1, COC(=O)[C@H](Cc1cccc(c1)C(N)=N)[C@@H](C)NC(=O)c1ccc(cc1)-c1cc[n+]([O-])cc1, COC(=O)[C@H](Cc1cccc(c1)C(N)=N)[C@@H](C)NC(=O)c1ccc(cc1)-c1cc[n+]([O-])cc1, COC(=O)[C@H](Cc1cccc(c1)C(N)=N)[C@@H](C)NC(=O)c1ccc(cc1)-c1cc[n+]([O-])cc1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2993","otenzepad","acetylcholine receptor antagonist","CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",NA,NA,"CCN(CC)C[C@H]1CCCCN1CC(=O)N1c2ccccc2C(=O)Nc2cccnc12 |&1:6,r|, CCN(CC)C[C@H]1CCCCN1CC(=O)N1c2ccccc2C(=O)Nc2cccnc12 |&1:6,r|, CCN(CC)C[C@H]1CCCCN1CC(=O)N1c2ccccc2C(=O)Nc2cccnc12 |&1:6,r|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,5,0,0,0,0,0,0
"2994","otilonium","acetylcholine receptor antagonist","CACNA1C","gastroenterology","irritable bowel syndrome","CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](C)(CC)CC, CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](C)(CC)CC, CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](C)(CC)CC, CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](C)(CC)CC, CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](C)(CC)CC, CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](C)(CC)CC","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2995","OTS167","maternal embryonic leucine zipper kinase inhibitor","MELK",NA,NA,"CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O |r|, CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O |r|, CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O |r|, CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O |r|, CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O |r|, CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O |r|","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2996","OTX015","bromodomain inhibitor","BRD2, BRD3, BRD4",NA,NA,"Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |c:8|, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |c:8|, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |c:8|, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |c:8|, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |c:8|, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |c:8|","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2997","ouabain","ATPase inhibitor","ATP1A1","cardiology","hypertension, cardiac arrythmia","C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"2998","OXA-06","rho associated kinase inhibitor","ROCK1, ROCK2",NA,NA,"Fc1ccccc1CNCc1ccc(cc1)-c1ccnc2[nH]ccc12, Fc1ccccc1CNCc1ccc(cc1)-c1ccnc2[nH]ccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"2999","oxaprozin","cyclooxygenase inhibitor","PTGS1, PTGS2","rheumatology","osteoarthritis, rheumatoid arthritis","OC(=O)CCc1nc(c(o1)-c1ccccc1)-c1ccccc1, OC(=O)CCc1nc(c(o1)-c1ccccc1)-c1ccccc1, OC(=O)CCc1nc(c(o1)-c1ccccc1)-c1ccccc1","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3000","oxatomide","histamine receptor antagonist","HRH1","allergy","allergic rhinitis","O=c1[nH]c2ccccc2n1CCCN1CCN(CC1)C(c1ccccc1)c1ccccc1, O=c1[nH]c2ccccc2n1CCCN1CCN(CC1)C(c1ccccc1)c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"3001","oxcarbazepine","sodium channel blocker","SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A","neurology/psychiatry","seizures","NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12","Launched",0,0,1,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3002","OXF-BD-02","bromodomain inhibitor","BRD4",NA,NA,"Cc1noc(C)c1-c1cc(O)cc(c1)[C@@H](O)c1ccccc1 |&1:14,r|, Cc1noc(C)c1-c1cc(O)cc(c1)[C@@H](O)c1ccccc1 |&1:14,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3003","oxfenicine","carnitine palmitoyltransferase inhibitor","CPT1A, CPT1B",NA,NA,"N[C@@H](C(O)=O)c1ccc(O)cc1, N[C@@H](C(O)=O)c1ccc(O)cc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3004","oxibendazole","tubulin polymerization inhibitor","TUBB, TUBB4B","infectious disease","strongyles","CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3005","oxotremorine-M","acetylcholine receptor agonist","CHRM1, CHRM2, CHRM3, CHRM4",NA,NA,"C[N+](C)(C)CC#CCN1CCCC1=O, C[N+](C)(C)CC#CCN1CCCC1=O, C[N+](C)(C)CC#CCN1CCCC1=O, C[N+](C)(C)CC#CCN1CCCC1=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0
"3006","oxotremorine-sesquifumarate","cholinergic receptor agonist","CHRM1, CHRM2, CHRM3, CHRM4",NA,NA,"O=C1CCCN1CC#CCN1CCCC1, O=C1CCCN1CC#CCN1CCCC1, O=C1CCCN1CC#CCN1CCCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0
"3007","oxprenolol","adrenergic receptor antagonist","ADRB1","cardiology","angina pectoris, hypertension, cardiac arrythmia","CC(C)NC[C@@H](O)COc1ccccc1OCC=C |&1:5|, CC(C)NC[C@@H](O)COc1ccccc1OCC=C |&1:5|, CC(C)NC[C@@H](O)COc1ccccc1OCC=C |&1:5|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"3008","oxybenzone","lipase inhibitor","LIPE","dermatology","sunscreen lotion","COc1ccc(C(=O)c2ccccc2)c(O)c1, COc1ccc(C(=O)c2ccccc2)c(O)c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3009","oxybuprocaine","local anesthetic","SCN10A","neurology/psychiatry","local anesthetic","CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC, CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC, CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC, CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC, CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC","Launched",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3010","oxybutynin","acetylcholine receptor antagonist","CHRM1, CHRM2, CHRM3","urology","urinary incontinence","CCN(CC)CC#CCOC(=O)[C@@](O)(C1CCCCC1)c1ccccc1 |&1:12,r|, CCN(CC)CC#CCOC(=O)[C@@](O)(C1CCCCC1)c1ccccc1 |&1:12,r|, CCN(CC)CC#CCOC(=O)[C@@](O)(C1CCCCC1)c1ccccc1 |&1:12,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,1,1,1,1
"3011","oxymetazoline","adrenergic receptor agonist","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C","otolaryngology","nasal congestion","Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C |t:11|, Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C |t:11|, Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C |t:11|","Launched",0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,1,6,1,1,1,1
"3012","oxyphenonium","cholinergic receptor antagonist","CHRM1, CHRM3","gastroenterology","peptic ulcer disease (PUD)","CC[N+](C)(CC)CCOC(=O)C(O)(C1CCCCC1)c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,1,1,1,1
"3013","oxypurinol","xanthine oxidase inhibitor","XDH",NA,NA,"O=c1nc2[nH][nH]cc2c(=O)[nH]1, O=c1nc2[nH][nH]cc2c(=O)[nH]1","Phase 2/Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3014","oxyquinoline","chelating agent","METAP2","dermatology","cosmetic","Oc1cccc2cccnc12, Oc1cccc2cccnc12, Oc1cccc2cccnc12, Oc1cccc2cccnc12, Oc1cccc2cccnc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3015","oxytetracycline","bacterial 30S ribosomal subunit inhibitor","30S-RIBOSOMAL SUBUNIT","infectious disease, urology, Infectious disease, Infectious disease, infectious disease, urology","chlamydia, urinary tract infections, skin infections, ear infections, gonorrhea, urethritis, Lyme disease, first-aid antibiotic, first-aid antibiotic, chlamydia, urinary tract infections, skin infections, ear infections, gonorrhea, urethritis, lyme disease","CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,5,7,11,30,&1:8,&2:15,t:8,15|, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,5,7,11,30,&1:8,&2:15,t:8,15|, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,5,7,11,30,&1:8,&2:15,t:8,15|, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,5,7,11,30,&1:8,&2:15,t:8,15|, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3[C@H](C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)[C@H](C(N)=O)C1=O |&1:27,&2:8|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3016","oxytocin","oxytocin receptor agonist","AVPR1A, AVPR1B, AVPR2, OXTR","obstetrics/gynecology","labor induction","CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O, CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3017","ozagrel","thromboxane synthase inhibitor","TBXAS1","neurology/psychiatry","stroke","OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1, OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1, OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1, OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1, OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3018","ozanimod","sphingosine 1-phosphate receptor agonist","S1PR1",NA,NA,"CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@H](CCc12)NCCO, CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@H](CCc12)NCCO","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3019","O4I1","Oct inducer","POU5F1",NA,NA,"COc1ccc(COc2ccc(CC#N)cc2)cc1, COc1ccc(COc2ccc(CC#N)cc2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3020","O6-benzylguanine","O6-alkylguanine-DNA alkyltransferase inhibitor","MGMT",NA,NA,"Nc1nc(OCc2ccccc2)c2[nH]cnc2n1, Nc1nc(OCc2ccccc2)c2[nH]cnc2n1, Nc1nc(OCc2ccccc2)c2[nH]cnc2n1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3021","PA-452","retinoid receptor antagonist","RXRA",NA,NA,"CCCCCCOc1cc2c(cc1N(C)c1ncc(cn1)C(O)=O)C(C)(C)CCC2(C)C, CCCCCCOc1cc2c(cc1N(C)c1ncc(cn1)C(O)=O)C(C)(C)CCC2(C)C, CCCCCCOc1cc2c(cc1N(C)c1ncc(cn1)C(O)=O)C(C)(C)CCC2(C)C, CCCCCCOc1cc2c(cc1N(C)c1ncc(cn1)C(O)=O)C(C)(C)CCC2(C)C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3022","PAC-1","caspase activator","CASP3",NA,NA,"Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3023","paclitaxel","tubulin polymerization inhibitor","BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8","oncology","ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)","CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3024","PACOCF3","phospholipase inhibitor","PLA2G4A",NA,NA,"CCCCCCCCCCCCCCCC(=O)C(F)(F)F, CCCCCCCCCCCCCCCC(=O)C(F)(F)F, CCCCCCCCCCCCCCCC(=O)C(F)(F)F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3025","pacritinib","FLT3 inhibitor, JAK inhibitor","FLT3, JAK1, JAK2, JAK3",NA,NA,"C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3026","palbociclib","CDK inhibitor","CDK4, CDK6","oncology","breast cancer","CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3027","paliperidone","dopamine receptor antagonist, serotonin receptor antagonist","DRD2, HTR2A","neurology/psychiatry","schizophrenia","Cc1nc2[C@@H](O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12 |&1:4,r|, Cc1nc2[C@@H](O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12 |&1:4,r|, Cc1nc2[C@@H](O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12 |&1:4,r|, Cc1nc2[C@@H](O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12 |&1:4,r|","Launched",0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,1,1,1
"3028","paliperidone palmitate","dopamine receptor antagonist","DRD2","neurology/psychiatry","schizophrenia","CCCCCCCCCCCCCCCC(=O)OC1CCCN2C(=O)C(=C(C)N=C12)CCN3CCC(CC3)c4noc5cc(F)ccc45","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1
"3029","palmatine-chloride","dopamine synthesis inhibitor","CYP3A4",NA,NA,"COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4cc3-c2cc1OC, COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4cc3-c2cc1OC, COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4cc3-c2cc1OC","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3030","palmitoylethanolamide","cannabinoid receptor agonist","CNR2, GPR119, GPR55",NA,NA,"CCCCCCCCCCCCCCCC(=O)NCCO, CCCCCCCCCCCCCCCC(=O)NCCO, CCCCCCCCCCCCCCCC(=O)NCCO","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3031","palomid-529","AKT inhibitor, mTOR inhibitor","MTOR",NA,NA,"COc1ccc(COc2cc3oc(=O)c4cc(ccc4c3cc2OC)[C@@H](C)O)cc1 |&1:25,r|, COc1ccc(COc2cc3oc(=O)c4cc(ccc4c3cc2OC)[C@@H](C)O)cc1 |&1:25,r|, COc1ccc(COc2cc3oc(=O)c4cc(ccc4c3cc2OC)[C@@H](C)O)cc1 |&1:25,r|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3032","palonosetron","serotonin receptor antagonist","HTR3A","gastroenterology","nausea, vomiting","O=C1N(C[C@H]2CCCc3cccc1c23)[C@@H]1CN2CCC1CC2, O=C1N(C[C@H]2CCCc3cccc1c23)[C@@H]1CN2CCC1CC2","Launched",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3033","palosuran","urotensin receptor antagonist","UTS2R",NA,NA,"Cc1cc(NC(=O)NCCN2CCC(O)(Cc3ccccc3)CC2)c2ccccc2n1, Cc1cc(NC(=O)NCCN2CCC(O)(Cc3ccccc3)CC2)c2ccccc2n1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3034","palovarotene","retinoid receptor agonist","RARG",NA,NA,"CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(O)=O)c(Cn3cccn3)cc12, CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(O)=O)c(Cn3cccn3)cc12, CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(O)=O)c(Cn3cccn3)cc12, CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(O)=O)c(Cn3cccn3)cc12, CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(O)=O)c(Cn3cccn3)cc12","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3035","pamapimod","p38 mapk inhibitor","MAPK10, MAPK11, MAPK14, MAPK8, MAPK9","rheumatology","rheumatoid arthritis","O=C1C(OC2=CC=C(F)C=C2F)=CC3=CN=C(NC(CCO)CCO)N=C3N1C","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3036","pamicogrel","cyclooxygenase inhibitor","PTGS2","hematology","thrombosis","O=C(OCC)CN1C(C2=NC(C3=CC=C(OC)C=C3)=C(C4=CC=C(OC)C=C4)S2)=CC=C1","Preclinical",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3037","pamidronate","bone resorption inhibitor","FDPS","endocrinology, oncology, hematologic malignancy","hypercalcemia, Paget's disease, breast cancer, multiple myeloma","NCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCC(O)(P(O)(O)=O)P(O)(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3038","pancuronium","acetylcholine receptor antagonist","CHRM2, CHRM3, CHRNA1, CHRNA2","critical care, neurology/psychiatry","endotracheal intubation, muscle relaxant","CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,1,1,1,1
"3039","panobinostat","HDAC inhibitor","HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9","hematologic malignancy","multiple myeloma","Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3040","pantoprazole","ATPase inhibitor","ATP4A","gastroenterology","gastroesophageal reflux disease (gerd), erosive esophagitis (ee), zollinger-ellison syndrome, gastroesophageal reflux disease (GERD), erosive esophagitis (EE), Zollinger-Ellison syndrome","COc1ccnc(CS(=O)c2nc3cc(OC(F)F)ccc3[nH]2)c1OC, COc1ccnc(C[S@@](=O)c2nc3ccc(OC(F)F)cc3[nH]2)c1OC |&1:8|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3041","pantoprazole (sodium)","h+/k+-atpase inhibitor","A1BG","Infectious disease","tuberculosis","COc1ccnc(C[S@@](=O)c2nc3ccc(OC(F)F)cc3[nH]2)c1OC |r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3042","PAOPA","dopamine receptor modulator","DRD2",NA,NA,"NC(=O)CN1CC[C@@H](NC(=O)[C@@H]2CCCN2)C1=O, NC(=O)CN1CC[C@@H](NC(=O)[C@@H]2CCCN2)C1=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0
"3043","papaverine","phosphodiesterase inhibitor","PDE10A, PDE4B, PDE5A","cardiology, hematology, gastroenterology","myocardial infarction, angina pectoris, pulmonary embolism (PE), colitis, vascular spasm","COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC, COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC, COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC, COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3044","paracetamol","cyclooxygenase inhibitor","FAAH, PTGS1, PTGS2, TRPV1","neurology/psychiatry, endocrinology","pain relief, fever","CC(=O)Nc1ccc(O)cc1, CC(=O)Nc1ccc(O)cc1, CC(=O)Nc1ccc(O)cc1, CC(=O)Nc1ccc(O)cc1, CC(=O)Nc1ccc(O)cc1, CC(=O)Nc1ccc(O)cc1, CC(=O)Nc1ccc(O)cc1, CC(=O)Nc1ccc(O)cc1","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3045","paramethadione","anticonvulsant","CACNA1G","neurology/psychiatry","seizures","CC[C@@]1(C)OC(=O)N(C)C1=O |&1:2,r|, CC[C@@]1(C)OC(=O)N(C)C1=O |&1:2,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3046","parbendazole","tubulin polymerization inhibitor","TUBB",NA,NA,"CCCCc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCCc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCCc1ccc2nc(NC(=O)OC)[nH]c2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3047","pardoprunox","dopamine receptor agonist, serotonin receptor agonist","DRD2, DRD3, DRD4, HTR1A, HTR7",NA,NA,"CN1CCN(CC1)c1cccc2[nH]c(=O)oc12, CN1CCN(CC1)c1cccc2[nH]c(=O)oc12, CN1CCN(CC1)c1cccc2[nH]c(=O)oc12, CN1CCN(CC1)c1cccc2[nH]c(=O)oc12","Phase 3",0,0,0,0,0,0,0,0,1,2,0,0,0,0,1,3,0,0,0,0,0,0,0,0
"3048","parecoxib","cyclooxygenase inhibitor","LTF","neurology/psychiatry","pain relief","CCC(=O)NS(=O)(=O)c1ccc(cc1)-c1c(C)onc1-c1ccccc1, CCC(=O)NS(=O)(=O)c1ccc(cc1)-c1c(C)onc1-c1ccccc1, CCC(=O)NS(=O)(=O)c1ccc(cc1)-c1c(C)onc1-c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3049","pargyline","monoamine oxidase inhibitor","MAOA, MAOB","cardiology","hypertension","CN(CC#C)Cc1ccccc1, CN(CC#C)Cc1ccccc1","Launched",0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3050","paricalcitol","vitamin D receptor agonist","VDR","nephrology, endocrinology","chronic kidney disease (CKD), hyperthyroidism","C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3051","paroxetine","selective serotonin reuptake inhibitor (SSRI)","CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR2A, SLC6A2, SLC6A4","neurology/psychiatry","depression, obsessive compulsive disorder (OCD), generalized anxiety disorder (GAD), panic disorders, posttraumatic stress disorder, social anxiety disorder","Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1, Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1, Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1, Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1, Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1, Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1, Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1","Launched",1,2,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,5,0,0,1,1,1,1
"3052","parthenolide-(-)","NFkB pathway inhibitor","HDAC1",NA,NA,"C\C1=C\CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |t:1|, C\C1=C\CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |t:1|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3053","parthenolide-(alternate-stereo)","NFkB pathway inhibitor","IKBKB, RELA",NA,NA,"C\C1=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|, C\C1=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|, C\C1=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|, C\C1=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|, C\C1=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3054","pasireotide","somatostatin receptor agonist","SSTR1, SSTR2, SSTR3, SSTR5","endocrinology","Cushing's syndrome, acromegaly","NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O)OC(=O)NCCN)c1ccccc1, NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O)OC(=O)NCCN)c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3055","pazopanib","KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3","oncology","renal cell carcinoma (RCC), soft tissue sarcoma (STS)","CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3056","PCA-4248","platelet activating factor receptor antagonist","PTAFR",NA,NA,"COC(=O)C1=C(C)NC(C)=C([C@@H]1C)C(=O)OCCSc1ccccc1 |&1:11,r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1C)C(=O)OCCSc1ccccc1 |&1:11,r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1C)C(=O)OCCSc1ccccc1 |&1:11,r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1C)C(=O)OCCSc1ccccc1 |&1:11,r,c:4,9|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3057","PCI-24781","HDAC inhibitor","HDAC1, HDAC2, HDAC3, HDAC6",NA,NA,"CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO, CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO, CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO, CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO, CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3058","PCI-29732","Bruton's tyrosine kinase (BTK) inhibitor","BTK",NA,NA,"Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)C1CCCC1, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)C1CCCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3059","PCI-34051","HDAC inhibitor","HDAC1, HDAC10, HDAC6, HDAC8",NA,NA,"COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1, COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1, COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1, COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1, COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3060","PCO-400","potassium channel activator","KCNJ8",NA,NA,"CC1(C)Oc2ccc(cc2[C@@H](OC2=CC(=O)CC2)[C@@H]1O)C#N |t:13|, CC1(C)Oc2ccc(cc2[C@@H](OC2=CC(=O)CC2)[C@@H]1O)C#N |t:13|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3061","PD-0325901","MEK inhibitor","MAP2K1",NA,NA,"OC[C@@H](O)CONC(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F, OC[C@@H](O)CONC(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F, OC[C@@H](O)CONC(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3062","PD-102807","acetylcholine receptor antagonist","CHRM4",NA,NA,"CCOC(=O)c1c(C)[nH]c2ccc3O[C@H]4N(CCc5cc(OC)ccc45)Cc3c12 |&1:14,r|, CCOC(=O)c1c(C)[nH]c2ccc3O[C@H]4N(CCc5cc(OC)ccc45)Cc3c12 |&1:14,r|, CCOC(=O)c1c(C)[nH]c2ccc3O[C@H]4N(CCc5cc(OC)ccc45)Cc3c12 |&1:14,r|, CCOC(=O)c1c(C)[nH]c2ccc3O[C@H]4N(CCc5cc(OC)ccc45)Cc3c12 |&1:14,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
"3063","PD-118057","potassium channel activator","KCNH2",NA,NA,"OC(=O)c1ccccc1Nc1ccc(CCc2ccc(Cl)c(Cl)c2)cc1, OC(=O)c1ccccc1Nc1ccc(CCc2ccc(Cl)c(Cl)c2)cc1, OC(=O)c1ccccc1Nc1ccc(CCc2ccc(Cl)c(Cl)c2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3064","PD-123319","angiotensin antagonist","AGTR2",NA,NA,"CN(C)c1ccc(Cn2cnc3CN([C@@H](Cc23)C(O)=O)C(=O)C(c2ccccc2)c2ccccc2)cc1C, CN(C)c1ccc(Cn2cnc3CN([C@@H](Cc23)C(O)=O)C(=O)C(c2ccccc2)c2ccccc2)cc1C, CN(C)c1ccc(Cn2cnc3CN([C@@H](Cc23)C(O)=O)C(=O)C(c2ccccc2)c2ccccc2)cc1C, CN(C)c1ccc(Cn2cnc3CN([C@@H](Cc23)C(O)=O)C(=O)C(c2ccccc2)c2ccccc2)cc1C","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3065","PD-128907","dopamine receptor agonist","DRD2, DRD3",NA,NA,"CCCN1CCO[C@H]2[C@H]1COc1ccc(O)cc21, CCCN1CCO[C@H]2[C@H]1COc1ccc(O)cc21, CCCN1CCO[C@H]2[C@H]1COc1ccc(O)cc21","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0
"3066","PD-153035","EGFR inhibitor","EGFR, KDR",NA,NA,"COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3067","PD-156707","endothelin receptor antagonist","EDNRA, EDNRB",NA,NA,"COc1ccc(cc1)C(=O)C(\Cc1cc(OC)c(OC)c(OC)c1)=C(/C(O)=O)c1ccc2OCOc2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3068","PD-158780","EGFR inhibitor","EGFR",NA,NA,"CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1, CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1, CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1, CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1, CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3069","PD-160170","neuropeptide receptor antagonist","NPY1R",NA,NA,"CC(C)c1ccccc1S(=O)(=O)c1cc(N)c2ncccc2c1[N+]([O-])=O, CC(C)c1ccccc1S(=O)(=O)c1cc(N)c2ncccc2c1[N+]([O-])=O, CC(C)c1ccccc1S(=O)(=O)c1cc(N)c2ncccc2c1[N+]([O-])=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3070","PD-161570","FGFR inhibitor","FGFR1",NA,NA,"CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1c(Cl)cccc1Cl, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1c(Cl)cccc1Cl, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1c(Cl)cccc1Cl, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1c(Cl)cccc1Cl","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3071","PD-166285","SRC inhibitor","EGFR, FGFR1, PDGFRB, PKMYT1, SRC, WEE1",NA,NA,"CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1, CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1, CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1, CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1, CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1, CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3072","PD-166793","collagenase inhibitor, metalloproteinase inhibitor","MMP13, MMP2, MMP3",NA,NA,"CC(C)[C@H](NS(=O)(=O)c1ccc(cc1)-c1ccc(Br)cc1)C(O)=O, CC(C)[C@H](NS(=O)(=O)c1ccc(cc1)-c1ccc(Br)cc1)C(O)=O, CC(C)[C@H](NS(=O)(=O)c1ccc(cc1)-c1ccc(Br)cc1)C(O)=O, CC(C)[C@H](NS(=O)(=O)c1ccc(cc1)-c1ccc(Br)cc1)C(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3073","PD-168077","dopamine receptor agonist","DRD2",NA,NA,"Cc1cccc(c1)C(=O)NCN1CCN(CC1)c1ccccc1C#N","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0
"3074","PD-168393","EGFR inhibitor","EGFR, ERBB2, SRC",NA,NA,"Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1, Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1, Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1, Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3075","PD-168568","dopamine receptor antagonist","DRD2, DRD4",NA,NA,"Cc1ccc(cc1C)N1CCN(CC[C@H]2NC(=O)c3ccccc23)CC1 |&1:14|, Cc1ccc(cc1C)N1CCN(CC[C@H]2NC(=O)c3ccccc23)CC1 |&1:14|, Cc1ccc(cc1C)N1CCN(CC[C@H]2NC(=O)c3ccccc23)CC1 |&1:14|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0
"3076","PD-173074","FGFR inhibitor, VEGFR inhibitor","FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB",NA,NA,"CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3077","PD-173212","calcium channel blocker","CACNA1B",NA,NA,"CC(C)C[C@H](N(C)Cc1ccc(cc1)C(C)(C)C)C(=O)N[C@@H](Cc1ccc(OCc2ccccc2)cc1)C(=O)NC(C)(C)C, CC(C)C[C@H](N(C)Cc1ccc(cc1)C(C)(C)C)C(=O)N[C@@H](Cc1ccc(OCc2ccccc2)cc1)C(=O)NC(C)(C)C, CC(C)C[C@H](N(C)Cc1ccc(cc1)C(C)(C)C)C(=O)N[C@@H](Cc1ccc(OCc2ccccc2)cc1)C(=O)NC(C)(C)C, CC(C)C[C@H](N(C)Cc1ccc(cc1)C(C)(C)C)C(=O)N[C@@H](Cc1ccc(OCc2ccccc2)cc1)C(=O)NC(C)(C)C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3078","PD-184352","MEK inhibitor","MAP2K1, MAP3K1, MAP3K2",NA,NA,"Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F, Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F, Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F, Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F, Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F, Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F, Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F, Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F, Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3079","PD-198306","MAP kinase inhibitor, MEK inhibitor","MAP2K1, MAP2K2",NA,NA,"Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1, Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1, Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1, Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1, Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1, Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1, Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3080","PD-407824","PKC inhibitor","WEE1",NA,NA,"Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1, Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1, Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1, Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1, Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1, Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3081","PD-81723","adenosine receptor agonist","ADORA1",NA,NA,"Cc1sc(N)c(C(=O)c2cccc(c2)C(F)(F)F)c1C, Cc1sc(N)c(C(=O)c2cccc(c2)C(F)(F)F)c1C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3082","PD-98059","MEK inhibitor","AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1",NA,NA,"COc1cccc(c1N)-c1cc(=O)c2ccccc2o1, COc1cccc(c1N)-c1cc(=O)c2ccccc2o1, COc1cccc(c1N)-c1cc(=O)c2ccccc2o1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3083","PDE10-IN-1","phosphodiesterase inhibitor","PDE10A",NA,NA,"Cc1c(nc2c3cccnc3ccn12)[C@@H]1C[C@H]1c1nc2c(C)ncc(C)n2n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3084","PDP-EA","FAAH activator","FAAH",NA,NA,"CCCCCCCCCCCCCCCc1cccc(OCC(=O)NCCO)c1, CCCCCCCCCCCCCCCc1cccc(OCC(=O)NCCO)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3085","PD1-PDL-inhibitor-1","programmed death ligand inhibitor","CD274",NA,NA,"COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN1CCCC[C@H]1C(O)=O, COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN1CCCC[C@H]1C(O)=O, COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN1CCCC[C@H]1C(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3086","peficitinib","JAK inhibitor","JAK1, JAK2, JAK3","rheumatology","rheumatoid arthritis","NC(=O)c1cnc2[nH]ccc2c1N[C@H]1[C@H]2C[C@H]3C[C@@H]1C[C@](O)(C3)C2 |&1:13,14,16,18,20,r|, NC(=O)c1cnc2[nH]ccc2c1N[C@H]1[C@H]2C[C@H]3C[C@@H]1C[C@](O)(C3)C2, NC(=O)c1cnc2[nH]ccc2c1N[C@H]1[C@H]2C[C@H]3C[C@@H]1C[C@](O)(C3)C2 |&1:13,14,16,18,20,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3087","pefloxacin","bacterial DNA gyrase inhibitor","TOP2A","infectious disease, urology","gastrointestinal infections, urethritis, gonorrhea, urinary tract infections","CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCN(C)CC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCN(C)CC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCN(C)CC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3088","pelanserin","serotonin receptor antagonist","HTR2A",NA,NA,"O=c1[nH]c2ccccc2c(=O)n1CCCN1CCN(CC1)c1ccccc1","Phase 2",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3089","pelitinib","EGFR inhibitor","EGFR",NA,NA,"CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3090","pemetrexed","dihydrofolate reductase inhibitor, thymidylate synthase inhibitor","ATIC, DHFR, GART, TYMS","oncology","non-small cell lung cancer (NSCLC), mesothelioma","Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3091","pemigatinib","fgfr inhibitor","FGFR1, FGFR2, FGFR3","oncology","colorectal cancer","CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3092","pemirolast","mediator release inhibitor","HRH1","pulmonary","asthma","Cc1cccn2c1ncc(-c1nn[nH]n1)c2=O, Cc1cccn2c1ncc(-c1nn[nH]n1)c2=O, Cc1cccn2c1ncc(-c1nn[nH]n1)c2=O","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"3093","penbutolol","adrenergic receptor antagonist","ADRB1, ADRB2, HTR1A, HTR1B","cardiology","hypertension","CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1, CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1, CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1, CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1, CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1, CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1","Launched",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,1,2,1,1,1,1
"3094","penfluridol","T-type calcium channel blocker","CACNA1G","neurology/psychiatry","schizophrenia","OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F, OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F, OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F, OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F, OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F, OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F, OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3095","pentagastrin","CCK receptor agonist","CCKBR","gastroenterology","anacidity diagnostic, gastric hypersecretion diagnostic","CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O, CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O, CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3096","pentamidine","anti-pneumocystis agent","TRDMT1","infectious disease","pneumonia","NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3097","pentolinium","cholinergic receptor antagonist","CHRNA10, CHRNA3, CHRNA4, CHRNB4","cardiology","hypertension","C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1, C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1, C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,1,1,1,1
"3098","pentostatin","adenosine deaminase inhibitor, ribonucleotide reductase inhibitor, adenosine deaminase inhibitor, ribonucleotide reductase inhibitor","ADA","hematologic malignancy","hairy cell leukemia","OC[C@H]1O[C@H](C[C@@H]1O)n1cnc2[C@H](O)CN=CNc12 |c:16|, OC[C@H]1O[C@H](C[C@@H]1O)n1cnc2[C@H](O)CN=CNc12 |c:16|, OC[C@H]1O[C@H](C[C@@H]1O)n1cnc2[C@H](O)CN=CNc12 |c:16|, OC[C@H]1O[C@H](C[C@@H]1O)n1cnc2[C@H](O)CN=CNc12 |c:16|, OC[C@H]1O[C@H](CC1O)n1cnc2[C@H](O)CNC=Nc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3099","pentoxifylline","phosphodiesterase inhibitor","ADORA1, ADORA2A, ADORA2B, ADRA2B, NT5E, PDE10A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, PDE6A, PDE6B, PDE6C, PDE6D, PDE6G, PDE6H, PDE7A, PDE7B, PDE8A, PDE8B, PDE9A, TNF","cardiology","claudication","CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O, CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O, CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O, CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O, CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O, CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"3100","pepstatin","aspartic protease inhibitor","CTSB, CTSD, CTSL, REN",NA,NA,"CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CC(C)C)C(C)C)C(C)C)[C@@H](O)CC(O)=O, CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CC(C)C)C(C)C)C(C)C)[C@@H](O)CC(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3101","peretinoin","retinoid receptor agonist","RXRA",NA,NA,"CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(\C)=C\C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(\C)=C\C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(\C)=C\C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(\C)=C\C(O)=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3102","pergolide","dopamine receptor agonist","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C",NA,NA,"CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13, CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13, CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13, CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13, CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13","Withdrawn",0,0,0,0,0,0,0,0,1,6,0,0,0,0,1,5,0,0,1,6,0,0,0,0
"3103","perhexiline","carnitine palmitoyltransferase inhibitor","CPT1A","cardiology","angina pectoris","C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|, C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|, C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|, C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|, C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|, C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|, C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|, C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|, C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3104","perhexiline maleate","potassium channel blocker","A1BG, KCNH2, SCN5A","Cardiology","angina pectoris","C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14,r|","Launched",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3105","periciazine","adrenergic receptor antagonist","ADRA1B, ADRA2A, AR, DRD1","neurology/psychiatry","psychosis","OC1CCN(CCCN2C3=CC=CC=C3SC4=CC=C(C=C24)C#N)CC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,2,1,1,1,1
"3106","perifosine","AKT inhibitor","AKT1",NA,NA,"CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1 |&1:19|, CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1 |&1:19|, CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1 |&1:19|, CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1 |&1:19|, CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1 |&1:19|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3107","perillyl-alcohol","apoptosis stimulant, farnesyltransferase inhibitor","FNTA",NA,NA,"CC(=C)[C@H]1CCC(CO)=CC1 |&1:3,r,c:8|, CC(=C)[C@H]1CCC(CO)=CC1 |&1:3,r,c:8|, CC(=C)[C@H]1CCC(CO)=CC1 |&1:3,r,c:8|, CC(=C)[C@H]1CCC(CO)=CC1 |&1:3,r,c:8|, CC(=C)[C@H]1CCC(CO)=CC1 |&1:3,r,c:8|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3108","perindopril","angiotensin converting enzyme inhibitor","ACE","cardiology","hypertension, myocardial infarction, coronary artery disease (CAD)","CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC, CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC, CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC, CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC, CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3109","perindoprilat","angiotensin converting enzyme inhibitor","ACE",NA,NA,"CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(O)=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3110","perospirone","dopamine receptor antagonist, serotonin receptor antagonist","DRD2, DRD3, DRD4","neurology/psychiatry","schizophrenia, bipolar disorder","O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)c1nsc2ccccc12, O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)c1nsc2ccccc12, O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)c1nsc2ccccc12, O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)c1nsc2ccccc12, O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)c1nsc2ccccc12, O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)c1nsc2ccccc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0,1,1,1,1
"3111","perphenazine","dopamine receptor antagonist","CALM1, DRD1, DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7","neurology/psychiatry, gastroenterology","schizophrenia, nausea, vomiting","OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1","Launched",0,0,0,0,0,0,0,0,1,4,1,1,0,0,1,2,0,0,0,0,1,1,1,1
"3112","perzinfotel","glutamate receptor antagonist","GRIN1, GRIN2A, GRIN2B",NA,NA,"OP(O)(=O)CCN1CCCNc2c1c(=O)c2=O, OP(O)(=O)CCN1CCCNc2c1c(=O)c2=O, OP(O)(=O)CCN1CCCNc2c1c(=O)c2=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3113","PETCM","caspase activator","CASP3",NA,NA,"O[C@@H](Cc1ccncc1)C(Cl)(Cl)Cl |&1:1,r|, O[C@@H](Cc1ccncc1)C(Cl)(Cl)Cl |&1:1,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3114","petesicatib","cathepsin inhibitor","CTSS, CTSV","rheumatology","sjogren's syndrome","O=C(N1[C@@H](C[C@@H](S(=O)(C2=C(C=C(C3=CN(C)N=C3)C=C2)C(F)(F)F)=O)C1)C(NC4(CC4)C#N)=O)C5(CC5)C(F)(F)F","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3115","pevonedistat","nedd activating enzyme inhibitor","NAE1, UBA3",NA,NA,"NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12, NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12, NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12, NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12, NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12, NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12, NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12, NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12, NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3116","pexacerfont","crf receptor antagonist","CRHR1, PLXNA2","neurology/psychiatry","generalized anxiety disorder (gad)","CC[C@@H](C)Nc1nc(C)nc2c(c(C)nn12)-c1ccc(OC)nc1C |a:2|","Phase 2/Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3117","pexidartinib","tyrosine kinase inhibitor","CSF1R, FLT3, KIT",NA,NA,"FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1, FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1, FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1, FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3118","pexmetinib","MAP kinase inhibitor, TIE tyrosine kinase inhibitor","MAPK14, TEK",NA,NA,"Cc1ccc(cc1)-n1nc(cc1NC(=O)NCc1cc(F)ccc1Oc1ccc2n(CCO)ncc2c1)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)NCc1cc(F)ccc1Oc1ccc2n(CCO)ncc2c1)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)NCc1cc(F)ccc1Oc1ccc2n(CCO)ncc2c1)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)NCc1cc(F)ccc1Oc1ccc2n(CCO)ncc2c1)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)NCc1cc(F)ccc1Oc1ccc2n(CCO)ncc2c1)C(C)(C)C","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3119","pf 03716556","h+/k+-atpase inhibitor","ATP4A","gastroenterology","gastroesophageal reflux disease (gerd)","CN(CCO)C(=O)c1cc(N[C@@H]2CCOc3cccc(C)c23)c2nc(C)cn2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3120","pf 04531083","voltage-gated sodium channel modulator","SCN10A","neurology/psychiatry","chronic pain","ClC1=CC=C(OC)C=C1C2=C(N=C(NC(C3=CC=NN3C)=O)C=C2)N","Phase 2",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3121","pf-00446687","melanocortin receptor agonist","MC4R","neurology/psychiatry","hypoactive sexual desire disorder","O=C([C@H]1[C@H](C2=C(C=C(F)C=C2)F)CN(C(C)(C)C)C1)N3C[C@H]([C@](O)(C4=CC=CC=C4)[C@@H](C)C3)C","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3122","PF-02545920","phosphodiesterase inhibitor","PDE10A",NA,NA,"Cn1cc(c(n1)-c1ccc(OCc2ccc3ccccc3n2)cc1)-c1ccncc1, Cn1cc(c(n1)-c1ccc(OCc2ccc3ccccc3n2)cc1)-c1ccncc1, Cn1cc(c(n1)-c1ccc(OCc2ccc3ccccc3n2)cc1)-c1ccncc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3123","PF-03049423","phosphodiesterase inhibitor","PDE5A",NA,NA,"CCCOCCn1c2cc(ncc2nc(N2CCN(CCO)CC2)c1=O)-c1ccc(OC)nc1, CCCOCCn1c2cc(ncc2nc(N2CCN(CCO)CC2)c1=O)-c1ccc(OC)nc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3124","pf-03463275","glycine transporter inhibitor","SLC6A9","neurology/psychiatry","schizophrenia","O=C(C(N=C1)=CN1C)N(CC(C=C2)=CC(Cl)=C2F)C[C@@H]3[C@](C4)([H])[C@@]3([H])CN4C","Phase 2",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3125","PF-03758309","p21 activated kinase inhibitor","PAK4",NA,NA,"CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3126","PF-03814735","Aurora kinase inhibitor","AURKA, AURKB",NA,NA,"CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21, CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21, CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21, CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3127","PF-04217903","c-Met inhibitor","MET",NA,NA,"OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1, OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1, OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1, OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1, OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3128","PF-04418948","prostaglandin inhibitor","PTGER2",NA,NA,"COc1ccc2cc(OCC3(CN(C3)C(=O)c3ccc(F)cc3)C(O)=O)ccc2c1, COc1ccc2cc(OCC3(CN(C3)C(=O)c3ccc(F)cc3)C(O)=O)ccc2c1, COc1ccc2cc(OCC3(CN(C3)C(=O)c3ccc(F)cc3)C(O)=O)ccc2c1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3129","PF-04447943","phosphodiesterase inhibitor","PDE9A",NA,NA,"C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1nc(=O)c2cnn(C3CCOCC3)c2[nH]1, C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1nc(=O)c2cnn(C3CCOCC3)c2[nH]1, C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1nc(=O)c2cnn(C3CCOCC3)c2[nH]1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3130","PF-04457845","FAAH inhibitor","FAAH",NA,NA,"FC(F)(F)c1ccc(Oc2cccc(C=C3CCN(CC3)C(=O)Nc3cccnn3)c2)nc1, FC(F)(F)c1ccc(Oc2cccc(C=C3CCN(CC3)C(=O)Nc3cccnn3)c2)nc1, FC(F)(F)c1ccc(Oc2cccc(C=C3CCN(CC3)C(=O)Nc3cccnn3)c2)nc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3131","PF-04620110","diacylglycerol O acyltransferase inhibitor","DGAT1",NA,NA,"Nc1ncnc2OCCN(c3ccc(cc3)[C@H]3CC[C@H](CC(O)=O)CC3)C(=O)c12 |r|, Nc1ncnc2OCCN(c3ccc(cc3)[C@H]3CC[C@H](CC(O)=O)CC3)C(=O)c12 |r|, Nc1ncnc2OCCN(c3ccc(cc3)[C@H]3CC[C@H](CC(O)=O)CC3)C(=O)c12 |r|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3132","PF-04691502","mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA",NA,NA,"COc1ccc(cn1)-c1cc2c(C)nc(N)nc2n([C@H]2CC[C@@H](CC2)OCCO)c1=O |r|, COc1ccc(cn1)-c1cc2c(C)nc(N)nc2n([C@H]2CC[C@@H](CC2)OCCO)c1=O |r|, COc1ccc(cn1)-c1cc2c(C)nc(N)nc2n([C@H]2CC[C@@H](CC2)OCCO)c1=O |r|, COc1ccc(cn1)-c1cc2c(C)nc(N)nc2n([C@H]2CC[C@@H](CC2)OCCO)c1=O |r|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3133","PF-04885614","voltage-gated sodium channel blocker","SCN10A",NA,NA,"CC(C)(N)c1nc(c[nH]1)-c1ccc(OC(F)(F)F)cc1, CC(C)(N)c1nc(c[nH]1)-c1ccc(OC(F)(F)F)cc1","Preclinical",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3134","PF-04937319","glucokinase activator","GCK",NA,NA,"CN(C)C(=O)c1ncc(Oc2cc(cc3oc(C)cc23)C(=O)Nc2cnc(C)cn2)cn1, CN(C)C(=O)c1ncc(Oc2cc(cc3oc(C)cc23)C(=O)Nc2cnc(C)cn2)cn1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3135","PF-05190457","growth hormone secretagogue receptor inverse agonist","GHSR",NA,NA,"Cc1cn2cc(CC(=O)N3CCC4(CN(C4)[C@@H]4CCc5cc(ccc45)-c4cc(C)ncn4)CC3)nc2s1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3136","PF-05212384","mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA",NA,NA,"CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1, CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1, CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3137","pf-06380101","tubulin inhibitor","TUBB","oncology","breast cancer","CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)C(C)(C)N)C(C)C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3138","PF-06447475","serine/threonine kinase inhibitor","LRRK2",NA,NA,"N#Cc1cccc(c1)-c1c[nH]c2ncnc(N3CCOCC3)c12, N#Cc1cccc(c1)-c1c[nH]c2ncnc(N3CCOCC3)c12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3139","PF-06463922","ALK tyrosine kinase receptor inhibitor","ALK, FES, ROS1","oncology","non-small cell lung cancer (NSCLC)","C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N |&1:1,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3140","pf-06952229","antineoplastic agent","TGFBR1","oncology","breast cancer","CC(C)c1cnc(cc1Nc1ccncc1C(=O)NC(CO)CO)-c1cc(Cl)ccc1F","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3141","PF-3274167","oxytocin receptor antagonist","AVPR1A, OXTR",NA,NA,"COCc1nnc(N2CC(C2)Oc2ccc(F)cc2Cl)n1-c1ccc(OC)nc1, COCc1nnc(N2CC(C2)Oc2ccc(F)cc2Cl)n1-c1ccc(OC)nc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3142","PF-3845","FAAH inhibitor","FAAH",NA,NA,"FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1, FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1, FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3143","PF-429242","SREBP inhibitor","MBTPS1",NA,NA,"CCN(CC)Cc1ccc(cc1)C(=O)N(CCc1ccccc1OC)[C@@H]1CCNC1, CCN(CC)Cc1ccc(cc1)C(=O)N(CCc1ccccc1OC)[C@@H]1CCNC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3144","PF-431396","focal adhesion kinase inhibitor","PTK2, PTK2B",NA,NA,"CN(c1ccccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ccccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ccccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ccccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3145","PF-4708671","ribosomal protein inhibitor","RPS6KB1",NA,NA,"CCc1cncnc1N1CCN(Cc2nc3ccc(cc3[nH]2)C(F)(F)F)CC1, CCc1cncnc1N1CCN(Cc2nc3ccc(cc3[nH]2)C(F)(F)F)CC1, CCc1cncnc1N1CCN(Cc2nc3ccc(cc3[nH]2)C(F)(F)F)CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3146","PF-477736","CHK inhibitor","CHEK1, CHEK2",NA,NA,"Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3147","PF-4800567","casein kinase inhibitor","CSNK1D, CSNK1E",NA,NA,"Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3148","PF-4981517","cytochrome P450 inhibitor","CYP3A4",NA,NA,"Cc1ccc(cc1)-c1c(cnn1C)-c1nn(C)c2ncnc(N3CC[C@@H](C3)N3CCCCC3)c12, Cc1ccc(cc1)-c1c(cnn1C)-c1nn(C)c2ncnc(N3CC[C@@H](C3)N3CCCCC3)c12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3149","PF-5274857","smoothened receptor antagonist","SMO",NA,NA,"Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O, Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O, Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O, Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O, Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O, Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3150","PF-562271","focal adhesion kinase inhibitor","PTK2, PTK2B",NA,NA,"CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3151","PF-573228","focal adhesion kinase inhibitor","CDK1, CDK2, CDK7, GSK3B, IKBKB",NA,NA,"CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1, CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1, CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1, CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1, CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1, CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3152","PF-670462","casein kinase inhibitor","CSNK1D, CSNK1E",NA,NA,"Nc1nccc(n1)-c1c(ncn1C1CCCCC1)-c1ccc(F)cc1, Nc1nccc(n1)-c1c(ncn1C1CCCCC1)-c1ccc(F)cc1, Nc1nccc(n1)-c1c(ncn1C1CCCCC1)-c1ccc(F)cc1, Nc1nccc(n1)-c1c(ncn1C1CCCCC1)-c1ccc(F)cc1, Nc1nccc(n1)-c1c(ncn1C1CCCCC1)-c1ccc(F)cc1, Nc1nccc(n1)-c1c(ncn1C1CCCCC1)-c1ccc(F)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3153","PF-750","FAAH inhibitor","FAAH",NA,NA,"O=C(Nc1ccccc1)N1CCC(Cc2cnc3ccccc3c2)CC1, O=C(Nc1ccccc1)N1CCC(Cc2cnc3ccccc3c2)CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3154","PF-8380","autotaxin inhibitor","ENPP2",NA,NA,"Clc1cc(Cl)cc(COC(=O)N2CCN(CCC(=O)c3ccc4[nH]c(=O)oc4c3)CC2)c1, Clc1cc(Cl)cc(COC(=O)N2CCN(CCC(=O)c3ccc4[nH]c(=O)oc4c3)CC2)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3155","PF-915275","11-beta hydroxysteroid dehydrogenase inhibitor","HSD11B1",NA,NA,"Nc1cccc(NS(=O)(=O)c2ccc(cc2)-c2ccc(cc2)C#N)n1, Nc1cccc(NS(=O)(=O)c2ccc(cc2)-c2ccc(cc2)C#N)n1, Nc1cccc(NS(=O)(=O)c2ccc(cc2)-c2ccc(cc2)C#N)n1, Nc1cccc(NS(=O)(=O)c2ccc(cc2)-c2ccc(cc2)C#N)n1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3156","PFI-1","bromodomain inhibitor","BRD4",NA,NA,"COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3157","PFI-3","bromodomain inhibitor","PBRM1, SMARCA4",NA,NA,"Oc1ccccc1C(=O)\C=C\N1C[C@H]2C[C@@H]1CN2c1ccccn1, Oc1ccccc1C(=O)\C=C\N1C[C@H]2C[C@@H]1CN2c1ccccn1, Oc1ccccc1C(=O)\C=C\N1C[C@H]2C[C@@H]1CN2c1ccccn1, Oc1ccccc1C(=O)\C=C\N1C[C@H]2C[C@@H]1CN2c1ccccn1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3158","PFI-4","bromodomain inhibitor","BRPF1",NA,NA,"COc1ccccc1C(=O)Nc1cc2n(C)c(=O)n(C)c2cc1N1CCCC1, COc1ccccc1C(=O)Nc1cc2n(C)c(=O)n(C)c2cc1N1CCCC1, COc1ccccc1C(=O)Nc1cc2n(C)c(=O)n(C)c2cc1N1CCCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3159","PFK-015","phosphofructokinase inhibitor","PFKFB3",NA,NA,"O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1, O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1, O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1, O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1, O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1, O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3160","PFK-158","phosphofructokinase inhibitor","PFKFB3",NA,NA,"FC(F)(F)c1ccc2ccc(\C=C\C(=O)c3ccncc3)nc2c1, FC(F)(F)c1ccc2ccc(\C=C\C(=O)c3ccncc3)nc2c1, FC(F)(F)c1ccc2ccc(\C=C\C(=O)c3ccncc3)nc2c1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3161","PGL5001","JNK inhibitor","MAPK10, MAPK8, MAPK9",NA,NA,"N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3162","PH-797804","p38 MAPK inhibitor","MAPK11, MAPK14",NA,NA,"CNC(=O)c1ccc(C)c(c1)-n1c(C)cc(OCc2ccc(F)cc2F)c(Br)c1=O, CNC(=O)c1ccc(C)c(c1)-n1c(C)cc(OCc2ccc(F)cc2F)c(Br)c1=O, CNC(=O)c1ccc(C)c(c1)-n1c(C)cc(OCc2ccc(F)cc2F)c(Br)c1=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3163","PHA-568487","nicotinic receptor agonist","CHRNA7",NA,NA,"O=C(N[C@H]1CN2CCC1CC2)c1ccc2OCCOc2c1, O=C(N[C@H]1CN2CCC1CC2)c1ccc2OCCOc2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
"3164","PHA-665752","c-Met inhibitor","MET",NA,NA,"Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3165","PHA-680632","Aurora kinase inhibitor","AURKA, AURKB, AURKC",NA,NA,"CCc1cccc(CC)c1NC(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1, CCc1cccc(CC)c1NC(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1, CCc1cccc(CC)c1NC(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1, CCc1cccc(CC)c1NC(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3166","PHA-767491","CDC inhibitor","CDK1, RPS6KB1",NA,NA,"O=C1NCCc2[nH]c(cc12)-c1ccncc1, O=C1NCCc2[nH]c(cc12)-c1ccncc1, O=C1NCCc2[nH]c(cc12)-c1ccncc1, O=C1NCCc2[nH]c(cc12)-c1ccncc1, O=C1NCCc2[nH]c(cc12)-c1ccncc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3167","PHA-793887","CDK inhibitor","CDK1, CDK2, CDK4, CDK5, CDK7, CDK9",NA,NA,"CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3168","PHA-848125","CDK inhibitor, growth factor receptor inhibitor","CDK2, CDK4, CDK7, NTRK1",NA,NA,"CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3169","PHCCC","glutamate receptor agonist","GRM1, GRM4",NA,NA,"O\N=C1/[C@@H]2C[C@@]2(Oc2ccccc12)C(=O)Nc1ccccc1 |&1:3,5|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3170","phenacemide","sodium channel blocker","SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A","neurology/psychiatry","epilepsy, seizures","NC(=O)NC(=O)Cc1ccccc1, NC(=O)NC(=O)Cc1ccccc1","Launched",0,0,1,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3171","phenacetin","cyclooxygenase inhibitor","PTGS1",NA,NA,"CCOc1ccc(NC(C)=O)cc1, CCOc1ccc(NC(C)=O)cc1, CCOc1ccc(NC(C)=O)cc1","Withdrawn",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3172","phenazone","cyclooxygenase inhibitor","PTGS1, PTGS2","neurology/psychiatry","pain relief","Cc1cc(=O)n(-c2ccccc2)n1C, Cc1cc(=O)n(-c2ccccc2)n1C, Cc1cc(=O)n(-c2ccccc2)n1C","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3173","phenazopyridine","local anesthetic","SCN1A","infectious disease","urinary tract infections","Nc1ccc(\N=N\c2ccccc2)c(N)n1, Nc1ccc(\N=N\c2ccccc2)c(N)n1, Nc1ccc(\N=N\c2ccccc2)c(N)n1, Nc1ccc(\N=N\c2ccccc2)c(N)n1, Nc1ccc(\N=N\c2ccccc2)c(N)n1","Launched",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3174","phenelzine","monoamine oxidase inhibitor","ABAT, AOC3, GAD2, GPT, GPT2, MAOA, MAOB, SLC6A2, SLC6A3, SLC6A4","neurology/psychiatry","depression","NNCCc1ccccc1, NNCCc1ccccc1, NNCCc1ccccc1, NNCCc1ccccc1, NNCCc1ccccc1","Launched",1,3,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3175","phenethyl-isothiocyanate","anticancer agent","CYP2E1",NA,NA,"S=C=NCCc1ccccc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3176","phenformin","AMPK activator","KCNJ8, PRKAA1",NA,NA,"NC(N)=NC(=N)NCCc1ccccc1, NC(N)=NC(=N)NCCc1ccccc1, NC(N)=NC(=N)NCCc1ccccc1, NC(N)=NC(=N)NCCc1ccccc1, NC(N)=NC(=N)NCCc1ccccc1","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3177","phenindamine","histamine receptor antagonist","HRH1","allergy, otolaryngology","allergic rhinitis, common cold","CN1CCC2=C(C1)[C@@H](c1ccccc21)c1ccccc1 |&1:7,r,c:4|, CN1CCC2=C(C1)[C@@H](c1ccccc21)c1ccccc1 |&1:7,r,c:4|","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"3178","phenindione","vitamin K antagonist","VKORC1","hematology","deep vein thrombosis (DVT)","O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3179","pheniramine","histamine receptor antagonist","HRH1","allergy","allergic rhinitis, urticaria","CN(C)CC[C@@H](c1ccccc1)c1ccccn1 |&1:5|, CN(C)CC[C@@H](c1ccccc1)c1ccccn1 |&1:5|, CN(C)CC[C@@H](c1ccccc1)c1ccccn1 |&1:5|, CN(C)CC[C@@H](c1ccccc1)c1ccccn1 |&1:5|","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"3180","phenolphthalein","indicator dye","UGT1A9",NA,NA,"Oc1ccc(cc1)C1(OC(=O)c2ccccc12)c1ccc(O)cc1, Oc1ccc(cc1)C1(OC(=O)c2ccccc12)c1ccc(O)cc1","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3181","phenoxybenzamine","adrenergic receptor antagonist","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C","cardiology, endocrinology","hypertension, pheochromocytoma","CC(COc1ccccc1)N(CCCl)Cc1ccccc1, CC(COc1ccccc1)N(CCCl)Cc1ccccc1, CC(COc1ccccc1)N(CCCl)Cc1ccccc1, CC(COc1ccccc1)N(CCCl)Cc1ccccc1, CC(COc1ccccc1)N(CCCl)Cc1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,6,1,1,1,1
"3182","phenprocoumon","vitamin K antagonist","VKORC1","hematology","thrombosis, pulmonary embolism (PE)","CC[C@@H](c1ccccc1)c1c(O)c2ccccc2oc1=O |&1:2,r|, CC[C@@H](c1ccccc1)c1c(O)c2ccccc2oc1=O |&1:2,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3183","phenserine","acetylcholinesterase inhibitor, beta amyloid synthesis inhibitor","ACHE, BCHE",NA,NA,"CN1CC[C@]2(C)[C@H]1N(C)c1ccc(OC(=O)Nc3ccccc3)cc21, CN1CC[C@]2(C)[C@H]1N(C)c1ccc(OC(=O)Nc3ccccc3)cc21, CN1CC[C@]2(C)[C@H]1N(C)c1ccc(OC(=O)Nc3ccccc3)cc21, CN1CC[C@]2(C)[C@H]1N(C)c1ccc(OC(=O)Nc3ccccc3)cc21","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3184","phentolamine","adrenergic receptor antagonist","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C","endocrinology, cardiology","pheochromocytoma, hypertension","Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|, Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|, Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|, Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|, Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|, Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|, Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,6,1,1,1,1
"3185","phenylbutazone","cyclooxygenase inhibitor, prostanoid receptor antagonist","PTGIS, PTGS1, PTGS2",NA,NA,"CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1","Withdrawn",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3186","phenylbutyrate","HDAC inhibitor","HDAC1","metabolism","urea cycle disorders","OC(=O)CCCc1ccccc1, OC(=O)CCCc1ccccc1, OC(=O)CCCc1ccccc1, OC(=O)CCCc1ccccc1, OC(=O)CCCc1ccccc1, OC(=O)CCCc1ccccc1, OC(=O)CCCc1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3187","phenylephrine","adrenergic receptor agonist","ADRA1A, ADRA1B, ADRA1D","otolaryngology, gastroenterology, cardiology","nasal congestion, hemorrhoids, hypotension","CNC[C@H](O)c1cccc(O)c1, CNC[C@H](O)c1cccc(O)c1, CNC[C@H](O)c1cccc(O)c1, CNC[C@H](O)c1cccc(O)c1, CNC[C@H](O)c1cccc(O)c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,1,1,1,1
"3188","phenytoin","hydantoin antiepileptic","SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A","neurology/psychiatry","seizures","O=C1NC(=O)C(N1)(c1ccccc1)c1ccccc1, O=C1NC(=O)C(N1)(c1ccccc1)c1ccccc1, O=C1NC(=O)C(N1)(c1ccccc1)c1ccccc1, O=C1NC(=O)C(N1)(c1ccccc1)c1ccccc1","Launched",0,0,1,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3189","PhiKan-083","p53 stabilizing agent","TP53",NA,NA,"CCn1c2ccccc2c2cc(CNC)ccc12, CCn1c2ccccc2c2cc(CNC)ccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3190","phloretin","sodium/glucose cotransporter inhibitor","AQP9, CLCN3, SLC23A1",NA,NA,"Oc1ccc(CCC(=O)c2c(O)cc(O)cc2O)cc1, Oc1ccc(CCC(=O)c2c(O)cc(O)cc2O)cc1, Oc1ccc(CCC(=O)c2c(O)cc(O)cc2O)cc1","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3191","phlorizin","sodium/glucose cotransporter inhibitor","SLC5A1, SLC5A11, SLC5A2, SLC5A3",NA,NA,"OC[C@H]1O[C@@H](Oc2cc(O)cc(O)c2C(=O)CCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O","Preclinical",1,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3192","phortress","aryl hydrocarbon receptor ligand","AHR",NA,NA,"Cc1cc(ccc1NC(=O)[C@@H](N)CCCCN)-c1nc2cc(F)ccc2s1, Cc1cc(ccc1NC(=O)[C@@H](N)CCCCN)-c1nc2cc(F)ccc2s1, Cc1cc(ccc1NC(=O)[C@@H](N)CCCCN)-c1nc2cc(F)ccc2s1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3193","PHP-501","GABA receptor antagonist","GABRA1, GABRB2, GABRG2",NA,NA,"On1ncc(C2CCNCC2)c1-c1cccc(c1)-c1ccccc1, On1ncc(C2CCNCC2)c1-c1cccc(c1)-c1ccccc1, On1ncc(C2CCNCC2)c1-c1cccc(c1)-c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0
"3194","PHT-427","AKT inhibitor, pyruvate dehydrogenase inhibitor","AKT2, PDPK1",NA,NA,"CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1, CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1, CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1, CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1, CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3195","PHTPP","estrogen receptor antagonist","ESR2",NA,NA,"Oc1ccc(cc1)-c1c(nn2c(cc(nc12)C(F)(F)F)C(F)(F)F)-c1ccccc1, Oc1ccc(cc1)-c1c(nn2c(cc(nc12)C(F)(F)F)C(F)(F)F)-c1ccccc1, Oc1ccc(cc1)-c1c(nn2c(cc(nc12)C(F)(F)F)C(F)(F)F)-c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3196","physostigmine","acetylcholinesterase inhibitor, cholinesterase inhibitor","ACHE, BCHE","cardiology, neurology/psychiatry, ophthalmology, gastroenterology","hypotension, Alzheimer's disease, glaucoma, gastroparesis","CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1, CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1, CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1, CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1, CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1, CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1, CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1, CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1, CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1, CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3197","PI-103","mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC",NA,NA,"Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3198","piboserod","serotonin receptor antagonist","HTR2B, HTR4",NA,NA,"CCCCN1CCC(CNC(=O)c2c3OCCCn3c3ccccc23)CC1, CCCCN1CCC(CNC(=O)c2c3OCCCn3c3ccccc23)CC1, CCCCN1CCC(CNC(=O)c2c3OCCCn3c3ccccc23)CC1","Phase 2",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3199","pibrentasvir","antiviral","NS5A","infectious disease","hepatitis c","C[C@H]([C@@H](C(=O)N1CCC[C@H]1c2[nH]c3cc(c(cc3n2)[C@H]4CC[C@@H](N4c5cc(c(c(c5)F)N6CCC(CC6)c7ccc(cc7)F)F)c8cc9c(cc8F)[nH]c(n9)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)OC)NC(=O)OC)F)NC(=O)OC)OC","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3200","picartamide","H+/K+-ATPase inhibitor","ATP4A",NA,NA,"CNC(=S)[C@]1(CCCS1)c1ccccn1 |&1:4,r|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3201","piceatannol","SYK inhibitor","ATP5A1, ATP5B, ATP5C1, IRF3",NA,NA,"Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1, Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1, Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1, Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1, Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1, Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1, Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1, Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3202","piclamilast","phosphodiesterase inhibitor","PDE4A, PDE4B, PDE4C, PDE4D",NA,NA,"COc1ccc(cc1OC1CCCC1)C(=O)Nc1c(Cl)cncc1Cl, COc1ccc(cc1OC1CCCC1)C(=O)Nc1c(Cl)cncc1Cl, COc1ccc(cc1OC1CCCC1)C(=O)Nc1c(Cl)cncc1Cl, COc1ccc(cc1OC1CCCC1)C(=O)Nc1c(Cl)cncc1Cl","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3203","picotamide","thromboxane receptor antagonist, thromboxane synthase inhibitor","TBXA2R","hematology","thrombosis","COc1ccc(cc1C(=O)NCc1cccnc1)C(=O)NCc1cccnc1, COc1ccc(cc1C(=O)NCc1cccnc1)C(=O)NCc1cccnc1, COc1ccc(cc1C(=O)NCc1cccnc1)C(=O)NCc1cccnc1, COc1ccc(cc1C(=O)NCc1cccnc1)C(=O)NCc1cccnc1, COc1ccc(cc1C(=O)NCc1cccnc1)C(=O)NCc1cccnc1, COc1ccc(cc1C(=O)NCc1cccnc1)C(=O)NCc1cccnc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3204","picrotin","GABA receptor antagonist","GABRA1, GABRR1, GLRA1, GLRA2, GLRA3, GLRB","Pulmonology","respiratory distress syndrome (rds)","CC(C)(O)[C@H]1[C@H]2OC(=O)[C@@H]1[C@@]1(O)C[C@H]3O[C@]33C(=O)O[C@@H]2[C@@]13C |&1:4,&2:5,&3:9,&4:10,&5:13,&6:15,&7:19,&8:20,r|, CC(C)(O)[C@H]1[C@H]2OC(=O)[C@@H]1[C@@]1(O)C[C@H]3O[C@]33C(=O)O[C@@H]2[C@@]13C |&1:4,&2:5,&3:9,&4:10,&5:13,&6:15,&7:19,&8:20,r|, CC(C)(O)[C@H]1[C@H]2OC(=O)[C@@H]1[C@@]1(O)C[C@H]3O[C@]33C(=O)O[C@@H]2[C@@]13C |&1:4,&2:5,&3:9,&4:10,&5:13,&6:15,&7:19,&8:20,r|, CC(C)(O)[C@H]1[C@H]2OC(=O)[C@@H]1[C@@]1(O)C[C@H]3O[C@]33C(=O)O[C@@H]2[C@@]13C |&1:4,&2:5,&3:9,&4:10,&5:13,&6:15,&7:19,&8:20,r|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,1,1,1,1
"3205","picrotoxinin","GABA receptor antagonist","GLRA1, GLRA2, GLRA3, GLRB, HTR3A, HTR3B",NA,NA,"CC(=C)[C@@H]1[C@H]2OC(=O)[C@H]1[C@]1(O)C[C@H]3O[C@]33C(=O)O[C@H]2[C@]13C, CC(=C)[C@@H]1[C@H]2OC(=O)[C@H]1[C@]1(O)C[C@H]3O[C@]33C(=O)O[C@H]2[C@]13C","Preclinical",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3206","pifithrin-alpha","TP53 inhibitor","TP53",NA,NA,"Cc1ccc(cc1)C(=O)Cn1c2CCCCc2sc1=N, Cc1ccc(cc1)C(=O)Cn1c2CCCCc2sc1=N, Cc1ccc(cc1)C(=O)Cn1c2CCCCc2sc1=N, Cc1ccc(cc1)C(=O)Cn1c2CCCCc2sc1=N","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3207","pifithrin-cyclic","TP53 inhibitor","TP53",NA,NA,"Cc1ccc(cc1)-c1cn2c3CCCCc3sc2n1, Cc1ccc(cc1)-c1cn2c3CCCCc3sc2n1, Cc1ccc(cc1)-c1cn2c3CCCCc3sc2n1, Cc1ccc(cc1)-c1cn2c3CCCCc3sc2n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3208","pifithrin-mu","HSP inhibitor","HSPA1A, TP53",NA,NA,"NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3209","PIK-293","PI3K inhibitor","PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,"Cc1ccccc1-n1c(Cn2ncc3c(N)ncnc23)nc2cccc(C)c2c1=O, Cc1ccccc1-n1c(Cn2ncc3c(N)ncnc23)nc2cccc(C)c2c1=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3210","PIK-294","PI3K inhibitor","PIK3CB, PIK3CD, PIK3CG",NA,NA,"Cc1ccccc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc23)nc2cccc(C)c2c1=O, Cc1ccccc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc23)nc2cccc(C)c2c1=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3211","PIK-75","DNA protein kinase inhibitor, PI3K inhibitor","PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC",NA,NA,"CN(\N=C\c1cnc2ccc(Br)cn12)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O, CN(\N=C\c1cnc2ccc(Br)cn12)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O, CN(\N=C\c1cnc2ccc(Br)cn12)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3212","PIK-93","PI3K inhibitor","PI4KB, PIK3C3, PIK3CG",NA,NA,"CC(=O)Nc1nc(C)c(s1)-c1ccc(Cl)c(c1)S(=O)(=O)NCCO, CC(=O)Nc1nc(C)c(s1)-c1ccc(Cl)c(c1)S(=O)(=O)NCCO, CC(=O)Nc1nc(C)c(s1)-c1ccc(Cl)c(c1)S(=O)(=O)NCCO, CC(=O)Nc1nc(C)c(s1)-c1ccc(Cl)c(c1)S(=O)(=O)NCCO, CC(=O)Nc1nc(C)c(s1)-c1ccc(Cl)c(c1)S(=O)(=O)NCCO","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3213","pilocarpine","acetylcholine receptor agonist","CHRM1, CHRM2, CHRM3, CHRM4, CHRM5","ophthalmology, cardiology","glaucoma, hypertension","CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,5,0,0,1,1,1,1
"3214","pilsicainide","sodium channel blocker","SCN5A","cardiology","cardiac arrythmia","Cc1cccc(C)c1NC(=O)CC12CCCN1CCC2, Cc1cccc(C)c1NC(=O)CC12CCCN1CCC2, Cc1cccc(C)c1NC(=O)CC12CCCN1CCC2","Launched",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3215","PIM-1-Inhibitor-2","Pim kinase inhibitor","PIM1",NA,NA,"Nc1nccc(n1)-c1ccc2noc(-c3ccc(Cl)cc3)c2c1, Nc1nccc(n1)-c1ccc2noc(-c3ccc(Cl)cc3)c2c1, Nc1nccc(n1)-c1ccc2noc(-c3ccc(Cl)cc3)c2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3216","pimavanserin","serotonin receptor inverse agonist","DRD2, HTR2A","neurology/psychiatry","Parkinson's Disease","CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1, CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1","Launched",0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,1,1,1
"3217","pimitespib","hsp90 inhibitor","HSP90AB1","oncology","gastrointestinal stromal tumors (gist)","CCc1cc(ccc1n2nc(C(C)C)c3c(ccnc23)n4cnc(c4)c5cnn(C)c5)C(=O)N","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3218","pimobendan","calcium sensitizer, phosphodiesterase inhibitor, calcium sensitizer, phosphodiesterase inhibitor","PDE3A","cardiology","congestive heart failure","COc1ccc(cc1)-c1nc2ccc(cc2[nH]1)C1=NNC(=O)C[C@H]1C |&1:23,t:20|, COc1ccc(cc1)-c1nc2ccc(cc2[nH]1)C1=NNC(=O)C[C@H]1C |&1:23,t:20|, COc1ccc(cc1)-c1nc2cc(ccc2[nH]1)C1=NNC(=O)CC1C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3219","pimozide","dopamine receptor antagonist","CACNA1I, CALM1, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, KCNA10, KCNH2","neurology/psychiatry","Tourette's disorder","Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1, Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1, Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1, Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1, Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1","Launched",0,0,0,0,0,0,0,0,1,2,1,1,0,0,1,5,0,0,0,0,1,1,1,1
"3220","pinacidil","ATP channel activator, potassium channel activator","ABCC8, ABCC9","cardiology","hypertension","C[C@@H](NC(Nc1ccncc1)=NC#N)C(C)(C)C |&1:1,r|, C[C@@H](NC(Nc1ccncc1)=NC#N)C(C)(C)C |&1:1,r|, C[C@@H](NC(Nc1ccncc1)=NC#N)C(C)(C)C |&1:1,r|, C[C@@H](NC(Nc1ccncc1)=NC#N)C(C)(C)C |&1:1,r|, C[C@@H](NC(Nc1ccncc1)=NC#N)C(C)(C)C |&1:1,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3221","pinaverium","T-type calcium channel blocker","CACNA1C","gastroenterology","irritable bowel syndrome","COc1cc(Br)c(C[N+]2(CCOCC[C@H]3CC[C@@H]4C[C@H]3C4(C)C)CCOCC2)cc1OC |&1:17,19,&2:14,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3222","pindolol","adrenergic receptor antagonist","ADRB1, ADRB2, HTR1A, HTR2A, HTR2B","cardiology","hypertension","CC(C)NC[C@@H](O)COc1cccc2[nH]ccc12 |&1:5,r|, CC(C)NC[C@@H](O)COc1cccc2[nH]ccc12 |&1:5,r|, CC(C)NC[C@@H](O)COc1cccc2[nH]ccc12 |&1:5,r|, CC(C)NC[C@@H](O)COc1cccc2[nH]ccc12 |&1:5,r|, CC(C)NC[C@@H](O)COc1cccc2[nH]ccc12 |&1:5,r|","Launched",0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,1,2,1,1,1,1
"3223","pindolol-(-)","adrenergic receptor antagonist, serotonin receptor antagonist","HTR1A",NA,NA,"CC(C)NC[C@H](O)COc1cccc2[nH]ccc12, CC(C)NC[C@H](O)COc1cccc2[nH]ccc12","Phase 2",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3224","pinocembrin","cytochrome P450 inhibitor","CYP1B1",NA,NA,"Oc1cc(O)c2C(=O)C[C@H](Oc2c1)c1ccccc1, Oc1cc(O)c2C(=O)C[C@H](Oc2c1)c1ccccc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3225","pioglitazone","insulin sensitizer, PPAR receptor agonist","PPARG, TRPM3","endocrinology","diabetes mellitus","CCc1ccc(CCOc2ccc(C[C@H]3SC(=O)NC3=O)cc2)nc1 |&1:14|, CCc1ccc(CCOc2ccc(C[C@H]3SC(=O)NC3=O)cc2)nc1 |&1:14|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3226","pipamperone","dopamine receptor antagonist","DRD2, HRH1, HTR1A, HTR1B, HTR1D, HTR2A","neurology/psychiatry","schizophrenia","NC(=O)C1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)N1CCCCC1, NC(=O)C1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)N1CCCCC1, NC(=O)C1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)N1CCCCC1","Launched",0,0,0,0,0,0,0,0,1,4,1,1,0,0,1,1,0,0,0,0,1,1,1,1
"3227","pipenzolate","cholinergic receptor antagonist","CHRM1","neurology/psychiatry","spasms","CC[N@@+]1(C)CCC[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:2,&2:7|, CC[N@@+]1(C)CCC[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:2,&2:7|, CC[N@@+]1(C)CCC[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:2,&2:7|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,1
"3228","pipequaline","benzodiazepine receptor agonist","ALB, GABRA1","neurology/psychiatry","drowsiness","C(Cc1cc(nc2ccccc12)-c1ccccc1)C1CCNCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1
"3229","piperazine","benzodiazepine receptor agonist","GABRB3","infectious disease","gastrointestinal roundworms","C1CNCCN1, C1CNCCN1, C1CNCCN1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1
"3230","piperidolate","acetylcholine receptor antagonist","CHRM1","neurology/psychiatry","spasms","CCN1CCC[C@@H](C1)OC(=O)C(c1ccccc1)c1ccccc1 |&1:6|, CCN1CCC[C@@H](C1)OC(=O)C(c1ccccc1)c1ccccc1 |&1:6|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,1
"3231","piperine","monoamine oxidase inhibitor","MAOA, MAOB, TRPV1",NA,NA,"O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1","Phase 1",0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3232","pipotiazine","dopamine receptor antagonist","DRD1, DRD2, HTR1A, HTR2A","neurology/psychiatry","schizophrenia","CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN3CCC(CCO)CC3)c2c1","Launched",0,0,0,0,0,0,0,0,1,2,0,0,0,0,1,2,0,0,0,0,1,1,1,1
"3233","pipotiazine-palmitate","dopamine receptor antagonist, serotonin receptor antagonist","DRD1, DRD2, HTR1A, HTR2A","neurology/psychiatry","schizophrenia","CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CCCN2c3ccccc3Sc3ccc(cc23)S(=O)(=O)N(C)C)CC1","Launched",0,0,0,0,0,0,0,0,1,2,0,0,0,0,1,2,0,0,0,0,1,1,1,1
"3234","piracetam","acetylcholine receptor agonist","GRIA1, GRIA2, GRIA3, GRIA4","neurology/psychiatry","senile dementia","NC(=O)CN1CCCC1=O, NC(=O)CN1CCCC1=O, NC(=O)CN1CCCC1=O, NC(=O)CN1CCCC1=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3235","pirarubicin","topoisomerase inhibitor","TOP2A","oncology","breast cancer","COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O[C@@H]6CCCCO6)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O[C@@H]6CCCCO6)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O[C@@H]6CCCCO6)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O[C@@H]6CCCCO6)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3236","pirbuterol","adrenergic receptor agonist","ADRB1, ADRB2","pulmonary","bronchospasm","Oc1ccc(nc1CO)C(O)CNC(C)(C)C","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,1,1,1,1
"3237","pirenperone","serotonin receptor antagonist","HTR2A, HTR7",NA,NA,"Cc1nc2ccccn2c(=O)c1CCN1CCC(CC1)C(=O)c1ccc(F)cc1, Cc1nc2ccccn2c(=O)c1CCN1CCC(CC1)C(=O)c1ccc(F)cc1, Cc1nc2ccccn2c(=O)c1CCN1CCC(CC1)C(=O)c1ccc(F)cc1","Preclinical",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3238","pirenzepine","acetylcholine receptor antagonist","CHRM1, CHRM2, CHRM3, CHRM4, CHRM5","gastroenterology","peptic ulcer disease (PUD)","CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1, CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1, CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,5,0,0,1,1,1,1
"3239","piretanide","glucocorticoid receptor agonist","SLC12A1, SLC12A2","cardiology","hypertension, edema","NS(=O)(=O)c1cc(cc(N2CCCC2)c1Oc1ccccc1)C(O)=O, NS(=O)(=O)c1cc(cc(N2CCCC2)c1Oc1ccccc1)C(O)=O, NS(=O)(=O)c1cc(cc(N2CCCC2)c1Oc1ccccc1)C(O)=O","Launched",1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3240","pirfenidone","TGF beta receptor inhibitor","FURIN, TNF","pulmonary","idiopathic pulmonary fibrosis (IPF)","Cc1ccc(=O)n(c1)-c1ccccc1, Cc1ccc(=O)n(c1)-c1ccccc1, Cc1ccc(=O)n(c1)-c1ccccc1, Cc1ccc(=O)n(c1)-c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3241","piribedil","dopamine receptor agonist","ADRA1A, ADRA2A, ADRA2C, DRD2, DRD3, DRD4, HTR1A, HTR2B","neurology/psychiatry","Parkinson's Disease, dizziness","C(N1CCN(CC1)c1ncccn1)c1ccc2OCOc2c1, C(N1CCN(CC1)c1ncccn1)c1ccc2OCOc2c1","Launched",0,0,0,0,0,0,0,0,1,2,0,0,0,0,1,3,0,0,1,3,1,1,1,1
"3242","piricapiron","dopamine receptor antagonist, serotonin receptor antagonist, dopamine receptor antagonist, serotonin receptor antagonist","HTR2A",NA,NA,"CC1(C)C2CCC1(C)C(=O)N(CCCCN1CCN(CC1)c1ccccn1)C2=O, CC1(C)[C@@H]2CC[C@@]1(C)C(=O)N(CCCCN1CCN(CC1)c1ccccn1)C2=O |&1:3,6|","Phase 2",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3243","pirinixic-acid","PPAR receptor agonist","PPARA",NA,NA,"Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C, Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C, Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C, Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C, Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3244","pirlindole","monoamine oxidase inhibitor","MAOA","neurology/psychiatry","depression","Cc1ccc2n3CCN[C@H]4CCCc(c34)c2c1 |&1:9|","Launched",0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3245","piroxicam","cyclooxygenase inhibitor","PTGS1, PTGS2","rheumatology","osteoarthritis, rheumatoid arthritis, osteoarthritis, rheumatoid arthritis","CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O |t:12|","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3246","piroximone","phosphodiesterase inhibitor","PDE3A",NA,NA,"CCc1[nH]c(=O)[nH]c1C(=O)c1ccncc1, CCc1[nH]c(=O)[nH]c1C(=O)c1ccncc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3247","PIT","purinergic receptor antagonist","P2RY1",NA,NA,"[O-][N+]1=C(C(=O)c2ccccc12)c1ccccn1 |t:1|, [O-][N+]1=C(C(=O)c2ccccc12)c1ccccn1 |t:1|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3248","pitavastatin","HMGCR inhibitor","HMGCR","endocrinology","hyperlipidemia","O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3249","pitolisant","histamine receptor antagonist","HRH3",NA,NA,"Clc1ccc(CCCOCCCN2CCCCC2)cc1, Clc1ccc(CCCOCCCN2CCCCC2)cc1, Clc1ccc(CCCOCCCN2CCCCC2)cc1, Clc1ccc(CCCOCCCN2CCCCC2)cc1, Clc1ccc(CCCOCCCN2CCCCC2)cc1","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
"3250","pivagabine","corticotropin releasing factor receptor antagonist","CRHR1, CRHR2","neurology/psychiatry","depression","CC(C)(C)C(=O)NCCCC(O)=O, CC(C)(C)C(=O)NCCCC(O)=O, CC(C)(C)C(=O)NCCCC(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3251","pivanex","HDAC inhibitor","HDAC1, HDAC2, HDAC3, HDAC8",NA,NA,"CCCC(=O)OCOC(=O)C(C)(C)C, CCCC(=O)OCOC(=O)C(C)(C)C, CCCC(=O)OCOC(=O)C(C)(C)C","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3252","pixantrone","topoisomerase inhibitor","TOP2A","hematologic malignancy","non-Hodgkin lymphoma (NHL)","NCCNc1ccc(NCCN)c2C(=O)c3cnccc3C(=O)c12, NCCNc1ccc(NCCN)c2C(=O)c3cnccc3C(=O)c12, NCCNc1ccc(NCCN)c2C(=O)c3cnccc3C(=O)c12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3253","pizotifen","serotonin receptor antagonist","HTR1A, HTR2A, HTR2C","neurology/psychiatry","migraine headache","CN1CCC(CC1)=C1c2ccsc2CCc2ccccc12, CN1CCC(CC1)=C1c2ccsc2CCc2ccccc12, CN1CCC(CC1)=C1c2ccsc2CCc2ccccc12, CN1CCC(CC1)=C1c2ccsc2CCc2ccccc12","Launched",0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3254","PI4KIII-beta-inhibitor-1","PI4K inhibitor","PI4K2B",NA,NA,"COc1ccc(cc1S(=O)(=O)Nc1ccc(O)cc1)-c1sc(NC(=O)C(C)(C)C)nc1C, COc1ccc(cc1S(=O)(=O)Nc1ccc(O)cc1)-c1sc(NC(=O)C(C)(C)C)nc1C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3255","PJ-34","PARP inhibitor","EEF2, PARP1, PARP15, PARP3",NA,NA,"CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3256","PK-THPP","potassium channel blocker","KCNK9",NA,NA,"CCCC(=O)C1CCN(CC1)c1ncnc2CCN(Cc12)C(=O)c1ccc(cc1)-c1ccccc1, CCCC(=O)C1CCN(CC1)c1ncnc2CCN(Cc12)C(=O)c1ccc(cc1)-c1ccccc1, CCCC(=O)C1CCN(CC1)c1ncnc2CCN(Cc12)C(=O)c1ccc(cc1)-c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3257","PK-11195","benzodiazepine receptor antagonist","TSPO",NA,NA,"CC[C@@H](C)N(C)C(=O)c1cc2ccccc2c(n1)-c1ccccc1Cl |&1:2,r|, CC[C@@H](C)N(C)C(=O)c1cc2ccccc2c(n1)-c1ccccc1Cl |&1:2,r|, CC[C@@H](C)N(C)C(=O)c1cc2ccccc2c(n1)-c1ccccc1Cl |&1:2,r|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3258","PK-44","dipeptidyl peptidase inhibitor","DPP4",NA,NA,"N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1[nH]nc2c(F)c(F)ccc12, N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1[nH]nc2c(F)c(F)ccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3259","PKI-166","EGFR inhibitor","EGFR",NA,NA,"C[C@@H](Nc1ncnc2[nH]c(cc12)-c1ccc(O)cc1)c1ccccc1, C[C@@H](Nc1ncnc2[nH]c(cc12)-c1ccc(O)cc1)c1ccccc1, C[C@@H](Nc1ncnc2[nH]c(cc12)-c1ccc(O)cc1)c1ccccc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3260","PKI-179","mTOR inhibitor, PI3K inhibitor","MTOR",NA,NA,"O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1[C@H]2CC[C@@H]1COC2 |&1:29,&2:32|, O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1[C@H]2CC[C@@H]1COC2 |&1:29,&2:32|, O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1[C@H]2CC[C@@H]1COC2 |&1:29,&2:32|, O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1[C@H]2CC[C@@H]1COC2 |&1:29,&2:32|, O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1[C@H]2CC[C@@H]1COC2 |&1:29,&2:32|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3261","plerixafor","CC chemokine receptor antagonist","ACKR3, CCR4, CXCR4","hematologic malignancy","non-Hodgkin lymphoma (NHL), multiple myeloma","C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3262","plurisin-1","stearoyl-CoA desaturase inhibitor","SCD",NA,NA,"O=C(NNc1ccccc1)c1ccncc1, O=C(NNc1ccccc1)c1ccncc1, O=C(NNc1ccccc1)c1ccncc1, O=C(NNc1ccccc1)c1ccncc1, O=C(NNc1ccccc1)c1ccncc1, O=C(NNc1ccccc1)c1ccncc1, O=C(NNc1ccccc1)c1ccncc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3263","PLX4720","RAF inhibitor","BRAF, KDR",NA,NA,"CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3264","PLX647","receptor tyrosine protein kinase inhibitor","CSF1R, KIT",NA,NA,"FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)cc1, FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3265","PLX8394","serine/threonine kinase inhibitor","BRAF",NA,NA,"F[C@@H]1CCN(C1)S(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2cnc(nc2)C2CC2)c1F, F[C@@H]1CCN(C1)S(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2cnc(nc2)C2CC2)c1F, F[C@@H]1CCN(C1)S(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2cnc(nc2)C2CC2)c1F","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3266","PMPA","glutamate receptor antagonist","FOLH1",NA,NA,"OC(=O)CC[C@@H](CP(O)(O)=O)C(O)=O |&1:5,r|, OC(=O)CC[C@@H](CP(O)(O)=O)C(O)=O |&1:5,r|, OC(=O)CC[C@@H](CP(O)(O)=O)C(O)=O |&1:5,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3267","PNU-120596","acetylcholine receptor agonist","CHRNA7",NA,NA,"COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl, COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl, COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl, COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl, COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl, COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl, COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
"3268","PNU-142633","serotonin receptor agonist","HTR1D",NA,NA,"CNC(=O)c1ccc2[C@H](CCN3CCN(CC3)c3ccc(cc3)C(N)=O)OCCc2c1, CNC(=O)c1ccc2[C@H](CCN3CCN(CC3)c3ccc(cc3)C(N)=O)OCCc2c1","Phase 2",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3269","PNU-177864","dopamine receptor antagonist","DRD3",NA,NA,"CCCNCCc1ccc(NS(=O)(=O)c2ccc(OC(F)(F)F)cc2)cc1, CCCNCCc1ccc(NS(=O)(=O)c2ccc(OC(F)(F)F)cc2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0
"3270","PNU-22394","serotonin receptor agonist","HTR2A, HTR2B, HTR2C, MAOA, MAOB",NA,NA,"Cn1c2CCNCCc2c2ccccc12, Cn1c2CCNCCc2c2ccccc12","Phase 2",0,0,0,0,0,0,1,2,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3271","PNU-282987","cholinergic receptor agonist","CHRNA7",NA,NA,"Clc1ccc(cc1)C(=O)N[C@H]1CN2CCC1CC2, Clc1ccc(cc1)C(=O)N[C@H]1CN2CCC1CC2, Clc1ccc(cc1)C(=O)N[C@H]1CN2CCC1CC2, Clc1ccc(cc1)C(=O)N[C@H]1CN2CCC1CC2","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
"3272","PNU-74654","beta-catenin inhibitor","CTNNB1, TCF4",NA,NA,"Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1, Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1, Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1, Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1, Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1, Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3273","PNU-89843","benzodiazepine receptor agonist","GABBR1",NA,NA,"Cc1cc2c(nc(nc2n1C)N1CCCC1)N1CCCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3274","podophyllotoxin","microtubule inhibitor, tubulin polymerization inhibitor","IGF1R, TOP2A, TUBA4A, TUBB","infectious disease","genital warts","COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3275","polydatin","ICAM1 expression inhibitor","ICAM1",NA,NA,"OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3276","polyinosine","immunostimulant","HPRT1, IMPDH2, PYGM",NA,NA,"O[C@H]1[C@@H](COP(O)(O)=O)O[C@@H]([C@@H]1O)n1cnc2c1[nH]cnc2=O |&1:1,&2:2,&3:10,&4:11,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3277","polythiazide","sodium/chloride cotransporter inhibitor","SLC12A3","cardiology, gastroenterology, rheumatology, nephrology","edema, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis (AGN), chronic renal failure, hypertension","CN1[C@@H](CSCC(F)(F)F)Nc2cc(Cl)c(cc2S1(=O)=O)S(N)(=O)=O |&1:2,r|, CN1[C@@H](CSCC(F)(F)F)Nc2cc(Cl)c(cc2S1(=O)=O)S(N)(=O)=O |&1:2,r|","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3278","ponatinib","Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK","hematologic malignancy","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3279","ponesimod","sphingosine 1-phosphate receptor agonist","S1PR1",NA,NA,"CCC\N=C1/S\C(=C/c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C, CCC\N=C1/S\C(=C/c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C, CCC\N=C1/S\C(=C/c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3280","posaconazole","sterol demethylase inhibitor","CYP3A4","infectious disease","oropharyngeal candidiasis","CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O, CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O, CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O, CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O, CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O, CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O, CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3281","potassium-canrenoate","mineralocorticoid receptor antagonist","NR3C2","cardiology","edema","C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O |c:6,t:8|, C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O |c:6,t:8|, C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O |c:6,t:8|, C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O |c:6,t:8|, C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O |c:6,t:8|, C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O |c:6,t:8|, C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O |c:6,t:8|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3282","pozanicline","acetylcholine receptor antagonist","CHRNA4, CHRNB2",NA,NA,"Cc1ncccc1OC[C@@H]1CCCN1, Cc1ncccc1OC[C@@H]1CCCN1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0
"3283","poziotinib","EGFR inhibitor","EGFR, ERBB2, ERBB4",NA,NA,"COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3284","PP-1","SRC inhibitor","HCK, RET",NA,NA,"Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C, Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C, Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C, Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3285","PP-121","protein tyrosine kinase inhibitor","ABL1, EGFR, HCK, KDR, MTOR, PDGFRA, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC, SRC",NA,NA,"Nc1ncnc2n(nc(-c3cnc4[nH]ccc4c3)c12)C1CCCC1, Nc1ncnc2n(nc(-c3cnc4[nH]ccc4c3)c12)C1CCCC1, Nc1ncnc2n(nc(-c3cnc4[nH]ccc4c3)c12)C1CCCC1, Nc1ncnc2n(nc(-c3cnc4[nH]ccc4c3)c12)C1CCCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3286","PP-2","SRC inhibitor","ABL1, LCK, RIPK2, SRC",NA,NA,"CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3287","PPT","estrogen receptor agonist","ESR1",NA,NA,"CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1, CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1, CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1, CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3288","PPY-A","Abl kinase inhibitor","ABL1, BCR",NA,NA,"COc1ccccc1-c1c[nH]c2ncc(cc12)-c1cncc(c1)C(=O)N(C)C, COc1ccccc1-c1c[nH]c2ncc(cc12)-c1cncc(c1)C(=O)N(C)C, COc1ccccc1-c1c[nH]c2ncc(cc12)-c1cncc(c1)C(=O)N(C)C, COc1ccccc1-c1c[nH]c2ncc(cc12)-c1cncc(c1)C(=O)N(C)C, COc1ccccc1-c1c[nH]c2ncc(cc12)-c1cncc(c1)C(=O)N(C)C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3289","PP242","mTOR inhibitor","MTOR, PASK",NA,NA,"CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3290","PQ-401","IGF-1 inhibitor","IGF1R",NA,NA,"COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3291","practolol","adrenergic receptor antagonist","ADRB1",NA,NA,"CC(C)NC[C@@H](O)COc1ccc(NC(C)=O)cc1 |&1:5,r|, CC(C)NC[C@@H](O)COc1ccc(NC(C)=O)cc1 |&1:5,r|","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
"3292","pralatrexate","dihydrofolate reductase inhibitor","DHFR","hematologic malignancy","peripheral T-cell lymphoma (PTCL)","Nc1nc(N)c2nc(C[C@@H](CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 |a:22,&1:9|, Nc1nc(N)c2nc(C[C@@H](CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 |a:22,&1:9|, Nc1nc(N)c2nc(C[C@@H](CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 |a:22,&1:9|, Nc1nc(N)c2nc(C[C@@H](CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 |a:22,&1:9|, Nc1nc(N)c2nc(C[C@@H](CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 |a:22,&1:9|, Nc1nc(N)c2nc(C[C@@H](CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 |a:22,&1:9|, Nc1nc(N)c2nc(C[C@@H](CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 |a:22,&1:9|, Nc1nc(N)c2nc(C[C@@H](CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 |a:22,&1:9|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3293","pralidoxime","acetylcholinesterase inhibitor","ACHE, BCHE","critical care","organophosphate poisoning","C[n+]1ccccc1\C=N\O, C[n+]1ccccc1\C=N\O, C[n+]1ccccc1\C=N\O, C[n+]1ccccc1\C=N\O, C[n+]1ccccc1\C=N\O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3294","pralidoxime-chloride","acetylcholinesterase inhibitor","ACHE, BCHE","pulmonary","respiratory depression","C[n+]1ccccc1CN=O, C[n+]1ccccc1CN=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3295","pramipexole","dopamine receptor agonist","ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C","neurology/psychiatry","Parkinson's Disease","CCCN[C@H]1CCc2nc(N)sc2C1, CCCN[C@H]1CCc2nc(N)sc2C1, CCCN[C@H]1CCc2nc(N)sc2C1, CCCN[C@H]1CCc2nc(N)sc2C1","Launched",0,0,0,0,0,0,0,0,1,6,0,0,0,0,1,5,0,0,1,3,1,1,1,1
"3296","pranidipine","calcium channel blocker","CACNA1C",NA,NA,"COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1 |r,c:4,9|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3297","pranlukast","leukotriene receptor antagonist","CYSLTR1, CYSLTR2, IL5, MUC2, NFKB1, RNASE3, TNF","pulmonary","bronchospasm, asthma","O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3298","prasugrel","purinergic receptor antagonist","P2RY12","cardiology","myocardial infarction, acute coronary syndrome (ACS)","CC(=O)Oc1cc2CN(CCc2s1)[C@@H](C(=O)C1CC1)c1ccccc1F |&1:13,r|, CC(=O)Oc1cc2CN(CCc2s1)[C@@H](C(=O)C1CC1)c1ccccc1F |&1:13,r|, CC(=O)Oc1cc2CN(CCc2s1)[C@@H](C(=O)C1CC1)c1ccccc1F |&1:13,r|, CC(=O)Oc1cc2CN(CCc2s1)[C@@H](C(=O)C1CC1)c1ccccc1F |&1:13,r|, CC(=O)Oc1cc2CN(CCc2s1)[C@@H](C(=O)C1CC1)c1ccccc1F |&1:13,r|, CC(=O)Oc1cc2CN(CCc2s1)[C@@H](C(=O)C1CC1)c1ccccc1F |&1:13,r|, CC(=O)Oc1cc2CN(CCc2s1)[C@@H](C(=O)C1CC1)c1ccccc1F |&1:13,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3299","pravadoline","cyclooxygenase inhibitor","CNR1, CNR2",NA,NA,"COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2ccccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3300","pravastatin","HMGCR inhibitor","HMGCR, SLCO1B1","endocrinology, cardiology","hypercholesterolemia, myocardial infarction, hyperlipidemia","CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12 |c:13,t:11|","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3301","prazosin","adrenergic receptor antagonist","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, KCNH2, KCNH6, KCNH7","cardiology","hypertension","COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,6,1,1,1,1
"3302","PRE-084","sigma receptor agonist","SIGMAR1",NA,NA,"O=C(OCCN1CCOCC1)C1(CCCCC1)c1ccccc1, O=C(OCCN1CCOCC1)C1(CCCCC1)c1ccccc1, O=C(OCCN1CCOCC1)C1(CCCCC1)c1ccccc1, O=C(OCCN1CCOCC1)C1(CCCCC1)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3303","preclamol","dopamine receptor agonist","DRD2",NA,NA,"CCCN1CCC[C@@H](C1)c1cccc(O)c1, CCCN1CCC[C@@H](C1)c1cccc(O)c1, CCCN1CCC[C@@H](C1)c1cccc(O)c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0
"3304","prednicarbate","glucocorticoid receptor agonist, phospholipase activator","NR3C1, PLA2G1B","Dermatology, dermatology, ophthalmology, neurology/psychiatry","dermatitis, eczema, contact dermatitis, itching","CCOC(=O)O[C@@]1(CC[C@H]2[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@H]3[C@@H](O)C[C@]12C)C(=O)COC(=O)CC |a:6,19,22,25,&1:9,&2:10,&3:21,c:17,t:13|, CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)COC(=O)CC |c:17,t:13|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3305","prednisolone","glucocorticoid receptor agonist","NR3C1, NR3C2, SERPINA6","ophthalmology, dermatology, infectious disease","conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis","C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |a:1,3,15,20,&1:5,&2:6,&3:17,c:13,t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |a:1,3,15,20,&1:5,&2:6,&3:17,c:13,t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |a:1,3,15,20,&1:5,&2:6,&3:17,c:13,t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |a:1,3,15,20,&1:5,&2:6,&3:17,c:13,t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |a:1,3,15,20,&1:5,&2:6,&3:17,c:13,t:9|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3306","prednisolone tebutate","glucocorticoid receptor agonist","NR3C1","General surgery","hemorrhoids","[H][C@@]12CC[C@](O)(C(=O)COC(=O)CC(C)(C)C)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C |c:34,t:30|","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3307","prednisolone-acetate","glucocorticoid receptor agonist","NR3C1","ophthalmology, dermatology, infectious disease","conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis","CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |c:19,t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@H]3CCC4=CC(=O)C=C[C@@]4(C)[C@@H]3[C@@H](O)C[C@]12C |a:7,24,27,&1:11,&2:12,&3:21,&4:23,c:19,t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |c:19,t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |c:19,t:15|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3308","prednisolone-hemisuccinate","glucocorticoid receptor agonist","NR3C1",NA,NA,"C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O |a:1,3,15,20,&1:5,&2:6,&3:17,c:13,t:9|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3309","prednisolone-sodium-phosphate","glucocorticoid receptor agonist","NR3C1","allergy, pulmonary, ophthalmology, infectious disease, rheumatology, endocrinology, neurology/psychiatry, gastroenterology, hematology","allergic rhinitis, asthma, contact dermatitis, mycosis, lupus, hypercalcemia, thyroiditis, congenital adrenal hyperplasia, multiple sclerosis, ulcerative colitis, enteritis, thrombocythemia, pneumonia, meningitis, psoriatic arthritis, rheumatoid arthritis","[H][C@@]12CC[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C |c:31,t:27|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3310","prednisone","glucocorticoid receptor agonist","HSD11B1, NR3C1","endocrinology, rheumatology, infectious disease, dermatology, ophthalmology, hematology, gastroenterology, neurology/psychiatry","congenital adrenal hyperplasia, hypercalcemia, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, bursitis, osteoarthritis, epicondylitis, dermatomyositis, psoriasis, mycosis, conjunctivitis, anemia, ulcerative colitis, enteritis, multiple sclerosis, meningitis","C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |c:13,t:9|, C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |c:13,t:9|, C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |c:13,t:9|, C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |c:13,t:9|, C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |c:13,t:9|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3311","pregnenolone","glutamate receptor modulator","SULT2B1","rheumatology","rheumatoid arthritis","CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:9|, CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:9|, CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:9|, CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:9|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3312","pregnenolone-succinate","GABA receptor negative allosteric modulator","CYP17A1",NA,NA,"CC(=O)[C@H]1CC[C@H]2[C@H]3CC=C4C[C@H](CC[C@]4(C)[C@@H]3CC[C@]12C)OC(=O)CCC(O)=O |a:3,12,15,20,&1:6,&2:7,&3:17,t:9|, CC(=O)[C@H]1CC[C@H]2[C@H]3CC=C4C[C@H](CC[C@]4(C)[C@@H]3CC[C@]12C)OC(=O)CCC(O)=O |a:3,12,15,20,&1:6,&2:7,&3:17,t:9|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3313","preladenant","adenosine receptor antagonist","ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,"COCCOc1ccc(cc1)N1CCN(CCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)CC1, COCCOc1ccc(cc1)N1CCN(CCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)CC1, COCCOc1ccc(cc1)N1CCN(CCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)CC1, COCCOc1ccc(cc1)N1CCN(CCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)CC1, COCCOc1ccc(cc1)N1CCN(CCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)CC1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3314","pretomanid","nitric oxide donor","FASN",NA,NA,"[O-][N+](=O)c1cn2C[C@@H](COc2n1)OCc1ccc(OC(F)(F)F)cc1, [O-][N+](=O)c1cn2C[C@@H](COc2n1)OCc1ccc(OC(F)(F)F)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3315","prilocaine","local anesthetic","SCN5A","neurology/psychiatry","anesthetic","CCCN[C@@H](C)C(=O)Nc1ccccc1C |&1:4,r|, CCCN[C@@H](C)C(=O)Nc1ccccc1C |&1:4,r|","Launched",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3316","PRIMA1","TP53 inhibitor","ACHE",NA,NA,"OCC1(CO)N2CCC(CC2)C1=O, OCC1(CO)N2CCC(CC2)C1=O, OCC1(CO)N2CCC(CC2)C1=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3317","primidone","GABA receptor antagonist","CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA2, GRIK2, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A","neurology/psychiatry","seizures","CCC1(C(=O)NCNC1=O)c1ccccc1, CCC1(C(=O)NCNC1=O)c1ccccc1, CCC1(C(=O)NCNC1=O)c1ccccc1, CCC1(C(=O)NCNC1=O)c1ccccc1, CCC1(C(=O)NCNC1=O)c1ccccc1, CCC1(C(=O)NCNC1=O)c1ccccc1","Launched",0,0,1,10,0,0,0,0,0,0,0,0,1,16,0,0,1,2,0,0,1,1,1,1
"3318","prinaberel","estrogen receptor agonist","ESR2, NCOA1",NA,NA,"Oc1cc(C=C)c2oc(nc2c1)-c1ccc(O)c(F)c1, Oc1cc(C=C)c2oc(nc2c1)-c1ccc(O)c(F)c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3319","priralfinamide","sodium channel blocker","CACNA1B",NA,NA,"C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O, C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O, C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3320","proadifen","nitric oxide synthase inhibitor","NOS1",NA,NA,"CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1, CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1, CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3321","probenecid","uricosuric blocker","PANX1, SLC22A11, SLC22A6, SLC22A8, SLCO1C1","nephrology, rheumatology","hyperuricemia, gout","CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O, CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O, CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O, CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O, CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O","Launched",1,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3322","probucol","atherogenesis inhibitor","ABCA1, ABCB11, CES1","cardiology","coronary artery disease (CAD)","CC(C)(Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3323","procainamide","sodium channel blocker","DNMT1, SCN5A","cardiology","ventricular arrhythmias, ventricular tachycardia (VT)","CCN(CC)CCNC(=O)c1ccc(N)cc1, CCN(CC)CCNC(=O)c1ccc(N)cc1, CCN(CC)CCNC(=O)c1ccc(N)cc1, CCN(CC)CCNC(=O)c1ccc(N)cc1","Launched",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3324","procaine","HMGCR inhibitor","CHRNA2, GRIN3A, HTR3A, KCNMA1, KCNMB1, KCNMB2, KCNMB3, KCNMB4, KCNN1, KCNN2, KCNN3, KCNN4, MAOA, MAOB, RYR1, RYR2, SCN10A, SLC6A3","neurology/psychiatry","anesthetic","CCN(CC)CCOC(=O)c1ccc(N)cc1, CCN(CC)CCOC(=O)c1ccc(N)cc1, CCN(CC)CCOC(=O)c1ccc(N)cc1","Launched",1,1,1,1,0,0,1,2,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,1
"3325","procaterol","adrenergic receptor agonist","ADRB2","pulmonary","asthma","CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12, CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12, CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12, CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"3326","prochlorperazine","dopamine receptor antagonist","DRD1, DRD2, DRD3, DRD4","gastroenterology","nausea, vomiting","CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,0,0,1,1,1,1
"3327","procyclidine","antispasmodic, acetylcholine receptor antagonist","CHRM1","neurology/psychiatry","parkinsonism, Parkinson's Disease, akathisia, dystonia","OC(CCN1CCCC1)(C2CCCCC2)c3ccccc3, COc1cc(N[C@@H](C)CCCN)c2ncccc2c1 |&1:6|","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,1
"3328","profenamine","butyrylcholinesterase inhibitor, cholinergic receptor antagonist","CHRM1","neurology/psychiatry","Parkinson's Disease","CCN(CC)[C@@H](C)CN1c2ccccc2Sc2ccccc12 |&1:5|, CCN(CC)[C@@H](C)CN1c2ccccc2Sc2ccccc12 |&1:5|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,1
"3329","proflavine-hemisulfate","topical anesthetic","F2",NA,NA,"Nc1ccc2cc3ccc(N)cc3nc2c1, Nc1ccc2cc3ccc(N)cc3nc2c1, Nc1ccc2cc3ccc(N)cc3nc2c1, Nc1ccc2cc3ccc(N)cc3nc2c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3330","progesterone","progesterone receptor agonist","CATSPER1, CATSPER2, CATSPER3, CATSPER4, CYP17A1, ESR1, NR3C2, OPRK1, PGR, TRPC5","obstetrics/gynecology, endocrinology","infertility, amenorrhea","CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:10|, CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:10|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3331","proglumetacin","cyclooxygenase inhibitor","PTGS1, PTGS2","neurology/psychiatry","pain relief","CCCN(CCC)C(=O)[C@@H](CCC(=O)OCCCN1CCN(CCOC(=O)Cc2c(C)n(C(=O)c3ccc(Cl)cc3)c3ccc(OC)cc23)CC1)NC(=O)c1ccccc1 |&1:9,r|","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3332","proglumide","CCK receptor antagonist","CCKAR, CCKBR",NA,NA,"CCCN(CCC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccccc1 |&1:9|, CCCN(CCC)C(=O)C(CCC(O)=O)NC(=O)c1ccccc1","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3333","proguanil","dihydrofolate reductase inhibitor","DHFR","infectious disease","malaria","CC(C)NC(=N)N=C(N)Nc1ccc(Cl)cc1, CC(C)NC(=N)N=C(N)Nc1ccc(Cl)cc1, CC(C)NC(=N)N=C(N)Nc1ccc(Cl)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3334","promazine","dopamine receptor antagonist","ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR2A, HTR2C","neurology/psychiatry","schizophrenia","CN(C)CCCN1c2ccccc2Sc2ccccc12, CN(C)CCCN1c2ccccc2Sc2ccccc12","Launched",0,0,0,0,0,0,0,0,1,2,1,1,0,0,1,4,1,5,1,3,1,1,1,1
"3335","promestriene","estrogen receptor agonist","ESR1","endocrinology","androgenetic alopecia","CCCOc1ccc2[C@H]3CC[C@]4(C)[C@H](CC[C@H]4[C@@H]3CCc2c1)OC","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3336","promethazine","histamine receptor antagonist","HRH1","neurology/psychiatry, allergy","sedative, allergic rhinitis","C[C@@H](CN1c2ccccc2Sc2ccccc12)N(C)C |&1:1,r|, CC(CN1c2ccccc2Sc2ccccc12)N(C)C, CC(CN1c2ccccc2Sc2ccccc12)N(C)C, CC(CN1c2ccccc2Sc2ccccc12)N(C)C, CC(CN1c2ccccc2Sc2ccccc12)N(C)C","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"3337","propacetamol","cyclooxygenase inhibitor","PTGS2","endocrinology, neurology/psychiatry","fever, pain relief","CCN(CC)CC(=O)Oc1ccc(NC(C)=O)cc1, CCN(CC)CC(=O)Oc1ccc(NC(C)=O)cc1","Launched",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3338","propafenone","antiarrhythmic","ADRB1, ADRB2, KCNA5, KCNH2","cardiology","atrial fibrillation (AF), ventricular tachycardia (VT), ventricular arrhythmias","CCCNC[C@@H](O)COc1ccccc1C(=O)CCc1ccccc1 |&1:5,r|, CCCNC[C@@H](O)COc1ccccc1C(=O)CCc1ccccc1 |&1:5,r|, CCCNC[C@@H](O)COc1ccccc1C(=O)CCc1ccccc1 |&1:5,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,1,1,1,1
"3339","propagermanium","CCR agonist, interferon receptor agonist","CCR2","infectious disease","hepatitis B","OC(=O)CC[Ge](=O)O[Ge](=O)CCC(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3340","propantheline","acetylcholine receptor antagonist","CHRM1, CHRM2, CHRM3, CHRM4","gastroenterology","peptic ulcer disease (PUD)","CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc12)C(C)C, CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc12)C(C)C, CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc12)C(C)C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,1,1,1,1
"3341","propentofylline","adenosine reuptake inhibitor, phosphodiesterase inhibitor","PDE1A","neurology/psychiatry","stroke","CCCn1cnc2n(C)c(=O)n(CCCCC(C)=O)c(=O)c12, CCCn1cnc2n(C)c(=O)n(CCCCC(C)=O)c(=O)c12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3342","propiverine","acetylcholine receptor antagonist","CHRM1","urology","urinary incontinence","CCCOC(C(=O)OC1CCN(C)CC1)(c1ccccc1)c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,1
"3343","propofol","benzodiazepine receptor agonist","FAAH, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, SCN2A, SCN4A","neurology/psychiatry","anesthetic","CC(C)c1cccc(C(C)C)c1O, CC(C)c1cccc(C(C)C)c1O","Launched",0,0,1,2,0,0,0,0,0,0,0,0,1,16,0,0,0,0,0,0,1,1,1,1
"3344","propranolol","adrenergic receptor antagonist","ADRB1, ADRB2","cardiology, neurology/psychiatry","hypertension, angina pectoris, migraine headache","CC(C)NCC(O)COc1cccc2ccccc12, CC(C)NCC(O)COc1cccc2ccccc12, CC(C)NCC(O)COc1cccc2ccccc12, CC(C)NCC(O)COc1cccc2ccccc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,1,1,1,1
"3345","propranolol hydrochloride","adrenergic receptor antagonist","ADRB1, ADRB2, ADRB3","Cardiology","angina pectoris","CC(C)NC[C@@H](O)COc1cccc2ccccc12 |&1:5,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,1,1,1,1
"3346","propranolol-(R)","adrenergic receptor antagonist","ADRB2, ADRB3",NA,NA,"CC(C)NC[C@@H](O)COc1cccc2ccccc12, CC(C)NC[C@@H](O)COc1cccc2ccccc12, CC(C)NC[C@@H](O)COc1cccc2ccccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0
"3347","propranolol-(S)","adrenergic receptor antagonist","ADRB1, HTR1A, HTR5A, SLC10A1",NA,NA,"CC(C)NC[C@H](O)COc1cccc2ccccc12, CC(C)NC[C@H](O)COc1cccc2ccccc12, CC(C)NC[C@H](O)COc1cccc2ccccc12, CC(C)NC[C@H](O)COc1cccc2ccccc12","Preclinical",1,1,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,1,1,0,0,0,0
"3348","propylthiouracil","thyroid peroxidase inhibitor","DIO1, TPO","endocrinology","hyperthyroidism, Grave's disease, goiter","CCCc1cc(=O)[nH]c(=S)[nH]1, CCCc1cc(=O)[nH]c(=S)[nH]1, CCCc1cc(=O)[nH]c(=S)[nH]1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3349","proquazone","cyclooxygenase inhibitor","PTGS1, PTGS2","neurology/psychiatry","pain relief","CC(C)n1c2cc(C)ccc2c(nc1=O)-c1ccccc1, CC(C)n1c2cc(C)ccc2c(nc1=O)-c1ccccc1","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3350","protirelin","thyrotropin releasing hormone receptor agonist","TRHR","radiology","thyroid function diagnostic","NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1, NC(=O)C1CCCN1C(=O)C(Cc1c[nH]cn1)NC(=O)C1CCC(=O)N1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3351","protokylol","adrenergic receptor agonist","ADRB2","infectious disease","respiratory tract infections","O1c2ccc(cc2OC1)CC(NCC(O)c3ccc(O)c(O)c3)C","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"3352","protoporphyrin-IX","heme oxygenase inhibitor","HMOX1",NA,NA,"Cc1c(C=C)c2cc3[nH]c(cc4[nH]c(cc5nc(cc1n2)c(C=C)c5C)c(C)c4CCC(O)=O)c(CCC(O)=O)c3C, Cc1c(C=C)c2cc3[nH]c(cc4[nH]c(cc5nc(cc1n2)c(C=C)c5C)c(C)c4CCC(O)=O)c(CCC(O)=O)c3C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3353","protriptyline","tricyclic antidepressant","SLC6A2, SLC6A4","neurology/psychiatry","depression","CNCCCC1c2ccccc2C=Cc2ccccc12 |c:13|, CNCCCC1c2ccccc2C=Cc2ccccc12 |c:13|, CNCCCC1c2ccccc2C=Cc2ccccc12 |c:13|, CNCCCC1c2ccccc2C=Cc2ccccc12 |c:13|","Launched",1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3354","proxyfan","histamine receptor modulator","HRH3",NA,NA,"C(COCc1ccccc1)Cc1cnc[nH]1, C(COCc1ccccc1)Cc1cnc[nH]1, C(COCc1ccccc1)Cc1cnc[nH]1","Preclinical",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
"3355","proxymetacaine","sodium channel blocker","SCN10A, SCN5A","neurology/psychiatry","anesthetic","CCCOc1ccc(cc1N)C(=O)OCCN(CC)CC, CCCOc1ccc(cc1N)C(=O)OCCN(CC)CC, CCCOc1ccc(cc1N)C(=O)OCCN(CC)CC","Launched",0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3356","PRT062070","JAK inhibitor, SYK inhibitor","SYK",NA,NA,"CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1","Phase 2/Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3357","PRT062607","SYK inhibitor","FGR, MAP3K9, SYK",NA,NA,"N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3358","PRT4165","polycomb repressive complex inhibitor","PRC1",NA,NA,"O=C1C(=Cc2cccnc2)C(=O)c2ccccc12, O=C1C(=Cc2cccnc2)C(=O)c2ccccc12, O=C1C(=Cc2cccnc2)C(=O)c2ccccc12, O=C1C(=Cc2cccnc2)C(=O)c2ccccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3359","prucalopride","serotonin receptor agonist","HTR4","gastroenterology","constipation","COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(N)c2CCOc12, COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(N)c2CCOc12, COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(N)c2CCOc12, COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(N)c2CCOc12","Launched",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3360","pruvanserin","serotonin receptor antagonist","HTR2A, HTR2C",NA,NA,"Fc1ccc(CCN2CCN(CC2)C(=O)c2cccc3c(c[nH]c23)C#N)cc1, Fc1ccc(CCN2CCN(CC2)C(=O)c2cccc3c(c[nH]c23)C#N)cc1, Fc1ccc(CCN2CCN(CC2)C(=O)c2cccc3c(c[nH]c23)C#N)cc1","Phase 2",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3361","PRX-08066","serotonin receptor antagonist","HTR2B",NA,NA,"Fc1ccc(CN2CCC(CC2)Nc2ncnc3sc(Cl)cc23)cc1C#N, Fc1ccc(CN2CCC(CC2)Nc2ncnc3sc(Cl)cc23)cc1C#N, Fc1ccc(CN2CCC(CC2)Nc2ncnc3sc(Cl)cc23)cc1C#N","Phase 2",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3362","PSB-06126","NTPDase inhibitor","ENTPD3",NA,NA,"Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O, Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O, Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O, Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O, Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O, Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O, Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O, Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3363","PSB-11","adenosine receptor antagonist","ADORA1, ADORA2A, ADORA3",NA,NA,"CC[C@@H]1CN2C(=N1)c1nc([nH]c1N(C)C2=O)-c1ccccc1 |c:5|, CC[C@@H]1CN2C(=N1)c1nc([nH]c1N(C)C2=O)-c1ccccc1 |c:5|, CC[C@@H]1CN2C(=N1)c1nc([nH]c1N(C)C2=O)-c1ccccc1 |c:5|, CC[C@@H]1CN2C(=N1)c1nc([nH]c1N(C)C2=O)-c1ccccc1 |c:5|, CC[C@@H]1CN2C(=N1)c1nc([nH]c1N(C)C2=O)-c1ccccc1 |c:5|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3364","PSB-1115","adenosine receptor antagonist","ADORA1, ADORA2B, ADORA3",NA,NA,"CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3365","PSB-36","adenosine receptor antagonist","ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,"[H][C@]12C[C@H]3C[C@]([H])(C[C@]3(C1)c1nc3n(CCCO)c(=O)n(CCCC)c(=O)c3[nH]1)C2 |r,THB:9:1:4:7.8|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3366","PSB-603","adenosine receptor antagonist","ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,"CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(=O)(=O)N1CCN(CC1)c1ccc(Cl)cc1, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(=O)(=O)N1CCN(CC1)c1ccc(Cl)cc1, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(=O)(=O)N1CCN(CC1)c1ccc(Cl)cc1, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(=O)(=O)N1CCN(CC1)c1ccc(Cl)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3367","PSN-375963","glucose dependent insulinotropic receptor agonist","GPR119",NA,NA,"CCCCC1CCC(CC1)c1nc(no1)-c1ccncc1, CCCCC1CCC(CC1)c1nc(no1)-c1ccncc1, CCCCC1CCC(CC1)c1nc(no1)-c1ccncc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3368","PSNCBAM-1","cannabinoid receptor modulator","CNR1",NA,NA,"Clc1ccc(NC(=O)Nc2cccc(c2)-c2cccc(n2)N2CCCC2)cc1, Clc1ccc(NC(=O)Nc2cccc(c2)-c2cccc(n2)N2CCCC2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3369","PS178990","androgen receptor modulator","AR",NA,NA,"Cc1c(Cl)c(ccc1N1C(=O)[C@@H]2[C@H](O)CCN2C1=O)C#N, Cc1c(Cl)c(ccc1N1C(=O)[C@@H]2[C@H](O)CCN2C1=O)C#N, Cc1c(Cl)c(ccc1N1C(=O)[C@@H]2[C@H](O)CCN2C1=O)C#N, Cc1c(Cl)c(ccc1N1C(=O)[C@@H]2[C@H](O)CCN2C1=O)C#N, Cc1c(Cl)c(ccc1N1C(=O)[C@@H]2[C@H](O)CCN2C1=O)C#N","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3370","PT-2385","hypoxia inducible factor inhibitor","EPAS1",NA,NA,"CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c2CC(F)(F)[C@@H](O)c12, CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c2CC(F)(F)[C@@H](O)c12, CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c2CC(F)(F)[C@@H](O)c12, CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c2CC(F)(F)[C@@H](O)c12","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3371","ptc596","polycomb protein inhibitor","BMI1","oncology","glioma","Cc1nc2ccc(F)cc2n1c3nc(N)c(F)c(Nc4ccc(cc4)C(F)(F)F)n3","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3372","pterostilbene","cyclooxygenase inhibitor, PPAR receptor agonist, cyclooxygenase inhibitor, ppar receptor agonist","PTGS2",NA,NA,"COc1cc(OC)cc(C=Cc2ccc(O)cc2)c1, COc1cc(OC)cc(\C=C\c2ccc(O)cc2)c1","Phase 2/Phase 3",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3373","pti-428","cftr channel potentiator","CFTR","pulmonary","cystic fibrosis","C[C@@H](O)c1oc(nn1)[C@@H]2C[C@H](C2)NC(=O)c3onc(c3)c4ccccc4","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3374","pt2399","hif modulator","EPAS1","oncology","renal cell carcinoma (rcc)","O[C@H]1c2c(CC1(F)F)c(Oc3cc(F)cc(c3)C#N)ccc2S(=O)(=O)C(F)F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3375","PU-H71","HSP inhibitor","HSP90AA1",NA,NA,"CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12, CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12, CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12, CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3376","pulrodemstat","histone lysine demethylase inhibitor","KDM1A, MBD2","hematologic malignancy","acute myeloid leukemia (aml)","COc1ccc(cc1F)-c1c(nc(N2CCC(N)CC2)n(C)c1=O)-c1ccc(C#N)c(F)c1.OS(=O)(=O)c1ccccc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3377","pumosetrag","serotonin receptor agonist","HTR3A, HTR4",NA,NA,"O=C(N[C@H]1CN2CCC1CC2)c1c[nH]c2ccsc2c1=O","Phase 2",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3378","purmorphamine","smoothened receptor agonist","SMO",NA,NA,"C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12, C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12, C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12, C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12, C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12, C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12, C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3379","puromycin","protein synthesis inhibitor","NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1",NA,NA,"COc1ccc(C[C@H](N)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)n2cnc3c(ncnc23)N(C)C)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3380","purvalanol-A","CDK inhibitor","CDK1, CDK2, CDK4, CDK5, CSNK1G3, RPS6KA1, SRC",NA,NA,"CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3381","purvalanol-B","tyrosine kinase inhibitor","CDK2, CDK4, CDK5, MAPK1, MAPK3, SRPK2",NA,NA,"CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(O)=O)c(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(O)=O)c(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(O)=O)c(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(O)=O)c(Cl)c2)c2ncn(C(C)C)c2n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3382","putrescine","tissue transglutaminase inhibitor","AMD1, KCNJ4, ODC1",NA,NA,"NCCCCN","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3383","PX-12","thioredoxin inhibitor","CNR1, TXN",NA,NA,"CC[C@@H](C)SSc1ncc[nH]1 |&1:2,r|, CC[C@@H](C)SSc1ncc[nH]1 |&1:2,r|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3384","pyrazinamide","fatty acid synthase inhibitor","FASN","infectious disease","tuberculosis","NC(=O)c1cnccn1, NC(=O)c1cnccn1, NC(=O)c1cnccn1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3385","pyrazolanthrone","JNK inhibitor","MAPK10, MAPK8, MAPK8IP1, MAPK9, TTK",NA,NA,"O=C1c2ccccc2-c2[nH]nc3cccc1c23, O=C1c2ccccc2-c2[nH]nc3cccc1c23, O=C1c2ccccc2-c2[nH]nc3cccc1c23, O=C1c2ccccc2-c2[nH]nc3cccc1c23, O=C1c2ccccc2-c2[nH]nc3cccc1c23","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3386","pyrazoloacridine","rna synthesis inhibitor, topoisomerase inhibitor","TOP1, TOP2A","oncology","melanoma","COc1ccc2nc3c(ccc4n(CCCN(C)C)[nH]c(c34)c2c1)[N+]([O-])=O, COc1ccc2nc3c(ccc4n(CCCN(C)C)[nH]c(c34)c2c1)[N+]([O-])=O, COc1ccc2Nc3c(ccc4c3c(nn4CCCN(C)C)c2c1)[N+](=O)[O-]","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3387","pyridoxine","vitamin B","DDC, PDXK","metabolism","vitamin B6 deficiency","Cc1ncc(CO)c(CO)c1O, Cc1ncc(CO)c(CO)c1O, Cc1ncc(CO)c(CO)c1O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3388","pyrimethamine","dihydrofolate reductase inhibitor","DHFR, SLC47A1","infectious disease","malaria","CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3389","pyrithione-zinc","ATP synthase inhibitor","KCNQ1, KCNQ2, KCNQ4, KCNQ5","dermatology","dandruff, cosmetic","O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3390","pyroxamide","HDAC inhibitor","HDAC1",NA,NA,"ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3391","pyrrolidine-dithiocarbamate","NFkB pathway inhibitor","HSD11B1, RELA",NA,NA,"SC(=S)N1CCCC1, SC(=S)N1CCCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3392","pyrvinium-pamoate","androgen receptor antagonist","AR","infectious disease","pinworm","CN(C)c1ccc2[n+](C)c(\C=C\c3cc(C)n(c3C)-c3ccccc3)ccc2c1, CN(C)c1ccc2[n+](C)c(\C=C\c3cc(C)n(c3C)-c3ccccc3)ccc2c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3393","P22077","ubiquitin specific protease inhibitor","USP7",NA,NA,"CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3394","P276-00","CDK inhibitor","CDK1, CDK4, CDK9",NA,NA,"CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3395","P5091","ubiquitin specific protease inhibitor","USP7",NA,NA,"CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3396","P7C3","NAMPT inhibitor","NAMPT",NA,NA,"O[C@@H](CNc1ccccc1)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:1,r|, O[C@@H](CNc1ccccc1)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:1,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3397","quazinone","phosphodiesterase inhibitor","PDE3A, PDE3B",NA,NA,"CC1N2Cc3c(Cl)cccc3NC2=NC1=O |c:14|, CC1N2Cc3c(Cl)cccc3NC2=NC1=O |c:14|, CC1N2Cc3c(Cl)cccc3NC2=NC1=O |c:14|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3398","quercetin","polar auxin transport inhibitor","ATP5A1, ATP5B, ATP5C1, HCK, HIBCH, PIK3CG, PIM1, STK17B, UGT3A1","neurology/psychiatry, allergy","fatigue, allergic rhinitis, drowsiness","Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3399","quetiapine","dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A2","neurology/psychiatry","schizophrenia, bipolar disorder","OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2ccccc12 |t:13|, OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2ccccc12 |t:13|, OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2ccccc12 |t:13|, OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2ccccc12 |t:13|, OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2ccccc12 |t:13|","Launched",1,1,0,0,0,0,0,0,1,10,1,1,0,0,1,5,1,5,1,6,1,1,1,1
"3400","quiflapon","leukotriene synthesis inhibitor","ALOX5, ALOX5AP",NA,NA,"CC(C)(C)Sc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3ccc4ccccc4n3)cc12, CC(C)(C)Sc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3ccc4ccccc4n3)cc12","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3401","quinagolide","dopamine receptor agonist","DRD2","endocrinology","hyperprolactinemia","CCCN1C[C@H](C[C@@H]2Cc3c(O)cccc3C[C@@H]12)NS(=O)(=O)N(CC)CC, CCCN1C[C@H](C[C@@H]2Cc3c(O)cccc3C[C@@H]12)NS(=O)(=O)N(CC)CC","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1
"3402","quinapril","angiotensin converting enzyme inhibitor","ACE","cardiology","hypertension, congestive heart failure, angioedema","CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3403","quinaprilat","angiotensin converting enzyme inhibitor","ACE","cardiology","hypertension, angioedema","C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3404","quinelorane","dopamine receptor agonist","DRD2, DRD3",NA,NA,"CCCN1CCC[C@@H]2Cc3nc(N)ncc3C[C@@H]12, CCCN1CCC[C@@H]2Cc3nc(N)ncc3C[C@@H]12","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0
"3405","quinestrol","estrogen receptor agonist","ESR1, ESR2","endocrinology","menopause","C[C@]12CCC3C(CCc4cc(OC5CCCC5)ccc34)C1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(OC5CCCC5)ccc34)[C@@H]1CC[C@@]2(O)C#C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3406","quinidine","sodium channel blocker","KCNA5, KCNA7, KCNH1, KCNH2, KCNH5, KCNK1, KCNK6, SCN5A, SLC29A4","infectious disease, cardiology","malaria, atrial fibrillation (AF), ventricular arrhythmias","COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1, COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1, COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1, COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1","Launched",1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3407","quinine","hemozoin biocrystallization inhibitor","GP9, KCNB2, KCNN4, SLC29A4","infectious disease","malaria","COc1ccc2nccc([C@@H](O)[C@@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1, COc1ccc2nccc([C@@H](O)[C@@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1, COc1ccc2nccc([C@@H](O)[C@@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1, COc1ccc2nccc([C@@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3408","quinpirol-(-)","dopamine receptor agonist","DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C",NA,NA,"CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@@H]12, CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@@H]12, CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@@H]12, CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@@H]12, CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@@H]12","Phase 2",0,0,0,0,0,0,0,0,1,4,0,0,0,0,1,4,0,0,0,0,0,0,0,0
"3409","quipazine","serotonin receptor agonist","HTR1A, HTR1D, HTR2A, HTR2B, HTR2C, HTR3A, HTR3B, HTR6, SLC6A4",NA,NA,"C1CN(CCN1)c1ccc2ccccc2n1, C1CN(CCN1)c1ccc2ccccc2n1, C1CN(CCN1)c1ccc2ccccc2n1, C1CN(CCN1)c1ccc2ccccc2n1","Preclinical",1,1,0,0,0,0,0,0,1,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3410","quizartinib","FLT3 inhibitor","CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET",NA,NA,"CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1, CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1, CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1, CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1, CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3411","QX-314","sodium channel blocker","MAPK14, TGFBR1",NA,NA,"CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C, CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C, CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C, CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3412","R-1485","serotonin receptor antagonist","HTR6",NA,NA,"Fc1ccccc1S(=O)(=O)N1CCOc2c(cccc12)N1CCNCC1, Fc1ccccc1S(=O)(=O)N1CCOc2c(cccc12)N1CCNCC1, Fc1ccccc1S(=O)(=O)N1CCOc2c(cccc12)N1CCNCC1","Phase 1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3413","R-268712","serine/threonine kinase inhibitor","TGFBR1",NA,NA,"Cc1cccc(n1)-c1n[nH]cc1-c1ccc(F)c(c1)-c1cnn(CCO)c1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc(F)c(c1)-c1cnn(CCO)c1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc(F)c(c1)-c1cnn(CCO)c1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc(F)c(c1)-c1cnn(CCO)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3414","R-428","AXL kinase inhibitor","AXL",NA,NA,"Nc1nc(Nc2ccc3CC[C@@H](CCc3c2)N2CCCC2)nn1-c1cc2CCCc3ccccc3-c2nn1, Nc1nc(Nc2ccc3CC[C@@H](CCc3c2)N2CCCC2)nn1-c1cc2CCCc3ccccc3-c2nn1, Nc1nc(Nc2ccc3CC[C@@H](CCc3c2)N2CCCC2)nn1-c1cc2CCCc3ccccc3-c2nn1, Nc1nc(Nc2ccc3CC[C@@H](CCc3c2)N2CCCC2)nn1-c1cc2CCCc3ccccc3-c2nn1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3415","R-59022","diacylglycerol kinase inhibitor, protein kinase inhibitor","DGKA",NA,NA,"Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccccc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccccc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccccc1)c1ccc(F)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3416","R-96544","serotonin receptor antagonist","HTR2A",NA,NA,"COc1cccc(CCc2ccccc2OCC[C@@H]2C[C@@H](O)CN2C)c1, COc1cccc(CCc2ccccc2OCC[C@@H]2C[C@@H](O)CN2C)c1, COc1cccc(CCc2ccccc2OCC[C@@H]2C[C@@H](O)CN2C)c1","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3417","rabeprazole","ATPase inhibitor, gastrin inhibitor","ATP4A","gastroenterology","gastroesophageal reflux disease (GERD), duodenal ulcer disease, Zollinger-Ellison syndrome","COCCCOc1ccnc(C[S@@](=O)c2nc3ccccc3[nH]2)c1C |r|, COCCCOc1ccnc(C[S@@](=O)c2nc3ccccc3[nH]2)c1C |r|, COCCCOc1ccnc(C[S@@](=O)c2nc3ccccc3[nH]2)c1C |r|, COCCCOc1ccnc(C[S@@](=O)c2nc3ccccc3[nH]2)c1C |r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3418","rac-BHFF","GABA receptor positive allosteric modulator","GABBR1",NA,NA,"CC(C)(C)c1cc2c(OC(=O)[C@@]2(O)C(F)(F)F)c(c1)C(C)(C)C |&1:11,r|, CC(C)(C)c1cc2c(OC(=O)[C@@]2(O)C(F)(F)F)c(c1)C(C)(C)C |&1:11,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3419","racecadotril","enkephalinase inhibitor","MME","gastroenterology","diarrhea","CC(=O)SC[C@@H](Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1 |&1:5,r|, CC(=O)SC[C@@H](Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1 |&1:5,r|, CC(=O)SC[C@@H](Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1 |&1:5,r|, CC(=O)SC[C@@H](Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1 |&1:5,r|, CC(=O)SC[C@@H](Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1 |&1:5,r|, CC(=O)SC[C@@H](Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1 |&1:5,r|, CC(=O)SC[C@@H](Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1 |&1:5,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3420","racepinephrine","adrenergic receptor agonist","ADRA1A, ADRA1B, ADRA1D, ADRA2A","Immunology","anaphylactic shock","CNCC(O)c1ccc(O)c(O)c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,4,1,1,1,1
"3421","raclopride","dopamine receptor antagonist","DRD2, DRD3, HTR1A",NA,NA,"CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC","Launched",0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,2,0,0,0,0,0,0,0,0
"3422","radafaxine","dopamine-norepinephrine reuptake inhibitor","SLC6A3",NA,NA,"C[C@@H]1NC(C)(C)CO[C@@]1(O)c1cccc(Cl)c1, C[C@@H]1NC(C)(C)CO[C@@]1(O)c1cccc(Cl)c1","Phase 2",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3423","RAF265","RAF inhibitor, VEGFR inhibitor","BRAF",NA,NA,"Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12, Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12, Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12, Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3424","raloxifene","estrogen receptor antagonist, selective estrogen receptor modulator (SERM)","ESR1, ESR2","orthopedics, oncology","osteoporosis, breast cancer","Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3425","raltitrexed","thymidylate synthase inhibitor","FPGS, TYMS","oncology","mesothelioma","CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3426","ramatroban","prostanoid receptor antagonist","PTGDR2, TBXA2R","cardiology, pulmonary","coronary artery disease (CAD), asthma","OC(=O)CCn1c2CC[C@H](Cc2c2ccccc12)NS(=O)(=O)c1ccc(F)cc1, OC(=O)CCn1c2CC[C@H](Cc2c2ccccc12)NS(=O)(=O)c1ccc(F)cc1, OC(=O)CCn1c2CC[C@H](Cc2c2ccccc12)NS(=O)(=O)c1ccc(F)cc1, OC(=O)CCn1c2CC[C@H](Cc2c2ccccc12)NS(=O)(=O)c1ccc(F)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3427","ramelteon","melatonin receptor agonist","MTNR1A, MTNR1B","neurology/psychiatry","insomnia","CCC(=O)NCC[C@@H]1CCc2ccc3OCCc3c12, CCC(=O)NCC[C@@H]1CCc2ccc3OCCc3c12, CCC(=O)NCC[C@@H]1CCc2ccc3OCCc3c12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3428","ramipril","angiotensin converting enzyme inhibitor","ACE","cardiology","hypertension","CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3429","ramosetron","serotonin receptor antagonist","HTR3A","gastroenterology","nausea, vomiting, irritable bowel syndrome","Cn1cc(C(=O)[C@@H]2CCc3nc[nH]c3C2)c2ccccc12, Cn1cc(C(=O)[C@@H]2CCc3nc[nH]c3C2)c2ccccc12","Launched",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3430","ranirestat","aldose reductase inhibitor","AKR1B1",NA,NA,"Fc1cc(Br)ccc1CN1C(=O)c2cccn2[C@@]2(CC(=O)NC2=O)C1=O, Fc1cc(Br)ccc1CN1C(=O)c2cccn2[C@@]2(CC(=O)NC2=O)C1=O, Fc1cc(Br)ccc1CN1C(=O)c2cccn2[C@@]2(CC(=O)NC2=O)C1=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3431","ranitidine","histamine receptor antagonist","HRH2","gastroenterology","heartburn","CN=C(C[N+]([O-])=O)NCCSCc1ccc(CN(C)C)o1, CN\C(=C/[N+](=O)[O-])\NCCSCc1oc(CN(C)C)cc1","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"3432","ranolazine","sodium channel blocker","SCN10A, SCN9A","cardiology","chronic stable angina","COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1, COc1ccccc1OC[C@@H](O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1 |&1:10|, COc1ccccc1OC[C@@H](O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1 |&1:10|, COc1ccccc1OC[C@@H](O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1 |&1:10|, COc1ccccc1OC[C@@H](O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1 |&1:10|","Launched",0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3433","rapacuronium bromide","acetylcholine receptor antagonist","CHRM2","neurology/psychiatry","general anaesthetic","[Br-].O=C(O[C@H]6[C@@H]([N+]1(C\C=C)CCCCC1)C[C@@H]5[C@]6(C)CC[C@H]3[C@H]5CC[C@H]4C[C@H](OC(=O)C)[C@@H](N2CCCCC2)C[C@]34C)CC","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,1
"3434","rasagiline","monoamine oxidase inhibitor","BCL2, MAOB","neurology/psychiatry","Parkinson's Disease","C#CCN[C@@H]1CCc2ccccc12, C#CCN[C@@H]1CCc2ccccc12, C#CCN[C@@H]1CCc2ccccc12, C#CCN[C@@H]1CCc2ccccc12, C#CCN[C@@H]1CCc2ccccc12, C#CCN[C@@H]1CCc2ccccc12, C#CCN[C@@H]1CCc2ccccc12","Launched",0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3435","rauwolscine","adrenergic receptor antagonist","ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR1E, HTR2B",NA,NA,"COC(=O)[C@@H]1[C@@H](O)CC[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12, COC(=O)[C@@H]1[C@@H](O)CC[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12, COC(=O)[C@@H]1[C@@H](O)CC[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12, COC(=O)[C@@H]1[C@@H](O)CC[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12","Preclinical",0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,1,3,0,0,0,0
"3436","ravoxertinib","ERK1 and ERK2 phosphorylation inhibitor","MAPK1, MAPK3",NA,NA,"Cn1nccc1Nc1nccc(n1)-c1ccn([C@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1, Cn1nccc1Nc1nccc(n1)-c1ccn([C@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1, Cn1nccc1Nc1nccc(n1)-c1ccn([C@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1, Cn1nccc1Nc1nccc(n1)-c1ccn([C@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1, Cn1nccc1Nc1nccc(n1)-c1ccn([C@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3437","RBC8","Ral GTPase inhibitor","RALA, RALB",NA,NA,"COc1ccc(OC)c(c1)[C@@H]1C(C#N)C(=N)Oc2[nH]nc(c12)-c1ccc2ccccc2c1 |&1:10,r|, COc1ccc(OC)c(c1)[C@@H]1C(C#N)C(=N)Oc2[nH]nc(c12)-c1ccc2ccccc2c1 |&1:10,r|, COc1ccc(OC)c(c1)[C@@H]1C(C#N)C(=N)Oc2[nH]nc(c12)-c1ccc2ccccc2c1 |&1:10,r|, COc1ccc(OC)c(c1)[C@@H]1C(C#N)C(=N)Oc2[nH]nc(c12)-c1ccc2ccccc2c1 |&1:10,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3438","rebamipide","free radical scavenger","FPR1","gastroenterology","peptic ulcer disease (PUD), gastritis","OC(=O)[C@@H](Cc1cc(=O)[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1 |&1:3,r|, OC(=O)[C@@H](Cc1cc(=O)[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1 |&1:3,r|, OC(=O)[C@@H](Cc1cc(=O)[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1 |&1:3,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3439","rebastinib","Bcr-Abl kinase inhibitor, TIE tyrosine kinase inhibitor, VEGFR inhibitor","ABL1, BCR, FGR, FLT3, HCK, LYN, SRC",NA,NA,"CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3440","reboxetine","adrenergic receptor antagonist","SLC6A2","neurology/psychiatry","depression","CCOc1ccccc1O[C@@H]([C@H]1CNCCO1)c1ccccc1 |&1:10,11|, CCOc1ccccc1O[C@@H]([C@H]1CNCCO1)c1ccccc1 |&1:10,11|, CCOc1ccccc1O[C@@H]([C@H]1CNCCO1)c1ccccc1 |&1:10,11|","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3441","Rec-15/2615","adrenergic receptor antagonist","ADRA1A",NA,NA,"COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)COc1c(OC)cccc1C(C)C, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)COc1c(OC)cccc1C(C)C","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
"3442","refametinib","MEK inhibitor","MAP2K1, MAP2K2",NA,NA,"COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1, COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1, COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1, COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1, COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1, COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3443","regadenoson","adenosine receptor agonist","ADORA1, ADORA2A, ADORA2B, ADORA3","radiology","myocardial perfusion imaging (MPI)","CNC(=O)c1cnn(c1)-c1nc(N)c2ncn([C@@H]3O[C@H](CO)C(O)C3O)c2n1, CNC(=O)c1cnn(c1)-c1nc(N)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3444","regorafenib","FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK","oncology","colorectal cancer, gastrointestinal stromal tumors (GIST)","CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3445","relcovaptan","vasopressin receptor antagonist","AVPR1A, AVPR1B, AVPR2, OXTR",NA,NA,"COc1ccc(cc1OC)S(=O)(=O)N1[C@@H](C(=O)N2CCC[C@H]2C(N)=O)[C@](O)(c2cc(Cl)ccc12)c1ccccc1Cl, COc1ccc(cc1OC)S(=O)(=O)N1[C@@H](C(=O)N2CCC[C@H]2C(N)=O)[C@](O)(c2cc(Cl)ccc12)c1ccccc1Cl, COc1ccc(cc1OC)S(=O)(=O)N1[C@@H](C(=O)N2CCC[C@H]2C(N)=O)[C@](O)(c2cc(Cl)ccc12)c1ccccc1Cl","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3446","remacemide","glutamate receptor antagonist","GRIN1",NA,NA,"C[C@@](Cc1ccccc1)(NC(=O)CN)c1ccccc1 |&1:1|, C[C@@](Cc1ccccc1)(NC(=O)CN)c1ccccc1 |&1:1|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3447","remimazolam","benzodiazepine receptor agonist","GABBR1",NA,NA,"COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc12 |t:7|, COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc12 |t:7|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3448","remodelin","transferase inhibitor","NAT10",NA,NA,"N#Cc1ccc(cc1)-c1csc(NN=C2CCCC2)n1, N#Cc1ccc(cc1)-c1csc(NN=C2CCCC2)n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3449","remogliflozin etabonate","sodium/glucose cotransporter inhibitor","SLC5A2","endocrinology","diabetes mellitus","CCOC(=O)OC[C@H]1O[C@@H](Oc2nn(C(C)C)c(C)c2Cc3ccc(OC(C)C)cc3)[C@H](O)[C@@H](O)[C@@H]1O","Phase 2",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3450","remoxipride","dopamine receptor antagonist","DRD2, DRD3, DRD4, HTR2A, SIGMAR1",NA,NA,"CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC","Withdrawn",0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,3,0,0,0,0,0,0,0,0
"3451","rentiapril","angiotensin converting enzyme inhibitor","ACE","cardiology","hypertension","OC(=O)[C@@H]1CS[C@@H](N1C(=O)CCS)c2ccccc2O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3452","repaglinide","insulin secretagogue","ABCC8, KCNJ11, PPARG","endocrinology","diabetes mellitus","CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3453","reparixin","CC chemokine receptor antagonist","CXCR1, CXCR2",NA,NA,"CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NS(C)(=O)=O, CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NS(C)(=O)=O, CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NS(C)(=O)=O, CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NS(C)(=O)=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3454","repsox","TGF beta receptor inhibitor","TGFBR1",NA,NA,"Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3455","resatorvid","toll-like receptor inhibitor","TLR4",NA,NA,"CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl |t:5|, CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl |t:5|, CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl |t:5|, CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl |t:5|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3456","reserpine","vesicular monoamine transporter inhibitor","SLC18A1, SLC18A2","cardiology","hypertension","CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1","Launched",1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3457","resiquimod","toll-like receptor agonist","TLR7, TLR8",NA,NA,"CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3458","resminostat","HDAC inhibitor","HDAC1, HDAC3, HDAC6, HDAC8",NA,NA,"CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3459","resorcinol","phosphodiesterase inhibitor","CA12, CA14, CA2, PTGS1","dermatology","acne vulgaris (AV), eczema, psoriasis, seborrheic dermatitis","Oc1cccc(O)c1, Oc1cccc(O)c1, Oc1cccc(O)c1","Launched",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3460","resveratrol","cytochrome P450 inhibitor, SIRT activator","CSNK2A1, NQO2, PTGS1, PTGS2",NA,NA,"Oc1ccc(\C=C\c2cc(O)cc(O)c2)cc1, Oc1ccc(\C=C\c2cc(O)cc(O)c2)cc1, Oc1ccc(\C=C\c2cc(O)cc(O)c2)cc1, Oc1ccc(\C=C\c2cc(O)cc(O)c2)cc1, Oc1ccc(\C=C\c2cc(O)cc(O)c2)cc1, Oc1ccc(\C=C\c2cc(O)cc(O)c2)cc1","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3461","retaspimycin","HSP inhibitor","HSP90AA1",NA,NA,"CO[C@H]1C[C@H](C)Cc2c(O)c(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)cc(O)c2NCC=C |c:17,t:15,28|, CO[C@H]1C[C@H](C)Cc2c(O)c(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)cc(O)c2NCC=C |c:17,t:15,28|, CO[C@H]1C[C@H](C)Cc2c(O)c(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)cc(O)c2NCC=C |c:17,t:15,28|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3462","retinol","retinoid receptor ligand","ALDH1A1, ALDH1A2, ALDH1A3, DHRS3, DHRS4, LRAT, NR2C2, RBP1, RBP3, RDH11, RDH12, RDH13, RDH14, RDH5, RDH8, RETSAT, RHO, RLBP1, RXRA, RXRB, RXRG","dermatology","cosmetic, acne vulgaris (AV), keratosis","C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C |c:12|, C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C |c:12|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3463","REV-5901","leukotriene receptor antagonist, lipoxygenase inhibitor","ALOX5",NA,NA,"CCCCC[C@@H](O)c1cccc(OCc2ccc3ccccc3n2)c1 |&1:5,r|, CCCCC[C@@H](O)c1cccc(OCc2ccc3ccccc3n2)c1 |&1:5,r|, CCCCC[C@@H](O)c1cccc(OCc2ccc3ccccc3n2)c1 |&1:5,r|, CCCCC[C@@H](O)c1cccc(OCc2ccc3ccccc3n2)c1 |&1:5,r|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3464","revaprazan","potassium-competitive acid antagonist","ATP4A","gastroenterology","gastritis","C[C@H]1N(CCc2ccccc12)c1nc(Nc2ccc(F)cc2)nc(C)c1C |&1:1,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3465","reversan","MRP inhibitor","ABCC1",NA,NA,"O=C(NCCCN1CCOCC1)c1cnn2c(cc(nc12)-c1ccccc1)-c1ccccc1, O=C(NCCCN1CCOCC1)c1cnn2c(cc(nc12)-c1ccccc1)-c1ccccc1, O=C(NCCCN1CCOCC1)c1cnn2c(cc(nc12)-c1ccccc1)-c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3466","reversine","Aurora kinase inhibitor","AURKB, INCENP, MAP2K1",NA,NA,"C1CCC(CC1)Nc1nc(Nc2ccc(cc2)N2CCOCC2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Nc2ccc(cc2)N2CCOCC2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Nc2ccc(cc2)N2CCOCC2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Nc2ccc(cc2)N2CCOCC2)nc2nc[nH]c12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3467","RGB-286638","CDK inhibitor","CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK9, FLT3, GSK3B, JAK2, MAP3K7, MAPK9",NA,NA,"COCCN1CCN(Cc2ccc(cc2)-c2n[nH]c3-c4cccc(NC(=O)NN5CCOCC5)c4C(=O)c23)CC1, COCCN1CCN(Cc2ccc(cc2)-c2n[nH]c3-c4cccc(NC(=O)NN5CCOCC5)c4C(=O)c23)CC1, COCCN1CCN(Cc2ccc(cc2)-c2n[nH]c3-c4cccc(NC(=O)NN5CCOCC5)c4C(=O)c23)CC1, COCCN1CCN(Cc2ccc(cc2)-c2n[nH]c3-c4cccc(NC(=O)NN5CCOCC5)c4C(=O)c23)CC1, COCCN1CCN(Cc2ccc(cc2)-c2n[nH]c3-c4cccc(NC(=O)NN5CCOCC5)c4C(=O)c23)CC1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3468","RGFP966","HDAC inhibitor","HDAC3",NA,NA,"Nc1cc(F)ccc1NC(=O)\C=C\c1cnn(C\C=C\c2ccccc2)c1, Nc1cc(F)ccc1NC(=O)\C=C\c1cnn(C\C=C\c2ccccc2)c1, Nc1cc(F)ccc1NC(=O)\C=C\c1cnn(C\C=C\c2ccccc2)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3469","RG108","DNA methyltransferase inhibitor","DNMT1, DNMT3B",NA,NA,"OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O, OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O, OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O, OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3470","RG1530","FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FGFR1, FGFR2",NA,NA,"COc1cc2N=C3NN=C(C)C3N=C(c3ccccc3Cl)c2cc1F |t:5,8,13|, COc1cc2N=C3NN=C(C)C3N=C(c3ccccc3Cl)c2cc1F |t:5,8,13|, COc1cc2N=C3NN=C(C)C3N=C(c3ccccc3Cl)c2cc1F |t:5,8,13|, COc1cc2N=C3NN=C(C)C3N=C(c3ccccc3Cl)c2cc1F |t:5,8,13|, COc1cc2N=C3NN=C(C)C3N=C(c3ccccc3Cl)c2cc1F |t:5,8,13|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3471","RG2833","HDAC inhibitor","HDAC1, HDAC3",NA,NA,"Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N, Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N, Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N, Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N, Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3472","RG4733","gamma secretase inhibitor","PSEN1",NA,NA,"CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2ccccc2NC1=O, CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2ccccc2NC1=O, CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2ccccc2NC1=O, CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2ccccc2NC1=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3473","RG7112","MDM inhibitor","MDM2",NA,NA,"CCOc1cc(ccc1C1=N[C@@](C)(c2ccc(Cl)cc2)[C@](C)(N1C(=O)N1CCN(CCCS(C)(=O)=O)CC1)c1ccc(Cl)cc1)C(C)(C)C |t:10|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3474","RHC-80267","triacylglycerol lipase inhibitor","DAGLA, DAGLB",NA,NA,"O=C(NCCCCCCNC(=O)ON=C1CCCCC1)ON=C1CCCCC1, O=C(NCCCCCCNC(=O)ON=C1CCCCC1)ON=C1CCCCC1, O=C(NCCCCCCNC(=O)ON=C1CCCCC1)ON=C1CCCCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3475","rheochrysidin","protein tyrosine kinase inhibitor","PTPN1",NA,NA,"COc1cc(O)c2C(=O)c3c(O)cc(C)cc3C(=O)c2c1, COc1cc(O)c2C(=O)c3c(O)cc(C)cc3C(=O)c2c1, COc1cc(O)c2C(=O)c3c(O)cc(C)cc3C(=O)c2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3476","ribavirin","antiviral","ADK, ENPP1, IMPDH1, IMPDH2, NT5C2","infectious disease","hepatitis C","NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3477","ribociclib","CDK inhibitor","CDK4, CDK6","oncology","breast cancer","CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3478","riboflavin","vitamin B","BLVRB, RFK","gastroenterology","jaundice","Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@@H](O)[C@@H](O)[C@@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3479","ribostamycin","bacterial 30S ribosomal subunit inhibitor","P4HB","infectious disease","human immunodeficiency virus (HIV-1)","NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)[C@H]2O[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)[C@H]2O[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)[C@H]2O[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)[C@H]2O[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3480","ricinoleic-acid","prostanoid receptor agonist","PTGER3",NA,NA,"CCCCCC[C@@H](O)C\C=C/CCCCCCCC(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3481","rifampin","RNA polymerase inhibitor","NR1I2, SLCO1A2, SLCO1B1, SLCO1B3","infectious disease","tuberculosis, meningitis, tuberculosis, meningitis","CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:33,t:3,35|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:33,t:3,35|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:33,t:3,35|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:33,t:3,35|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:33,t:3,35|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(C=NN4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/C(C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C","Launched",1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3482","rifamycin","DNA directed RNA polymerase inhibitor","SLCO1A2, SLCO1B1, SLCO1B3, SLCO2B1","infectious disease","tuberculosis, leprosy","CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)cc(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:23,t:3,25|","Launched",1,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3483","rifapentine","RNA polymerase inhibitor","CYP2C8, CYP2C9, CYP3A4","infectious disease","tuberculosis","CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(CC4)C4CCCC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:38,t:3,40|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(CC4)C4CCCC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:38,t:3,40|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(CC4)C4CCCC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:38,t:3,40|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(CC4)C4CCCC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:38,t:3,40|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(CC4)C4CCCC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:38,t:3,40|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3484","rigosertib","cell cycle inhibitor, PLK inhibitor","PLK1",NA,NA,"COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3485","rilmenidine","adrenergic receptor agonist, imidazoline receptor agonist","ADRA2A","cardiology","hypertension","C1CC1C(NC1=NCCO1)C1CC1 |t:6|, C1CC1C(NC1=NCCO1)C1CC1 |t:6|, C1CC1C(NC1=NCCO1)C1CC1 |t:6|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"3486","rilpivirine","non-nucleoside reverse transcriptase inhibitor","NR1I2, SCN10A","infectious disease","human immunodeficiency virus (HIV-1)","Cc1cc(\C=C\C#N)cc(C)c1Nc1ccnc(Nc2ccc(cc2)C#N)n1, Cc1cc(\C=C\C#N)cc(C)c1Nc1ccnc(Nc2ccc(cc2)C#N)n1, Cc1cc(\C=C\C#N)cc(C)c1Nc1ccnc(Nc2ccc(cc2)C#N)n1","Launched",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3487","riluzole","glutamate inhibitor","KCNK10, KCNK2, KCNK4, KCNN4, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A, SLC7A11","neurology/psychiatry","amyotrophic lateral sclerosis (ALS)","Nc1nc2ccc(OC(F)(F)F)cc2s1, Nc1nc2ccc(OC(F)(F)F)cc2s1, Nc1nc2ccc(OC(F)(F)F)cc2s1, Nc1nc2ccc(OC(F)(F)F)cc2s1, Nc1nc2ccc(OC(F)(F)F)cc2s1","Launched",1,1,1,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3488","rimacalib","calcium/calmodulin dependent protein kinase inhibitor","CAMK2A","rheumatology","rheumatoid arthritis","N=C(N1CCOCC1)NC2=CC([C@H](C3=CC=C(C4=CC=CC=C4)C(F)=C3)C)=NO2","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3489","rimcazole","sigma receptor antagonist","SIGMAR1",NA,NA,"C[C@H]1CN(CCCn2c3ccccc3c3ccccc23)C[C@@H](C)N1, C[C@H]1CN(CCCn2c3ccccc3c3ccccc23)C[C@@H](C)N1, C[C@H]1CN(CCCn2c3ccccc3c3ccccc23)C[C@@H](C)N1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3490","rimegepant","calcitonin antagonist","CALCA",NA,NA,"N[C@H]1[C@@H](CC[C@@H](OC(=O)N2CCC(CC2)n2c3cccnc3[nH]c2=O)c2ncccc12)c1cccc(F)c1F, N[C@H]1[C@@H](CC[C@@H](OC(=O)N2CCC(CC2)n2c3cccnc3[nH]c2=O)c2ncccc12)c1cccc(F)c1F, N[C@H]1[C@@H](CC[C@@H](OC(=O)N2CCC(CC2)n2c3cccnc3[nH]c2=O)c2ncccc12)c1cccc(F)c1F","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3491","rimexolone","glucocorticoid receptor agonist","NR3C1, SERPINA6","ophthalmology","anterior uveitis","CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |c:17,t:13|, CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |c:17,t:13|, CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |c:17,t:13|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3492","rimonabant","cannabinoid receptor antagonist","CNR1, GPR55",NA,NA,"Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3493","riociguat","guanylate cyclase stimulant","GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3","cardiology","hypertension","COC(=O)N(C)c1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12, COC(=O)N(C)c1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12, COC(=O)N(C)c1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3494","ripasudil","rho associated kinase inhibitor","ROCK1, ROCK2","ophthalmology","glaucoma, ocular hypertension","C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12, C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12, C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12, C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12, C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12, C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3495","ripazepam","benzodiazepine receptor agonist","GABRA1",NA,NA,"CCn1nc(C)c2NC(=O)CN=C(c12)c1ccccc1 |c:11|, CCn1nc(C)c2NC(=O)CN=C(c12)c1ccccc1 |c:11|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0
"3496","risedronate","osteoclast inhibitor","FDPS","orthopedics, endocrinology","osteoporosis, Paget's disease","OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O, OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O, OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O, OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O, OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O, OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3497","risperidone","dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, HTR7","neurology/psychiatry","schizophrenia, bipolar disorder, irritability","Cc1nc2CCCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12, Cc1nc2CCCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12, Cc1nc2CCCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12","Launched",0,0,0,0,0,0,0,0,1,9,1,1,0,0,1,4,0,0,1,6,1,1,1,1
"3498","RITA","MDM inhibitor","MDM2",NA,NA,"OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1, OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1, OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3499","ritanserin","serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7",NA,NA,"Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1","Phase 3",0,0,0,0,0,0,0,0,1,9,0,0,0,0,0,0,0,0,1,3,0,0,0,0
"3500","ritonavir","HIV protease inhibitor","CYP1A2, CYP2B6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP2E1, CYP3A4, CYP3A5, CYP3A7","infectious disease","human immunodeficiency virus (HIV-1)","CC(C)[C@H](NC(=O)N(C)Cc1csc(n1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1, CC(C)[C@H](NC(=O)N(C)Cc1csc(n1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1, CC(C)[C@H](NC(=O)N(C)Cc1csc(n1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1, CC(C)[C@H](NC(=O)N(C)Cc1csc(n1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3501","rivanicline","acetylcholine receptor agonist","CHRNA4, CHRNB2, CXCL8",NA,NA,"CNCC\C=C\c1cccnc1, CNCC\C=C\c1cccnc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0
"3502","rivaroxaban","coagulation factor inhibitor","F10","neurology/psychiatry, hematology, cardiology","stroke, systemic embolism, atrial fibrillation (AF), deep vein thrombosis (DVT), pulmonary embolism (PE)","Clc1ccc(s1)C(=O)NC[C@H]1CN(C(=O)O1)c1ccc(cc1)N1CCOCC1=O, Clc1ccc(s1)C(=O)NC[C@H]1CN(C(=O)O1)c1ccc(cc1)N1CCOCC1=O, Clc1ccc(s1)C(=O)NC[C@H]1CN(C(=O)O1)c1ccc(cc1)N1CCOCC1=O, Clc1ccc(s1)C(=O)NC[C@H]1CN(C(=O)O1)c1ccc(cc1)N1CCOCC1=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3503","rivastigmine","acetylcholinesterase inhibitor","ACHE, BCHE","neurology/psychiatry","Alzheimer's disease, Parkinson's Disease, senile dementia","CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C, CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C, CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C, CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C, CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C, CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C, CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3504","rizatriptan","serotonin receptor agonist","HTR1A, HTR1B, HTR1D, HTR1E, HTR1F","neurology/psychiatry","migraine headache","CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12, CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12, CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12, CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12, CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12","Launched",0,0,0,0,0,0,0,0,1,5,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3505","RKI-1447","rho associated kinase inhibitor","CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2",NA,NA,"Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1, Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1, Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1, Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3506","RN-1","histone demethylase inhibitor","KDM1A",NA,NA,"CN1CCN(CC1)C(=O)CN[C@@H]1C[C@H]1c1ccc(OCc2ccccc2)cc1, CN1CCN(CC1)C(=O)CN[C@@H]1C[C@H]1c1ccc(OCc2ccccc2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3507","RN-1734","TRPV antagonist","TRPV4",NA,NA,"CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3508","RN-1747","TRPV agonist","TRPV4",NA,NA,"[O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1, [O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1, [O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1, [O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3509","Ro-04-5595","glutamate receptor antagonist","GRIN2B",NA,NA,"COc1cc2CCN(C)[C@@H](CCc3ccc(Cl)cc3)c2cc1O |&1:9|, COc1cc2CCN(C)[C@@H](CCc3ccc(Cl)cc3)c2cc1O |&1:9|, COc1cc2CCN(C)[C@@H](CCc3ccc(Cl)cc3)c2cc1O |&1:9|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3510","Ro-08-2750","NGF binding inhibitor","NGF, NGFR",NA,NA,"Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C)c2cc1C=O, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C)c2cc1C=O, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C)c2cc1C=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3511","Ro-10-5824","dopamine receptor agonist","DRD4",NA,NA,"Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1 |c:9|, Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1 |c:9|, Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1 |c:9|, Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1 |c:9|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0
"3512","Ro-1138452","prostanoid receptor antagonist","PTGIR",NA,NA,"CC(C)Oc1ccc(Cc2ccc(NC3=NCCN3)cc2)cc1 |t:14|, CC(C)Oc1ccc(Cc2ccc(NC3=NCCN3)cc2)cc1 |t:14|, CC(C)Oc1ccc(Cc2ccc(NC3=NCCN3)cc2)cc1 |t:14|, CC(C)Oc1ccc(Cc2ccc(NC3=NCCN3)cc2)cc1 |t:14|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3513","Ro-15-4513","GABA benzodiazepine site receptor inverse agonist","GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB2, GABRG2",NA,NA,"CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(ccc-21)N=[N+]=[N-], CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(ccc-21)N=[N+]=[N-]","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,1,8,0,0,0,0,0,0,0,0,0,0
"3514","Ro-19-4605","GABA benzodiazepine site receptor inverse agonist","GABRA1, GABRA2, GABRA3, GABRA5",NA,NA,"CN1Cc2c(ncn2-c2ccsc2C1=O)C(=O)OC(C)(C)C, CN1Cc2c(ncn2-c2ccsc2C1=O)C(=O)OC(C)(C)C, CN1Cc2c(ncn2-c2ccsc2C1=O)C(=O)OC(C)(C)C, CN1Cc2c(ncn2-c2ccsc2C1=O)C(=O)OC(C)(C)C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,0,0
"3515","Ro-20-1724","phosphodiesterase inhibitor","PDE3A, PDE4A, PDE4B, PDE4C, PDE4D",NA,NA,"CCCCOc1cc(C[C@H]2CNC(=O)N2)ccc1OC |&1:9,r|, CCCCOc1cc(C[C@H]2CNC(=O)N2)ccc1OC |&1:9,r|, CCCCOc1cc(C[C@H]2CNC(=O)N2)ccc1OC |&1:9,r|, CCCCOc1cc(C[C@H]2CNC(=O)N2)ccc1OC |&1:9,r|, CCCCOc1cc(C[C@H]2CNC(=O)N2)ccc1OC |&1:9,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3516","Ro-25-6981","glutamate receptor antagonist, monamine transporter modulator","GRIN2B",NA,NA,"C[C@@H](CN1CCC(Cc2ccccc2)CC1)[C@@H](O)c1ccc(O)cc1, C[C@@H](CN1CCC(Cc2ccccc2)CC1)[C@@H](O)c1ccc(O)cc1, C[C@@H](CN1CCC(Cc2ccccc2)CC1)[C@@H](O)c1ccc(O)cc1, C[C@@H](CN1CCC(Cc2ccccc2)CC1)[C@@H](O)c1ccc(O)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3517","Ro-28-1675","glucokinase activator","GCK",NA,NA,"CS(=O)(=O)c1ccc(cc1)[C@@H](CC1CCCC1)C(=O)Nc1nccs1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3518","Ro-3","purinergic receptor antagonist","P2RX3",NA,NA,"COc1cc(Cc2cnc(N)nc2N)c(cc1OC)C(C)C, COc1cc(Cc2cnc(N)nc2N)c(cc1OC)C(C)C, COc1cc(Cc2cnc(N)nc2N)c(cc1OC)C(C)C, COc1cc(Cc2cnc(N)nc2N)c(cc1OC)C(C)C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3519","Ro-3306","CDK inhibitor","CDK1",NA,NA,"O=C1N=C(NCc2cccs2)S\C1=C/c1ccc2ncccc2c1 |t:2|, O=C1N=C(NCc2cccs2)S\C1=C/c1ccc2ncccc2c1 |t:2|, O=C1N=C(NCc2cccs2)S\C1=C/c1ccc2ncccc2c1 |t:2|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3520","Ro-48-8071","oxidosqualene cyclase inhibitor","LSS",NA,NA,"CN(CCCCCCOc1ccc(C(=O)c2ccc(Br)cc2)c(F)c1)CC=C, CN(CCCCCCOc1ccc(C(=O)c2ccc(Br)cc2)c(F)c1)CC=C, CN(CCCCCCOc1ccc(C(=O)c2ccc(Br)cc2)c(F)c1)CC=C, CN(CCCCCCOc1ccc(C(=O)c2ccc(Br)cc2)c(F)c1)CC=C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3521","Ro-4987655","MEK inhibitor","MAP2K1",NA,NA,"OCCONC(=O)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F, OCCONC(=O)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F, OCCONC(=O)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3522","Ro-5126766","MEK inhibitor, RAF inhibitor","BRAF, MAP2K1, MAP2K2, RAF1",NA,NA,"CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F, CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F, CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3523","Ro-60-0175","serotonin receptor agonist","HTR2A, HTR2B, HTR2C",NA,NA,"C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12, C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12, C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12, C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12, C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12","Preclinical",0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3524","Ro-61-8048","kynurenine 3-monooxygenase inhibitor","KMO",NA,NA,"COc1ccc(cc1OC)S(=O)(=O)Nc1nc(cs1)-c1cccc(c1)[N+]([O-])=O, COc1ccc(cc1OC)S(=O)(=O)Nc1nc(cs1)-c1cccc(c1)[N+]([O-])=O, COc1ccc(cc1OC)S(=O)(=O)Nc1nc(cs1)-c1cccc(c1)[N+]([O-])=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3525","Ro-67-7476","glutamate receptor positive allosteric modulator","GRM1",NA,NA,"Cc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1c1ccc(F)cc1, Cc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1c1ccc(F)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3526","Ro-90-7501","beta amyloid protein neurotoxicity inhibitor","APP",NA,NA,"Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1, Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1, Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1, Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3527","robalzotan","serotonin receptor antagonist","HTR1A",NA,NA,"NC(=O)c1ccc(F)c2OC[C@@H](Cc12)N(C1CCC1)C1CCC1, NC(=O)c1ccc(F)c2OC[C@@H](Cc12)N(C1CCC1)C1CCC1, NC(=O)c1ccc(F)c2OC[C@@H](Cc12)N(C1CCC1)C1CCC1","Phase 2",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3528","rociletinib","EGFR inhibitor","EGFR",NA,NA,"COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3529","rocuronium","acetylcholine receptor antagonist","CHRM2, CHRNA2, HTR3A","neurology/psychiatry","anesthetic","CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1","Launched",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,2,0,0,1,1,1,1
"3530","rofecoxib","cyclooxygenase inhibitor","ELN, PTGS2",NA,NA,"CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|","Withdrawn",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3531","roflumilast","phosphodiesterase inhibitor","PDE4A, PDE4B, PDE4C, PDE4D","pulmonary","chronic obstructive pulmonary disease (COPD), bronchitis","FC(F)Oc1ccc(cc1OCC1CC1)C(=O)Nc1c(Cl)cncc1Cl, FC(F)Oc1ccc(cc1OCC1CC1)C(=O)Nc1c(Cl)cncc1Cl, FC(F)Oc1ccc(cc1OCC1CC1)C(=O)Nc1c(Cl)cncc1Cl","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3532","romidepsin","HDAC inhibitor","HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9","hematologic malignancy","cutaneous T-cell lymphoma (CTCL)","C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C |t:12|, C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C |t:12|, C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C |t:12|, C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C |t:12|, C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C |t:12|, C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C |t:12|, C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C |t:12|, C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C |t:12|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3533","romifidine","adrenergic receptor agonist","ADRA1A","neurology/psychiatry","sedative","C1CN=C(N1)NC2=C(C=CC=C2Br)F","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"3534","ropinirole","dopamine receptor agonist","ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C","neurology/psychiatry","Parkinson's Disease, restless leg syndrome","CCCN(CCC)CCc1cccc2NC(=O)Cc12, CCCN(CCC)CCc1cccc2NC(=O)Cc12, CCCN(CCC)CCc1cccc2NC(=O)Cc12, CCCN(CCC)CCc1cccc2NC(=O)Cc12","Launched",0,0,0,0,0,0,0,0,1,6,0,0,0,0,1,5,0,0,1,3,1,1,1,1
"3535","ropivacaine","sodium channel blocker","SCN10A","neurology/psychiatry","anesthetic","CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C, CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C, CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C","Launched",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3536","roscovitine","CDK inhibitor","CDK2, CDK9",NA,NA,"CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3537","rosiglitazone","insulin sensitizer, PPAR receptor agonist, insulin sensitizer, ppar receptor agonist","FFAR1, PPARG, TRPC5, TRPM3","Insulin sensitizer","diabetes mellitus","CN(CCOc1ccc(C[C@H]2SC(=O)NC2=O)cc1)c1ccccn1 |&1:10|, CN(CCOc1ccc(C[C@H]2SC(=O)NC2=O)cc1)c1ccccn1 |&1:10|, CN(CCOc1ccc(C[C@H]2SC(=O)NC2=O)cc1)c1ccccn1 |&1:10|, CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3538","rosmarinic-acid","GABA transaminase inhibitor","MCL1, TYR",NA,NA,"OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c(O)c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3539","rostafuroxine","ATPase inhibitor","ATP1A1",NA,NA,"C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)c1ccoc1, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)c1ccoc1, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)c1ccoc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3540","rosuvastatin","HMGCR inhibitor","HMGCR","endocrinology, cardiology","hyperlipidemia, dyslipidemia, hypertriglyceridemia, hypercholesterolemia, atherosclerosis","CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O, CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O, CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O, CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O, CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O, CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O, CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3541","rotigotine","dopamine receptor agonist","ADRA2B, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A","neurology/psychiatry","Parkinson's Disease, restless leg syndrome","CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1, CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1, CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1","Launched",0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,5,0,0,1,1,1,1,1,1
"3542","rotundine","serotonin receptor agonist","DRD1, DRD2, DRD3, HTR1A","neurology/psychiatry","anxiety, sedative","COc1cc2CCN3Cc4c(C[C@H]3c2cc1OC)ccc(OC)c4OC, COc1cc2CCN3Cc4c(C[C@H]3c2cc1OC)ccc(OC)c4OC","Launched",0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,3,0,0,0,0,1,1,1,1
"3543","roxatidine-acetate","histamine receptor antagonist","HRH2","gastroenterology","Zollinger-Ellison syndrome, erosive esophagitis (EE), gastroesophageal reflux disease (GERD), gastritis","CC(=O)OCC(=O)NCCCOc1cccc(CN2CCCCC2)c1, CC(=O)OCC(=O)NCCCOc1cccc(CN2CCCCC2)c1, CC(=O)OCC(=O)NCCCOc1cccc(CN2CCCCC2)c1, CC(=O)OCC(=O)NCCCOc1cccc(CN2CCCCC2)c1","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"3544","roxithromycin","bacterial 50S ribosomal subunit inhibitor","MLNR","infectious disease","respiratory tract infections, urinary tract infections, skin infections","CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)\C(=N/OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)\C(=N/OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)\C(=N/OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3545","RP-001","sphingosine 1-phosphate receptor agonist","S1PR1",NA,NA,"CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCC(O)=O |&1:22|, CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCC(O)=O |&1:22|, CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCC(O)=O |&1:22|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3546","rp-54745","interleukin inhibitor","IL6","rheumatology","rheumatoid arthritis","C[C@@H]1N(CCc2ccccc12)c1ssc(=O)c1Cl |&1:1,r|",NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3547","RQ-00203078","transient receptor potential channel antagonist","TRPM8",NA,NA,"OC(=O)c1ccc(cc1)S(=O)(=O)N(Cc1ccc(OC(F)(F)F)cc1)c1ncc(cc1Cl)C(F)(F)F, OC(=O)c1ccc(cc1)S(=O)(=O)N(Cc1ccc(OC(F)(F)F)cc1)c1ncc(cc1Cl)C(F)(F)F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3548","RRx-001","glucose 6-phosphate dehydrogenase inhibitor","G6PD",NA,NA,"[O-][N+](=O)C1(CN(C1)C(=O)CBr)[N+]([O-])=O, [O-][N+](=O)C1(CN(C1)C(=O)CBr)[N+]([O-])=O, [O-][N+](=O)C1(CN(C1)C(=O)CBr)[N+]([O-])=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3549","RS-100329","adrenergic receptor antagonist","ADRA1A, ADRA1D",NA,NA,"Cc1c[nH]c(=O)n(CCCN2CCN(CC2)c2ccccc2OCC(F)(F)F)c1=O, Cc1c[nH]c(=O)n(CCCN2CCN(CC2)c2ccccc2OCC(F)(F)F)c1=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0
"3550","RS-102221","serotonin receptor antagonist","HTR2A, HTR2B, HTR2C",NA,NA,"COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O, COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O, COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O, COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O, COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O","Preclinical",0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3551","RS-102895","CCR antagonist","CCR2",NA,NA,"FC(F)(F)c1ccc(CCN2CCC3(CC2)OC(=O)Nc2ccccc32)cc1, FC(F)(F)c1ccc(CCN2CCC3(CC2)OC(=O)Nc2ccccc32)cc1, FC(F)(F)c1ccc(CCN2CCC3(CC2)OC(=O)Nc2ccccc32)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3552","RS-127445","serotonin receptor antagonist","HTR2A, HTR2B, HTR2C",NA,NA,"CC(C)c1cc(nc(N)n1)-c1ccc(F)c2ccccc12, CC(C)c1cc(nc(N)n1)-c1ccc(F)c2ccccc12, CC(C)c1cc(nc(N)n1)-c1ccc(F)c2ccccc12","Phase 1",0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3553","RS-17053","adrenergic receptor antagonist","ADRA1A, ADRA1D",NA,NA,"CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0
"3554","RS-23597-190","serotonin receptor antagonist","HTR4",NA,NA,"COc1cc(N)c(Cl)cc1C(=O)OCCCN1CCCCC1","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3555","RS-39604","serotonin receptor antagonist","HTR4",NA,NA,"COc1cc(COc2cc(N)c(Cl)cc2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)cc(OC)c1, COc1cc(COc2cc(N)c(Cl)cc2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)cc(OC)c1, COc1cc(COc2cc(N)c(Cl)cc2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)cc(OC)c1, COc1cc(COc2cc(N)c(Cl)cc2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)cc(OC)c1","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3556","RS-504393","CC chemokine receptor antagonist","CCL2, CCR2",NA,NA,"Cc1oc(nc1CCN1CCC2(CC1)OC(=O)Nc1ccc(C)cc21)-c1ccccc1, Cc1oc(nc1CCN1CCC2(CC1)OC(=O)Nc1ccc(C)cc21)-c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3557","RS-56812","serotonin receptor partial agonist","HTR3A",NA,NA,"Cn1cc(C(=O)C(=O)N[C@H]2C[N@@]3CC[C@H]2CC3)c2ccccc12","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3558","RS-67333","serotonin receptor partial agonist","HTR4",NA,NA,"CCCCN1CCC(CCC(=O)c2cc(Cl)c(N)cc2OC)CC1, CCCCN1CCC(CCC(=O)c2cc(Cl)c(N)cc2OC)CC1, CCCCN1CCC(CCC(=O)c2cc(Cl)c(N)cc2OC)CC1","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3559","RS-67506","serotonin receptor partial agonist","HTR4",NA,NA,"COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1, COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1, COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1, COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3560","RS-79948","adrenergic receptor antagonist","ADRA2A",NA,NA,"CCS(=O)(=O)N1CCC[C@@H]2CN3CCc4cc(OC)ccc4[C@@H]3C[C@H]12, CCS(=O)(=O)N1CCC[C@@H]2CN3CCc4cc(OC)ccc4[C@@H]3C[C@H]12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
"3561","RTA-408","nitric oxide production inhibitor","NFE2L2",NA,NA,"CC(F)(F)C(=O)N[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:19,23|, CC(F)(F)C(=O)N[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:19,23|, CC(F)(F)C(=O)N[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:19,23|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3562","RU-SKI-43","hedgehog pathway inhibitor","HHAT",NA,NA,"CC[C@@H](C)CNCC(=O)N1CCc2sccc2[C@@H]1COc1cccc(C)c1 |&1:2,&2:17|, CC[C@@H](C)CNCC(=O)N1CCc2sccc2[C@@H]1COc1cccc(C)c1 |&1:2,&2:17|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3563","RU-24969","serotonin receptor agonist","HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR5A, HTR6",NA,NA,"COc1ccc2[nH]cc(C3=CCNCC3)c2c1 |t:9|, COc1ccc2[nH]cc(C3=CCNCC3)c2c1 |t:9|, COc1ccc2[nH]cc(C3=CCNCC3)c2c1 |t:9|, COc1ccc2[nH]cc(C3=CCNCC3)c2c1 |t:9|","Phase 1",0,0,0,0,0,0,0,0,1,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3564","RU-28318","cytochrome P450 inhibitor","NR3C2",NA,NA,"CCC[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)CCC(O)=O)[C@H]12 |t:5|, CCC[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)CCC(O)=O)[C@H]12 |t:5|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3565","RU-42173","adrenergic receptor agonist","ADRB2",NA,NA,"CC(C)N[C@@H]1CCn2c3c(cccc3[nH]c2=O)[C@H]1O, CC(C)N[C@@H]1CCn2c3c(cccc3[nH]c2=O)[C@H]1O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
"3566","RU-58841","androgen receptor antagonist","AR",NA,NA,"CC1(C)N(CCCCO)C(=O)N(C1=O)c1ccc(C#N)c(c1)C(F)(F)F, CC1(C)N(CCCCO)C(=O)N(C1=O)c1ccc(C#N)c(c1)C(F)(F)F","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3567","rubitecan","topoisomerase inhibitor","TOP1",NA,NA,"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3568","rucaparib","PARP inhibitor","PARP1, PARP2",NA,NA,"CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3569","rucinol","tyrosinase inhibitor","TYR",NA,NA,"CCCCc1ccc(O)cc1O, CCCCc1ccc(O)cc1O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3570","rufinamide","voltage-gated sodium channel blocker","GRM5, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A","neurology/psychiatry","seizures","NC(=O)c1cn(Cc2c(F)cccc2F)nn1, NC(=O)c1cn(Cc2c(F)cccc2F)nn1","Launched",0,0,1,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3571","rupatadine","histamine receptor antagonist, platelet activating factor receptor antagonist","HRH1, PTAFR","allergy","allergic rhinitis, urticaria","Cc1cncc(CN2CCC(CC2)=C2c3ccc(Cl)cc3CCc3cccnc23)c1, Cc1cncc(CN2CCC(CC2)=C2c3ccc(Cl)cc3CCc3cccnc23)c1","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"3572","rutaecarpine","cyclooxygenase inhibitor","PTGS2",NA,NA,"O=c1n2CCc3c([nH]c4ccccc34)-c2nc2ccccc12, O=c1n2CCc3c([nH]c4ccccc34)-c2nc2ccccc12, O=c1n2CCc3c([nH]c4ccccc34)-c2nc2ccccc12","Preclinical",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3573","rutin","antioxidant, capillary stabilizing agent, nitric oxide scavenger","AKR1C3","rheumatology, otolaryngology, gastroenterology, neurology/psychiatry, allergy","joint pain, nasal congestion, constipation, irritability, allergic rhinitis","C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3574","ruxolitinib","JAK inhibitor","JAK1, JAK2, JAK3, TYK2","hematologic malignancy, hematology","myelofibrosis, polycythemia vera","N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12, N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12, N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12, N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12, N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12, N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12, N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12, N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3575","ruxolitinib-(S)","JAK inhibitor","JAK1, JAK2",NA,NA,"N#CC[C@@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12, N#CC[C@@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12, N#CC[C@@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3576","RWJ-21757","toll-like receptor agonist","TLR7",NA,NA,"Nc1nc(=O)c2n(CC=C)c(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1, Nc1nc(=O)c2n(CC=C)c(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1, Nc1nc(=O)c2n(CC=C)c(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1, Nc1nc(=O)c2n(CC=C)c(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1, Nc1nc(=O)c2n(CC=C)c(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3577","RWJ-50271","integrin inhibitor","ICAM1",NA,NA,"Cc1c(cnn1-c1nc(cs1)-c1cccc(c1)C(F)(F)F)C(=O)NCCCO, Cc1c(cnn1-c1nc(cs1)-c1cccc(c1)C(F)(F)F)C(=O)NCCCO, Cc1c(cnn1-c1nc(cs1)-c1cccc(c1)C(F)(F)F)C(=O)NCCCO","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3578","RWJ-67657","MAP kinase inhibitor","MAPK14, PTGS2",NA,NA,"OCCC#Cc1nc(c(-c2ccncc2)n1CCCc1ccccc1)-c1ccc(F)cc1, OCCC#Cc1nc(c(-c2ccncc2)n1CCCc1ccccc1)-c1ccc(F)cc1, OCCC#Cc1nc(c(-c2ccncc2)n1CCCc1ccccc1)-c1ccc(F)cc1, OCCC#Cc1nc(c(-c2ccncc2)n1CCCc1ccccc1)-c1ccc(F)cc1, OCCC#Cc1nc(c(-c2ccncc2)n1CCCc1ccccc1)-c1ccc(F)cc1","Phase 1",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3579","RX-3117","CDK inhibitor, DNA synthesis inhibitor","CDK2, DNMT1",NA,NA,"Nc1ccn([C@H]2[C@H](O)[C@H](O)C(CO)=C2F)c(=O)n1 |c:12|, Nc1ccn([C@H]2[C@H](O)[C@H](O)C(CO)=C2F)c(=O)n1 |c:12|, Nc1ccn([C@H]2[C@H](O)[C@H](O)C(CO)=C2F)c(=O)n1 |c:12|, Nc1ccn([C@H]2[C@H](O)[C@H](O)C(CO)=C2F)c(=O)n1 |c:12|","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3580","RX-821002","adrenergic receptor antagonist","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C",NA,NA,"CO[C@]1(COc2ccccc2O1)C1=NCCN1 |&1:2,t:14|, CO[C@]1(COc2ccccc2O1)C1=NCCN1 |&1:2,t:14|, CO[C@]1(COc2ccccc2O1)C1=NCCN1 |&1:2,t:14|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,6,0,0,0,0
"3581","ryuvidine","histone lysine methyltransferase inhibitor","CDK2, CDK4",NA,NA,"Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3582","R112","SYK inhibitor","SYK",NA,NA,"Oc1cccc(Nc2ncc(F)c(Nc3cccc(O)c3)n2)c1, Oc1cccc(Nc2ncc(F)c(Nc3cccc(O)c3)n2)c1, Oc1cccc(Nc2ncc(F)c(Nc3cccc(O)c3)n2)c1, Oc1cccc(Nc2ncc(F)c(Nc3cccc(O)c3)n2)c1, Oc1cccc(Nc2ncc(F)c(Nc3cccc(O)c3)n2)c1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3583","R406","SYK inhibitor","RET, SYK",NA,NA,"COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3584","R547","CDK inhibitor","CDK1, CDK2, CDK4, CDK7",NA,NA,"COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N, COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N, COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N, COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3585","S-isopropylisothiourea","nitric oxide synthase inhibitor","NOS3",NA,NA,"CC(C)SC(N)=N, CC(C)SC(N)=N","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3586","S-07662","CAR antagonist","NR1I3",NA,NA,"Cc1oc2ccccc2c1CNC(=O)NCc1cccs1, Cc1oc2ccccc2c1CNC(=O)NCc1cccs1, Cc1oc2ccccc2c1CNC(=O)NCc1cccs1, Cc1oc2ccccc2c1CNC(=O)NCc1cccs1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3587","S-111","PARP inhibitor","PARP1",NA,NA,"CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3588","S-14506","serotonin receptor agonist","HTR1A",NA,NA,"COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1, COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1, COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1, COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1, COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1, COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3589","SA-47","FAAH inhibitor","FAAH",NA,NA,"CNC(=O)COC(=O)NCCC1CCN(CC1)c1cccc(C)n1, CNC(=O)COC(=O)NCCC1CCN(CC1)c1cccc(C)n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3590","saccharin","DNA polymerase inhibitor","CA1, CA12, CA2, CA9",NA,NA,"O=C1NS(=O)(=O)c2ccccc12, O=C1NS(=O)(=O)c2ccccc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3591","saclofen","GABA receptor antagonist","GABBR1, GABBR2, KCTD12, KCTD16, KCTD8",NA,NA,"NC[C@@H](CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@H](CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@H](CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3592","sacubitril","neprilysin inhibitor","MME","cardiology","congestive heart failure","CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O, CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O, CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O, CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3593","sacubitril valsartan cocrystal","neprilysin inhibitor","AGTR1, MME","Cardiovascular","hypertension","CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O.CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3594","safinamide","dopamine reuptake inhibitor, glutamate inhibitor, monoamine oxidase inhibitor","MAOB","neurology/psychiatry","Parkinson's Disease","C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O, C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O","Launched",0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3595","safingol","PKC inhibitor","TRPM3",NA,NA,"CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO, CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO, CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3596","safranal","benzodiazepine receptor agonist","GABBR1",NA,NA,"CC1=C(C=O)C(C)(C)CC=C1 |c:1,9|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3597","SAG","smoothened receptor agonist","SMO, TRPC6",NA,NA,"CN[C@H]1CC[C@@H](CC1)N(Cc1cccc(c1)-c1ccncc1)C(=O)c1sc2ccccc2c1Cl |r|, CN[C@H]1CC[C@@H](CC1)N(Cc1cccc(c1)-c1ccncc1)C(=O)c1sc2ccccc2c1Cl |r|, CN[C@H]1CC[C@@H](CC1)N(Cc1cccc(c1)-c1ccncc1)C(=O)c1sc2ccccc2c1Cl |r|, CN[C@H]1CC[C@@H](CC1)N(Cc1cccc(c1)-c1ccncc1)C(=O)c1sc2ccccc2c1Cl |r|, CN[C@H]1CC[C@@H](CC1)N(Cc1cccc(c1)-c1ccncc1)C(=O)c1sc2ccccc2c1Cl |r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3598","salicylic-acid","cyclooxygenase inhibitor, prostanoid receptor antagonist","AKR1C1, ASIC3, PTGS1, PTGS2","dermatology, endocrinology, neurology/psychiatry","acne vulgaris (AV), fever, pain relief","OC(=O)c1ccccc1O, OC(=O)c1ccccc1O, OC(=O)c1ccccc1O, OC(=O)c1ccccc1O, OC(=O)c1ccccc1O","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3599","salidroside","beta amyloid protein neurotoxicity inhibitor","APP",NA,NA,"OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3600","salirasib","mTOR inhibitor","TRPA1",NA,NA,"CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(O)=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3601","salmeterol","adrenergic receptor agonist","ADRB2","pulmonary","asthma, chronic obstructive pulmonary disease (COPD), bronchospasm","OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCCCc1ccccc1 |&1:9|, OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCCCc1ccccc1 |&1:9|, OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCCCc1ccccc1 |&1:9|, OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCCCc1ccccc1 |&1:9|, OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCCCc1ccccc1 |&1:9|, OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCCCc1ccccc1 |&1:9|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"3602","salubrinal","eukaryotic translation initiation factor inhibitor","EIF2S1",NA,NA,"ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|, ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|, ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|, ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|, ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|, ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|, ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3603","salvianolic-acid-B","EGFR inhibitor, metalloproteinase inhibitor","MMP9",NA,NA,"OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c2O[C@H]([C@H](C(=O)O[C@H](Cc3ccc(O)c(O)c3)C(O)=O)c12)c1ccc(O)c(O)c1, OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c2O[C@H]([C@H](C(=O)O[C@H](Cc3ccc(O)c(O)c3)C(O)=O)c12)c1ccc(O)c(O)c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3604","salvinorin-A","opioid receptor agonist","OPRD1, OPRK1, OPRM1",NA,NA,"COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)c1ccoc1, COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)c1ccoc1, COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)c1ccoc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3605","sal003","eukaryotic translation initiation factor inhibitor","EIF2A",NA,NA,"Clc1ccc(NC(=S)N[C@H](NC(=O)\C=C\c2ccccc2)C(Cl)(Cl)Cl)cc1 |&1:9,r|, Clc1ccc(NC(=S)N[C@H](NC(=O)\C=C\c2ccccc2)C(Cl)(Cl)Cl)cc1 |&1:9,r|, Clc1ccc(NC(=S)N[C@H](NC(=O)\C=C\c2ccccc2)C(Cl)(Cl)Cl)cc1 |&1:9,r|, Clc1ccc(NC(=S)N[C@H](NC(=O)\C=C\c2ccccc2)C(Cl)(Cl)Cl)cc1 |&1:9,r|, Clc1ccc(NC(=S)N[C@H](NC(=O)\C=C\c2ccccc2)C(Cl)(Cl)Cl)cc1 |&1:9,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3606","sanguinarium-chloride","apoptosis stimulant","CASP3",NA,NA,"C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12, C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12, C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12, C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12, C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12, C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12, C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12, C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12, C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3607","SANT-1","smoothened receptor antagonist","SHH, SMO",NA,NA,"Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1, Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1, Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1, Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1, Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1, Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1, Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3608","SANT-2","smoothened receptor antagonist","SHH, SMO",NA,NA,"CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1, CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1, CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1, CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1, CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1, CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3609","sapropterin","phenylalanine 4-hydroxylase stimulant","NOS3, PAH, TH, TPH1","metabolism","hyperphenylalaninemia (HPA)","C[C@H](O)[C@H](O)[C@H]1CNc2[nH]c(N)nc(=O)c2N1, C[C@H](O)[C@H](O)[C@H]1CNc2[nH]c(N)nc(=O)c2N1, C[C@H](O)[C@H](O)[C@H]1CNc2[nH]c(N)nc(=O)c2N1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3610","saquinavir","HIV protease inhibitor","CYP3A4","infectious disease","human immunodeficiency virus (HIV-1)","CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1, CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1, CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1, CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1, CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1, CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3611","SAR-245409","PI3K inhibitor","MTOR, PIK3CG",NA,NA,"COc1cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(NC(=O)c3ccc(C)c(OC)c3)cc2)cc(OC)c1, COc1cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(NC(=O)c3ccc(C)c(OC)c3)cc2)cc(OC)c1","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3612","sar-260301","pi3k inhibitor","PIK3C2G, PIK3C3, PIK3CA, PIK3CB, PIK3CD","oncology","melanoma","O=C1N=C(CC(N2[C@@H](C)CC3=C2C=CC=C3)=O)NC(N4CCOCC4)=C1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3613","saracatinib","SRC inhibitor","ABL1, LCK, SRC, YES1",NA,NA,"CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1","Phase 2/Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3614","saralasin","angiotensin receptor antagonist","AGTR1","cardiology","hypertension","C[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3615","sarcosine","glycine transporter inhibitor","SLC6A9",NA,NA,"CNCC(O)=O","Phase 2",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3616","saredutant","neurokinin receptor antagonist","TACR2","neurology/psychiatry","depression","CC(NC1(C2=CC=CC=C2)CCN(CC[C@@H](C3=CC(Cl)=C(Cl)C=C3)CN(C)C(C4=CC=CC=C4)=O)CC1)=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3617","saroglitazar","PPAR receptor agonist","PPARA, PPARG","endocrinology, cardiology, gastroenterology","diabetes mellitus, dyslipidemia, non-alcoholic steatohepatitis (NASH)","CCO[C@@H](Cc1ccc(OCCn2c(C)ccc2-c2ccc(SC)cc2)cc1)C(O)=O, CCO[C@@H](Cc1ccc(OCCn2c(C)ccc2-c2ccc(SC)cc2)cc1)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3618","sarolaner","gaba gated chloride channel blocker","GABRD","infectious disease","flea control","CS(=O)(=O)CC(=O)N1CC2(C1)C3=C(CO2)C=C(C=C3)C4=NO[C@@](C4)(C5=CC(=C(C(=C5)Cl)F)Cl)C(F)(F)F","Launched",0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1
"3619","sarpogrelate","serotonin receptor antagonist","HTR2A, HTR2B, HTR2C","endocrinology, cardiology, rheumatology","diabetes mellitus, angina pectoris, Raynaud's disease, atherosclerosis, Buerger's disease","COc1cccc(CCc2ccccc2OC[C@@H](CN(C)C)OC(=O)CCC(O)=O)c1 |&1:17|, COc1cccc(CCc2ccccc2OC[C@@H](CN(C)C)OC(=O)CCC(O)=O)c1 |&1:17|, COc1cccc(CCc2ccccc2OC[C@@H](CN(C)C)OC(=O)CCC(O)=O)c1 |&1:17|, COc1cccc(CCc2ccccc2OC[C@@H](CN(C)C)OC(=O)CCC(O)=O)c1 |&1:17|","Launched",0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3620","sar125844","c-met inhibitor","MET","oncology","gastric adenocarcinoma","Fc1ccc(cc1)c2ccc3nnc(Sc4ccc5nc(NC(=O)NCCN6CCOCC6)sc5c4)n3n2","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3621","SAR131675","VEGFR inhibitor","FLT4",NA,NA,"CCn1c(N)c(C(=O)NC)c(=O)c2ccc(nc12)C#C[C@@](C)(O)COC, CCn1c(N)c(C(=O)NC)c(=O)c2ccc(nc12)C#C[C@@](C)(O)COC","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3622","SAR405","PI3K inhibitor","PIK3C3",NA,NA,"C[C@@H]1COCCN1c1cc(=O)n2CC[C@H](N(Cc3cncc(Cl)c3)c2n1)C(F)(F)F, C[C@@H]1COCCN1c1cc(=O)n2CC[C@H](N(Cc3cncc(Cl)c3)c2n1)C(F)(F)F, C[C@@H]1COCCN1c1cc(=O)n2CC[C@H](N(Cc3cncc(Cl)c3)c2n1)C(F)(F)F, C[C@@H]1COCCN1c1cc(=O)n2CC[C@H](N(Cc3cncc(Cl)c3)c2n1)C(F)(F)F, C[C@@H]1COCCN1c1cc(=O)n2CC[C@H](N(Cc3cncc(Cl)c3)c2n1)C(F)(F)F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3623","SAR405838","MDM inhibitor","MDM2",NA,NA,"CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1, CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1, CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1, CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1, CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1, CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1, CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1, CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3624","SAR407899","rho associated kinase inhibitor","ROCK1",NA,NA,"O=c1[nH]ccc2cc(OC3CCNCC3)ccc12, O=c1[nH]ccc2cc(OC3CCNCC3)ccc12, O=c1[nH]ccc2cc(OC3CCNCC3)ccc12, O=c1[nH]ccc2cc(OC3CCNCC3)ccc12","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3625","sasapyrine","NFkB pathway inhibitor","PTGS1, PTGS2","rheumatology","osteoarthritis, rheumatoid arthritis","OC(=O)c1ccccc1OC(=O)c1ccccc1O, OC(=O)c1ccccc1OC(=O)c1ccccc1O, OC(=O)c1ccccc1OC(=O)c1ccccc1O","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3626","savolitinib","c-Met inhibitor","MET",NA,NA,"C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(nc12)-c1cnn(C)c1, C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(nc12)-c1cnn(C)c1, C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(nc12)-c1cnn(C)c1, C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(nc12)-c1cnn(C)c1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3627","saxagliptin","dipeptidyl peptidase inhibitor","DPP4","endocrinology","diabetes mellitus","N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)[C@]12C[C@H]3C[C@H](C[C@](O)(C3)C1)C2","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3628","SB-200646","serotonin receptor antagonist","HTR2B, HTR2C",NA,NA,"Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12, Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12, Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12, Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12, Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12","Preclinical",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3629","SB-202190","p38 MAPK inhibitor","AKT1, ALOX5, CHEK1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SGK1",NA,NA,"Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1, Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1, Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3630","SB-203186","serotonin receptor antagonist","HTR4",NA,NA,"O=C(OCCN1CCCCC1)c1c[nH]c2ccccc12, O=C(OCCN1CCCCC1)c1c[nH]c2ccccc12","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3631","SB-203580","p38 MAPK inhibitor","AKT1, ALOX5, CHEK1, CYP2D6, CYP3A4, GAK, GSK3B, LCK, MAPK1, MAPK10, MAPK11, MAPK12, MAPK14, MAPK8, MAPK9, PRKCA, RAF1, RIPK2, ROCK1, RPS6KB1, SGK1, SRC, TNF",NA,NA,"C[S@@](=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1 |&1:1|, C[S@@](=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1 |&1:1|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3632","SB-205384","GABA receptor modulator","GABRA3, GABRA5, GABRA6",NA,NA,"CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|, CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|, CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|, CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|, CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|, CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|, CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0
"3633","SB-206553","serotonin receptor antagonist","HTR2A, HTR2B, HTR2C",NA,NA,"Cn1ccc2cc3N(CCc3cc12)C(=O)Nc1cccnc1, Cn1ccc2cc3N(CCc3cc12)C(=O)Nc1cccnc1, Cn1ccc2cc3N(CCc3cc12)C(=O)Nc1cccnc1","Preclinical",0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3634","SB-216641","serotonin receptor antagonist","HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C",NA,NA,"COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1OCCN(C)C, COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1OCCN(C)C","Preclinical",0,0,0,0,0,0,0,0,1,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3635","SB-216763","glycogen synthase kinase inhibitor","CCNA2, CDK2, GSK3A, GSK3B",NA,NA,"Cn1cc(C2=C(C(=O)NC2=O)c2ccc(Cl)cc2Cl)c2ccccc12 |t:4|, Cn1cc(C2=C(C(=O)NC2=O)c2ccc(Cl)cc2Cl)c2ccccc12 |t:4|, Cn1cc(C2=C(C(=O)NC2=O)c2ccc(Cl)cc2Cl)c2ccccc12 |t:4|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3636","sb-218078","chk inhibitor","CHEK1",NA,NA,"[H][C@]12CC[C@]([H])(O1)n1c3ccccc3c3c4C(=O)NC(=O)c4c4c5ccccc5n2c4c13 |r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3637","SB-218795","tachykinin antagonist","TACR3",NA,NA,"COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1, COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1, COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3638","SB-221284","serotonin receptor antagonist","HTR2A, HTR2B, HTR2C",NA,NA,"CSc1cc2CCN(C(=O)Nc3cccnc3)c2cc1C(F)(F)F, CSc1cc2CCN(C(=O)Nc3cccnc3)c2cc1C(F)(F)F, CSc1cc2CCN(C(=O)Nc3cccnc3)c2cc1C(F)(F)F","Preclinical",0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3639","SB-222200","tachykinin antagonist","TACR3",NA,NA,"CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c1ccccc1)c1ccccc1, CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c1ccccc1)c1ccccc1, CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c1ccccc1)c1ccccc1, CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c1ccccc1)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3640","SB-225002","CC chemokine receptor antagonist","CXCR2",NA,NA,"Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3641","SB-228357","serotonin receptor antagonist","HTR2A, HTR2B, HTR2C",NA,NA,"COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F, COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F, COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F, COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F","Preclinical",0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3642","SB-2343","mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,"CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1, CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1, CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1, CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1, CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3643","SB-239063","p38 MAPK inhibitor","MAPK11, MAPK14, PTGS2",NA,NA,"COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|, COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|, COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|, COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|, COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|, COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|, COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|","Preclinical",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3644","SB-242235","p38 MAPK inhibitor","HSPB1, MAPK14",NA,NA,"COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1, COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1, COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1, COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3645","SB-243213","serotonin receptor inverse agonist","HTR2A, HTR2B, HTR2C, HTR6",NA,NA,"Cc1cc2CCN(C(=O)Nc3ccc(Oc4cccnc4C)nc3)c2cc1C(F)(F)F, Cc1cc2CCN(C(=O)Nc3ccc(Oc4cccnc4C)nc3)c2cc1C(F)(F)F, Cc1cc2CCN(C(=O)Nc3ccc(Oc4cccnc4C)nc3)c2cc1C(F)(F)F, Cc1cc2CCN(C(=O)Nc3ccc(Oc4cccnc4C)nc3)c2cc1C(F)(F)F","Phase 1",0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3646","SB-258585","serotonin receptor antagonist","HTR6",NA,NA,"COc1ccc(NS(=O)(=O)c2ccc(I)cc2)cc1N1CCN(C)CC1, COc1ccc(NS(=O)(=O)c2ccc(I)cc2)cc1N1CCN(C)CC1","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3647","SB-268262","calcitonin antagonist","CALCA",NA,NA,"CN(C(=O)c1ccc(c(c1)[N+]([O-])=O)[S@@](=O)c1nccs1)c1ccccc1C |&1:13,r|, CN(C(=O)c1ccc(c(c1)[N+]([O-])=O)[S@@](=O)c1nccs1)c1ccccc1C |&1:13,r|, CN(C(=O)c1ccc(c(c1)[N+]([O-])=O)[S@@](=O)c1nccs1)c1ccccc1C |&1:13,r|, CN(C(=O)c1ccc(c(c1)[N+]([O-])=O)[S@@](=O)c1nccs1)c1ccccc1C |&1:13,r|, CN(C(=O)c1ccc(c(c1)[N+]([O-])=O)[S@@](=O)c1nccs1)c1ccccc1C |&1:13,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3648","SB-269970","serotonin receptor antagonist","HTR7",NA,NA,"CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1, CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1, CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1, CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1, CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3649","SB-271046","serotonin receptor antagonist","HTR6",NA,NA,"COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1, COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1, COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1, COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1, COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1, COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1, COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1, COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1","Phase 1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3650","SB-297006","CC chemokine receptor antagonist","CCR3",NA,NA,"CCOC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1ccccc1, CCOC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3651","SB-334867","orexin receptor antagonist","HCRTR1, HCRTR2",NA,NA,"Cc1nc2ccc(NC(=O)Nc3ccnc4cccnc34)cc2o1, Cc1nc2ccc(NC(=O)Nc3ccnc4cccnc34)cc2o1, Cc1nc2ccc(NC(=O)Nc3ccnc4cccnc34)cc2o1, Cc1nc2ccc(NC(=O)Nc3ccnc4cccnc34)cc2o1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3652","SB-366791","TRPV antagonist","TRPV1",NA,NA,"COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1, COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1, COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1, COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1, COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3653","SB-399885","serotonin receptor antagonist","HTR6",NA,NA,"COc1ccc(cc1N1CCNCC1)S(=O)(=O)Nc1cc(Cl)cc(Cl)c1OC, COc1ccc(cc1N1CCNCC1)S(=O)(=O)Nc1cc(Cl)cc(Cl)c1OC","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3654","SB-408124","orexin receptor antagonist","HCRTR1, HCRTR2",NA,NA,"CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1, CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1, CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1, CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1, CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3655","SB-415286","glycogen synthase kinase inhibitor","GSK3A, GSK3B, RPS6KB1",NA,NA,"Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|, Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|, Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|, Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|, Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|, Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3656","sb-431542","activin receptor inhibitor","A1BG, ACVR1B, ACVR1C, TGFBR1","Oncology","brain tumors","NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3657","SB-431542","TGF beta receptor inhibitor","ACVR1C, TGFBR1",NA,NA,"NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3658","SB-452533","TRPV antagonist","TRPV1",NA,NA,"CCN(CCNC(=O)Nc1ccccc1Br)c1cccc(C)c1, CCN(CCNC(=O)Nc1ccccc1Br)c1cccc(C)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3659","SB-505124","ALK tyrosine kinase receptor inhibitor","TGFBR1",NA,NA,"Cc1cccc(n1)-c1nc([nH]c1-c1ccc2OCOc2c1)C(C)(C)C, Cc1cccc(n1)-c1nc([nH]c1-c1ccc2OCOc2c1)C(C)(C)C, Cc1cccc(n1)-c1nc([nH]c1-c1ccc2OCOc2c1)C(C)(C)C, Cc1cccc(n1)-c1nc([nH]c1-c1ccc2OCOc2c1)C(C)(C)C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3660","SB-525334","TGF beta receptor inhibitor","TGFBR1",NA,NA,"Cc1cccc(n1)-c1nc([nH]c1-c1ccc2nccnc2c1)C(C)(C)C, Cc1cccc(n1)-c1nc([nH]c1-c1ccc2nccnc2c1)C(C)(C)C, Cc1cccc(n1)-c1nc([nH]c1-c1ccc2nccnc2c1)C(C)(C)C, Cc1cccc(n1)-c1nc([nH]c1-c1ccc2nccnc2c1)C(C)(C)C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3661","SB-590885","RAF inhibitor","BRAF",NA,NA,"CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2\C(CCc2c1)=N\O)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2\C(CCc2c1)=N\O)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2\C(CCc2c1)=N\O)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2\C(CCc2c1)=N\O)-c1ccncc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3662","SB-612111","nociceptin/orphanin FQ receptor antagonist","OPRL1",NA,NA,"Cc1cccc2[C@@H](O)C[C@@H](CN3CCC(CC3)c3c(Cl)cccc3Cl)CCc12, Cc1cccc2[C@@H](O)C[C@@H](CN3CCC(CC3)c3c(Cl)cccc3Cl)CCc12, Cc1cccc2[C@@H](O)C[C@@H](CN3CCC(CC3)c3c(Cl)cccc3Cl)CCc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3663","SB-657510","urotensin receptor antagonist","UTS2R",NA,NA,"COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1, COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1, COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1, COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3664","SB-683698","integrin antagonist","ITGA4, ITGAV, ITGB1, ITGB7",NA,NA,"COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(O)=O)cc1, COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(O)=O)cc1, COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(O)=O)cc1, COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(O)=O)cc1, COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(O)=O)cc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3665","SB-705498","TRPV antagonist","TRPV1",NA,NA,"FC(F)(F)c1ccc(nc1)N1CC[C@H](C1)NC(=O)Nc1ccccc1Br, FC(F)(F)c1ccc(nc1)N1CC[C@H](C1)NC(=O)Nc1ccccc1Br, FC(F)(F)c1ccc(nc1)N1CC[C@H](C1)NC(=O)Nc1ccccc1Br, FC(F)(F)c1ccc(nc1)N1CC[C@H](C1)NC(=O)Nc1ccccc1Br, FC(F)(F)c1ccc(nc1)N1CC[C@H](C1)NC(=O)Nc1ccccc1Br","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3666","SB-706375","urotensin receptor antagonist","UTS2R",NA,NA,"COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(c(O[C@@H]2CCN(C)C2)c1)C(F)(F)F, COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(c(O[C@@H]2CCN(C)C2)c1)C(F)(F)F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3667","SB-742457","serotonin receptor antagonist","HTR6",NA,NA,"O=S(=O)(c1ccccc1)c1cnc2c(cccc2c1)N1CCNCC1, O=S(=O)(c1ccccc1)c1cnc2c(cccc2c1)N1CCNCC1, O=S(=O)(c1ccccc1)c1cnc2c(cccc2c1)N1CCNCC1","Phase 3",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3668","SB-743921","kinesin-like spindle protein inhibitor","KIF11",NA,NA,"CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3669","SB-747651A","kinase inhibitor","AKT1, AKT3, ROCK1, RPS6KA5, RPS6KB1",NA,NA,"CCn1c(nc2cncc(CNC3CCNCC3)c12)-c1nonc1N, CCn1c(nc2cncc(CNC3CCNCC3)c12)-c1nonc1N, CCn1c(nc2cncc(CNC3CCNCC3)c12)-c1nonc1N, CCn1c(nc2cncc(CNC3CCNCC3)c12)-c1nonc1N","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3670","SB-756050","G protein-coupled receptor agonist","GPBAR1",NA,NA,"COc1ccc(cc1OC)S(=O)(=O)N1CCCN(CC1)S(=O)(=O)c1ccc(OC)c(OC)c1, COc1ccc(cc1OC)S(=O)(=O)N1CCCN(CC1)S(=O)(=O)c1ccc(OC)c(OC)c1, COc1ccc(cc1OC)S(=O)(=O)N1CCCN(CC1)S(=O)(=O)c1ccc(OC)c(OC)c1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3671","SB-772077B","rho associated kinase inhibitor","ROCK1, ROCK2",NA,NA,"CCn1c(nc2cncc(C(=O)N3CC[C@H](N)C3)c12)-c1nonc1N, CCn1c(nc2cncc(C(=O)N3CC[C@H](N)C3)c12)-c1nonc1N","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3672","SB-939","HDAC inhibitor","HDAC1, HDAC10, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC9",NA,NA,"CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC, CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC, CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC, CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC, CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC, CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC, CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3673","SBE-13","PLK inhibitor","PLK1",NA,NA,"COc1ccc(CCNCc2ccc(OCc3ccc(Cl)nc3)c(OC)c2)cc1OC, COc1ccc(CCNCc2ccc(OCc3ccc(Cl)nc3)c(OC)c2)cc1OC","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3674","SBHA","HDAC inhibitor","HDAC1, HDAC3",NA,NA,"ONC(=O)CCCCCCC(=O)NO, ONC(=O)CCCCCCC(=O)NO, ONC(=O)CCCCCCC(=O)NO","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3675","SC-10","protein kinase activator","PRKCA",NA,NA,"CCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12, CCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3676","SC-12267","dihydroorotate dehydrogenase inhibitor","IL17A",NA,NA,"COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1 |t:16|, COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1 |t:16|, COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1 |t:16|, COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1 |t:16|, COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1 |t:16|, COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1 |t:16|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3677","SC-19220","prostanoid receptor antagonist","PTGER1",NA,NA,"CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc12, CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc12, CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc12, CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3678","SC-236","cyclooxygenase inhibitor","PTGS2",NA,NA,"NS(=O)(=O)c1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F, NS(=O)(=O)c1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F, NS(=O)(=O)c1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F","Preclinical",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3679","SC-51089","prostanoid receptor antagonist","PTGER1",NA,NA,"Clc1ccc2Oc3ccccc3CN(C(=O)NNC(=O)CCc3ccncc3)c2c1, Clc1ccc2Oc3ccccc3CN(C(=O)NNC(=O)CCc3ccncc3)c2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3680","SC-560","cyclooxygenase inhibitor","PTGS1",NA,NA,"COc1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F, COc1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F, COc1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F, COc1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F","Preclinical",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3681","SC-9","protein tyrosine kinase activator","PRKCA",NA,NA,"Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1, Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1, Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1, Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1, Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3682","SCH-202676","G protein-coupled receptor modulator","CHRM1, CHRM2, DRD1, DRD2",NA,NA,"CN=c1nc(-c2ccccc2)n(s1)-c1ccccc1, CN=c1nc(-c2ccccc2)n(s1)-c1ccccc1, CN=c1nc(-c2ccccc2)n(s1)-c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,1,2,0,0,0,0,0,0
"3683","SCH-221510","nociceptin/orphanin FQ receptor agonist","OPRL1",NA,NA,"Cc1ccccc1C(N1[C@H]2CC[C@@H]1C[C@](O)(C2)c1ccccc1)c1ccccc1C |&1:9,12,14,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3684","SCH-23390","dopamine receptor antagonist","DRD1, DRD5, HTR2C, KCNJ4, KCNJ6",NA,NA,"CN1CCc2cc(Cl)c(O)cc2[C@H](C1)c1ccccc1, CN1CCc2cc(Cl)c(O)cc2[C@H](C1)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,2,0,0,0,0,0,0,0,0
"3685","SCH-28080","ATPase inhibitor","ATP4A",NA,NA,"Cc1nc2c(OCc3ccccc3)cccn2c1CC#N, Cc1nc2c(OCc3ccccc3)cccn2c1CC#N","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3686","SCH-51344","MTH1 inhibitor","NUDT1",NA,NA,"COc1ccc2nc3n[nH]c(C)c3c(NCCOCCO)c2c1, COc1ccc2nc3n[nH]c(C)c3c(NCCOCCO)c2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3687","SCH-58261","adenosine receptor antagonist","ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,"Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3688","SCH-900776","CHK inhibitor","CDK2, CHEK1",NA,NA,"Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3689","schisandrin-B","antioxidant","ATR",NA,NA,"COc1cc2C[C@H](C)[C@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC |r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3690","SCMC-Lys","mucolytic agent","GSTP1","pulmonary","chronic obstructive pulmonary disease (COPD)","N[C@@H](CSCC(O)=O)C(O)=O, N[C@@H](CSCC(O)=O)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3691","scopolamine","acetylcholine receptor antagonist","CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, SI","neurology/psychiatry, gastroenterology","motion sickness, vomiting, nausea","CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,5,0,0,1,1,1,1
"3692","scopolamine-N-oxide","acetylcholine receptor antagonist","CHRM1, CHRM2, CHRM3, CHRM4",NA,NA,"C[N@@+]1([O-])[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1 |a:3,5,7,8,10,14,&1:1,TLB:0:1:4.5.6:8.10,THB:2:1:4.5.6:8.10,9:8:1:4.5.6,9:10:1:4.5.6,11:5:1:8.10|, C[N@@+]1([O-])[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1 |a:3,5,7,8,10,14,&1:1,TLB:0:1:4.5.6:8.10,THB:2:1:4.5.6:8.10,9:8:1:4.5.6,9:10:1:4.5.6,11:5:1:8.10|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0
"3693","scriptaid","HDAC inhibitor","HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",NA,NA,"ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23, ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23, ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3694","SD-169","p38 MAPK inhibitor","MAPK14",NA,NA,"NC(=O)c1ccc2[nH]ccc2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3695","SD-208","TGF beta receptor inhibitor","TGFBR1",NA,NA,"Fc1ccc(Cl)cc1-c1nc(Nc2ccncc2)c2nccnc2n1, Fc1ccc(Cl)cc1-c1nc(Nc2ccncc2)c2nccnc2n1, Fc1ccc(Cl)cc1-c1nc(Nc2ccncc2)c2nccnc2n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3696","SD-2590","matrix metalloprotease inhibitor","MMP1, MMP13, MMP2",NA,NA,"COCCN1CCC(CC1)(C(=O)NO)S(=O)(=O)c1ccc(Oc2ccc(OC(F)(F)F)cc2)cc1, COCCN1CCC(CC1)(C(=O)NO)S(=O)(=O)c1ccc(Oc2ccc(OC(F)(F)F)cc2)cc1, COCCN1CCC(CC1)(C(=O)NO)S(=O)(=O)c1ccc(Oc2ccc(OC(F)(F)F)cc2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3697","SDM25N","opioid receptor antagonist","OPRD1",NA,NA,"CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O |a:7,8,15,&1:14,TLB:17:15:4.5.6:11.12.13,THB:16:15:4.5.6:11.12.13|, CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O |a:7,8,15,&1:14,TLB:17:15:4.5.6:11.12.13,THB:16:15:4.5.6:11.12.13|, CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O |a:7,8,15,&1:14,TLB:17:15:4.5.6:11.12.13,THB:16:15:4.5.6:11.12.13|, CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O |a:7,8,15,&1:14,TLB:17:15:4.5.6:11.12.13,THB:16:15:4.5.6:11.12.13|, CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O |a:7,8,15,&1:14,TLB:17:15:4.5.6:11.12.13,THB:16:15:4.5.6:11.12.13|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3698","sdz-mks 492","phosphodiesterase inhibitor","PDE3A","pulmonary","asthma","COCCn1c(N[C@@H](CO)c2ccc(OC)c(OC)c2)nc2n(C)c(=O)n(C)c(=O)c12 |a:7|",NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3699","SDZ-NKT-343","tachykinin antagonist","TACR1",NA,NA,"CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3700","SDZ-SER-082","serotonin receptor antagonist","HTR2A, HTR2B, HTR2C",NA,NA,"CN1CC[C@@H]2CN3CCc4cccc([C@@H]2C1)c34, CN1CC[C@@H]2CN3CCc4cccc([C@@H]2C1)c34","Preclinical",0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3701","SDZ-WAG-994","adenosine receptor agonist","ADORA1",NA,NA,"CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12, CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12, CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12, CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3702","SDZ-205-557","serotonin receptor antagonist","HTR3A, HTR3B",NA,NA,"CCN(CC)CCOC(=O)c1cc(Cl)c(N)cc1OC, CCN(CC)CCOC(=O)c1cc(Cl)c(N)cc1OC","Preclinical",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3703","SDZ-21009","adrenergic receptor antagonist, serotonin receptor antagonist","HTR1A, HTR1B",NA,NA,"CC(C)OC(=O)c1cc2c(OC[C@@H](O)CNC(C)(C)C)cccc2[nH]1 |&1:12,r|, CC(C)OC(=O)c1cc2c(OC[C@@H](O)CNC(C)(C)C)cccc2[nH]1 |&1:12,r|, CC(C)OC(=O)c1cc2c(OC[C@@H](O)CNC(C)(C)C)cccc2[nH]1 |&1:12,r|","Preclinical",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3704","SDZ-220-040","glutamate receptor antagonist","GRIN1",NA,NA,"N[C@@H](Cc1cc(cc(CP(O)(O)=O)c1O)-c1ccc(Cl)cc1Cl)C(O)=O, N[C@@H](Cc1cc(cc(CP(O)(O)=O)c1O)-c1ccc(Cl)cc1Cl)C(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3705","SDZ-220-581","glutamate receptor antagonist","GRIN1",NA,NA,"N[C@@H](Cc1cc(CP(O)(O)=O)cc(c1)-c1ccccc1Cl)C(O)=O, N[C@@H](Cc1cc(CP(O)(O)=O)cc(c1)-c1ccccc1Cl)C(O)=O, N[C@@H](Cc1cc(CP(O)(O)=O)cc(c1)-c1ccccc1Cl)C(O)=O, N[C@@H](Cc1cc(CP(O)(O)=O)cc(c1)-c1ccccc1Cl)C(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3706","secalciferol","vitamin D receptor agonist","VDR","critical care","bone fracture","C[C@H](CC[C@@H](O)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, C[C@H](CC[C@@H](O)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, C[C@H](CC[C@@H](O)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, C[C@H](CC[C@@H](O)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3707","securinine","GABA receptor antagonist, TP53 activator","GABRA1",NA,NA,"O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31 |c:6,9|, O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31 |c:6,9|, O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31 |c:6,9|, O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31 |c:6,9|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0
"3708","segesterone","progesterone receptor agonist","PGR","obstetrics/gynecology","endometriosis","O=C4\C=C2/[C@@H]([C@H]1CC[C@@]3([C@](OC(=O)C)(C(=C)\C[C@H]3[C@@H]1CC2)C(=O)C)C)CC4","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3709","segesterone-acetate","progesterone receptor agonist","PGR",NA,NA,"[H][C@@]12CC(=C)[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H] |c:26|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3710","selegiline","monoamine oxidase inhibitor","MAOA, MAOB","neurology/psychiatry","Parkinson's Disease","C[C@H](Cc1ccccc1)N(C)CC#C","Launched",0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3711","selexipag","IP1 prostacyclin receptor agonist, platelet aggregation inhibitor","PTGIR","pulmonary","pulmonary arterial hypertension (PAH)","CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(n1)-c1ccccc1, CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(n1)-c1ccccc1, CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(n1)-c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3712","selfotel","glutamate receptor antagonist","GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,"OC(=O)[C@H]1C[C@@H](CP(O)(O)=O)CCN1, OC(=O)[C@H]1C[C@@H](CP(O)(O)=O)CCN1, OC(=O)[C@H]1C[C@@H](CP(O)(O)=O)CCN1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3713","selinexor","exportin antagonist","XPO1","hematologic malignancy","multiple myeloma","FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1, FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1, FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1, FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1, FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3714","selpercatinib","ret tyrosine kinase inhibitor","RET","oncology","medullary thyroid cancer (mtc)","COc1ccc(CN2[C@H]3C[C@@H]2CN(C3)c2ccc(cn2)-c2cc(OCC(C)(C)O)cn3ncc(C#N)c23)cn1 |&1:8,10,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3715","seltorexant","orexin receptor antagonist","HCRTR2","neurology/psychiatry","depression","Cc1cc(C)nc(n1)N2CC3CN(CC3C2)C(=O)c4c(F)cccc4n5nccn5","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3716","selumetinib","MEK inhibitor","MAP2K1",NA,NA,"Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3717","sel120-34a (monohydrochloride)","cdk inhibitor","CDK19, CDK8","hematologic malignancy","acute myeloid leukemia (aml)","Cc1c(Br)c(Br)c2CCCn3c(nc1c23)N1CCNCC1.Cl","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3718","semagacestat","gamma secretase inhibitor","PSEN1",NA,NA,"CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@H]1c2ccccc2CCN(C)C1=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3719","semapimod","cytokine production inhibitor, p38 MAPK inhibitor","MAPK14",NA,NA,"CC(=NNC(N)=N)c1cc(NC(=O)CCCCCCCCC(=O)Nc2cc(cc(c2)C(C)=NNC(N)=N)C(C)=NNC(N)=N)cc(c1)C(C)=NNC(N)=N, CC(=NNC(N)=N)c1cc(NC(=O)CCCCCCCCC(=O)Nc2cc(cc(c2)C(C)=NNC(N)=N)C(C)=NNC(N)=N)cc(c1)C(C)=NNC(N)=N, CC(=NNC(N)=N)c1cc(NC(=O)CCCCCCCCC(=O)Nc2cc(cc(c2)C(C)=NNC(N)=N)C(C)=NNC(N)=N)cc(c1)C(C)=NNC(N)=N","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3720","semaxanib","VEGFR inhibitor","FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET",NA,NA,"Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3721","SEN-1269","beta amyloid inhibitor","APP",NA,NA,"CN(C)c1cccc(Oc2cnc(Nc3cccc(O)c3)nc2)c1, CN(C)c1cccc(Oc2cnc(Nc3cccc(O)c3)nc2)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3722","senaparib","parp inhibitor","PARP1","oncology","breast cancer","Fc1ccc(CN2C(=O)NC(=O)c3c(F)cccc23)cc1C(=O)N4CCN(CC4)c5ncccn5","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3723","senicapoc","intermediate conductance potassium channel blocker","KCNN4",NA,NA,"NC(=O)C(c1ccccc1)(c1ccc(F)cc1)c1ccc(F)cc1, NC(=O)C(c1ccccc1)(c1ccc(F)cc1)c1ccc(F)cc1, NC(=O)C(c1ccccc1)(c1ccc(F)cc1)c1ccc(F)cc1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3724","seocalcitol","vitamin D receptor agonist","VDR",NA,NA,"CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3725","SEP-227900","D-amino acid oxidase Inhibitor","DAO",NA,NA,"OC(=O)c1cc2occc2[nH]1, OC(=O)c1cc2occc2[nH]1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3726","sep-363856","trace amine associated receptor agonist","HTR1A, TAAR1","neurology/psychiatry","schizophrenia","CNC[C@@H]1OCCc2ccsc12","Phase 2",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3727","seratrodast","prostanoid receptor antagonist","TBXA2R","pulmonary","asthma","CC1=C(C)C(=O)C([C@@H](CCCCCC(O)=O)c2ccccc2)=C(C)C1=O |r,c:1,t:22|, CC1=C(C)C(=O)C([C@@H](CCCCCC(O)=O)c2ccccc2)=C(C)C1=O |r,c:1,t:22|, CC1=C(C)C(=O)C([C@@H](CCCCCC(O)=O)c2ccccc2)=C(C)C1=O |r,c:1,t:22|, CC1=C(C)C(=O)C([C@@H](CCCCCC(O)=O)c2ccccc2)=C(C)C1=O |r,c:1,t:22|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3728","serdemetan","MDM inhibitor","MDM2",NA,NA,"C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3729","serotonin","growth factor receptor activator","DRD1, DRD5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR3B, HTR4, HTR5A, HTR6, HTR7, SLC36A1","neurology/psychiatry","anxiety, depression, sleeplessness","NCCc1c[nH]c2ccc(O)cc12, NCCc1c[nH]c2ccc(O)cc12, NCCc1c[nH]c2ccc(O)cc12","Launched",1,1,0,0,0,0,0,0,1,14,0,0,0,0,1,2,0,0,0,0,1,1,1,1
"3730","sertindole","dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA1D, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, KCNH2",NA,NA,"Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12, Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12, Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12, Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12, Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12","Withdrawn",0,0,0,0,0,0,0,0,1,8,1,1,0,0,1,3,0,0,1,3,0,0,0,0
"3731","sertraline","selective serotonin reuptake inhibitor (SSRI)","SLC6A3, SLC6A4","neurology/psychiatry, obstetrics/gynecology","depression, obsessive compulsive disorder (OCD), panic disorders, posttraumatic stress disorder, premenstrual syndrome, social anxiety disorder","CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12, CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12, CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12, CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12, CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12, CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12, CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12","Launched",1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3732","setipiprant","prostaglandin inhibitor","PTGDR2",NA,NA,"OC(=O)Cn1c2CCN(Cc2c2cc(F)ccc12)C(=O)c1cccc2ccccc12, OC(=O)Cn1c2CCN(Cc2c2cc(F)ccc12)C(=O)c1cccc2ccccc12","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3733","setiptiline","adrenergic receptor antagonist","HRH1, HTR2A, HTR2C","neurology/psychiatry","depression","CN1CCC2=C(C1)c1ccccc1Cc1ccccc21 |c:4|, CN1CCC2=C(C1)c1ccccc1Cc1ccccc21 |c:4|","Launched",0,0,0,0,0,0,0,0,1,2,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"3734","sevoflurane","membrane integrity inhibitor","ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9, MT-ND1","neurology/psychiatry","anesthetic","FCOC(C(F)(F)F)C(F)(F)F, FCOC(C(F)(F)F)C(F)(F)F","Launched",0,0,0,0,0,0,0,0,0,0,0,0,1,16,0,0,0,0,0,0,1,1,1,1
"3735","SEW-2871","lysophospholipid receptor agonist","S1PR1",NA,NA,"FC(F)(F)c1sc(cc1-c1ccccc1)-c1nc(no1)-c1cccc(c1)C(F)(F)F, FC(F)(F)c1sc(cc1-c1ccccc1)-c1nc(no1)-c1cccc(c1)C(F)(F)F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3736","SF-11","neuropeptide receptor antagonist","MCOLN3, NPY2R",NA,NA,"CCOc1ccc(NC(=S)N2CCC(CC2)C(O)(c2ccccc2)c2ccccc2)cc1, CCOc1ccc(NC(=S)N2CCC(CC2)C(O)(c2ccccc2)c2ccccc2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3737","SGC-CBP30","bromodomain inhibitor","CREBBP, EP300",NA,NA,"COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl, COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl, COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl, COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl, COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl, COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl, COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3738","SGC-707","protein arginine N-methyltransferase inhibitor","PRMT3",NA,NA,"O=C(NCC(=O)N1CCCC1)Nc1ccc2cnccc2c1, O=C(NCC(=O)N1CCCC1)Nc1ccc2cnccc2c1, O=C(NCC(=O)N1CCCC1)Nc1ccc2cnccc2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3739","SGI-1027","DNA methyltransferase inhibitor","DNMT1, DNMT3A, DNMT3B",NA,NA,"Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1, Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1, Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1, Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3740","SGI-1776","Pim kinase inhibitor","FLT3, PIM1, PIM2, PIM3",NA,NA,"CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1, CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1, CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1, CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1, CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1, CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1, CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1, CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3741","SGS-742","GABA receptor antagonist","GABBR1, GABBR2",NA,NA,"CCCCP(O)(=O)CCCN","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3742","SGX523","hepatocyte growth factor receptor inhibitor","MET",NA,NA,"Cn1cc(cn1)-c1ccc2nnc(Sc3ccc4ncccc4c3)n2n1, Cn1cc(cn1)-c1ccc2nnc(Sc3ccc4ncccc4c3)n2n1, Cn1cc(cn1)-c1ccc2nnc(Sc3ccc4ncccc4c3)n2n1, Cn1cc(cn1)-c1ccc2nnc(Sc3ccc4ncccc4c3)n2n1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3743","SHA-68","neuropeptide receptor antagonist","NPSR1",NA,NA,"Fc1ccc(CNC(=O)N2CCN3[C@@H](C2)C(OC3=O)(c2ccccc2)c2ccccc2)cc1 |&1:13,r|, Fc1ccc(CNC(=O)N2CCN3[C@@H](C2)C(OC3=O)(c2ccccc2)c2ccccc2)cc1 |&1:13,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3744","SHP099","protein tyrosine kinase inhibitor","PTPN11",NA,NA,"CC1(N)CCN(CC1)c1cnc(c(N)n1)-c1cccc(Cl)c1Cl, CC1(N)CCN(CC1)c1cnc(c(N)n1)-c1cccc(Cl)c1Cl, CC1(N)CCN(CC1)c1cnc(c(N)n1)-c1cccc(Cl)c1Cl, CC1(N)CCN(CC1)c1cnc(c(N)n1)-c1cccc(Cl)c1Cl","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3745","SIB-1553A","acetylcholine receptor agonist","CHRNB4",NA,NA,"CN1CCC[C@@H]1CCSc1ccc(O)cc1 |&1:5|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
"3746","SIB-1757","glutamate receptor antagonist","GRM5",NA,NA,"C=C1NC(=NNc2ccccc2)C(=O)C=C1 |c:15|, C=C1NC(=NNc2ccccc2)C(=O)C=C1 |c:15|, C=C1NC(=NNc2ccccc2)C(=O)C=C1 |c:15|, C=C1NC(=NNc2ccccc2)C(=O)C=C1 |c:15|, C=C1NC(=NNc2ccccc2)C(=O)C=C1 |c:15|, C=C1NC(=NNc2ccccc2)C(=O)C=C1 |c:15|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3747","SIB-1893","glutamate receptor antagonist","GRM4, GRM5",NA,NA,"Cc1cccc(\C=C\c2ccccc2)n1, Cc1cccc(\C=C\c2ccccc2)n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3748","SID-7969543","steroidogenic factor antagonist","NR5A1",NA,NA,"CCOC(=O)[C@@H](C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O |&1:5,r|, CCOC(=O)[C@@H](C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O |&1:5,r|, CCOC(=O)[C@@H](C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O |&1:5,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3749","sigma-2 receptor antagonist 1","sigma receptor antagonist","PGRMC1, TMEM97","neurology/psychiatry","alzheimer's disease","CC(C)(C)Oc1cc(CCC(C)(C)N2Cc3ccc(cc3C2)S(=O)(=O)C)ccc1O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3750","siguazodan","phosphodiesterase inhibitor","PDE3A, PDE3B","Cardiology","heart failure therapy","CN\C(NC#N)=N/c1ccc(cc1)C1=NNC(=O)C[C@@H]1C |r,t:14|, CN\C(NC#N)=N/c1ccc(cc1)C1=NNC(=O)C[C@@H]1C |r,t:14|, CN\C(NC#N)=N/c1ccc(cc1)C1=NNC(=O)C[C@@H]1C |r,t:14|, CN\C(NC#N)=N/c1ccc(cc1)C1=NNC(=O)C[C@@H]1C |r,t:14|, CN\C(NC#N)=N/c1ccc(cc1)C1=NNC(=O)C[C@@H]1C |&1:19,t:14|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3751","sildenafil","phosphodiesterase inhibitor","PDE5A, PDE6G, PDE6H, SLCO1B1, SLCO1B3","urology","erectile dysfunction","CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1, CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1, CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1, CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1, CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1, CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1","Launched",1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3752","silibinin","cytochrome P450 inhibitor","ALOX5","gastroenterology","hepatic cirrhosis","COc1cc(ccc1O)[C@H]1Oc2cc(ccc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O, COc1cc(ccc1O)[C@H]1Oc2cc(ccc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O, COc1cc(ccc1O)[C@H]1Oc2cc(ccc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O, COc1cc(ccc1O)[C@H]1Oc2cc(ccc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3753","silodosin","adrenergic receptor antagonist","ADRA1A, ADRA1B, ADRA1D","urology","benign prostatic hyperplasia (BPH)","C[C@H](Cc1cc2CCN(CCCO)c2c(c1)C(N)=O)NCCOc1ccccc1OCC(F)(F)F, C[C@H](Cc1cc2CCN(CCCO)c2c(c1)C(N)=O)NCCOc1ccccc1OCC(F)(F)F, C[C@H](Cc1cc2CCN(CCCO)c2c(c1)C(N)=O)NCCOc1ccccc1OCC(F)(F)F","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,1,1,1,1
"3754","simeprevir","HCV inhibitor","CYP1A2, CYP3A4","infectious disease","hepatitis C","COc1ccc2c(O[C@@H]3C[C@@H]4[C@@H](C3)C(=O)N(C)CCCC\C=C/[C@@H]3C[C@]3(NC4=O)C(=O)NS(=O)(=O)C3CC3)cc(nc2c1C)-c1nc(cs1)C(C)C |c:22|, COc1ccc2c(O[C@@H]3C[C@@H]4[C@@H](C3)C(=O)N(C)CCCC\C=C/[C@@H]3C[C@]3(NC4=O)C(=O)NS(=O)(=O)C3CC3)cc(nc2c1C)-c1nc(cs1)C(C)C |c:22|, COc1ccc2c(O[C@@H]3C[C@@H]4C(C3)C(=O)N(C)CCCC\C=C/[C@@H]3C[C@]3(NC4=O)C(=O)NS(=O)(=O)C3CC3)cc(nc2c1C)-c1nc(cs1)C(C)C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3755","simvastatin","HMGCR inhibitor","HMGCR, ITGB2","endocrinology, cardiology, neurology/psychiatry","hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia","CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3756","sinefungin","DNA methyltransferase inhibitor, RNA synthesis inhibitor","CARM1",NA,NA,"N[C@@H](CC[C@H](N)C(O)=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12, N[C@@H](CC[C@H](N)C(O)=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3757","sipatrigine","voltage-gated sodium channel blocker","CACNA1D, SCN10A, SCN1A, SCN3A, SCN4A, SCN5A, SCN9A",NA,NA,"CN1CCN(CC1)c1ncc(c(N)n1)-c1cc(Cl)cc(Cl)c1Cl, CN1CCN(CC1)c1ncc(c(N)n1)-c1cc(Cl)cc(Cl)c1Cl, CN1CCN(CC1)c1ncc(c(N)n1)-c1cc(Cl)cc(Cl)c1Cl","Phase 2",0,0,1,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3758","siponimod","sphingosine 1-phosphate receptor modulator","S1PR1","neurology/psychiatry","multiple sclerosis","CCc1cc(ccc1CN1CC(C1)C(O)=O)C(\C)=N\OCc1ccc(C2CCCCC2)c(c1)C(F)(F)F, CCc1cc(ccc1CN1CC(C1)C(O)=O)C(\C)=N\OCc1ccc(C2CCCCC2)c(c1)C(F)(F)F, CCc1cc(ccc1CN1CC(C1)C(O)=O)C(\C)=N\OCc1ccc(C2CCCCC2)c(c1)C(F)(F)F, CCc1cc(ccc1CN1CC(C1)C(O)=O)C(\C)=N\OCc1ccc(C2CCCCC2)c(c1)C(F)(F)F, CCc1cc(ccc1CN1CC(C1)C(O)=O)C(\C)=N\OCc1ccc(C2CCCCC2)c(c1)C(F)(F)F, CCc1cc(ccc1CN1CC(C1)C(O)=O)C(\C)=N\OCc1ccc(C2CCCCC2)c(c1)C(F)(F)F","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3759","siramesine","sigma receptor antagonist","ADRA1A, ADRA1B, ADRA1D",NA,NA,"Fc1ccc(cc1)-n1cc(CCCCN2CCC3(CC2)OCc2ccccc32)c2ccccc12, Fc1ccc(cc1)-n1cc(CCCCN2CCC3(CC2)OCc2ccccc32)c2ccccc12, Fc1ccc(cc1)-n1cc(CCCCN2CCC3(CC2)OCc2ccccc32)c2ccccc12","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0
"3760","sirolimus","mTOR inhibitor","FKBP1A, MTOR","transplant, pulmonary, transplant, pulmonary","organ rejection, lymphangioleiomyomatosis, organ rejection, lymphangioleiomyomatosis","CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14,33,t:29,31|, COC1CC(CC(C)C2CC(=O)C(C)\C=C(C)\C(O)C(OC)C(=O)C(C)CC(C)\C=C\C=C\C=C(C)\C(CC3CCC(C)C(O)(O3)C(=O)C(=O)N3CCCCC3C(=O)O2)OC)CCC1O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3761","SirReal-2","SIRT inhibitor","SIRT2",NA,NA,"Cc1cc(C)nc(SCC(=O)Nc2ncc(Cc3cccc4ccccc34)s2)n1, Cc1cc(C)nc(SCC(=O)Nc2ncc(Cc3cccc4ccccc34)s2)n1, Cc1cc(C)nc(SCC(=O)Nc2ncc(Cc3cccc4ccccc34)s2)n1, Cc1cc(C)nc(SCC(=O)Nc2ncc(Cc3cccc4ccccc34)s2)n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3762","sirtinol","SIRT inhibitor","SIRT1, SIRT2",NA,NA,"C[C@@H](NC(=O)c1ccccc1\N=C\c1c(O)ccc2ccccc12)c1ccccc1 |&1:1,r|, C[C@@H](NC(=O)c1ccccc1\N=C\c1c(O)ccc2ccccc12)c1ccccc1 |&1:1,r|, C[C@@H](NC(=O)c1ccccc1\N=C\c1c(O)ccc2ccccc12)c1ccccc1 |&1:1,r|, C[C@@H](NC(=O)c1ccccc1\N=C\c1c(O)ccc2ccccc12)c1ccccc1 |&1:1,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3763","SIS3","serine/threonine kinase inhibitor","SMAD3, TGFBR1",NA,NA,"COc1cc2CCN(Cc2cc1OC)C(=O)\C=C\c1c(-c2ccccc2)n(C)c2ncccc12, COc1cc2CCN(Cc2cc1OC)C(=O)\C=C\c1c(-c2ccccc2)n(C)c2ncccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3764","sitagliptin","dipeptidyl peptidase inhibitor","DPP4","endocrinology","diabetes mellitus","N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1cc(F)c(F)cc1F, N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1cc(F)c(F)cc1F, N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1cc(F)c(F)cc1F, N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1cc(F)c(F)cc1F","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3765","sitaxentan","endothelin receptor antagonist","EDNRA, EDNRB",NA,NA,"Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl, Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl, Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl, Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl, Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3766","sivelestat","elastase inhibitor","CELA1, ELANE","pulmonary","acute lung injury","CC(C)(C)C(=O)Oc1ccc(cc1)S(=O)(=O)Nc1ccccc1C(=O)NCC(O)=O, CC(C)(C)C(=O)Oc1ccc(cc1)S(=O)(=O)Nc1ccccc1C(=O)NCC(O)=O, CC(C)(C)C(=O)Oc1ccc(cc1)S(=O)(=O)Nc1ccccc1C(=O)NCC(O)=O, CC(C)(C)C(=O)Oc1ccc(cc1)S(=O)(=O)Nc1ccccc1C(=O)NCC(O)=O, CC(C)(C)C(=O)Oc1ccc(cc1)S(=O)(=O)Nc1ccccc1C(=O)NCC(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3767","SJ-172550","MDM inhibitor","MDM4",NA,NA,"CCOc1cc(\C=C2/C(C)=NN(C2=O)c2ccccc2)cc(Cl)c1OCC(=O)OC |c:9|, CCOc1cc(\C=C2/C(C)=NN(C2=O)c2ccccc2)cc(Cl)c1OCC(=O)OC |c:9|, CCOc1cc(\C=C2/C(C)=NN(C2=O)c2ccccc2)cc(Cl)c1OCC(=O)OC |c:9|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3768","SK&F-10047-(+)","sigma receptor agonist","SIGMAR1",NA,NA,"C[C@@H]1[C@@H]2Cc3ccc(O)cc3[C@@]1(C)CCN2CC=C, C[C@@H]1[C@@H]2Cc3ccc(O)cc3[C@@]1(C)CCN2CC=C","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3769","SKA-31","potassium channel activator","KCNN4",NA,NA,"Nc1nc2c(ccc3ccccc23)s1, Nc1nc2c(ccc3ccccc23)s1, Nc1nc2c(ccc3ccccc23)s1, Nc1nc2c(ccc3ccccc23)s1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3770","skepinone-L","p38 MAPK inhibitor","MAPK14",NA,NA,"OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1, OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1, OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1, OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3771","SKF-38393","dopamine receptor agonist","CALY, DRD1, DRD5",NA,NA,"Oc1cc2CCNC[C@@H](c3ccccc3)c2cc1O |&1:8|, Oc1cc2CCNC[C@@H](c3ccccc3)c2cc1O |&1:8|, Oc1cc2CCNC[C@@H](c3ccccc3)c2cc1O |&1:8|, Oc1cc2CCNC[C@@H](c3ccccc3)c2cc1O |&1:8|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0
"3772","SKF-77434","dopamine receptor agonist","DRD1",NA,NA,"Oc1cc2CCN(CC=C)C[C@@H](c3ccccc3)c2cc1O |&1:11|, Oc1cc2CCN(CC=C)C[C@@H](c3ccccc3)c2cc1O |&1:11|, Oc1cc2CCN(CC=C)C[C@@H](c3ccccc3)c2cc1O |&1:11|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0
"3773","SKF-81297","dopamine receptor agonist","DRD1, DRD5",NA,NA,"Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1, Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1, Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1, Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1, Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0
"3774","SKF-83566","dopamine receptor antagonist","DRD1, DRD5",NA,NA,"CN1CCc2cc(Br)c(O)cc2[C@@H](C1)c1ccccc1 |&1:12|, CN1CCc2cc(Br)c(O)cc2[C@@H](C1)c1ccccc1 |&1:12|, CN1CCc2cc(Br)c(O)cc2[C@@H](C1)c1ccccc1 |&1:12|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0
"3775","SKF-86002","p38 MAPK inhibitor","ALOX5, MAPK14",NA,NA,"Fc1ccc(cc1)-c1nc2SCCn2c1-c1ccncc1, Fc1ccc(cc1)-c1nc2SCCn2c1-c1ccncc1, Fc1ccc(cc1)-c1nc2SCCn2c1-c1ccncc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3776","SKF-89976A","GABA uptake inhibitor","SLC6A1",NA,NA,"OC(=O)[C@H]1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1 |&1:3|, OC(=O)[C@H]1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1 |&1:3|, OC(=O)[C@H]1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1 |&1:3|, OC(=O)[C@H]1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1 |&1:3|","Preclinical",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3777","SKF-91488","histamine N-methyltransferase inhibitor","HNMT",NA,NA,"CN(C)CCCCSC(N)=N, CN(C)CCCCSC(N)=N, CN(C)CCCCSC(N)=N","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3778","SKF-96365","calcium channel blocker","CYP3A4, PKD2, TRPC1, TRPC3, TRPC4, TRPC5, TRPV2",NA,NA,"COc1ccc(CCCO[C@@H](Cn2ccnc2)c2ccc(OC)cc2)cc1 |&1:10|, COc1ccc(CCCO[C@@H](Cn2ccnc2)c2ccc(OC)cc2)cc1 |&1:10|, COc1ccc(CCCO[C@@H](Cn2ccnc2)c2ccc(OC)cc2)cc1 |&1:10|, COc1ccc(CCCO[C@@H](Cn2ccnc2)c2ccc(OC)cc2)cc1 |&1:10|, COc1ccc(CCCO[C@@H](Cn2ccnc2)c2ccc(OC)cc2)cc1 |&1:10|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3779","SKI-II","sphingosine kinase inhibitor","SPHK1",NA,NA,"Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3780","SKLB1002","VEGFR inhibitor","KDR",NA,NA,"COc1cc2ncnc(Sc3nnc(C)s3)c2cc1OC, COc1cc2ncnc(Sc3nnc(C)s3)c2cc1OC, COc1cc2ncnc(Sc3nnc(C)s3)c2cc1OC","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3781","SLV-319-(+/-)","cannabinoid receptor antagonist","CNR1, DRD2, HTR1A",NA,NA,"C\N=C(\NS(=O)(=O)c1ccc(Cl)cc1)N1C[C@@H](C(=N1)c1ccc(Cl)cc1)c1ccccc1 |&1:16,r,c:18|","Phase 2",0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0
"3782","SLV-320","adenosine receptor antagonist","ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,"O[C@H]1CC[C@@H](CC1)Nc1nc(nc2[nH]ccc12)-c1ccccc1 |r|, O[C@H]1CC[C@@H](CC1)Nc1nc(nc2[nH]ccc12)-c1ccccc1 |r|, O[C@H]1CC[C@@H](CC1)Nc1nc(nc2[nH]ccc12)-c1ccccc1 |r|, O[C@H]1CC[C@@H](CC1)Nc1nc(nc2[nH]ccc12)-c1ccccc1 |r|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3783","SM-164","XIAP inhibitor","BIRC2, BIRC3, XIAP",NA,NA,"CN[C@@H](C)C(=O)N[C@H]1CCCC[C@H]2CC[C@H](N2C1=O)C(=O)N[C@H](c1cn(CCCCc2ccc(CCCCn3cc(nn3)[C@@H](NC(=O)[C@@H]3CC[C@@H]4CCCC[C@H](NC(=O)[C@H](C)NC)C(=O)N34)c3ccccc3)cc2)nn1)c1ccccc1, CN[C@@H](C)C(=O)N[C@H]1CCCC[C@H]2CC[C@H](N2C1=O)C(=O)N[C@H](c1cn(CCCCc2ccc(CCCCn3cc(nn3)[C@@H](NC(=O)[C@@H]3CC[C@@H]4CCCC[C@H](NC(=O)[C@H](C)NC)C(=O)N34)c3ccccc3)cc2)nn1)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3784","SM-21","sigma receptor antagonist","PGRMC1",NA,NA,"CC[C@H](Oc1ccc(Cl)cc1)C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)N2C |&1:14,16,19,&2:2,r,TLB:22:21:17.18:14.15.20|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3785","SMER-28","autophagy inducer","SNCA",NA,NA,"Brc1ccc2ncnc(NCC=C)c2c1, Brc1ccc2ncnc(NCC=C)c2c1, Brc1ccc2ncnc(NCC=C)c2c1, Brc1ccc2ncnc(NCC=C)c2c1, Brc1ccc2ncnc(NCC=C)c2c1, Brc1ccc2ncnc(NCC=C)c2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3786","SMI-4a","Pim kinase inhibitor","PIM1",NA,NA,"FC(F)(F)c1cccc(\C=C2/SC(=O)NC2=O)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3787","smn-c3","cell splicing inhibitor","SMN2",NA,NA,"CCN1CCC(CC1)c1cc(C)c2nc(cc(=O)n2c1)-c1cc2c(C)nc(C)cn2n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3788","SN-2","transient receptor potential channel agonist","MCOLN3",NA,NA,"Cc1cc(C)c(C2=NO[C@@H]3[C@H]4CC[C@H](C4)[C@H]23)c(C)c1 |&1:9,10,13,15,t:6|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3789","SN-38","topoisomerase inhibitor","TOP1","oncology","colorectal cancer","CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3790","SNAP","nitric oxide donor","PTPN1",NA,NA,"CC(=O)N[C@@H](C(O)=O)C(C)(C)S[NH2+][O-] |&1:4,r|, CC(=O)N[C@@H](C(O)=O)C(C)(C)S[NH2+][O-] |&1:4,r|, CC(=O)N[C@@H](C(O)=O)C(C)(C)S[NH2+][O-] |&1:4,r|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3791","SNAP-5089","adrenergic receptor antagonist","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CACNA1C, CACNA1D",NA,NA,"COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccc(cc1)[N+]([O-])=O)C(=O)NCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |&1:11,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccc(cc1)[N+]([O-])=O)C(=O)NCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |&1:11,c:4,9|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,6,0,0,0,0
"3792","SNG-1153","selective estrogen receptor modulator (SERM)","ESR1",NA,NA,"CC(C)=CCc1c(O)cc(O)c2c1oc(c(O)c2=O)-c1ccc(cc1)C(F)(F)F, CC(C)=CCc1c(O)cc(O)c2c1oc(c(O)c2=O)-c1ccc(cc1)C(F)(F)F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3793","SNS-314","Aurora kinase inhibitor","AURKA, AURKB, AURKC",NA,NA,"Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1, Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1, Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1, Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1, Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3794","SNX-5422","HSP inhibitor","HSP90AA1, HSP90AB1",NA,NA,"CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1 |r|, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1 |r|, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1 |r|, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1 |r|, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1 |r|","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3795","sobetirome","thyroid hormone receptor agonist","THRA, THRB",NA,NA,"CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3796","sodium-butyrate","HDAC inhibitor","BCHE, FFAR2, FFAR3, HDAC1, HDAC2, HDAC3, HDAC8",NA,NA,"CCCC(O)=O, CCCC(O)=O, CCCC(O)=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3797","sodium-stibogluconate","tyrosine phosphatase inhibitor","PTPN6","infectious disease","leishmaniasis","[H][C@@]1(O[Sb]2(O)(O[Sb]34(O)O[C@H]([C@@H](O3)[C@]([H])(O4)[C@H](O)CO)C(O)=O)O[C@H]([C@H]1O2)C(O)=O)[C@H](O)CO","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3798","sofalcone","mucus protecting agent","CBR1","gastroenterology","peptic ulcer disease (PUD)","CC(C)=CCOc1ccc(\C=C\C(=O)c2ccc(OCC=C(C)C)cc2OCC(O)=O)cc1, CC(C)=CCOc1ccc(\C=C\C(=O)c2ccc(OCC=C(C)C)cc2OCC(O)=O)cc1, CC(C)=CCOc1ccc(\C=C\C(=O)c2ccc(OCC=C(C)C)cc2OCC(O)=O)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3799","solasonine","hedgehog pathway inhibitor","CYCS, MAPK14, MAPK8","dermatology","actinic keratosis (ak)","C[C@@H]1CC[C@@]2(NC1)O[C@H]3C[C@H]4[C@@H]5CC=C6C[C@H](CC[C@]6(C)[C@H]5CC[C@]4(C)[C@H]3[C@@H]2C)O[C@@H]7O[C@H](CO)[C@H](O)[C@H](O[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O)[C@H]7O[C@@H]9O[C@@H](C)[C@H](O)[C@@H](O)[C@H]9O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3800","solcitinib","JAK inhibitor","JAK1",NA,NA,"CC1(C)CN(C1)C(=O)c1ccc(cc1)-c1cccc2nc(NC(=O)C3CC3)nn12, CC1(C)CN(C1)C(=O)c1ccc(cc1)-c1cccc2nc(NC(=O)C3CC3)nn12, CC1(C)CN(C1)C(=O)c1ccc(cc1)-c1cccc2nc(NC(=O)C3CC3)nn12","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3801","solifenacin-succinate","acetylcholine receptor antagonist","CHRM1, CHRM2, CHRM3, CHRM4, CHRM5","urology","urinary incontinence, urinary frequency","[H][C@@]1(C[N@@]2CC[C@H]1CC2)OC(=O)N1CCc2ccccc2[C@@H]1c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,5,0,0,1,1,1,1
"3802","somatostatin","somatostatin receptor agonist","OPRD1, OPRM1, SSTR1, SSTR2, SSTR3, SSTR4, SSTR5","hematology","hemorrhage","C[C@@H](O)[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O, C[C@@H](O)[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3803","sonidegib","smoothened receptor antagonist","SMO","oncology","basal cell carcinoma (BCC)","C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(c2C)-c2ccc(OC(F)(F)F)cc2)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(c2C)-c2ccc(OC(F)(F)F)cc2)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(c2C)-c2ccc(OC(F)(F)F)cc2)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(c2C)-c2ccc(OC(F)(F)F)cc2)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(c2C)-c2ccc(OC(F)(F)F)cc2)cn1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3804","sorafenib","FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET","oncology","renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)","CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3805","sorbinil","aldose reductase inhibitor","AKR1B1",NA,NA,"Fc1ccc2OCC[C@]3(NC(=O)NC3=O)c2c1 |&1:8,r|, Fc1ccc2OCC[C@]3(NC(=O)NC3=O)c2c1 |&1:8,r|, Fc1ccc2OCC[C@]3(NC(=O)NC3=O)c2c1 |&1:8,r|, Fc1ccc2OCC[C@]3(NC(=O)NC3=O)c2c1 |&1:8,r|, Fc1ccc2OCC[C@]3(NC(=O)NC3=O)c2c1 |&1:8,r|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3806","sorivudine","dna polymerase inhibitor","DPYD","infectious disease","virus herpes simplex (hsv)","OC[C@H]1O[C@H]([C@@H](O)[C@@H]1O)N2C=C(\C=C\Br)C(=O)NC2=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3807","sotagliflozin","sodium/glucose cotransporter inhibitor","SLC5A1, SLC5A2",NA,NA,"CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)cc1, CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)cc1, CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)cc1","Phase 3",1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3808","sotalol","adrenergic receptor antagonist","ADRB1, ADRB2, ADRB3, KCNH2","cardiology, Cardiology","atrial fibrillation (AF), ventricular arrhythmias, angina pectoris","CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1, CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1, CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1, CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1, CC(C)NC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:5,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,1,1,1,1
"3809","sotorasib","ras gtpase inhibitor","KRAS","oncology","non-small cell lung cancer (nsclc)","CC(C)c1nccc(C)c1N2C(=O)N=C(N3CCN(C[C@@H]3C)C(=O)C=C)c4cc(F)c(nc24)c5c(O)cccc5F","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3810","sotrastaurin","PKC inhibitor","PRKCA, PRKCB, PRKCD, PRKCE, PRKCH, PRKCQ",NA,NA,"CN1CCN(CC1)c1nc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc2n1 |t:11|, CN1CCN(CC1)c1nc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc2n1 |t:11|, CN1CCN(CC1)c1nc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc2n1 |t:11|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3811","SP-100030","NFkB pathway inhibitor","JUN, NFKB1",NA,NA,"FC(F)(F)c1cc(NC(=O)c2cnc(Cl)nc2C(F)(F)F)cc(c1)C(F)(F)F, FC(F)(F)c1cc(NC(=O)c2cnc(Cl)nc2C(F)(F)F)cc(c1)C(F)(F)F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3812","SP-141","ubiquitin ligase inhibitor","MDM2",NA,NA,"COc1ccc2[nH]c3c(nccc3c2c1)-c1cccc2ccccc12, COc1ccc2[nH]c3c(nccc3c2c1)-c1cccc2ccccc12, COc1ccc2[nH]c3c(nccc3c2c1)-c1cccc2ccccc12, COc1ccc2[nH]c3c(nccc3c2c1)-c1cccc2ccccc12, COc1ccc2[nH]c3c(nccc3c2c1)-c1cccc2ccccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3813","spaglumic-acid","glutamate receptor antagonist","GRM3","allergy","allergic conjunctivitis, allergic rhinitis","CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3814","sparfloxacin","bacterial DNA gyrase inhibitor","TOP2A",NA,NA,"C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3815","sparfosate","aspartate carbamoyltransferase inhibitor","CA2, CA4",NA,NA,"OC(=O)C[C@@H](NC(=O)CP(O)(O)=O)C(O)=O |&1:4|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3816","spautin-1","deubiquitinase inhibitor","USP10, USP13",NA,NA,"Fc1ccc(CNc2ncnc3ccc(F)cc23)cc1, Fc1ccc(CNc2ncnc3ccc(F)cc23)cc1, Fc1ccc(CNc2ncnc3ccc(F)cc23)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3817","spermidine","glutamate receptor modulator","KCNJ4, TXNRD1",NA,NA,"NCCCCNCCCN, NCCCCNCCCN","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3818","sphingosylphosphorylcholine","gene expression stimulant","GPR12",NA,NA,"CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(=O)OCC[N+](C)(C)C |a:15,17,&1:21|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3819","spinosad","acetylcholine receptor agonist","CHRNA7","infectious disease","lice","CC[C@H]1CCC[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@@H](C)C(=O)C3=C[C@H]4[C@@H]5C[C@@H](C[C@H]5C=C[C@H]4[C@@H]3CC(=O)O1)O[C@@H]6O[C@@H](C)[C@H](OC)[C@@H](OC)[C@H]6OC","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,1
"3820","spiperone","dopamine receptor antagonist","ADRA1A, ADRA1B, ADRA1D, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7","neurology/psychiatry","schizophrenia","Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1, Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1, Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1","Launched",0,0,0,0,0,0,0,0,1,7,0,0,0,0,1,5,0,0,1,3,1,1,1,1
"3821","spiradoline","opioid receptor agonist","OPRK1",NA,NA,"CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3822","spirapril","angiotensin converting enzyme inhibitor","ACE","cardiology","hypertension","O=C(OCC)[C@@H](N[C@H](C(=O)N2[C@H](C(=O)O)CC1(SCCS1)C2)C)CCc3ccccc3","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3823","spironolactone","mineralocorticoid receptor antagonist","AR, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CYP11B2, NR3C1, NR3C2, PGR, SHBG","endocrinology, cardiology, gastroenterology, rheumatology","hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia","CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3824","spiroxatrine","serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR2B",NA,NA,"O=C1NCN(c2ccccc2)C11CCN(C[C@H]2COc3ccccc3O2)CC1 |&1:16,r|, O=C1NCN(c2ccccc2)C11CCN(C[C@H]2COc3ccccc3O2)CC1 |&1:16,r|","Preclinical",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,1,6,0,0,0,0
"3825","splitomycin","SIRT inhibitor","SIRT1",NA,NA,"O=C1CCc2c(O1)ccc1ccccc21, O=C1CCc2c(O1)ccc1ccccc21","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3826","SPP301","endothelin receptor antagonist","EDNRA",NA,NA,"COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C)cn2)nc(nc1OC)-c1ccncc1, COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C)cn2)nc(nc1OC)-c1ccncc1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3827","SPP86","receptor tyrosine protein kinase inhibitor","RET",NA,NA,"CC(C)n1nc(C#Cc2ccccc2)c2c(N)ncnc12, CC(C)n1nc(C#Cc2ccccc2)c2c(N)ncnc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3828","SQ-109","bacterial cell wall synthesis inhibitor","FDFT1",NA,NA,"CC(C)=CCC\C(C)=C\CNCCNC1[C@H]2C[C@@H]3C[C@@H](C[C@H]1C3)C2 |r|, CC(C)=CCC\C(C)=C\CNCCNC1[C@H]2C[C@@H]3C[C@@H](C[C@H]1C3)C2 |r|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3829","SQ-22536","adenylyl cyclase inhibitor","ADCY1",NA,NA,"Nc1ncnc2n(cnc12)[C@H]1CCCO1 |&1:10,r|, Nc1ncnc2n(cnc12)[C@H]1CCCO1 |&1:10,r|, Nc1ncnc2n(cnc12)[C@H]1CCCO1 |&1:10,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3830","sr 146131","cck receptor agonist","CCKAR","oncology","neuroblastoma","O=C(O)CN1C(C(NC2=NC(C3=CC(OC)=C(Cl)C=C3OC)=C(CCC4CCCCC4)S2)=O)=CC5=C1C(C)=CC(C)=C5","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3831","SR-1078","retinoid receptor agonist","RORA, RORC",NA,NA,"OC(c1ccc(NC(=O)c2ccc(cc2)C(F)(F)F)cc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(NC(=O)c2ccc(cc2)C(F)(F)F)cc1)(C(F)(F)F)C(F)(F)F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3832","SR-140333","neurokinin receptor antagonist","TACR1",NA,NA,"CC(C)Oc1cccc(CC(=O)N2CCC[C@@](CC[N+]34CCC(CC3)(CC4)c3ccccc3)(C2)c2ccc(Cl)c(Cl)c2)c1, CC(C)Oc1cccc(CC(=O)N2CCC[C@@](CC[N+]34CCC(CC3)(CC4)c3ccccc3)(C2)c2ccc(Cl)c(Cl)c2)c1, CC(C)Oc1cccc(CC(=O)N2CCC[C@@](CC[N+]34CCC(CC3)(CC4)c3ccccc3)(C2)c2ccc(Cl)c(Cl)c2)c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3833","SR-1664","PPAR receptor ligand","PPARG",NA,NA,"C[C@H](NC(=O)c1ccc2n(Cc3ccc(cc3)-c3ccccc3C(O)=O)c(C)c(C)c2c1)c1ccc(cc1)[N+]([O-])=O, C[C@H](NC(=O)c1ccc2n(Cc3ccc(cc3)-c3ccccc3C(O)=O)c(C)c(C)c2c1)c1ccc(cc1)[N+]([O-])=O, C[C@H](NC(=O)c1ccc2n(Cc3ccc(cc3)-c3ccccc3C(O)=O)c(C)c(C)c2c1)c1ccc(cc1)[N+]([O-])=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3834","SR-2211","retinoid receptor inverse agonist","RORC",NA,NA,"OC(c1ccc(c(F)c1)-c1ccc(CN2CCN(Cc3ccncc3)CC2)cc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(c(F)c1)-c1ccc(CN2CCN(Cc3ccncc3)CC2)cc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(c(F)c1)-c1ccc(CN2CCN(Cc3ccncc3)CC2)cc1)(C(F)(F)F)C(F)(F)F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3835","SR-2640","leukotriene receptor antagonist","CYSLTR1",NA,NA,"OC(=O)c1ccccc1Nc1cccc(OCc2ccc3ccccc3n2)c1, OC(=O)c1ccccc1Nc1cccc(OCc2ccc3ccccc3n2)c1, OC(=O)c1ccccc1Nc1cccc(OCc2ccc3ccccc3n2)c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3836","SR-27897","CCK receptor antagonist","CCKAR",NA,NA,"OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl, OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl, OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl, OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl, OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3837","sr-31747","immunosuppressant","SIGMAR1","oncology","prostate cancer","CCN(C/C=C\C1=CC=C(C2CCCCC2)C(Cl)=C1)C3CCCCC3.Cl","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3838","SR-3306","JNK inhibitor","MAPK10, MAPK8, MAPK9",NA,NA,"Cc1ccc(cn1)-c1ncn(n1)-c1ccc(Nc2nccc(n2)-c2cccc(c2)N2CCOCC2)cc1, Cc1ccc(cn1)-c1ncn(n1)-c1ccc(Nc2nccc(n2)-c2cccc(c2)N2CCOCC2)cc1, Cc1ccc(cn1)-c1ncn(n1)-c1ccc(Nc2nccc(n2)-c2cccc(c2)N2CCOCC2)cc1, Cc1ccc(cn1)-c1ncn(n1)-c1ccc(Nc2nccc(n2)-c2cccc(c2)N2CCOCC2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3839","SR-3576","JNK inhibitor","MAPK10",NA,NA,"COc1cc(NC(=O)c2cccc(c2)-n2cc(NC(=O)Nc3cccc(C)c3)cn2)cc(OC)c1OC, COc1cc(NC(=O)c2cccc(c2)-n2cc(NC(=O)Nc3cccc(C)c3)cn2)cc(OC)c1OC, COc1cc(NC(=O)c2cccc(c2)-n2cc(NC(=O)Nc3cccc(C)c3)cn2)cc(OC)c1OC","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3840","SR-3677","rho associated kinase inhibitor","ROCK2",NA,NA,"CN(C)CCOc1cc(ccc1NC(=O)[C@H]1COc2ccccc2O1)-c1cn[nH]c1 |&1:15|, CN(C)CCOc1cc(ccc1NC(=O)[C@H]1COc2ccccc2O1)-c1cn[nH]c1 |&1:15|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3841","SR-57227A","serotonin receptor agonist","HTR3A",NA,NA,"NC1CCN(CC1)c1cccc(Cl)n1, NC1CCN(CC1)c1cccc(Cl)n1","Phase 2",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3842","SR-59230A","adrenergic receptor antagonist","ADRB1, ADRB2, ADRB3",NA,NA,"CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc12, CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc12, CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc12, CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0
"3843","SR-95639A","acetylcholine receptor agonist","CHRM1",NA,NA,"C(CN1CCOCC1)Nc1cc2CCCc3ccccc3-c2nn1, C(CN1CCOCC1)Nc1cc2CCCc3ccccc3-c2nn1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
"3844","SRC-kinase-inhibitor-I","SRC inhibitor","CSK, LCK, RIPK2",NA,NA,"COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC, COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC, COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC, COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3845","SRPIN340","serine arginine protein kinase inhibitor","SRPK1, SRPK2",NA,NA,"FC(F)(F)c1ccc(N2CCCCC2)c(NC(=O)c2ccncc2)c1, FC(F)(F)c1ccc(N2CCCCC2)c(NC(=O)c2ccncc2)c1, FC(F)(F)c1ccc(N2CCCCC2)c(NC(=O)c2ccncc2)c1, FC(F)(F)c1ccc(N2CCCCC2)c(NC(=O)c2ccncc2)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3846","SRT1720","SIRT activator","SIRT1",NA,NA,"O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1, O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1, O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1, O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1, O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1, O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3847","SRT2104","SIRT activator","SIRT1",NA,NA,"Cc1nc(sc1C(=O)Nc1ccccc1-c1cn2c(CN3CCOCC3)csc2n1)-c1cccnc1, Cc1nc(sc1C(=O)Nc1ccccc1-c1cn2c(CN3CCOCC3)csc2n1)-c1cccnc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3848","SSR180711","acetylcholine receptor agonist","CHRNA7",NA,NA,"Brc1ccc(OC(=O)N2CC[N@@]3CC[C@H]2CC3)cc1 |r|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
"3849","ST-2825","myeloid differentiation primary response inhibitor","MYD88",NA,NA,"NC(=O)[C@H]1CCS[C@@H]2C[C@]3(CCCN3C(=O)Cc3ccc(NC(=O)COc4ccc(Cl)cc4Cl)cc3)C(=O)N12, NC(=O)[C@H]1CCS[C@@H]2C[C@]3(CCCN3C(=O)Cc3ccc(NC(=O)COc4ccc(Cl)cc4Cl)cc3)C(=O)N12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3850","STA-5326","interleukin synthesis inhibitor","IL12A",NA,NA,"Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1, Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1, Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1, Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1, Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1, Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1, Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1, Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3851","stanozolol","androgen receptor agonist","AR","Oncology","breast cancer","C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4Cc5n[nH]cc5C[C@]4(C)[C@H]3CC[C@]12C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3852","STAT3-inhibitor-VI","STAT inhibitor","STAT3",NA,NA,"Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1, Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1, Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1, Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1, Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1, Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3853","stemregenin-1","aryl hydrocarbon receptor antagonist","AHR",NA,NA,"CC(C)n1cnc2c(NCCc3ccc(O)cc3)nc(nc12)-c1csc2ccccc12, CC(C)n1cnc2c(NCCc3ccc(O)cc3)nc(nc12)-c1csc2ccccc12, CC(C)n1cnc2c(NCCc3ccc(O)cc3)nc(nc12)-c1csc2ccccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3854","STF-083010","serine/threonine kinase inhibitor","ERN1",NA,NA,"Oc1ccc2ccccc2c1\C=N\S(=O)(=O)c1cccs1, Oc1ccc2ccccc2c1\C=N\S(=O)(=O)c1cccs1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3855","STF-118804","NAMPT inhibitor","NAMPT",NA,NA,"Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1, Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1, Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1, Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1, Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1, Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3856","STF-31","NAMPT inhibitor","NAMPT, SLC2A1",NA,NA,"CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1","Preclinical",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3857","stiripentol","GABA uptake inhibitor","GABRA3","neurology/psychiatry","epilepsy","CC(C)(C)[C@@H](O)\C=C\c1ccc2OCOc2c1 |&1:4,r|, CC(C)(C)[C@@H](O)\C=C\c1ccc2OCOc2c1 |&1:4,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1
"3858","stobadine","adrenergic receptor antagonist","ADRA1A",NA,NA,"CN1CC[C@H]2Nc3ccc(C)cc3[C@H]2C1, CN1CC[C@H]2Nc3ccc(C)cc3[C@H]2C1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
"3859","strontium-ranelate","bone formation stimulant, bone resorption inhibitor","CASR","orthopedics, rheumatology","osteoporosis, osteoarthritis","OC1=CN(C=C(O)O[Sr]O1)c1sc2c(CC(=O)O[Sr]OC2=O)c1C#N, OC1=CN(C=C(O)O[Sr]O1)c1sc2c(CC(=O)O[Sr]OC2=O)c1C#N, OC1=CN(C=C(O)O[Sr]O1)c1sc2c(CC(=O)O[Sr]OC2=O)c1C#N, OC1=CN(C=C(O)O[Sr]O1)c1sc2c(CC(=O)O[Sr]OC2=O)c1C#N, OC1=CN(C=C(O)O[Sr]O1)c1sc2c(CC(=O)O[Sr]OC2=O)c1C#N","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3860","strychnine","acetylcholine receptor antagonist","CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA10, CHRNA9, GLRA1, GLRA2, GLRA3, GLRB",NA,NA,"O=C1CC2OCC=C3CN4CC[C@@]56C4C[C@@H]3[C@@H]2C5N1c1ccccc61, O=C1C[C@@H]2OCC=C3CN4CC[C@@]56[C@@H]4C[C@@H]3[C@@H]2[C@@H]5N1c1ccccc61 |t:6|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,7,0,0,0,0,0,0
"3861","substance-P","neurokinin receptor antagonist","TACR1, TACR2, TACR3",NA,NA,"CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(N)=O, CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(N)=O, CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(N)=O, CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(N)=O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3862","succinobucol","antioxidant","VCAM1",NA,NA,"CC(C)(C)c1cc(SC(C)(C)Sc2cc(c(OC(=O)CCC(O)=O)c(c2)C(C)(C)C)C(C)(C)C)cc(c1O)C(C)(C)C","Phase 2/Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3863","succinylsulfathiazole","dihydrofolate reductase inhibitor","DHFR",NA,NA,"OC(=O)CCC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1, OC(=O)CCC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3864","sulfameter","dihydrofolate reductase inhibitor","DHFR","infectious disease","urinary tract infections","COc1cnc(NS(=O)(=O)c2ccc(N)cc2)nc1, COc1cnc(NS(=O)(=O)c2ccc(N)cc2)nc1, COc1cnc(NS(=O)(=O)c2ccc(N)cc2)nc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3865","sulfanilamide","carbonic anhydrase inhibitor","CYP2C19, CYP2C9, CYP2D6, CYP2E1, CYP3A4","infectious disease","vulvovaginal candidiasis","Nc1ccc(cc1)S(N)(=O)=O, Nc1ccc(cc1)S(N)(=O)=O, Nc1ccc(cc1)S(N)(=O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3866","sulfaphenazole","dihydropteroate synthetase inhibitor","DHPS","infectious disease","urinary tract infections","Nc1ccc(cc1)S(=O)(=O)Nc1ccnn1-c1ccccc1, Nc1ccc(cc1)S(=O)(=O)Nc1ccnn1-c1ccccc1, Nc1ccc(cc1)S(=O)(=O)Nc1ccnn1-c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3867","sulfasalazine","cyclooxygenase inhibitor","ACAT1, ALOX5, CHUK, IKBKB, PLA2G1B, PPARG, PTGS1, PTGS2, SLC46A1, SLC7A11, TBXAS1","gastroenterology","ulcerative colitis","OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1, OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1, OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1, OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1, OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1","Launched",1,2,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3868","sulfinpyrazone","uricosuric blocker","ABCC1, FPR1, SLC22A12","rheumatology","gout","O=C1C(CC[S@@](=O)c2ccccc2)C(=O)N(N1c1ccccc1)c1ccccc1 |r|, O=C1C(CC[S@](=O)c2ccccc2)C(=O)N(N1c1ccccc1)c1ccccc1 |&1:5,r|","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3869","sulforaphane","anticancer agent, aryl hydrocarbon receptor antagonist","NFE2L2",NA,NA,"C[S@@](=O)CCCCN=C=S |r|, C[S@@](=O)CCCCN=C=S |r|, C[S@@](=O)CCCCN=C=S |r|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3870","sulindac","cyclooxygenase inhibitor","AKR1B1","rheumatology","osteoarthritis, rheumatoid arthritis, ankylosing spondylitis","CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)[S@@](C)=O |r,c:1|, CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)[S@@](C)=O |r,c:1|, CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)[S@@](C)=O |r,c:1|, CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)[S@@](C)=O |r,c:1|, CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)[S@@](C)=O |r,c:1|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3871","sulmetozine","gastrin inhibitor","GAST","gastroenterology","peptic ulcer disease (PUD)","COc1cc(cc(OC)c1OC)C(=S)N1CCOCC1, COc1cc(cc(OC)c1OC)C(=S)N1CCOCC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3872","sultiame","carbonic anhydrase inhibitor","CA2",NA,NA,"NS(=O)(=O)c1ccc(cc1)N1CCCCS1(=O)=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3873","sumanirole","dopamine receptor agonist","DRD2",NA,NA,"CN[C@@H]1Cc2cccc3[nH]c(=O)n(C1)c23, CN[C@@H]1Cc2cccc3[nH]c(=O)n(C1)c23","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0
"3874","sumatriptan","serotonin receptor agonist","HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR5A, HTR6, HTR7","neurology/psychiatry","migraine headache","CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1, CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1, CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1, CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1, CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1","Launched",0,0,0,0,0,0,0,0,1,8,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3875","SUN-B-8155","calcitonin agonist","CALCR",NA,NA,"C\C(=N/c1ccccc1N)c1c(C)cc(=O)n(O)c1O, C\C(=N/c1ccccc1N)c1c(C)cc(=O)n(O)c1O, C\C(=N/c1ccccc1N)c1c(C)cc(=O)n(O)c1O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3876","SUN-11602","fibroblast growth factor mimetic","FGFR1",NA,NA,"CN(C1CCN(Cc2ccc(cc2)C(N)=O)CC1)C(=O)CNc1c(C)c(C)c(N)c(C)c1C, CN(C1CCN(Cc2ccc(cc2)C(N)=O)CC1)C(=O)CNc1c(C)c(C)c(N)c(C)c1C, CN(C1CCN(Cc2ccc(cc2)C(N)=O)CC1)C(=O)CNc1c(C)c(C)c(N)c(C)c1C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3877","sunitinib","FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET","oncology","gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)","CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3878","suprofen","cyclooxygenase inhibitor","PTGS1, PTGS2",NA,NA,"C[C@@H](C(O)=O)c1ccc(cc1)C(=O)c1cccs1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc(cc1)C(=O)c1cccs1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc(cc1)C(=O)c1cccs1 |&1:1,r|","Withdrawn",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3879","suramin","DNA synthesis inhibitor","F2, FSHR, P2RY1, P2RY11, P2RY13, P2RY2, PLA2G2A, RYR1, RYR2, SIRT5","infectious disease","African trypanosomiasis, onchocerciasis","Cc1ccc(cc1NC(=O)c1cccc(NC(=O)Nc2cccc(c2)C(=O)Nc2cc(ccc2C)C(=O)Nc2ccc(c3cc(cc(c23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)c1)C(=O)Nc1ccc(c2cc(cc(c12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O, Cc1ccc(cc1NC(=O)c1cccc(NC(=O)Nc2cccc(c2)C(=O)Nc2cc(ccc2C)C(=O)Nc2ccc(c3cc(cc(c23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)c1)C(=O)Nc1ccc(c2cc(cc(c12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3880","suritozole","GABA receptor inverse agonist","GABBR1",NA,NA,"Cn1nc(-c2cccc(F)c2)n(C)c1=S, Cn1nc(-c2cccc(F)c2)n(C)c1=S","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3881","SU014813","PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","KDR",NA,NA,"Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3882","SU11274","hepatocyte growth factor receptor inhibitor, tyrosine kinase inhibitor","MET",NA,NA,"CN(c1cccc(Cl)c1)S(=O)(=O)c1ccc2NC(=O)\C(=C/c3[nH]c(C)c(C(=O)N4CCN(C)CC4)c3C)c2c1, CN(c1cccc(Cl)c1)S(=O)(=O)c1ccc2NC(=O)\C(=C/c3[nH]c(C)c(C(=O)N4CCN(C)CC4)c3C)c2c1, CN(c1cccc(Cl)c1)S(=O)(=O)c1ccc2NC(=O)\C(=C/c3[nH]c(C)c(C(=O)N4CCN(C)CC4)c3C)c2c1, CN(c1cccc(Cl)c1)S(=O)(=O)c1ccc2NC(=O)\C(=C/c3[nH]c(C)c(C(=O)N4CCN(C)CC4)c3C)c2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3883","SU16f","PDGFR tyrosine kinase receptor inhibitor","PDGFRB",NA,NA,"Cc1[nH]c(\C=C2/C(=O)Nc3cc(ccc23)-c2ccccc2)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3cc(ccc23)-c2ccccc2)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3cc(ccc23)-c2ccccc2)c(C)c1CCC(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3884","SU3327","JNK inhibitor","MAPK8",NA,NA,"Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1, Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1, Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1, Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1, Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1, Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3885","SU4312","PDGFR tyrosine kinase receptor inhibitor, tyrosine kinase inhibitor, VEGFR inhibitor","KDR, PDGFRB",NA,NA,"CN(C)c1ccc(\C=C2/C(=O)Nc3ccccc23)cc1, CN(C)c1ccc(\C=C2/C(=O)Nc3ccccc23)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3886","SU9516","CDK inhibitor","CDK1, CDK2, CDK4, CDK5",NA,NA,"COc1ccc2NC(=O)\C(=C/c3cnc[nH]3)c2c1, COc1ccc2NC(=O)\C(=C/c3cnc[nH]3)c2c1, COc1ccc2NC(=O)\C(=C/c3cnc[nH]3)c2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3887","swainsonine","alpha mannosidase inhibitor","MAN2A1",NA,NA,"O[C@@H]1CN2CCC[C@@H](O)[C@@H]2[C@@H]1O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3888","SX-011","MAP kinase inhibitor","MAPK14",NA,NA,"CN(C)C(=O)C(=O)c1cn(C)c2cc(Cl)c(cc12)C(=O)N1CCC(Cc2ccc(F)cc2)CC1, CN(C)C(=O)C(=O)c1cn(C)c2cc(Cl)c(cc12)C(=O)N1CCC(Cc2ccc(F)cc2)CC1, CN(C)C(=O)C(=O)c1cn(C)c2cc(Cl)c(cc12)C(=O)N1CCC(Cc2ccc(F)cc2)CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3889","sx-682","antitumor agent","CXCL11, CXCR1, CXCR2","hematologic malignancy","myeloproliferative neoplasms","OB(O)c1ccc(OC(F)(F)F)cc1CSc1ncc(cn1)C(=O)Nc1ccc(F)cc1","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3890","SYM-2081","kainate receptor antagonist","GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, SLC1A2",NA,NA,"C[C@H](C[C@H](N)C(O)=O)C(O)=O, C[C@H](C[C@H](N)C(O)=O)C(O)=O","Preclinical",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3891","SYM-2206","glutamate receptor antagonist","GRIA1, GRIA2, GRIA3, GRIA4",NA,NA,"CCCNC(=O)N1N=C(c2ccc(N)cc2)c2cc3OCOc3cc2[C@@H]1C |r,t:7|, CCCNC(=O)N1N=C(c2ccc(N)cc2)c2cc3OCOc3cc2[C@@H]1C |r,t:7|, CCCNC(=O)N1N=C(c2ccc(N)cc2)c2cc3OCOc3cc2[C@@H]1C |r,t:7|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3892","synephrine","adrenergic receptor agonist","ADRA1A","otolaryngology","sinusitis","CNC[C@@H](O)c1ccc(O)cc1 |&1:3|, CNC[C@@H](O)c1ccc(O)cc1 |&1:3|, CNC[C@@H](O)c1ccc(O)cc1 |&1:3|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"3893","S1P1-agonist-III","sphingosine kinase inhibitor","S1PR1",NA,NA,"COc1ccncc1C(=O)NC(=O)Nc1ccc(-c2ccccc2)c(c1)C(F)(F)F, COc1ccncc1C(=O)NC(=O)Nc1ccc(-c2ccccc2)c(c1)C(F)(F)F, COc1ccncc1C(=O)NC(=O)Nc1ccc(-c2ccccc2)c(c1)C(F)(F)F, COc1ccncc1C(=O)NC(=O)Nc1ccc(-c2ccccc2)c(c1)C(F)(F)F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3894","S18986","glutamate receptor modulator","GRIA1, GRIA2, GRIA3, GRIA4",NA,NA,"O=S1(=O)N[C@H]2CCCN2c2ccccc12, O=S1(=O)N[C@H]2CCCN2c2ccccc12","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3895","S26948","PPAR receptor agonist","PPARG",NA,NA,"COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC, COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC, COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3896","S4","carbonic anhydrase inhibitor","CA12, CA9",NA,NA,"Cc1cc(C)cc(NC(=O)Nc2ccc(OS(N)(=O)=O)cc2)c1, Cc1cc(C)cc(NC(=O)Nc2ccc(OS(N)(=O)=O)cc2)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3897","s55746","bcl inhibitor","BCL2","hematologic malignancy","chronic lymphocytic leukemia (cll)","Oc1ccc(cc1)N(C(=O)c1cc(-c2cc3OCOc3cc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n2CCCCc12)c1ccccc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3898","T-0070907","PPAR receptor antagonist","PPARG",NA,NA,"[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3899","T-0156","phosphodiesterase inhibitor","PDE5A",NA,NA,"COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1, COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1, COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1, COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1, COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3900","T-0901317","LXR agonist","NCOA1, NCOA2, NR1H2, NR1H3, NR1I2, RXRB",NA,NA,"OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3901","t-1101 (tosylate)","hec1 inhibitor","NDC80, NEK2","oncology","prostate cancer","COCCOc1cnc(Sc2cc(C)c(-c3csc(NC(=O)c4ccncc4)n3)c(C)c2)cn1.Cc1ccc(cc1)S(=O)(=O)O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3902","T-5224","AP inhibitor","JUN",NA,NA,"OC(=O)CCc1cc(ccc1OCc1ccc2c(c1)o[nH]c2=O)C(=O)c1ccc(OC2CCCC2)cc1O, OC(=O)CCc1cc(ccc1OCc1ccc2c(c1)o[nH]c2=O)C(=O)c1ccc(OC2CCCC2)cc1O, OC(=O)CCc1cc(ccc1OCc1ccc2c(c1)o[nH]c2=O)C(=O)c1ccc(OC2CCCC2)cc1O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3903","T-5601640","LIM kinase inhibitor","LIMK2",NA,NA,"Cc1cc(on1)C(=O)Nc1cccc(c1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1cc(on1)C(=O)Nc1cccc(c1)C(=O)Nc1cccc(c1)C(F)(F)F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3904","T-62","adenosine receptor modulator","ADORA2A",NA,NA,"Nc1sc2CCCCc2c1C(=O)c1ccc(Cl)cc1, Nc1sc2CCCCc2c1C(=O)c1ccc(Cl)cc1, Nc1sc2CCCCc2c1C(=O)c1ccc(Cl)cc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3905","TA-01","casein kinase inhibitor, MAP kinase inhibitor","CSNK1D, CSNK1E, MAPK14",NA,NA,"Fc1ccc(cc1)-c1[nH]c(nc1-c1ccncc1)-c1c(F)cccc1F, Fc1ccc(cc1)-c1[nH]c(nc1-c1ccncc1)-c1c(F)cccc1F, Fc1ccc(cc1)-c1[nH]c(nc1-c1ccncc1)-c1c(F)cccc1F, Fc1ccc(cc1)-c1[nH]c(nc1-c1ccncc1)-c1c(F)cccc1F, Fc1ccc(cc1)-c1[nH]c(nc1-c1ccncc1)-c1c(F)cccc1F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3906","tabimorelin","growth hormone secretagogue receptor agonist","GHSR",NA,NA,"CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1ccc2ccccc2c1)N(C)C(=O)\C=C\CC(C)(C)N, CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1ccc2ccccc2c1)N(C)C(=O)\C=C\CC(C)(C)N, CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1ccc2ccccc2c1)N(C)C(=O)\C=C\CC(C)(C)N","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3907","tacalcitol","vitamin D receptor agonist","VDR","dermatology","psoriasis, chapped lips","CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3908","tacedinaline","HDAC inhibitor","HDAC1",NA,NA,"CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3909","tacrine","acetylcholinesterase inhibitor","ACHE, BCHE","neurology/psychiatry","Alzheimer's disease","Nc1c2CCCCc2nc2ccccc12, Nc1c2CCCCc2nc2ccccc12, Nc1c2CCCCc2nc2ccccc12, Nc1c2CCCCc2nc2ccccc12, Nc1c2CCCCc2nc2ccccc12, Nc1c2CCCCc2nc2ccccc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3910","tacrolimus","calcineurin inhibitor","FKBP1A","transplant","organ rejection","CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC |t:45|, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC |t:45|, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC |t:45|, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC |t:45|, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC |t:45|, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC |t:45|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3911","tadalafil","phosphodiesterase inhibitor","PDE11A, PDE5A","urology","erectile dysfunction","CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O, CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O, CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O, CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O, CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O, CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3912","tafamidis-meglumine","transthyretin amyloid inhibitor","TTR","neurology/psychiatry","familial amyloid polyneuropathy (FAP)","OC(=O)c1ccc2nc(oc2c1)-c1cc(Cl)cc(Cl)c1, OC(=O)c1ccc2nc(oc2c1)-c1cc(Cl)cc(Cl)c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3913","tafluprost","prostaglandin inhibitor","PTGFR","ophthalmology","glaucoma, ocular hypertension","CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COc1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3914","tagatose","phosphorylase inhibitor","PYGL",NA,NA,"OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO, OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3915","TAK-063","phosphodiesterase inhibitor","PDE10A",NA,NA,"COc1cn(nc(-c2ccnn2-c2ccccc2)c1=O)-c1ccc(cc1F)-n1cccn1, COc1cn(nc(-c2ccnn2-c2ccccc2)c1=O)-c1ccc(cc1F)-n1cccn1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3916","tak-071","mitotic inhibitor","FOS, SNCA","neurology/psychiatry","parkinson's disease","Cc1c(Cc2ccc(cc2)n3cccn3)cc4C(=O)N(Cc4c1F)[C@H]5COCC[C@@H]5O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3917","TAK-220","CC chemokine receptor antagonist","CCR5",NA,NA,"CC(=O)N1CCC(CC1)C(=O)N(CCCN1CCC(Cc2ccc(cc2)C(N)=O)CC1)c1ccc(C)c(Cl)c1, CC(=O)N1CCC(CC1)C(=O)N(CCCN1CCC(Cc2ccc(cc2)C(N)=O)CC1)c1ccc(C)c(Cl)c1, CC(=O)N1CCC(CC1)C(=O)N(CCCN1CCC(Cc2ccc(cc2)C(N)=O)CC1)c1ccc(C)c(Cl)c1, CC(=O)N1CCC(CC1)C(=O)N(CCCN1CCC(Cc2ccc(cc2)C(N)=O)CC1)c1ccc(C)c(Cl)c1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3918","TAK-285","EGFR inhibitor","ERBB2",NA,NA,"CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12, CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12, CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12, CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3919","TAK-593","VEGFR inhibitor","PDGFRA",NA,NA,"Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1, Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1, Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3920","TAK-632","RAF inhibitor","BRAF",NA,NA,"Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C#N)cc1NC(=O)Cc1cccc(c1)C(F)(F)F, Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C#N)cc1NC(=O)Cc1cccc(c1)C(F)(F)F, Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C#N)cc1NC(=O)Cc1cccc(c1)C(F)(F)F, Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C#N)cc1NC(=O)Cc1cccc(c1)C(F)(F)F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3921","TAK-715","p38 MAPK inhibitor","MAPK14",NA,NA,"CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1, CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1, CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1, CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1, CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3922","TAK-733","MEK inhibitor","MAP2K1",NA,NA,"Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O, Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O, Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O, Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3923","TAK-875","insulin secretagogue","FFAR1",NA,NA,"Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1, Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1, Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1, Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1, Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1, Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3924","TAK-901","Aurora kinase inhibitor","AURKB",NA,NA,"CCS(=O)(=O)c1cccc(c1)-c1cc(C(=O)NC2CCN(C)CC2)c(C)c2[nH]c3ncc(C)cc3c12, CCS(=O)(=O)c1cccc(c1)-c1cc(C(=O)NC2CCN(C)CC2)c(C)c2[nH]c3ncc(C)cc3c12, CCS(=O)(=O)c1cccc(c1)-c1cc(C(=O)NC2CCN(C)CC2)c(C)c2[nH]c3ncc(C)cc3c12","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3925","TAK-960","PLK inhibitor","PLK1",NA,NA,"COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc2N(C)C(=O)C(F)(F)CN(C3CCCC3)c2n1, COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc2N(C)C(=O)C(F)(F)CN(C3CCCC3)c2n1, COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc2N(C)C(=O)C(F)(F)CN(C3CCCC3)c2n1, COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc2N(C)C(=O)C(F)(F)CN(C3CCCC3)c2n1, COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc2N(C)C(=O)C(F)(F)CN(C3CCCC3)c2n1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3926","talabostat","dipeptidyl peptidase inhibitor, fibroblast activation protein inhibitor","DPP4",NA,NA,"CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O, CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O, CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3927","taladegib","smoothened receptor antagonist","DHH, IHH, SMO",NA,NA,"CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F, CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F, CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F, CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F, CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F, CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3928","talampanel","glutamate receptor antagonist","GRIA1, GRIA2, GRIA3, GRIA4",NA,NA,"C[C@@H]1Cc2cc3OCOc3cc2C(=NN1C(C)=O)c1ccc(N)cc1 |c:14|, C[C@@H]1Cc2cc3OCOc3cc2C(=NN1C(C)=O)c1ccc(N)cc1 |c:14|, C[C@@H]1Cc2cc3OCOc3cc2C(=NN1C(C)=O)c1ccc(N)cc1 |c:14|, C[C@@H]1Cc2cc3OCOc3cc2C(=NN1C(C)=O)c1ccc(N)cc1 |c:14|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3929","talarozole","cytochrome P450 inhibitor","CYP26A1",NA,NA,"CCC(CC)[C@@H](c1ccc(Nc2nc3ccccc3s2)cc1)n1cncn1 |&1:5,r|, CCC(CC)[C@@H](c1ccc(Nc2nc3ccccc3s2)cc1)n1cncn1 |&1:5,r|, CCC(CC)[C@@H](c1ccc(Nc2nc3ccccc3s2)cc1)n1cncn1 |&1:5,r|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3930","talazoparib","PARP inhibitor","PARP2","oncology","breast cancer","Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1, Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1, Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1, Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1, Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1, Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1, Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3931","taletrectinib","proto-oncogene tyrosine protein kinase inhibitor","ROS1","oncology","non-small cell lung cancer (nsclc)","C[C@@H](N)COc1ccc(cc1)-c1cnc2ccc(N[C@H](C)c3cccc(F)c3)nn12.OC(=O)CCCCC(=O)O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3932","talinolol","adrenergic receptor antagonist","ADRB1","cardiology","hypertension","CC(C)(C)NC[C@@H](O)COc1ccc(NC(=O)NC2CCCCC2)cc1 |&1:6,r|, CC(C)(C)NC[C@@H](O)COc1ccc(NC(=O)NC2CCCCC2)cc1 |&1:6,r|, CC(C)(C)NC[C@@H](O)COc1ccc(NC(=O)NC2CCCCC2)cc1 |&1:6,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"3933","talipexole","adrenergic receptor agonist, dopamine receptor agonist","ADRA2A, DRD2, HTR3A","infectious disease","genitial herpes","Nc1nc2CCN(CC=C)CCc2s1, Nc1nc2CCN(CC=C)CCc2s1, Nc1nc2CCN(CC=C)CCc2s1, Nc1nc2CCN(CC=C)CCc2s1, Nc1nc2CCN(CC=C)CCc2s1","Launched",0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,1,1
"3934","talmapimod","p38 MAPK inhibitor","IL1B, MAPK11, MAPK14, MT-CO2, TNF",NA,NA,"C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3935","talnetant","tachykinin antagonist","TACR2, TACR3",NA,NA,"CC[C@H](NC(=O)c1c(O)c(nc2ccccc12)-c1ccccc1)c1ccccc1, CC[C@H](NC(=O)c1c(O)c(nc2ccccc12)-c1ccccc1)c1ccccc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3936","talniflumate","cyclooxygenase inhibitor","CLCA1","neurology/psychiatry","pain relief","FC(F)(F)c1cccc(Nc2ncccc2C(=O)O[C@H]2OC(=O)c3ccccc23)c1 |&1:19,r|, FC(F)(F)c1cccc(Nc2ncccc2C(=O)O[C@H]2OC(=O)c3ccccc23)c1 |&1:19,r|, FC(F)(F)c1cccc(Nc2ncccc2C(=O)O[C@H]2OC(=O)c3ccccc23)c1 |&1:19,r|, FC(F)(F)c1cccc(Nc2ncccc2C(=O)O[C@H]2OC(=O)c3ccccc23)c1 |&1:19,r|, FC(F)(F)c1cccc(Nc2ncccc2C(=O)O[C@H]2OC(=O)c3ccccc23)c1 |&1:19,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3937","talopram","adrenergic inhibitor","SLC6A2",NA,NA,"CNCCC[C@]1(OC(C)(C)c2ccccc12)c1ccccc1 |&1:5|, CNCCC[C@]1(OC(C)(C)c2ccccc12)c1ccccc1 |&1:5|, CNCCC[C@]1(OC(C)(C)c2ccccc12)c1ccccc1 |&1:5|","Phase 2",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3938","taltirelin","thyrotropin releasing hormone receptor agonist","TRHR","neurology/psychiatry","spinocerebellar ataxia","CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(N)=O, CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(N)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3939","tamibarotene","retinoid receptor agonist","RARA, RARB","hematologic malignancy","acute promyelocytic leukemia (APL)","CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12, CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12, CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12, CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12, CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3940","tamoxifen","estrogen receptor antagonist, selective estrogen receptor modulator (SERM)","EBP, ESR1, ESR2, GPER1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCI, PRKCQ, PRKCZ","oncology","breast cancer","CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1, CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1, CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1, CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1, CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1, CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1, CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3941","tamsulosin","adrenergic receptor antagonist","ADRA1A, ADRA1B, ADRA1D","urology","benign prostatic hyperplasia (BPH)","CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(c1)S(N)(=O)=O, CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(c1)S(N)(=O)=O, CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(c1)S(N)(=O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,1,1,1,1
"3942","tanaproget","progesterone receptor agonist","PGR",NA,NA,"Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N, Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N, Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N, Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N, Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N, Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3943","tandospirone","serotonin receptor agonist","HTR1A","neurology/psychiatry","generalized anxiety disorder (GAD), dysthymic disorder","O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCN1CCN(CC1)c1ncccn1, O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCN1CCN(CC1)c1ncccn1, O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCN1CCN(CC1)c1ncccn1, O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCN1CCN(CC1)c1ncccn1","Launched",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3944","tandutinib","FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","CSF1R, FLT3, KIT, PDGFD, PDGFRB",NA,NA,"COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1, COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1, COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1, COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1, COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1, COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3945","tanespimycin","HSP inhibitor","HSP90AA1",NA,NA,"CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3946","tannic-acid","PARG inhibitor","ANO1","gastroenterology","constipation","Oc1cc(cc(O)c1O)C(=O)Oc1cc(cc(O)c1O)C(=O)OC[C@H]1O[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H]1OC(=O)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3947","tanshinone-I","AP inhibitor","IFNG",NA,NA,"Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12, Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12, Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12, Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3948","tanshinone-IIA","anti-inflammatory agent, interleukin inhibitor","IL1B, NR1I2, TNF",NA,NA,"Cc1coc-2c1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc-21, Cc1coc-2c1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc-21, Cc1coc-2c1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc-21, Cc1coc-2c1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc-21","Phase 2/Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3949","taprenepag","prostaglandin receptor agonist","PTGER2",NA,NA,"OC(=O)COc1cccc(CN(Cc2ccc(cc2)-n2cccn2)S(=O)(=O)c2cccnc2)c1, OC(=O)COc1cccc(CN(Cc2ccc(cc2)-n2cccn2)S(=O)(=O)c2cccnc2)c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3950","tarafenacin","acetylcholine receptor antagonist","CHRM3",NA,NA,"Fc1cccc(c1)N(Cc1cc(F)c(F)c(F)c1)C(=O)O[C@H]1C[N@@]2CC[C@H]1CC2","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
"3951","taranabant","cannabinoid receptor inverse agonist","CNR1",NA,NA,"C[C@H](NC(=O)C(C)(C)Oc1ccc(cn1)C(F)(F)F)[C@@H](Cc1ccc(Cl)cc1)c1cccc(c1)C#N, C[C@H](NC(=O)C(C)(C)Oc1ccc(cn1)C(F)(F)F)[C@@H](Cc1ccc(Cl)cc1)c1cccc(c1)C#N, C[C@H](NC(=O)C(C)(C)Oc1ccc(cn1)C(F)(F)F)[C@@H](Cc1ccc(Cl)cc1)c1cccc(c1)C#N, C[C@H](NC(=O)C(C)(C)Oc1ccc(cn1)C(F)(F)F)[C@@H](Cc1ccc(Cl)cc1)c1cccc(c1)C#N, C[C@H](NC(=O)C(C)(C)Oc1ccc(cn1)C(F)(F)F)[C@@H](Cc1ccc(Cl)cc1)c1cccc(c1)C#N","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3952","targinine","nitric oxide synthase inhibitor","NOS3",NA,NA,"CNC(=N)NCCC[C@H](N)C(O)=O, CNC(=N)NCCC[C@H](N)C(O)=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3953","tariquidar","P glycoprotein inhibitor","ABCB1",NA,NA,"COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3954","TAS-103","topoisomerase inhibitor","TOP1",NA,NA,"CN(C)CCNc1nc2cc(O)ccc2c2-c3ccccc3C(=O)c12, CN(C)CCNc1nc2cc(O)ccc2c2-c3ccccc3C(=O)c12, CN(C)CCNc1nc2cc(O)ccc2c2-c3ccccc3C(=O)c12","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3955","tas-115 mesylate","protein tyrosine kinase inhibitor","HGF, PDGFRA, TNK1","oncology","osteosarcoma","CNC(=O)c1cc2c(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)ccnc2cc1OC.CS(=O)(=O)O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3956","taselisib","PI3K inhibitor","PIK3CA",NA,NA,"CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3957","tasimelteon","melatonin receptor agonist","MTNR1A, MTNR1B","neurology/psychiatry","Non-24-Hour Sleep-Wake Disorder","CCC(=O)NC[C@@H]1C[C@H]1c1cccc2OCCc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3958","tasquinimod","angiogenesis inhibitor, S100A9 inhibitor","HDAC4",NA,NA,"COc1cccc2n(C)c(=O)c(C(=O)N(C)c3ccc(cc3)C(F)(F)F)c(O)c12, COc1cccc2n(C)c(=O)c(C(=O)N(C)c3ccc(cc3)C(F)(F)F)c(O)c12, COc1cccc2n(C)c(=O)c(C(=O)N(C)c3ccc(cc3)C(F)(F)F)c(O)c12, COc1cccc2n(C)c(=O)c(C(=O)N(C)c3ccc(cc3)C(F)(F)F)c(O)c12","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3959","tas4464","nedd activating enzyme inhibitor","NAE1","hematologic malignancy","multiple myeloma","NC1=NC=NC2=C1C(C#CC3=C(F)C=CC=C3OCC)=CN2[C@@H]4O[C@H](CNS(=O)(N)=O)[C@@H](O)[C@H]4O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3960","taurocholate","G protein-coupled receptor agonist","CEL, FABP6, SLCO1C1",NA,NA,"C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C, C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C","Phase 1",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3961","tavapadon","dopamine agonist","DRD1, DRD5","neurology/psychiatry","parkinson's disease","CN1C(=O)NC(=O)C(=C1c2ccc(Oc3ncccc3C(F)(F)F)cc2C)C","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,1,1,1,1
"3962","taxifolin","opioid receptor antagonist","ADIPOR2",NA,NA,"O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3963","tazarotene","retinoid receptor agonist","RARA, RARB, RARG, RXRB","dermatology","cosmetic, sunscreen lotion","CCOC(=O)c1ccc(nc1)C#Cc1ccc2SCCC(C)(C)c2c1, CCOC(=O)c1ccc(nc1)C#Cc1ccc2SCCC(C)(C)c2c1, CCOC(=O)c1ccc(nc1)C#Cc1ccc2SCCC(C)(C)c2c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"3964","tazemetostat","histone lysine methyltransferase inhibitor","EZH2",NA,NA,"CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1, CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1, CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1, CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1, CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3965","TBOA-(DL)","excitatory amino acid transporter inhibitor","SLC1A1, SLC1A2, SLC1A3, SLC1A6, SLC1A7",NA,NA,"N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O, N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O, N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O, N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O, N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O","Preclinical",1,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3966","TC-A-2317","Aurora kinase inhibitor","AURKA",NA,NA,"C[C@@H](CCCC(C)(C)O)Nc1nc(Nc2cc(C)n[nH]2)cc(C)c1C#N |&1:1|, C[C@@H](CCCC(C)(C)O)Nc1nc(Nc2cc(C)n[nH]2)cc(C)c1C#N |&1:1|, C[C@@H](CCCC(C)(C)O)Nc1nc(Nc2cc(C)n[nH]2)cc(C)c1C#N |&1:1|, C[C@@H](CCCC(C)(C)O)Nc1nc(Nc2cc(C)n[nH]2)cc(C)c1C#N |&1:1|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3967","TC-ASK-10","MAP kinase inhibitor","MAP3K5, MAP3K6",NA,NA,"CC(C)(C)c1ccc(cc1)C(=O)Nc1cn2cc(ccc2n1)-n1ccnc1, CC(C)(C)c1ccc(cc1)C(=O)Nc1cn2cc(ccc2n1)-n1ccnc1, CC(C)(C)c1ccc(cc1)C(=O)Nc1cn2cc(ccc2n1)-n1ccnc1, CC(C)(C)c1ccc(cc1)C(=O)Nc1cn2cc(ccc2n1)-n1ccnc1, CC(C)(C)c1ccc(cc1)C(=O)Nc1cn2cc(ccc2n1)-n1ccnc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3968","TC-E-5002","histone demethylase inhibitor","KDM2A, KDM4A, KDM4C, KDM5A, KDM6A, KDM7A, PHF8",NA,NA,"ON(CCC(O)=O)C(=O)CCCCCCCCC1CC1, ON(CCC(O)=O)C(=O)CCCCCCCCC1CC1, ON(CCC(O)=O)C(=O)CCCCCCCCC1CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3969","TC-E-5006","gamma secretase modulator","APP",NA,NA,"C[C@@H](C(O)=O)c1ccc([C@@H](N2CCC(C)CC2)c2ccc(F)cc2)c(c1)-c1ccc(cc1)C(F)(F)F |&1:1,&2:9,r|, C[C@@H](C(O)=O)c1ccc([C@@H](N2CCC(C)CC2)c2ccc(F)cc2)c(c1)-c1ccc(cc1)C(F)(F)F |&1:1,&2:9,r|, C[C@@H](C(O)=O)c1ccc([C@@H](N2CCC(C)CC2)c2ccc(F)cc2)c(c1)-c1ccc(cc1)C(F)(F)F |&1:1,&2:9,r|, C[C@@H](C(O)=O)c1ccc([C@@H](N2CCC(C)CC2)c2ccc(F)cc2)c(c1)-c1ccc(cc1)C(F)(F)F |&1:1,&2:9,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3970","TC-F-2","FAAH inhibitor","FAAH",NA,NA,"CCn1c2ccccc2n([C@H]2CCCN(C2)c2nccc(n2)-c2cc3ccccc3o2)c1=O, CCn1c2ccccc2n([C@H]2CCCN(C2)c2nccc(n2)-c2cc3ccccc3o2)c1=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3971","TC-FPR-43","formyl peptide receptor agonist","FPR2",NA,NA,"CC(C)c1c(NC(=O)Nc2ccc(Cl)cc2)c(=O)n(-c2ccccc2)n1C, CC(C)c1c(NC(=O)Nc2ccc(Cl)cc2)c(=O)n(-c2ccccc2)n1C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3972","TC-G-1000","adrenergic receptor agonist","ADRA2A, ADRA2B, ADRA2C",NA,NA,"Cc1sc(C)c2c1CCC=C2c1cnc[nH]1 |c:10|, Cc1sc(C)c2c1CCC=C2c1cnc[nH]1 |c:10|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0
"3973","TC-G-1004","adenosine receptor antagonist","ADORA2A",NA,NA,"COC1CCN(CC1)c1cccc(n1)-c1cc(NC(C)=O)nc(n1)-n1nc(C)cc1C, COC1CCN(CC1)c1cccc(n1)-c1cc(NC(C)=O)nc(n1)-n1nc(C)cc1C, COC1CCN(CC1)c1cccc(n1)-c1cc(NC(C)=O)nc(n1)-n1nc(C)cc1C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3974","TC-G-1005","G protein-coupled receptor agonist","GPBAR1",NA,NA,"Cc1ccc(C)c(Oc2ccncc2C(=O)N2CCN(C3CC3)c3ccccc23)c1, Cc1ccc(C)c(Oc2ccncc2C(=O)N2CCN(C3CC3)c3ccccc23)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3975","TC-G-1008","G protein-coupled receptor agonist","GPR39",NA,NA,"CNc1nc(NCc2ccc(NS(C)(=O)=O)cc2Cl)cc(n1)-c1ccccn1, CNc1nc(NCc2ccc(NS(C)(=O)=O)cc2Cl)cc(n1)-c1ccccn1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3976","TC-H-106","HDAC inhibitor","HDAC1, HDAC2, HDAC3, HDAC8",NA,NA,"Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1, Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1, Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1, Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1, Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1, Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3977","TC-I-15","integrin inhibitor","ITGA2, ITGB1",NA,NA,"CC1(C)SCN([C@@H]1C(=O)N[C@@H](CNC(=O)NCc1ccccc1)C(O)=O)S(=O)(=O)c1ccccc1, CC1(C)SCN([C@@H]1C(=O)N[C@@H](CNC(=O)NCc1ccccc1)C(O)=O)S(=O)(=O)c1ccccc1, CC1(C)SCN([C@@H]1C(=O)N[C@@H](CNC(=O)NCc1ccccc1)C(O)=O)S(=O)(=O)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3978","TC-I-2000","transient receptor potential channel antagonist","TRPM8",NA,NA,"Fc1ccc(NC(=O)N2CCc3ccccc3[C@@H]2c2ccc(cc2)C(F)(F)F)cc1 |&1:17,r|, Fc1ccc(NC(=O)N2CCc3ccccc3[C@@H]2c2ccc(cc2)C(F)(F)F)cc1 |&1:17,r|, Fc1ccc(NC(=O)N2CCc3ccccc3[C@@H]2c2ccc(cc2)C(F)(F)F)cc1 |&1:17,r|, Fc1ccc(NC(=O)N2CCc3ccccc3[C@@H]2c2ccc(cc2)C(F)(F)F)cc1 |&1:17,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3979","TC-I-2014","transient receptor potential channel antagonist","TRPM8",NA,NA,"FC(F)(F)c1ccccc1-c1cc(c2[nH]c(nc2c1)C1=NOC2(C1)CCCCC2)C(F)(F)F |t:22|, FC(F)(F)c1ccccc1-c1cc(c2[nH]c(nc2c1)C1=NOC2(C1)CCCCC2)C(F)(F)F |t:22|, FC(F)(F)c1ccccc1-c1cc(c2[nH]c(nc2c1)C1=NOC2(C1)CCCCC2)C(F)(F)F |t:22|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3980","TC-LPA5-4","lysophosphatidic acid receptor antagonist","LPAR5",NA,NA,"COc1cccc(c1)-n1nc(cc1-c1ccc(C2CCCCC2)c(Cl)c1)C(O)=O, COc1cccc(c1)-n1nc(cc1-c1ccc(C2CCCCC2)c(Cl)c1)C(O)=O, COc1cccc(c1)-n1nc(cc1-c1ccc(C2CCCCC2)c(Cl)c1)C(O)=O, COc1cccc(c1)-n1nc(cc1-c1ccc(C2CCCCC2)c(Cl)c1)C(O)=O, COc1cccc(c1)-n1nc(cc1-c1ccc(C2CCCCC2)c(Cl)c1)C(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3981","TC-Mps1-12","monopolar spindle 1 kinase inhibitor","TTK",NA,NA,"CC(C)(C)Nc1nc(Nc2ccc(cc2)C(N)=O)cc(N)c1C#N, CC(C)(C)Nc1nc(Nc2ccc(cc2)C(N)=O)cc(N)c1C#N","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3982","TC-N-1752","sodium channel blocker","SCN9A",NA,NA,"CC(=O)Nc1cccc(Nc2ncnc(n2)N2CCC(CC2)OCc2ccc(OC(F)(F)F)cc2)c1C, CC(=O)Nc1cccc(Nc2ncnc(n2)N2CCC(CC2)OCc2ccc(OC(F)(F)F)cc2)c1C, CC(=O)Nc1cccc(Nc2ncnc(n2)N2CCC(CC2)OCc2ccc(OC(F)(F)F)cc2)c1C","Preclinical",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3983","TC-NTR1-17","neurotensin agonist","NTSR1",NA,NA,"COc1cccc(OC)c1-c1cc(nn1-c1ccnc2cc(Cl)ccc12)C(=O)N[C@@H](CC(C)C)C(O)=O, COc1cccc(OC)c1-c1cc(nn1-c1ccnc2cc(Cl)ccc12)C(=O)N[C@@H](CC(C)C)C(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3984","TC-O-9311","G protein-coupled receptor agonist","GPR139",NA,NA,"COc1cc(OC)cc(c1)C(=O)NNC(=O)Nc1cccc2ccccc12, COc1cc(OC)cc(c1)C(=O)NNC(=O)Nc1cccc2ccccc12, COc1cc(OC)cc(c1)C(=O)NNC(=O)Nc1cccc2ccccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3985","TC-OT-39","oxytocin receptor agonist, vasopressin receptor agonist","AVPR1A, OXT",NA,NA,"CN1CCCN(CC1)C(=S)[C@@H]1CCCN1C(=O)NCc1ccc(cc1C)C(=O)N1Cc2cnn(C)c2Nc2ccccc12, CN1CCCN(CC1)C(=S)[C@@H]1CCCN1C(=O)NCc1ccc(cc1C)C(=O)N1Cc2cnn(C)c2Nc2ccccc12, CN1CCCN(CC1)C(=S)[C@@H]1CCCN1C(=O)NCc1ccc(cc1C)C(=O)N1Cc2cnn(C)c2Nc2ccccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3986","TC-S-7003","SRC inhibitor","LCK",NA,NA,"CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n2c(nc4ccccc24)n(-c2c(C)cccc2C)c3=O)cc1, CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n2c(nc4ccccc24)n(-c2c(C)cccc2C)c3=O)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3987","TC-S-7004","DYRK inhibitor","DYRK1A, DYRK1B",NA,NA,"COc1ncc2cc(C(=O)Nc3cc(ccc3Cl)C(=O)NCc3cccc(Cl)c3)c(=O)[nH]c2n1, COc1ncc2cc(C(=O)Nc3cc(ccc3Cl)C(=O)NCc3cccc(Cl)c3)c(=O)[nH]c2n1, COc1ncc2cc(C(=O)Nc3cc(ccc3Cl)C(=O)NCc3cccc(Cl)c3)c(=O)[nH]c2n1, COc1ncc2cc(C(=O)Nc3cc(ccc3Cl)C(=O)NCc3cccc(Cl)c3)c(=O)[nH]c2n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3988","TC-S-7005","PLK inhibitor","PLK2",NA,NA,"C[C@H](Nc1cc2c(noc2cn1)-c1ccc2OCOc2c1)c1ccccc1, C[C@H](Nc1cc2c(noc2cn1)-c1ccc2OCOc2c1)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3989","TC-S-7006","MAP kinase inhibitor","MAP3K8",NA,NA,"Fc1ccc(Nc2c(cnc3cnc(NCc4cccnc4)cc23)C#N)cc1Cl, Fc1ccc(Nc2c(cnc3cnc(NCc4cccnc4)cc23)C#N)cc1Cl","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3990","TC-S-7009","hypoxia inducible factor inhibitor","EPAS1",NA,NA,"[O-][N+](=O)c1c(Nc2cc(F)cc(Cl)c2)ccc2nonc12, [O-][N+](=O)c1c(Nc2cc(F)cc(Cl)c2)ccc2nonc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3991","TC-SP-14","sphingosine 1-phosphate receptor agonist","S1PR1",NA,NA,"OC(=O)C1CN(Cc2ccc(-c3nc4cc(Cc5ccccc5F)ccc4s3)c(F)c2)C1, OC(=O)C1CN(Cc2ccc(-c3nc4cc(Cc5ccccc5F)ccc4s3)c(F)c2)C1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3992","TCN201","glutamate receptor antagonist","GRIN2A",NA,NA,"Fc1ccc(cc1Cl)S(=O)(=O)NCc1ccc(cc1)C(=O)NNC(=O)c1ccccc1, Fc1ccc(cc1Cl)S(=O)(=O)NCc1ccc(cc1)C(=O)NNC(=O)c1ccccc1, Fc1ccc(cc1Cl)S(=O)(=O)NCc1ccc(cc1)C(=O)NNC(=O)c1ccccc1, Fc1ccc(cc1Cl)S(=O)(=O)NCc1ccc(cc1)C(=O)NNC(=O)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3993","TCN238","glutamate receptor positive allosteric modulator","GRM4",NA,NA,"Nc1nccc(\C=C\c2ccccc2)n1, Nc1nccc(\C=C\c2ccccc2)n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3994","TCS-HDAC6-20b","HDAC inhibitor","HDAC6",NA,NA,"CC(C)C(=O)SCCCCC[C@H](NC(=O)OC(C)(C)C)C(=O)NC12CC3CC(CC(C3)C1)C2, CC(C)C(=O)SCCCCC[C@H](NC(=O)OC(C)(C)C)C(=O)NC12CC3CC(CC(C3)C1)C2, CC(C)C(=O)SCCCCC[C@H](NC(=O)OC(C)(C)C)C(=O)NC12CC3CC(CC(C3)C1)C2","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3995","TCS-OX2-29","orexin receptor antagonist","HCRTR2",NA,NA,"COc1cc2CCN(Cc2cc1OC)C(=O)[C@@H](NCc1ccncc1)C(C)(C)C, COc1cc2CCN(Cc2cc1OC)C(=O)[C@@H](NCc1ccncc1)C(C)(C)C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3996","TCS-PIM-1-1","Pim kinase inhibitor","PIM1",NA,NA,"Oc1ccc(Br)cc1-c1cc(-c2ccccc2)c(C#N)c(=O)[nH]1, Oc1ccc(Br)cc1-c1cc(-c2ccccc2)c(C#N)c(=O)[nH]1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3997","TCS-2002","glycogen synthase kinase inhibitor","GSK3B",NA,NA,"Cc1nnc(o1)-c1ccc2occ(-c3ccc(cc3)[S@](C)=O)c2c1 |&1:19,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3998","TCS-21311","JAK inhibitor","JAK3",NA,NA,"CC(C)(O)C(=O)N1CCN(CC1)c1ccc(c(c1)C1=C(C(=O)NC1=O)c1c[nH]c2ccccc12)C(F)(F)F |t:20|, CC(C)(O)C(=O)N1CCN(CC1)c1ccc(c(c1)C1=C(C(=O)NC1=O)c1c[nH]c2ccccc12)C(F)(F)F |t:20|, CC(C)(O)C(=O)N1CCN(CC1)c1ccc(c(c1)C1=C(C(=O)NC1=O)c1c[nH]c2ccccc12)C(F)(F)F |t:20|, CC(C)(O)C(=O)N1CCN(CC1)c1ccc(c(c1)C1=C(C(=O)NC1=O)c1c[nH]c2ccccc12)C(F)(F)F |t:20|, CC(C)(O)C(=O)N1CCN(CC1)c1ccc(c(c1)C1=C(C(=O)NC1=O)c1c[nH]c2ccccc12)C(F)(F)F |t:20|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"3999","TCS-2314","integrin inhibitor","ITGA4, ITGB1",NA,NA,"Cc1ccccc1NC(=O)Nc1ccc(CC(=O)N2CCOC[C@H]2C(=O)N2CCC(CC(O)=O)CC2)cc1, Cc1ccccc1NC(=O)Nc1ccc(CC(=O)N2CCOC[C@H]2C(=O)N2CCC(CC(O)=O)CC2)cc1, Cc1ccccc1NC(=O)Nc1ccc(CC(=O)N2CCOC[C@H]2C(=O)N2CCC(CC(O)=O)CC2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4000","TCS-3035","G protein-coupled receptor agonist","GPR35",NA,NA,"OC(=O)COc1ccc(\C=C2/SC(=O)NC2=O)cc1, OC(=O)COc1ccc(\C=C2/SC(=O)NC2=O)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4001","TCS-359","FLT3 inhibitor","FLT3",NA,NA,"COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4002","TCS-5861528","transient receptor potential channel antagonist","TRPA1",NA,NA,"CC[C@@H](C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1 |&1:2,r|, CC[C@@H](C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1 |&1:2,r|, CC[C@@H](C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1 |&1:2,r|, CC[C@@H](C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1 |&1:2,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4003","TC1","beta-secretase inhibitor","BACE1",NA,NA,"O[C@@]12[C@H]3[C@H]4[C@H]5[C@@H]3[C@@H]([C@H]3[C@@H]5C[C@@H]4[C@@H]13)N2CCc1cccc(F)c1 |&1:1,&2:2,&3:3,&4:4,&5:5,&6:6,&7:7,&8:8,&9:10,&10:11,r,TLB:13:12:2.5:7.11|, O[C@@]12[C@H]3[C@H]4[C@H]5[C@@H]3[C@@H]([C@H]3[C@@H]5C[C@@H]4[C@@H]13)N2CCc1cccc(F)c1 |&1:1,&2:2,&3:3,&4:4,&5:5,&6:6,&7:7,&8:8,&9:10,&10:11,r,TLB:13:12:2.5:7.11|, O[C@@]12[C@H]3[C@H]4[C@H]5[C@@H]3[C@@H]([C@H]3[C@@H]5C[C@@H]4[C@@H]13)N2CCc1cccc(F)c1 |&1:1,&2:2,&3:3,&4:4,&5:5,&6:6,&7:7,&8:8,&9:10,&10:11,r,TLB:13:12:2.5:7.11|, O[C@@]12[C@H]3[C@H]4[C@H]5[C@@H]3[C@@H]([C@H]3[C@@H]5C[C@@H]4[C@@H]13)N2CCc1cccc(F)c1 |&1:1,&2:2,&3:3,&4:4,&5:5,&6:6,&7:7,&8:8,&9:10,&10:11,r,TLB:13:12:2.5:7.11|, O[C@@]12[C@H]3[C@H]4[C@H]5[C@@H]3[C@@H]([C@H]3[C@@H]5C[C@@H]4[C@@H]13)N2CCc1cccc(F)c1 |&1:1,&2:2,&3:3,&4:4,&5:5,&6:6,&7:7,&8:8,&9:10,&10:11,r,TLB:13:12:2.5:7.11|, O[C@@]12[C@H]3[C@H]4[C@H]5[C@@H]3[C@@H]([C@H]3[C@@H]5C[C@@H]4[C@@H]13)N2CCc1cccc(F)c1 |&1:1,&2:2,&3:3,&4:4,&5:5,&6:6,&7:7,&8:8,&9:10,&10:11,r,TLB:13:12:2.5:7.11|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4004","TC2559","acetylcholine receptor agonist","CHRNA4",NA,NA,"CCOc1cncc(\C=C\CCNC)c1, CCOc1cncc(\C=C\CCNC)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
"4005","tebanicline (dihydrochloride)","acetylcholine receptor agonist","CHRNA4, CHRNB2","neurology/psychiatry","chronic pain","[H]Cl.ClC(C=C1)=NC=C1OC[C@@H]2NCC2.[H]Cl","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,1,1,1,1
"4006","tebipenem","bacterial cell wall synthesis inhibitor","CNR1","infectious disease, otolaryngology","pneumonia, otitis","C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C3=NCCS3)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C |c:19,t:14|, O=C(C(N1C2=O)=C(SC3CN(C4=NCCS4)C3)[C@H](C)[C@]1([H])[C@@]2([H])[C@H](O)C)O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4007","tecadenoson","adenosine receptor agonist","ADORA1",NA,NA,"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@@H]3CCOC3)ncnc12","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4008","tecalcet","calcium-sensing receptor agonist","CASR",NA,NA,"COc1cccc(c1)[C@@H](C)NCCCc1ccccc1Cl, COc1cccc(c1)[C@@H](C)NCCCc1ccccc1Cl, COc1cccc(c1)[C@@H](C)NCCCc1ccccc1Cl","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4009","tecarfarin","vitamin k antagonist","VKORC1","hematology","thrombosis","CC(OC(=O)c1ccc(CC2=C(O)c3ccccc3OC2=O)cc1)(C(F)(F)F)C(F)(F)F","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4010","tecastemizole","histamine receptor antagonist","KCNH2",NA,NA,"Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc23)cc1, Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc23)cc1, Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc23)cc1, Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc23)cc1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4011","tefinostat","hdac inhibitor","HDAC1","oncology","hepatocellular carcinoma (hcc)","ONC(=O)CCCCCCC(=O)Nc1ccc(CN[C@H](C(=O)OC2CCCC2)c2ccccc2)cc1","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4012","tegaserod","serotonin receptor partial agonist","HTR2A, HTR2B, HTR2C, HTR4",NA,NA,"CCCCCNC(=N)N\N=C\c1c[nH]c2ccc(OC)cc12, CCCCCNC(=N)N\N=C\c1c[nH]c2ccc(OC)cc12, CCCCCNC(=N)N\N=C\c1c[nH]c2ccc(OC)cc12, CCCCCNC(=N)N\N=C\c1c[nH]c2ccc(OC)cc12, CCCCCNC(=N)N\N=C\c1c[nH]c2ccc(OC)cc12","Withdrawn",0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4013","teglicar","carnitine palmitoyltransferase inhibitor","CPT1A","endocrinology","diabetes mellitus","CCCCCCCCCCCCCCNC(=O)N[C@H](CC(O)=O)C[N+](C)(C)C |a:18|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4014","teijin-compound-1","CC chemokine receptor antagonist","CCR2",NA,NA,"FC(F)(F)c1cccc(c1)C(=O)NCC(=O)N[C@@H]1CCN(Cc2ccc(Cl)cc2)C1, FC(F)(F)c1cccc(c1)C(=O)NCC(=O)N[C@@H]1CCN(Cc2ccc(Cl)cc2)C1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4015","telaprevir","HCV inhibitor","CTSA, PGR","infectious disease","hepatitis C","CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1, CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1, CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1, CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1, CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1, CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1, CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4016","telatinib","KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","KDR",NA,NA,"CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1, CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1, CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4017","telcagepant","calcitonin antagonist","CALCRL, RAMP1",NA,NA,"Fc1cccc([C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)n3c4cccnc4[nH]c3=O)C(=O)N(CC(F)(F)F)C2)c1F, Fc1cccc([C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)n3c4cccnc4[nH]c3=O)C(=O)N(CC(F)(F)F)C2)c1F, Fc1cccc([C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)n3c4cccnc4[nH]c3=O)C(=O)N(CC(F)(F)F)C2)c1F, Fc1cccc([C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)n3c4cccnc4[nH]c3=O)C(=O)N(CC(F)(F)F)C2)c1F","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4018","telenzepine","acetylcholine receptor antagonist","CHRM1",NA,NA,"CN1CCN(CC(=O)N2c3c(C)scc3C(=O)Nc3ccccc23)CC1, CN1CCN(CC(=O)N2c3c(C)scc3C(=O)Nc3ccccc23)CC1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
"4019","telithromycin","bacterial 30S ribosomal subunit inhibitor, bacterial 50S ribosomal subunit inhibitor, bacterial 30s ribosomal subunit inhibitor, bacterial 50s ribosomal subunit inhibitor","CYP1A2, CYP2D6, CYP3A4, CYP3A5, CYP3A7","infectious disease","pneumonia","CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(c3)-c3cccnc3)C(=O)O[C@]12C)OC, CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(c3)-c3cccnc3)C(=O)O[C@]12C)OC, CCC1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](OC2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@@H](C)[C@@H]2N(CCCCn3cnc(c3)-c3cccnc3)C(=O)O[C@]12C)OC","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4020","telmisartan","angiotensin receptor antagonist","AGTR1, PPARG","cardiology","hypertension","CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C, CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C, CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C, CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C, CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C, CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C, CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C, CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C, CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4021","telotristat","tryptophan hydroxylase inhibitor","TPH1","gastroenterology","diarrhea","Cc1ccn(n1)-c1cc(Cl)ccc1[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F, Cc1ccn(n1)-c1cc(Cl)ccc1[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4022","telotristat-ethyl","tryptophan hydroxylase inhibitor","TPH1","gastroenterology","diarrhea","CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1, CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1, CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1, CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1, CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4023","temocapril","angiotensin converting enzyme inhibitor","ACE","cardiology, nephrology","hypertension, congestive heart failure, diabetic nephropathy, coronary artery disease (CAD)","CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)c1cccs1, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)c1cccs1, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)c1cccs1, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)c1cccs1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4024","temozolomide","DNA alkylating agent","MGMT","oncology","glioblastoma, astrocytoma","Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4025","temsirolimus","mTOR inhibitor","MTOR","oncology","renal cell carcinoma (RCC)","CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO |c:14,33,t:29,31|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4026","tenatoprazole","ATPase inhibitor","IDO1",NA,NA,"COc1ccc2[nH]c(nc2n1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|, COc1ccc2[nH]c(nc2n1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4027","teneligliptin","dipeptidyl peptidase inhibitor","DPP4","endocrinology","diabetes mellitus","Cc1cc(N2CCN(CC2)[C@@H]2CN[C@@H](C2)C(=O)N2CCSC2)n(n1)-c1ccccc1, Cc1cc(N2CCN(CC2)[C@@H]2CN[C@@H](C2)C(=O)N2CCSC2)n(n1)-c1ccccc1, Cc1cc(N2CCN(CC2)[C@@H]2CN[C@@H](C2)C(=O)N2CCSC2)n(n1)-c1ccccc1, Cc1cc(N2CCN(CC2)[C@@H]2CN[C@@H](C2)C(=O)N2CCSC2)n(n1)-c1ccccc1, Cc1cc(N2CCN(CC2)[C@@H]2CN[C@@H](C2)C(=O)N2CCSC2)n(n1)-c1ccccc1, Cc1cc(N2CCN(CC2)[C@@H]2CN[C@@H](C2)C(=O)N2CCSC2)n(n1)-c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4028","tenidap","cyclooxygenase inhibitor","KCNJ4, PTGS1",NA,NA,"NC(=O)N1C(=O)[C@@H](C(=O)c2cccs2)c2cc(Cl)ccc12 |&1:6,r|, NC(=O)N1C(=O)C(C(=O)c2cccs2)c2cc(Cl)ccc12","Phase 3",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4029","teniposide","topoisomerase inhibitor","TOP2A, TOP2B","hematologic malignancy","acute lymphoblastic leukemia (ALL)","COc1cc(cc(OC)c1O)[C@H]1[C@@H]2C(COC2=O)C(O[C@@H]2O[C@@H]3CO[C@H](OC3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4030","tenofovir alafenamide","hiv gag inhibitor","GAG-POL","Infectious disease","human immunodeficiency virus (hiv-1)","CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)Oc1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4031","tenofovir-disoproxil","nucleoside reverse transcriptase inhibitor","CYP1A2","infectious disease","human immunodeficiency virus (HIV-1), hepatitis B","CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)OCOC(=O)OC(C)C, CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)OCOC(=O)OC(C)C, CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)OCOC(=O)OC(C)C, CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)OCOC(=O)OC(C)C, CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)OCOC(=O)OC(C)C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4032","tenovin-1","SIRT inhibitor, TP53 activator","SIRT1",NA,NA,"CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4033","tenovin-6","SIRT inhibitor","SIRT1, SIRT2, SIRT3",NA,NA,"CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4034","tenoxicam","cyclooxygenase inhibitor","PTGS1, PTGS2","rheumatology, orthopedics","rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendinitis, bursitis, periarthritis","CN1C(C(=O)Nc2ccccn2)=C(O)c2sccc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2ccccn2)=C(O)c2sccc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2ccccn2)=C(O)c2sccc2S1(=O)=O |t:12|","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4035","tepilamide fumarate","nuclear factor erythroid derived, like (nrf2) activator","GSTP1, HCAR2, NFE2L2","neurology/psychiatry","multiple sclerosis","CCN(CC)C(=O)COC(=O)\C=C\C(=O)OC","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4036","tepoxalin","cyclooxygenase inhibitor, lipoxygenase inhibitor","ALOX5","rheumatology, orthopedics","rheumatoid arthritis, hip dysplasia","COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1, COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1, COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1, COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1, COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4037","TEPP-46","pyruvate kinase isozyme activator","PKM",NA,NA,"Cn1c2cc(sc2c2cnn(Cc3cccc(N)c3)c(=O)c12)[S@@](C)=O |r|, Cn1c2cc(sc2c2cnn(Cc3cccc(N)c3)c(=O)c12)[S@@](C)=O |r|, Cn1c2cc(sc2c2cnn(Cc3cccc(N)c3)c(=O)c12)[S@@](C)=O |r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4038","terameprocol","lipoxygenase inhibitor","BIRC5, CDK1",NA,NA,"COc1ccc(C[C@H](C)[C@H](C)Cc2ccc(OC)c(OC)c2)cc1OC","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4039","terazosin","adrenergic receptor antagonist","ADRA1A, ADRA1B, ADRA1D","urology, cardiology","benign prostatic hyperplasia (BPH), hypertension","COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)[C@H]1CCCO1 |&1:23,r|, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)[C@H]1CCCO1 |&1:23,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,1,1,1,1
"4040","terbinafine","fungal squalene epoxidase inhibitor","SQLE","infectious disease","tinea pedis, tinea cruris, tinea corporis","CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12, CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12, CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12, CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12, CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12, CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4041","terbutaline","adrenergic receptor agonist","ADRB2","pulmonary","bronchospasm, bronchitis, emphysema","CC(C)(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:6|, CC(C)(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:6|, CC(C)(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:6|, CC(C)(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:6|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"4042","terfenadine","histamine receptor antagonist","HRH1, KCNH1, KCNH2",NA,NA,"CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10,r|, CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10,r|, CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10,r|, CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10,r|, CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10,r|, CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10,r|","Withdrawn",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
"4043","terguride","dopamine receptor agonist, serotonin receptor antagonist","ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD2, DRD3, DRD4, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C","neurology/psychiatry","Parkinson's Disease","CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(C)C1 |a:8,&1:10,&2:11|","Launched",0,0,0,0,0,0,0,0,1,6,0,0,0,0,1,3,0,0,1,4,1,1,1,1
"4044","teriflunomide","dihydroorotate dehydrogenase inhibitor","DHODH","neurology/psychiatry","multiple sclerosis","CC(=O)[C@@H](C#N)C(=O)Nc1ccc(cc1)C(F)(F)F |&1:3,r|, CC(=O)[C@@H](C#N)C(=O)Nc1ccc(cc1)C(F)(F)F |&1:3,r|, CC(=O)[C@@H](C#N)C(=O)Nc1ccc(cc1)C(F)(F)F |&1:3,r|, CC(=O)[C@@H](C#N)C(=O)Nc1ccc(cc1)C(F)(F)F |&1:3,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4045","terlipressin","vasopressin receptor agonist","AVPR1A","cardiology","hypotension","NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O, NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O, NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4046","terpinen-4-ol","anti-inflammatory agent","BCL2, BIRC5, XIAP","oncology","melanoma","CC(C)[C@@]1(O)CCC(C)=CC1 |&1:3,r,c:8|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4047","terutroban","prostanoid receptor antagonist","TBXA2R",NA,NA,"Cc1ccc2C[C@@H](CCc2c1CCC(O)=O)NS(=O)(=O)c1ccc(Cl)cc1, Cc1ccc2C[C@@H](CCc2c1CCC(O)=O)NS(=O)(=O)c1ccc(Cl)cc1, Cc1ccc2C[C@@H](CCc2c1CCC(O)=O)NS(=O)(=O)c1ccc(Cl)cc1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4048","tesaglitazar","insulin sensitizer, PPAR receptor agonist","PPARA, PPARG",NA,NA,"CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(O)=O, CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(O)=O, CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(O)=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4049","tetomilast","phosphodiesterase inhibitor","PDE4D",NA,NA,"CCOc1ccc(cc1OCC)-c1nc(cs1)-c1cccc(n1)C(O)=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4050","tetrabenazine","vesicular monoamine transporter inhibitor","SLC18A1, SLC18A2","infectious disease, neurology/psychiatry","cholera, Huntington's disease","COc1cc2CCN3C[C@H](CC(C)C)C(=O)C[C@H]3c2cc1OC, COc1cc2CCN3C[C@H](CC(C)C)C(=O)C[C@H]3c2cc1OC, COc1cc2CCN3C[C@H](CC(C)C)C(=O)C[C@H]3c2cc1OC, COc1cc2CCN3C[C@H](CC(C)C)C(=O)C[C@H]3c2cc1OC, COc1cc2CCN3C[C@H](CC(C)C)C(=O)C[C@H]3c2cc1OC","Launched",1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4051","tetracaine","membrane integrity inhibitor","SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A","neurology/psychiatry","anesthetic","CCCCNc1ccc(cc1)C(=O)OCCN(C)C, CCCCNc1ccc(cc1)C(=O)OCCN(C)C, CCCCNc1ccc(cc1)C(=O)OCCN(C)C","Launched",0,0,1,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4052","tetraethylenepentamine","superoxide dismutase inhibitor","SOD1, SOD2",NA,NA,"NCCNCCNCCNCCN, NCCNCCNCCNCCN, NCCNCCNCCNCCN, NCCNCCNCCNCCN, NCCNCCNCCNCCN","Phase 2/Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4053","tetrahydrouridine","cytidine deaminase inhibitor","CDA",NA,NA,"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CC[C@@H](O)NC1=O |a:2,4,5,7,&1:12|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4054","tetramisole","immunostimulant","ALPPL2, CHRNA3","infectious disease","gastrointestinal parasites","C1CN2C[C@@H](N=C2S1)c1ccccc1 |&1:4,c:5|, C1CN2C[C@@H](N=C2S1)c1ccccc1 |&1:4,c:5|, C1CN2C[C@@H](N=C2S1)c1ccccc1 |&1:4,c:5|, C1CN2C[C@@H](N=C2S1)c1ccccc1 |&1:4,c:5|, C1CN2C[C@@H](N=C2S1)c1ccccc1 |&1:4,c:5|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,1
"4055","tetrandrine","calcium channel blocker","SLC6A3",NA,NA,"COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34, COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34, COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34, COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34, COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34","Preclinical",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4056","tetrazol-5-yl-glycine-(RS)","glutamate receptor agonist","GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,"N[C@@H](C(O)=O)c1nn[nH]n1 |&1:1,r|, N[C@@H](C(O)=O)c1nn[nH]n1 |&1:1,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4057","tetrindole","monoamine oxidase inhibitor","MAOA",NA,NA,"C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1, C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1, C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1, C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1, C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1, C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1, C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1","Phase 3",0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4058","TFC-007","prostaglandin inhibitor","HPGDS",NA,NA,"O=C(Nc1ccc(cc1)N1CCC(CC1)C(=O)N1CCOCC1)c1cnc(Oc2ccccc2)nc1, O=C(Nc1ccc(cc1)N1CCC(CC1)C(=O)N1CCOCC1)c1cnc(Oc2ccccc2)nc1, O=C(Nc1ccc(cc1)N1CCC(CC1)C(=O)N1CCOCC1)c1cnc(Oc2ccccc2)nc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4059","TG-003","CLK inhibitor","CLK1, CLK4, DYRK1A, DYRK1B",NA,NA,"CCN1\C(Sc2ccc(OC)cc12)=C\C(C)=O, CCN1\C(Sc2ccc(OC)cc12)=C\C(C)=O, CCN1\C(Sc2ccc(OC)cc12)=C\C(C)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4060","TG-02","CDK inhibitor, FLT3 inhibitor, JAK inhibitor","CDK1, CDK2, CDK7, CDK9, FLT3, JAK2",NA,NA,"CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|, CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|, CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|, CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|, CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|, CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|, CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|, CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4061","TG-100572","SRC inhibitor, VEGFR inhibitor","KDR, SRC",NA,NA,"Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl, Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl, Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl, Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl, Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4062","TG-100801","SRC inhibitor, VEGFR inhibitor","CSK, FGFR1, FLT1, FLT4, KDR, SRC",NA,NA,"Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(OC(=O)c2ccccc2)ccc1Cl, Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(OC(=O)c2ccccc2)ccc1Cl, Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(OC(=O)c2ccccc2)ccc1Cl, Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(OC(=O)c2ccccc2)ccc1Cl","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4063","TG-101209","JAK inhibitor","JAK2, JAK3",NA,NA,"CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4064","TGX-221","PI3K inhibitor","PIK3CB, PIK3CD",NA,NA,"C[C@@H](Nc1ccccc1)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1 |&1:1,r|, C[C@@H](Nc1ccccc1)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1 |&1:1,r|, C[C@@H](Nc1ccccc1)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1 |&1:1,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4065","TG100-115","PI3K inhibitor","PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,"Nc1nc(N)c2nc(-c3cccc(O)c3)c(nc2n1)-c1cccc(O)c1, Nc1nc(N)c2nc(-c3cccc(O)c3)c(nc2n1)-c1cccc(O)c1","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4066","TH-588","MTH1 inhibitor","NUDT1",NA,NA,"Nc1nc(NC2CC2)cc(n1)-c1cccc(Cl)c1Cl, Nc1nc(NC2CC2)cc(n1)-c1cccc(Cl)c1Cl, Nc1nc(NC2CC2)cc(n1)-c1cccc(Cl)c1Cl, Nc1nc(NC2CC2)cc(n1)-c1cccc(Cl)c1Cl, Nc1nc(NC2CC2)cc(n1)-c1cccc(Cl)c1Cl, Nc1nc(NC2CC2)cc(n1)-c1cccc(Cl)c1Cl","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4067","thalidomide","tumor necrosis factor production inhibitor","TNF","oncology","myeloma","O=C1N([C@H]2CCC(=O)NC2=O)C(=O)c2ccccc12 |&1:3,r|, O=C1N([C@H]2CCC(=O)NC2=O)C(=O)c2ccccc12 |&1:3,r|, O=C1N([C@H]2CCC(=O)NC2=O)C(=O)c2ccccc12 |&1:3,r|, O=C1N([C@H]2CCC(=O)NC2=O)C(=O)c2ccccc12 |&1:3,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4068","theobromine","phosphodiesterase inhibitor","ADORA1, ADORA2A, PDE4B",NA,NA,"Cn1cnc2n(C)c(=O)[nH]c(=O)c12, Cn1cnc2n(C)c(=O)[nH]c(=O)c12, Cn1cnc2n(C)c(=O)[nH]c(=O)c12, Cn1cnc2n(C)c(=O)[nH]c(=O)c12, Cn1cnc2n(C)c(=O)[nH]c(=O)c12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4069","thiamet-g","GLCNAC phosphotransferase inhibitor","MGEA5",NA,NA,"CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1 |t:3|, CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1 |t:3|, CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1 |t:3|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4070","thiamine","vitamin B","SLC19A2, SLC19A3, TPK1","metabolism","thiamine deficiency","Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N, Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N, Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N","Launched",1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4071","thiamylal","glutamate receptor antagonist","GABRA1","neurology/psychiatry","sedative","CCC[C@@H](C)C1(CC=C)C(=O)NC(=S)NC1=O |&1:3,&2:5|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1
"4072","thiethylperazine","dopamine receptor antagonist","DRD1, DRD2, DRD4","gastroenterology","nausea","CCSc1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1, CCSc1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1, CCSc1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1, CCSc1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1, CCSc1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0,1,1,1,1
"4073","thiocolchicoside","GABA receptor antagonist","GABRA1, GABRB2, GABRG2, GLRA1, GLRB","neurology/psychiatry","muscle relaxant","COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC, COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC, COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC, COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC, COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC","Launched",0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,1,1,1,1
"4074","thioctic-acid","reducing agent","ACHE, PTGS2","nephrology","diabetic nephropathy","OC(=O)CCCC[C@H]1CCSS1 |&1:7,r|, OC(=O)CCCC[C@H]1CCSS1 |&1:7,r|","Launched",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4075","thioguanine","purine antagonist","IMPDH1, IMPDH2","hematologic malignancy","acute myeloid leukemia (AML)","Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4076","thiomersal","other antibiotic","OXCT1","infectious disease","preservative","CC[Hg]Sc1ccccc1C(O)=O, CC[Hg]Sc1ccccc1C(O)=O, CC[Hg]Sc1ccccc1C(O)=O, CC[Hg]Sc1ccccc1C(O)=O, CC[Hg]Sc1ccccc1C(O)=O, CC[Hg]Sc1ccccc1C(O)=O, CC[Hg]Sc1ccccc1C(O)=O, CC[Hg]Sc1ccccc1C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4077","thiopental","GABA receptor antagonist","FAAH","neurology/psychiatry","anesthetic","CCC[C@@H](C)C1(CC)C(=O)NC(=S)NC1=O |&1:3,&2:5|, CCC[C@@H](C)C1(CC)C(=O)NC(=S)NC1=O |&1:3,&2:5|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4078","thioperamide","histamine receptor antagonist","HRH3, HRH4",NA,NA,"S=C(NC1CCCCC1)N1CCC(CC1)[C@H]1C=NC=N1 |r,c:18,20|","Preclinical",0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0
"4079","thioproperazine","dopamine receptor antagonist","ADRA1A, ADRA1B, DRD1, DRD2, HTR1A, HTR2A","neurology/psychiatry","schizophrenia","CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1, CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1","Launched",0,0,0,0,0,0,0,0,1,2,0,0,0,0,1,2,0,0,1,2,1,1,1,1
"4080","thioridazine","dopamine receptor antagonist","CHRNA7, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7, MALT1","Neurology","psychosis","CSc1ccc2Sc3ccccc3N(CC[C@H]3CCCCN3C)c2c1 |&1:16,r|, CSc1ccc2Sc3ccccc3N(CCC3CCCCN3C)c2c1, CSc1ccc2Sc3ccccc3N(CCC3CCCCN3C)c2c1, CSc1ccc2Sc3ccccc3N(CCC3CCCCN3C)c2c1, CSc1ccc2Sc3ccccc3N(CCC3CCCCN3C)c2c1","Launched",0,0,0,0,0,0,0,0,1,5,1,1,0,0,1,5,1,1,0,0,1,1,1,1
"4081","thiorphan","membrane metalloendopeptidase inhibitor","MME",NA,NA,"OC(=O)CNC(=O)[C@@H](CS)Cc1ccccc1 |&1:7,r|, OC(=O)CNC(=O)[C@@H](CS)Cc1ccccc1 |&1:7,r|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4082","thiostrepton","foxm1 inhibitor, protein synthesis inhibitor, FOXM1 inhibitor, protein synthesis inhibitor","FOXM1","obstetrics/gynecology","mastitis","CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O |c:7,41,61|, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O |c:7,41,61|, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O |c:7,41,61|, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O |c:7,41,61|, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O |c:7,41,61|, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O |c:7,41,61|, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O |c:7,41,61|, CCC(C)C1NC2C=Cc3c(cc(nc3C2O)C(=O)OC(C)C2NC(=O)c3csc(n3)C(NC(=O)C3CSC(=N3)\C(NC(=O)C(NC(=O)c3csc(n3)C3(CCC(=NC3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)C(C)NC(=O)C(=C)NC(=O)C(C)NC1=O)C(C)O)=C/C)C(C)(O)C(C)O)C(C)O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4083","thiotepa","cytochrome P450 inhibitor","CYP2B6, CYP3A4","oncology","breast cancer, ovarian cancer, bladder cancer","S=P(N1CC1)(N1CC1)N1CC1, S=P(N1CC1)(N1CC1)N1CC1, S=P(N1CC1)(N1CC1)N1CC1, S=P(N1CC1)(N1CC1)N1CC1, S=P(N1CC1)(N1CC1)N1CC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4084","thiothixene","dopamine receptor antagonist","DRD1, DRD2, HRH1, HTR2A","neurology/psychiatry","schizophrenia","CN(C)S(=O)(=O)c1ccc2Sc3ccccc3\C(=C\CCN3CCN(C)CC3)c2c1, CN(C)S(=O)(=O)c1ccc2Sc3ccccc3\C(=C/CCN3CCN(C)CC3)c2c1","Launched",0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,2,0,0,0,0,1,1,1,1
"4085","thymol","GABA receptor positive allosteric modulator","TRPA1","infectious disease","ringworm, antiseptic","CC(C)c1ccc(C)cc1O, CC(C)c1ccc(C)cc1O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4086","THZ1","CDK inhibitor","CDK7",NA,NA,"CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4087","THZ1-R","CDK inhibitor","CDK7",NA,NA,"CN(C)CCCC(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)CCCC(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4088","THZ2","CDK inhibitor","CDK7",NA,NA,"CN(C)C\C=C\C(=O)Nc1cccc(c1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1cccc(c1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1cccc(c1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1cccc(c1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1cccc(c1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4089","tiagabine","GABA uptake inhibitor","SLC6A1","neurology/psychiatry","seizures","Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C, Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C, Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C, Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4090","tianeptine","selective serotonin reuptake enhancer (SSRE)","OPRD1, OPRK1, OPRM1","neurology/psychiatry, pulmonary, gastroenterology","depression, asthma, irritable bowel syndrome","CN1c2ccccc2[C@@H](NCCCCCCC(O)=O)c2ccc(Cl)cc2S1(=O)=O |&1:8,r|, CN1c2ccccc2[C@@H](NCCCCCCC(O)=O)c2ccc(Cl)cc2S1(=O)=O |&1:8,r|, CN1c2ccccc2[C@@H](NCCCCCCC(O)=O)c2ccc(Cl)cc2S1(=O)=O |&1:8,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4091","tiapride","dopamine receptor antagonist","DRD2, DRD3","neurology/psychiatry","dyskinesia, abstinence from alcohol, psychosis","CCN(CC)CCNC(=O)c1cc(ccc1OC)S(C)(=O)=O, CCN(CC)CCNC(=O)c1cc(ccc1OC)S(C)(=O)=O, CCN(CC)CCNC(=O)c1cc(ccc1OC)S(C)(=O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,1,1,1,1
"4092","tiaprofenic-acid","cyclooxygenase inhibitor","PTGS2","rheumatology","rheumatoid arthritis","C[C@@H](C(O)=O)c1ccc(s1)C(=O)c1ccccc1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc(s1)C(=O)c1ccccc1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc(s1)C(=O)c1ccccc1 |&1:1,r|","Launched",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4093","tibolone","androgen receptor agonist, estrogen receptor agonist, progesterone receptor agonist","AR, ESR1, PGR, STS","Oncology, obstetrics/gynecology","breast cancer, endometriosis","C[C@@H]1CC2=C(CCC(=O)C2)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)C#C)[C@H]12 |t:3|, C[C@@H]1CC2=C(CCC(=O)C2)[C@H]2CC[C@@]3(C)[C@H](CC[C@@]3(O)C#C)[C@@H]12 |a:1,10,13,15,18,&1:22,t:3|, C[C@@H]1CC2=C(CCC(=O)C2)[C@H]2CC[C@@]3(C)[C@H](CC[C@@]3(O)C#C)[C@@H]12 |a:1,10,13,15,18,&1:22,t:3|, C[C@@H]1CC2=C(CCC(=O)C2)[C@H]2CC[C@@]3(C)[C@H](CC[C@@]3(O)C#C)[C@@H]12 |a:1,10,13,15,18,&1:22,t:3|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4094","ticagrelor","purinergic receptor antagonist","P2RY12","cardiology","acute coronary syndrome (acs), myocardial infarction, acute coronary syndrome (ACS), myocardial infarction","CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1, CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1, CCCSc1nc(N[C@@H]2C[C@@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@H](O)[C@H]3O)c2n1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4095","ticlopidine","purinergic receptor antagonist","P2RY12","hematology, neurology/psychiatry","thrombosis, stroke","Clc1ccccc1CN1CCc2sccc2C1, Clc1ccccc1CN1CCc2sccc2C1, Clc1ccccc1CN1CCc2sccc2C1, Clc1ccccc1CN1CCc2sccc2C1, Clc1ccccc1CN1CCc2sccc2C1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4096","TIC10","AKT inhibitor, TRAIL modulator","AKT1, MAPK1",NA,NA,"Cc1ccccc1CN1C2=NCCN2C(=O)C2=C1CCN(Cc1ccccc1)C2 |c:18,t:10|, Cc1ccccc1CN1C2=NCCN2C(=O)C2=C1CCN(Cc1ccccc1)C2 |c:18,t:10|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4097","tideglusib","glycogen synthase kinase inhibitor","GSK3B",NA,NA,"O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1, O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1, O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1, O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1, O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1, O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4098","tienilic-acid","cytochrome P450 inhibitor, sodium/potassium/chloride transporter inhibitor","CYP2C9, SLC12A1",NA,NA,"OC(=O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl, OC(=O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl, OC(=O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl","Withdrawn",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4099","tie2-kinase-inhibitor","TIE tyrosine kinase inhibitor","KDR, MAPK14",NA,NA,"COc1ccc2cc(ccc2c1)-c1[nH]c(nc1-c1ccncc1)-c1ccc(cc1)[S@@](C)=O |r|, COc1ccc2cc(ccc2c1)-c1[nH]c(nc1-c1ccncc1)-c1ccc(cc1)[S@@](C)=O |r|, COc1ccc2cc(ccc2c1)-c1[nH]c(nc1-c1ccncc1)-c1ccc(cc1)[S@@](C)=O |r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4100","tifenazoxide","ATP-sensitive potassium channel agonist","ABCC8, KCNJ11",NA,NA,"CC1(CC1)NC1=NS(=O)(=O)c2sc(Cl)cc2N1 |t:6|, CC1(CC1)NC1=NS(=O)(=O)c2sc(Cl)cc2N1 |t:6|, CC1(CC1)NC1=NS(=O)(=O)c2sc(Cl)cc2N1 |t:6|, CC1(CC1)NC1=NS(=O)(=O)c2sc(Cl)cc2N1 |t:6|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4101","tiludronate","bone resorption inhibitor, osteoclast inhibitor","ATP6V1A, MMP2, PTPN1","orthopedics","navicular syndrome","OP(O)(=O)C(Sc1ccc(Cl)cc1)P(O)(O)=O, OP(O)(=O)C(Sc1ccc(Cl)cc1)P(O)(O)=O, OP(O)(=O)C(Sc1ccc(Cl)cc1)P(O)(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4102","timofibrate","cholesterol inhibitor, lipase clearing factor inhibitor","LPL",NA,NA,"CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSC[C@@H]1C(O)=O |&1:17,r|, CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSC[C@@H]1C(O)=O |&1:17,r|, CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSC[C@@H]1C(O)=O |&1:17,r|, CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSC[C@@H]1C(O)=O |&1:17,r|, CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSC[C@@H]1C(O)=O |&1:17,r|, CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSC[C@@H]1C(O)=O |&1:17,r|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4103","timolol","adrenergic receptor antagonist","ADRB1, ADRB2","ophthalmology","ocular hypertension, glaucoma","CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1, CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1, CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,1,1,1,1
"4104","tiotidine","histamine receptor antagonist","HRH2",NA,NA,"CN\C(NCCSCc1csc(N=C(N)N)n1)=N/C#N, CN=C(NCCSCc1csc(NC(N)=N)n1)NC#N","Phase 2",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
"4105","tiotropium","acetylcholine receptor antagonist","CHRM1, CHRM2, CHRM3","pulmonary","chronic obstructive pulmonary disease (COPD), bronchitis, emphysema","C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1, C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,1,1,1,1
"4106","tioxolone","carbonic anhydrase inhibitor","CA2",NA,NA,"Oc1ccc2sc(=O)oc2c1, Oc1ccc2sc(=O)oc2c1, Oc1ccc2sc(=O)oc2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4107","tipepidine","g protein signaling inhibitor","KCNJ3","neurology/psychiatry","attention-deficit/hyperactivity disorder (adhd)","CN1CCCC(=C(c2cccs2)c3cccs3)C1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4108","tipifarnib","farnesyltransferase inhibitor","FNTA, FNTB",NA,NA,"Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1, Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1, Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1, Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1, Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1, Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1, Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4109","tiplaxtinin","plasminogen activator inhibitor","SERPINE1",NA,NA,"OC(=O)C(=O)c1cn(Cc2ccccc2)c2ccc(cc12)-c1ccc(OC(F)(F)F)cc1, OC(=O)C(=O)c1cn(Cc2ccccc2)c2ccc(cc12)-c1ccc(OC(F)(F)F)cc1, OC(=O)C(=O)c1cn(Cc2ccccc2)c2ccc(cc12)-c1ccc(OC(F)(F)F)cc1, OC(=O)C(=O)c1cn(Cc2ccccc2)c2ccc(cc12)-c1ccc(OC(F)(F)F)cc1, OC(=O)C(=O)c1cn(Cc2ccccc2)c2ccc(cc12)-c1ccc(OC(F)(F)F)cc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4110","tiprenolol","adrenergic receptor antagonist","ADRB1, ADRB2, ADRB3",NA,NA,"CSc1ccccc1OC[C@@H](O)CNC(C)C |&1:10,r|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0
"4111","tirabrutinib","bruton's tyrosine kinase (btk) inhibitor","BTK","hematologic malignancy","small lymphocytic lymphoma (sll)","CC#CC(=O)N1CC[C@H](C1)N2C3=NC=NC(=C3N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5)N","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4112","tiracizine","sodium channel blocker","SCN5A",NA,NA,"CCOC(=O)Nc1ccc2CCc3ccccc3N(C(=O)CN(C)C)c2c1, CCOC(=O)Nc1ccc2CCc3ccccc3N(C(=O)CN(C)C)c2c1","Withdrawn",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4113","tiratricol","thyroid hormone stimulant","THRA, THRB","endocrinology","Refetoff syndrome","OC(=O)Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1, OC(=O)Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1, OC(=O)Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4114","tirbanibulin","protein tyrosine kinase inhibitor","SRC, TUBB","dermatology","actinic keratosis (ak)","C1COCCN1CCOC2=CC=C(C=C2)C3=CN=C(C=C3)CC(=O)NCC4=CC=CC=C4","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4115","tirofiban","platelet aggregation inhibitor, structural glycoprotein antagonist","ITGA2B, ITGB3","cardiology","myocardial infarction, refactory angina","CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(O)=O, CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(O)=O, CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4116","tivantinib","tyrosine kinase inhibitor","MET",NA,NA,"O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23, O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23, O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23, O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23, O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4117","tivozanib","VEGFR inhibitor","FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB","oncology","renal cell carcinoma (RCC)","COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4118","tizanidine","adrenergic receptor agonist","ADRA2A, ADRA2B, ADRA2C, NISCH","neurology/psychiatry","spasms","Clc1ccc2nsnc2c1NC1=NCCN1 |t:13|, Clc1ccc2nsnc2c1NC1=NCCN1 |t:13|, Clc1ccc2nsnc2c1NC1=NCCN1 |t:13|, Clc1ccc2nsnc2c1NC1=NCCN1 |t:13|, Clc1ccc2nsnc2c1NC1=NCCN1 |t:13|, Clc1ccc2nsnc2c1NC1=NCCN1 |t:13|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,1,1,1,1
"4119","tk216","binding of rna helicase a to the transcription factor ews-fli1 inhibitor","EWSR1, FLI1","oncology","ewing's sarcoma","OC1(CC(=O)c2ccc(cc2)C3CC3)C(=O)Nc4c(Cl)ccc(Cl)c14","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4120","TMN-355","cyclophilin inhibitor","PPIA",NA,NA,"Fc1cccc(Cl)c1C(=O)NC(=O)NC1c2ccccc2-c2ccccc12, Fc1cccc(Cl)c1C(=O)NC(=O)NC1c2ccccc2-c2ccccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4121","tno155","tyrosine phosphatase inhibitor","PTPN11","oncology","colorectal cancer","C[C@@H]1OCC2(CCN(CC2)c2cnc(Sc3ccnc(N)c3Cl)c(N)n2)[C@@H]1N |a:1,26|","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4122","TNP-470","methionine aminopeptidase inhibitor","METAP2",NA,NA,"CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)NC(=O)CCl, CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)NC(=O)CCl, CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)NC(=O)CCl, CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)NC(=O)CCl","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4123","tocainide","sodium channel blocker","SCN5A","cardiology","cardiac arrythmia","C[C@@H](N)C(=O)Nc1c(C)cccc1C |&1:1,r|, C[C@@H](N)C(=O)Nc1c(C)cccc1C |&1:1,r|","Launched",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4124","toceranib","protein tyrosine kinase inhibitor","FLT1, FLT3, KDR, PDGFRA, PDGFRB","oncology","cutaneous mast cell tumors","Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NCCN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NCCN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NCCN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NCCN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NCCN1CCCC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4125","tofacitinib","JAK inhibitor","JAK1, JAK2, JAK3","rheumatology","rheumatoid arthritis","C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N, C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N, C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N, C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N, C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N, C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N, C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N, C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N, C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4126","tofisopam","cytochrome P450 inhibitor, phosphodiesterase inhibitor","CYP3A4","neurology/psychiatry","anxiety, abstinence from alcohol","CCC1=C(C)NN=C(c2ccc(OC)c(OC)c2)c2cc(OC)c(OC)cc12 |c:2,t:6|, CCC1=C(C)NN=C(c2ccc(OC)c(OC)c2)c2cc(OC)c(OC)cc12 |c:2,t:6|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4127","tofogliflozin","sodium/glucose cotransporter inhibitor","GCK","endocrinology","diabetes mellitus","CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1, CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1, CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1, CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1, CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1, CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4128","tolamolol","adrenergic receptor antagonist","ADRB1, ADRB2, ADRB3",NA,NA,"Cc1ccccc1OC[C@@H](O)CNCCOc1ccc(cc1)C(N)=O |&1:9,r|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0
"4129","tolazamide","ATP channel blocker","ABCC8, KCNJ1, KCNJ10, KCNJ11","endocrinology","diabetes mellitus","Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CCCCCC1, Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CCCCCC1, Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CCCCCC1, Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CCCCCC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4130","tolazoline","adrenergic receptor antagonist","ADRA1A, ADRA2A, ADRA2B, ADRA2C, HRH1, HRH2","neurology/psychiatry","reverse sedative","C(C1=NCCN1)c1ccccc1 |t:1|, C(C1=NCCN1)c1ccccc1 |t:1|, C(C1=NCCN1)c1ccccc1 |t:1|","Launched",0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,1,4,1,1,1,1
"4131","tolbutamide","ATP channel blocker","ABCC8, KCNJ1, KCNJ11, KCNJ8","endocrinology","diabetes mellitus","CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1, CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1, CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4132","tolcapone","catechol O methyltransferase inhibitor","COMT",NA,NA,"Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4133","tolebrutinib","bruton's tyrosine kinase (btk) inhibitor","BTK","neurology/psychiatry","multiple sclerosis","Nc1nccc2n([C@@H]3CCCN(C3)C(=O)C=C)c(=O)n(-c3ccc(Oc4ccccc4)cc3)c12","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4134","tolimidone","SRC activator","LYN, SRC",NA,NA,"Cc1cccc(Oc2cnc(=O)[nH]c2)c1, Cc1cccc(Oc2cnc(=O)[nH]c2)c1, Cc1cccc(Oc2cnc(=O)[nH]c2)c1, Cc1cccc(Oc2cnc(=O)[nH]c2)c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4135","tolmetin","cyclooxygenase inhibitor","PTGS1, PTGS2","rheumatology","rheumatoid arthritis, osteoarthritis","Cc1ccc(cc1)C(=O)c1ccc(CC(O)=O)n1C, Cc1ccc(cc1)C(=O)c1ccc(CC(O)=O)n1C, Cc1ccc(cc1)C(=O)c1ccc(CC(O)=O)n1C","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4136","tolonidine","adrenergic receptor antagonist","ADRA2A",NA,NA,"Cc1ccc(NC2=NCCN2)c(Cl)c1 |t:6|, Cc1ccc(NC2=NCCN2)c(Cl)c1 |t:6|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
"4137","toloxatone","monoamine oxidase inhibitor","MAOA, MAOB","neurology/psychiatry","depression","Cc1cccc(c1)N1C[C@@H](CO)OC1=O |&1:9,r|, Cc1cccc(c1)N1C[C@@H](CO)OC1=O |&1:9,r|, Cc1cccc(c1)N1C[C@@H](CO)OC1=O |&1:9,r|","Launched",0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4138","tolperisone","voltage-gated sodium channel blocker","CYP2C19, CYP2D6","neurology/psychiatry, infectious disease, rheumatology, cardiology","muscle relaxant, multiple sclerosis, encephalomyelitis, ankylosing spondylitis, atherosclerosis, Raynaud's disease","C[C@@H](CN1CCCCC1)C(=O)c1ccc(C)cc1 |r|, C[C@@H](CN1CCCCC1)C(=O)c1ccc(C)cc1 |r|, C[C@@H](CN1CCCCC1)C(=O)c1ccc(C)cc1 |r|, C[C@@H](CN1CCCCC1)C(=O)c1ccc(C)cc1 |r|, C[C@@H](CN1CCCCC1)C(=O)c1ccc(C)cc1 |r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4139","tolrestat","aldose reductase inhibitor","AKR1A1, AKR1B1, AKR1B10",NA,NA,"COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O, COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O, COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O, COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O, COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O, COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4140","tolterodine","acetylcholine receptor antagonist","CHRM1, CHRM2, CHRM3, CHRM4, CHRM5","urology","urinary incontinence, urinary frequency","CC(C)N(CC[C@H](c1ccccc1)c1cc(C)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(C)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(C)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(C)ccc1O)C(C)C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,5,0,0,1,1,1,1
"4141","tolvaptan","vasopressin receptor antagonist","AVPR1A, AVPR2","endocrinology, cardiology, gastroenterology","hyponatremia, congestive heart failure, hepatic cirrhosis","Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc23)c(C)c1 |&1:20,r|, Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc23)c(C)c1 |&1:20,r|, Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc23)c(C)c1 |&1:20,r|, Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc23)c(C)c1 |&1:20,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4142","tomelukast","leukotriene receptor antagonist","CYSLTR1",NA,NA,"CCCc1c(OCCCCc2nn[nH]n2)ccc(C(C)=O)c1O, CCCc1c(OCCCCc2nn[nH]n2)ccc(C(C)=O)c1O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4143","topiramate","carbonic anhydrase inhibitor, glutamate receptor antagonist, kainate receptor antagonist","CA1, CA12, CA2, CA4, CA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A","neurology/psychiatry","epilepsy, migraine headache","CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1, CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1, CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1, CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1, CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1, CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1, CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1","Launched",0,0,1,10,0,0,0,0,0,0,0,0,1,16,0,0,0,0,0,0,1,1,1,1
"4144","topiroxostat","xanthine oxidase inhibitor","XDH","rheumatology, nephrology","gout, hyperuricemia","N#Cc1cc(ccn1)-c1nnc([nH]1)-c1ccncc1, N#Cc1cc(ccn1)-c1nnc([nH]1)-c1ccncc1, N#Cc1cc(ccn1)-c1nnc([nH]1)-c1ccncc1, N#Cc1cc(ccn1)-c1nnc([nH]1)-c1ccncc1, N#Cc1cc(ccn1)-c1nnc([nH]1)-c1ccncc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4145","topotecan","topoisomerase inhibitor","TOP1, TOP1MT","oncology","small cell lung cancer, cervical cancer","CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4146","torasemide","electrolyte reabsorption inhibitor, thromboxane receptor antagonist","SLC12A1","cardiology","edema, congestive heart failure, hypertension","CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1, CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1, CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1, CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4147","torcetrapib","cholesteryl ester transfer protein inhibitor","CETP",NA,NA,"CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F, CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F, CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F, CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4148","torcitabine","DNA polymerase inhibitor","DCK, TK2",NA,NA,"Nc1ccn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ccn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4149","toremifene","estrogen receptor antagonist, selective estrogen receptor modulator (SERM)","ESR1","oncology","breast cancer","CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4150","torin-1","mTOR inhibitor","MTOR",NA,NA,"CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1, CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1, CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1, CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1, CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4151","torin-2","mTOR inhibitor","MTOR",NA,NA,"Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1, Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1, Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1, Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1, Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1, Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4152","tosedostat","peptidase inhibitor","ANPEP, LAP3, NPEPPS",NA,NA,"CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4153","toyocamycin","serine/threonine kinase inhibitor","ERN1",NA,NA,"Nc1ncnc2n(cc(C#N)c12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1ncnc2n(cc(C#N)c12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1ncnc2n(cc(C#N)c12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4154","tozadenant","adenosine receptor antagonist","ADORA2A",NA,NA,"COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CCC(C)(O)CC3)nc12, COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CCC(C)(O)CC3)nc12, COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CCC(C)(O)CC3)nc12, COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CCC(C)(O)CC3)nc12","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4155","tozasertib","Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor","AURKA, AURKB, AURKC, LCK",NA,NA,"CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4156","TP-003","GABA receptor inverse agonist","GABRA1, GABRA2, GABRA3, GABRA5",NA,NA,"CC(C)(O)c1ccn2c(cnc2c1F)-c1ccc(F)c(c1)-c1ccc(F)cc1C#N, CC(C)(O)c1ccn2c(cnc2c1F)-c1ccc(F)c(c1)-c1ccc(F)cc1C#N","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,0,0
"4157","TP-0903","AXL kinase inhibitor","AXL",NA,NA,"CN(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(CN3CCN(C)CC3)cc2)ncc1Cl, CN(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(CN3CCN(C)CC3)cc2)ncc1Cl, CN(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(CN3CCN(C)CC3)cc2)ncc1Cl, CN(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(CN3CCN(C)CC3)cc2)ncc1Cl, CN(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(CN3CCN(C)CC3)cc2)ncc1Cl","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4158","TPCA-1","IKK inhibitor","IKBKB",NA,NA,"NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4159","tracazolate","GABA receptor modulator","GABRA1",NA,NA,"CCCCNc1c(C(=O)OCC)c(C)nc2n(CC)ncc12, CCCCNc1c(C(=O)OCC)c(C)nc2n(CC)ncc12, CCCCNc1c(C(=O)OCC)c(C)nc2n(CC)ncc12, CCCCNc1c(C(=O)OCC)c(C)nc2n(CC)ncc12","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0
"4160","TRAM-34","potassium channel antagonist","KCNN4",NA,NA,"Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1cccn1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1cccn1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4161","TRAM-39","calcium-activated potassium channel activator","KCNN4",NA,NA,"Clc1ccccc1C(C#N)(c1ccccc1)c1ccccc1, Clc1ccccc1C(C#N)(c1ccccc1)c1ccccc1, Clc1ccccc1C(C#N)(c1ccccc1)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4162","trametinib","MEK inhibitor","MAP2K1, MAP2K2","oncology","melanoma","CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4163","tramiprosate","beta amyloid protein neurotoxicity inhibitor","APP",NA,NA,"NCCCS(O)(=O)=O, NCCCS(O)(=O)=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4164","trandolapril","angiotensin converting enzyme inhibitor","ACE","cardiology","hypertension, myocardial infarction, hypertension, myocardial infarction","CCOC(=O)[C@H](CCc1ccccc1)N[C@H](C)C(=O)N1C2CCCCC2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@@H]2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@@H]2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@H](C)C(=O)N1C2CCCCC2C[C@H]1C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4165","tranexamic-acid","antifibrinolytic, plasminogen activator inhibitor","PLG","hematology","hemophilia","NC[C@H]1CC[C@@H](CC1)C(O)=O |r|, NC[C@H]1CC[C@@H](CC1)C(O)=O |r|, NC[C@H]1CC[C@@H](CC1)C(O)=O |r|, NC[C@H]1CC[C@@H](CC1)C(O)=O |r|, NC[C@H]1CC[C@@H](CC1)C(O)=O |r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4166","tranilast","angiogenesis inhibitor","HPGDS, HRH1","pulmonary","asthma","COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"4167","tranylcypromine","monoamine oxidase inhibitor","KDM1A, MAOA, MAOB","neurology/psychiatry","depression","N[C@H]1C[C@@H]1c1ccccc1 |&1:1,3|","Launched",0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4168","trap-101","nociceptin/orphanin FQ receptor antagonist, opioid receptor antagonist","OPRL1",NA,NA,"CCn1c2ccccc2n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c1=O |c:11|, CCn1c2ccccc2n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c1=O |c:11|, CCn1c2ccccc2n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c1=O |c:11|, CCn1c2ccccc2n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c1=O |c:11|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4169","trapidil","PDGFR tyrosine kinase receptor inhibitor","PDGFRA","cardiology","coronary artery disease (CAD)","CCN(CC)c1cc(C)nc2ncnn12, CCN(CC)c1cc(C)nc2ncnn12, CCN(CC)c1cc(C)nc2ncnn12","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4170","travoprost","prostanoid receptor agonist","PTGFR","ophthalmology","ocular hypertension, glaucoma","CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COc1cccc(c1)C(F)(F)F, CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COc1cccc(c1)C(F)(F)F","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4171","traxoprodil","glutamate receptor antagonist","GRIN2B",NA,NA,"C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(CC1)c1ccccc1, C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(CC1)c1ccccc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4172","trazodone","adrenergic receptor antagonist, serotonin receptor antagonist, serotonin reuptake inhibitor","ADRA1A, ADRA2A, HRH1, HTR1A, HTR2A, HTR2B, HTR2C, SLC6A4","neurology/psychiatry","depression","Clc1cccc(c1)N1CCN(CCCn2nc3ccccn3c2=O)CC1, Clc1cccc(c1)N1CCN(CCCn2nc3ccccn3c2=O)CC1, Clc1cccc(c1)N1CCN(CCCn2nc3ccccn3c2=O)CC1","Launched",1,1,0,0,0,0,0,0,1,4,1,1,0,0,0,0,0,0,1,2,1,1,1,1
"4173","trelagliptin","dipeptidyl peptidase inhibitor","DPP4","endocrinology","diabetes mellitus","Cn1c(=O)cc(N2CCCC(N)C2)n(Cc2cc(F)ccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2cc(F)ccc2C#N)c1=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4174","trepibutone","cholinergic receptor antagonist","CHRM1, CHRM2, CHRM3, CHRM4","gastroenterology","irritable bowel syndrome","CCOc1cc(OCC)c(cc1OCC)C(=O)CCC(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,1,1,1,1
"4175","treprostinil","prostanoid receptor agonist","P2RY12, PPARD, PTGIR","pulmonary","pulmonary arterial hypertension (PAH)","CCCCC[C@H](O)CC[C@H]1[C@H](O)C[C@@H]2Cc3c(C[C@H]12)cccc3OCC(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4176","trequinsin","phosphodiesterase inhibitor","PDE5A",NA,NA,"COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC, COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC, COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC, COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4177","tretazicar","DNA replication inhibitor","NQO2",NA,NA,"NC(=O)c1cc(N2CC2)c(cc1[N+]([O-])=O)[N+]([O-])=O, NC(=O)c1cc(N2CC2)c(cc1[N+]([O-])=O)[N+]([O-])=O, NC(=O)c1cc(N2CC2)c(cc1[N+]([O-])=O)[N+]([O-])=O, NC(=O)c1cc(N2CC2)c(cc1[N+]([O-])=O)[N+]([O-])=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4178","tretinoin","retinoid receptor agonist, retinoid receptor ligand","ALDH1A1, ALDH1A2, GPRC5A, NR0B1, NR2C2, PPARD, RARA, RARB, RARG, RARRES1, RORB, RORC, RXRB, RXRG","hematologic malignancy","acute promyelocytic leukemia (APL)","C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4179","triamcinolone","glucocorticoid receptor agonist","NR3C1","dermatology","corticosteroid-responsive dermatoses","C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4180","triamcinolone-acetonide","glucocorticoid receptor agonist, immunosuppressant","NR3C1, SERPINA6","dermatology","corticosteroid-responsive dermatoses","CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4181","triamterene","sodium channel blocker","SCNN1A, SCNN1B, SCNN1D, SCNN1G","endocrinology, cardiology","hypokalemia, hypertension, edema","Nc1nc(N)c2nc(c(N)nc2n1)-c1ccccc1, Nc1nc(N)c2nc(c(N)nc2n1)-c1ccccc1, Nc1nc(N)c2nc(c(N)nc2n1)-c1ccccc1, Nc1nc(N)c2nc(c(N)nc2n1)-c1ccccc1, Nc1nc(N)c2nc(c(N)nc2n1)-c1ccccc1, Nc1nc(N)c2nc(c(N)nc2n1)-c1ccccc1, Nc1nc(N)c2nc(c(N)nc2n1)-c1ccccc1","Launched",0,0,1,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4182","triapine","ribonucleotide reductase inhibitor","RRM1, RRM2",NA,NA,"NC(=S)N\N=C\c1ncccc1N, NC(=S)N\N=C\c1ncccc1N, NC(=S)N\N=C\c1ncccc1N","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4183","tricaine","sodium channel blocker","SCN1A","neurology/psychiatry","anesthetic","CCOC(=O)C1=CC=CC(N)=C1","Withdrawn",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4184","trichlormethiazide","chloride channel blocker","PTGS1, PTGS2, SLC12A1","cardiology","hypertension, edema","NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)C(Cl)Cl)cc1Cl |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)C(Cl)Cl)cc1Cl |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)C(Cl)Cl)cc1Cl |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)C(Cl)Cl)cc1Cl |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)C(Cl)Cl)cc1Cl |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)C(Cl)Cl)cc1Cl |&1:9,r|","Launched",1,1,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4185","trichostatin-a","HDAC inhibitor","HDAC1, HDAC10, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",NA,NA,"C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4186","triciribine","AKT inhibitor","AKT1, AKT2, AKT3",NA,NA,"Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4187","triclabendazole","microtubule inhibitor","DNMT1","infectious disease","tapeworm","CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4188","triclosan","antibacterial agent","DNMT1","infectious disease","first-aid antiseptic","Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1Cl, Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1Cl, Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1Cl, Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1Cl, Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1Cl","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4189","trientine","chelating agent","CA14","metabolism","Wilson's disease","NCCNCCNCCN, NCCNCCNCCN","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4190","trifarotene","retinoid receptor agonist","RARA, RARB, RARG","dermatology","acne vulgaris (av)","CC(C)(C)C1=C(C=CC(=C1)C2=C(C=CC(=C2)C3=CC=C(C=C3)C(=O)O)OCCO)N4CCCC4","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4191","trifluoperazine","dopamine receptor antagonist","ADRA1A, CALM1, CALY, DRD2, DRD4, HRH1, HTR2A, HTR2C, S100A4, TNNC1","neurology/psychiatry","schizophrenia","CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1","Launched",0,0,0,0,0,0,0,0,1,2,1,1,0,0,1,2,0,0,1,1,1,1,1,1
"4192","triflupromazine","dopamine receptor antagonist","CHRM1, CHRM2, DRD1, DRD2, HTR2B","neurology/psychiatry, gastroenterology","psychosis, nausea, vomiting","CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F, CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F, CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F, CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F, CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F, CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F, CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F","Launched",0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,2,1,2,0,0,1,1,1,1
"4193","trifluridine","DNA directed DNA polymerase inhibitor, thymidylate synthase inhibitor","TYMS","infectious disease","virus herpes simplex (HSV)","OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4194","triflusal","cyclooxygenase inhibitor, platelet aggregation inhibitor, thromboxane synthase inhibitor","NFKB1, NOS2, PDE10A, PTGS1","neurology/psychiatry, cardiology","stroke, myocardial infarction, atrial fibrillation (AF)","CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F, CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F, CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F, CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F, CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F, CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F, CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F","Launched",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4195","trihexyphenidyl","acetylcholine receptor antagonist","CHRM1","neurology/psychiatry","parkinsonism","O[C@@](CCN1CCCCC1)(C1CCCCC1)c1ccccc1 |&1:1|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,1
"4196","trimebutine","opioid receptor agonist","OPRD1, OPRK1, OPRM1","gastroenterology","irritable bowel syndrome","CC[C@](COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c1ccccc1 |&1:2|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4197","trimetaphan camsilate","acetylcholine receptor antagonist","CHRNA10","cardiology","hypertension","CC1(C)C2CCC1(CS([O-])(=O)=O)C(=O)C2.O=C1N(Cc2ccccc2)C2C[S+]3CCCC3C2N1Cc1ccccc1","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,1
"4198","trimetazidine","3-ketoacyl CoA thiolase inhibitor","ACAA2","cardiology","angina pectoris","COc1ccc(CN2CCNCC2)c(OC)c1OC, COc1ccc(CN2CCNCC2)c(OC)c1OC, COc1ccc(CN2CCNCC2)c(OC)c1OC","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4199","trimethadione","oxazolidine antiepileptic","CACNA1G, CACNA1H, CACNA1I","neurology/psychiatry","seizures","CN1C(=O)OC(C)(C)C1=O, CN1C(=O)OC(C)(C)C1=O, CN1C(=O)OC(C)(C)C1=O, CN1C(=O)OC(C)(C)C1=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4200","trimethobenzamide","histamine receptor antagonist","DRD2","gastroenterology","vomiting, nausea, gastroenteritis","COc1cc(cc(OC)c1OC)C(=O)NCc1ccc(OCCN(C)C)cc1, COc1cc(cc(OC)c1OC)C(=O)NCc1ccc(OCCN(C)C)cc1, COc1cc(cc(OC)c1OC)C(=O)NCc1ccc(OCCN(C)C)cc1, COc1cc(cc(OC)c1OC)C(=O)NCc1ccc(OCCN(C)C)cc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1
"4201","trimethoprim","dihydrofolate reductase inhibitor","DHFR, TYMS","infectious disease, gastroenterology","urinary tract infections, ear infections, diarrhea","COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC, COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC, COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4202","trimethoquinol","adrenergic receptor antagonist","ADRB2, ADRB3","pulmonary","asthma","COc1cc(C[C@H]2NCCc3cc(O)c(O)cc23)cc(OC)c1OC |&1:6|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,1,1,1,1
"4203","trimetrexate","dihydrofolate reductase inhibitor","DHFR",NA,NA,"COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4204","trimipramine","norepinephrine reputake inhibitor, tricyclic antidepressant","SLC6A2, SLC6A3, SLC6A4","neurology/psychiatry","depression","C[C@@H](CN(C)C)CN1c2ccccc2CCc2ccccc12 |&1:1|","Launched",1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4205","tripelennamine","histamine receptor antagonist","HRH1","pulmonary, allergy","asthma, allergic rhinitis, urticaria","CN(C)CCN(Cc1ccccc1)c1ccccn1, CN(C)CCN(Cc1ccccc1)c1ccccn1, CN(C)CCN(Cc1ccccc1)c1ccccn1","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"4206","triprolidine","histamine receptor antagonist","HRH1","allergy","allergic rhinitis","Cc1ccc(cc1)C(=C/CN1CCCC1)\c1ccccn1, Cc1ccc(cc1)C(=C/CN1CCCC1)\c1ccccn1, Cc1ccc(cc1)C(=C/CN1CCCC1)\c1ccccn1","Launched",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1
"4207","triptan","serotonin receptor agonist","HTR1B, HTR1D",NA,NA,"CC(C)C(C)(C)C","Phase 1",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4208","triptolide","RNA polymerase inhibitor","RELA",NA,NA,"CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4209","triptorelin","gonadotropin releasing factor hormone receptor agonist","GNRHR","oncology, endocrinology, obstetrics/gynecology","prostate cancer, breast cancer, precocious puberty, endometriosis, myoma, gender dysphoria","CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O, CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4210","trofinetide","anti-inflammatory agent, cytokine production inhibitor","ATF3, IFNG, IL6, TNF",NA,NA,"NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O, C[C@]1(CCCN1C(=O)CN)C(=O)N[C@@H](CCC(O)=O)C(O)=O |a:1,13|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4211","troglitazone","insulin sensitizer, PPAR receptor agonist","CYP2C8, PPARG, TRPM3",NA,NA,"Cc1c(C)c2O[C@@](C)(COc3ccc(C[C@H]4SC(=O)NC4=O)cc3)CCc2c(C)c1O |&1:6,r|, Cc1c(C)c2O[C@@](C)(COc3ccc(C[C@H]4SC(=O)NC4=O)cc3)CCc2c(C)c1O |&1:6,r|, Cc1c(C)c2O[C@@](C)(COc3ccc(C[C@H]4SC(=O)NC4=O)cc3)CCc2c(C)c1O |&1:6,r|, Cc1c(C)c2O[C@@](C)(COc3ccc(C[C@H]4SC(=O)NC4=O)cc3)CCc2c(C)c1O |&1:6,r|","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4212","tropanyl-3,5-dimethylbenzoate","serotonin receptor antagonist","HTR3A, HTR3B",NA,NA,"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1cc(C)cc(C)c1 |&1:2,&2:5,&3:7,r,TLB:0:1:3.4:6.7.8|","Preclinical",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4213","tropesin","cyclooxygenase inhibitor","PTGS1, PTGS2",NA,NA,"COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OC[C@@H](C(O)=O)c3ccccc3)c2c1 |&1:24,r|","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4214","tropicamide","acetylcholine receptor antagonist","CHRM3, CHRM4","ophthalmology","mydriasis diagnostic, cycloplegia diagnostic","CCN(Cc1ccncc1)C(=O)[C@@H](CO)c1ccccc1 |&1:12,r|, CCN(Cc1ccncc1)C(=O)[C@@H](CO)c1ccccc1 |&1:12,r|, CCN(Cc1ccncc1)C(=O)[C@@H](CO)c1ccccc1 |&1:12,r|, CCN(Cc1ccncc1)C(=O)[C@@H](CO)c1ccccc1 |&1:12,r|, CCN(Cc1ccncc1)C(=O)[C@@H](CO)c1ccccc1 |&1:12,r|, CCN(Cc1ccncc1)C(=O)[C@@H](CO)c1ccccc1 |&1:12,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,1,1,1,1
"4215","tropisetron","serotonin receptor antagonist","GLRA1, GLRA2, GLRB, HTR3A, HTR4","gastroenterology","nausea, vomiting","CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12","Launched",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4216","trospium","acetylcholine receptor antagonist","CHRM1","urology","urinary incontinence, urinary frequency","[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1)[N+]21CCCC1 |&1:1,4,7|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,1
"4217","trovafloxacin","bacterial DNA gyrase inhibitor","TOP2A",NA,NA,"N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F, N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F, N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F, N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F, N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4218","TRV130","opioid receptor agonist","OPRM1",NA,NA,"COc1ccsc1CNCC[C@]1(CCOC2(CCCC2)C1)c1ccccn1, COc1ccsc1CNCC[C@]1(CCOC2(CCCC2)C1)c1ccccn1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4219","tryptanthrin","cyclooxygenase inhibitor","IDO1",NA,NA,"O=C1c2ccccc2-n2c1nc1ccccc1c2=O, O=C1c2ccccc2-n2c1nc1ccccc1c2=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4220","tryptophan","serotonin receptor partial agonist","CASR, IDO1, SLC36A1, WARS, WARS2","neurology/psychiatry, gastroenterology","anxiety, bloating, constipation, fatigue, sleeplessness","N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O, N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O, N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4221","TTNPB","retinoid receptor agonist","RARA, RARB, RARG",NA,NA,"C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C, C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C, C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C, C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4222","TTP-22","casein kinase inhibitor","CSNK2A1",NA,NA,"Cc1ccc(cc1)-c1csc2ncnc(SCCC(O)=O)c12, Cc1ccc(cc1)-c1csc2ncnc(SCCC(O)=O)c12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4223","tubastatin-A","HDAC inhibitor","HDAC6",NA,NA,"CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO, CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO, CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO, CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO, CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO, CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4224","tubocurarine","acetylcholine receptor antagonist","ACHE, CHRNA2, HTR3A, HTR3B, KCNN1, KCNN2, KCNN3, ZACN","neurology/psychiatry","anesthetic","COc1cc2CC[N+](C)(C)[C@@H]3Cc4ccc(O)c(Oc5cc6[C@H](Cc7ccc(Oc(c1O)c23)cc7)N(C)CCc6cc5OC)c4, COc1cc2CC[N+](C)(C)[C@@H]3Cc4ccc(O)c(Oc5cc6[C@H](Cc7ccc(Oc(c1O)c23)cc7)N(C)CCc6cc5OC)c4, COc1cc2CC[N+](C)(C)[C@@H]3Cc4ccc(O)c(Oc5cc6[C@H](Cc7ccc(Oc(c1O)c23)cc7)N(C)CCc6cc5OC)c4","Launched",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,1,1,0,0,1,1,1,1
"4225","tucatinib","EGFR inhibitor","ERBB2",NA,NA,"Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 |t:14|, Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 |t:14|, Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 |t:14|, Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 |t:14|, Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 |t:14|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4226","TUG-770","free fatty acid receptor agonist","FFAR1",NA,NA,"OC(=O)CCc1ccc(cc1F)C#Cc1ccccc1CC#N","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4227","TUG-891","free fatty acid receptor agonist","FFAR4",NA,NA,"Cc1ccc(cc1)-c1ccc(F)cc1COc1ccc(CCC(O)=O)cc1, Cc1ccc(cc1)-c1ccc(F)cc1COc1ccc(CCC(O)=O)cc1, Cc1ccc(cc1)-c1ccc(F)cc1COc1ccc(CCC(O)=O)cc1, Cc1ccc(cc1)-c1ccc(F)cc1COc1ccc(CCC(O)=O)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4228","tulobuterol","adrenergic receptor agonist","ADRB2","pulmonary","asthma","CC(C)(C)NC[C@H](O)c1ccccc1Cl |&1:6|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"4229","TW-37","BCL inhibitor","BCL2, BCL2L1, MCL1",NA,NA,"CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O, CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O, CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O, CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4230","TWS-119","glycogen synthase kinase inhibitor","GSK3B, JUN, MYC",NA,NA,"Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1, Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1, Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1, Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1, Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4231","TY-52156","sphingosine 1-phosphate receptor antagonist","S1PR3",NA,NA,"CC(C)(C)C(=O)C(Nc1ccc(Cl)cc1)=NNc1ccc(Cl)cc1, CC(C)(C)C(=O)C(Nc1ccc(Cl)cc1)=NNc1ccc(Cl)cc1, CC(C)(C)C(=O)C(Nc1ccc(Cl)cc1)=NNc1ccc(Cl)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4232","tyroserleutide","antitumor agent","PIK3CA","oncology","hepatocellular carcinoma (hcc)","CC(C)C[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4233","tyrphostin-AG-1296","FLT3 inhibitor","FLT3",NA,NA,"COc1cc2ncc(nc2cc1OC)-c1ccccc1, COc1cc2ncc(nc2cc1OC)-c1ccccc1, COc1cc2ncc(nc2cc1OC)-c1ccccc1, COc1cc2ncc(nc2cc1OC)-c1ccccc1, COc1cc2ncc(nc2cc1OC)-c1ccccc1, COc1cc2ncc(nc2cc1OC)-c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4234","tyrphostin-AG-1478","EGFR inhibitor","EGFR, MAPK14",NA,NA,"COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC, COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4235","tyrphostin-AG-18","EGFR inhibitor, tyrosine kinase inhibitor","EGFR",NA,NA,"Oc1ccc(C=C(C#N)C#N)cc1O, Oc1ccc(C=C(C#N)C#N)cc1O, Oc1ccc(C=C(C#N)C#N)cc1O, Oc1ccc(C=C(C#N)C#N)cc1O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4236","tyrphostin-AG-494","EGFR inhibitor","EGFR",NA,NA,"Oc1ccc(\C=C(/C#N)C(=O)Nc2ccccc2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)Nc2ccccc2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)Nc2ccccc2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)Nc2ccccc2)cc1O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4237","tyrphostin-AG-825","protein tyrosine kinase inhibitor","ERBB2",NA,NA,"COc1cc(\C=C(/C#N)C(N)=O)cc(CSc2nc3ccccc3s2)c1O, COc1cc(\C=C(/C#N)C(N)=O)cc(CSc2nc3ccccc3s2)c1O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4238","tyrphostin-AG-835","protein tyrosine kinase inhibitor","EGFR",NA,NA,"C[C@H](NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N)c1ccccc1, C[C@H](NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4239","tyrphostin-AG-879","tyrosine kinase inhibitor","ERBB2, KDR, NTRK1",NA,NA,"CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4240","tyrphostin-AG-99","tyrosine kinase inhibitor","EGFR",NA,NA,"NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N, NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N, NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4241","U-0126","MEK inhibitor","AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1",NA,NA,"Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N, Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N, Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N, Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N, Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N, Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4242","U-0521","catechol O methyltransferase inhibitor","COMT",NA,NA,"CC(C)C(=O)c1ccc(O)c(O)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4243","U-104","carbonic anhydrase inhibitor","CA1, CA12, CA2, CA9",NA,NA,"NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1, NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1, NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1, NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1, NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4244","U-50488-(-)","opioid receptor agonist","OPRK1",NA,NA,"CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4245","U-54494A","opioid receptor agonist","OPRK1",NA,NA,"CN([C@@H]1CCCC[C@@H]1N1CCCC1)C(=O)c1ccc(Cl)c(Cl)c1, CN([C@@H]1CCCC[C@@H]1N1CCCC1)C(=O)c1ccc(Cl)c(Cl)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4246","U-75799E","growth hormone releasing factor agonist","GHSR",NA,NA,"C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O, C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O, C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4247","U-99194","dopamine receptor antagonist","DRD3",NA,NA,"CCCN(CCC)C1Cc2cc(OC)c(OC)cc2C1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0
"4248","UAMC-00039","dipeptidyl peptidase inhibitor","DPP4, DPP7",NA,NA,"N[C@@H](CCNCc1ccc(Cl)cc1)C(=O)N1CCCCC1, N[C@@H](CCNCc1ccc(Cl)cc1)C(=O)N1CCCCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4249","UB-165","acetylcholine receptor agonist","CHRNA3, CHRNA4, CHRNB2",NA,NA,"Clc1ccc(cn1)C1=CCC[C@H]2CC[C@@H]1N2 |&1:11,&2:14,t:8,THB:4:7:12.13:15|, Clc1ccc(cn1)C1=CCC[C@H]2CC[C@@H]1N2 |&1:11,&2:14,t:8,THB:4:7:12.13:15|, Clc1ccc(cn1)C1=CCC[C@H]2CC[C@@H]1N2 |&1:11,&2:14,t:8,THB:4:7:12.13:15|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0
"4250","ubenimex","leukotriene synthesis inhibitor","LTA4H, RNPEP","hematologic malignancy","acute myeloid leukemia (AML)","CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O, CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O, CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O, CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4251","UBP-296","glutamate receptor antagonist","GRIK1",NA,NA,"N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O |&1:1,r|, N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O |&1:1,r|, N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O |&1:1,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4252","UBP-302","glutamate receptor antagonist","GRIK1",NA,NA,"N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O, N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O, N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O, N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4253","UBP-310","glutamate receptor antagonist","GRIK1, GRIK5",NA,NA,"Cc1cn(C[C@H](N)C(O)=O)c(=O)n(Cc2ccsc2C(O)=O)c1=O, Cc1cn(C[C@H](N)C(O)=O)c(=O)n(Cc2ccsc2C(O)=O)c1=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4254","ubrogepant","calcitonin antagonist","CALCRL","neurology/psychiatry","migraine headache","C[C@@H]1[C@@H](C[C@H](NC(=O)c2cnc3C[C@]4(Cc3c2)C(=O)Nc5ncccc45)C(=O)N1CC(F)(F)F)c6ccccc6","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4255","UC-112","XIAP inhibitor","XIAP",NA,NA,"Oc1c(CN2CCCC2)cc(COCc2ccccc2)c2cccnc12, Oc1c(CN2CCCC2)cc(COCc2ccccc2)c2cccnc12, Oc1c(CN2CCCC2)cc(COCc2ccccc2)c2cccnc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4256","UF-010","HDAC inhibitor","HDAC1, HDAC2, HDAC3, HDAC8",NA,NA,"CCCCNNC(=O)c1ccc(Br)cc1, CCCCNNC(=O)c1ccc(Br)cc1, CCCCNNC(=O)c1ccc(Br)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4257","ufenamate","cyclooxygenase inhibitor","PTGS1, PTGS2","dermatology","eczema, dermatitis","CCCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F, CCCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F","Launched",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4258","UH-232-(+)","dopamine receptor antagonist","DRD2, DRD3, DRD4, HTR1A",NA,NA,"CCCN(CCC)[C@@H]1CCc2c(OC)cccc2[C@@H]1C, CCCN(CCC)[C@@H]1CCc2c(OC)cccc2[C@@H]1C","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,3,0,0,0,0,0,0,0,0
"4259","UK-356618","metalloproteinase inhibitor","MMP13, MMP14, MMP2, MMP3, MMP9",NA,NA,"C[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCc1ccc(c(C)c1)-c1ccccc1)CC(=O)NO)C(C)(C)C)c1ccccc1, C[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCc1ccc(c(C)c1)-c1ccccc1)CC(=O)NO)C(C)(C)C)c1ccccc1, C[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCc1ccc(c(C)c1)-c1ccccc1)CC(=O)NO)C(C)(C)C)c1ccccc1, C[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCc1ccc(c(C)c1)-c1ccccc1)CC(=O)NO)C(C)(C)C)c1ccccc1, C[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCc1ccc(c(C)c1)-c1ccccc1)CC(=O)NO)C(C)(C)C)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4260","UK-383367","procollagen C-endopeptidase inhibitor","BMP1",NA,NA,"NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4261","UK-5099","monocarboxylate transporter inhibitor","SLC16A1",NA,NA,"OC(=O)C(=C\c1cn(-c2ccccc2)c2ccccc12)\C#N, OC(=O)C(=C\c1cn(-c2ccccc2)c2ccccc12)\C#N, OC(=O)C(=C\c1cn(-c2ccccc2)c2ccccc12)\C#N","Preclinical",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4262","ulipristal","progesterone receptor antagonist","PGR","endocrinology","contraceptive","CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12 |t:29,36|, CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12 |t:29,36|, CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12 |t:29,36|, CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12 |t:29,36|, CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12 |t:29,36|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4263","umbralisib","casein kinase inhibitor","ABL1, CSNK1E, PIK3CD","hematologic malignancy","non-hodgkin lymphoma (nhl)","CC(C)OC1=C(C=C(C=C1)C2=NN(C3=NC=NC(=C23)N)C(C)C4=C(C(=O)C5=C(O4)C=CC(=C5)F)C6=CC(=CC=C6)F)F","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4264","umeclidinium","acetylcholine receptor antagonist","CHRM1, CHRM2, CHRM3","pulmonary","chronic obstructive pulmonary disease (COPD), bronchitis, emphysema","OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2, OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2, OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2, OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,1,1,1,1
"4265","UNC0224","histone lysine methyltransferase inhibitor","EHMT1, EHMT2",NA,NA,"COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCCN(C)C)N1CCCN(C)CC1, COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCCN(C)C)N1CCCN(C)CC1, COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCCN(C)C)N1CCCN(C)CC1, COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCCN(C)C)N1CCCN(C)CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4266","UNC0321","histone lysine methyltransferase inhibitor","EHMT2",NA,NA,"COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCOCCN(C)C)N1CCCN(C)CC1, COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCOCCN(C)C)N1CCCN(C)CC1, COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCOCCN(C)C)N1CCCN(C)CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4267","UNC0631","histone lysine methyltransferase inhibitor","EHMT2",NA,NA,"COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4268","UNC0638","histone lysine methyltransferase inhibitor","EHMT1, EHMT2",NA,NA,"COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4269","UNC0642","histone lysine methyltransferase inhibitor","EHMT1, EHMT2",NA,NA,"COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4270","UNC0646","histone lysine methyltransferase inhibitor","EHMT2",NA,NA,"COc1cc2c(NC3CCN(CC3)C3CCCCC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC3)C3CCCCC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC3)C3CCCCC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC3)C3CCCCC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4271","UNC0737","histone lysine methyltransferase inhibitor","EHMT1, EHMT2",NA,NA,"COc1cc2c(nc(nc2cc1OCCCN1CCCC1)C1CCCCC1)N(C)C1CCN(CC1)C(C)C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4272","UNC1215","L3MBTL antagonist","L3MBTL3",NA,NA,"O=C(N1CCC(CC1)N1CCCC1)c1ccc(C(=O)N2CCC(CC2)N2CCCC2)c(Nc2ccccc2)c1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(C(=O)N2CCC(CC2)N2CCCC2)c(Nc2ccccc2)c1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(C(=O)N2CCC(CC2)N2CCCC2)c(Nc2ccccc2)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4273","UNC1999","histone lysine methyltransferase inhibitor","EZH2",NA,NA,"CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C, CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C, CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C, CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C, CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C, CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C, CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C, CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4274","UNC2025","FLT3 inhibitor, MER tyrosine kinase inhibitor","FLT3, MERTK",NA,NA,"CCCCNc1ncc2c(cn([C@H]3CC[C@H](O)CC3)c2n1)-c1ccc(CN2CCN(C)CC2)cc1 |r|, CCCCNc1ncc2c(cn([C@H]3CC[C@H](O)CC3)c2n1)-c1ccc(CN2CCN(C)CC2)cc1 |r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4275","UNC2250","MER tyrosine kinase inhibitor","MERTK",NA,NA,"CCCCNc1ncc(c(N[C@H]2CC[C@H](O)CC2)n1)-c1ccc(CN2CCOCC2)cn1 |r|, CCCCNc1ncc(c(N[C@H]2CC[C@H](O)CC2)n1)-c1ccc(CN2CCOCC2)cn1 |r|, CCCCNc1ncc(c(N[C@H]2CC[C@H](O)CC2)n1)-c1ccc(CN2CCOCC2)cn1 |r|, CCCCNc1ncc(c(N[C@H]2CC[C@H](O)CC2)n1)-c1ccc(CN2CCOCC2)cn1 |r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4276","UNC2327","protein arginine N-methyltransferase inhibitor","PRMT3",NA,NA,"O=C(NCC(=O)N1CCCCC1)Nc1ccc2nnsc2c1, O=C(NCC(=O)N1CCCCC1)Nc1ccc2nnsc2c1, O=C(NCC(=O)N1CCCCC1)Nc1ccc2nnsc2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4277","UNC3230","phosphatidyl-inositol activator","PIP5K1C",NA,NA,"NC(=O)c1nc(Nc2ccccc2)sc1NC(=O)C1CCCCC1, NC(=O)c1nc(Nc2ccccc2)sc1NC(=O)C1CCCCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4278","UNC669","L3MBTL antagonist","L3MBTL1",NA,NA,"Brc1cncc(c1)C(=O)N1CCC(CC1)N1CCCC1, Brc1cncc(c1)C(=O)N1CCC(CC1)N1CCCC1, Brc1cncc(c1)C(=O)N1CCC(CC1)N1CCCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4279","UNC926","MBT inhibitor","L3MBTL1",NA,NA,"Brc1cccc(c1)C(=O)N1CCC(CC1)N1CCCC1, Brc1cccc(c1)C(=O)N1CCC(CC1)N1CCCC1, Brc1cccc(c1)C(=O)N1CCC(CC1)N1CCCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4280","UPF-1069","PARP inhibitor","PARP2",NA,NA,"O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1, O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1, O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1, O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1, O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4281","uprosertib","AKT inhibitor","AKT1, AKT2, AKT3",NA,NA,"Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1, Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1, Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1, Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4282","urapidil","adrenergic receptor antagonist","HTR1A","cardiology","hypertension","COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1, COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1, COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1, COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1, COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1, COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1","Launched",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4283","URB597","FAAH inhibitor","FAAH, FAAH2, TRPA1",NA,NA,"NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1, NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1, NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1, NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1, NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1, NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1, NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4284","urea","hydroxy radical formation stimulant","ARG1, CA2, CTNNB1","dermatology","psoriasis, xerosis cutis, ichthyosis vulgaris, eczema, keratosis, dermatitis","NC(N)=O, NC(N)=O, NC(N)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4285","uridine","dopamine receptor agonist","LSM6, TYMP",NA,NA,"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4286","uridine-5'-triphosphate","purinergic receptor activator","P2RY11, P2RY2, P2RY4, P2RY6, UCK2",NA,NA,"O[C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]([C@@H]1O)n1ccc(=O)[nH]c1=O |a:1,2,18,19,&1:5,&2:9|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4287","URMC-099","mixed lineage kinase inhibitor","CDKL2, DAPK3, FLT3, LRRK2, MAP3K10, MAP3K11, MAP3K2, MAP3K9, SRPK2",NA,NA,"CN1CCN(Cc2ccc(cc2)-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)CC1, CN1CCN(Cc2ccc(cc2)-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)CC1, CN1CCN(Cc2ccc(cc2)-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4288","ursodiol","nuclear factor erythroid derived, like (NRF2) activator","AKR1C2, NR1H4","gastroenterology","gallstones","C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4289","ursolic-acid","ATPase inhibitor, NFkB pathway inhibitor, STAT inhibitor","HSD11B1, PLA2G1B, PTPN1, PYGM",NA,NA,"C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|","Phase 2/Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4290","usl311","cc chemokine receptor antagonist","CXCR4","oncology","glioblastoma","CC(C)N1CCC(CC1)N1CCCN(CC1)c1cccc(n1)C(=O)Nc1ccncc1","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4291","usniacin-(+)","MAP kinase activator","PTPN1",NA,NA,"CC(O)=C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@]2(C)C1=O |a:21,&1:3,t:6|, CC(O)=C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O |a:21,&1:3,t:6|, CC(O)=C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O |a:21,&1:3,t:6|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4292","vabicaserin hydrochloride","serotonin receptor agonist","HTR2A, HTR2B, HTR2C","neurology/psychiatry","schizophrenia","[H][C@@]12C3=CC=CC4=C3N(CCNC4)C[C@]1([H])CCC2.Cl","Phase 2",0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4293","valdecoxib","cyclooxygenase inhibitor","CA12, PTGS2",NA,NA,"Cc1onc(c1-c1ccc(cc1)S(N)(=O)=O)-c1ccccc1, Cc1onc(c1-c1ccc(cc1)S(N)(=O)=O)-c1ccccc1, Cc1onc(c1-c1ccc(cc1)S(N)(=O)=O)-c1ccccc1, Cc1onc(c1-c1ccc(cc1)S(N)(=O)=O)-c1ccccc1","Withdrawn",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4294","valethamate","acetylcholine receptor antagonist","CHRM1, CHRM4, CHRM5","obstetrics/gynecology","labor induction","CC[C@@H](C)[C@@H](C(=O)OCC[N+](C)(CC)CC)c1ccccc1 |&1:2,&2:4|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,1,1,1,1
"4295","valproic-acid","benzodiazepine receptor agonist, HDAC inhibitor","ABAT, ACADSB, ALDH5A1, HDAC1, HDAC2, HDAC9, OGDH, SCN10A, SCN11A, SCN1A, SCN1B, SCN2A, SCN2B, SCN3A, SCN3B, SCN4A, SCN4B, SCN5A, SCN7A, SCN8A, SCN9A","neurology/psychiatry","epilepsy, seizures, seizures","CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O","Launched",0,0,1,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4296","valrubicin","DNA inhibitor, topoisomerase inhibitor","TOP2A","oncology","bladder cancer","CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1, CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1, CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1, CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4297","valsartan","angiotensin receptor antagonist","AGTR1","cardiology","hypertension, congestive heart failure, congestive heart failure","CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4298","valspodar","P glycoprotein inhibitor","ABCB1",NA,NA,"C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@@H](NC1=O)C(C)C)C(C)C, C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@@H](NC1=O)C(C)C)C(C)C, C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@@H](NC1=O)C(C)C)C(C)C, C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@@H](NC1=O)C(C)C)C(C)C","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4299","vamorolone","glucocorticoid receptor agonist","DMD, NFKB1, NR3C1","genetics","duchenne muscular dystrophy (dmd)","[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)CC=C1[C@@]2([H])CCC2=CC(=O)C=C[C@]12C |c:15,26,t:22|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4300","vandetanib","EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA","oncology","medullary thyroid cancer (MTC)","COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1, COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1, COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1, COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1, COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1, COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1, COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1, COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4301","vanoxerine","dopamine reuptake inhibitor","SLC6A3",NA,NA,"Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1","Phase 3",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4302","vardenafil","phosphodiesterase inhibitor","PDE5A, PDE6G, PDE6H","urology","erectile dysfunction","CCCc1nc(C)c2n1[nH]c(nc2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC)CC1, CCCc1nc(C)c2n1[nH]c(nc2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC)CC1, CCCc1nc(C)c2n1[nH]c(nc2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC)CC1, CCCc1nc(C)c2n1[nH]c(nc2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC)CC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4303","varenicline","acetylcholine receptor agonist","CHRNA3, CHRNA4, CHRNA6, CHRNA7","neurology/psychiatry","smoking cessation","C1[C@H]2CNC[C@@H]1c1cc3nccnc3cc21 |&1:1,5|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,1,1,1,1
"4304","varespladib","secretory phospholipase inhibitor","PLA2G2A",NA,NA,"CCc1c(C(=O)C(N)=O)c2c(OCC(O)=O)cccc2n1Cc1ccccc1, CCc1c(C(=O)C(N)=O)c2c(OCC(O)=O)cccc2n1Cc1ccccc1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4305","vasopressin","vasopressin receptor agonist","AVPR1A, AVPR1B, AVPR2, OXTR","gastroenterology","abdominal distension","N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4306","vatalanib","KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","EGFR, FLT1, FLT4, KDR, PDGFRB",NA,NA,"Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1, Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1, Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1, Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4307","VBY-825","cathepsin inhibitor","CTSB, CTSL, CTSS",NA,NA,"CC[C@H](NC(=O)[C@H](CS(=O)(=O)CC1CC1)N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)C(=O)NC1CC1, CC[C@H](NC(=O)[C@H](CS(=O)(=O)CC1CC1)N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)C(=O)NC1CC1, CC[C@H](NC(=O)[C@H](CS(=O)(=O)CC1CC1)N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)C(=O)NC1CC1, CC[C@H](NC(=O)[C@H](CS(=O)(=O)CC1CC1)N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)C(=O)NC1CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4308","VE-821","ATR kinase inhibitor","ATR",NA,NA,"CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1, CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1, CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1, CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4309","VE-822","ATR kinase inhibitor","ATM, ATR, MTOR, PIK3CG",NA,NA,"CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4310","vecuronium","acetylcholine receptor antagonist","CHRNA2","neurology/psychiatry","muscle relaxant","CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,1
"4311","vedaprofen","anti-inflammatory agent","PTGS2","neurology/psychiatry, endocrinology","pain relief, fever","C[C@H](C(O)=O)c1ccc(C2CCCCC2)c2ccccc12 |&1:1,r|","Launched",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4312","vedotin","antimitotic agent","TNFRSF10B, TPPP","hematologic malignancy","acute lymphoblastic leukemia (all)","[H][C@]1(CCCN1C(=O)C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@@H](NC)C(C)C)C(C)C)[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4313","veliflapon","leukotriene synthesis inhibitor","ALOX5AP",NA,NA,"OC(=O)[C@H](C1CCCC1)c1ccc(OCc2ccc3ccccc3n2)cc1, OC(=O)[C@H](C1CCCC1)c1ccc(OCc2ccc3ccccc3n2)cc1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4314","veliparib","PARP inhibitor","PARP1, PARP2",NA,NA,"C[C@@]1(CCCN1)c1nc2cccc(C(N)=O)c2[nH]1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4315","velneperit","neuropeptide receptor antagonist","NPY5R",NA,NA,"CC(C)(C)S(=O)(=O)N[C@H]1CC[C@@H](CC1)C(=O)Nc1ccc(cn1)C(F)(F)F |r|, CC(C)(C)S(=O)(=O)N[C@H]1CC[C@@H](CC1)C(=O)Nc1ccc(cn1)C(F)(F)F |r|, CC(C)(C)S(=O)(=O)N[C@H]1CC[C@@H](CC1)C(=O)Nc1ccc(cn1)C(F)(F)F |r|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4316","vemurafenib","RAF inhibitor","BRAF, RAF1","oncology","melanoma","CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4317","venetoclax","BCL inhibitor","BCL2","hematologic malignancy","chronic lymphocytic leukemia (CLL)","CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4318","venlafaxine","adrenergic inhibitor, norepinephrine reuptake inhibitor, serotonin‚Äìnorepinephrine reuptake inhibitor (SNRI)","SLC6A2, SLC6A4","neurology/psychiatry","depression, generalized anxiety disorder (GAD), panic disorders, social anxiety disorder","COc1ccc(cc1)[C@@H](CN(C)C)C1(O)CCCCC1 |&1:8|, COc1ccc(cc1)[C@@H](CN(C)C)C1(O)CCCCC1 |&1:8|, COc1ccc(cc1)[C@@H](CN(C)C)C1(O)CCCCC1 |&1:8|, COc1ccc(cc1)[C@@H](CN(C)C)C1(O)CCCCC1 |&1:8|, COc1ccc(cc1)[C@@H](CN(C)C)C1(O)CCCCC1 |&1:8|","Launched",1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4319","VER-155008","HSP inhibitor","HSPA1A",NA,NA,"Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4320","VER-49009","HSP inhibitor","HSP90AA1",NA,NA,"CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O, CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O, CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O, CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O, CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4321","verapamil","calcium channel blocker","CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CYP3A4, KCNA10, KCNA7, KCNH2, KCNJ11, NALCN, SCN5A, SLC29A4, SLC6A4","cardiology","hypertension","COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC |&1:13|, COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC |&1:13|, COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC |&1:13|, COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC |&1:13|, COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC |&1:13|","Launched",1,2,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4322","vercirnon","CC chemokine receptor antagonist","CCR9",NA,NA,"CC(C)(C)c1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)cc1C(=O)c1cc[n+]([O-])cc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)cc1C(=O)c1cc[n+]([O-])cc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)cc1C(=O)c1cc[n+]([O-])cc1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4323","verinurad","urate transporter inhibitor","SLC22A12",NA,NA,"CC(C)(Sc1ccncc1-c1ccc(C#N)c2ccccc12)C(O)=O, CC(C)(Sc1ccncc1-c1ccc(C#N)c2ccccc12)C(O)=O","Phase 2",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4324","vernakalant","potassium channel blocker","KCNA5","cardiology","atrial fibrillation (AF)","COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC, COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC, COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC, COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4325","verubulin","tubulin polymerization inhibitor","TUBB",NA,NA,"COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12, COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12, COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12, COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12, COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4326","vesamicol","acetylcholinesterase inhibitor","SLC18A3",NA,NA,"O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1, O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1, O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1, O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1, O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1","Preclinical",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4327","vesnarinone","phosphodiesterase inhibitor","KCNH2, PDE3A","cardiology","congestive heart failure","COc1ccc(cc1OC)C(=O)N1CCN(CC1)c1ccc2NC(=O)CCc2c1, COc1ccc(cc1OC)C(=O)N1CCN(CC1)c1ccc2NC(=O)CCc2c1, COc1ccc(cc1OC)C(=O)N1CCN(CC1)c1ccc2NC(=O)CCc2c1, COc1ccc(cc1OC)C(=O)N1CCN(CC1)c1ccc2NC(=O)CCc2c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4328","VGX-1027","tumor necrosis factor receptor antagonist","TLR4",NA,NA,"OC(=O)C[C@H]1CC(=NO1)c1ccccc1 |&1:4,r,c:6|, OC(=O)C[C@H]1CC(=NO1)c1ccccc1 |&1:4,r,c:6|, OC(=O)C[C@H]1CC(=NO1)c1ccccc1 |&1:4,r,c:6|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4329","vicagrel","platelet aggregation inhibitor","P2RY12","cardiology","coronary artery disease (cad)","COC(=O)[C@@H](N1CCc2sc(OC(=O)C)cc2C1)c3ccccc3Cl","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4330","vicriviroc","CC chemokine receptor antagonist","CCR5",NA,NA,"COC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)c1c(C)ncnc1C)c1ccc(cc1)C(F)(F)F, COC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)c1c(C)ncnc1C)c1ccc(cc1)C(F)(F)F, COC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)c1c(C)ncnc1C)c1ccc(cc1)C(F)(F)F","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4331","vidarabine","antiviral","ADA","infectious disease","virus herpes simplex (HSV), varicella-zoster virus (VZV)","Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4332","vigabatrin","GABA aminotransferase inhibitor","ABAT, SLC32A1","neurology/psychiatry","seizures, spasms","N[C@@H](CCC(O)=O)C=C |&1:1|, N[C@@H](CCC(O)=O)C=C |&1:1|, N[C@@H](CCC(O)=O)C=C |&1:1|","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4333","vilanterol","adrenergic receptor agonist","ADRB2","pulmonary","chronic obstructive pulmonary disease (COPD)","OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCOCc2c(Cl)cccc2Cl","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"4334","vilanterol trifenatate","adrenergic receptor agonist","ADRB2","Lung diseases","chronic obstructive pulmonary disease (copd)","OC(=O)C(c1ccccc1)(c1ccccc1)c1ccccc1.OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCOCc1c(Cl)cccc1Cl","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"4335","vilazodone","serotonin reuptake inhibitor","DRD2, DRD3, HRH1, HTR1A, HTR4, SLC6A4","neurology/psychiatry","depression","NC(=O)c1cc2cc(ccc2o1)N1CCN(CCCCc2c[nH]c3ccc(cc23)C#N)CC1, NC(=O)c1cc2cc(ccc2o1)N1CCN(CCCCc2c[nH]c3ccc(cc23)C#N)CC1, NC(=O)c1cc2cc(ccc2o1)N1CCN(CCCCc2c[nH]c3ccc(cc23)C#N)CC1, NC(=O)c1cc2cc(ccc2o1)N1CCN(CCCCc2c[nH]c3ccc(cc23)C#N)CC1, NC(=O)c1cc2cc(ccc2o1)N1CCN(CCCCc2c[nH]c3ccc(cc23)C#N)CC1","Launched",1,1,0,0,0,0,0,0,1,2,1,1,0,0,1,2,0,0,0,0,1,1,1,1
"4336","vildagliptin","dipeptidyl peptidase inhibitor","DPP4","endocrinology","diabetes mellitus","O[C@]12C[C@@H]3C[C@H](C1)C[C@@](C3)(C2)NCC(=O)N1CCC[C@H]1C#N","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4337","viloxazine","norepinephrine reuptake inhibitor","SLC6A2","neurology/psychiatry","depression","CCOc1ccccc1OC[C@H]1CNCCO1 |&1:11|, CCOc1ccccc1OC[C@H]1CNCCO1 |&1:11|, CCOc1ccccc1OC[C@H]1CNCCO1 |&1:11|","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4338","vimirogant","ror antagonist","RORC","neurology/psychiatry","multiple sclerosis","CCS(=O)(=O)c1ccc(CNC(=O)c2cnc3[C@H](C(C)C)N(C[C@@H]4CC[C@H](CC4)C(F)(F)F)Cc3c2)nc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4339","vimseltinib","csf1r inhibitor","CSF1R",NA,NA,"CC(C)Nc1ncc(-c2ccc(Oc3ccnc(c3)-c3cnn(C)c3)c(C)n2)c(=O)n1C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4340","vinblastine","microtubule inhibitor, tubulin polymerization inhibitor","JUN, TUBA1A, TUBB, TUBD1, TUBE1, TUBG1","hematologic malignancy, infectious disease, oncology","Hodgkin's lymphoma, true histiocytic lymphoma (THL), mycosis, small lymphocytic lymphoma (SLL), testicular carcinoma, Kaposi sarcoma","CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4341","vinburnine","adrenergic receptor antagonist","CHRM1, CHRM2, CHRM3, CHRM4","neurology/psychiatry","stroke","CC[C@@]12CCCN3CCc4c([C@H]13)n(C(=O)C2)c1ccccc41, CC[C@@]12CCCN3CCc4c([C@H]13)n(C(=O)C2)c1ccccc41","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,1,1,1,1
"4342","vincamine","adrenergic receptor antagonist","CHRM1, CHRM2, CHRM3, CHRM4",NA,NA,"CC[C@@]12CCCN3CCc4c([C@H]13)n(c1ccccc41)[C@](O)(C2)C(=O)OC, CC[C@@]12CCCN3CCc4c([C@H]13)n(c1ccccc41)[C@@](O)(C2)C(=O)OC","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0
"4343","vincristine","tubulin polymerization inhibitor","TUBA4A, TUBB","hematologic malignancy","acute lymphoblastic leukemia (ALL)","CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4344","vindesine","tubulin polymerization inhibitor","TUBB, TUBB1","oncology","breast cancer, non-small cell lung cancer (NSCLC), melanoma","CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](O)[C@]1(O)C(N)=O |c:48|, CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](O)[C@]1(O)C(N)=O |c:48|, CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](O)[C@]1(O)C(N)=O |c:48|, CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](O)[C@]1(O)C(N)=O |c:48|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4345","vinorelbine","tubulin polymerization inhibitor","TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8","oncology","non-small cell lung cancer (NSCLC)","CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CCC1=C[C@@H]2C[N@](C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:46,t:2|, CCC1=C[C@@H]2C[N@](C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:46,t:2|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4346","vinpocetine","phosphodiesterase inhibitor, sodium channel blocker","PDE1A, PDE1C","neurology/psychiatry","stroke, senile dementia","CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41 |t:5|, CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41 |t:5|, CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41 |t:5|, CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41 |t:5|, CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41 |t:5|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4347","vipadenant","adenosine receptor antagonist","ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,"Cc1cc(Cn2nnc3c(nc(N)nc23)-c2ccco2)ccc1N, Cc1cc(Cn2nnc3c(nc(N)nc23)-c2ccco2)ccc1N, Cc1cc(Cn2nnc3c(nc(N)nc23)-c2ccco2)ccc1N, Cc1cc(Cn2nnc3c(nc(N)nc23)-c2ccco2)ccc1N, Cc1cc(Cn2nnc3c(nc(N)nc23)-c2ccco2)ccc1N","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4348","vipivotide tetraxetan","glutamate carboxypeptidase inhibitor","FOLH1","oncology","prostate cancer","O=C(O)[C@H](CCCCNC([C@H](CC1=CC=C2C=CC=CC2=C1)NC([C@H]3CC[C@H](CNC(CN4CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC4)=O)CC3)=O)=O)NC(N[C@H](C(O)=O)CCC(O)=O)=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4349","vismodegib","hedgehog pathway inhibitor, smoothened receptor antagonist","SMO","oncology","basal cell carcinoma (BCC)","CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(c2)-c2ccccn2)c(Cl)c1, CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(c2)-c2ccccn2)c(Cl)c1, CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(c2)-c2ccccn2)c(Cl)c1, CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(c2)-c2ccccn2)c(Cl)c1, CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(c2)-c2ccccn2)c(Cl)c1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4350","vitamin-E","LDL oxidation inhibitor, PKC inhibitor","ALOX5, DGKA, NR1I2, PPP2CA, PPP2CB, PRKCA, PRKCB, SEC14L2, SEC14L3, SEC14L4",NA,NA,"CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2c(C)c(O)c(C)c(C)c2O1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4351","VLX600","antitumor agent, ubiquitin C-terminal hydrolase inhibitor","TP53, USP14",NA,NA,"CC(=NNc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1, CC(=NNc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1, C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1, C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1, C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1, C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4352","voglibose","glucosidase inhibitor","MGAM","endocrinology","diabetes mellitus, hyperglycemia","OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O, OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O, OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4353","volasertib","PLK inhibitor","PLK1",NA,NA,"CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4354","volinanserin","serotonin receptor antagonist","HTR2A, HTR2B, HTR2C, KCNH2",NA,NA,"COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC, COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC","Phase 3",0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4355","vonoprazan","potassium-competitive acid antagonist","ATP4A","gastroenterology","peptic ulcer disease (PUD)","CNCc1cc(-c2ccccc2F)n(c1)S(=O)(=O)c1cccnc1, CNCc1cc(-c2ccccc2F)n(c1)S(=O)(=O)c1cccnc1, CNCc1cc(-c2ccccc2F)n(c1)S(=O)(=O)c1cccnc1, CNCc1cc(-c2ccccc2F)n(c1)S(=O)(=O)c1cccnc1, CNCc1cc(-c2ccccc2F)n(c1)S(=O)(=O)c1cccnc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4356","vorapaxar","thrombin inhibitor","F2R","cardiology","myocardial infarction, peripheral artery disease (PAD)","CCOC(=O)N[C@@H]1CC[C@@H]2[C@H](C[C@@H]3[C@@H]([C@@H](C)OC3=O)[C@H]2\C=C\c2ccc(cn2)-c2cccc(F)c2)C1, CCOC(=O)N[C@@H]1CC[C@@H]2[C@H](C[C@@H]3[C@@H]([C@@H](C)OC3=O)[C@H]2\C=C\c2ccc(cn2)-c2cccc(F)c2)C1, CCOC(=O)N[C@@H]1CC[C@@H]2[C@H](C[C@@H]3[C@@H]([C@@H](C)OC3=O)[C@H]2\C=C\c2ccc(cn2)-c2cccc(F)c2)C1, CCOC(=O)N[C@@H]1CC[C@@H]2[C@H](C[C@@H]3[C@@H]([C@@H](C)OC3=O)[C@H]2\C=C\c2ccc(cn2)-c2cccc(F)c2)C1, CCOC(=O)N[C@@H]1CC[C@@H]2[C@H](C[C@@H]3[C@@H]([C@@H](C)OC3=O)[C@H]2\C=C\c2ccc(cn2)-c2cccc(F)c2)C1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4357","voreloxin","topoisomerase inhibitor","TOP2A",NA,NA,"CN[C@H]1CN(C[C@@H]1OC)c1ccc2c(n1)n(cc(C(O)=O)c2=O)-c1nccs1, CN[C@H]1CN(C[C@@H]1OC)c1ccc2c(n1)n(cc(C(O)=O)c2=O)-c1nccs1, CN[C@H]1CN(C[C@@H]1OC)c1ccc2c(n1)n(cc(C(O)=O)c2=O)-c1nccs1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4358","voriconazole","cytochrome P450 inhibitor","CYP2C19, CYP2C9, CYP3A4, CYP3A5, PTGS1","infectious disease","esophageal candidiasis, aspergillosis, skin infections","C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F, C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F, C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F, C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F, C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F","Launched",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4359","vorinostat","HDAC inhibitor","HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9","hematologic malignancy","cutaneous T-cell lymphoma (CTCL)","ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4360","vortioxetine","serotonin receptor agonist, serotonin receptor antagonist","HTR1A, HTR1B, HTR2A, HTR2C, HTR3A, HTR5A, HTR6, HTR7, SLC6A4","neurology/psychiatry","depression","Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1, Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1, Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1, Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1, Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1","Launched",1,1,0,0,0,0,0,0,1,8,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4361","voxtalisib","mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA",NA,NA,"CCn1c2nc(N)nc(C)c2cc(-c2cc[nH]n2)c1=O, CCn1c2nc(N)nc(C)c2cc(-c2cc[nH]n2)c1=O, CCn1c2nc(N)nc(C)c2cc(-c2cc[nH]n2)c1=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4362","VP-20629","beta amyloid antagonist","PLA2G2E, SLC36A1",NA,NA,"OC(=O)CCc1c[nH]c2ccccc12, OC(=O)CCc1c[nH]c2ccccc12","Phase 1",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4363","VT-464","cytochrome P450 inhibitor","CYP17A1",NA,NA,"CC(C)[C@@](O)(c1cn[nH]n1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1, CC(C)[C@@](O)(c1cn[nH]n1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1, CC(C)[C@@](O)(c1cn[nH]n1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1, CC(C)[C@@](O)(c1cn[nH]n1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1, CC(C)[C@@](O)(c1cn[nH]n1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4364","VTP-27999","renin inhibitor","REN",NA,NA,"CN[C@H](CNC(=O)N1CCC[C@H](C1)[C@@H](OCCNC(=O)OC)c1cccc(Cl)c1)C[C@H]1CCCOC1, CN[C@H](CNC(=O)N1CCC[C@H](C1)[C@@H](OCCNC(=O)OC)c1cccc(Cl)c1)C[C@H]1CCCOC1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4365","VUF10166","serotonin receptor antagonist","HTR3A, HTR3B",NA,NA,"CN1CCN(CC1)c1nc2ccccc2nc1Cl, CN1CCN(CC1)c1nc2ccccc2nc1Cl","Preclinical",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4366","VUF10460","histamine receptor agonist","HRH4",NA,NA,"CN1CCN(CC1)c1cc(nc(N)n1)-c1ccccc1, CN1CCN(CC1)c1cc(nc(N)n1)-c1ccccc1, CN1CCN(CC1)c1cc(nc(N)n1)-c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
"4367","VUF11207","CC chemokine receptor agonist","ACKR3",NA,NA,"COc1cc(cc(OC)c1OC)C(=O)N(CC[C@H]1CCCN1C)C\C(C)=C\c1ccccc1F |&1:17|, COc1cc(cc(OC)c1OC)C(=O)N(CC[C@H]1CCCN1C)C\C(C)=C\c1ccccc1F |&1:17|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4368","VU0155069","phospholipase inhibitor","PLD1",NA,NA,"C[C@@H](CN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O)NC(=O)c1ccc2ccccc2c1, C[C@@H](CN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O)NC(=O)c1ccc2ccccc2c1, C[C@@H](CN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O)NC(=O)c1ccc2ccccc2c1, C[C@@H](CN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O)NC(=O)c1ccc2ccccc2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4369","VU0238429","acetylcholine receptor allosteric modulator","CHRM5",NA,NA,"COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1, COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1, COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1, COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1, COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1, COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
"4370","VU0240551","potassium/chloride cotransporter inhibitor","SLC12A5",NA,NA,"Cc1csc(NC(=O)CSc2ccc(nn2)-c2ccccc2)n1","Preclinical",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4371","VU0357121","glutamate receptor positive allosteric modulator","GRM5",NA,NA,"CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F, CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F, CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F, CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F, CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F, CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F, CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4372","VU0360172","glutamate receptor positive allosteric modulator","GRM5",NA,NA,"Fc1cccc(c1)C#Cc1ccc(cn1)C(=O)NC1CCC1, Fc1cccc(c1)C#Cc1ccc(cn1)C(=O)NC1CCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4373","VU0361737","glutamate receptor positive allosteric modulator","GRM4",NA,NA,"COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4374","VU0364439","glutamate receptor positive allosteric modulator","GRM4",NA,NA,"Clc1ccccc1NS(=O)(=O)c1ccc(NC(=O)c2ccccn2)cc1Cl, Clc1ccccc1NS(=O)(=O)c1ccc(NC(=O)c2ccccn2)cc1Cl, Clc1ccccc1NS(=O)(=O)c1ccc(NC(=O)c2ccccn2)cc1Cl","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4375","VU0364739","phospholipase inhibitor","PLD2",NA,NA,"Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc3ccccc3c2)CC1, Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc3ccccc3c2)CC1, Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc3ccccc3c2)CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4376","VU0364770","glutamate receptor positive allosteric modulator","GRM4",NA,NA,"Clc1cccc(NC(=O)c2ccccn2)c1, Clc1cccc(NC(=O)c2ccccn2)c1, Clc1cccc(NC(=O)c2ccccn2)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4377","VU0422288","glutamate receptor positive allosteric modulator","GRM3",NA,NA,"Clc1ccc(Oc2ccc(NC(=O)c3ccccn3)cc2Cl)nc1, Clc1ccc(Oc2ccc(NC(=O)c3ccccn3)cc2Cl)nc1, Clc1ccc(Oc2ccc(NC(=O)c3ccccn3)cc2Cl)nc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4378","VU10010","acetylcholine receptor allosteric modulator","CHRM4",NA,NA,"Cc1cc(C)c2c(N)c(sc2n1)C(=O)NCc1ccc(Cl)cc1, Cc1cc(C)c2c(N)c(sc2n1)C(=O)NCc1ccc(Cl)cc1, Cc1cc(C)c2c(N)c(sc2n1)C(=O)NCc1ccc(Cl)cc1, Cc1cc(C)c2c(N)c(sc2n1)C(=O)NCc1ccc(Cl)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
"4379","VU152100","acetylcholine receptor allosteric modulator","CHRM4",NA,NA,"COc1ccc(CNC(=O)c2sc3nc(C)cc(C)c3c2N)cc1, COc1ccc(CNC(=O)c2sc3nc(C)cc(C)c3c2N)cc1, COc1ccc(CNC(=O)c2sc3nc(C)cc(C)c3c2N)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
"4380","VU1545","glutamate receptor positive allosteric modulator","GRM5",NA,NA,"[O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1F)-c1ccccc1, [O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1F)-c1ccccc1, [O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1F)-c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4381","VU29","glutamate receptor potentiator","GRM5",NA,NA,"[O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1)-c1ccccc1, [O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1)-c1ccccc1, [O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1)-c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4382","VU591","potassium channel blocker","KCNJ1",NA,NA,"[O-][N+](=O)c1ccc2nc(COCc3nc4ccc(cc4[nH]3)[N+]([O-])=O)[nH]c2c1, [O-][N+](=O)c1ccc2nc(COCc3nc4ccc(cc4[nH]3)[N+]([O-])=O)[nH]c2c1, [O-][N+](=O)c1ccc2nc(COCc3nc4ccc(cc4[nH]3)[N+]([O-])=O)[nH]c2c1, [O-][N+](=O)c1ccc2nc(COCc3nc4ccc(cc4[nH]3)[N+]([O-])=O)[nH]c2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4383","VX-11e","MAP kinase inhibitor","MAPK1",NA,NA,"Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(c1)C(=O)N[C@H](CO)c1cccc(Cl)c1, Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(c1)C(=O)N[C@H](CO)c1cccc(Cl)c1, Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(c1)C(=O)N[C@H](CO)c1cccc(Cl)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4384","VX-702","p38 MAPK inhibitor","IL1B, IL6, MAPK11, MAPK12, MAPK14, TNF",NA,NA,"NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F, NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F, NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F, NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F, NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F, NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4385","VX-745","p38 MAPK inhibitor","MAPK11, MAPK12, MAPK14",NA,NA,"Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1, Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1, Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1, Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1, Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1, Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1, Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4386","VX-765","caspase inhibitor","CASP1",NA,NA,"CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)c1ccc(N)c(Cl)c1)C(C)(C)C","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4387","W-54011","anaphylatoxin chemotactic receptor antagonist","C5AR1",NA,NA,"COc1ccc2CCC[C@@H](C(=O)N(Cc3ccc(cc3)N(C)C)c3ccc(cc3)C(C)C)c2c1 |&1:9|, COc1ccc2CCC[C@@H](C(=O)N(Cc3ccc(cc3)N(C)C)c3ccc(cc3)C(C)C)c2c1 |&1:9|, COc1ccc2CCC[C@@H](C(=O)N(Cc3ccc(cc3)N(C)C)c3ccc(cc3)C(C)C)c2c1 |&1:9|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4388","warfarin","vitamin K antagonist","VKORC1","hematology, cardiology, hematology, cardiology","deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation (AF), myocardial infarction, deep vein thrombosis (dvt), pulmonary embolism (pe), atrial fibrillation (af), myocardial infarction","CC(=O)C[C@@H](c1ccccc1)c1c(O)c2ccccc2oc1=O |&1:4|, CC(=O)C[C@@H](c1ccccc1)c1c(O)c2ccccc2oc1=O |&1:4|, CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4389","WAY-100635","serotonin receptor antagonist","HTR1A",NA,NA,"COc1ccccc1N1CCN(CCN(C(=O)C2CCCCC2)c2ccccn2)CC1, COc1ccccc1N1CCN(CCN(C(=O)C2CCCCC2)c2ccccn2)CC1, COc1ccccc1N1CCN(CCN(C(=O)C2CCCCC2)c2ccccn2)CC1","Phase 1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4390","WAY-161503","serotonin receptor agonist","HTR2C",NA,NA,"Clc1cc2NC(=O)[C@H]3CNCCN3c2cc1Cl |&1:7|, Clc1cc2NC(=O)[C@H]3CNCCN3c2cc1Cl |&1:7|, Clc1cc2NC(=O)[C@H]3CNCCN3c2cc1Cl |&1:7|, Clc1cc2NC(=O)[C@H]3CNCCN3c2cc1Cl |&1:7|","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4391","WAY-170523","metalloproteinase inhibitor","MMP13",NA,NA,"Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO, Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO, Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO, Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO, Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4392","way-181187","serotonin receptor agonist","HTR2A","neurology/psychiatry","depression","NCCc1cn(c2ccccc12)S(=O)(=O)c1c(Cl)nc2sccn12","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4393","WAY-200070","estrogen receptor agonist","ERBB2, ERBB3, ERBB4, ESR2",NA,NA,"Oc1ccc(cc1)-c1nc2cc(O)cc(Br)c2o1, Oc1ccc(cc1)-c1nc2cc(O)cc(Br)c2o1, Oc1ccc(cc1)-c1nc2cc(O)cc(Br)c2o1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4394","WAY-207024","gonadotropin releasing factor hormone receptor antagonist","GNRHR, HRH2, TACR2",NA,NA,"CC(C)(C)c1ccc(cc1)-c1nc2c(cccc2[nH]1)N1CCN(Cc2ccc3nccnc3c2)CC1, CC(C)(C)c1ccc(cc1)-c1nc2c(cccc2[nH]1)N1CCN(Cc2ccc3nccnc3c2)CC1, CC(C)(C)c1ccc(cc1)-c1nc2c(cccc2[nH]1)N1CCN(Cc2ccc3nccnc3c2)CC1, CC(C)(C)c1ccc(cc1)-c1nc2c(cccc2[nH]1)N1CCN(Cc2ccc3nccnc3c2)CC1, CC(C)(C)c1ccc(cc1)-c1nc2c(cccc2[nH]1)N1CCN(Cc2ccc3nccnc3c2)CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
"4395","WAY-208466","serotonin receptor agonist","DRD2, HTR2A, HTR2C, HTR6, HTR7",NA,NA,"CN(C)CCn1cc(c2cccnc12)S(=O)(=O)c1cccc(F)c1, CN(C)CCn1cc(c2cccnc12)S(=O)(=O)c1cccc(F)c1, CN(C)CCn1cc(c2cccnc12)S(=O)(=O)c1cccc(F)c1","Preclinical",0,0,0,0,0,0,0,0,1,4,0,0,0,0,1,1,0,0,0,0,0,0,0,0
"4396","WAY-213613","glutamate inhibitor","SLC1A2",NA,NA,"N[C@@H](CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(O)=O, N[C@@H](CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(O)=O, N[C@@H](CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(O)=O, N[C@@H](CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(O)=O","Preclinical",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4397","WAY-316606","secreted frizzled related protein inhibitor","SFRP1",NA,NA,"FC(F)(F)c1ccc(cc1S(=O)(=O)NC1CCNCC1)S(=O)(=O)c1ccccc1, FC(F)(F)c1ccc(cc1S(=O)(=O)NC1CCNCC1)S(=O)(=O)c1ccccc1, FC(F)(F)c1ccc(cc1S(=O)(=O)NC1CCNCC1)S(=O)(=O)c1ccccc1, FC(F)(F)c1ccc(cc1S(=O)(=O)NC1CCNCC1)S(=O)(=O)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4398","WAY-362450","FXR agonist","NR1H4",NA,NA,"CC(C)OC(=O)C1=CN(CC(C)(C)c2c1[nH]c1ccccc21)C(=O)c1ccc(F)c(F)c1 |t:6|, CC(C)OC(=O)C1=CN(CC(C)(C)c2c1[nH]c1ccccc21)C(=O)c1ccc(F)c(F)c1 |t:6|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4399","WAY-600","mTOR inhibitor","MTOR",NA,NA,"C(N1CCC(CC1)n1ncc2c(nc(nc12)-c1ccc2[nH]ccc2c1)N1CCOCC1)c1cccnc1, C(N1CCC(CC1)n1ncc2c(nc(nc12)-c1ccc2[nH]ccc2c1)N1CCOCC1)c1cccnc1, C(N1CCC(CC1)n1ncc2c(nc(nc12)-c1ccc2[nH]ccc2c1)N1CCOCC1)c1cccnc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4400","WAY-629","serotonin receptor agonist","HTR2C",NA,NA,"C1CCc2c(C1)n1CCNCc3cccc2c13, C1CCc2c(C1)n1CCNCc3cccc2c13","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4401","WB-4101","adrenergic receptor antagonist","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1A",NA,NA,"COc1cccc(OC)c1OCCNC[C@H]1COc2ccccc2O1 |&1:15|, COc1cccc(OC)c1OCCNC[C@H]1COc2ccccc2O1 |&1:15|, COc1cccc(OC)c1OCCNC[C@H]1COc2ccccc2O1 |&1:15|","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,6,0,0,0,0
"4402","WDR5-0103","histone lysine methyltransferase inhibitor","WDR5",NA,NA,"COC(=O)c1ccc(N2CCN(C)CC2)c(NC(=O)c2cccc(OC)c2)c1, COC(=O)c1ccc(N2CCN(C)CC2)c(NC(=O)c2cccc(OC)c2)c1, COC(=O)c1ccc(N2CCN(C)CC2)c(NC(=O)c2cccc(OC)c2)c1, COC(=O)c1ccc(N2CCN(C)CC2)c(NC(=O)c2cccc(OC)c2)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4403","WH-4-023","SRC inhibitor","LCK, SRC",NA,NA,"COc1ccc(N(C(=O)Oc2c(C)cccc2C)c2ccnc(Nc3ccc(cc3)N3CCN(C)CC3)n2)c(OC)c1, COc1ccc(N(C(=O)Oc2c(C)cccc2C)c2ccnc(Nc3ccc(cc3)N3CCN(C)CC3)n2)c(OC)c1, COc1ccc(N(C(=O)Oc2c(C)cccc2C)c2ccnc(Nc3ccc(cc3)N3CCN(C)CC3)n2)c(OC)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4404","WHI-P154","JAK inhibitor","EGFR, JAK1, JAK2, JAK3",NA,NA,"COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4405","WIKI4","tankyrase inhibitor, WNT pathway inhibitor","TNKS2",NA,NA,"COc1ccc(cc1)-n1c(SCCCN2C(=O)c3cccc4cccc(C2=O)c34)nnc1-c1ccncc1, COc1ccc(cc1)-n1c(SCCCN2C(=O)c3cccc4cccc(C2=O)c34)nnc1-c1ccncc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4406","WIN-18446","aldehyde dehydrogenase inhibitor","ALDH1A2",NA,NA,"ClC(Cl)C(=O)NCCCCCCCCNC(=O)C(Cl)Cl","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4407","WIN-64338","bradykinin receptor antagonist","BDKRB2",NA,NA,"CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1, CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1, CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1, CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1, CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4408","wiskostatin","actin related protein inhibitor, neural Wiskott-Aldrich syndrome protein inhibitor","WASL",NA,NA,"CN(C)C[C@@H](O)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:4,r|, CN(C)C[C@@H](O)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:4,r|, CN(C)C[C@@H](O)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:4,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4409","wnt-c59","porcupine inhibitor","PORCN",NA,NA,"Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1, Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1, Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1, Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1, Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1, Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1, Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1, Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4410","wortmannin","PI3K inhibitor","PI4KA, PI4KB, PIK3CA, PIK3CD, PIK3CG, PIK3R1, PLK1, PRKDC",NA,NA,"COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C([C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O)C3=O |t:16|, COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C([C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O)C3=O |t:16|, COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C([C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O)C3=O |t:16|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4411","WP1066","STAT inhibitor","STAT3",NA,NA,"C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4412","WP1130","deubiquitinase inhibitor","JAK2, UCHL5, USP14, USP9X",NA,NA,"CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4413","WR99210","dihydrofolate reductase inhibitor","TYMS","infectious disease","malaria","CC1(C)N=C(N)N=C(N)N1OCCCOc1cc(Cl)c(Cl)cc1Cl |t:3,6|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4414","WWL-113","carboxylesterase inhibitor","CES3",NA,NA,"CCOC(=O)c1ccc(cc1)-c1ccc(OC(=O)N(C)Cc2cccc(c2)-c2ccncc2)cc1, CCOC(=O)c1ccc(cc1)-c1ccc(OC(=O)N(C)Cc2cccc(c2)-c2ccncc2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4415","WWL-123","monoacylglycerol lipase inhibitor","ABHD6",NA,NA,"CN(Cc1cccc(c1)-c1ccccc1)C(=O)Oc1ccc(cc1)-c1ccc(cc1)C(N)=O, CN(Cc1cccc(c1)-c1ccccc1)C(=O)Oc1ccc(cc1)-c1ccc(cc1)C(N)=O, CN(Cc1cccc(c1)-c1ccccc1)C(=O)Oc1ccc(cc1)-c1ccc(cc1)C(N)=O, CN(Cc1cccc(c1)-c1ccccc1)C(=O)Oc1ccc(cc1)-c1ccc(cc1)C(N)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4416","WYE-125132","mTOR inhibitor","MTOR",NA,NA,"CNC(=O)Nc1ccc(cc1)-c1nc(N2C[C@@H]3CC[C@H](C2)O3)c2cnn(C3CCC4(CC3)OCCO4)c2n1 |&1:16,19|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4417","WYE-354","mTOR inhibitor","MTOR",NA,NA,"COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(CC3)C(=O)OC)c2n1, COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(CC3)C(=O)OC)c2n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4418","WYE-687","mTOR inhibitor","MTOR",NA,NA,"COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(Cc4cccnc4)CC3)c2n1, COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(Cc4cccnc4)CC3)c2n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4419","WZ-3146","EGFR inhibitor","EGFR",NA,NA,"CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Oc3cccc(NC(=O)C=C)c3)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Oc3cccc(NC(=O)C=C)c3)n2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4420","WZ-4002","EGFR inhibitor","EGFR, ERBB2",NA,NA,"COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4421","WZ4003","AMPK inhibitor","NUAK1, NUAK2",NA,NA,"CCC(=O)Nc1cccc(Oc2nc(Nc3ccc(cc3OC)N3CCN(C)CC3)ncc2Cl)c1, CCC(=O)Nc1cccc(Oc2nc(Nc3ccc(cc3OC)N3CCN(C)CC3)ncc2Cl)c1, CCC(=O)Nc1cccc(Oc2nc(Nc3ccc(cc3OC)N3CCN(C)CC3)ncc2Cl)c1, CCC(=O)Nc1cccc(Oc2nc(Nc3ccc(cc3OC)N3CCN(C)CC3)ncc2Cl)c1, CCC(=O)Nc1cccc(Oc2nc(Nc3ccc(cc3OC)N3CCN(C)CC3)ncc2Cl)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4422","WZ8040","EGFR inhibitor","EGFR",NA,NA,"CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Sc3cccc(NC(=O)C=C)c3)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Sc3cccc(NC(=O)C=C)c3)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Sc3cccc(NC(=O)C=C)c3)n2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4423","WZ811","CC chemokine receptor antagonist","CXCR4",NA,NA,"C(Nc1ccccn1)c1ccc(CNc2ccccn2)cc1, C(Nc1ccccn1)c1ccc(CNc2ccccn2)cc1, C(Nc1ccccn1)c1ccc(CNc2ccccn2)cc1, C(Nc1ccccn1)c1ccc(CNc2ccccn2)cc1, C(Nc1ccccn1)c1ccc(CNc2ccccn2)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4424","xaliproden","serotonin receptor agonist","HTR1A",NA,NA,"FC(F)(F)c1cccc(c1)C1=CCN(CCc2ccc3ccccc3c2)CC1 |t:11|, FC(F)(F)c1cccc(c1)C1=CCN(CCc2ccc3ccccc3c2)CC1 |t:11|, FC(F)(F)c1cccc(c1)C1=CCN(CCc2ccc3ccccc3c2)CC1 |t:11|, FC(F)(F)c1cccc(c1)C1=CCN(CCc2ccc3ccccc3c2)CC1 |t:11|","Phase 3",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4425","xamoterol","adrenergic receptor agonist","ADRB1",NA,NA,"OC(CNCCNC(=O)N1CCOCC1)COc1ccc(O)cc1, OC(CNCCNC(=O)N1CCOCC1)COc1ccc(O)cc1, OC(CNCCNC(=O)N1CCOCC1)COc1ccc(O)cc1, OC(CNCCNC(=O)N1CCOCC1)COc1ccc(O)cc1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
"4426","xanomeline","acetylcholine receptor agonist","CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7",NA,NA,"CCCCCCOc1nsnc1C1=CCCN(C)C1 |t:13|, CCCCCCOc1nsnc1C1=CCCN(C)C1 |t:13|, CCCCCCOc1nsnc1C1=CCCN(C)C1 |t:13|","Phase 3",0,0,0,0,0,0,0,0,1,10,0,0,0,0,0,0,1,5,0,0,0,0,0,0
"4427","XAV-939","tankyrase inhibitor","TNKS, TNKS2",NA,NA,"FC(F)(F)c1ccc(cc1)-c1nc(=O)c2CSCCc2[nH]1, FC(F)(F)c1ccc(cc1)-c1nc(=O)c2CSCCc2[nH]1, FC(F)(F)c1ccc(cc1)-c1nc(=O)c2CSCCc2[nH]1, FC(F)(F)c1ccc(cc1)-c1nc(=O)c2CSCCc2[nH]1, FC(F)(F)c1ccc(cc1)-c1nc(=O)c2CSCCc2[nH]1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4428","XBD173","benzodiazepine receptor ligand","TSPO",NA,NA,"CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1, CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1, CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4429","XD-14","bromodomain inhibitor","BRD2, BRD3, BRD4, BRDT",NA,NA,"CCN(CC)S(=O)(=O)c1ccc(O)c(NC(=O)c2[nH]c(C)c(C(C)=O)c2CC)c1, CCN(CC)S(=O)(=O)c1ccc(O)c(NC(=O)c2[nH]c(C)c(C(C)=O)c2CC)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4430","XE-991","potassium channel blocker","KCNQ1, KCNQ2, KCNQ3, KCNQ4, KCNQ5",NA,NA,"O=C1c2ccccc2C(Cc2ccncc2)(Cc2ccncc2)c2ccccc12, O=C1c2ccccc2C(Cc2ccncc2)(Cc2ccncc2)c2ccccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4431","xiliertinib","egfr inhibitor","EGFR, ERBB4","oncology","esophageal cancer","O=C(N1C[C@]2([H])N(C)CC[C@]2([H])C1)NC3=CC4=C(NC5=CC=CC(C#C)=C5)N=CN=C4C=C3OC","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4432","xipamide","carbonic anhydrase inhibitor","SLC12A3","cardiology","edema, hypertension","Cc1cccc(C)c1NC(=O)c1cc(c(Cl)cc1O)S(N)(=O)=O, Cc1cccc(C)c1NC(=O)c1cc(c(Cl)cc1O)S(N)(=O)=O, Cc1cccc(C)c1NC(=O)c1cc(c(Cl)cc1O)S(N)(=O)=O","Launched",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4433","XL019","JAK inhibitor","JAK1, JAK2, JAK3",NA,NA,"O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1, O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1, O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1, O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1, O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1, O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4434","XL147","PI3K inhibitor","PIK3CA, PIK3CD, PIK3CG",NA,NA,"Cc1ccc(cc1)S(=O)(=O)Nc1nc2ccccc2nc1Nc1ccc2nsnc2c1, Cc1ccc(cc1)S(=O)(=O)Nc1nc2ccccc2nc1Nc1ccc2nsnc2c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4435","XL228","Abl kinase inhibitor, insulin growth factor receptor inhibitor, SRC inhibitor","IGF1R, SRC",NA,NA,"CC(C)c1cc(CNc2nc(Nc3cc(n[nH]3)C3CC3)cc(n2)N2CCN(C)CC2)on1, CC(C)c1cc(CNc2nc(Nc3cc(n[nH]3)C3CC3)cc(n2)N2CCN(C)CC2)on1, CC(C)c1cc(CNc2nc(Nc3cc(n[nH]3)C3CC3)cc(n2)N2CCN(C)CC2)on1, CC(C)c1cc(CNc2nc(Nc3cc(n[nH]3)C3CC3)cc(n2)N2CCN(C)CC2)on1, CC(C)c1cc(CNc2nc(Nc3cc(n[nH]3)C3CC3)cc(n2)N2CCN(C)CC2)on1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4436","XL388","mTOR inhibitor","MTOR",NA,NA,"Cc1c(F)c(ccc1C(=O)N1CCOc2ccc(cc2C1)-c1ccc(N)nc1)S(C)(=O)=O, Cc1c(F)c(ccc1C(=O)N1CCOc2ccc(cc2C1)-c1ccc(N)nc1)S(C)(=O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4437","XL647","EGFR inhibitor, VEGFR inhibitor","EGFR, EPHB4, ERBB2, FLT4, KDR",NA,NA,"COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1, COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1, COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1, COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1, COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4438","XMD17-109","MAP kinase inhibitor","MAPK7",NA,NA,"CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C3CCCC3)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1, CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C3CCCC3)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1, CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C3CCCC3)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1, CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C3CCCC3)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1, CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C3CCCC3)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4439","XMD8-92","MAP kinase inhibitor","DCLK2, MAPK7, PLK4, TNK1",NA,NA,"CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCC(O)CC1, CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCC(O)CC1, CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCC(O)CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4440","xylazine","adrenergic receptor agonist","ADRA2A, ADRA2B, ADRA2C","neurology/psychiatry","anesthetic","Cc1cccc(C)c1NC1=NCCCS1 |t:10|, Cc1cccc(C)c1NC1=NCCCS1 |t:10|, Cc1cccc(C)c1NC1=NCCCS1 |t:10|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,1,1,1,1
"4441","xylometazoline","adrenergic receptor agonist","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C","otolaryngology, allergy","nasal congestion, allergic rhinitis","Cc1cc(cc(C)c1CC1=NCCN1)C(C)(C)C |t:10|, Cc1cc(cc(C)c1CC1=NCCN1)C(C)(C)C |t:10|, Cc1cc(cc(C)c1CC1=NCCN1)C(C)(C)C |t:10|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,6,1,1,1,1
"4442","Y-11","focal adhesion kinase inhibitor","PTK2",NA,NA,"OCC[N+]12CN3CN(CN(C3)C1)C2, OCC[N+]12CN3CN(CN(C3)C1)C2","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4443","Y-134","estrogen receptor antagonist","ESR1, ESR2",NA,NA,"CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1, CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1, CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1, CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1, CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4444","Y-26763","potassium channel activator","KCNJ8",NA,NA,"CC(=O)N(O)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N, CC(=O)N(O)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N, CC(=O)N(O)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4445","Y-27152","potassium channel activator","KCNJ8",NA,NA,"CC(=O)N(OCc1ccccc1)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N, CC(=O)N(OCc1ccccc1)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4446","Y-27632","rho associated kinase inhibitor","PKIA, PKN2, PRKACA, PRKCE, ROCK1, ROCK2",NA,NA,"C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4447","Y-29794","prolyl endopeptidase inhibitor","PREP",NA,NA,"CC(C)c1ccc(C(=O)c2cccs2)c(SCCCCCCCCN(C)C)n1, CC(C)c1ccc(C(=O)c2cccs2)c(SCCCCCCCCN(C)C)n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4448","Y-320","interleukin inhibitor","IL17A",NA,NA,"Cc1c(cnn1-c1ccc(Cl)cc1)C(=O)Nc1ccc(N2CCC(CC2)N2CCOCC2)c(c1)C#N, Cc1c(cnn1-c1ccc(Cl)cc1)C(=O)Nc1ccc(N2CCC(CC2)N2CCOCC2)c(c1)C#N","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4449","Y-39983","rho associated kinase inhibitor","ROCK1, ROCK2",NA,NA,"C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12, C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12, C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12, C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12, C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12, C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12, C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4450","YC-1","guanylyl cyclase activator","GUCY1A2, GUCY1A3, GUCY1B3, HIF1A",NA,NA,"OCc1ccc(o1)-c1nn(Cc2ccccc2)c2ccccc12, OCc1ccc(o1)-c1nn(Cc2ccccc2)c2ccccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4451","YIL-781","ghrelin receptor antagonist","GHSR",NA,NA,"CC(C)N1CCC[C@H](Cn2c(C)nc3ccc(Oc4ccc(F)cc4)cc3c2=O)C1, CC(C)N1CCC[C@H](Cn2c(C)nc3ccc(Oc4ccc(F)cc4)cc3c2=O)C1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4452","YK-4-279","apoptosis inhibitor","EWSR1, FLI1",NA,NA,"COc1ccc(cc1)C(=O)C[C@@]1(O)C(=O)Nc2c1c(Cl)ccc2Cl |&1:11,r|, COc1ccc(cc1)C(=O)C[C@@]1(O)C(=O)Nc2c1c(Cl)ccc2Cl |&1:11,r|, COc1ccc(cc1)C(=O)C[C@@]1(O)C(=O)Nc2c1c(Cl)ccc2Cl |&1:11,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4453","YM-022","CCK receptor antagonist","CCKBR",NA,NA,"Cc1cccc(NC(=O)N[C@@H]2N=C(c3ccccc3)c3ccccc3N(CC(=O)c3ccccc3C)C2=O)c1 |t:11|, Cc1cccc(NC(=O)N[C@@H]2N=C(c3ccccc3)c3ccccc3N(CC(=O)c3ccccc3C)C2=O)c1 |t:11|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4454","YM-155","survivin inhibitor","BIRC5",NA,NA,"COCCn1c(C)[n+](Cc2cnccn2)c2c1C(=O)c1ccccc1C2=O, COCCn1c(C)[n+](Cc2cnccn2)c2c1C(=O)c1ccccc1C2=O, COCCn1c(C)[n+](Cc2cnccn2)c2c1C(=O)c1ccccc1C2=O, COCCn1c(C)[n+](Cc2cnccn2)c2c1C(=O)c1ccccc1C2=O, COCCn1c(C)[n+](Cc2cnccn2)c2c1C(=O)c1ccccc1C2=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4455","YM-298198","glutamate receptor antagonist","GRM1",NA,NA,"CN(C1CCCCC1)C(=O)c1sc2nc3ccc(N)cc3n2c1C, CN(C1CCCCC1)C(=O)c1sc2nc3ccc(N)cc3n2c1C, CN(C1CCCCC1)C(=O)c1sc2nc3ccc(N)cc3n2c1C","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4456","YM-298198-desmethyl","glutamate receptor antagonist","GRM1",NA,NA,"Cc1c(sc2nc3ccc(N)cc3n12)C(=O)NC1CCCCC1, Cc1c(sc2nc3ccc(N)cc3n12)C(=O)NC1CCCCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4457","YM-511","aromatase inhibitor","CYP19A1",NA,NA,"Brc1ccc(CN(c2ccc(cc2)C#N)n2cnnc2)cc1, Brc1ccc(CN(c2ccc(cc2)C#N)n2cnnc2)cc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4458","YM-58483","calcium channel blocker","TRPC3, TRPC5, TRPM4",NA,NA,"Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4459","YM-750","ACAT inhibitor","SOAT1",NA,NA,"Cc1cc(C)c(NC(=O)N(Cc2ccc-3c(Cc4ccccc-34)c2)C2CCCCCC2)c(C)c1, Cc1cc(C)c(NC(=O)N(Cc2ccc-3c(Cc4ccccc-34)c2)C2CCCCCC2)c(C)c1, Cc1cc(C)c(NC(=O)N(Cc2ccc-3c(Cc4ccccc-34)c2)C2CCCCCC2)c(C)c1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4460","YM-90709","IL5 inhibitor","CSF2RB, IL5RA",NA,NA,"COc1cc2CC(C)(C)n3c(cc4nc5ccccc5nc34)-c2cc1OC, COc1cc2CC(C)(C)n3c(cc4nc5ccccc5nc34)-c2cc1OC, COc1cc2CC(C)(C)n3c(cc4nc5ccccc5nc34)-c2cc1OC","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4461","YM-976","phosphodiesterase inhibitor","PDE4A",NA,NA,"CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1, CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1, CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1, CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4462","yoda-1","piezo channel activator","PIEZO1",NA,NA,"Clc1cccc(Cl)c1CSc1nnc(s1)-c1cnccn1, Clc1cccc(Cl)c1CSc1nnc(s1)-c1cnccn1, Clc1cccc(Cl)c1CSc1nnc(s1)-c1cnccn1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4463","yohimbine","adrenergic receptor antagonist","ADRA2A, ADRA2B, ADRA2C, DRD2, DRD3, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR7, KCNJ1, KCNJ10, KCNJ11, KCNJ12, KCNJ14, KCNJ15, KCNJ8","cardiology","cardiac arrythmia, bradycardia","COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12, COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12, COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12, COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12, COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12","Launched",0,0,0,0,0,0,0,0,1,10,0,0,0,0,1,2,0,0,1,3,1,1,1,1
"4464","YZ9","phosphofructokinase inhibitor","MIF, PFKFB3",NA,NA,"CCOC(=O)c1cc2ccc(O)cc2oc1=O, CCOC(=O)c1cc2ccc(O)cc2oc1=O, CCOC(=O)c1cc2ccc(O)cc2oc1=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4465","Y16","rho associated kinase inhibitor","RHOA",NA,NA,"Cc1cccc(COc2cccc(\C=C3/C(=O)NN(C3=O)c3ccccc3)c2)c1, Cc1cccc(COc2cccc(\C=C3/C(=O)NN(C3=O)c3ccccc3)c2)c1, Cc1cccc(COc2cccc(\C=C3/C(=O)NN(C3=O)c3ccccc3)c2)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4466","zacopride","serotonin receptor antagonist","HTR3A, HTR3B, HTR4, HTR5A",NA,NA,"COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CN2CCC1CC2 |&1:13,THB:12:13:16.17:19.20|, COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CN2CCC1CC2 |&1:13,THB:12:13:16.17:19.20|, COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CN2CCC1CC2 |&1:13,THB:12:13:16.17:19.20|","Phase 2",0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4467","zafirlukast","leukotriene receptor antagonist","CYSLTR1, CYSLTR2","pulmonary","asthma","COc1cc(ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12)C(=O)NS(=O)(=O)c1ccccc1C, COc1cc(ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12)C(=O)NS(=O)(=O)c1ccccc1C, COc1cc(ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12)C(=O)NS(=O)(=O)c1ccccc1C, COc1cc(ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12)C(=O)NS(=O)(=O)c1ccccc1C","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4468","zaldaride","calmodulin antagonist","CALM1",NA,NA,"C[C@@]1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12 |&1:1|, C[C@@]1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12 |&1:1|, C[C@@]1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12 |&1:1|, C[C@@]1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12 |&1:1|","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4469","zaltidine","histamine receptor antagonist","HRH2",NA,NA,"Cc1nc(c[nH]1)-c1csc(NC(N)=N)n1, Cc1nc(c[nH]1)-c1csc(NC(N)=N)n1, Cc1nc(c[nH]1)-c1csc(NC(N)=N)n1","Phase 3",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
"4470","zamicastat","dopamine beta hydroxylase inhibitor","DBH","pulmonary","pulmonary arterial hypertension (pah)","Fc1cc(F)c2OC[C@@H](Cc2c1)n1c(CCNCc2ccccc2)c[nH]c1=S","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4471","zamifenacin","acetylcholine receptor antagonist","CHRM3",NA,NA,"C(Cc1ccc2OCOc2c1)N1CCC[C@H](C1)OC(c1ccccc1)c1ccccc1, C(Cc1ccc2OCOc2c1)N1CCC[C@H](C1)OC(c1ccccc1)c1ccccc1, C(Cc1ccc2OCOc2c1)N1CCC[C@H](C1)OC(c1ccccc1)c1ccccc1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
"4472","zanamivir","neuraminidase inhibitor","NEU2","infectious disease","influenza A virus infection","CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O |c:10|, CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O |c:10|, CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O |c:10|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4473","zandelisib","pi3k inhibitor","PIK3CD","oncology","non-hodgkin lymphoma (nhl)","CN1CCC(CC1)c1ccccc1CC(C)(C)Nc1nc(nc(n1)-n1c(nc2ccccc12)C(F)F)N1CCOCC1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4474","zaprinast","phosphodiesterase inhibitor","GPR35, PDE1A, PDE4D, PDE5A, PDE9A",NA,NA,"CCCOc1ccccc1-c1nc(=O)c2n[nH]nc2[nH]1, CCCOc1ccccc1-c1nc(=O)c2n[nH]nc2[nH]1, CCCOc1ccccc1-c1nc(=O)c2n[nH]nc2[nH]1, CCCOc1ccccc1-c1nc(=O)c2n[nH]nc2[nH]1, CCCOc1ccccc1-c1nc(=O)c2n[nH]nc2[nH]1, CCCOc1ccccc1-c1nc(=O)c2n[nH]nc2[nH]1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4475","zardaverine","phosphodiesterase inhibitor","PDE4D",NA,NA,"COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4476","zatebradine","HCN channel blocker","HCN1, HCN2, HCN3, HCN4",NA,NA,"COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC, COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC, COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC, COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4477","zaurategrast ethyl ester","integrin antagonist","ITGA4, ITGB7","neurology/psychiatry","multiple sclerosis","O=C(OCC)[C@H](CC1=CC=C(NC2=NC=CC3=C2C=NC=C3)C=C1)NC4=C(Br)C(C45CCCCC5)=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4478","ZCL-278","CDC inhibitor","CDC42",NA,NA,"Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4479","ZD-2079","adrenergic receptor agonist","ADRB3",NA,NA,"O[C@@H](CNCCOc1ccc(CC(O)=O)cc1)c1ccccc1, O[C@@H](CNCCOc1ccc(CC(O)=O)cc1)c1ccccc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
"4480","zd-4190","antitumor agent","EGFR, KDR","oncology","gastric adenocarcinoma","COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCn1ccnn1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4481","ZD-7114","adrenergic receptor agonist","ADRB3",NA,NA,"COCCNC(=O)COc1ccc(OCCNC[C@H](O)COc2ccccc2)cc1, COCCNC(=O)COc1ccc(OCCNC[C@H](O)COc2ccccc2)cc1, COCCNC(=O)COc1ccc(OCCNC[C@H](O)COc2ccccc2)cc1, COCCNC(=O)COc1ccc(OCCNC[C@H](O)COc2ccccc2)cc1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
"4482","ZD-7155","angiotensin receptor antagonist","AGTR1",NA,NA,"CCc1cc2N(Cc3ccc(cc3)-c3ccccc3-c3nn[nH]n3)C(=O)CCc2c(CC)n1, CCc1cc2N(Cc3ccc(cc3)-c3ccccc3-c3nn[nH]n3)C(=O)CCc2c(CC)n1, CCc1cc2N(Cc3ccc(cc3)-c3ccccc3-c3nn[nH]n3)C(=O)CCc2c(CC)n1, CCc1cc2N(Cc3ccc(cc3)-c3ccccc3-c3nn[nH]n3)C(=O)CCc2c(CC)n1, CCc1cc2N(Cc3ccc(cc3)-c3ccccc3-c3nn[nH]n3)C(=O)CCc2c(CC)n1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4483","ZD-7288","HCN channel blocker","HCN1, HCN2, HCN3, HCN4",NA,NA,"CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1, CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1, CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1, CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1, CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1, CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4484","zebularine","DNA methyltransferase inhibitor","CDA, DNMT1",NA,NA,"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cccnc1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cccnc1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cccnc1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cccnc1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cccnc1=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4485","zeranol","estrogen receptor agonist","ACTA2, ESR1, NR1I2, SHBG",NA,NA,"C[C@H]1CCC[C@H](O)CCCCCC2=CC(O)=CC(O)=C2C(=O)O1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4486","zibotentan","endothelin receptor antagonist","EDNRA",NA,NA,"COc1nc(C)cnc1NS(=O)(=O)c1cccnc1-c1ccc(cc1)-c1nnco1, COc1nc(C)cnc1NS(=O)(=O)c1cccnc1-c1ccc(cc1)-c1nnco1, COc1nc(C)cnc1NS(=O)(=O)c1cccnc1-c1ccc(cc1)-c1nnco1, COc1nc(C)cnc1NS(=O)(=O)c1cccnc1-c1ccc(cc1)-c1nnco1","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4487","zidovudine","nucleoside reverse transcriptase inhibitor","TERT","infectious disease","human immunodeficiency virus (HIV-1), acquired immunodeficiency syndrome (AIDS)","Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O, Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O, Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4488","zileuton","leukotriene synthesis inhibitor, lipoxygenase inhibitor","ALOX5","pulmonary","asthma","C[C@@H](N(O)C(N)=O)c1cc2ccccc2s1 |&1:1,r|, C[C@@H](N(O)C(N)=O)c1cc2ccccc2s1 |&1:1,r|, C[C@@H](N(O)C(N)=O)c1cc2ccccc2s1 |&1:1,r|, C[C@@H](N(O)C(N)=O)c1cc2ccccc2s1 |&1:1,r|, C[C@@H](N(O)C(N)=O)c1cc2ccccc2s1 |&1:1,r|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4489","zilpaterol","adrenergic receptor agonist","ADRB2","endocrinology","weight-gain aid","CC(C)N[C@H]1CCn2c3c(cccc3[nH]c2=O)[C@@H]1O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1
"4490","zimelidine","selective serotonin reuptake inhibitor (SSRI)","MAOA, MAOB, SLC6A4",NA,NA,"CN(C)C\C=C(\c1ccc(Br)cc1)c1cccnc1, CN(C)C\C=C(\c1ccc(Br)cc1)c1cccnc1","Withdrawn",1,1,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4491","ziprasidone","dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A4","neurology/psychiatry","schizophrenia, bipolar disorder","Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12, Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12, Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12","Launched",1,1,0,0,0,0,0,0,1,9,1,1,0,0,1,5,1,5,1,5,1,1,1,1
"4492","ZK-164015","estrogen receptor antagonist","ESR1, ESR2",NA,NA,"CCCCCS(=O)(=O)CCCCCCCCCCn1c(c(C)c2cc(O)ccc12)-c1ccc(O)cc1, CCCCCS(=O)(=O)CCCCCCCCCCn1c(c(C)c2cc(O)ccc12)-c1ccc(O)cc1, CCCCCS(=O)(=O)CCCCCCCCCCn1c(c(C)c2cc(O)ccc12)-c1ccc(O)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4493","ZK-811752","CC chemokine receptor antagonist","CCR1",NA,NA,"C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4494","ZK-93423","benzodiazepine receptor agonist","GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2",NA,NA,"CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,1,6,0,0,0,0,0,0,0,0,0,0
"4495","ZK-93426","benzodiazepine receptor antagonist","GABRA1, GABRA2, GABRA3, GABRA5",NA,NA,"CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C, CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C, CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C, CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,0,0
"4496","ZLN024","AMPK activator","PRKAA1, PRKAB1, PRKAG1",NA,NA,"Cc1ccc(OCCSc2ncccn2)c(Br)c1, Cc1ccc(OCCSc2ncccn2)c(Br)c1, Cc1ccc(OCCSc2ncccn2)c(Br)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4497","ZM-241385","adenosine receptor antagonist","ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,"Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1, Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1, Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1, Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1, Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1, Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4498","ZM-306416","Abl kinase inhibitor, SRC inhibitor, VEGFR inhibitor","EGFR, FLT1, FLT4, KDR",NA,NA,"COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC, COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC, COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC, COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC, COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC, COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4499","ZM-323881","VEGFR inhibitor","KDR",NA,NA,"Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O, Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O, Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O, Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O, Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4500","ZM-336372","RAF inhibitor","BRAF, LCK, MAPK14, RAF1",NA,NA,"CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1, CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1, CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1, CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4501","ZM-39923","JAK inhibitor","JAK1, JAK3",NA,NA,"CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1, CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1, CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1, CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1, CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4502","ZM-447439","Aurora kinase inhibitor","AURKA, AURKB",NA,NA,"COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4503","zofenopril-calcium","angiotensin converting enzyme inhibitor","ACE","cardiology","hypertension","C[C@H](CSC(=O)c1ccccc1)C(=O)N1C[C@H](C[C@H]1C(O)=O)Sc1ccccc1, C[C@H](CSC(=O)c1ccccc1)C(=O)N1C[C@H](C[C@H]1C(O)=O)Sc1ccccc1, C[C@H](CSC(=O)c1ccccc1)C(=O)N1C[C@H](C[C@H]1C(O)=O)Sc1ccccc1, C[C@H](CSC(=O)c1ccccc1)C(=O)N1C[C@H](C[C@H]1C(O)=O)Sc1ccccc1, C[C@H](CSC(=O)c1ccccc1)C(=O)N1C[C@H](C[C@H]1C(O)=O)Sc1ccccc1","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4504","zoledronic-acid","bone resorption inhibitor","FDPS, GGPS1","endocrinology","Paget's disease","OC(Cn1ccnc1)(P(O)(O)=O)P(O)(O)=O, OC(Cn1ccnc1)(P(O)(O)=O)P(O)(O)=O, OC(Cn1ccnc1)(P(O)(O)=O)P(O)(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4505","zolmitriptan","serotonin receptor agonist","HTR1A, HTR1B, HTR1D, HTR1E, HTR1F","neurology/psychiatry","migraine headache","CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12, CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12, CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12, CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12","Launched",0,0,0,0,0,0,0,0,1,5,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4506","zomepirac","prostaglandin synthesis inhibitor","PTGDR2",NA,NA,"Cc1cc(CC(O)=O)n(C)c1C(=O)c1ccc(Cl)cc1, Cc1cc(CC(O)=O)n(C)c1C(=O)c1ccc(Cl)cc1, Cc1cc(CC(O)=O)n(C)c1C(=O)c1ccc(Cl)cc1","Withdrawn",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4507","zoniporide","sodium/hydrogen exchanger inhibitor","SLC9A1",NA,NA,"NC(N)=NC(=O)c1cnn(c1C1CC1)-c1cccc2ncccc12, NC(N)=NC(=O)c1cnn(c1C1CC1)-c1cccc2ncccc12","Phase 3",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4508","zonisamide","sodium channel blocker, T-type calcium channel blocker","CA1, CA10, CA11, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA8, CA9, CACNA1G, CACNA1H, CACNA1I, MAOA, MAOB, SCN10A, SCN11A, SCN1A, SCN1B, SCN2A, SCN2B, SCN3A, SCN3B, SCN4A, SCN4B, SCN5A, SCN7A, SCN8A, SCN9A","neurology/psychiatry","seizures, epilepsy","NS(=O)(=O)Cc1noc2ccccc12, NS(=O)(=O)Cc1noc2ccccc12, NS(=O)(=O)Cc1noc2ccccc12, NS(=O)(=O)Cc1noc2ccccc12, NS(=O)(=O)Cc1noc2ccccc12","Launched",0,0,1,14,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4509","zosuquidar","P glycoprotein inhibitor","ABCB1, ABCB4",NA,NA,"O[C@@H](COc1cccc2ncccc12)CN1CCN(CC1)[C@@H]1c2ccccc2[C@@H]2[C@H](c3ccccc13)C2(F)F, O[C@@H](COc1cccc2ncccc12)CN1CCN(CC1)[C@@H]1c2ccccc2[C@@H]2[C@H](c3ccccc13)C2(F)F","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4510","zotarolimus","mTOR inhibitor","FKBP1A","cardiology","coronary artery restenosis","CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1n1cnnn1 |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1n1cnnn1 |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1n1cnnn1 |c:14,33,t:29,31|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4511","zotatifin","eukaryotic translation initiation factor inhibitor","EIF4A1",NA,NA,"COc1cc2O[C@]3([C@@H]([C@@H](CN(C)C)[C@@H](O)[C@@]3(O)c2c(OC)n1)c4ccccc4)c5ccc(cc5)C#N","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4512","zotepine","dopamine receptor antagonist, serotonin receptor antagonist","ADRA2B, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR6, HTR7, SLC6A2, SLC6A4","neurology/psychiatry","schizophrenia","CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc12 |t:6|, CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc12 |t:6|, CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc12 |t:6|, CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc12 |t:6|","Launched",1,2,0,0,0,0,0,0,1,8,1,1,0,0,1,3,0,0,1,1,1,1,1,1
"4513","ZSTK-474","PI3K inhibitor","PIK3CB, PIK3CD, PIK3CG",NA,NA,"FC(F)c1nc2ccccc2n1-c1nc(nc(n1)N1CCOCC1)N1CCOCC1, FC(F)c1nc2ccccc2n1-c1nc(nc(n1)N1CCOCC1)N1CCOCC1","Phase 1/Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4514","zuclopenthixol","dopamine receptor antagonist","ADRA1A, ADRA2A, DRD1, DRD2, DRD5, HRH1, HTR2A","neurology/psychiatry","schizophrenia, bipolar disorder","OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(Cl)cc23)CC1, OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(Cl)cc23)CC1, OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(Cl)cc23)CC1","Launched",0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,3,0,0,1,2,1,1,1,1
"4515","Z160","N-type calcium channel blocker","CACNA2D1",NA,NA,"O=C(CC(c1ccccc1)c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1, O=C(CC(c1ccccc1)c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1, O=C(CC(c1ccccc1)c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4516","1,2,3,4,5,6-hexabromocyclohexane","JAK inhibitor","JAK2",NA,NA,"BrC1C(Br)C(Br)C(Br)C(Br)C1Br, BrC1C(Br)C(Br)C(Br)C(Br)C1Br, BrC1C(Br)C(Br)C(Br)C(Br)C1Br","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4517","1,4-butanediol","benzodiazepine receptor agonist, gamma hydroxybutyric acid agonist","MAN1B1, PLA2G2A, PLA2G2E",NA,NA,"OCCCCO","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4518","1-azakenpaullone","glycogen synthase kinase inhibitor","CCNB1, CDK1, CDK5, GSK3B",NA,NA,"Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4519","1-deoxymannojirimycin","alpha mannosidase inhibitor","MAN2A1",NA,NA,"OC[C@H]1NC[C@@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1NC[C@@H](O)[C@@H](O)[C@@H]1O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4520","1-EBIO","potassium channel activator","KCNN1, KCNN2, KCNN3, KCNN4",NA,NA,"CCn1c2ccccc2[nH]c1=O, CCn1c2ccccc2[nH]c1=O, CCn1c2ccccc2[nH]c1=O, CCn1c2ccccc2[nH]c1=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4521","1-hexadecanal","sphingosine 1-phosphate receptor substrate","DBI, RHO",NA,NA,"CCCCCCCCCCCCCCCC=O, CCCCCCCCCCCCCCCC=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4522","1-naphthyl-PP1","SRC inhibitor","SRC",NA,NA,"CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12, CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12, CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12, CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12, CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12, CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4523","1-phenylbiguanide","serotonin receptor agonist","HTR3A, HTR3B",NA,NA,"NC(N)=NC(=N)Nc1ccccc1, NC(N)=NC(=N)Nc1ccccc1","Preclinical",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4524","10-DEBC","AKT inhibitor","PIM1",NA,NA,"CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc12, CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc12, CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc12, CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4525","10-hydroxycamptothecin","topoisomerase inhibitor","TOP1",NA,NA,"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4526","12-O-tetradecanoylphorbol-13-acetate","PKC activator","KCNT2, TRPV4",NA,NA,"CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33,t:22|, CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33,t:22|, CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33,t:22|, CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33,t:22|, CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33,t:22|, CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33,t:22|, CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33,t:22|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4527","1400W","nitric oxide synthase inhibitor","NOS1, NOS2, NOS3",NA,NA,"CC(=N)NCc1cccc(CN)c1, CC(=N)NCc1cccc(CN)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4528","16,16-dimethylprostaglandin-e2","prostanoid receptor agonist","HPGD",NA,NA,"CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O, CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O, CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4529","17-hydroxyprogesterone-caproate","progesterone receptor agonist","AR, ESR1, ESR2, NR1H4, NR1I2, NR3C1, PGR","obstetrics/gynecology","spontaneous preterm birth","CCCCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:15|","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4530","2'-MeCCPA","adenosine receptor agonist","ADORA1",NA,NA,"C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12, C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12, C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12, C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12, C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4531","2,3-DCPE","BCL-XL downregulator","BCL2L1",NA,NA,"OCCNCCCOc1cccc(Cl)c1Cl, OCCNCCCOc1cccc(Cl)c1Cl, OCCNCCCOc1cccc(Cl)c1Cl, OCCNCCCOc1cccc(Cl)c1Cl","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4532","2,4-dinitrochlorobenzene","thioredoxin inhibitor","TXN",NA,NA,"[O-][N+](=O)c1ccc(Cl)c(c1)[N+]([O-])=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4533","2,4-dinitrophenol","ATP synthase inhibitor","APP",NA,NA,"Oc1ccc(cc1[N+]([O-])=O)[N+]([O-])=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4534","2,5-furandimethanol","hemoglobin modulator","HBB",NA,NA,"OCc1ccc(CO)o1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4535","2-(3-mercaptopropyl)pentanedioic-acid","glutamate carboxypeptidase inhibitor","FOLH1",NA,NA,"OC(=O)CC[C@@H](CCCS)C(O)=O |&1:5,r|, OC(=O)CC[C@@H](CCCS)C(O)=O |&1:5,r|, OC(=O)CC[C@@H](CCCS)C(O)=O |&1:5,r|","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4536","2-[1-(4-piperonyl)piperazinyl]benzothiazole","serotonin receptor agonist","HTR4",NA,NA,"C(N1CCN(CC1)c1nc2ccccc2s1)c1ccc2OCOc2c1, C(N1CCN(CC1)c1nc2ccccc2s1)c1ccc2OCOc2c1","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4537","2-aminobenzenesulfonamide","carbonic anhydrase inhibitor","CA12, CA14, CA2, CA6, CA9",NA,NA,"Nc1ccccc1S(N)(=O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4538","2-APB","1,4,5-trisphosphate inhibitor","TRPC1, TRPC3, TRPC4, TRPC5, TRPC6, TRPC7, TRPM2, TRPM3, TRPM6, TRPV1, TRPV6",NA,NA,"NCCOB(c1ccccc1)c1ccccc1, NCCOB(c1ccccc1)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4539","2-BFI","imidazoline receptor ligand","ADRA2A, ADRA2B, ADRA2C, MAOA, MAOB",NA,NA,"C1CN=C(N1)c1cc2ccccc2o1 |c:2|","Preclinical",0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0
"4540","2-chloro-N6-cyclopentyladenosine","adenosine receptor agonist","ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)nc(Cl)nc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)nc(Cl)nc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)nc(Cl)nc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)nc(Cl)nc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4541","2-chloroadenosine","adenosine receptor agonist","ADORA1, ADORA2A, ADORA2B",NA,NA,"Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4542","2-CMDO","dopamine receptor antagonist","DRD2, DRD4",NA,NA,"CN1CCN(CC1)C1=Cc2ccccc2Oc2ccc(Cl)cc12 |t:8|, CN1CCN(CC1)C1=Cc2ccccc2Oc2ccc(Cl)cc12 |t:8|, CN1CCN(CC1)C1=Cc2ccccc2Oc2ccc(Cl)cc12 |t:8|, CN1CCN(CC1)C1=Cc2ccccc2Oc2ccc(Cl)cc12 |t:8|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0
"4543","2-deoxyglucose","glycolysis inhibitor","SLC2A1, SLC2A2, SLC2A3, SLC2A4",NA,NA,"OC[C@H]1O[C@H](O)C[C@@H](O)[C@@H]1O, OC[C@H]1O[C@H](O)C[C@@H](O)[C@@H]1O, OC[C@H]1O[C@H](O)C[C@@H](O)[C@@H]1O","Phase 2",1,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4544","2-hydroxyflutamide","androgen receptor antagonist","AR",NA,NA,"CC(C)(O)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)(O)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)(O)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4545","2-hydroxysaclofen","GABA receptor antagonist","GABBR1, GABBR2",NA,NA,"NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4546","2-iminobiotin","nitric oxide synthase inhibitor","NOS1, NOS2",NA,NA,"NC1=N[C@H]2CS[C@@H](CCCCC(O)=O)[C@H]2N1 |t:1|, NC1=N[C@H]2CS[C@@H](CCCCC(O)=O)[C@H]2N1 |t:1|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4547","2-iodomelatonin","melatonin receptor agonist","MTNR1A, MTNR1B, NQO2",NA,NA,"COc1ccc2[nH]c(I)c(CCNC(C)=O)c2c1, COc1ccc2[nH]c(I)c(CCNC(C)=O)c2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4548","2-methoxyestradiol","hypoxia inducible factor inhibitor","COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB",NA,NA,"COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4549","2-methyl-5-hydroxytryptamine","serotonin receptor agonist","HTR1B, HTR1D, HTR1E, HTR1F, HTR3A, HTR3B, HTR6",NA,NA,"Cc1[nH]c2ccc(O)cc2c1CCN, Cc1[nH]c2ccc(O)cc2c1CCN, Cc1[nH]c2ccc(O)cc2c1CCN","Preclinical",0,0,0,0,0,0,0,0,1,7,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4550","2-oleoylglycerol","glucose dependent insulinotropic receptor ligand","GPR119",NA,NA,"CCCCCCCC\C=C/CCCCCCCC(=O)OC(CO)CO, CCCCCCCC\C=C/CCCCCCCC(=O)OC(CO)CO, CCCCCCCC\C=C/CCCCCCCC(=O)OC(CO)CO","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4551","2-oxopropanoate","pyruvate dehydrogenase kinase inhibitor","ABAT",NA,NA,"OC(=C)C(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4552","2-phenylmelatonin","melatonin receptor agonist","MTNR1A, MTNR1B",NA,NA,"COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1, COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1, COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1, COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1, COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4553","2-PMDQ","adrenergic receptor antagonist","ADRA1A",NA,NA,"O=C1Nc2ccccc2C2=N[C@@H](CN3CCN(CC3)c3ccccc3)CN12 |&1:11,r,t:10|, O=C1Nc2ccccc2C2=N[C@@H](CN3CCN(CC3)c3ccccc3)CN12 |&1:11,r,t:10|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
"4554","2-pyridylethylamine","histamine receptor agonist","HRH1",NA,NA,"NCCc1ccccn1, NCCc1ccccn1, NCCc1ccccn1","Preclinical",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
"4555","2-TEDC","lipoxygenase inhibitor","ALOX12",NA,NA,"Oc1ccc(\C=C(/C#N)C(=O)OCCc2cccs2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)OCCc2cccs2)cc1O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4556","3'-fluorobenzylspiperone","dopamine receptor ligand","DRD2",NA,NA,"Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1, Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1, Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1, Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0
"4557","3,3'-dichlorobenzaldazine","glutamate receptor modulator","GRM5",NA,NA,"Clc1cccc(\C=N\N=C\c2cccc(Cl)c2)c1, Clc1cccc(\C=N\N=C\c2cccc(Cl)c2)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4558","3,3'-diindolylmethane","CHK inhibitor, cytochrome P450 activator, indoleamine 2,3-dioxygenase inhibitor","AR, HIF1A, IFNG, PI3",NA,NA,"C(c1c[nH]c2ccccc12)c1c[nH]c2ccccc12, C(c1c[nH]c2ccccc12)c1c[nH]c2ccccc12, C(c1c[nH]c2ccccc12)c1c[nH]c2ccccc12, C(c1c[nH]c2ccccc12)c1c[nH]c2ccccc12","Phase 3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4559","3,4-DCPG-(+/-)","glutamate receptor agonist","GRM8",NA,NA,"N[C@@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O |&1:1,r|, N[C@@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O |&1:1,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4560","3,4-DCPG-(S)","glutamate receptor agonist","GRM8",NA,NA,"N[C@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O, N[C@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O, N[C@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4561","3,4-methylenedioxy-beta-nitrostyrene","SRC inhibitor, SYK inhibitor","SRC, SYK",NA,NA,"[O-][N+](=O)\C=C\c1ccc2OCOc2c1, [O-][N+](=O)\C=C\c1ccc2OCOc2c1, [O-][N+](=O)\C=C\c1ccc2OCOc2c1, [O-][N+](=O)\C=C\c1ccc2OCOc2c1, [O-][N+](=O)\C=C\c1ccc2OCOc2c1, [O-][N+](=O)\C=C\c1ccc2OCOc2c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4562","3,5-DHPG-(S)","glutamate receptor agonist","GRM1",NA,NA,"N[C@H](C(O)=O)c1cc(O)cc(O)c1, N[C@H](C(O)=O)c1cc(O)cc(O)c1, N[C@H](C(O)=O)c1cc(O)cc(O)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4563","3-alpha-bis-(4-fluorophenyl)-methoxytropane","dopamine uptake inhibitor","CHRM1, SLC6A2, SLC6A3, SLC6A4",NA,NA,"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccc(F)cc1)c1ccc(F)cc1 |&1:2,5,7|","Preclinical",1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
"4564","3-amino-benzamide","PARP inhibitor","PARP1",NA,NA,"NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4565","3-AQC","serotonin receptor agonist","HTR3A",NA,NA,"C=CCN1CCN(CC1)c1nc2ccccc2nc1C#N, C=CCN1CCN(CC1)c1nc2ccccc2nc1C#N, C=CCN1CCN(CC1)c1nc2ccccc2nc1C#N","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4566","3-bromo-7-nitroindazole","nitric oxide synthase inhibitor","NOS1, NOS2, NOS3",NA,NA,"[O-][N+](=O)c1cccc2c(Br)[nH]nc12, [O-][N+](=O)c1cccc2c(Br)[nH]nc12, [O-][N+](=O)c1cccc2c(Br)[nH]nc12, [O-][N+](=O)c1cccc2c(Br)[nH]nc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4567","3-bromopyruvate","hexokinase inhibitor","HK2",NA,NA,"OC(=O)C(O)=CBr, OC(=O)C(O)=CBr, OC(=O)C(O)=CBr, OC(=O)C(O)=CBr","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4568","3-carboxy-4-hydroxyphenylglycine-(R)","glutamate receptor antagonist","GRIN1, GRIN2A, GRIN2B, GRIN2C",NA,NA,"N[C@@H](C(O)=O)c1ccc(O)c(c1)C(O)=O, N[C@@H](C(O)=O)c1ccc(O)c(c1)C(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4569","3-carboxy-4-hydroxyphenylglycine-(S)","glutamate receptor antagonist","GRM1, GRM5",NA,NA,"N[C@H](C(O)=O)c1ccc(O)c(c1)C(O)=O, N[C@H](C(O)=O)c1ccc(O)c(c1)C(O)=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4570","3-deazaadenosine","adenosylhomocysteinase inhibitor","AHCY",NA,NA,"Nc1nccc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O |a:10,12,&1:15,&2:17|, Nc1nccc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O |a:10,12,&1:15,&2:17|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4571","3-deazaadenosine (hydrochloride)","adenosylhomocysteinase inhibitor","AHCY","Immunology","rheumatoid arthritis","Nc1nccc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4572","3-deazaneplanocin-A","histone lysine methyltransferase inhibitor","EZH2",NA,NA,"Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O |t:13|, Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O |t:13|, Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O |t:13|, Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O |t:13|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4573","3-MATIDA","glutamate receptor antagonist","GRM1",NA,NA,"Cc1cc(sc1[C@@H](N)C(O)=O)C(O)=O |&1:6,r|, Cc1cc(sc1[C@@H](N)C(O)=O)C(O)=O |&1:6,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4574","3-methyl-GABA","GABA aminotransferase activator","ABAT",NA,NA,"C[C@@H](CN)CC(O)=O |&1:1|, C[C@@H](CN)CC(O)=O |&1:1|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4575","3-methyladenine","PI3K inhibitor","PI3",NA,NA,"Cn1cnc(=N)c2[nH]cnc12, Cn1cnc(=N)c2[nH]cnc12, Cn1cnc(=N)c2[nH]cnc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4576","3-MPPI","adrenergic receptor ligand","ADRA1A",NA,NA,"COc1ccccc1N1CCN(CCn2c(=O)[nH]c3c4ccccc4[nH]c3c2=O)CC1, COc1ccccc1N1CCN(CCn2c(=O)[nH]c3c4ccccc4[nH]c3c2=O)CC1, COc1ccccc1N1CCN(CCn2c(=O)[nH]c3c4ccccc4[nH]c3c2=O)CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
"4577","3PO","phosphofructokinase inhibitor","PFKFB3",NA,NA,"O=C(\C=C\c1cccnc1)c1ccncc1, O=C(\C=C\c1cccnc1)c1ccncc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4578","4,5,6,7-tetrabromobenzotriazole","casein kinase inhibitor","AKT1, CHEK1, CSNK2A1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SGK1",NA,NA,"Brc1c(Br)c(Br)c2n[nH]nc2c1Br, Brc1c(Br)c(Br)c2n[nH]nc2c1Br, Brc1c(Br)c(Br)c2n[nH]nc2c1Br, Brc1c(Br)c(Br)c2n[nH]nc2c1Br","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4579","4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine","serotonin receptor antagonist","HTR2A",NA,NA,"Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1","Preclinical",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4580","4-carboxy-3-hydroxyphenylglycine-(RS)","glutamate receptor agonist, glutamate receptor antagonist","GRM1",NA,NA,"N[C@@H](C(O)=O)c1ccc(C(O)=O)c(O)c1 |&1:1,r|, N[C@@H](C(O)=O)c1ccc(C(O)=O)c(O)c1 |&1:1,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4581","4-carboxy-3-hydroxyphenylglycine-(S)","glutamate receptor agonist, glutamate receptor antagonist","GRM1, GRM2",NA,NA,"N[C@H](C(O)=O)c1ccc(C(O)=O)c(O)c1, N[C@H](C(O)=O)c1ccc(C(O)=O)c(O)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4582","4-chlorophenylguanidine","urokinase inhibitor","PLAUR",NA,NA,"NC(=N)Nc1ccc(Cl)cc1, NC(=N)Nc1ccc(Cl)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4583","4-CMTB","free fatty acid receptor agonist","FFAR2",NA,NA,"CC(C)[C@@H](C(=O)Nc1nccs1)c1ccc(Cl)cc1 |&1:3,r|, CC(C)[C@@H](C(=O)Nc1nccs1)c1ccc(Cl)cc1 |&1:3,r|, CC(C)[C@@H](C(=O)Nc1nccs1)c1ccc(Cl)cc1 |&1:3,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4584","4-cpa","pesticide","DPP9",NA,NA,"OC(=O)COc1ccc(Cl)cc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4585","4-DAMP","cholinergic receptor antagonist","CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",NA,NA,"C[N+]1(C)CCC(CC1)OC(=O)C(c1ccccc1)c1ccccc1, C[N+]1(C)CCC(CC1)OC(=O)C(c1ccccc1)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,5,0,0,0,0,0,0
"4586","4-HQN","PARP inhibitor","PARP1",NA,NA,"O=c1nc[nH]c2ccccc12, O=c1nc[nH]c2ccccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4587","4-IBP","sigma receptor agonist","SIGMAR1",NA,NA,"Ic1ccc(cc1)C(=O)NC1CCN(Cc2ccccc2)CC1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4588","4-iodo-6-phenylpyrimidine","macrophage migration inhibiting factor inhibitor","MIF",NA,NA,"Ic1cc(ncn1)-c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4589","4-methylgenistein","protein tyrosine kinase inhibitor","CYP19A1, ESRRA, ESRRB, ESRRG, FASN",NA,NA,"COc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4590","4-methylhistamine","histamine receptor agonist","HRH4",NA,NA,"Cc1nc[nH]c1CCN","Preclinical",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
"4591","4-mu-8C","IRE1 inhibitor","ERN1",NA,NA,"Cc1cc(=O)oc2c(C=O)c(O)ccc12, Cc1cc(=O)oc2c(C=O)c(O)ccc12, Cc1cc(=O)oc2c(C=O)c(O)ccc12, Cc1cc(=O)oc2c(C=O)c(O)ccc12, Cc1cc(=O)oc2c(C=O)c(O)ccc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4592","4-P-PDOT","melatonin receptor antagonist","MTNR1A, MTNR1B",NA,NA,"CCC(=O)N[C@H]1C[C@@H](c2ccccc2)c2ccccc2C1 |&1:5,7|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4593","4-PPBP","sigma receptor ligand","SIGMAR1",NA,NA,"C(CCc1ccccc1)CN1CCC(CC1)c1ccccc1, C(CCc1ccccc1)CN1CCC(CC1)c1ccccc1, C(CCc1ccccc1)CN1CCC(CC1)c1ccccc1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4594","4BP-TQS","nicotinic receptor agonist","CHRNA7",NA,NA,"NS(=O)(=O)c1ccc2N[C@@H]([C@H]3CC=C[C@@H]3c2c1)c1ccc(Br)cc1 |&1:9,&2:10,&3:14,r,c:12|, NS(=O)(=O)c1ccc2N[C@@H]([C@H]3CC=C[C@@H]3c2c1)c1ccc(Br)cc1 |&1:9,&2:10,&3:14,r,c:12|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
"4595","4EGI-1","protein synthesis inhibitor","EIF4E",NA,NA,"OC(=O)C(Cc1ccccc1[N+]([O-])=O)=NNc1nc(cs1)-c1ccc(Cl)c(Cl)c1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4596","4E1RCat","protein synthesis inhibitor","EIF4E, EIF4G1",NA,NA,"OC(=O)c1ccc(cc1)N1C(=O)\C(=C\c2ccc(o2)-c2ccc(cc2)[N+]([O-])=O)C=C1c1ccccc1 |c:31|, OC(=O)c1ccc(cc1)N1C(=O)\C(=C\c2ccc(o2)-c2ccc(cc2)[N+]([O-])=O)C=C1c1ccccc1 |c:31|, OC(=O)c1ccc(cc1)N1C(=O)\C(=C\c2ccc(o2)-c2ccc(cc2)[N+]([O-])=O)C=C1c1ccccc1 |c:31|, OC(=O)c1ccc(cc1)N1C(=O)\C(=C\c2ccc(o2)-c2ccc(cc2)[N+]([O-])=O)C=C1c1ccccc1 |c:31|, OC(=O)c1ccc(cc1)N1C(=O)\C(=C\c2ccc(o2)-c2ccc(cc2)[N+]([O-])=O)C=C1c1ccccc1 |c:31|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4597","4SC-202","HDAC inhibitor","HDAC1",NA,NA,"Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4598","5'-chloro-5'-deoxy-ENBA-(+/-)","adenosine receptor agonist","ADORA1",NA,NA,"O[C@@H]1[C@@H](CCl)O[C@H]([C@@H]1O)n1cnc2c(N[C@H]3C[C@@H]4CC[C@H]3C4)ncnc12 |a:1,2,6,7,&1:17,20,&2:15|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4599","5,7-dichlorokynurenic-acid","glutamate receptor antagonist","GLRA2, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,"OC(=O)c1cc(=O)c2c(Cl)cc(Cl)cc2[nH]1, OC(=O)c1cc(=O)c2c(Cl)cc(Cl)cc2[nH]1, OC(=O)c1cc(=O)c2c(Cl)cc(Cl)cc2[nH]1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4600","5-aminolevulinic-acid","oxidizing agent","ALAD","oncology, dermatology","glioma, actinic keratosis (AK)","NCC(=O)CCC(O)=O, NCC(=O)CCC(O)=O, NCC(=O)CCC(O)=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4601","5-BDBD","purinergic receptor antagonist","P2RX4",NA,NA,"Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |t:8|, Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |t:8|, Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |t:8|, Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |t:8|, Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |t:8|, Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |t:8|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4602","5-carboxamidotryptamine","serotonin receptor agonist","HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7",NA,NA,"NCCc1c[nH]c2ccc(cc12)C(N)=O, NCCc1c[nH]c2ccc(cc12)C(N)=O","Preclinical",0,0,0,0,0,0,0,0,1,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4603","5-fluorouracil","thymidylate synthase inhibitor","DPYD, TYMS","oncology","colorectal cancer, breast cancer, pancreatic cancer, gastric adenocarcinoma","Fc1c[nH]c(=O)[nH]c1=O, Fc1c[nH]c(=O)[nH]c1=O, Fc1c[nH]c(=O)[nH]c1=O, Fc1c[nH]c(=O)[nH]c1=O, Fc1c[nH]c(=O)[nH]c1=O, Fc1c[nH]c(=O)[nH]c1=O","Launched",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4604","5-FP","thymidylate synthase inhibitor","TYMS",NA,NA,"Fc1cnc(=O)[nH]c1, Fc1cnc(=O)[nH]c1","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4605","5-hydroxymethyl-tolterodine","acetylcholine receptor antagonist","CHRM3",NA,NA,"CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C","Phase 1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
"4606","5-hydroxytryptophan","neurotransmitter","SLC36A1, SLC36A2","neurology/psychiatry","insomnia","N[C@@H](Cc1c[nH]c2ccc(O)cc12)C(O)=O |&1:1,r|, N[C@@H](Cc1c[nH]c2ccc(O)cc12)C(O)=O |&1:1,r|, N[C@@H](Cc1c[nH]c2ccc(O)cc12)C(O)=O |&1:1,r|","Launched",1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4607","5-methylfurmethiodide","acetylcholine receptor agonist","CHRM1, CHRM2, CHRM3, CHRM4",NA,NA,"Cc1ccc(C[N+](C)(C)C)o1, Cc1ccc(C[N+](C)(C)C)o1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0
"4608","6-chloromelatonin","melatonin receptor agonist","MTNR1A, MTNR1B",NA,NA,"COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl, COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl, COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl, COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4609","6-diazo-5-oxo-l-nor-leucine","glutaminase inhibitor","GGT1, GLS","hematologic malignancy","burkitt's lymphoma","N[C@@H](CCC(=O)C=[N+]=[N-])C(=O)O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4610","6-iodo-nordihydrocapsaicin","TRPV antagonist","TRPV1",NA,NA,"CCCCCCCCC(=O)NCc1cc(OC)c(O)cc1I, CCCCCCCCC(=O)NCc1cc(OC)c(O)cc1I","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4611","6-thio-2'-deoxyguanosine","telomerase inhibitor","TERT","oncology","non-small cell lung cancer (nsclc)","OC[C@@H]1[C@H](C[C@H](N2C=NC3=C2NC(N)=NC3=S)O1)O","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
"4612","7-chlorokynurenic-acid","glutamate receptor antagonist","GRIN1, GRIN2A, GRIN2B, GRIN2C",NA,NA,"OC(=O)c1cc(=O)c2ccc(Cl)cc2[nH]1, OC(=O)c1cc(=O)c2ccc(Cl)cc2[nH]1, OC(=O)c1cc(=O)c2ccc(Cl)cc2[nH]1, OC(=O)c1cc(=O)c2ccc(Cl)cc2[nH]1","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4613","7-hydroxy-DPAT","dopamine receptor agonist","DRD2, DRD3",NA,NA,"CCCN(CCC)[C@H]1CCc2ccc(O)cc2C1 |&1:7|, CCCN(CCC)[C@H]1CCc2ccc(O)cc2C1 |&1:7|, CCCN(CCC)[C@H]1CCc2ccc(O)cc2C1 |&1:7|, CCCN(CCC)[C@H]1CCc2ccc(O)cc2C1 |&1:7|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0
"4614","7-hydroxy-PIPAT","dopamine receptor ligand","DRD3",NA,NA,"CCCN(C\C=C\I)[C@H]1CCc2ccc(O)cc2C1 |&1:8|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0
"4615","7-hydroxystaurosporine","CDK inhibitor, CHK inhibitor, PKC inhibitor","CDK1, CHEK1, CHEK2, GSK3B, LCK, MAPK14, MARK1, MARK3, PDPK1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG",NA,NA,"CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4[C@H](O)NC(=O)c4c4c5ccccc5n2c4c13, CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4[C@H](O)NC(=O)c4c4c5ccccc5n2c4c13, CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4[C@H](O)NC(=O)c4c4c5ccccc5n2c4c13","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4616","7-methoxytacrine","acetylcholinesterase inhibitor","ACHE",NA,NA,"COc1ccc2nc3CCCCc3c(N)c2c1, COc1ccc2nc3CCCCc3c(N)c2c1","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4617","7-nitroindazole","nitric oxide synthase inhibitor","NOS1, NOS2, NOS3",NA,NA,"[O-][N+](=O)c1cccc2c[nH]nc12, [O-][N+](=O)c1cccc2c[nH]nc12, [O-][N+](=O)c1cccc2c[nH]nc12","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4618","8-bromo-cGMP","PKA activator","PRKG1",NA,NA,"Nc1nc(=O)c2nc(Br)n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c2[nH]1 |a:10,12,19,20,&1:15|, Nc1nc(=O)c2nc(Br)n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c2[nH]1 |a:10,12,19,20,&1:15|, Nc1nc(=O)c2nc(Br)n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c2[nH]1 |a:10,12,19,20,&1:15|, Nc1nc(=O)c2nc(Br)n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c2[nH]1 |a:10,12,19,20,&1:15|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4619","8-hydroxy-DPAT","serotonin receptor agonist","HTR5A, HTR7",NA,NA,"CCCN(CCC)[C@H]1CCc2cccc(O)c2C1 |&1:7|, CCCN(CCC)[C@H]1CCc2cccc(O)c2C1 |&1:7|","Preclinical",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4620","8-hydroxy-PIPAT","dopamine receptor ligand","DRD2, DRD3",NA,NA,"CCCN(C\C=C\I)[C@H]1CCc2cccc(O)c2C1 |&1:8|, CCCN(C\C=C\I)[C@H]1CCc2cccc(O)c2C1 |&1:8|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0
"4621","8-M-PDOT","melatonin receptor agonist","MTNR1A, MTNR1B",NA,NA,"CCC(=O)N[C@H]1CCc2cccc(OC)c2C1 |&1:5,r|, CCC(=O)N[C@H]1CCc2cccc(OC)c2C1 |&1:5,r|","Preclinical",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4622","9-aminocamptothecin","topoisomerase inhibitor","TOP1",NA,NA,"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc(N)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc(N)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc(N)c4cc3Cn1c2=O","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"4623","9-ing-41","gsk3b inhibitor","GSK3B, MARK2","hematologic malignancy","myelofibrosis","Cn1cc(C2=C(C(=O)NC2=O)c2coc3ccc(F)cc23)c2cc3OCOc3cc12 |t:4|","Phase 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1
